(lp0
(dp1
S'line'
p2
VWestern-blot, RT-PCR and cDNA sequencing analyses allowed us to identify two RHBDD2 alternatively spliced mRNA isoforms expressed in breast cancer cell lines.
p3
sS'genes'
p4
(lp5
sS'diseases'
p6
(lp7
(dp8
S'index'
p9
I133
sS'cui'
p10
VC0678222
p11
sS'lengthInChars'
p12
I13
sS'name'
p13
Vbreast cancer
p14
sS'lengthInWords'
p15
I2
sasa(dp16
g2
VInterestingly, siRNA-mediated silencing of RHBDD2 expression results in a decrease of MCF7 breast cancer cells proliferation compared with the corresponding controls (p=0.001).
p17
sg4
(lp18
(dp19
g9
I43
sS'uniprot'
p20
S''
p21
sg12
I6
sg13
VRHBDD2
p22
sg15
I1
sasg6
(lp23
(dp24
g9
I111
sg10
VC0334094
p25
sg12
I13
sg13
Vproliferation
p26
sg15
I1
sa(dp27
g9
I91
sg10
VC0678222
p28
sg12
I13
sg13
Vbreast cancer
p29
sg15
I2
sasa(dp30
g2
VIn conclusion, our findings suggest that RHBDD2 over-expression behaves as an indicator of poor prognosis and may play a role facilitating breast cancer progression.
p31
sg4
(lp32
(dp33
g9
I41
sg20
g21
sg12
I6
sg13
VRHBDD2
p34
sg15
I1
sasg6
(lp35
(dp36
g9
I146
sg10
VC0178874
p37
sg12
I18
sg13
Vcancer progression
p38
sg15
I2
sasa(dp39
g2
VThese effects could also be exerted via the upregulation of eight specific target genes, the subsequent over-activation of the PKC and PI3 K-Akt pathways, and the eventual abnormal cardiac development and VSD.
p40
sg4
(lp41
(dp42
g9
I141
sg20
g21
sg12
I3
sg13
VAkt
p43
sg15
I1
sa(dp44
g9
I127
sg20
VP17252
p45
sg12
I3
sg13
VPKC
p46
sg15
I1
sa(dp47
g9
I135
sg20
VP19957
p48
sg12
I5
sg13
VPI3 K
p49
sg15
I2
sasg6
(lp50
(dp51
g9
I205
sg10
VC0018818
p52
sg12
I3
sg13
VVSD
p53
sg15
I1
sa(dp54
g9
I127
sg10
VC1868682
p55
sg12
I3
sg13
VPKC
p56
sg15
I1
sasa(dp57
g2
VReduced translation of CEBPA mRNA has been associated with increased proliferation of bronchial smooth muscle (BSM) cells of asthma patients.
p58
sg4
(lp59
(dp60
g9
I23
sg20
VP49715
p61
sg12
I10
sg13
VCEBPA mRNA
p62
sg15
I2
sasg6
(lp63
(dp64
g9
I125
sg10
VC0004096
p65
sg12
I6
sg13
Vasthma
p66
sg15
I1
sa(dp67
g9
I69
sg10
VC0334094
p68
sg12
I13
sg13
Vproliferation
p69
sg15
I1
sasa(dp70
g2
VHDM extract reduced the C/EBPAlfa expression in BSM cells of asthma patients, which coincided with significantly increased levels of calreticulin (CRT) protein, an inhibitor of CEBPA mRNA translation.
p71
sg4
(lp72
(dp73
g9
I133
sg20
VP27797
p74
sg12
I12
sg13
Vcalreticulin
p75
sg15
I1
sa(dp76
g9
I177
sg20
VP49715
p77
sg12
I10
sg13
VCEBPA mRNA
p78
sg15
I2
sa(dp79
g9
I147
sg20
VP27797
p80
sg12
I3
sg13
VCRT
p81
sg15
I1
sasg6
(lp82
(dp83
g9
I61
sg10
VC0004096
p84
sg12
I6
sg13
Vasthma
p85
sg15
I1
sasa(dp86
g2
VIn conclusion, HDM extract reduced CEBPA mRNA translation, specifically in asthmatic BSM cells, and 1) upregulated CRT, 2) activated PAR2, and increased 3) IL-6 expression and 4) the proliferation of asthmatic BSM cells.
p87
sg4
(lp88
(dp89
g9
I35
sg20
VP49715
p90
sg12
I10
sg13
VCEBPA mRNA
p91
sg15
I2
sa(dp92
g9
I156
sg20
VP05231
p93
sg12
I4
sg13
VIL-6
p94
sg15
I1
sa(dp95
g9
I133
sg20
VP55085
p96
sg12
I4
sg13
VPAR2
p97
sg15
I1
sasg6
(lp98
(dp99
g9
I183
sg10
VC0334094
p100
sg12
I13
sg13
Vproliferation
p101
sg15
I1
sa(dp102
g9
I75
sg10
VC0004096
p103
sg12
I9
sg13
Vasthmatic
p104
sg15
I1
sa(dp105
g9
I75
sg10
VC0004096
p106
sg12
I9
sg13
Vasthmatic
p107
sg15
I1
sasa(dp108
g2
VAirway smooth muscle cells from persons with asthma are deficient in C/EBP-alpha, which may explain the finding that CSs do not inhibit the proliferation of these cells in vitro.
p109
sg4
(lp110
(dp111
g9
I69
sg20
g21
sg12
I11
sg13
VC/EBP-alpha
p112
sg15
I1
sasg6
(lp113
(dp114
g9
I45
sg10
VC0004096
p115
sg12
I6
sg13
Vasthma
p116
sg15
I1
sa(dp117
g9
I117
sg10
VC0265338
p118
sg12
I3
sg13
VCSs
p119
sg15
I1
sa(dp120
g9
I140
sg10
VC0334094
p121
sg12
I13
sg13
Vproliferation
p122
sg15
I1
sasa(dp123
g2
VCCAAT/enhancer-binding proteins (C/EBPs) control cell proliferation; lack of C/EBPalpha correlates with increased proliferation of bronchial smooth muscle cells (BSMCs) of asthmatic patients.
p124
sg4
(lp125
(dp126
g9
I33
sg20
g21
sg12
I6
sg13
VC/EBPs
p127
sg15
I1
sa(dp128
g9
I0
sg20
VP63244
p129
sg12
I31
sg13
VCCAAT/enhancer-binding proteins
p130
sg15
I2
sasg6
(lp131
(dp132
g9
I54
sg10
VC0334094
p133
sg12
I13
sg13
Vproliferation
p134
sg15
I1
sa(dp135
g9
I54
sg10
VC0334094
p136
sg12
I13
sg13
Vproliferation
p137
sg15
I1
sa(dp138
g9
I172
sg10
VC0004096
p139
sg12
I9
sg13
Vasthmatic
p140
sg15
I1
sasa(dp141
g2
VExpression and function of C/EBPalpha, beta, delta, and epsilon BSMCs of control subjects (n = 9), asthmatic patients (n = 12), and patients with chronic obstructive pulmonary disease (COPD; n = 10) were determined.
p142
sg4
(lp143
sg6
(lp144
(dp145
g9
I185
sg10
VC0024117
p146
sg12
I4
sg13
VCOPD
p147
sg15
I1
sa(dp148
g9
I146
sg10
VC0024117
p149
sg12
I37
sg13
Vchronic obstructive pulmonary disease
p150
sg15
I4
sa(dp151
g9
I99
sg10
VC0004096
p152
sg12
I9
sg13
Vasthmatic
p153
sg15
I1
sasa(dp154
g2
VThe asthmatic group did not appropriately express C/EBPalpha.
p155
sg4
(lp156
sg6
(lp157
(dp158
g9
I4
sg10
VC0004096
p159
sg12
I9
sg13
Vasthmatic
p160
sg15
I1
sasa(dp161
g2
VProtein analysis and electrophoretic mobility shift assay confirmed the disease-specific expression pattern of C/EBPalpha in asthmatic patients and C/EBPdelta in patients with COPD.
p162
sg4
(lp163
sg6
(lp164
(dp165
g9
I176
sg10
VC0024117
p166
sg12
I4
sg13
VCOPD
p167
sg15
I1
sa(dp168
g9
I125
sg10
VC0004096
p169
sg12
I9
sg13
Vasthmatic
p170
sg15
I1
sasa(dp171
g2
VThe reason for the differences which have been observed in the in vitro properties of airway smooth muscle derived from asthmatic individuals may result from an inherent "supercontractility", an increased tendency to proliferate due to the absence of an inhibitory transcription factor C/EBP-alpha, the influence of an altered extracellular matrix and/or a decrease in release of factors such as PGE(2) which would under normal circumstances inhibit both proliferation and contraction.
p172
sg4
(lp173
(dp174
g9
I265
sg20
g21
sg12
I32
sg13
Vtranscription factor C/EBP-alpha
p175
sg15
I3
sasg6
(lp176
(dp177
g9
I455
sg10
VC0334094
p178
sg12
I13
sg13
Vproliferation
p179
sg15
I1
sa(dp180
g9
I120
sg10
VC0004096
p181
sg12
I9
sg13
Vasthmatic
p182
sg15
I1
sa(dp183
g9
I473
sg10
VC1140999
p184
sg12
I11
sg13
Vcontraction
p185
sg15
I1
sasa(dp186
g2
VHepatocellular carcinoma etiology had no detectable influence on miR-122 expression, whereas miR-152 was increased in HCV+ tissue samples.
p187
sg4
(lp188
(dp189
g9
I93
sg20
g21
sg12
I7
sg13
VmiR-152
p190
sg15
I1
sa(dp191
g9
I65
sg20
g21
sg12
I7
sg13
VmiR-122
p192
sg15
I1
sasg6
(lp193
(dp194
g9
I0
sg10
VC1512411
p195
sg12
I24
sg13
VHepatocellular carcinoma
p196
sg15
I2
sasa(dp197
g2
VAberrant expressions of the miR-148/152 family (miR-148a, miR-148b, and miR-152) have been documented in many tumor tissues, including hepatocellular carcinoma (HCC).
p198
sg4
(lp199
(dp200
g9
I28
sg20
g21
sg12
I18
sg13
VmiR-148/152 family
p201
sg15
I2
sa(dp202
g9
I58
sg20
g21
sg12
I8
sg13
VmiR-148b
p203
sg15
I1
sa(dp204
g9
I48
sg20
g21
sg12
I8
sg13
VmiR-148a
p205
sg15
I1
sasg6
(lp206
(dp207
g9
I135
sg10
VC2239176
p208
sg12
I24
sg13
Vhepatocellular carcinoma
p209
sg15
I2
sa(dp210
g9
I110
sg10
VC0027651
p211
sg12
I5
sg13
Vtumor
p212
sg15
I1
sa(dp213
g9
I161
sg10
VC2239176
p214
sg12
I3
sg13
VHCC
p215
sg15
I1
sasa(dp216
g2
VAnd high expression of HLA-G further suppressed NK against cancer cells, providing a new concept that miR-152 was involved in HBV-induced hepatocellular carcinoma.
p217
sg4
(lp218
(dp219
g9
I23
sg20
VP30486
p220
sg12
I3
sg13
VHLA
p221
sg15
I1
sasg6
(lp222
(dp223
g9
I59
sg10
VC0006826
p224
sg12
I6
sg13
Vcancer
p225
sg15
I1
sa(dp226
g9
I138
sg10
VC1512411
p227
sg12
I24
sg13
Vhepatocellular carcinoma
p228
sg15
I2
sa(dp229
g9
I126
sg10
VC0019163
p230
sg12
I3
sg13
VHBV
p231
sg15
I1
sasa(dp232
g2
VFurther, FDA-approved arsenic trioxide (ATO) and the ND2-SmoA1 mouse model of Medulloblastoma (MB) were used to extend our analyses of combined MRI and Reverse Phase Protein Microarray (RPMA) data to assess tumor responses to ATO and to uncover the complexity of therapeutic molecular biology.
p233
sg4
(lp234
(dp235
g9
I53
sg20
VP03891
p236
sg12
I9
sg13
VND2-SmoA1
p237
sg15
I1
sasg6
(lp238
(dp239
g9
I95
sg10
VC0025149
p240
sg12
I2
sg13
VMB
p241
sg15
I1
sa(dp242
g9
I78
sg10
VC0025149
p243
sg12
I15
sg13
VMedulloblastoma
p244
sg15
I1
sa(dp245
g9
I207
sg10
VC0027651
p246
sg12
I5
sg13
Vtumor
p247
sg15
I1
sasa(dp248
g2
VImportantly, while ASC deficiency did not affect normal cerebellar development, ASC knockout mice on the Smoothened (ND2:SmoA1) transgenic model of medulloblastoma exhibited a profound reduction in medulloblastoma incidence and a delayed tumor onset.
p249
sg4
(lp250
(dp251
g9
I117
sg20
VP03891
p252
sg12
I3
sg13
VND2
p253
sg15
I1
sa(dp254
g9
I19
sg20
VP08842
p255
sg12
I3
sg13
VASC
p256
sg15
I1
sasg6
(lp257
(dp258
g9
I148
sg10
VC0025149
p259
sg12
I15
sg13
Vmedulloblastoma
p260
sg15
I1
sa(dp261
g9
I148
sg10
VC0025149
p262
sg12
I15
sg13
Vmedulloblastoma
p263
sg15
I1
sa(dp264
g9
I238
sg10
VC0027651
p265
sg12
I5
sg13
Vtumor
p266
sg15
I1
sasa(dp267
g2
VWe report the use of IRDye 800CW chlorotoxin (CLTX) as a targeted imaging agent for brain tumors in a spontaneous mouse model of medulloblastoma, ND2:SmoA1.
p268
sg4
(lp269
(dp270
g9
I146
sg20
VP03891
p271
sg12
I3
sg13
VND2
p272
sg15
I1
sasg6
(lp273
(dp274
g9
I129
sg10
VC0025149
p275
sg12
I15
sg13
Vmedulloblastoma
p276
sg15
I1
sa(dp277
g9
I84
sg10
VC0006118
p278
sg12
I12
sg13
Vbrain tumors
p279
sg15
I2
sasa(dp280
g2
VImportantly, genetic deletion of Bax in medulloblastoma-prone ND2:SmoA1 transgenic mice greatly accelerated tumorigenesis.
p281
sg4
(lp282
(dp283
g9
I62
sg20
VP03891
p284
sg12
I3
sg13
VND2
p285
sg15
I1
sasg6
(lp286
(dp287
g9
I108
sg10
VC0007621
p288
sg12
I13
sg13
Vtumorigenesis
p289
sg15
I1
sa(dp290
g9
I40
sg10
VC0025149
p291
sg12
I15
sg13
Vmedulloblastoma
p292
sg15
I1
sasa(dp293
g2
VFive common variants were associated with pancreatic cancer at nominal statistical significance (P &lt; 0.05) with the strongest finding for mt5460g in the ND2 gene [OR = 3.9; 95% confidence interval (CI), 1.5-10; P = 0.004] which encodes an A331T substitution.
p294
sg4
(lp295
(dp296
g9
I156
sg20
VP03891
p297
sg12
I8
sg13
VND2 gene
p298
sg15
I2
sasg6
(lp299
(dp300
g9
I42
sg10
VC0235974
p301
sg12
I17
sg13
Vpancreatic cancer
p302
sg15
I2
sasa(dp303
g2
VOur findings indicate a critical role of HspBP1 in differential CHIP/Hsp70 activities in neuronal and glial cells and the greater neuronal vulnerability to misfolded proteins in neurodegenerative diseases.
p304
sg4
(lp305
(dp306
g9
I41
sg20
g21
sg12
I6
sg13
VHspBP1
p307
sg15
I1
sa(dp308
g9
I69
sg20
VP34932
p309
sg12
I5
sg13
VHsp70
p310
sg15
I1
sa(dp311
g9
I64
sg20
g21
sg12
I4
sg13
VCHIP
p312
sg15
I1
sasg6
(lp313
(dp314
g9
I178
sg10
VC0524851
p315
sg12
I26
sg13
Vneurodegenerative diseases
p316
sg15
I2
sasa(dp317
g2
VIn this study the adenoviral mediated over-expression of HSP70 interacting protein (HIP) alone was shown to significantly reduce inclusion formation in both an in vitro model of Spinal Bulbar Muscular Atrophy and a primary neuronal model of polyglutamine disease.
p318
sg4
(lp319
(dp320
g9
I57
sg20
VP50502
p321
sg12
I25
sg13
VHSP70 interacting protein
p322
sg15
I3
sa(dp323
g9
I84
sg20
VP47914
p324
sg12
I3
sg13
VHIP
p325
sg15
I1
sasg6
(lp326
(dp327
g9
I192
sg10
VC0026846
p328
sg12
I16
sg13
VMuscular Atrophy
p329
sg15
I2
sasa(dp330
g2
VTo explore the relationship of telomerase, MYC and JAK2 in chronic myeloproliferative diseases, we investigated hTERT and MYC expression in bone marrow cells of essential thrombocythemia (ET) and polycythemia vera (PV).
p331
sg4
(lp332
(dp333
g9
I112
sg20
g21
sg12
I5
sg13
VhTERT
p334
sg15
I1
sa(dp335
g9
I51
sg20
g21
sg12
I4
sg13
VJAK2
p336
sg15
I1
sa(dp337
g9
I43
sg20
VP12524
p338
sg12
I3
sg13
VMYC
p339
sg15
I1
sa(dp340
g9
I43
sg20
VP12524
p341
sg12
I3
sg13
VMYC
p342
sg15
I1
sasg6
(lp343
(dp344
g9
I161
sg10
VC0040028
p345
sg12
I25
sg13
Vessential thrombocythemia
p346
sg15
I2
sa(dp347
g9
I188
sg10
VC0040028
p348
sg12
I2
sg13
VET
p349
sg15
I1
sa(dp350
g9
I196
sg10
VC0032463
p351
sg12
I17
sg13
Vpolycythemia vera
p352
sg15
I2
sa(dp353
g9
I215
sg10
VC0032463
p354
sg12
I2
sg13
VPV
p355
sg15
I1
sasa(dp356
g2
VDCAF17 mutations are associated with Woodhouse-Sakati syndrome, a rare disorder characterized by alopecia, hypogonadotropic hypogonadism, sensorineural hearing loss, diabetes mellitus, and extrapyramidal movements.
p357
sg4
(lp358
(dp359
g9
I0
sg20
g21
sg12
I6
sg13
VDCAF17
p360
sg15
I1
sasg6
(lp361
(dp362
g9
I166
sg10
VC0011849
p363
sg12
I17
sg13
Vdiabetes mellitus
p364
sg15
I2
sa(dp365
g9
I107
sg10
VC0022735
p366
sg12
I29
sg13
Vhypogonadotropic hypogonadism
p367
sg15
I2
sa(dp368
g9
I66
sg10
VC0678236
p369
sg12
I13
sg13
Vrare disorder
p370
sg15
I2
sa(dp371
g9
I138
sg10
VC0018784
p372
sg12
I26
sg13
Vsensorineural hearing loss
p373
sg15
I3
sa(dp374
g9
I37
sg10
VC0342286
p375
sg12
I25
sg13
VWoodhouse-Sakati syndrome
p376
sg15
I2
sasa(dp377
g2
VWoodhouse-Sakati syndrome (WSS) is a rare autosomal recessive disorder characterized by alopecia, hypogonadism, diabetes mellitus, intellectual disability, sensorineural deafness, extrapyramidal signs, and low insulinlike growth factor 1 levels.
p378
sg4
(lp379
(dp380
g9
I206
sg20
VP05019
p381
sg12
I31
sg13
Vlow insulinlike growth factor 1
p382
sg15
I5
sasg6
(lp383
(dp384
g9
I180
sg10
VC0234133
p385
sg12
I20
sg13
Vextrapyramidal signs
p386
sg15
I2
sa(dp387
g9
I98
sg10
VC0020619
p388
sg12
I12
sg13
Vhypogonadism
p389
sg15
I1
sa(dp390
g9
I0
sg10
VC0342286
p391
sg12
I25
sg13
VWoodhouse-Sakati syndrome
p392
sg15
I2
sa(dp393
g9
I27
sg10
VC0406587
p394
sg12
I3
sg13
VWSS
p395
sg15
I1
sa(dp396
g9
I156
sg10
VC0018784
p397
sg12
I22
sg13
Vsensorineural deafness
p398
sg15
I2
sa(dp399
g9
I131
sg10
VC0025362
p400
sg12
I23
sg13
Vintellectual disability
p401
sg15
I2
sa(dp402
g9
I112
sg10
VC0011849
p403
sg12
I17
sg13
Vdiabetes mellitus
p404
sg15
I2
sasa(dp405
g2
VWoodhouse-Sakati syndrome consists of alopecia, hypogonadism, diabetes mellitus, mild mental retardation, sensorineural deafness and ECG abnormalities.
p406
sg4
(lp407
sg6
(lp408
(dp409
g9
I62
sg10
VC0011849
p410
sg12
I17
sg13
Vdiabetes mellitus
p411
sg15
I2
sa(dp412
g9
I81
sg10
VC0026106
p413
sg12
I23
sg13
Vmild mental retardation
p414
sg15
I3
sa(dp415
g9
I48
sg10
VC0020619
p416
sg12
I12
sg13
Vhypogonadism
p417
sg15
I1
sa(dp418
g9
I106
sg10
VC0018784
p419
sg12
I22
sg13
Vsensorineural deafness
p420
sg15
I2
sa(dp421
g9
I0
sg10
VC0342286
p422
sg12
I25
sg13
VWoodhouse-Sakati syndrome
p423
sg15
I2
sasa(dp424
g2
VA population of CD80+Gr-1+ myeloid cells was found to be expanded in conventional as well as in bone marrow-transplanted mice with disseminated candidiasis, but its depletion increased the IFN-gamma-mediated antifungal resistance.
p425
sg4
(lp426
(dp427
g9
I16
sg20
VP00390
p428
sg12
I10
sg13
VCD80+Gr-1+
p429
sg15
I1
sa(dp430
g9
I189
sg20
VP01579
p431
sg12
I9
sg13
VIFN-gamma
p432
sg15
I1
sasg6
(lp433
(dp434
g9
I131
sg10
VC0153252
p435
sg12
I24
sg13
Vdisseminated candidiasis
p436
sg15
I2
sasa(dp437
g2
VThe patients with esophageal candidiasis had lower CD4+ cell counts (129/microliter) and CD4:CD8 ratios (0.23) than those with oropharyngeal candidiasis (CD4 179/microliter; CD4:CD8 0.35).
p438
sg4
(lp439
(dp440
g9
I178
sg20
VP01732
p441
sg12
I8
sg13
VCD8 0.35
p442
sg15
I2
sa(dp443
g9
I51
sg20
VP01730
p444
sg12
I3
sg13
VCD4
p445
sg15
I1
sa(dp446
g9
I51
sg20
VP01730
p447
sg12
I4
sg13
VCD4+
p448
sg15
I1
sa(dp449
g9
I51
sg20
VP01730
p450
sg12
I3
sg13
VCD4
p451
sg15
I1
sa(dp452
g9
I93
sg20
VP01732
p453
sg12
I3
sg13
VCD8
p454
sg15
I1
sa(dp455
g9
I51
sg20
VP01730
p456
sg12
I3
sg13
VCD4
p457
sg15
I1
sasg6
(lp458
(dp459
g9
I18
sg10
VC0239295
p460
sg12
I22
sg13
Vesophageal candidiasis
p461
sg15
I2
sa(dp462
g9
I127
sg10
VC0919659
p463
sg12
I25
sg13
Voropharyngeal candidiasis
p464
sg15
I2
sasa(dp465
g2
VWe served patients with cystic fibrosis (CF, n=29), cystic fibrosis related diabetes (CFRD, n=19) and healthy controls (n=18) a standardized breakfast (23 g protein, 25 g fat and 76 g carbohydrates) after an overnight fasting.
p466
sg4
(lp467
sg6
(lp468
(dp469
g9
I41
sg10
VC0010674
p470
sg12
I2
sg13
VCF
p471
sg15
I1
sa(dp472
g9
I24
sg10
VC0010674
p473
sg12
I15
sg13
Vcystic fibrosis
p474
sg15
I2
sa(dp475
g9
I52
sg10
VC2242728
p476
sg12
I32
sg13
Vcystic fibrosis related diabetes
p477
sg15
I4
sa(dp478
g9
I86
sg10
VC2242728
p479
sg12
I4
sg13
VCFRD
p480
sg15
I1
sasa(dp481
g2
VCNS anomalies included 12 Chiari malformations, 2 Dandy-Walker malformations (DWM), 1 variant of Dandy-Walker syndrome (DWS), 3 iniencephalies, 15 anencephalies, 1 alobar holoprosencephaly, 2 isolated hydrocephalies, 3 hydrocephalies with cerebellar hypoplasia, 1 occipital encephalocele, 1 lumbosacral myelomeningocele accompanied with microcephaly.
p482
sg4
(lp483
sg6
(lp484
(dp485
g9
I50
sg10
VC0010964
p486
sg12
I26
sg13
VDandy-Walker malformations
p487
sg15
I2
sa(dp488
g9
I303
sg10
VC0025312
p489
sg12
I16
sg13
Vmyelomeningocele
p490
sg15
I1
sa(dp491
g9
I239
sg10
VC0266470
p492
sg12
I21
sg13
Vcerebellar hypoplasia
p493
sg15
I2
sa(dp494
g9
I26
sg10
VC0003803
p495
sg12
I20
sg13
VChiari malformations
p496
sg15
I2
sa(dp497
g9
I78
sg10
VC0010964
p498
sg12
I3
sg13
VDWM
p499
sg15
I1
sa(dp500
g9
I264
sg10
VC0014067
p501
sg12
I23
sg13
Voccipital encephalocele
p502
sg15
I2
sa(dp503
g9
I97
sg10
VC0010964
p504
sg12
I21
sg13
VDandy-Walker syndrome
p505
sg15
I2
sa(dp506
g9
I337
sg10
VC0025958
p507
sg12
I12
sg13
Vmicrocephaly
p508
sg15
I1
sa(dp509
g9
I120
sg10
VC0010964
p510
sg12
I3
sg13
VDWS
p511
sg15
I1
sa(dp512
g9
I128
sg10
VC0152234
p513
sg12
I14
sg13
Viniencephalies
p514
sg15
I1
sa(dp515
g9
I164
sg10
VC0431363
p516
sg12
I24
sg13
Valobar holoprosencephaly
p517
sg15
I2
sasa(dp518
g2
VAcrania, alobar holoprosencephaly, cephaloceles, and spina bifida can confidently be diagnosed at that stage and should actively be looked for in every fetus undergoing first-trimester ultrasound.
p519
sg4
(lp520
sg6
(lp521
(dp522
g9
I9
sg10
VC0431363
p523
sg12
I24
sg13
Valobar holoprosencephaly
p524
sg15
I2
sa(dp525
g9
I53
sg10
VC0080178
p526
sg12
I12
sg13
Vspina bifida
p527
sg15
I2
sa(dp528
g9
I0
sg10
VC0702169
p529
sg12
I7
sg13
VAcrania
p530
sg15
I1
sa(dp531
g9
I35
sg10
VC0014065
p532
sg12
I12
sg13
Vcephaloceles
p533
sg15
I1
sasa(dp534
g2
VWe present a new case with 13q deletion syndrome phenotypically characterized by severe major malformations, some of them still undescribed, consisting of left diaphragmatic hernia, right pulmonary sequestration, hypoplastic left heart syndrome, pancreatic agenesis, polysplenia, and catastrophic central nervous system malformations: semilobar holoprosencephaly, occipital myelomeningocele, partial agenesis of the corpus callosum and agenesis of olfactory bulbs.
p535
sg4
(lp536
sg6
(lp537
(dp538
g9
I257
sg10
VC0332907
p539
sg12
I8
sg13
Vagenesis
p540
sg15
I1
sa(dp541
g9
I213
sg10
VC0152101
p542
sg12
I31
sg13
Vhypoplastic left heart syndrome
p543
sg15
I4
sa(dp544
g9
I188
sg10
VC0006288
p545
sg12
I23
sg13
Vpulmonary sequestration
p546
sg15
I2
sa(dp547
g9
I335
sg10
VC0751617
p548
sg12
I27
sg13
Vsemilobar holoprosencephaly
p549
sg15
I2
sa(dp550
g9
I305
sg10
VC0497552
p551
sg12
I28
sg13
Vnervous system malformations
p552
sg15
I3
sa(dp553
g9
I374
sg10
VC0025312
p554
sg12
I16
sg13
Vmyelomeningocele
p555
sg15
I1
sa(dp556
g9
I392
sg10
VC0431368
p557
sg12
I39
sg13
Vpartial agenesis of the corpus callosum
p558
sg15
I6
sa(dp559
g9
I160
sg10
VC0019284
p560
sg12
I20
sg13
Vdiaphragmatic hernia
p561
sg15
I2
sa(dp562
g9
I94
sg10
VC0000768
p563
sg12
I13
sg13
Vmalformations
p564
sg15
I1
sa(dp565
g9
I267
sg10
VC0266631
p566
sg12
I11
sg13
Vpolysplenia
p567
sg15
I1
sa(dp568
g9
I27
sg10
VC0265451
p569
sg12
I21
sg13
V13q deletion syndrome
p570
sg15
I3
sa(dp571
g9
I257
sg10
VC0332907
p572
sg12
I8
sg13
Vagenesis
p573
sg15
I1
sasa(dp574
g2
VThe early scan detected all cases of acrania, alobar holoprosencephaly, exomphalos, gastroschisis, megacystis and body stalk anomaly, 77% of absent hand or foot, 50% of diaphragmatic hernia, 50% of lethal skeletal dysplasias, 60% of polydactyly, 34% of major cardiac defects, 5% of facial clefts and 14% of open spina bifida, but none of agenesis of the corpus callosum, cerebellar or vermian hypoplasia, echogenic lung lesions, bowel obstruction, most renal defects or talipes.
p575
sg4
(lp576
sg6
(lp577
(dp578
g9
I393
sg10
VC0243069
p579
sg12
I10
sg13
Vhypoplasia
p580
sg15
I1
sa(dp581
g9
I214
sg10
VC0334044
p582
sg12
I10
sg13
Vdysplasias
p583
sg15
I1
sa(dp584
g9
I307
sg10
VC0917813
p585
sg12
I17
sg13
Vopen spina bifida
p586
sg15
I3
sa(dp587
g9
I338
sg10
VC0175754
p588
sg12
I31
sg13
Vagenesis of the corpus callosum
p589
sg15
I5
sa(dp590
g9
I84
sg10
VC0265706
p591
sg12
I13
sg13
Vgastroschisis
p592
sg15
I1
sa(dp593
g9
I37
sg10
VC0702169
p594
sg12
I7
sg13
Vacrania
p595
sg15
I1
sa(dp596
g9
I429
sg10
VC0021843
p597
sg12
I17
sg13
Vbowel obstruction
p598
sg15
I2
sa(dp599
g9
I470
sg10
VC0009081
p600
sg12
I7
sg13
Vtalipes
p601
sg15
I1
sa(dp602
g9
I259
sg10
VC0741916
p603
sg12
I15
sg13
Vcardiac defects
p604
sg15
I2
sa(dp605
g9
I46
sg10
VC0431363
p606
sg12
I24
sg13
Valobar holoprosencephaly
p607
sg15
I2
sa(dp608
g9
I282
sg10
VC0685787
p609
sg12
I13
sg13
Vfacial clefts
p610
sg15
I2
sa(dp611
g9
I169
sg10
VC0019284
p612
sg12
I20
sg13
Vdiaphragmatic hernia
p613
sg15
I2
sa(dp614
g9
I72
sg10
VC1306503
p615
sg12
I10
sg13
Vexomphalos
p616
sg15
I1
sa(dp617
g9
I233
sg10
VC0152427
p618
sg12
I11
sg13
Vpolydactyly
p619
sg15
I1
sa(dp620
g9
I119
sg10
VC0935572
p621
sg12
I5
sg13
Vstalk
p622
sg15
I1
sasa(dp623
g2
VThe case presented is, to our knowledge, the first published report comprising a combination of a semilobar holoprosencephaly associated with a Chiari II malformation and a myelomeningocele diagnosed prenatally and confirmed by postmortem neuropathologic evaluation.
p624
sg4
(lp625
sg6
(lp626
(dp627
g9
I154
sg10
VC0000768
p628
sg12
I12
sg13
Vmalformation
p629
sg15
I1
sa(dp630
g9
I98
sg10
VC0751617
p631
sg12
I27
sg13
Vsemilobar holoprosencephaly
p632
sg15
I2
sa(dp633
g9
I173
sg10
VC0025312
p634
sg12
I16
sg13
Vmyelomeningocele
p635
sg15
I1
sasa(dp636
g2
VThese findings indicate that in the case of pre- and postnatal detection of a myelomeningocele and/or Chiari II malformation, possible additional intracranial malformation, such as a semilobar holoprosencephaly, should also be taken into account and vice versa.
p637
sg4
(lp638
sg6
(lp639
(dp640
g9
I78
sg10
VC0025312
p641
sg12
I16
sg13
Vmyelomeningocele
p642
sg15
I1
sa(dp643
g9
I183
sg10
VC0751617
p644
sg12
I27
sg13
Vsemilobar holoprosencephaly
p645
sg15
I2
sa(dp646
g9
I112
sg10
VC0000768
p647
sg12
I12
sg13
Vmalformation
p648
sg15
I1
sa(dp649
g9
I112
sg10
VC0000768
p650
sg12
I12
sg13
Vmalformation
p651
sg15
I1
sasa(dp652
g2
VWe report on a female still-birth with cebocephaly, alobar holoprosencephaly, cleft palate, lumbar spina bifida, sirenomelia, a single umbilical artery, and a 46,XX karyotype, but without maternal diabetes mellitus.
p653
sg4
(lp654
sg6
(lp655
(dp656
g9
I188
sg10
VC1283034
p657
sg12
I26
sg13
Vmaternal diabetes mellitus
p658
sg15
I3
sa(dp659
g9
I99
sg10
VC0080178
p660
sg12
I12
sg13
Vspina bifida
p661
sg15
I2
sa(dp662
g9
I113
sg10
VC0037205
p663
sg12
I11
sg13
Vsirenomelia
p664
sg15
I1
sa(dp665
g9
I78
sg10
VC0008925
p666
sg12
I12
sg13
Vcleft palate
p667
sg15
I2
sa(dp668
g9
I39
sg10
VC0266679
p669
sg12
I11
sg13
Vcebocephaly
p670
sg15
I1
sa(dp671
g9
I52
sg10
VC0431363
p672
sg12
I24
sg13
Valobar holoprosencephaly
p673
sg15
I2
sa(dp674
g9
I128
sg10
VC0266795
p675
sg12
I23
sg13
Vsingle umbilical artery
p676
sg15
I3
sasa(dp677
g2
VThe current study provides novel evidence that TGFBeta upregulates the expression of multiple receptor tyrosine kinases (RTKs), including IGF1R, EGFR, PDGFBetaR, and FGFR1 in human hepatocellular carcinoma (HCC) cells.
p678
sg4
(lp679
(dp680
g9
I47
sg20
VP01137
p681
sg12
I7
sg13
VTGFBeta
p682
sg15
I1
sa(dp683
g9
I166
sg20
VP20930
p684
sg12
I5
sg13
VFGFR1
p685
sg15
I1
sa(dp686
g9
I94
sg20
VP29401
p687
sg12
I25
sg13
Vreceptor tyrosine kinases
p688
sg15
I3
sa(dp689
g9
I121
sg20
VP35968
p690
sg12
I4
sg13
VRTKs
p691
sg15
I1
sa(dp692
g9
I138
sg20
VP08069
p693
sg12
I5
sg13
VIGF1R
p694
sg15
I1
sasg6
(lp695
(dp696
g9
I207
sg10
VC2239176
p697
sg12
I3
sg13
VHCC
p698
sg15
I1
sa(dp699
g9
I181
sg10
VC2239176
p700
sg12
I24
sg13
Vhepatocellular carcinoma
p701
sg15
I2
sasa(dp702
g2
VWhile numerical and functional defects of invariant NKT cells have been demonstrated in rheumatoid arthritis (RA), the detailed characterization of proliferative and secretory responses following CD1d-mediated presentation is lacking; the presence of non-invariant populations has never been assessed in human autoimmunity.
p703
sg4
(lp704
(dp705
g9
I196
sg20
VP15813
p706
sg12
I4
sg13
VCD1d
p707
sg15
I1
sasg6
(lp708
(dp709
g9
I310
sg10
VC0004368
p710
sg12
I12
sg13
Vautoimmunity
p711
sg15
I1
sa(dp712
g9
I110
sg10
VC0003873
p713
sg12
I2
sg13
VRA
p714
sg15
I1
sa(dp715
g9
I148
sg10
VC0334094
p716
sg12
I13
sg13
Vproliferative
p717
sg15
I1
sa(dp718
g9
I88
sg10
VC0003873
p719
sg12
I20
sg13
Vrheumatoid arthritis
p720
sg15
I2
sasa(dp721
g2
VIn adults, angiopoietin-2 (Ang-2) and its soluble receptor (sTie-2) are associated with diabetes, hypertension, and obesity and could be increased in children with OSA and obesity, particularly those with evidence of cardiometabolic alterations.
p722
sg4
(lp723
(dp724
g9
I27
sg20
VP03950
p725
sg12
I5
sg13
VAng-2
p726
sg15
I1
sa(dp727
g9
I11
sg20
g21
sg12
I14
sg13
Vangiopoietin-2
p728
sg15
I1
sasg6
(lp729
(dp730
g9
I98
sg10
VC0020538
p731
sg12
I12
sg13
Vhypertension
p732
sg15
I1
sa(dp733
g9
I88
sg10
VC0011849
p734
sg12
I8
sg13
Vdiabetes
p735
sg15
I1
sa(dp736
g9
I116
sg10
VC0028754
p737
sg12
I7
sg13
Vobesity
p738
sg15
I1
sa(dp739
g9
I116
sg10
VC0028754
p740
sg12
I7
sg13
Vobesity
p741
sg15
I1
sa(dp742
g9
I164
sg10
VC0520679
p743
sg12
I3
sg13
VOSA
p744
sg15
I1
sasa(dp745
g2
VChildren with obesity and OSA had significantly elevated plasma Ang-2 and sTie-2 levels compared to corresponding controls with and without obesity.
p746
sg4
(lp747
(dp748
g9
I57
sg20
VP03950
p749
sg12
I12
sg13
Vplasma Ang-2
p750
sg15
I2
sasg6
(lp751
(dp752
g9
I14
sg10
VC0028754
p753
sg12
I7
sg13
Vobesity
p754
sg15
I1
sa(dp755
g9
I14
sg10
VC0028754
p756
sg12
I7
sg13
Vobesity
p757
sg15
I1
sa(dp758
g9
I26
sg10
VC0520679
p759
sg12
I3
sg13
VOSA
p760
sg15
I1
sasa(dp761
g2
VAng-2 and sTie-2 plasma levels are increased in pediatric OSA and obesity, particularly when endothelial dysfunction or insulin resistance is detectable, and appear to decrease upon OSA treatment.
p762
sg4
(lp763
(dp764
g9
I120
sg20
VP01308
p765
sg12
I7
sg13
Vinsulin
p766
sg15
I1
sa(dp767
g9
I0
sg20
VP03950
p768
sg12
I5
sg13
VAng-2
p769
sg15
I1
sasg6
(lp770
(dp771
g9
I58
sg10
VC0520679
p772
sg12
I3
sg13
VOSA
p773
sg15
I1
sa(dp774
g9
I66
sg10
VC0028754
p775
sg12
I7
sg13
Vobesity
p776
sg15
I1
sa(dp777
g9
I58
sg10
VC0520679
p778
sg12
I3
sg13
VOSA
p779
sg15
I1
sa(dp780
g9
I120
sg10
VC0021655
p781
sg12
I18
sg13
Vinsulin resistance
p782
sg15
I2
sa(dp783
g9
I93
sg10
VC0856169
p784
sg12
I23
sg13
Vendothelial dysfunction
p785
sg15
I2
sasa(dp786
g2
VANG-2 overexpressing mice show increased sWAT vascularization and are resistant to HFD-induced obesity.
p787
sg4
(lp788
(dp789
g9
I0
sg20
VP03950
p790
sg12
I5
sg13
VANG-2
p791
sg15
I1
sasg6
(lp792
(dp793
g9
I95
sg10
VC0028754
p794
sg12
I7
sg13
Vobesity
p795
sg15
I1
sa(dp796
g9
I46
sg10
VC0027686
p797
sg12
I15
sg13
Vvascularization
p798
sg15
I1
sasa(dp799
g2
VWe studied the effect of sleeve gastrectomy and the influence of FTO rs9930506 polymorphism on Tie-2, angiopoietin-1 and angiopoietin-2 expression in morbid obesity.
p800
sg4
(lp801
(dp802
g9
I102
sg20
g21
sg12
I14
sg13
Vangiopoietin-1
p803
sg15
I1
sa(dp804
g9
I121
sg20
g21
sg12
I14
sg13
Vangiopoietin-2
p805
sg15
I1
sa(dp806
g9
I65
sg20
g21
sg12
I13
sg13
VFTO rs9930506
p807
sg15
I2
sa(dp808
g9
I95
sg20
g21
sg12
I5
sg13
VTie-2
p809
sg15
I1
sasg6
(lp810
(dp811
g9
I150
sg10
VC0028756
p812
sg12
I14
sg13
Vmorbid obesity
p813
sg15
I2
sasa(dp814
g2
VThose most at risk report a family history of at least one parent with a pre-existing G-alpha protein defect, including night blindness, pseudohypoparathyroidism or adenoma of the thyroid or pituitary gland.
p815
sg4
(lp816
sg6
(lp817
(dp818
g9
I165
sg10
VC0151468
p819
sg12
I22
sg13
Vadenoma of the thyroid
p820
sg15
I4
sa(dp821
g9
I137
sg10
VC3494506
p822
sg12
I24
sg13
Vpseudohypoparathyroidism
p823
sg15
I1
sa(dp824
g9
I120
sg10
VC0028077
p825
sg12
I15
sg13
Vnight blindness
p826
sg15
I2
sasa(dp827
g2
VWe have previously shown that the ethanol extract of dried Angelica gigas Nakai (AGN) root exerts anticancer activity against androgen receptor (AR)-negative human DU145 and PC-3 prostate cancer xenografts and primary carcinogenesis in the transgenic adenocarcinoma of mouse prostate (TRAMP) model.
p828
sg4
(lp829
(dp830
g9
I126
sg20
VP10275
p831
sg12
I17
sg13
Vandrogen receptor
p832
sg15
I2
sa(dp833
g9
I145
sg20
VP10275
p834
sg12
I2
sg13
VAR
p835
sg15
I1
sasg6
(lp836
(dp837
g9
I251
sg10
VC0001418
p838
sg12
I14
sg13
Vadenocarcinoma
p839
sg15
I1
sa(dp840
g9
I218
sg10
VC0596263
p841
sg12
I14
sg13
Vcarcinogenesis
p842
sg15
I1
sa(dp843
g9
I179
sg10
VC0600139
p844
sg12
I15
sg13
Vprostate cancer
p845
sg15
I2
sasa(dp846
g2
VWe showed previously that nuclear localization of the androgen receptor (AR) and expression of the androgen-responsive gene FK506-binding protein 5 (FKBP5) in esophageal adenocarcinoma (EAC) tissues were associated with decreased patient survival, suggesting a role for androgens in this cancer.
p847
sg4
(lp848
(dp849
g9
I73
sg20
VP10275
p850
sg12
I2
sg13
VAR
p851
sg15
I1
sa(dp852
g9
I99
sg20
g21
sg12
I48
sg13
Vandrogen-responsive gene FK506-binding protein 5
p853
sg15
I5
sa(dp854
g9
I149
sg20
g21
sg12
I5
sg13
VFKBP5
p855
sg15
I1
sa(dp856
g9
I54
sg20
VP10275
p857
sg12
I17
sg13
Vandrogen receptor
p858
sg15
I2
sasg6
(lp859
(dp860
g9
I159
sg10
VC0279628
p861
sg12
I25
sg13
Vesophageal adenocarcinoma
p862
sg15
I2
sa(dp863
g9
I288
sg10
VC0006826
p864
sg12
I6
sg13
Vcancer
p865
sg15
I1
sa(dp866
g9
I186
sg10
VC1275122
p867
sg12
I3
sg13
VEAC
p868
sg15
I1
sasa(dp869
g2
VOnly 5 samples were ERG-/AR- corresponding to adenocarcinoma GS of 6.
p870
sg4
(lp871
(dp872
g9
I46
sg20
VP15104
p873
sg12
I17
sg13
Vadenocarcinoma GS
p874
sg15
I2
sasg6
(lp875
(dp876
g9
I46
sg10
VC0001418
p877
sg12
I14
sg13
Vadenocarcinoma
p878
sg15
I1
sasa(dp879
g2
VAR was expressed by 54% (27/50) of ECA including 60% of low grade endometrioid carcinomas, 70% high grade endometrioid carcinomas, 70% serous carcinomas, 50% carcinosarcomas, and 20% clear cell carcinomas.
p880
sg4
(lp881
sg6
(lp882
(dp883
g9
I79
sg10
VC0007097
p884
sg12
I10
sg13
Vcarcinomas
p885
sg15
I1
sa(dp886
g9
I66
sg10
VC0206687
p887
sg12
I23
sg13
Vendometrioid carcinomas
p888
sg15
I2
sa(dp889
g9
I79
sg10
VC0007097
p890
sg12
I10
sg13
Vcarcinomas
p891
sg15
I1
sa(dp892
g9
I158
sg10
VC0007140
p893
sg12
I15
sg13
Vcarcinosarcomas
p894
sg15
I1
sa(dp895
g9
I66
sg10
VC0206687
p896
sg12
I23
sg13
Vendometrioid carcinomas
p897
sg15
I2
sasa(dp898
g2
VHigh AR expression was chiefly restricted to a subset of serous carcinomas (50%).
p899
sg4
(lp900
sg6
(lp901
(dp902
g9
I64
sg10
VC0007097
p903
sg12
I10
sg13
Vcarcinomas
p904
sg15
I1
sasa(dp905
g2
VAR expression occurred most often in concert with ER staining, although 5 high grade cancers (1 serous carcinoma, 4 carcinosarcomas) showed AR expression in the absence of ER.
p906
sg4
(lp907
sg6
(lp908
(dp909
g9
I85
sg10
VC0006826
p910
sg12
I7
sg13
Vcancers
p911
sg15
I1
sa(dp912
g9
I116
sg10
VC0007140
p913
sg12
I15
sg13
Vcarcinosarcomas
p914
sg15
I1
sa(dp915
g9
I96
sg10
VC0206701
p916
sg12
I16
sg13
Vserous carcinoma
p917
sg15
I2
sasa(dp918
g2
VIn summary, AR positivity is seen in over half of ECA in our study, including the majority of low grade endometrioid carcinomas, high grade endometrioid carcinomas, and serous carcinomas.
p919
sg4
(lp920
sg6
(lp921
(dp922
g9
I104
sg10
VC0206687
p923
sg12
I23
sg13
Vendometrioid carcinomas
p924
sg15
I2
sa(dp925
g9
I117
sg10
VC0007097
p926
sg12
I10
sg13
Vcarcinomas
p927
sg15
I1
sa(dp928
g9
I104
sg10
VC0206687
p929
sg12
I23
sg13
Vendometrioid carcinomas
p930
sg15
I2
sasa(dp931
g2
VHigh level expression is seen in half of serous carcinomas and a subset of serous carcinomas and carcinosarcomas show some degree of AR staining in the absence of ER, suggesting a possible role for androgen inhibition in treatment of these cases.
p932
sg4
(lp933
sg6
(lp934
(dp935
g9
I48
sg10
VC0007097
p936
sg12
I10
sg13
Vcarcinomas
p937
sg15
I1
sa(dp938
g9
I97
sg10
VC0007140
p939
sg12
I15
sg13
Vcarcinosarcomas
p940
sg15
I1
sa(dp941
g9
I48
sg10
VC0007097
p942
sg12
I10
sg13
Vcarcinomas
p943
sg15
I1
sasa(dp944
g2
VIL-6 and the MSC markers CD166 and nestin were colocalized in macroscopically normal human cartilage taken from the lateral femoral compartment of knees with medial tibiofemoral osteoarthritis.
p945
sg4
(lp946
(dp947
g9
I35
sg20
VP48681
p948
sg12
I6
sg13
Vnestin
p949
sg15
I1
sa(dp950
g9
I25
sg20
g21
sg12
I5
sg13
VCD166
p951
sg15
I1
sa(dp952
g9
I13
sg20
g21
sg12
I3
sg13
VMSC
p953
sg15
I1
sa(dp954
g9
I0
sg20
VP05231
p955
sg12
I4
sg13
VIL-6
p956
sg15
I1
sasg6
(lp957
(dp958
g9
I178
sg10
VC0029408
p959
sg12
I14
sg13
Vosteoarthritis
p960
sg15
I1
sasa(dp961
g2
VIn conclusion, our findings support a model where Sirt3 plays a protective role against oxidative stress in oocytes exposed to maternal diabetes through deacetylating SOD2K68.
p962
sg4
(lp963
(dp964
g9
I50
sg20
g21
sg12
I5
sg13
VSirt3
p965
sg15
I1
sasg6
(lp966
(dp967
g9
I127
sg10
VC0085207
p968
sg12
I17
sg13
Vmaternal diabetes
p969
sg15
I2
sa(dp970
g9
I88
sg10
VC0242606
p971
sg12
I16
sg13
Voxidative stress
p972
sg15
I2
sasa(dp973
g2
VThe aim of our study was to investigate the effects of LPL (rs320), LIPC (rs2070895), SCARB1 (rs5888), LCAT (rs2292318), CETP (rs708272), ADIPOQ (rs1501299), RETN (rs3745367), PON1 (rs662), and MNSOD (rs4880) gene polymorphisms on lipid metabolism and diabetic dyslipidemia.
p974
sg4
(lp975
(dp976
g9
I55
sg20
VP06858
p977
sg12
I3
sg13
VLPL
p978
sg15
I1
sa(dp979
g9
I194
sg20
VP04179
p980
sg12
I5
sg13
VMNSOD
p981
sg15
I1
sa(dp982
g9
I121
sg20
VP11597
p983
sg12
I4
sg13
VCETP
p984
sg15
I1
sa(dp985
g9
I86
sg20
g21
sg12
I6
sg13
VSCARB1
p986
sg15
I1
sa(dp987
g9
I158
sg20
g21
sg12
I4
sg13
VRETN
p988
sg15
I1
sa(dp989
g9
I68
sg20
VP11150
p990
sg12
I16
sg13
VLIPC (rs2070895)
p991
sg15
I2
sa(dp992
g9
I176
sg20
VP27169
p993
sg12
I4
sg13
VPON1
p994
sg15
I1
sasg6
(lp995
(dp996
g9
I252
sg10
VC3160761
p997
sg12
I21
sg13
Vdiabetic dyslipidemia
p998
sg15
I2
sasa(dp999
g2
VSignificant associations were observed between LPL (rs320) (p&lt;0.001), LIPC (rs2070895) (p&lt;0.001), SCARB1 (rs5888) (p&lt;0.001), LCAT (rs2292318) (p&lt;0.001), CETP (rs708272) (p&lt;0.001), ADIPOQ (rs1501299) (p=0.01), RETN (rs3745367) (p&lt;0.001), and MNSOD (rs4880) (p&lt;0.001) polymorphisms and diabetic dyslipidemia.
p1000
sg4
(lp1001
(dp1002
g9
I73
sg20
VP11150
p1003
sg12
I4
sg13
VLIPC
p1004
sg15
I1
sa(dp1005
g9
I47
sg20
VP06858
p1006
sg12
I3
sg13
VLPL
p1007
sg15
I1
sa(dp1008
g9
I104
sg20
g21
sg12
I6
sg13
VSCARB1
p1009
sg15
I1
sa(dp1010
g9
I259
sg20
VP04179
p1011
sg12
I5
sg13
VMNSOD
p1012
sg15
I1
sa(dp1013
g9
I165
sg20
VP11597
p1014
sg12
I4
sg13
VCETP
p1015
sg15
I1
sa(dp1016
g9
I224
sg20
g21
sg12
I4
sg13
VRETN
p1017
sg15
I1
sasg6
(lp1018
(dp1019
g9
I305
sg10
VC3160761
p1020
sg12
I21
sg13
Vdiabetic dyslipidemia
p1021
sg15
I2
sasa(dp1022
g2
VLPL (rs320), LIPC (rs2070895), SCARB1 (rs5888), LCAT (rs2292318), CETP (rs708272), ADIPOQ (rs1501299), RETN (rs3745367), and MNSOD (rs4880) polymorphisms play an important role in basic molecular metabolism in diabetic dyslipidemia.
p1023
sg4
(lp1024
(dp1025
g9
I31
sg20
g21
sg12
I6
sg13
VSCARB1
p1026
sg15
I1
sa(dp1027
g9
I13
sg20
VP11150
p1028
sg12
I16
sg13
VLIPC (rs2070895)
p1029
sg15
I2
sa(dp1030
g9
I103
sg20
g21
sg12
I4
sg13
VRETN
p1031
sg15
I1
sa(dp1032
g9
I0
sg20
VP06858
p1033
sg12
I3
sg13
VLPL
p1034
sg15
I1
sa(dp1035
g9
I66
sg20
VP11597
p1036
sg12
I4
sg13
VCETP
p1037
sg15
I1
sa(dp1038
g9
I125
sg20
VP04179
p1039
sg12
I5
sg13
VMNSOD
p1040
sg15
I1
sasg6
(lp1041
(dp1042
g9
I210
sg10
VC3160761
p1043
sg12
I21
sg13
Vdiabetic dyslipidemia
p1044
sg15
I2
sasa(dp1045
g2
VWe studied if YKL-40 is related to inflammation, fibrosis, and/or lung function in subjects exposed to asbestosis.
p1046
sg4
(lp1047
sg6
(lp1048
(dp1049
g9
I35
sg10
VC0021368
p1050
sg12
I12
sg13
Vinflammation
p1051
sg15
I1
sa(dp1052
g9
I103
sg10
VC0003949
p1053
sg12
I10
sg13
Vasbestosis
p1054
sg15
I1
sa(dp1055
g9
I49
sg10
VC0016059
p1056
sg12
I8
sg13
Vfibrosis
p1057
sg15
I1
sasa(dp1058
g2
VPlasma YKL-40 levels were significantly higher in subjects with asbestosis (n = 19) than in those with no fibrotic findings in HRCT following asbestos exposure (n = 66) or in unexposed healthy controls.
p1059
sg4
(lp1060
(dp1061
g9
I0
sg20
VP36222
p1062
sg12
I13
sg13
VPlasma YKL-40
p1063
sg15
I2
sasg6
(lp1064
(dp1065
g9
I64
sg10
VC0003949
p1066
sg12
I10
sg13
Vasbestosis
p1067
sg15
I1
sasa(dp1068
g2
VYKL-40 is a promising marker of cardiovascular disease and liver siderosis in Beta-TM patients.
p1069
sg4
(lp1070
(dp1071
g9
I0
sg20
VP36222
p1072
sg12
I6
sg13
VYKL-40
p1073
sg15
I1
sasg6
(lp1074
(dp1075
g9
I65
sg10
VC0037061
p1076
sg12
I9
sg13
Vsiderosis
p1077
sg15
I1
sa(dp1078
g9
I32
sg10
VC0007222
p1079
sg12
I22
sg13
Vcardiovascular disease
p1080
sg15
I2
sasa(dp1081
g2
VThe aim of the study was to analyse the level of serum YKL-40 and plasma chitotriosidase activity of patients with beta-thalassemia to assess whether their expression correlates with liver disease and degree of liver siderosis.
p1082
sg4
(lp1083
(dp1084
g9
I49
sg20
VP36222
p1085
sg12
I12
sg13
Vserum YKL-40
p1086
sg15
I2
sa(dp1087
g9
I66
sg20
g21
sg12
I22
sg13
Vplasma chitotriosidase
p1088
sg15
I2
sasg6
(lp1089
(dp1090
g9
I115
sg10
VC0005283
p1091
sg12
I16
sg13
Vbeta-thalassemia
p1092
sg15
I1
sa(dp1093
g9
I217
sg10
VC0037061
p1094
sg12
I9
sg13
Vsiderosis
p1095
sg15
I1
sa(dp1096
g9
I183
sg10
VC0023895
p1097
sg12
I13
sg13
Vliver disease
p1098
sg15
I2
sasa(dp1099
g2
VOur results demonstrated that (1) Invasive ductal carcinoma patients with low expression of Slit2 or Robo1 exhibited worse prognosis and brain-specific metastasis, but not liver, bone or lung.
p1100
sg4
(lp1101
(dp1102
g9
I101
sg20
g21
sg12
I5
sg13
VRobo1
p1103
sg15
I1
sa(dp1104
g9
I92
sg20
g21
sg12
I5
sg13
VSlit2
p1105
sg15
I1
sasg6
(lp1106
(dp1107
g9
I152
sg10
VC0027627
p1108
sg12
I10
sg13
Vmetastasis
p1109
sg15
I1
sa(dp1110
g9
I34
sg10
VC1134719
p1111
sg12
I25
sg13
VInvasive ductal carcinoma
p1112
sg15
I3
sasa(dp1113
g2
VTen prognostic and diagnostic epigenetic breast cancer biomarkers (PITX2, RASSF1A, PLAU, LHX3, PITX3, LIMK1, SLITRK1, SLIT2, HS3ST2, and TFF1) were analyzed in tissue samples obtained from two patients with invasive ductal carcinoma of the breast.
p1114
sg4
(lp1115
(dp1116
g9
I102
sg20
VP53667
p1117
sg12
I5
sg13
VLIMK1
p1118
sg15
I1
sa(dp1119
g9
I137
sg20
VP04155
p1120
sg12
I4
sg13
VTFF1
p1121
sg15
I1
sa(dp1122
g9
I125
sg20
g21
sg12
I6
sg13
VHS3ST2
p1123
sg15
I1
sa(dp1124
g9
I83
sg20
VP00749
p1125
sg12
I4
sg13
VPLAU
p1126
sg15
I1
sa(dp1127
g9
I109
sg20
g21
sg12
I7
sg13
VSLITRK1
p1128
sg15
I1
sa(dp1129
g9
I89
sg20
g21
sg12
I4
sg13
VLHX3
p1130
sg15
I1
sa(dp1131
g9
I67
sg20
g21
sg12
I5
sg13
VPITX2
p1132
sg15
I1
sa(dp1133
g9
I118
sg20
g21
sg12
I5
sg13
VSLIT2
p1134
sg15
I1
sa(dp1135
g9
I95
sg20
g21
sg12
I5
sg13
VPITX3
p1136
sg15
I1
sasg6
(lp1137
(dp1138
g9
I41
sg10
VC0678222
p1139
sg12
I13
sg13
Vbreast cancer
p1140
sg15
I2
sa(dp1141
g9
I207
sg10
VC1134719
p1142
sg12
I39
sg13
Vinvasive ductal carcinoma of the breast
p1143
sg15
I6
sasa(dp1144
g2
VThe aim of this study is to determine the correlation between methylation status of multiple cancer genes, p16(INK4A), p14(ARF), Cyclin D2 and Slit2 in invasive ductal carcinoma of the breast and paired serum DNA and clinicopathological parameters.
p1145
sg4
(lp1146
(dp1147
g9
I119
sg20
VP03971
p1148
sg12
I3
sg13
Vp14
p1149
sg15
I1
sa(dp1150
g9
I129
sg20
VP30279
p1151
sg12
I9
sg13
VCyclin D2
p1152
sg15
I2
sa(dp1153
g9
I107
sg20
VP42771
p1154
sg12
I3
sg13
Vp16
p1155
sg15
I1
sa(dp1156
g9
I123
sg20
VP42771
p1157
sg12
I3
sg13
VARF
p1158
sg15
I1
sa(dp1159
g9
I143
sg20
g21
sg12
I5
sg13
VSlit2
p1160
sg15
I1
sa(dp1161
g9
I111
sg20
VP42771
p1162
sg12
I5
sg13
VINK4A
p1163
sg15
I1
sasg6
(lp1164
(dp1165
g9
I123
sg10
VC0264490
p1166
sg12
I3
sg13
VARF
p1167
sg15
I1
sa(dp1168
g9
I152
sg10
VC1134719
p1169
sg12
I39
sg13
Vinvasive ductal carcinoma of the breast
p1170
sg15
I6
sa(dp1171
g9
I84
sg10
VC0346429
p1172
sg12
I15
sg13
Vmultiple cancer
p1173
sg15
I2
sasa(dp1174
g2
VTo examine the role of IRS2 in allergic disease, we evaluated the responses of IRS2-deficient (IRS2(-/-)) mice.
p1175
sg4
(lp1176
(dp1177
g9
I23
sg20
g21
sg12
I4
sg13
VIRS2
p1178
sg15
I1
sa(dp1179
g9
I23
sg20
g21
sg12
I4
sg13
VIRS2
p1180
sg15
I1
sa(dp1181
g9
I23
sg20
g21
sg12
I4
sg13
VIRS2
p1182
sg15
I1
sasg6
(lp1183
sa(dp1184
g2
VAdditional work further confirmed CDK6, RICTOR, and CTSB (cathepsin B) as targets of miR-218 and examined the functional role of one of these targets, CDK6, in medulloblastoma.
p1185
sg4
(lp1186
(dp1187
g9
I34
sg20
g21
sg12
I4
sg13
VCDK6
p1188
sg15
I1
sa(dp1189
g9
I34
sg20
g21
sg12
I4
sg13
VCDK6
p1190
sg15
I1
sa(dp1191
g9
I40
sg20
g21
sg12
I6
sg13
VRICTOR
p1192
sg15
I1
sasg6
(lp1193
(dp1194
g9
I160
sg10
VC0025149
p1195
sg12
I15
sg13
Vmedulloblastoma
p1196
sg15
I1
sasa(dp1197
g2
VOverexpression of CDK6 is present in approximately one-third of medulloblastomas and is an independent poor prognostic marker for this disease.
p1198
sg4
(lp1199
(dp1200
g9
I18
sg20
g21
sg12
I4
sg13
VCDK6
p1201
sg15
I1
sasg6
(lp1202
(dp1203
g9
I64
sg10
VC0025149
p1204
sg12
I16
sg13
Vmedulloblastomas
p1205
sg15
I1
sasa(dp1206
g2
VMicroRNA (miR)-124 inhibits expression of CDK6 and prevents proliferation of glioblastoma and medulloblastoma cells in vitro.
p1207
sg4
(lp1208
(dp1209
g9
I42
sg20
g21
sg12
I4
sg13
VCDK6
p1210
sg15
I1
sasg6
(lp1211
(dp1212
g9
I94
sg10
VC0025149
p1213
sg12
I15
sg13
Vmedulloblastoma
p1214
sg15
I1
sa(dp1215
g9
I77
sg10
VC0017636
p1216
sg12
I12
sg13
Vglioblastoma
p1217
sg15
I1
sa(dp1218
g9
I60
sg10
VC0334094
p1219
sg12
I13
sg13
Vproliferation
p1220
sg15
I1
sasa(dp1221
g2
VWe examined the effects of miR-124 overexpression on medulloblastoma cells both in vitro and in vivo and compared cell lines that have low and high CDK6 expression.
p1222
sg4
(lp1223
(dp1224
g9
I148
sg20
g21
sg12
I4
sg13
VCDK6
p1225
sg15
I1
sasg6
(lp1226
(dp1227
g9
I53
sg10
VC0025149
p1228
sg12
I15
sg13
Vmedulloblastoma
p1229
sg15
I1
sasa(dp1230
g2
VMiR-124 overexpression inhibits the proliferation of medulloblastoma cells, and this effect is mediated mostly through the action of miR-124 upon CDK6.
p1231
sg4
(lp1232
(dp1233
g9
I133
sg20
g21
sg12
I7
sg13
VmiR-124
p1234
sg15
I1
sa(dp1235
g9
I0
sg20
g21
sg12
I3
sg13
VMiR
p1236
sg15
I1
sa(dp1237
g9
I146
sg20
g21
sg12
I4
sg13
VCDK6
p1238
sg15
I1
sasg6
(lp1239
(dp1240
g9
I53
sg10
VC0025149
p1241
sg12
I15
sg13
Vmedulloblastoma
p1242
sg15
I1
sa(dp1243
g9
I36
sg10
VC0334094
p1244
sg12
I13
sg13
Vproliferation
p1245
sg15
I1
sasa(dp1246
g2
VCDK6 is overexpressed in medulloblastoma patients and is associated with an adverse prognosis.
p1247
sg4
(lp1248
(dp1249
g9
I0
sg20
g21
sg12
I4
sg13
VCDK6
p1250
sg15
I1
sasg6
(lp1251
(dp1252
g9
I25
sg10
VC0025149
p1253
sg12
I15
sg13
Vmedulloblastoma
p1254
sg15
I1
sasa(dp1255
g2
VTo investigate the role of CDK6 in medulloblastoma, we assayed the effect of CDK6 inhibition on proliferation by depleting expression with RNA interference (RNAi) or by inhibiting kinase function with a small molecule inhibitor, PD0332991.
p1256
sg4
(lp1257
(dp1258
g9
I27
sg20
g21
sg12
I4
sg13
VCDK6
p1259
sg15
I1
sa(dp1260
g9
I27
sg20
g21
sg12
I4
sg13
VCDK6
p1261
sg15
I1
sasg6
(lp1262
(dp1263
g9
I35
sg10
VC0025149
p1264
sg12
I15
sg13
Vmedulloblastoma
p1265
sg15
I1
sa(dp1266
g9
I96
sg10
VC0334094
p1267
sg12
I13
sg13
Vproliferation
p1268
sg15
I1
sasa(dp1269
g2
VGene expression analysis revealed that CDK6 mRNA expression is higher than normal cerebellum in fifteen out of sixteen medulloblastoma patient samples.
p1270
sg4
(lp1271
(dp1272
g9
I39
sg20
g21
sg12
I9
sg13
VCDK6 mRNA
p1273
sg15
I2
sasg6
(lp1274
(dp1275
g9
I119
sg10
VC0025149
p1276
sg12
I15
sg13
Vmedulloblastoma
p1277
sg15
I1
sasa(dp1278
g2
VInhibition of CDK6 by RNAi significantly decreased medulloblastoma cell proliferation and colony forming potential.
p1279
sg4
(lp1280
(dp1281
g9
I14
sg20
g21
sg12
I4
sg13
VCDK6
p1282
sg15
I1
sasg6
(lp1283
(dp1284
g9
I51
sg10
VC0025149
p1285
sg12
I15
sg13
Vmedulloblastoma
p1286
sg15
I1
sa(dp1287
g9
I72
sg10
VC0334094
p1288
sg12
I13
sg13
Vproliferation
p1289
sg15
I1
sasa(dp1290
g2
VOur findings suggest that targeting CDK6 with small molecule inhibitors may prove beneficial in the treatment of medulloblastoma, especially when combined with radiation.
p1291
sg4
(lp1292
(dp1293
g9
I36
sg20
g21
sg12
I4
sg13
VCDK6
p1294
sg15
I1
sasg6
(lp1295
(dp1296
g9
I113
sg10
VC0025149
p1297
sg12
I15
sg13
Vmedulloblastoma
p1298
sg15
I1
sasa(dp1299
g2
VIn trichoblastic fibroma (three cases), CK1/5/10/14, CK7, CK8/18, CK10/11, CK14, CK17 and CK19 were expressed in the basaloid nests, and CK6 and involucrin were detected in the inner layers of keratinous cysts.
p1300
sg4
(lp1301
(dp1302
g9
I75
sg20
VP02533
p1303
sg12
I4
sg13
VCK14
p1304
sg15
I1
sa(dp1305
g9
I145
sg20
VP07476
p1306
sg12
I10
sg13
Vinvolucrin
p1307
sg15
I1
sa(dp1308
g9
I66
sg20
VP13645
p1309
sg12
I7
sg13
VCK10/11
p1310
sg15
I1
sa(dp1311
g9
I53
sg20
VP08729
p1312
sg12
I3
sg13
VCK7
p1313
sg15
I1
sa(dp1314
g9
I40
sg20
VP48729
p1315
sg12
I11
sg13
VCK1/5/10/14
p1316
sg15
I1
sasg6
(lp1317
(dp1318
g9
I3
sg10
VC1704236
p1319
sg12
I21
sg13
Vtrichoblastic fibroma
p1320
sg15
I2
sa(dp1321
g9
I204
sg10
VC0010709
p1322
sg12
I5
sg13
Vcysts
p1323
sg15
I1
sasa(dp1324
g2
VSince type 1 diabetes mellitus often begins in childhood, we used juvenile (4- to 5-wk-old) rats to demonstrate that a single bout of IIH (5 U/kg sc) reduced plasma glucose by 24% and peak epinephrine by 59% 1 day later.
p1325
sg4
(lp1326
sg6
(lp1327
(dp1328
g9
I6
sg10
VC0011854
p1329
sg12
I24
sg13
Vtype 1 diabetes mellitus
p1330
sg15
I4
sasa(dp1331
g2
VPlasma membrane NADH oxidoreductase activity, studied using cytosolic NADH as substrate and assayed with DCIP as acceptor, was significantly increased in IDDM patients, suggesting a response to a deficient mitochondrial energetic activity.
p1332
sg4
(lp1333
(dp1334
g9
I60
sg20
VP0C870
p1335
sg12
I14
sg13
Vcytosolic NADH
p1336
sg15
I2
sa(dp1337
g9
I0
sg20
VP28331
p1338
sg12
I35
sg13
VPlasma membrane NADH oxidoreductase
p1339
sg15
I4
sasg6
(lp1340
(dp1341
g9
I154
sg10
VC0011854
p1342
sg12
I4
sg13
VIDDM
p1343
sg15
I1
sasa(dp1344
g2
VNon insulin-dependent diabetic (NIDDM) mortality is 1.4 to 3.7 times that of non-diabetics.
p1345
sg4
(lp1346
(dp1347
g9
I4
sg20
VP01308
p1348
sg12
I7
sg13
Vinsulin
p1349
sg15
I1
sasg6
(lp1350
(dp1351
g9
I32
sg10
VC0011860
p1352
sg12
I5
sg13
VNIDDM
p1353
sg15
I1
sasa(dp1354
g2
VIn the COPD and asthma patients, the median urinary cotinine concentration was 167 ng/mL (range, 2-5,348 ng/mL) and 47 ng/mL (range, 5-2,735 ng/mL), respectively (p &lt; 0.0001), whereas the median eCO level was 8 ppm (range, 0-31 ppm) and 5 ppm (range, 2-45 ppm), respectively (p &lt; 0.05).
p1355
sg4
(lp1356
(dp1357
g9
I198
sg20
g21
sg12
I3
sg13
VeCO
p1358
sg15
I1
sasg6
(lp1359
(dp1360
g9
I16
sg10
VC0004096
p1361
sg12
I6
sg13
Vasthma
p1362
sg15
I1
sa(dp1363
g9
I198
sg10
VC2675227
p1364
sg12
I3
sg13
VeCO
p1365
sg15
I1
sa(dp1366
g9
I7
sg10
VC0024117
p1367
sg12
I4
sg13
VCOPD
p1368
sg15
I1
sasa(dp1369
g2
VIn 30 (29%) of the patients with asthma or COPD, the urinary cotinine concentration and the eCO level both belied the patient claims of not being current smokers.
p1370
sg4
(lp1371
(dp1372
g9
I92
sg20
g21
sg12
I3
sg13
VeCO
p1373
sg15
I1
sasg6
(lp1374
(dp1375
g9
I43
sg10
VC0024117
p1376
sg12
I4
sg13
VCOPD
p1377
sg15
I1
sa(dp1378
g9
I33
sg10
VC0004096
p1379
sg12
I6
sg13
Vasthma
p1380
sg15
I1
sa(dp1381
g9
I92
sg10
VC2675227
p1382
sg12
I3
sg13
VeCO
p1383
sg15
I1
sasa(dp1384
g2
VWe aimed to study eCO levels in asthmatics and detect the possible factors influencing them.
p1385
sg4
(lp1386
sg6
(lp1387
(dp1388
g9
I18
sg10
VC2675227
p1389
sg12
I3
sg13
VeCO
p1390
sg15
I1
sa(dp1391
g9
I32
sg10
VC0004096
p1392
sg12
I10
sg13
Vasthmatics
p1393
sg15
I1
sasa(dp1394
g2
VThe differences in eCO levels among various asthmatic phenotypes and the correlations between eCO and other measured parameters (spirometric indices, Asthma Control Test score, exhaled nitric oxide, total IgE, blood eosinophils and marker of oxidative damage of proteins) were analysed.
p1395
sg4
(lp1396
(dp1397
g9
I19
sg20
g21
sg12
I3
sg13
VeCO
p1398
sg15
I1
sa(dp1399
g9
I19
sg20
g21
sg12
I3
sg13
VeCO
p1400
sg15
I1
sa(dp1401
g9
I205
sg20
VP01854
p1402
sg12
I3
sg13
VIgE
p1403
sg15
I1
sasg6
(lp1404
(dp1405
g9
I19
sg10
VC2675227
p1406
sg12
I3
sg13
VeCO
p1407
sg15
I1
sa(dp1408
g9
I44
sg10
VC0004096
p1409
sg12
I9
sg13
Vasthmatic
p1410
sg15
I1
sa(dp1411
g9
I19
sg10
VC2675227
p1412
sg12
I3
sg13
VeCO
p1413
sg15
I1
sa(dp1414
g9
I150
sg10
VC0004096
p1415
sg12
I6
sg13
VAsthma
p1416
sg15
I1
sa(dp1417
g9
I205
sg10
VC0270850
p1418
sg12
I3
sg13
VIgE
p1419
sg15
I1
sasa(dp1420
g2
VLevels of eCO widely differed according to the selected characteristics of asthma.
p1421
sg4
(lp1422
sg6
(lp1423
(dp1424
g9
I10
sg10
VC2675227
p1425
sg12
I3
sg13
VeCO
p1426
sg15
I1
sa(dp1427
g9
I75
sg10
VC0004096
p1428
sg12
I6
sg13
Vasthma
p1429
sg15
I1
sasa(dp1430
g2
VAsthmatics showed higher eCO concentrations than controls (1.44 +/- 0.12 ppm vs. 0.91 +/- 0.11 ppm, p &lt; 0.001).
p1431
sg4
(lp1432
(dp1433
g9
I25
sg20
g21
sg12
I3
sg13
VeCO
p1434
sg15
I1
sasg6
(lp1435
(dp1436
g9
I0
sg10
VC0004096
p1437
sg12
I10
sg13
VAsthmatics
p1438
sg15
I1
sa(dp1439
g9
I25
sg10
VC2675227
p1440
sg12
I3
sg13
VeCO
p1441
sg15
I1
sasa(dp1442
g2
VAcute exacerbation of asthma was accompanied by a significant increase in eCO compared to the clinically controlled stage (2.17 +/- 0.36 ppm vs. 1.33 +/- 0.13 ppm, p &lt; 0.001).
p1443
sg4
(lp1444
sg6
(lp1445
(dp1446
g9
I74
sg10
VC2675227
p1447
sg12
I3
sg13
VeCO
p1448
sg15
I1
sa(dp1449
g9
I22
sg10
VC0004096
p1450
sg12
I6
sg13
Vasthma
p1451
sg15
I1
sasa(dp1452
g2
VAtopic, non-atopic asthma and asthma associated with allergic rhinitis (AR) showed elevated levels of eCO.
p1453
sg4
(lp1454
(dp1455
g9
I53
sg20
g21
sg12
I22
sg13
Vallergic rhinitis (AR)
p1456
sg15
I3
sa(dp1457
g9
I102
sg20
g21
sg12
I3
sg13
VeCO
p1458
sg15
I1
sasg6
(lp1459
(dp1460
g9
I12
sg10
VC0155877
p1461
sg12
I13
sg13
Vatopic asthma
p1462
sg15
I2
sa(dp1463
g9
I53
sg10
VC2607914
p1464
sg12
I17
sg13
Vallergic rhinitis
p1465
sg15
I2
sa(dp1466
g9
I19
sg10
VC0004096
p1467
sg12
I6
sg13
Vasthma
p1468
sg15
I1
sa(dp1469
g9
I102
sg10
VC2675227
p1470
sg12
I3
sg13
VeCO
p1471
sg15
I1
sa(dp1472
g9
I72
sg10
VC2607914
p1473
sg12
I2
sg13
VAR
p1474
sg15
I1
sa(dp1475
g9
I0
sg10
VC0392707
p1476
sg12
I6
sg13
VAtopic
p1477
sg15
I1
sasa(dp1478
g2
VThe levels of eCO negatively correlated with the marker of protein oxidation in asthmatics, especially in atopic form and during acute exacerbation.
p1479
sg4
(lp1480
(dp1481
g9
I14
sg20
g21
sg12
I3
sg13
VeCO
p1482
sg15
I1
sasg6
(lp1483
(dp1484
g9
I14
sg10
VC2675227
p1485
sg12
I3
sg13
VeCO
p1486
sg15
I1
sa(dp1487
g9
I80
sg10
VC0004096
p1488
sg12
I10
sg13
Vasthmatics
p1489
sg15
I1
sa(dp1490
g9
I106
sg10
VC0392707
p1491
sg12
I6
sg13
Vatopic
p1492
sg15
I1
sasa(dp1493
g2
VIn a population of asthmatic children, eCO levels could be considered as a marker of both allergic inflammation and oxidative stress in the airways.
p1494
sg4
(lp1495
(dp1496
g9
I39
sg20
g21
sg12
I3
sg13
VeCO
p1497
sg15
I1
sasg6
(lp1498
(dp1499
g9
I90
sg10
VC0021375
p1500
sg12
I21
sg13
Vallergic inflammation
p1501
sg15
I2
sa(dp1502
g9
I116
sg10
VC0242606
p1503
sg12
I16
sg13
Voxidative stress
p1504
sg15
I2
sa(dp1505
g9
I39
sg10
VC2675227
p1506
sg12
I3
sg13
VeCO
p1507
sg15
I1
sa(dp1508
g9
I19
sg10
VC0004096
p1509
sg12
I9
sg13
Vasthmatic
p1510
sg15
I1
sasa(dp1511
g2
VConcomitant AR and asthma control were the most important factors affecting the levels of eCO in asthmatic children.
p1512
sg4
(lp1513
(dp1514
g9
I90
sg20
g21
sg12
I3
sg13
VeCO
p1515
sg15
I1
sasg6
(lp1516
(dp1517
g9
I97
sg10
VC0004096
p1518
sg12
I9
sg13
Vasthmatic
p1519
sg15
I1
sa(dp1520
g9
I90
sg10
VC2675227
p1521
sg12
I3
sg13
VeCO
p1522
sg15
I1
sa(dp1523
g9
I19
sg10
VC0004096
p1524
sg12
I6
sg13
Vasthma
p1525
sg15
I1
sasa(dp1526
g2
VeCO values have been evaluated as potential indicators of inflammation in asthma, stable COPD and exacerbations, cystic fibrosis, lung cancer, or during surgery or critical care.
p1527
sg4
(lp1528
(dp1529
g9
I0
sg20
g21
sg12
I3
sg13
VeCO
p1530
sg15
I1
sasg6
(lp1531
(dp1532
g9
I0
sg10
VC2675227
p1533
sg12
I3
sg13
VeCO
p1534
sg15
I1
sa(dp1535
g9
I58
sg10
VC0021368
p1536
sg12
I12
sg13
Vinflammation
p1537
sg15
I1
sa(dp1538
g9
I113
sg10
VC0010674
p1539
sg12
I15
sg13
Vcystic fibrosis
p1540
sg15
I2
sa(dp1541
g9
I74
sg10
VC0004096
p1542
sg12
I6
sg13
Vasthma
p1543
sg15
I1
sa(dp1544
g9
I130
sg10
VC0684249
p1545
sg12
I11
sg13
Vlung cancer
p1546
sg15
I2
sa(dp1547
g9
I89
sg10
VC0024117
p1548
sg12
I4
sg13
VCOPD
p1549
sg15
I1
sasa(dp1550
g2
VTwenty-four non-smokers (10 male, 14 female, mean age 17.6 years) and 24 smokers (mean of 3.5 pack-years; 15 male, 9 female, mean age 17.8 years) were compared in terms of lung function, bronchial hyperreactivity (BHR), levels of exhaled carbon monoxide (eCO), exhaled nitric oxide (eNO), and blood counts.
p1551
sg4
(lp1552
sg6
(lp1553
(dp1554
g9
I214
sg10
VC0085129
p1555
sg12
I3
sg13
VBHR
p1556
sg15
I1
sa(dp1557
g9
I255
sg10
VC2675227
p1558
sg12
I3
sg13
VeCO
p1559
sg15
I1
sa(dp1560
g9
I187
sg10
VC0085129
p1561
sg12
I25
sg13
Vbronchial hyperreactivity
p1562
sg15
I2
sa(dp1563
g9
I230
sg10
VC2675227
p1564
sg12
I23
sg13
Vexhaled carbon monoxide
p1565
sg15
I3
sasa(dp1566
g2
VThe concentration of exhaled carbon monoxide (eCO) in young children with stable asthma and during acute asthma attack is not known.
p1567
sg4
(lp1568
sg6
(lp1569
(dp1570
g9
I46
sg10
VC2675227
p1571
sg12
I3
sg13
VeCO
p1572
sg15
I1
sa(dp1573
g9
I21
sg10
VC2675227
p1574
sg12
I23
sg13
Vexhaled carbon monoxide
p1575
sg15
I3
sa(dp1576
g9
I105
sg10
VC0347950
p1577
sg12
I13
sg13
Vasthma attack
p1578
sg15
I2
sa(dp1579
g9
I81
sg10
VC0004096
p1580
sg12
I6
sg13
Vasthma
p1581
sg15
I1
sasa(dp1582
g2
VIn preschool-age children, eCO levels of those with asthma attacks (mean +/- SE, 2.7 +/- 0.3 p.p.m., n= 43) were significantly higher than those of subjects with asymptomatic asthma (0.5 +/- 0.1 p.p.m., P &lt; 0.05), URI (0.8 +/- 0.1 p.p.m., P &lt; 0.05) and healthy children (0.4 +/- 0.1 p.p.m., P &lt; 0.05).
p1583
sg4
(lp1584
(dp1585
g9
I27
sg20
g21
sg12
I3
sg13
VeCO
p1586
sg15
I1
sasg6
(lp1587
(dp1588
g9
I52
sg10
VC0004096
p1589
sg12
I6
sg13
Vasthma
p1590
sg15
I1
sa(dp1591
g9
I27
sg10
VC2675227
p1592
sg12
I3
sg13
VeCO
p1593
sg15
I1
sa(dp1594
g9
I52
sg10
VC0347950
p1595
sg12
I14
sg13
Vasthma attacks
p1596
sg15
I2
sasa(dp1597
g2
VA multivariate linear regression model showed that eCO was higher in children with asthma attacks independent of age and gender.
p1598
sg4
(lp1599
(dp1600
g9
I51
sg20
g21
sg12
I3
sg13
VeCO
p1601
sg15
I1
sasg6
(lp1602
(dp1603
g9
I51
sg10
VC2675227
p1604
sg12
I3
sg13
VeCO
p1605
sg15
I1
sa(dp1606
g9
I83
sg10
VC0347950
p1607
sg12
I14
sg13
Vasthma attacks
p1608
sg15
I2
sasa(dp1609
g2
VIn 33 asthmatic children followed before and after treatment, eCO levels during asthma attacks significantly decreased after inhalation therapy with a combination of salbutamol and sodium cromoglycate (before therapy, 2.9 +/- 0.4 p.p.m.
p1610
sg4
(lp1611
(dp1612
g9
I62
sg20
g21
sg12
I3
sg13
VeCO
p1613
sg15
I1
sasg6
(lp1614
(dp1615
g9
I80
sg10
VC0347950
p1616
sg12
I14
sg13
Vasthma attacks
p1617
sg15
I2
sa(dp1618
g9
I62
sg10
VC2675227
p1619
sg12
I3
sg13
VeCO
p1620
sg15
I1
sa(dp1621
g9
I6
sg10
VC0004096
p1622
sg12
I9
sg13
Vasthmatic
p1623
sg15
I1
sasa(dp1624
g2
VThe measurement of eCO using a novel collecting system is useful in the recognition of asthma in preschool children.
p1625
sg4
(lp1626
(dp1627
g9
I19
sg20
g21
sg12
I3
sg13
VeCO
p1628
sg15
I1
sasg6
(lp1629
(dp1630
g9
I87
sg10
VC0004096
p1631
sg12
I6
sg13
Vasthma
p1632
sg15
I1
sa(dp1633
g9
I19
sg10
VC2675227
p1634
sg12
I3
sg13
VeCO
p1635
sg15
I1
sasa(dp1636
g2
VElevations in E-CO have been observed in critically ill or post-surgical patients and those with various pulmonary diseases associated with inflammation, including chronic obstructive pulmonary disease (COPD), asthma, cystic fibrosis and infections.
p1637
sg4
(lp1638
sg6
(lp1639
(dp1640
g9
I238
sg10
VC0021311
p1641
sg12
I10
sg13
Vinfections
p1642
sg15
I1
sa(dp1643
g9
I164
sg10
VC0024117
p1644
sg12
I37
sg13
Vchronic obstructive pulmonary disease
p1645
sg15
I4
sa(dp1646
g9
I210
sg10
VC0004096
p1647
sg12
I6
sg13
Vasthma
p1648
sg15
I1
sa(dp1649
g9
I203
sg10
VC0024117
p1650
sg12
I4
sg13
VCOPD
p1651
sg15
I1
sa(dp1652
g9
I140
sg10
VC0021368
p1653
sg12
I12
sg13
Vinflammation
p1654
sg15
I1
sa(dp1655
g9
I105
sg10
VC0024115
p1656
sg12
I18
sg13
Vpulmonary diseases
p1657
sg15
I2
sa(dp1658
g9
I218
sg10
VC0010674
p1659
sg12
I15
sg13
Vcystic fibrosis
p1660
sg15
I2
sa(dp1661
g9
I41
sg10
VC0010340
p1662
sg12
I14
sg13
Vcritically ill
p1663
sg15
I2
sasa(dp1664
g2
VThe purpose of this meta-analysis is to determine whether eCO is elevated in asthmatics, is regulated by steroid treatment and reflects disease severity and control.
p1665
sg4
(lp1666
(dp1667
g9
I58
sg20
g21
sg12
I3
sg13
VeCO
p1668
sg15
I1
sasg6
(lp1669
(dp1670
g9
I58
sg10
VC2675227
p1671
sg12
I3
sg13
VeCO
p1672
sg15
I1
sa(dp1673
g9
I77
sg10
VC0004096
p1674
sg12
I10
sg13
Vasthmatics
p1675
sg15
I1
sasa(dp1676
g2
VObservational studies comparing eCO in non-smoking asthmatics and healthy subjects or asthmatics before and after steroid treatment were included.
p1677
sg4
(lp1678
sg6
(lp1679
(dp1680
g9
I32
sg10
VC2675227
p1681
sg12
I3
sg13
VeCO
p1682
sg15
I1
sa(dp1683
g9
I51
sg10
VC0004096
p1684
sg12
I10
sg13
Vasthmatics
p1685
sg15
I1
sa(dp1686
g9
I51
sg10
VC0004096
p1687
sg12
I10
sg13
Vasthmatics
p1688
sg15
I1
sasa(dp1689
g2
VThe eCO level was significantly higher in asthmatics as compared to healthy subjects and in intermittent asthma as compared to persistent asthma.
p1690
sg4
(lp1691
(dp1692
g9
I4
sg20
g21
sg12
I3
sg13
VeCO
p1693
sg15
I1
sasg6
(lp1694
(dp1695
g9
I42
sg10
VC0004096
p1696
sg12
I10
sg13
Vasthmatics
p1697
sg15
I1
sa(dp1698
g9
I92
sg10
VC1740754
p1699
sg12
I19
sg13
Vintermittent asthma
p1700
sg15
I2
sa(dp1701
g9
I4
sg10
VC2675227
p1702
sg12
I3
sg13
VeCO
p1703
sg15
I1
sa(dp1704
g9
I127
sg10
VC3266628
p1705
sg12
I17
sg13
Vpersistent asthma
p1706
sg15
I2
sasa(dp1707
g2
VHowever, eCO could not distinguish between steroid-treated asthmatics and steroid-free patients nor separate controlled and partly-controlled asthma from uncontrolled asthma in cross-sectional studies.
p1708
sg4
(lp1709
(dp1710
g9
I9
sg20
g21
sg12
I3
sg13
VeCO
p1711
sg15
I1
sasg6
(lp1712
(dp1713
g9
I59
sg10
VC0004096
p1714
sg12
I6
sg13
Vasthma
p1715
sg15
I1
sa(dp1716
g9
I9
sg10
VC2675227
p1717
sg12
I3
sg13
VeCO
p1718
sg15
I1
sa(dp1719
g9
I59
sg10
VC0004096
p1720
sg12
I10
sg13
Vasthmatics
p1721
sg15
I1
sa(dp1722
g9
I59
sg10
VC0004096
p1723
sg12
I6
sg13
Vasthma
p1724
sg15
I1
sasa(dp1725
g2
VeCO is elevated in asthmatics but levels only partially reflect disease severity and control.
p1726
sg4
(lp1727
(dp1728
g9
I0
sg20
g21
sg12
I3
sg13
VeCO
p1729
sg15
I1
sasg6
(lp1730
(dp1731
g9
I19
sg10
VC0004096
p1732
sg12
I10
sg13
Vasthmatics
p1733
sg15
I1
sa(dp1734
g9
I0
sg10
VC2675227
p1735
sg12
I3
sg13
VeCO
p1736
sg15
I1
sasa(dp1737
g2
VeCO might be a potentially useful non-invasive biomarker of airway inflammation and oxidative stress in nonsmoking asthmatics.
p1738
sg4
(lp1739
(dp1740
g9
I0
sg20
g21
sg12
I3
sg13
VeCO
p1741
sg15
I1
sasg6
(lp1742
(dp1743
g9
I67
sg10
VC0021368
p1744
sg12
I12
sg13
Vinflammation
p1745
sg15
I1
sa(dp1746
g9
I0
sg10
VC2675227
p1747
sg12
I3
sg13
VeCO
p1748
sg15
I1
sa(dp1749
g9
I115
sg10
VC0004096
p1750
sg12
I10
sg13
Vasthmatics
p1751
sg15
I1
sa(dp1752
g9
I84
sg10
VC0242606
p1753
sg12
I16
sg13
Voxidative stress
p1754
sg15
I2
sasa(dp1755
g2
VHowever, recent studies revealed that genetic inhibition of SphK2 did not significantly impact the severity or progression of inflammatory arthritis, while pharmacologic inhibition of SphK2 led to significantly more severe arthritis.
p1756
sg4
(lp1757
(dp1758
g9
I60
sg20
g21
sg12
I5
sg13
VSphK2
p1759
sg15
I1
sa(dp1760
g9
I60
sg20
g21
sg12
I5
sg13
VSphK2
p1761
sg15
I1
sasg6
(lp1762
(dp1763
g9
I139
sg10
VC0003864
p1764
sg12
I9
sg13
Varthritis
p1765
sg15
I1
sa(dp1766
g9
I126
sg10
VC0003864
p1767
sg12
I22
sg13
Vinflammatory arthritis
p1768
sg15
I2
sasa(dp1769
g2
VTherefore, SphK2 plays a controversial role in arthritis.
p1770
sg4
(lp1771
(dp1772
g9
I11
sg20
g21
sg12
I5
sg13
VSphK2
p1773
sg15
I1
sasg6
(lp1774
(dp1775
g9
I47
sg10
VC0003864
p1776
sg12
I9
sg13
Varthritis
p1777
sg15
I1
sasa(dp1778
g2
VA specific SphK2 inhibitor inhibited inflammatory arthritis in one model, while siRNA knockdown of SphK2 worsened arthritis in another.
p1779
sg4
(lp1780
(dp1781
g9
I11
sg20
g21
sg12
I5
sg13
VSphK2
p1782
sg15
I1
sa(dp1783
g9
I11
sg20
g21
sg12
I5
sg13
VSphK2
p1784
sg15
I1
sasg6
(lp1785
(dp1786
g9
I37
sg10
VC0003864
p1787
sg12
I22
sg13
Vinflammatory arthritis
p1788
sg15
I2
sa(dp1789
g9
I50
sg10
VC0003864
p1790
sg12
I9
sg13
Varthritis
p1791
sg15
I1
sasa(dp1792
g2
VTo investigate the role of SphK2 in TNF-Alfa-induced arthritis, we developed SphK2 deficient hTNF-Alfa overexpressing mice and separately treated hTNF-Alfa mice with ABC294640, a SphK2-specific inhibitor.
p1793
sg4
(lp1794
(dp1795
g9
I27
sg20
g21
sg12
I5
sg13
VSphK2
p1796
sg15
I1
sa(dp1797
g9
I27
sg20
g21
sg12
I5
sg13
VSphK2
p1798
sg15
I1
sa(dp1799
g9
I27
sg20
g21
sg12
I5
sg13
VSphK2
p1800
sg15
I1
sa(dp1801
g9
I36
sg20
VP01375
p1802
sg12
I3
sg13
VTNF
p1803
sg15
I1
sasg6
(lp1804
(dp1805
g9
I53
sg10
VC0003864
p1806
sg12
I9
sg13
Varthritis
p1807
sg15
I1
sasa(dp1808
g2
VOur data show that genetic inhibition of SphK2 did not significantly impact the severity or progression of inflammatory arthritis, while pharmacologic inhibition of SphK2 led to significantly more severe arthritis.
p1809
sg4
(lp1810
(dp1811
g9
I41
sg20
g21
sg12
I5
sg13
VSphK2
p1812
sg15
I1
sa(dp1813
g9
I41
sg20
g21
sg12
I5
sg13
VSphK2
p1814
sg15
I1
sasg6
(lp1815
(dp1816
g9
I107
sg10
VC0003864
p1817
sg12
I22
sg13
Vinflammatory arthritis
p1818
sg15
I2
sa(dp1819
g9
I120
sg10
VC0003864
p1820
sg12
I9
sg13
Varthritis
p1821
sg15
I1
sasa(dp1822
g2
VIn this study, we examined the role of SphK1 and SphK2 in a murine collagen-induced arthritis model by down-regulating each isoenzyme via specific small interfering RNA (siRNA).
p1823
sg4
(lp1824
(dp1825
g9
I39
sg20
g21
sg12
I5
sg13
VSphK1
p1826
sg15
I1
sa(dp1827
g9
I49
sg20
g21
sg12
I5
sg13
VSphK2
p1828
sg15
I1
sasg6
(lp1829
(dp1830
g9
I84
sg10
VC0003864
p1831
sg12
I9
sg13
Varthritis
p1832
sg15
I1
sasa(dp1833
g2
VTogether, these results demonstrate the distinct immunomodulatory roles of SphK1 and SphK2 in the development of inflammatory arthritis by regulating the release of proinflammatory cytokines and T cell responses.
p1834
sg4
(lp1835
(dp1836
g9
I75
sg20
g21
sg12
I5
sg13
VSphK1
p1837
sg15
I1
sa(dp1838
g9
I85
sg20
g21
sg12
I5
sg13
VSphK2
p1839
sg15
I1
sasg6
(lp1840
(dp1841
g9
I113
sg10
VC0003864
p1842
sg12
I22
sg13
Vinflammatory arthritis
p1843
sg15
I2
sasa(dp1844
g2
VPrefrontal Brodmann Areas (BA) BA46, BA47, and BA9 in autism and age-matched controls were analyzed by blinded researchers.
p1845
sg4
(lp1846
sg6
(lp1847
(dp1848
g9
I54
sg10
VC0004352
p1849
sg12
I6
sg13
Vautism
p1850
sg15
I1
sasa(dp1851
g2
VWe show that the number of parvalbumin+ interneurons in these 3 cortical areas-BA46, BA47, and BA9-is significantly reduced in autism compared with controls.
p1852
sg4
(lp1853
(dp1854
g9
I27
sg20
VP20472
p1855
sg12
I12
sg13
Vparvalbumin+
p1856
sg15
I1
sasg6
(lp1857
(dp1858
g9
I127
sg10
VC0004352
p1859
sg12
I6
sg13
Vautism
p1860
sg15
I1
sasa(dp1861
g2
VThese fetal structures generate regions with abnormal activity in autism, including the dorsolateral prefrontal cortex (BA46), the pars opercularis of the inferior frontal cortex and the fusiform gyrus.
p1862
sg4
(lp1863
sg6
(lp1864
(dp1865
g9
I66
sg10
VC0004352
p1866
sg12
I6
sg13
Vautism
p1867
sg15
I1
sasa(dp1868
g2
VAt the site of disease in leprosy, we found that S100A12 was more strongly expressed in skin lesions from tuberculoid leprosy (T-lep), the self-limiting form of the disease, compared to lepromatous leprosy (L-lep), the progressive form of the disease.
p1869
sg4
(lp1870
(dp1871
g9
I49
sg20
VP80511
p1872
sg12
I7
sg13
VS100A12
p1873
sg15
I1
sasg6
(lp1874
(dp1875
g9
I26
sg10
VC0023343
p1876
sg12
I7
sg13
Vleprosy
p1877
sg15
I1
sa(dp1878
g9
I127
sg10
VC0023351
p1879
sg12
I5
sg13
VT-lep
p1880
sg15
I1
sa(dp1881
g9
I186
sg10
VC0023348
p1882
sg12
I19
sg13
Vlepromatous leprosy
p1883
sg15
I2
sa(dp1884
g9
I106
sg10
VC0023351
p1885
sg12
I19
sg13
Vtuberculoid leprosy
p1886
sg15
I2
sa(dp1887
g9
I207
sg10
VC0023348
p1888
sg12
I5
sg13
VL-lep
p1889
sg15
I1
sasa(dp1890
g2
VThe aim of this study was to predict right ventricular dysfunction (RVD) using plasma concentration of D-dimer, pro-atrial natriuretic peptide (pro-ANP), brain natriuretic peptide (BNP), endothelin-1 (ET-1) and cardiac troponin I (TNI) in patients with pulmonary embolism (PE).
p1891
sg4
(lp1892
(dp1893
g9
I201
sg20
VP05305
p1894
sg12
I4
sg13
VET-1
p1895
sg15
I1
sa(dp1896
g9
I187
sg20
VP20800
p1897
sg12
I12
sg13
Vendothelin-1
p1898
sg15
I1
sa(dp1899
g9
I231
sg20
VP48788
p1900
sg12
I3
sg13
VTNI
p1901
sg15
I1
sa(dp1902
g9
I103
sg20
VP16066
p1903
sg12
I76
sg13
VD-dimer, pro-atrial natriuretic peptide (pro-ANP), brain natriuretic peptide
p1904
sg15
I8
sa(dp1905
g9
I181
sg20
VP16860
p1906
sg12
I3
sg13
VBNP
p1907
sg15
I1
sa(dp1908
g9
I211
sg20
VP24821
p1909
sg12
I18
sg13
Vcardiac troponin I
p1910
sg15
I3
sasg6
(lp1911
(dp1912
g9
I37
sg10
VC0242707
p1913
sg12
I29
sg13
Vright ventricular dysfunction
p1914
sg15
I3
sa(dp1915
g9
I273
sg10
VC0034065
p1916
sg12
I2
sg13
VPE
p1917
sg15
I1
sa(dp1918
g9
I68
sg10
VC0242707
p1919
sg12
I3
sg13
VRVD
p1920
sg15
I1
sa(dp1921
g9
I253
sg10
VC0034065
p1922
sg12
I18
sg13
Vpulmonary embolism
p1923
sg15
I2
sasa(dp1924
g2
VAtrial natriuretic petide (ANP), brain natriuretic peptide (BNP) and endothelin-1 (ET-1) may reflect the severity of right ventricular dysfunction (RVD) in patients with pulmonary embolism (PE).
p1925
sg4
(lp1926
(dp1927
g9
I27
sg20
VP16066
p1928
sg12
I3
sg13
VANP
p1929
sg15
I1
sa(dp1930
g9
I83
sg20
VP05305
p1931
sg12
I4
sg13
VET-1
p1932
sg15
I1
sa(dp1933
g9
I69
sg20
VP20800
p1934
sg12
I12
sg13
Vendothelin-1
p1935
sg15
I1
sa(dp1936
g9
I0
sg20
VP16066
p1937
sg12
I25
sg13
VAtrial natriuretic petide
p1938
sg15
I3
sasg6
(lp1939
(dp1940
g9
I190
sg10
VC0034065
p1941
sg12
I2
sg13
VPE
p1942
sg15
I1
sa(dp1943
g9
I148
sg10
VC0242707
p1944
sg12
I3
sg13
VRVD
p1945
sg15
I1
sa(dp1946
g9
I117
sg10
VC0242707
p1947
sg12
I29
sg13
Vright ventricular dysfunction
p1948
sg15
I3
sa(dp1949
g9
I170
sg10
VC0034065
p1950
sg12
I18
sg13
Vpulmonary embolism
p1951
sg15
I2
sasa(dp1952
g2
VAcute pulmonary embolism (PE) is a life-threatening disease, and several vasoconstrictors, including endothelin-1 (ET-1), play a key role in vasoconstriction and hypoxemia during the development of PE.
p1953
sg4
(lp1954
(dp1955
g9
I101
sg20
VP20800
p1956
sg12
I12
sg13
Vendothelin-1
p1957
sg15
I1
sa(dp1958
g9
I115
sg20
VP05305
p1959
sg12
I4
sg13
VET-1
p1960
sg15
I1
sasg6
(lp1961
(dp1962
g9
I6
sg10
VC0034065
p1963
sg12
I18
sg13
Vpulmonary embolism
p1964
sg15
I2
sa(dp1965
g9
I26
sg10
VC0034065
p1966
sg12
I2
sg13
VPE
p1967
sg15
I1
sa(dp1968
g9
I26
sg10
VC0034065
p1969
sg12
I2
sg13
VPE
p1970
sg15
I1
sa(dp1971
g9
I141
sg10
VC1456863
p1972
sg12
I16
sg13
Vvasoconstriction
p1973
sg15
I1
sasa(dp1974
g2
VImpaired repression of cone-specific genes by the corepressors atrophin-1 (dentatorubral-pallidoluysian atrophy [DRPLA] gene product) and atrophin-2 (arginine-glutamic acid dipeptide repeat [RERE] protein) appeared to be a molecular mechanism mediating the beneficial effect of the p.R311Q mutation.
p1975
sg4
(lp1976
sg6
(lp1977
(dp1978
g9
I113
sg10
VC0751781
p1979
sg12
I5
sg13
VDRPLA
p1980
sg15
I1
sa(dp1981
g9
I75
sg10
VC0751781
p1982
sg12
I36
sg13
Vdentatorubral-pallidoluysian atrophy
p1983
sg15
I2
sa(dp1984
g9
I0
sg10
VC0684336
p1985
sg12
I8
sg13
VImpaired
p1986
sg15
I1
sasa(dp1987
g2
VRE repeats encoded (RERE) was identified recently as a protein with high homology to the atrophin-1 protein, which appears to be causal in the hereditary neurodegenerative disorder termed dentatorubral-pallidoluysian atrophy (DRPLA) caused by an abnormal glutamine expansion.
p1988
sg4
(lp1989
(dp1990
g9
I89
sg20
VP54259
p1991
sg12
I18
sg13
Vatrophin-1 protein
p1992
sg15
I2
sasg6
(lp1993
(dp1994
g9
I188
sg10
VC0751781
p1995
sg12
I36
sg13
Vdentatorubral-pallidoluysian atrophy
p1996
sg15
I2
sa(dp1997
g9
I226
sg10
VC0751781
p1998
sg12
I5
sg13
VDRPLA
p1999
sg15
I1
sa(dp2000
g9
I143
sg10
VC3273225
p2001
sg12
I37
sg13
Vhereditary neurodegenerative disorder
p2002
sg15
I3
sasa(dp2003
g2
VThe gene isolated, designated RERE, has an open reading frame of 1566 amino acids, of which the C-terminal portion has 67% homology to DRPLA, whereas the N-terminal portion is distinctive.
p2004
sg4
(lp2005
(dp2006
g9
I135
sg20
VP54259
p2007
sg12
I5
sg13
VDRPLA
p2008
sg15
I1
sa(dp2009
g9
I30
sg20
g21
sg12
I4
sg13
VRERE
p2010
sg15
I1
sasg6
(lp2011
(dp2012
g9
I135
sg10
VC0751781
p2013
sg12
I5
sg13
VDRPLA
p2014
sg15
I1
sasa(dp2015
g2
VImmunoprecipitation and in vitro binding assays demonstrate that the DRPLA and RERE proteins bind each other, for which one of the RE repeats has a primary role, and extended polyglutamine enhances the binding.
p2016
sg4
(lp2017
(dp2018
g9
I79
sg20
g21
sg12
I13
sg13
VRERE proteins
p2019
sg15
I2
sa(dp2020
g9
I69
sg20
VP54259
p2021
sg12
I5
sg13
VDRPLA
p2022
sg15
I1
sasg6
(lp2023
(dp2024
g9
I69
sg10
VC0751781
p2025
sg12
I5
sg13
VDRPLA
p2026
sg15
I1
sasa(dp2027
g2
VMoreover, when RERE is overexpressed, the distribution of endogenous DRPLA protein alters from the diffused to the speckled pattern in the nucleus so as to co-localize with RERE.
p2028
sg4
(lp2029
(dp2030
g9
I15
sg20
g21
sg12
I4
sg13
VRERE
p2031
sg15
I1
sa(dp2032
g9
I58
sg20
VP54259
p2033
sg12
I24
sg13
Vendogenous DRPLA protein
p2034
sg15
I3
sasg6
(lp2035
(dp2036
g9
I69
sg10
VC0751781
p2037
sg12
I5
sg13
VDRPLA
p2038
sg15
I1
sasa(dp2039
g2
VMore RERE protein is recruited into nuclear aggregates of the DRPLA protein with extended polyglutamine than into those of pure polyglutamine.
p2040
sg4
(lp2041
(dp2042
g9
I62
sg20
VP54259
p2043
sg12
I13
sg13
VDRPLA protein
p2044
sg15
I2
sasg6
(lp2045
(dp2046
g9
I62
sg10
VC0751781
p2047
sg12
I5
sg13
VDRPLA
p2048
sg15
I1
sasa(dp2049
g2
VThe DNB1/ARPh gene, which was found to be ubiquitously expressed in human adult and fetal tissues, is highly related to the DRPLA gene, in which expansion of a CAG triplet appears to be causal in the dentatorubral and pallidolysian atrophy disease phenotype.
p2050
sg4
(lp2051
(dp2052
g9
I124
sg20
VP54259
p2053
sg12
I10
sg13
VDRPLA gene
p2054
sg15
I2
sa(dp2055
g9
I4
sg20
VP55145
p2056
sg12
I4
sg13
VDNB1
p2057
sg15
I1
sasg6
(lp2058
(dp2059
g9
I124
sg10
VC0751781
p2060
sg12
I5
sg13
VDRPLA
p2061
sg15
I1
sa(dp2062
g9
I232
sg10
VC0333641
p2063
sg12
I7
sg13
Vatrophy
p2064
sg15
I1
sasa(dp2065
g2
VTherefore, we evaluated the roles of CSNK2A1, SIRT6, and phosphorylated SIRT6 and their relationships in breast carcinoma.
p2066
sg4
(lp2067
(dp2068
g9
I37
sg20
VP19784
p2069
sg12
I7
sg13
VCSNK2A1
p2070
sg15
I1
sasg6
(lp2071
(dp2072
g9
I105
sg10
VC0678222
p2073
sg12
I16
sg13
Vbreast carcinoma
p2074
sg15
I2
sasa(dp2075
g2
VThis study demonstrates that CSNK2A1 and SIRT6 are indicators of poor prognosis for breast carcinomas and that CSNK2A1-mediated phosphorylation of SIRT6 might be involved in the progression of breast carcinoma.
p2076
sg4
(lp2077
(dp2078
g9
I29
sg20
VP19784
p2079
sg12
I7
sg13
VCSNK2A1
p2080
sg15
I1
sa(dp2081
g9
I29
sg20
VP19784
p2082
sg12
I7
sg13
VCSNK2A1
p2083
sg15
I1
sasg6
(lp2084
(dp2085
g9
I84
sg10
VC0678222
p2086
sg12
I16
sg13
Vbreast carcinoma
p2087
sg15
I2
sa(dp2088
g9
I84
sg10
VC0678222
p2089
sg12
I17
sg13
Vbreast carcinomas
p2090
sg15
I2
sasa(dp2091
g2
VRNA expression levels of CDC2L1, CDC2L2, CCNL1, CCNL2, CSNK2A1, CSNK2A2, and CSNK2B genes in breast cancer subtypes were analyzed.
p2092
sg4
(lp2093
(dp2094
g9
I77
sg20
VP67870
p2095
sg12
I12
sg13
VCSNK2B genes
p2096
sg15
I2
sa(dp2097
g9
I64
sg20
VP19784
p2098
sg12
I7
sg13
VCSNK2A2
p2099
sg15
I1
sa(dp2100
g9
I41
sg20
VP49736
p2101
sg12
I5
sg13
VCCNL1
p2102
sg15
I1
sa(dp2103
g9
I55
sg20
VP19784
p2104
sg12
I7
sg13
VCSNK2A1
p2105
sg15
I1
sasg6
(lp2106
(dp2107
g9
I93
sg10
VC0678222
p2108
sg12
I13
sg13
Vbreast cancer
p2109
sg15
I2
sasa(dp2110
g2
VRecent evidence suggests the role of Wnt signaling in human breast cancer involves elevated levels of nuclear and/or cytoplasmic beta-catenin using immunohistochemistry, overexpression or downregulation of specific Wnt proteins, overexpression of CKII and sFRP4, downregulation of WIF-1 and sFRP1, as well as amplification of DVL-1.
p2111
sg4
(lp2112
(dp2113
g9
I117
sg20
g21
sg12
I24
sg13
Vcytoplasmic beta-catenin
p2114
sg15
I2
sa(dp2115
g9
I247
sg20
VP68400
p2116
sg12
I4
sg13
VCKII
p2117
sg15
I1
sa(dp2118
g9
I326
sg20
VP54792
p2119
sg12
I5
sg13
VDVL-1
p2120
sg15
I1
sa(dp2121
g9
I291
sg20
g21
sg12
I5
sg13
VsFRP1
p2122
sg15
I1
sa(dp2123
g9
I256
sg20
g21
sg12
I5
sg13
VsFRP4
p2124
sg15
I1
sasg6
(lp2125
(dp2126
g9
I60
sg10
VC0678222
p2127
sg12
I13
sg13
Vbreast cancer
p2128
sg15
I2
sa(dp2129
g9
I309
sg10
VC1705759
p2130
sg12
I13
sg13
Vamplification
p2131
sg15
I1
sasa(dp2132
g2
VBy combining the mutational data in the Catalogue of Somatic Mutations in Cancer (COSMIC) and the spatial information in the Protein Data Bank (PDB), SpacePAC is able to identify novel mutation clusters in many proteins such as FGFR3 and CHRM2.
p2133
sg4
(lp2134
(dp2135
g9
I228
sg20
VP22607
p2136
sg12
I5
sg13
VFGFR3
p2137
sg15
I1
sa(dp2138
g9
I238
sg20
VP08172
p2139
sg12
I5
sg13
VCHRM2
p2140
sg15
I1
sasg6
(lp2141
(dp2142
g9
I53
sg10
VC0544886
p2143
sg12
I17
sg13
VSomatic Mutations
p2144
sg15
I2
sa(dp2145
g9
I125
sg10
VC0029401
p2146
sg12
I17
sg13
VProtein Data Bank
p2147
sg15
I3
sa(dp2148
g9
I179
sg10
VC2985438
p2149
sg12
I14
sg13
Vnovel mutation
p2150
sg15
I2
sa(dp2151
g9
I74
sg10
VC0006826
p2152
sg12
I6
sg13
VCancer
p2153
sg15
I1
sa(dp2154
g9
I144
sg10
VC0029401
p2155
sg12
I3
sg13
VPDB
p2156
sg15
I1
sasa(dp2157
g2
VColorectal cancer (HCT 116, LoVo, C 170 HM 2, CaCO-2), fibroblast (46-BR.IGI, CCD-18 Co) and fibrosarcoma (HT1080) cell lines were irradiated at 4 gray (4 Gy) and matrix metalloproteinase gene and protein expression examined over a 96 h period by real time polymerase chain reaction and gelatin zymography.
p2158
sg4
(lp2159
(dp2160
g9
I78
sg20
VP21817
p2161
sg12
I9
sg13
VCCD-18 Co
p2162
sg15
I2
sa(dp2163
g9
I163
sg20
g21
sg12
I29
sg13
Vmatrix metalloproteinase gene
p2164
sg15
I3
sa(dp2165
g9
I73
sg20
VP12018
p2166
sg12
I3
sg13
VIGI
p2167
sg15
I1
sasg6
(lp2168
(dp2169
g9
I0
sg10
VC1527249
p2170
sg12
I17
sg13
VColorectal cancer
p2171
sg15
I2
sa(dp2172
g9
I93
sg10
VC0016057
p2173
sg12
I12
sg13
Vfibrosarcoma
p2174
sg15
I1
sa(dp2175
g9
I78
sg10
VC0008928
p2176
sg12
I3
sg13
VCCD
p2177
sg15
I1
sasa(dp2178
g2
VIn addition, because HBL is a major enterotoxin, we also designed HBL gene-specific polymerase chain reaction (PCR) primers, i.e., Hm1 and Hm2, that generated the same results as those of the hemolysis and BCET-RPLA assays.
p2179
sg4
(lp2180
(dp2181
g9
I66
sg20
VP09382
p2182
sg12
I8
sg13
VHBL gene
p2183
sg15
I2
sa(dp2184
g9
I131
sg20
VP11229
p2185
sg12
I3
sg13
VHm1
p2186
sg15
I1
sa(dp2187
g9
I21
sg20
VP09382
p2188
sg12
I3
sg13
VHBL
p2189
sg15
I1
sa(dp2190
g9
I139
sg20
VP08172
p2191
sg12
I3
sg13
VHm2
p2192
sg15
I1
sasg6
(lp2193
(dp2194
g9
I192
sg10
VC0019054
p2195
sg12
I9
sg13
Vhemolysis
p2196
sg15
I1
sasa(dp2197
g2
VPrimers B16S1/B16S2 and Hm1/Hm2 could be combined into a multiplex PCR system for the simultaneous detection of B. cereus group cells and the possible presence of their HBL enterotoxins.
p2198
sg4
(lp2199
(dp2200
g9
I24
sg20
VP11229
p2201
sg12
I3
sg13
VHm1
p2202
sg15
I1
sa(dp2203
g9
I169
sg20
VP09382
p2204
sg12
I16
sg13
VHBL enterotoxins
p2205
sg15
I2
sa(dp2206
g9
I28
sg20
VP08172
p2207
sg12
I3
sg13
VHm2
p2208
sg15
I1
sasg6
(lp2209
sa(dp2210
g2
VPositive cancer invasion in the cut end was classified as hm2 or dm2 in 8 patients and em2 in 13.
p2211
sg4
(lp2212
(dp2213
g9
I58
sg20
VP08172
p2214
sg12
I3
sg13
Vhm2
p2215
sg15
I1
sasg6
(lp2216
(dp2217
g9
I16
sg10
VC2699153
p2218
sg12
I8
sg13
Vinvasion
p2219
sg15
I1
sa(dp2220
g9
I65
sg10
VC2931689
p2221
sg12
I3
sg13
Vdm2
p2222
sg15
I1
sa(dp2223
g9
I9
sg10
VC0006826
p2224
sg12
I6
sg13
Vcancer
p2225
sg15
I1
sasa(dp2226
g2
VBiopsy samples from five acquired immune deficiency syndrome (AIDS)-Kaposi's sarcomas and one non-AIDS-associated Kaposi's sarcoma were assayed by in situ RNA hybridization onto paraformaldehyde-fixed, paraffin-embedded skin sections for the presence of two fibroblast growth factor gene transcripts, FGFB and FGF5.
p2227
sg4
(lp2228
(dp2229
g9
I258
sg20
g21
sg12
I41
sg13
Vfibroblast growth factor gene transcripts
p2230
sg15
I5
sa(dp2231
g9
I310
sg20
VP12034
p2232
sg12
I4
sg13
VFGF5
p2233
sg15
I1
sasg6
(lp2234
(dp2235
g9
I25
sg10
VC0001175
p2236
sg12
I35
sg13
Vacquired immune deficiency syndrome
p2237
sg15
I4
sa(dp2238
g9
I62
sg10
VC0001175
p2239
sg12
I4
sg13
VAIDS
p2240
sg15
I1
sa(dp2241
g9
I77
sg10
VC1261473
p2242
sg12
I8
sg13
Vsarcomas
p2243
sg15
I1
sa(dp2244
g9
I68
sg10
VC0036220
p2245
sg12
I16
sg13
VKaposi's sarcoma
p2246
sg15
I2
sa(dp2247
g9
I62
sg10
VC0001175
p2248
sg12
I4
sg13
VAIDS
p2249
sg15
I1
sasa(dp2250
g2
VFGF5 gene expression was detected in the characteristic Kaposi's sarcoma spindle-shaped cells in the five samples from human immunodeficiency-positive (HIV+) patients.
p2251
sg4
(lp2252
(dp2253
g9
I0
sg20
VP12034
p2254
sg12
I9
sg13
VFGF5 gene
p2255
sg15
I2
sasg6
(lp2256
(dp2257
g9
I125
sg10
VC0021051
p2258
sg12
I16
sg13
Vimmunodeficiency
p2259
sg15
I1
sa(dp2260
g9
I56
sg10
VC0036220
p2261
sg12
I16
sg13
VKaposi's sarcoma
p2262
sg15
I2
sasa(dp2263
g2
VFurthermore, they demonstrate a contrasting expression pattern of FGF5 and FGFB genes, both involved in the growth factor pathogenic cascade leading to Kaposi's sarcoma.
p2264
sg4
(lp2265
(dp2266
g9
I75
sg20
VP01893
p2267
sg12
I10
sg13
VFGFB genes
p2268
sg15
I2
sa(dp2269
g9
I66
sg20
VP12034
p2270
sg12
I4
sg13
VFGF5
p2271
sg15
I1
sasg6
(lp2272
(dp2273
g9
I152
sg10
VC0036220
p2274
sg12
I16
sg13
VKaposi's sarcoma
p2275
sg15
I2
sasa(dp2276
g2
VObjective To explore the efficacy of ganoderma lucidum preparation(Ling Zhi) in treating APP/PS-1 transgenic mouse models of Alzheimer's disease(AD).Methods APP/PS-1 transgenic mice of 4 months were randomly divided into model group,ganoderma lucidum treatment groups,including high [2250 mg/(kg*d)] and middle [750 mg/(kg*d)] dose groups,i.e.LZ-H and LZ-M groups,and the positive control group(treated with donepezil hydrochloride [2 mg/(kg*d)]).In addition,C57BL/6J wild mice were selected as normal group.The animals were administered for 4 months.Histopathological examinations including hematoxylin-eosin(HE) staining,immunohistochemistry,special staining,and electron microscopy were applied,and then the pathological morphology and structures in different groups were compared.
p2277
sg4
(lp2278
(dp2279
g9
I89
sg20
g21
sg12
I3
sg13
VAPP
p2280
sg15
I1
sa(dp2281
g9
I93
sg20
VP48651
p2282
sg12
I4
sg13
VPS-1
p2283
sg15
I1
sasg6
(lp2284
(dp2285
g9
I125
sg10
VC1521724
p2286
sg12
I19
sg13
VAlzheimer's disease
p2287
sg15
I2
sasa(dp2288
g2
VFor the hydrogel prepared using the comonomer mixture with 5.0 wt % SBMA, the amount of adsorbed Lyz is 0.91 myg/cm2, which corresponds to only 56.8% of the amount adsorbed on EASY DAY(R) SCLs.
p2289
sg4
(lp2290
sg6
(lp2291
(dp2292
g9
I68
sg10
VC1839259
p2293
sg12
I4
sg13
VSBMA
p2294
sg15
I1
sa(dp2295
g9
I113
sg10
VC0555206
p2296
sg12
I3
sg13
Vcm2
p2297
sg15
I1
sasa(dp2298
g2
VObjective To evaluate the efficacy of Ganoderma lucidum preparation on the behaviors,biochemistry,and autoimmunity parameters of mouse models of APP/PS-1 double transgenic Alzheimer's disease(AD).Methods A total of 44 4-month-old APP/PS-1 double transgenic AD mice were randomly divided into AD model group,Aricept group,Ganoderma lucidum middle-dose(LZ-M)group,and Ganoderma lucidum high-dose(LZ-H)group,with 11 mice in each group.In addition,10 4-month-old C57BL/6 mice were used as the control group.Water maze test was conducted to observe the behavior changes,and the protein expressions in brain tissues were detected by Western blot analysis.The autoimmune indicators were detected by indirect immunofluorescence method.Results In the navigation experiment,the time of finding the platform was gradually shortened since the 2nd day in the control,LZ-H,and LZ-M groups,and the time of searching the platform in the AD model group gradually increased.On the 5th day,the time of finding platform was significantly shorter in control group (t=5.607,P=0.000) and LZ-H group(t=2.750,P=0.010)than AD model group.In the space exploration experiment,the number of crossing the target platform(t=2.452,P=0.025)and the residence time in the target quadrant(t=2.530,P=0.020)in AD model group mice was significantly smaller/shorter than those in control group;in addition,the number of crossing the target platform in the AD model group was significantly smaller than that in LZ-H group(t=2.317,P=0.030)and LZ-M group(t=2.443,P=0.030),while the residence time in target quadrant decreased significantly(t=2.770,P=0.020)compared with LZ-H group;the number of crossing through the target platform quadrant(t=2.493,P=0.022)and residence time in the target quadrant(t=2.683,P=0.015)in LZ-H group were significantly higher than in Aricept group.Western blot analysis showed that the expression of ApoA1 in the brain tissues of mice in LZ-H and LZ-M groups were significantly higher than those in AD model group(P&lt;0.01,P&lt;0.05);ABeta-40 expression in LZ-H group was significantly lower than that in AD model group(P&lt;0.05);the expressions of Syt1,ApoE,and ABCA1 in brain tissues of mice in LZ-H group were significantly higher than those in model group(P&lt;0.01,P&lt;0.05).The plasma IgG level in Aricept group(t=30.945,P=0.000),LZ-M group(t=25.639,P=0.000)and LZ-H group(t=4.689,P=0.001)were significantly higher than that in the control group.Conclusion Ganoderma lucidum preparation can improve behavior disorders of AD model mice,promote the expressions of ApoA1,ApoE and Syt1,inhibit the expression of ABeta-40 protein,and improve the autoimmune function.
p2299
sg4
(lp2300
(dp2301
g9
I2137
sg20
VP21579
p2302
sg12
I4
sg13
VSyt1
p2303
sg15
I1
sa(dp2304
g9
I1886
sg20
VP02647
p2305
sg12
I5
sg13
VApoA1
p2306
sg15
I1
sa(dp2307
g9
I1065
sg20
VP00390
p2308
sg12
I10
sg13
VLZ-H group
p2309
sg15
I2
sa(dp2310
g9
I2142
sg20
VP02649
p2311
sg12
I4
sg13
VApoE
p2312
sg15
I1
sa(dp2313
g9
I145
sg20
VP48651
p2314
sg12
I8
sg13
VAPP/PS-1
p2315
sg15
I1
sa(dp2316
g9
I2142
sg20
VP02649
p2317
sg12
I4
sg13
VApoE
p2318
sg15
I1
sa(dp2319
g9
I2603
sg20
g21
sg12
I16
sg13
VABeta-40 protein
p2320
sg15
I2
sa(dp2321
g9
I1886
sg20
VP02647
p2322
sg12
I5
sg13
VApoA1
p2323
sg15
I1
sa(dp2324
g9
I2021
sg20
g21
sg12
I8
sg13
VABeta-40
p2325
sg15
I1
sa(dp2326
g9
I1065
sg20
VP00390
p2327
sg12
I10
sg13
VLZ-H group
p2328
sg15
I2
sa(dp2329
g9
I145
sg20
g21
sg12
I3
sg13
VAPP
p2330
sg15
I1
sa(dp2331
g9
I1065
sg20
VP00390
p2332
sg12
I10
sg13
VLZ-H group
p2333
sg15
I2
sa(dp2334
g9
I149
sg20
VP48651
p2335
sg12
I4
sg13
VPS-1
p2336
sg15
I1
sa(dp2337
g9
I2137
sg20
VP21579
p2338
sg12
I4
sg13
VSyt1
p2339
sg15
I1
sasg6
(lp2340
(dp2341
g9
I102
sg10
VC0004368
p2342
sg12
I12
sg13
Vautoimmunity
p2343
sg15
I1
sa(dp2344
g9
I172
sg10
VC1521724
p2345
sg12
I19
sg13
VAlzheimer's disease
p2346
sg15
I2
sa(dp2347
g9
I2494
sg10
VC0004930
p2348
sg12
I18
sg13
Vbehavior disorders
p2349
sg15
I2
sa(dp2350
g9
I653
sg10
VC0443146
p2351
sg12
I10
sg13
Vautoimmune
p2352
sg15
I1
sa(dp2353
g9
I653
sg10
VC0443146
p2354
sg12
I10
sg13
Vautoimmune
p2355
sg15
I1
sasa(dp2356
g2
VSomatic v-Raf murine sarcoma viral oncogene homolog B (BRAF) mutation, present in approximately 10% of metastatic colorectal cancer (mCRC) cases, is associated with poor prognosis.
p2357
sg4
(lp2358
(dp2359
g9
I55
sg20
VP15056
p2360
sg12
I4
sg13
VBRAF
p2361
sg15
I1
sa(dp2362
g9
I0
sg20
VP04049
p2363
sg12
I53
sg13
VSomatic v-Raf murine sarcoma viral oncogene homolog B
p2364
sg15
I8
sasg6
(lp2365
(dp2366
g9
I21
sg10
VC1261473
p2367
sg12
I7
sg13
Vsarcoma
p2368
sg15
I1
sa(dp2369
g9
I133
sg10
VC0948380
p2370
sg12
I4
sg13
VmCRC
p2371
sg15
I1
sa(dp2372
g9
I103
sg10
VC0948380
p2373
sg12
I28
sg13
Vmetastatic colorectal cancer
p2374
sg15
I3
sasa(dp2375
g2
VAll colorectal cancer patients tested for BRAF mutation, from October 2010 to November 2014 were identified.
p2376
sg4
(lp2377
(dp2378
g9
I42
sg20
VP15056
p2379
sg12
I4
sg13
VBRAF
p2380
sg15
I1
sasg6
(lp2381
(dp2382
g9
I4
sg10
VC1527249
p2383
sg12
I17
sg13
Vcolorectal cancer
p2384
sg15
I2
sasa(dp2385
g2
VThe prognostic role of the V600E mutation of v-raf murine sarcoma viral oncogene homolog B1 (BRAF) in metastatic colorectal cancer (mCRC) is well established, but the therapeutic regimen targeting this disease is lacking.
p2386
sg4
(lp2387
(dp2388
g9
I45
sg20
VP15056
p2389
sg12
I92
sg13
Vv-raf murine sarcoma viral oncogene homolog B1 (BRAF) in metastatic colorectal cancer (mCRC)
p2390
sg15
I13
sasg6
(lp2391
(dp2392
g9
I132
sg10
VC0948380
p2393
sg12
I4
sg13
VmCRC
p2394
sg15
I1
sa(dp2395
g9
I102
sg10
VC0948380
p2396
sg12
I28
sg13
Vmetastatic colorectal cancer
p2397
sg15
I3
sa(dp2398
g9
I58
sg10
VC1261473
p2399
sg12
I7
sg13
Vsarcoma
p2400
sg15
I1
sasa(dp2401
g2
VThe aim of our study was to evaluate the incidence of KRAS, NRAS, BRAF and PIK3CA mutations in metastatic colorectal cancer patients receiving first line oxaliplatin based chemotherapy with or without bevacizumab and to evaluate their prognostic and predictive significance.
p2402
sg4
(lp2403
(dp2404
g9
I66
sg20
VP15056
p2405
sg12
I4
sg13
VBRAF
p2406
sg15
I1
sa(dp2407
g9
I60
sg20
VP01111
p2408
sg12
I4
sg13
VNRAS
p2409
sg15
I1
sa(dp2410
g9
I75
sg20
VP42336
p2411
sg12
I6
sg13
VPIK3CA
p2412
sg15
I1
sa(dp2413
g9
I54
sg20
VP01116
p2414
sg12
I4
sg13
VKRAS
p2415
sg15
I1
sasg6
(lp2416
(dp2417
g9
I95
sg10
VC0948380
p2418
sg12
I28
sg13
Vmetastatic colorectal cancer
p2419
sg15
I3
sasa(dp2420
g2
VActivating BRAF (V-raf murine sarcoma viral oncogene homolog B) mutations occur in approximately 5% to 10% of patients with metastatic colorectal cancer, mostly V600E mutation, and it is associated with distinct clinical and pathological features.
p2421
sg4
(lp2422
(dp2423
g9
I11
sg20
VP15056
p2424
sg12
I4
sg13
VBRAF
p2425
sg15
I1
sa(dp2426
g9
I17
sg20
VP04049
p2427
sg12
I45
sg13
VV-raf murine sarcoma viral oncogene homolog B
p2428
sg15
I7
sasg6
(lp2429
(dp2430
g9
I30
sg10
VC1261473
p2431
sg12
I7
sg13
Vsarcoma
p2432
sg15
I1
sa(dp2433
g9
I124
sg10
VC0948380
p2434
sg12
I28
sg13
Vmetastatic colorectal cancer
p2435
sg15
I3
sasa(dp2436
g2
VThis review aims to provide data about new strategies to target to BRAF gene mutation in metastatic colorectal cancer.
p2437
sg4
(lp2438
(dp2439
g9
I67
sg20
VP15056
p2440
sg12
I9
sg13
VBRAF gene
p2441
sg15
I2
sasg6
(lp2442
(dp2443
g9
I89
sg10
VC0948380
p2444
sg12
I28
sg13
Vmetastatic colorectal cancer
p2445
sg15
I3
sa(dp2446
g9
I67
sg10
VC1511021
p2447
sg12
I18
sg13
VBRAF gene mutation
p2448
sg15
I3
sasa(dp2449
g2
VThe variables of age, incidence of autoimmune hepatitis, model of end-stage liver disease (MELD) score, values for total bilirubin and prothrombin time-international ratio (PT-INR), and Japan Hepatic Encephalopathy Prediction Model (JHEPM) probability at registration were significantly higher in ALF patients than in ALI patients.
p2450
sg4
(lp2451
(dp2452
g9
I135
sg20
VP00734
p2453
sg12
I11
sg13
Vprothrombin
p2454
sg15
I1
sasg6
(lp2455
(dp2456
g9
I35
sg10
VC0241910
p2457
sg12
I20
sg13
Vautoimmune hepatitis
p2458
sg15
I2
sa(dp2459
g9
I76
sg10
VC0023895
p2460
sg12
I13
sg13
Vliver disease
p2461
sg15
I2
sa(dp2462
g9
I192
sg10
VC0019151
p2463
sg12
I22
sg13
VHepatic Encephalopathy
p2464
sg15
I2
sasa(dp2465
g2
VOn the other hand, the multivariate Cox proportional hazard model showed that positivity for serum anti-PD-1 antibody, probable diagnosis based on the revised scoring system proposed by the International Autoimmune Hepatitis Group, and prothrombin activity of less than 60% were associated with the later normalization of serum transaminase levels.
p2466
sg4
(lp2467
(dp2468
g9
I93
sg20
VP18621
p2469
sg12
I24
sg13
Vserum anti-PD-1 antibody
p2470
sg15
I3
sa(dp2471
g9
I322
sg20
g21
sg12
I18
sg13
Vserum transaminase
p2472
sg15
I2
sa(dp2473
g9
I236
sg20
VP00734
p2474
sg12
I11
sg13
Vprothrombin
p2475
sg15
I1
sasg6
(lp2476
(dp2477
g9
I204
sg10
VC0241910
p2478
sg12
I20
sg13
VAutoimmune Hepatitis
p2479
sg15
I2
sasa(dp2480
g2
VMyeloma cell maturity was classified via immunophenotyping: myeloma cells showing mature plasma cell 1 (MPC-1)-positive and CD49e-positive cells were considered mature type; MPC-1-positive and CD49e-negative cells were considered intermediate type; and MPC-1-negative cells were considered immature type.
p2481
sg4
(lp2482
(dp2483
g9
I124
sg20
VP08648
p2484
sg12
I5
sg13
VCD49e
p2485
sg15
I1
sa(dp2486
g9
I124
sg20
VP08648
p2487
sg12
I5
sg13
VCD49e
p2488
sg15
I1
sasg6
(lp2489
(dp2490
g9
I60
sg10
VC0026764
p2491
sg12
I7
sg13
Vmyeloma
p2492
sg15
I1
sa(dp2493
g9
I0
sg10
VC0026764
p2494
sg12
I7
sg13
VMyeloma
p2495
sg15
I1
sasa(dp2496
g2
VThe findings of this study demonstrate the clinical importance of myeloma cell classification according to immunophenotyping using MPC-1 and CD49e antibodies to determine patient prognosis in this era of novel therapeutic agents.
p2497
sg4
(lp2498
(dp2499
g9
I131
sg20
VP28062
p2500
sg12
I5
sg13
VMPC-1
p2501
sg15
I1
sa(dp2502
g9
I141
sg20
VP08648
p2503
sg12
I16
sg13
VCD49e antibodies
p2504
sg15
I2
sasg6
(lp2505
(dp2506
g9
I66
sg10
VC0026764
p2507
sg12
I7
sg13
Vmyeloma
p2508
sg15
I1
sasa(dp2509
g2
VOn the basis of biopsies of the masses in the pharynx and finger, he was diagnosed with extramedullary plasmablastic plasmacytoma, with somewhat immature CD45(+), MPC-1(-), and CD49e(-).
p2510
sg4
(lp2511
(dp2512
g9
I177
sg20
VP08648
p2513
sg12
I5
sg13
VCD49e
p2514
sg15
I1
sa(dp2515
g9
I154
sg20
VP08575
p2516
sg12
I7
sg13
VCD45(+)
p2517
sg15
I1
sa(dp2518
g9
I163
sg20
VP28062
p2519
sg12
I5
sg13
VMPC-1
p2520
sg15
I1
sasg6
(lp2521
(dp2522
g9
I117
sg10
VC0032131
p2523
sg12
I12
sg13
Vplasmacytoma
p2524
sg15
I1
sasa(dp2525
g2
VChanges to CD45 negativity and MPC-1 partial positivity were seen, while CD49e negativity persisted, suggesting that the plasmablastic plasmacytoma had reverted to a more immature state.
p2526
sg4
(lp2527
(dp2528
g9
I31
sg20
VP28062
p2529
sg12
I5
sg13
VMPC-1
p2530
sg15
I1
sa(dp2531
g9
I73
sg20
VP08648
p2532
sg12
I5
sg13
VCD49e
p2533
sg15
I1
sa(dp2534
g9
I11
sg20
VP08575
p2535
sg12
I15
sg13
VCD45 negativity
p2536
sg15
I2
sasg6
(lp2537
(dp2538
g9
I135
sg10
VC0032131
p2539
sg12
I12
sg13
Vplasmacytoma
p2540
sg15
I1
sasa(dp2541
g2
VHe had the following poor prognostic factors: 1) multiple extramedullary plasmacytomas, 2) massive myelomatous effusion, 3) increasing immature myeloma cells with plasmablastic morphology, and 4) predominance of MPC1-CD49e-CD45+ phenotype immature myeloma cells.
p2542
sg4
(lp2543
(dp2544
g9
I212
sg20
VP28062
p2545
sg12
I4
sg13
VMPC1
p2546
sg15
I1
sa(dp2547
g9
I223
sg20
VP08575
p2548
sg12
I5
sg13
VCD45+
p2549
sg15
I1
sa(dp2550
g9
I217
sg20
VP08648
p2551
sg12
I5
sg13
VCD49e
p2552
sg15
I1
sasg6
(lp2553
(dp2554
g9
I99
sg10
VC0026764
p2555
sg12
I7
sg13
Vmyeloma
p2556
sg15
I1
sa(dp2557
g9
I111
sg10
VC0013687
p2558
sg12
I8
sg13
Veffusion
p2559
sg15
I1
sa(dp2560
g9
I99
sg10
VC0026764
p2561
sg12
I7
sg13
Vmyeloma
p2562
sg15
I1
sa(dp2563
g9
I73
sg10
VC0032131
p2564
sg12
I13
sg13
Vplasmacytomas
p2565
sg15
I1
sasa(dp2566
g2
VCD32 was significantly expressed on primary myeloma cells, but immature, MPC-1- myeloma cells expressed CD32 more weakly than mature, MPC-1+ cells.
p2567
sg4
(lp2568
(dp2569
g9
I0
sg20
VP12318
p2570
sg12
I4
sg13
VCD32
p2571
sg15
I1
sa(dp2572
g9
I73
sg20
VP28062
p2573
sg12
I5
sg13
VMPC-1
p2574
sg15
I1
sa(dp2575
g9
I0
sg20
VP12318
p2576
sg12
I4
sg13
VCD32
p2577
sg15
I1
sasg6
(lp2578
(dp2579
g9
I44
sg10
VC0026764
p2580
sg12
I7
sg13
Vmyeloma
p2581
sg15
I1
sa(dp2582
g9
I44
sg10
VC0026764
p2583
sg12
I7
sg13
Vmyeloma
p2584
sg15
I1
sasa(dp2585
g2
VTreatment with anti-CD32 antibody decreased the viability of normal plasma cells (CD38++ CD19+) more than that of myeloma cells (CD38++ CD19-); CD32-mediated growth suppression was greater in mature MPC-1+ cells than in immature MPC-1- cells.
p2586
sg4
(lp2587
(dp2588
g9
I15
sg20
VP12318
p2589
sg12
I18
sg13
Vanti-CD32 antibody
p2590
sg15
I2
sa(dp2591
g9
I82
sg20
VP28907
p2592
sg12
I12
sg13
VCD38++ CD19+
p2593
sg15
I2
sa(dp2594
g9
I20
sg20
VP12318
p2595
sg12
I4
sg13
VCD32
p2596
sg15
I1
sasg6
(lp2597
(dp2598
g9
I158
sg10
VC0151686
p2599
sg12
I18
sg13
Vgrowth suppression
p2600
sg15
I2
sa(dp2601
g9
I114
sg10
VC0026764
p2602
sg12
I7
sg13
Vmyeloma
p2603
sg15
I1
sasa(dp2604
g2
VTo date, at least 5 subpopulations of plasma cells have been identified in the bone marrow of multiple myeloma (MM) patients with regard to the expression of MPC-1, CD49e (VLA-5), and CD45: MPC-1(-)CD49e(-)CD45(+) proliferative immature cells, MPC-1(-)CD49e(-)CD45(-) immature myeloma cells, MPC-1(+)CD49e(-)CD45(-) and MPC-1(+)CD49e(-)CD45(+) intermediate myeloma cells, and MPC-1(+)CD49e(+)CD45(+) mature myeloma cells.
p2605
sg4
(lp2606
(dp2607
g9
I376
sg20
VP28062
p2608
sg12
I23
sg13
VMPC-1(+)CD49e(+)CD45(+)
p2609
sg15
I1
sa(dp2610
g9
I184
sg20
VP08575
p2611
sg12
I26
sg13
VCD45: MPC-1(-)CD49e(-)CD45
p2612
sg15
I2
sa(dp2613
g9
I158
sg20
VP28062
p2614
sg12
I5
sg13
VMPC-1
p2615
sg15
I1
sa(dp2616
g9
I260
sg20
VP08575
p2617
sg12
I7
sg13
VCD45(-)
p2618
sg15
I1
sa(dp2619
g9
I190
sg20
VP28062
p2620
sg12
I16
sg13
VMPC-1(-)CD49e(-)
p2621
sg15
I1
sa(dp2622
g9
I292
sg20
VP28062
p2623
sg12
I23
sg13
VMPC-1(+)CD49e(-)CD45(-)
p2624
sg15
I1
sa(dp2625
g9
I172
sg20
VP08648
p2626
sg12
I5
sg13
VVLA-5
p2627
sg15
I1
sa(dp2628
g9
I165
sg20
VP08648
p2629
sg12
I5
sg13
VCD49e
p2630
sg15
I1
sa(dp2631
g9
I320
sg20
VP28062
p2632
sg12
I23
sg13
VMPC-1(+)CD49e(-)CD45(+)
p2633
sg15
I1
sasg6
(lp2634
(dp2635
g9
I103
sg10
VC0026764
p2636
sg12
I7
sg13
Vmyeloma
p2637
sg15
I1
sa(dp2638
g9
I94
sg10
VC0026764
p2639
sg12
I16
sg13
Vmultiple myeloma
p2640
sg15
I2
sa(dp2641
g9
I214
sg10
VC0334094
p2642
sg12
I13
sg13
Vproliferative
p2643
sg15
I1
sa(dp2644
g9
I112
sg10
VC0026764
p2645
sg12
I2
sg13
VMM
p2646
sg15
I1
sa(dp2647
g9
I103
sg10
VC0026764
p2648
sg12
I7
sg13
Vmyeloma
p2649
sg15
I1
sa(dp2650
g9
I103
sg10
VC0026764
p2651
sg12
I7
sg13
Vmyeloma
p2652
sg15
I1
sasa(dp2653
g2
VIn 31 cases of progressive MM disease, MPC-1(-) immature and MPC-1(-)CD45(+) proliferative immature myeloma cells were significantly increased up to &gt;25% and &gt;10%, respectively, of the plasma cell fractions (CD38(++) cells), whereas there were no increases in MPC-1(-) or MPC-1(-)CD45(+) proliferative immature myeloma cells in 15 cases of stable disease.
p2654
sg4
(lp2655
(dp2656
g9
I61
sg20
VP28062
p2657
sg12
I15
sg13
VMPC-1(-)CD45(+)
p2658
sg15
I1
sa(dp2659
g9
I214
sg20
VP28907
p2660
sg12
I4
sg13
VCD38
p2661
sg15
I1
sa(dp2662
g9
I61
sg20
VP28062
p2663
sg12
I15
sg13
VMPC-1(-)CD45(+)
p2664
sg15
I1
sa(dp2665
g9
I39
sg20
VP28062
p2666
sg12
I8
sg13
VMPC-1(-)
p2667
sg15
I1
sasg6
(lp2668
(dp2669
g9
I77
sg10
VC0334094
p2670
sg12
I13
sg13
Vproliferative
p2671
sg15
I1
sa(dp2672
g9
I77
sg10
VC0334094
p2673
sg12
I13
sg13
Vproliferative
p2674
sg15
I1
sa(dp2675
g9
I100
sg10
VC0026764
p2676
sg12
I7
sg13
Vmyeloma
p2677
sg15
I1
sa(dp2678
g9
I100
sg10
VC0026764
p2679
sg12
I7
sg13
Vmyeloma
p2680
sg15
I1
sasa(dp2681
g2
VInterestingly, the proportions of MPC-1(-) and MPC-1(-)CD45(+) immature monoclonal plasma cells also increased in the 7 progressive cases of MGUS.
p2682
sg4
(lp2683
(dp2684
g9
I47
sg20
VP28062
p2685
sg12
I15
sg13
VMPC-1(-)CD45(+)
p2686
sg15
I1
sa(dp2687
g9
I34
sg20
VP28062
p2688
sg12
I5
sg13
VMPC-1
p2689
sg15
I1
sasg6
(lp2690
(dp2691
g9
I141
sg10
VC0026470
p2692
sg12
I4
sg13
VMGUS
p2693
sg15
I1
sasa(dp2694
g2
VResults with flow cytometry using a combination of MPC1, CD49e, and CD45 supported the morphologic findings for the myeloma cells.
p2695
sg4
(lp2696
(dp2697
g9
I51
sg20
VP28062
p2698
sg12
I4
sg13
VMPC1
p2699
sg15
I1
sa(dp2700
g9
I57
sg20
VP08648
p2701
sg12
I5
sg13
VCD49e
p2702
sg15
I1
sa(dp2703
g9
I68
sg20
VP08575
p2704
sg12
I4
sg13
VCD45
p2705
sg15
I1
sasg6
(lp2706
(dp2707
g9
I116
sg10
VC0026764
p2708
sg12
I7
sg13
Vmyeloma
p2709
sg15
I1
sasa(dp2710
g2
VInterestingly, the region encompassing the SNF1LK locus has been implicated in congenital heart defects often observed in patients with Down syndrome.
p2711
sg4
(lp2712
(dp2713
g9
I43
sg20
VP57059
p2714
sg12
I12
sg13
VSNF1LK locus
p2715
sg15
I2
sasg6
(lp2716
(dp2717
g9
I136
sg10
VC0013080
p2718
sg12
I13
sg13
VDown syndrome
p2719
sg15
I2
sa(dp2720
g9
I79
sg10
VC0018798
p2721
sg12
I24
sg13
Vcongenital heart defects
p2722
sg15
I3
sasa(dp2723
g2
VOn the other hand, a significant increase was demonstrated in CD14-positive cells at 3 weeks after immunization in only arthritis-developed monkeys regardless of sex.
p2724
sg4
(lp2725
(dp2726
g9
I62
sg20
VP08571
p2727
sg12
I4
sg13
VCD14
p2728
sg15
I1
sasg6
(lp2729
(dp2730
g9
I120
sg10
VC0003864
p2731
sg12
I9
sg13
Varthritis
p2732
sg15
I1
sasa(dp2733
g2
VWe previously reported the accumulation of abnormal myeloid cell populations reacting with CD14 (MY4) monoclonal antibody in the iliac and epiphyseal bone marrow of patients with severe rheumatoid arthritis (RA).
p2734
sg4
(lp2735
(dp2736
g9
I91
sg20
VP08571
p2737
sg12
I4
sg13
VCD14
p2738
sg15
I1
sasg6
(lp2739
(dp2740
g9
I208
sg10
VC0003873
p2741
sg12
I2
sg13
VRA
p2742
sg15
I1
sa(dp2743
g9
I186
sg10
VC0003873
p2744
sg12
I20
sg13
Vrheumatoid arthritis
p2745
sg15
I2
sasa(dp2746
g2
VPrior to treatment, monocyte-macrophage activation in rheumatoid arthritis was signified by an increased expression of HLA-class II antigens and the CD14 antigen, and by an increased production of neopterin and interleukin-1.
p2747
sg4
(lp2748
(dp2749
g9
I149
sg20
VP08571
p2750
sg12
I12
sg13
VCD14 antigen
p2751
sg15
I2
sa(dp2752
g9
I211
sg20
VP60568
p2753
sg12
I13
sg13
Vinterleukin-1
p2754
sg15
I1
sa(dp2755
g9
I119
sg20
VP30486
p2756
sg12
I21
sg13
VHLA-class II antigens
p2757
sg15
I3
sasg6
(lp2758
(dp2759
g9
I54
sg10
VC0003873
p2760
sg12
I20
sg13
Vrheumatoid arthritis
p2761
sg15
I2
sasa(dp2762
g2
VMonocytes, defined by staining with the Mo-2 and Leu-M3 monoclonal antibodies which both detect the CD14 antigen, were studied in peripheral blood of control subjects and patients with rheumatoid arthritis as well as in rheumatoid synovial fluid of the latter for expression of activation/differentiation markers.
p2763
sg4
(lp2764
(dp2765
g9
I49
sg20
VP30740
p2766
sg12
I28
sg13
VLeu-M3 monoclonal antibodies
p2767
sg15
I3
sa(dp2768
g9
I100
sg20
VP08571
p2769
sg12
I12
sg13
VCD14 antigen
p2770
sg15
I2
sasg6
(lp2771
(dp2772
g9
I185
sg10
VC0003873
p2773
sg12
I20
sg13
Vrheumatoid arthritis
p2774
sg15
I2
sasa(dp2775
g2
VWe review recent findings implicating variants of FCRL3 (gene for FC receptor-like-3 protein), SCGB3A2 (gene for secretory uteroglobin-related protein 1- UGRP1) as well as other unverified possible candidate genes for GD selected through their documented association with type 1 diabetes mellitus: Tenr-IL2-IL21, CAPSL (encoding calcyphosine-like protein), IFIH1(gene for interferon-induced helicase C domain 1), AFF3, CD226 and PTPN2.
p2776
sg4
(lp2777
(dp2778
g9
I413
sg20
VP51826
p2779
sg12
I4
sg13
VAFF3
p2780
sg15
I1
sa(dp2781
g9
I307
sg20
g21
sg12
I4
sg13
VIL21
p2782
sg15
I1
sa(dp2783
g9
I113
sg20
VP11684
p2784
sg12
I46
sg13
Vsecretory uteroglobin-related protein 1- UGRP1
p2785
sg15
I5
sa(dp2786
g9
I50
sg20
g21
sg12
I5
sg13
VFCRL3
p2787
sg15
I1
sa(dp2788
g9
I329
sg20
g21
sg12
I25
sg13
Vcalcyphosine-like protein
p2789
sg15
I2
sa(dp2790
g9
I429
sg20
VP17706
p2791
sg12
I5
sg13
VPTPN2
p2792
sg15
I1
sa(dp2793
g9
I66
sg20
g21
sg12
I26
sg13
VFC receptor-like-3 protein
p2794
sg15
I3
sa(dp2795
g9
I372
sg20
VP01563
p2796
sg12
I38
sg13
Vinterferon-induced helicase C domain 1
p2797
sg15
I5
sa(dp2798
g9
I357
sg20
g21
sg12
I5
sg13
VIFIH1
p2799
sg15
I1
sa(dp2800
g9
I95
sg20
g21
sg12
I7
sg13
VSCGB3A2
p2801
sg15
I1
sa(dp2802
g9
I303
sg20
VP60568
p2803
sg12
I3
sg13
VIL2
p2804
sg15
I1
sa(dp2805
g9
I419
sg20
g21
sg12
I5
sg13
VCD226
p2806
sg15
I1
sa(dp2807
g9
I313
sg20
g21
sg12
I5
sg13
VCAPSL
p2808
sg15
I1
sasg6
(lp2809
(dp2810
g9
I272
sg10
VC0011854
p2811
sg12
I24
sg13
Vtype 1 diabetes mellitus
p2812
sg15
I4
sasa(dp2813
g2
VAutoantibody-positive diabetic subjects (n = 1,384) and population-based control subjects (n = 2,235) were genotyped at 20 childhood-onset type 1 diabetes loci and FCRL3, GAD2, TCF7L2, and FTO.
p2814
sg4
(lp2815
(dp2816
g9
I171
sg20
g21
sg12
I4
sg13
VGAD2
p2817
sg15
I1
sasg6
(lp2818
(dp2819
g9
I139
sg10
VC0011854
p2820
sg12
I15
sg13
Vtype 1 diabetes
p2821
sg15
I3
sasa(dp2822
g2
VWe analyzed the same four 5' FCRL3 single nucleotide polymorphism markers, together with three additional exonic single nucleotide polymorphisms in the FCRL3 gene, in cohorts of white Caucasians with Graves' disease (n = 625), type 1 diabetes (n = 279), autoimmune Addison's disease (AAD; n = 200), and RA (n = 769).
p2823
sg4
(lp2824
sg6
(lp2825
(dp2826
g9
I227
sg10
VC0011854
p2827
sg12
I15
sg13
Vtype 1 diabetes
p2828
sg15
I3
sa(dp2829
g9
I254
sg10
VC0271737
p2830
sg12
I28
sg13
Vautoimmune Addison's disease
p2831
sg15
I3
sa(dp2832
g9
I200
sg10
VC0018213
p2833
sg12
I15
sg13
VGraves' disease
p2834
sg15
I2
sa(dp2835
g9
I284
sg10
VC0271737
p2836
sg12
I3
sg13
VAAD
p2837
sg15
I1
sasa(dp2838
g2
VIn vivo, in a model of experimental autoimmune encephalomyelitis, we show that an agonist of DR3 suppressed disease, correlating with expansion of CD4+Foxp3+ Tregs, and this protective effect was lost in Galectin-9-/- mice.
p2839
sg4
(lp2840
(dp2841
g9
I147
sg20
VP01730
p2842
sg12
I10
sg13
VCD4+Foxp3+
p2843
sg15
I1
sa(dp2844
g9
I204
sg20
g21
sg12
I10
sg13
VGalectin-9
p2845
sg15
I1
sasg6
(lp2846
(dp2847
g9
I36
sg10
VC0443146
p2848
sg12
I10
sg13
Vautoimmune
p2849
sg15
I1
sa(dp2850
g9
I47
sg10
VC0014070
p2851
sg12
I17
sg13
Vencephalomyelitis
p2852
sg15
I1
sasa(dp2853
g2
VGalectin-9 concentrations in CSF were higher in SPMS patients than healthy controls and RRMS patients in both cohorts.
p2854
sg4
(lp2855
(dp2856
g9
I0
sg20
g21
sg12
I10
sg13
VGalectin-9
p2857
sg15
I1
sasg6
(lp2858
sa(dp2859
g2
VOur objective is to identify phenotypically the position of CD43(+) B cells among peripheral B-lineage cell compartments in healthy donors, with reference to B-cell subsets from patients with systemic lupus erythematosus (SLE).
p2860
sg4
(lp2861
(dp2862
g9
I60
sg20
VP16150
p2863
sg12
I4
sg13
VCD43
p2864
sg15
I1
sasg6
(lp2865
(dp2866
g9
I192
sg10
VC0024141
p2867
sg12
I28
sg13
Vsystemic lupus erythematosus
p2868
sg15
I3
sa(dp2869
g9
I222
sg10
VC0024141
p2870
sg12
I3
sg13
VSLE
p2871
sg15
I1
sasa(dp2872
g2
VPrevious studies indicate that CD43 plays a role in regulating the adhesion of lymphocytes, cell mutation and activation, however, little is known about its effect on systemic lupus erythematosus (SLE).
p2873
sg4
(lp2874
(dp2875
g9
I31
sg20
VP16150
p2876
sg12
I4
sg13
VCD43
p2877
sg15
I1
sasg6
(lp2878
(dp2879
g9
I197
sg10
VC0024141
p2880
sg12
I3
sg13
VSLE
p2881
sg15
I1
sa(dp2882
g9
I67
sg10
VC0001511
p2883
sg12
I8
sg13
Vadhesion
p2884
sg15
I1
sa(dp2885
g9
I167
sg10
VC0024141
p2886
sg12
I28
sg13
Vsystemic lupus erythematosus
p2887
sg15
I3
sasa(dp2888
g2
VTwo new cases of primary Ficolin-3 deficiency are reported here: a 50-year old male, suffering from membranous nephropathy and an 11-month old male infant who was operated on to repair congenital heart disease.
p2889
sg4
(lp2890
(dp2891
g9
I25
sg20
g21
sg12
I9
sg13
VFicolin-3
p2892
sg15
I1
sasg6
(lp2893
(dp2894
g9
I185
sg10
VC0152021
p2895
sg12
I24
sg13
Vcongenital heart disease
p2896
sg15
I3
sa(dp2897
g9
I85
sg10
VC0683278
p2898
sg12
I9
sg13
Vsuffering
p2899
sg15
I1
sa(dp2900
g9
I100
sg10
VC0017665
p2901
sg12
I22
sg13
Vmembranous nephropathy
p2902
sg15
I2
sasa(dp2903
g2
VIn order to investigate its potential pathogenicity for turkeys a UK isolate of Mim from a partridge with sinusitis was first passaged through turkey poults and then assessed for pathogenicity in turkey embryo tracheal organ cultures (TOCs) and in one-day-old turkey poults with or without turkey rhinotracheitis virus (TRTV).
p2904
sg4
(lp2905
(dp2906
g9
I80
sg20
g21
sg12
I3
sg13
VMim
p2907
sg15
I1
sasg6
(lp2908
(dp2909
g9
I290
sg10
VC0275744
p2910
sg12
I22
sg13
Vturkey rhinotracheitis
p2911
sg15
I2
sa(dp2912
g9
I106
sg10
VC0037199
p2913
sg12
I9
sg13
Vsinusitis
p2914
sg15
I1
sasa(dp2915
g2
VBoth up- and down-regulation of the Toll-like receptors (TLRs) and antimicrobial peptides (AMPs) of the sinonasal mucosa have already been associated with the pathogenesis of chronic rhinosinusitis with (CRSwNP) or without (CRSsNP) nasal polyps.
p2916
sg4
(lp2917
(dp2918
g9
I36
sg20
g21
sg12
I19
sg13
VToll-like receptors
p2919
sg15
I2
sa(dp2920
g9
I57
sg20
g21
sg12
I4
sg13
VTLRs
p2921
sg15
I1
sasg6
(lp2922
(dp2923
g9
I159
sg10
VC0699748
p2924
sg12
I12
sg13
Vpathogenesis
p2925
sg15
I1
sa(dp2926
g9
I175
sg10
VC0149516
p2927
sg12
I22
sg13
Vchronic rhinosinusitis
p2928
sg15
I2
sa(dp2929
g9
I232
sg10
VC0027430
p2930
sg12
I12
sg13
Vnasal polyps
p2931
sg15
I2
sasa(dp2932
g2
VIt is suggested that elevated plasma nociceptin level found in Wilson disease patients is due to inhibition of nociceptin-inactivating Zn-metallopeptidases (aminopeptidase N (APN) and endopeptidase 24.15) by the toxic copper deposits in liver and/or brain.
p2933
sg4
(lp2934
(dp2935
g9
I175
sg20
g21
sg12
I3
sg13
VAPN
p2936
sg15
I1
sa(dp2937
g9
I111
sg20
g21
sg12
I44
sg13
Vnociceptin-inactivating Zn-metallopeptidases
p2938
sg15
I2
sa(dp2939
g9
I184
sg20
VP52888
p2940
sg12
I19
sg13
Vendopeptidase 24.15
p2941
sg15
I2
sa(dp2942
g9
I157
sg20
VP15144
p2943
sg12
I16
sg13
Vaminopeptidase N
p2944
sg15
I2
sa(dp2945
g9
I30
sg20
g21
sg12
I17
sg13
Vplasma nociceptin
p2946
sg15
I2
sasg6
(lp2947
(dp2948
g9
I63
sg10
VC0019202
p2949
sg12
I14
sg13
VWilson disease
p2950
sg15
I2
sasa(dp2951
g2
VIt is evident from the study that body iron (serum iron, TIBC &amp; transferrin saturation) level significantly increases among acute myocardial infarction patients in Bangladesh.
p2952
sg4
(lp2953
(dp2954
g9
I68
sg20
VP02787
p2955
sg12
I11
sg13
Vtransferrin
p2956
sg15
I1
sasg6
(lp2957
(dp2958
g9
I128
sg10
VC0155626
p2959
sg12
I27
sg13
Vacute myocardial infarction
p2960
sg15
I3
sasa(dp2961
g2
VWe investigated the relation of NTBI, serum iron, transferrin saturation, and serum ferritin with risk of CHD and acute myocardial infarction (AMI).
p2962
sg4
(lp2963
(dp2964
g9
I78
sg20
VP02794
p2965
sg12
I14
sg13
Vserum ferritin
p2966
sg15
I2
sa(dp2967
g9
I50
sg20
VP02787
p2968
sg12
I11
sg13
Vtransferrin
p2969
sg15
I1
sasg6
(lp2970
(dp2971
g9
I114
sg10
VC0155626
p2972
sg12
I27
sg13
Vacute myocardial infarction
p2973
sg15
I3
sa(dp2974
g9
I143
sg10
VC0155626
p2975
sg12
I3
sg13
VAMI
p2976
sg15
I1
sasa(dp2977
g2
VIn this study, the effects of chiral pesticide metalaxyl on CYP1A1, CYP1A2, CYP2B1, CYP2B2, CYP2E1 and CYP3A were investigated in human hepatoma HepG2, rat hepatic H4IIE, chicken hepatic LMH and grass carp hepatic L8824 cells.
p2978
sg4
(lp2979
(dp2980
g9
I171
sg20
g21
sg12
I19
sg13
Vchicken hepatic LMH
p2981
sg15
I3
sa(dp2982
g9
I68
sg20
VP05177
p2983
sg12
I6
sg13
VCYP1A2
p2984
sg15
I1
sa(dp2985
g9
I92
sg20
VP05181
p2986
sg12
I6
sg13
VCYP2E1
p2987
sg15
I1
sa(dp2988
g9
I60
sg20
VP04798
p2989
sg12
I6
sg13
VCYP1A1
p2990
sg15
I1
sa(dp2991
g9
I103
sg20
VP08684
p2992
sg12
I5
sg13
VCYP3A
p2993
sg15
I1
sasg6
(lp2994
(dp2995
g9
I201
sg10
VC0263385
p2996
sg12
I4
sg13
Vcarp
p2997
sg15
I1
sa(dp2998
g9
I136
sg10
VC0023903
p2999
sg12
I8
sg13
Vhepatoma
p3000
sg15
I1
sasa(dp3001
g2
VER+ cancers exhibited lower ADORA1, ADORA2B, and RYR1 and elevated PDE4A, CYP2A6, and CYP2E expressions.
p3002
sg4
(lp3003
(dp3004
g9
I28
sg20
VP30542
p3005
sg12
I6
sg13
VADORA1
p3006
sg15
I1
sa(dp3007
g9
I36
sg20
VP29275
p3008
sg12
I7
sg13
VADORA2B
p3009
sg15
I1
sa(dp3010
g9
I86
sg20
VP05181
p3011
sg12
I5
sg13
VCYP2E
p3012
sg15
I1
sa(dp3013
g9
I49
sg20
VP21817
p3014
sg12
I4
sg13
VRYR1
p3015
sg15
I1
sasg6
(lp3016
(dp3017
g9
I4
sg10
VC0006826
p3018
sg12
I7
sg13
Vcancers
p3019
sg15
I1
sasa(dp3020
g2
VThe mechanisms were investigated by detecting levels of NADPH Oxidase 4 (NOX4),p22phox, cytochrome P4502E1 (CYP2E1),Bax,B-cell lymphoma 2 (Bcl-2),cleaved-caspase 3 and 9 and phosphorylated extracellular regulated protein kinases(ERK),phosphorylated c-Jun N-terminal kinase (JNK), and phosphorylated p38 mitogen-activated protein kinase (MAPK) using real-time polymerase chain reaction (PCR) and Western blotting.
p3021
sg4
(lp3022
(dp3023
g9
I337
sg20
VP53779
p3024
sg12
I4
sg13
VMAPK
p3025
sg15
I1
sa(dp3026
g9
I249
sg20
VP53779
p3027
sg12
I23
sg13
Vc-Jun N-terminal kinase
p3028
sg15
I3
sa(dp3029
g9
I79
sg20
VP13498
p3030
sg12
I7
sg13
Vp22phox
p3031
sg15
I1
sa(dp3032
g9
I299
sg20
g21
sg12
I36
sg13
Vp38 mitogen-activated protein kinase
p3033
sg15
I4
sa(dp3034
g9
I108
sg20
VP05181
p3035
sg12
I6
sg13
VCYP2E1
p3036
sg15
I1
sa(dp3037
g9
I274
sg20
VP53779
p3038
sg12
I3
sg13
VJNK
p3039
sg15
I1
sa(dp3040
g9
I88
sg20
VP05181
p3041
sg12
I18
sg13
Vcytochrome P4502E1
p3042
sg15
I2
sa(dp3043
g9
I154
sg20
VP39880
p3044
sg12
I7
sg13
Vcaspase
p3045
sg15
I1
sa(dp3046
g9
I115
sg20
VP10415
p3047
sg12
I22
sg13
V,Bax,B-cell lymphoma 2
p3048
sg15
I3
sa(dp3049
g9
I56
sg20
g21
sg12
I15
sg13
VNADPH Oxidase 4
p3050
sg15
I3
sa(dp3051
g9
I189
sg20
VP10398
p3052
sg12
I39
sg13
Vextracellular regulated protein kinases
p3053
sg15
I4
sa(dp3054
g9
I73
sg20
g21
sg12
I4
sg13
VNOX4
p3055
sg15
I1
sa(dp3056
g9
I229
sg20
VP29323
p3057
sg12
I3
sg13
VERK
p3058
sg15
I1
sa(dp3059
g9
I139
sg20
VP10415
p3060
sg12
I5
sg13
VBcl-2
p3061
sg15
I1
sasg6
(lp3062
(dp3063
g9
I120
sg10
VC0079731
p3064
sg12
I15
sg13
VB-cell lymphoma
p3065
sg15
I2
sasa(dp3066
g2
VTwenty-two variants from 21 genes (APEX1 rs1130409 and rs1760944, ATM rs664677, AXIN2 rs2240308, CHRNA3 rs6495309, CHRNA5 rs16969968, CLPTM1L rs402710, CXCR2 rs1126579, CYP1A1 rs4646903, CYP2E1 rs6413432, ERCC1 rs11615, ERCC2 rs13181, FGFR4 rs351855, HYKK rs931794, MIR146A rs2910164, MIR196A2 rs11614913, OGG1 rs1052133, PON1 rs662, REV3L rs462779, SOD2 rs4880, TERT rs2736098, and TP53 rs1042522) showed significant associations with lung cancer susceptibility with strong cumulative epidemiological evidence.
p3067
sg4
(lp3068
(dp3069
g9
I322
sg20
VP27169
p3070
sg12
I10
sg13
VPON1 rs662
p3071
sg15
I2
sa(dp3072
g9
I35
sg20
VP27695
p3073
sg12
I15
sg13
VAPEX1 rs1130409
p3074
sg15
I2
sa(dp3075
g9
I205
sg20
VP07992
p3076
sg12
I13
sg13
VERCC1 rs11615
p3077
sg15
I2
sa(dp3078
g9
I334
sg20
g21
sg12
I14
sg13
VREV3L rs462779
p3079
sg15
I2
sa(dp3080
g9
I436
sg20
g21
sg12
I26
sg13
Vlung cancer susceptibility
p3081
sg15
I3
sa(dp3082
g9
I363
sg20
g21
sg12
I14
sg13
VTERT rs2736098
p3083
sg15
I2
sa(dp3084
g9
I80
sg20
g21
sg12
I15
sg13
VAXIN2 rs2240308
p3085
sg15
I2
sa(dp3086
g9
I350
sg20
VP04179
p3087
sg12
I11
sg13
VSOD2 rs4880
p3088
sg15
I2
sa(dp3089
g9
I169
sg20
VP04798
p3090
sg12
I16
sg13
VCYP1A1 rs4646903
p3091
sg15
I2
sa(dp3092
g9
I235
sg20
VP22455
p3093
sg12
I14
sg13
VFGFR4 rs351855
p3094
sg15
I2
sa(dp3095
g9
I97
sg20
VP32297
p3096
sg12
I16
sg13
VCHRNA3 rs6495309
p3097
sg15
I2
sa(dp3098
g9
I66
sg20
g21
sg12
I12
sg13
VATM rs664677
p3099
sg15
I2
sa(dp3100
g9
I187
sg20
VP05181
p3101
sg12
I16
sg13
VCYP2E1 rs6413432
p3102
sg15
I2
sa(dp3103
g9
I115
sg20
VP30532
p3104
sg12
I17
sg13
VCHRNA5 rs16969968
p3105
sg15
I2
sa(dp3106
g9
I134
sg20
g21
sg12
I16
sg13
VCLPTM1L rs402710
p3107
sg15
I2
sa(dp3108
g9
I220
sg20
VP18074
p3109
sg12
I13
sg13
VERCC2 rs13181
p3110
sg15
I2
sa(dp3111
g9
I152
sg20
VP25025
p3112
sg12
I15
sg13
VCXCR2 rs1126579
p3113
sg15
I2
sasg6
(lp3114
(dp3115
g9
I436
sg10
VC0684249
p3116
sg12
I11
sg13
Vlung cancer
p3117
sg15
I2
sasa(dp3118
g2
VThis study aimed to determine the serum levels of angiopoietin-like 4 (ANGPTL4) in patients with renal cell carcinoma (RCC) and explore its potential as a biomarker.
p3119
sg4
(lp3120
(dp3121
g9
I50
sg20
g21
sg12
I19
sg13
Vangiopoietin-like 4
p3122
sg15
I2
sa(dp3123
g9
I71
sg20
g21
sg12
I7
sg13
VANGPTL4
p3124
sg15
I1
sasg6
(lp3125
(dp3126
g9
I119
sg10
VC0007134
p3127
sg12
I3
sg13
VRCC
p3128
sg15
I1
sa(dp3129
g9
I97
sg10
VC0007134
p3130
sg12
I20
sg13
Vrenal cell carcinoma
p3131
sg15
I3
sasa(dp3132
g2
VWe have previously shown that angiopoietin-like 4 (angptl4) mRNA, a hypoxia-inducible gene, is highly expressed in clear cell renal-cell carcinoma (ccRCC), the most common subtype of RCC for which no specific marker is available.
p3133
sg4
(lp3134
(dp3135
g9
I51
sg20
g21
sg12
I7
sg13
Vangptl4
p3136
sg15
I1
sa(dp3137
g9
I30
sg20
g21
sg12
I19
sg13
Vangiopoietin-like 4
p3138
sg15
I2
sasg6
(lp3139
(dp3140
g9
I68
sg10
VC0242184
p3141
sg12
I7
sg13
Vhypoxia
p3142
sg15
I1
sa(dp3143
g9
I137
sg10
VC0007097
p3144
sg12
I9
sg13
Vcarcinoma
p3145
sg15
I1
sa(dp3146
g9
I150
sg10
VC0007134
p3147
sg12
I3
sg13
VRCC
p3148
sg15
I1
sasa(dp3149
g2
VWe observed particularly high levels of ANGPTL4 mRNA in tumor cells of conventional renal cell carcinoma.
p3150
sg4
(lp3151
(dp3152
g9
I40
sg20
g21
sg12
I12
sg13
VANGPTL4 mRNA
p3153
sg15
I2
sasg6
(lp3154
(dp3155
g9
I56
sg10
VC0027651
p3156
sg12
I5
sg13
Vtumor
p3157
sg15
I1
sa(dp3158
g9
I71
sg10
VC0279702
p3159
sg12
I33
sg13
Vconventional renal cell carcinoma
p3160
sg15
I4
sasa(dp3161
g2
VResults The smoking subgroup (n=15) of NSIP patients had a significantly lower % diffusing capacity for carbon monoxide/ alveolar ventilation (DLCO/VA) and tended to have higher SP-D values than the nonsmoking subgroup (n=16).
p3162
sg4
(lp3163
sg6
(lp3164
sa(dp3165
g2
VAs compared with major IIPs such as idiopathic pulmonary fibrosis and fibrotic nonspecific interstitial pneumonia, IPPFE significantly showed higher frequency of cases with a unique pattern of serum biomarkers, which is characterized by an elevated level of SP-D with a normal range of KL-6.
p3166
sg4
(lp3167
(dp3168
g9
I258
sg20
VP35247
p3169
sg12
I4
sg13
VSP-D
p3170
sg15
I1
sasg6
(lp3171
(dp3172
g9
I36
sg10
VC3161101
p3173
sg12
I29
sg13
Vidiopathic pulmonary fibrosis
p3174
sg15
I3
sa(dp3175
g9
I79
sg10
VC1290344
p3176
sg12
I34
sg13
Vnonspecific interstitial pneumonia
p3177
sg15
I3
sasa(dp3178
g2
VHowever, associations of serum KL-6 and SP-D with radiologic findings in nonspecific interstitial pneumonia (NSIP) remain unclear.
p3179
sg4
(lp3180
(dp3181
g9
I25
sg20
g21
sg12
I10
sg13
Vserum KL-6
p3182
sg15
I2
sa(dp3183
g9
I40
sg20
VP35247
p3184
sg12
I4
sg13
VSP-D
p3185
sg15
I1
sasg6
(lp3186
(dp3187
g9
I109
sg10
VC1290344
p3188
sg12
I4
sg13
VNSIP
p3189
sg15
I1
sa(dp3190
g9
I73
sg10
VC1290344
p3191
sg12
I34
sg13
Vnonspecific interstitial pneumonia
p3192
sg15
I3
sasa(dp3193
g2
VTo determine whether serum levels of KL-6 and SP-D reflect fibrotic and/or inflammatory processes in NSIP, we investigated the correlation between high-resolution computed tomography (HRCT) findings and serum KL-6 and SP-D levels.
p3194
sg4
(lp3195
(dp3196
g9
I46
sg20
VP35247
p3197
sg12
I4
sg13
VSP-D
p3198
sg15
I1
sa(dp3199
g9
I46
sg20
VP35247
p3200
sg12
I4
sg13
VSP-D
p3201
sg15
I1
sasg6
(lp3202
sa(dp3203
g2
VSerum levels of KL-6 and SP-D were measured in 21 patients with biopsy-confirmed NSIP.
p3204
sg4
(lp3205
(dp3206
g9
I25
sg20
VP35247
p3207
sg12
I4
sg13
VSP-D
p3208
sg15
I1
sasg6
(lp3209
sa(dp3210
g2
VSerum levels of SP-D in NSIP showed a positive correlation with the area of ground-glass attenuation without traction bronchiectasis and the inflammatory CT pattern, but the levels were inversely correlated with the area of ground-glass attenuation with traction bronchiectasis and the fibrotic CT pattern.
p3211
sg4
(lp3212
(dp3213
g9
I16
sg20
VP35247
p3214
sg12
I4
sg13
VSP-D
p3215
sg15
I1
sasg6
(lp3216
(dp3217
g9
I109
sg10
VC0264361
p3218
sg12
I23
sg13
Vtraction bronchiectasis
p3219
sg15
I2
sa(dp3220
g9
I109
sg10
VC0264361
p3221
sg12
I23
sg13
Vtraction bronchiectasis
p3222
sg15
I2
sasa(dp3223
g2
VThe results indicate that serum levels of KL-6 in NSIP reflect the overall extent of interstitial lesions, which include both inflammatory and fibrotic lesions, while the levels of SP-D mainly reflect the extent of inflammatory lesions.
p3224
sg4
(lp3225
(dp3226
g9
I181
sg20
VP35247
p3227
sg12
I4
sg13
VSP-D
p3228
sg15
I1
sasg6
(lp3229
sa(dp3230
g2
VRecently, we identified high expression of 2 RHOGAPs, ARHGAP11A and RACGAP1, in the basal-like breast cancer subtype.
p3231
sg4
(lp3232
(dp3233
g9
I68
sg20
g21
sg12
I7
sg13
VRACGAP1
p3234
sg15
I1
sa(dp3235
g9
I54
sg20
g21
sg12
I9
sg13
VARHGAP11A
p3236
sg15
I1
sasg6
(lp3237
(dp3238
g9
I95
sg10
VC0678222
p3239
sg12
I13
sg13
Vbreast cancer
p3240
sg15
I2
sasa(dp3241
g2
VWe have established that, via the suppression of RhoA, ArhGAP11A and RacGAP1 are both critical drivers of BLBC growth, and propose that RhoGAPs can act as oncogenes in cancer.
p3242
sg4
(lp3243
(dp3244
g9
I69
sg20
g21
sg12
I7
sg13
VRacGAP1
p3245
sg15
I1
sa(dp3246
g9
I49
sg20
VP61586
p3247
sg12
I4
sg13
VRhoA
p3248
sg15
I1
sa(dp3249
g9
I55
sg20
g21
sg12
I9
sg13
VArhGAP11A
p3250
sg15
I1
sasg6
(lp3251
(dp3252
g9
I168
sg10
VC0006826
p3253
sg12
I6
sg13
Vcancer
p3254
sg15
I1
sa(dp3255
g9
I34
sg10
VC0221103
p3256
sg12
I11
sg13
Vsuppression
p3257
sg15
I1
sasa(dp3258
g2
VWe found significant methylation differences at a number of experimentally implicated breast cancer-related genes, including attenuated 5' untranslated region (UTR)/first exon methylation at the proinvasive ARHGAP11A gene in variant mimic-transfected cells.
p3259
sg4
(lp3260
(dp3261
g9
I207
sg20
g21
sg12
I14
sg13
VARHGAP11A gene
p3262
sg15
I2
sasg6
(lp3263
(dp3264
g9
I86
sg10
VC0678222
p3265
sg12
I13
sg13
Vbreast cancer
p3266
sg15
I2
sasa(dp3267
g2
VFollow-up functional analyses revealed both concurrent increased ARHGAP11A mRNA expression and enhanced invasiveness in variant versus WT piR-021285 mimic-transfected breast cancer cell lines.
p3268
sg4
(lp3269
(dp3270
g9
I65
sg20
g21
sg12
I14
sg13
VARHGAP11A mRNA
p3271
sg15
I2
sasg6
(lp3272
(dp3273
g9
I167
sg10
VC0678222
p3274
sg12
I13
sg13
Vbreast cancer
p3275
sg15
I2
sasa(dp3276
g2
VExpression of ARHGAP11A in cancer cells suppressed RhoA-dependent mechanisms, such as stress fiber formation and focal adhesion, which made the cells more prone to migrate.
p3277
sg4
(lp3278
(dp3279
g9
I14
sg20
g21
sg12
I9
sg13
VARHGAP11A
p3280
sg15
I1
sa(dp3281
g9
I51
sg20
VP61586
p3282
sg12
I4
sg13
VRhoA
p3283
sg15
I1
sasg6
(lp3284
(dp3285
g9
I119
sg10
VC0001511
p3286
sg12
I8
sg13
Vadhesion
p3287
sg15
I1
sa(dp3288
g9
I27
sg10
VC0006826
p3289
sg12
I6
sg13
Vcancer
p3290
sg15
I1
sasa(dp3291
g2
VRNAi-based inhibition of Arhgap11a reduced the invasion and in vivo expansion of cancers.
p3292
sg4
(lp3293
(dp3294
g9
I25
sg20
g21
sg12
I9
sg13
VArhgap11a
p3295
sg15
I1
sasg6
(lp3296
(dp3297
g9
I81
sg10
VC0006826
p3298
sg12
I7
sg13
Vcancers
p3299
sg15
I1
sa(dp3300
g9
I47
sg10
VC2699153
p3301
sg12
I8
sg13
Vinvasion
p3302
sg15
I1
sasa(dp3303
g2
VAdditionally, analysis of human specimens showed the significant up-regulation of Arhgap11a in colon cancers, which was correlated with clinical invasion status.
p3304
sg4
(lp3305
(dp3306
g9
I82
sg20
g21
sg12
I9
sg13
VArhgap11a
p3307
sg15
I1
sasg6
(lp3308
(dp3309
g9
I95
sg10
VC0007102
p3310
sg12
I13
sg13
Vcolon cancers
p3311
sg15
I2
sa(dp3312
g9
I145
sg10
VC2699153
p3313
sg12
I8
sg13
Vinvasion
p3314
sg15
I1
sasa(dp3315
g2
VThe present study suggests that ARHGAP11A, a cell cycle-dependent RhoGAP, is a critical regulator of cancer cell mobility and is thus a promising therapeutic target in invasive cancers.
p3316
sg4
(lp3317
(dp3318
g9
I66
sg20
g21
sg12
I6
sg13
VRhoGAP
p3319
sg15
I1
sa(dp3320
g9
I32
sg20
g21
sg12
I9
sg13
VARHGAP11A
p3321
sg15
I1
sasg6
(lp3322
(dp3323
g9
I177
sg10
VC0006826
p3324
sg12
I7
sg13
Vcancers
p3325
sg15
I1
sa(dp3326
g9
I101
sg10
VC0006826
p3327
sg12
I6
sg13
Vcancer
p3328
sg15
I1
sasa(dp3329
g2
VIdentified genome-wide significant loci: 1) corroborated genes implicated in other studies (MTNR1B, ZNF259/APOA5, XPA/FOXE1 (TTF-2), DARC, CCR3, ABO); 2) localized novel genes in plausible biological pathways (PCSK2, ARHGAP11A, CHRNA3); and 3) revealed novel genes with unknown function in obesity pathogenesis (MATK, COL4A1).
p3330
sg4
(lp3331
(dp3332
g9
I312
sg20
VP42679
p3333
sg12
I4
sg13
VMATK
p3334
sg15
I1
sa(dp3335
g9
I114
sg20
VP23025
p3336
sg12
I3
sg13
VXPA
p3337
sg15
I1
sa(dp3338
g9
I139
sg20
VP51677
p3339
sg12
I4
sg13
VCCR3
p3340
sg15
I1
sa(dp3341
g9
I118
sg20
g21
sg12
I5
sg13
VFOXE1
p3342
sg15
I1
sa(dp3343
g9
I125
sg20
g21
sg12
I5
sg13
VTTF-2
p3344
sg15
I1
sa(dp3345
g9
I318
sg20
VP02462
p3346
sg12
I6
sg13
VCOL4A1
p3347
sg15
I1
sa(dp3348
g9
I210
sg20
VP16519
p3349
sg12
I5
sg13
VPCSK2
p3350
sg15
I1
sa(dp3351
g9
I217
sg20
g21
sg12
I9
sg13
VARHGAP11A
p3352
sg15
I1
sa(dp3353
g9
I100
sg20
g21
sg12
I6
sg13
VZNF259
p3354
sg15
I1
sa(dp3355
g9
I92
sg20
VP49286
p3356
sg12
I6
sg13
VMTNR1B
p3357
sg15
I1
sa(dp3358
g9
I228
sg20
VP32297
p3359
sg12
I6
sg13
VCHRNA3
p3360
sg15
I1
sa(dp3361
g9
I107
sg20
g21
sg12
I5
sg13
VAPOA5
p3362
sg15
I1
sasg6
(lp3363
(dp3364
g9
I290
sg10
VC0028754
p3365
sg12
I7
sg13
Vobesity
p3366
sg15
I1
sa(dp3367
g9
I298
sg10
VC0699748
p3368
sg12
I12
sg13
Vpathogenesis
p3369
sg15
I1
sasa(dp3370
g2
VIn contrast to GTG banding, array CGH determined the exact number of deleted genes and thus allowed the identification of candidate genes for cleft palate (GREM1, CX36, MEIS2), congenital heart defect (ACTC, GREM1, CX36, MEIS2), and mental retardation (ARHGAP11A, CHRNA7, CHRM5).
p3371
sg4
(lp3372
(dp3373
g9
I169
sg20
g21
sg12
I5
sg13
VMEIS2
p3374
sg15
I1
sa(dp3375
g9
I163
sg20
g21
sg12
I4
sg13
VCX36
p3376
sg15
I1
sa(dp3377
g9
I272
sg20
VP08912
p3378
sg12
I5
sg13
VCHRM5
p3379
sg15
I1
sa(dp3380
g9
I202
sg20
VP68032
p3381
sg12
I4
sg13
VACTC
p3382
sg15
I1
sa(dp3383
g9
I264
sg20
VP36544
p3384
sg12
I6
sg13
VCHRNA7
p3385
sg15
I1
sa(dp3386
g9
I169
sg20
g21
sg12
I5
sg13
VMEIS2
p3387
sg15
I1
sa(dp3388
g9
I156
sg20
g21
sg12
I5
sg13
VGREM1
p3389
sg15
I1
sa(dp3390
g9
I156
sg20
g21
sg12
I5
sg13
VGREM1
p3391
sg15
I1
sa(dp3392
g9
I163
sg20
g21
sg12
I4
sg13
VCX36
p3393
sg15
I1
sa(dp3394
g9
I253
sg20
g21
sg12
I9
sg13
VARHGAP11A
p3395
sg15
I1
sasg6
(lp3396
(dp3397
g9
I233
sg10
VC0025362
p3398
sg12
I18
sg13
Vmental retardation
p3399
sg15
I2
sa(dp3400
g9
I142
sg10
VC0008925
p3401
sg12
I12
sg13
Vcleft palate
p3402
sg15
I2
sa(dp3403
g9
I34
sg10
VC1855900
p3404
sg12
I3
sg13
VCGH
p3405
sg15
I1
sa(dp3406
g9
I177
sg10
VC0018798
p3407
sg12
I23
sg13
Vcongenital heart defect
p3408
sg15
I3
sasa(dp3409
g2
VThe expression levels of four genes identified by microarray screening (PLCB2, HVCN1, CTSS, and DEF8) and one purine/thiopurine related gene (NME6) correlated significantly with the clinical activity of Crohn's disease.
p3410
sg4
(lp3411
(dp3412
g9
I86
sg20
VP25774
p3413
sg12
I4
sg13
VCTSS
p3414
sg15
I1
sa(dp3415
g9
I110
sg20
g21
sg12
I30
sg13
Vpurine/thiopurine related gene
p3416
sg15
I3
sa(dp3417
g9
I79
sg20
g21
sg12
I5
sg13
VHVCN1
p3418
sg15
I1
sa(dp3419
g9
I96
sg20
g21
sg12
I4
sg13
VDEF8
p3420
sg15
I1
sa(dp3421
g9
I142
sg20
g21
sg12
I4
sg13
VNME6
p3422
sg15
I1
sa(dp3423
g9
I72
sg20
g21
sg12
I5
sg13
VPLCB2
p3424
sg15
I1
sasg6
(lp3425
(dp3426
g9
I203
sg10
VC0010346
p3427
sg12
I15
sg13
VCrohn's disease
p3428
sg15
I2
sasa(dp3429
g2
VZNF366, involved in estrogen metabolism and progression of breast cancer, is a new biologically plausible candidate for endometriosis.
p3430
sg4
(lp3431
(dp3432
g9
I0
sg20
g21
sg12
I6
sg13
VZNF366
p3433
sg15
I1
sasg6
(lp3434
(dp3435
g9
I59
sg10
VC0678222
p3436
sg12
I13
sg13
Vbreast cancer
p3437
sg15
I2
sa(dp3438
g9
I120
sg10
VC0014175
p3439
sg12
I13
sg13
Vendometriosis
p3440
sg15
I1
sasa(dp3441
g2
VRecently, we have identified DC-SCRIPT (ZNF366) as a co-suppressor of ERAlfa and as a strong and independent prognostic marker in ESR1 (ERAlfa gene)-positive breast cancer patients.
p3442
sg4
(lp3443
(dp3444
g9
I29
sg20
g21
sg12
I9
sg13
VDC-SCRIPT
p3445
sg15
I1
sa(dp3446
g9
I40
sg20
g21
sg12
I6
sg13
VZNF366
p3447
sg15
I1
sa(dp3448
g9
I130
sg20
VP03372
p3449
sg12
I4
sg13
VESR1
p3450
sg15
I1
sasg6
(lp3451
(dp3452
g9
I158
sg10
VC0678222
p3453
sg12
I13
sg13
Vbreast cancer
p3454
sg15
I2
sasa(dp3455
g2
VIn this study, we further investigated the molecular mechanism on how DC-SCRIPT inhibits breast cancer cell growth.
p3456
sg4
(lp3457
sg6
(lp3458
(dp3459
g9
I96
sg10
VC1516170
p3460
sg12
I18
sg13
Vcancer cell growth
p3461
sg15
I3
sasa(dp3462
g2
VDC-SCRIPT mRNA levels from 190 primary ESR1-positive breast tumors were related to global gene expression, followed by gene ontology and pathway analysis.
p3463
sg4
(lp3464
(dp3465
g9
I0
sg20
g21
sg12
I14
sg13
VDC-SCRIPT mRNA
p3466
sg15
I2
sasg6
(lp3467
(dp3468
g9
I53
sg10
VC1458155
p3469
sg12
I13
sg13
Vbreast tumors
p3470
sg15
I2
sasa(dp3471
g2
VThe effect of DC-SCRIPT on breast cancer cell growth and cell cycle arrest was investigated using novel DC-SCRIPT-inducible MCF7 breast cancer cell lines.
p3472
sg4
(lp3473
sg6
(lp3474
(dp3475
g9
I27
sg10
VC0678222
p3476
sg12
I13
sg13
Vbreast cancer
p3477
sg15
I2
sa(dp3478
g9
I34
sg10
VC1516170
p3479
sg12
I18
sg13
Vcancer cell growth
p3480
sg15
I3
sasa(dp3481
g2
VIn the primary ESR1-positive breast tumors, DC-SCRIPT expression negatively correlated with several cell cycle gene ontologies and pathways.
p3482
sg4
(lp3483
(dp3484
g9
I15
sg20
VP03372
p3485
sg12
I4
sg13
VESR1
p3486
sg15
I1
sasg6
(lp3487
(dp3488
g9
I29
sg10
VC1458155
p3489
sg12
I13
sg13
Vbreast tumors
p3490
sg15
I2
sasa(dp3491
g2
VDC-SCRIPT expression strongly reduced breast cancer cell growth in vitro, breast tumor growth in vivo, and induced cell cycle arrest.
p3492
sg4
(lp3493
(dp3494
g9
I0
sg20
g21
sg12
I9
sg13
VDC-SCRIPT
p3495
sg15
I1
sasg6
(lp3496
(dp3497
g9
I45
sg10
VC1516170
p3498
sg12
I18
sg13
Vcancer cell growth
p3499
sg15
I3
sa(dp3500
g9
I81
sg10
VC0598934
p3501
sg12
I12
sg13
Vtumor growth
p3502
sg15
I2
sasa(dp3503
g2
VMoreover, in 1,132 primary ESR1-positive breast tumors, DC-SCRIPT expression also correlated with CDKN2B expression.
p3504
sg4
(lp3505
(dp3506
g9
I98
sg20
VP42772
p3507
sg12
I6
sg13
VCDKN2B
p3508
sg15
I1
sa(dp3509
g9
I27
sg20
VP03372
p3510
sg12
I4
sg13
VESR1
p3511
sg15
I1
sasg6
(lp3512
(dp3513
g9
I41
sg10
VC1458155
p3514
sg12
I13
sg13
Vbreast tumors
p3515
sg15
I2
sasa(dp3516
g2
VCollectively, these data show that DC-SCRIPT acts as a novel regulator of CDKN2B and induces cell cycle arrest in ESR1-positive breast cancer cells.
p3517
sg4
(lp3518
(dp3519
g9
I74
sg20
VP42772
p3520
sg12
I6
sg13
VCDKN2B
p3521
sg15
I1
sa(dp3522
g9
I114
sg20
VP03372
p3523
sg12
I4
sg13
VESR1
p3524
sg15
I1
sasg6
(lp3525
(dp3526
g9
I128
sg10
VC0678222
p3527
sg12
I13
sg13
Vbreast cancer
p3528
sg15
I2
sasa(dp3529
g2
VWe recently found that DC-SCRIPT is a prognostic marker in breast cancer and a unique NR coregulator differentially regulating different classes of NRs.
p3530
sg4
(lp3531
sg6
(lp3532
(dp3533
g9
I59
sg10
VC0678222
p3534
sg12
I13
sg13
Vbreast cancer
p3535
sg15
I2
sasa(dp3536
g2
VIn this study we aimed to validate the prognostic value of DC-SCRIPT mRNA expression in a large independent breast cancer cohort.
p3537
sg4
(lp3538
(dp3539
g9
I59
sg20
g21
sg12
I14
sg13
VDC-SCRIPT mRNA
p3540
sg15
I2
sasg6
(lp3541
(dp3542
g9
I108
sg10
VC0678222
p3543
sg12
I13
sg13
Vbreast cancer
p3544
sg15
I2
sasa(dp3545
g2
VDC-SCRIPT mRNA levels were measured by real-time PCR in 1,505 primary invasive breast cancers and associated with outcome (disease-free survival (DFS), metastasis-free survival (MFS) and overall survival (OS)) using univariate and multivariable Cox regression analysis.
p3546
sg4
(lp3547
(dp3548
g9
I0
sg20
g21
sg12
I14
sg13
VDC-SCRIPT mRNA
p3549
sg15
I2
sasg6
(lp3550
(dp3551
g9
I152
sg10
VC0027627
p3552
sg12
I10
sg13
Vmetastasis
p3553
sg15
I1
sa(dp3554
g9
I79
sg10
VC0006142
p3555
sg12
I14
sg13
Vbreast cancers
p3556
sg15
I2
sa(dp3557
g9
I178
sg10
VC0024796
p3558
sg12
I3
sg13
VMFS
p3559
sg15
I1
sasa(dp3560
g2
VThis study provides a higher level of evidence that DC-SCRIPT is indeed an independent, pure prognostic, factor for primary breast cancer and shows that DC-SCRIPT mRNA expression is most informative for either ESR1-positive and/or ESR2-low pT1 tumors.
p3561
sg4
(lp3562
(dp3563
g9
I153
sg20
g21
sg12
I14
sg13
VDC-SCRIPT mRNA
p3564
sg15
I2
sa(dp3565
g9
I52
sg20
g21
sg12
I9
sg13
VDC-SCRIPT
p3566
sg15
I1
sasg6
(lp3567
(dp3568
g9
I244
sg10
VC0027651
p3569
sg12
I6
sg13
Vtumors
p3570
sg15
I1
sa(dp3571
g9
I124
sg10
VC0678222
p3572
sg12
I13
sg13
Vbreast cancer
p3573
sg15
I2
sasa(dp3574
g2
VWe investigated the role of dendritic cell-specific transcript (DC-SCRIPT) as coregulator of these nuclear receptors and as a prognostic factor in breast cancer.
p3575
sg4
(lp3576
sg6
(lp3577
(dp3578
g9
I147
sg10
VC0678222
p3579
sg12
I13
sg13
Vbreast cancer
p3580
sg15
I2
sasa(dp3581
g2
VDC-SCRIPT expression in normal and tumor tissue from breast cancer patients was analyzed by polymerase chain reaction and immunohistochemistry.
p3582
sg4
(lp3583
sg6
(lp3584
(dp3585
g9
I35
sg10
VC0027651
p3586
sg12
I5
sg13
Vtumor
p3587
sg15
I1
sa(dp3588
g9
I53
sg10
VC0678222
p3589
sg12
I13
sg13
Vbreast cancer
p3590
sg15
I2
sasa(dp3591
g2
VThe prognostic value of tumor DC-SCRIPT mRNA expression was assessed in three independent cohorts of breast cancer patients: a discovery group (n = 47) and a validation group (n = 97) (neither of which had received systemic adjuvant therapy) and in a tamoxifen-treated validation group (n = 68) by using a DC-SCRIPT to porphobilinogen deaminase transcript ratio cutoff of 0.15 determined in the discovery group.
p3592
sg4
(lp3593
(dp3594
g9
I319
sg20
VP08397
p3595
sg12
I36
sg13
Vporphobilinogen deaminase transcript
p3596
sg15
I3
sa(dp3597
g9
I30
sg20
g21
sg12
I9
sg13
VDC-SCRIPT
p3598
sg15
I1
sasg6
(lp3599
(dp3600
g9
I101
sg10
VC0678222
p3601
sg12
I13
sg13
Vbreast cancer
p3602
sg15
I2
sa(dp3603
g9
I24
sg10
VC0027651
p3604
sg12
I5
sg13
Vtumor
p3605
sg15
I1
sasa(dp3606
g2
VDC-SCRIPT is a key regulator of nuclear receptor activity that has prognostic value in breast cancer.
p3607
sg4
(lp3608
sg6
(lp3609
(dp3610
g9
I87
sg10
VC0678222
p3611
sg12
I13
sg13
Vbreast cancer
p3612
sg15
I2
sasa(dp3613
g2
VBoth SNP and gene-based analyses showed promising associations with breast cancer risk for 17 genes: OR10J3, FCER1A, NCF4, CNTNAP1, CTNNB1, KLKB1, ITGB2, ALOX12B, KLK2, IRAK3, KLK4, STAT6, NCF2, CCL1, C1QR1, MBP and NOS1.
p3614
sg4
(lp3615
(dp3616
g9
I140
sg20
VP03952
p3617
sg12
I5
sg13
VKLKB1
p3618
sg15
I1
sa(dp3619
g9
I176
sg20
g21
sg12
I4
sg13
VKLK4
p3620
sg15
I1
sa(dp3621
g9
I189
sg20
VP19878
p3622
sg12
I4
sg13
VNCF2
p3623
sg15
I1
sa(dp3624
g9
I195
sg20
VP22362
p3625
sg12
I4
sg13
VCCL1
p3626
sg15
I1
sa(dp3627
g9
I201
sg20
g21
sg12
I5
sg13
VC1QR1
p3628
sg15
I1
sa(dp3629
g9
I182
sg20
VP42226
p3630
sg12
I5
sg13
VSTAT6
p3631
sg15
I1
sa(dp3632
g9
I169
sg20
g21
sg12
I5
sg13
VIRAK3
p3633
sg15
I1
sa(dp3634
g9
I123
sg20
VP78357
p3635
sg12
I7
sg13
VCNTNAP1
p3636
sg15
I1
sa(dp3637
g9
I132
sg20
VP35222
p3638
sg12
I6
sg13
VCTNNB1
p3639
sg15
I1
sa(dp3640
g9
I147
sg20
VP05107
p3641
sg12
I5
sg13
VITGB2
p3642
sg15
I1
sa(dp3643
g9
I109
sg20
VP12319
p3644
sg12
I6
sg13
VFCER1A
p3645
sg15
I1
sa(dp3646
g9
I117
sg20
g21
sg12
I4
sg13
VNCF4
p3647
sg15
I1
sa(dp3648
g9
I208
sg20
VP13727
p3649
sg12
I3
sg13
VMBP
p3650
sg15
I1
sa(dp3651
g9
I101
sg20
g21
sg12
I6
sg13
VOR10J3
p3652
sg15
I1
sa(dp3653
g9
I216
sg20
VP29475
p3654
sg12
I4
sg13
VNOS1
p3655
sg15
I1
sa(dp3656
g9
I154
sg20
g21
sg12
I7
sg13
VALOX12B
p3657
sg15
I1
sa(dp3658
g9
I163
sg20
VP20151
p3659
sg12
I4
sg13
VKLK2
p3660
sg15
I1
sasg6
(lp3661
(dp3662
g9
I68
sg10
VC0678222
p3663
sg12
I13
sg13
Vbreast cancer
p3664
sg15
I2
sasa(dp3665
g2
VWhen the data were divided by menopausal status, the optimal models to predict breast cancer, which included NAF hK2 or PSA and age, were 100% sensitive and 41% specific in pre- vs. 93% sensitive and 12% specific in postmenopausal women.
p3666
sg4
(lp3667
(dp3668
g9
I120
sg20
VP55786
p3669
sg12
I3
sg13
VPSA
p3670
sg15
I1
sa(dp3671
g9
I109
sg20
VP20151
p3672
sg12
I7
sg13
VNAF hK2
p3673
sg15
I2
sasg6
(lp3674
(dp3675
g9
I120
sg10
VC1519176
p3676
sg12
I3
sg13
VPSA
p3677
sg15
I1
sa(dp3678
g9
I79
sg10
VC0678222
p3679
sg12
I13
sg13
Vbreast cancer
p3680
sg15
I2
sasa(dp3681
g2
VSeveral lines of evidence suggest that members of the kallikrein family are involved in various malignancies such as prostate (PSA, KLK2, KLK15), ovarian (KLK4, KLK5, KLK6, KLK8, KLK10), and breast cancer (KLK10, KLK13, KLK14).
p3682
sg4
(lp3683
(dp3684
g9
I173
sg20
g21
sg12
I4
sg13
VKLK8
p3685
sg15
I1
sa(dp3686
g9
I155
sg20
g21
sg12
I4
sg13
VKLK4
p3687
sg15
I1
sa(dp3688
g9
I179
sg20
g21
sg12
I5
sg13
VKLK10
p3689
sg15
I1
sa(dp3690
g9
I213
sg20
g21
sg12
I5
sg13
VKLK13
p3691
sg15
I1
sa(dp3692
g9
I132
sg20
VP20151
p3693
sg12
I4
sg13
VKLK2
p3694
sg15
I1
sa(dp3695
g9
I54
sg20
VP06870
p3696
sg12
I17
sg13
Vkallikrein family
p3697
sg15
I2
sa(dp3698
g9
I167
sg20
VP06870
p3699
sg12
I4
sg13
VKLK6
p3700
sg15
I1
sa(dp3701
g9
I138
sg20
g21
sg12
I5
sg13
VKLK15
p3702
sg15
I1
sa(dp3703
g9
I220
sg20
g21
sg12
I5
sg13
VKLK14
p3704
sg15
I1
sa(dp3705
g9
I179
sg20
g21
sg12
I5
sg13
VKLK10
p3706
sg15
I1
sa(dp3707
g9
I161
sg20
g21
sg12
I4
sg13
VKLK5
p3708
sg15
I1
sa(dp3709
g9
I117
sg20
VP55786
p3710
sg12
I8
sg13
Vprostate
p3711
sg15
I1
sa(dp3712
g9
I127
sg20
VP55786
p3713
sg12
I3
sg13
VPSA
p3714
sg15
I1
sasg6
(lp3715
(dp3716
g9
I127
sg10
VC1519176
p3717
sg12
I3
sg13
VPSA
p3718
sg15
I1
sa(dp3719
g9
I191
sg10
VC0678222
p3720
sg12
I13
sg13
Vbreast cancer
p3721
sg15
I2
sa(dp3722
g9
I96
sg10
VC0006826
p3723
sg12
I12
sg13
Vmalignancies
p3724
sg15
I1
sa(dp3725
g9
I117
sg10
VC1519176
p3726
sg12
I8
sg13
Vprostate
p3727
sg15
I1
sasa(dp3728
g2
VWe examined previously the steroid hormone regulation of 2 known androgen-regulated kallikreins, KLK3 (encoding PSA) and KLK2 (encoding human kallikrein 2 or hK2) in BT-474, T-47D, ZR75-1, MCF-7, MFM-223 and BT-20 human breast cancer cells and found that they were differentially regulated, with the cells showing variable responses to androgen.
p3729
sg4
(lp3730
(dp3731
g9
I121
sg20
VP20151
p3732
sg12
I4
sg13
VKLK2
p3733
sg15
I1
sa(dp3734
g9
I142
sg20
VP20151
p3735
sg12
I19
sg13
Vkallikrein 2 or hK2
p3736
sg15
I4
sa(dp3737
g9
I65
sg20
VP10398
p3738
sg12
I30
sg13
Vandrogen-regulated kallikreins
p3739
sg15
I2
sa(dp3740
g9
I136
sg20
VP20151
p3741
sg12
I18
sg13
Vhuman kallikrein 2
p3742
sg15
I3
sasg6
(lp3743
(dp3744
g9
I220
sg10
VC0678222
p3745
sg12
I13
sg13
Vbreast cancer
p3746
sg15
I2
sa(dp3747
g9
I112
sg10
VC1519176
p3748
sg12
I3
sg13
VPSA
p3749
sg15
I1
sasa(dp3750
g2
VEvery breast cancer cell line exhibited a distinct expression pattern of the nuclear receptor co-regulators examined raising the possibility that the relative levels of these co-activators/-repressors might differentially modulate androgen receptor transcriptional activity within the promoter/enhancer region of KLK2 and KLK3 of these cells.
p3751
sg4
(lp3752
(dp3753
g9
I231
sg20
VP10275
p3754
sg12
I17
sg13
Vandrogen receptor
p3755
sg15
I2
sa(dp3756
g9
I322
sg20
VP03952
p3757
sg12
I4
sg13
VKLK3
p3758
sg15
I1
sa(dp3759
g9
I313
sg20
VP20151
p3760
sg12
I4
sg13
VKLK2
p3761
sg15
I1
sasg6
(lp3762
(dp3763
g9
I6
sg10
VC0678222
p3764
sg12
I13
sg13
Vbreast cancer
p3765
sg15
I2
sasa(dp3766
g2
VLike KLK2 and KLK3, the KLK5 gene is regulated by steroid hormones in the BT-474 breast cancer cell line.
p3767
sg4
(lp3768
(dp3769
g9
I5
sg20
VP20151
p3770
sg12
I4
sg13
VKLK2
p3771
sg15
I1
sa(dp3772
g9
I14
sg20
VP03952
p3773
sg12
I4
sg13
VKLK3
p3774
sg15
I1
sa(dp3775
g9
I24
sg20
g21
sg12
I9
sg13
VKLK5 gene
p3776
sg15
I2
sasg6
(lp3777
(dp3778
g9
I81
sg10
VC0678222
p3779
sg12
I13
sg13
Vbreast cancer
p3780
sg15
I2
sasa(dp3781
g2
VKLK2 and KLK3 have important applications in prostate cancer diagnostics and, more recently, in breast cancer diagnostics.
p3782
sg4
(lp3783
(dp3784
g9
I9
sg20
VP03952
p3785
sg12
I4
sg13
VKLK3
p3786
sg15
I1
sa(dp3787
g9
I0
sg20
VP20151
p3788
sg12
I4
sg13
VKLK2
p3789
sg15
I1
sasg6
(lp3790
(dp3791
g9
I96
sg10
VC0678222
p3792
sg12
I13
sg13
Vbreast cancer
p3793
sg15
I2
sa(dp3794
g9
I45
sg10
VC0600139
p3795
sg12
I15
sg13
Vprostate cancer
p3796
sg15
I2
sasa(dp3797
g2
VOligonucleotide 5'-SH-(A)(12)-AGACAAGAGAGG-3' (Oligo 1) modified AuNPs and oligonucleotide 5'-CAACAGAGAACG-(A)(12)-HS-3' (Oligo 2) modified AuNPs could hybridize with oligonulceotide 5'-CGTTCTCTGTTGCCTCTCTTGTCT-3' (Oligo 3), which resulted in the aggregation of Oligo-AuNPs probes, and triggered the increase of their average diameter.
p3798
sg4
(lp3799
sg6
(lp3800
sa(dp3801
g2
VTo observe the effect of Bushen Huoxue Recipe (BHR) on inhibiting vascular calcification (VC) in chronic renal failure (CRF) rats by regulating BMP-2/Runx2/Osterix signal pathway, and to explore its possible mechanism.
p3802
sg4
(lp3803
(dp3804
g9
I144
sg20
VP12643
p3805
sg12
I5
sg13
VBMP-2
p3806
sg15
I1
sa(dp3807
g9
I150
sg20
g21
sg12
I5
sg13
VRunx2
p3808
sg15
I1
sa(dp3809
g9
I156
sg20
g21
sg12
I7
sg13
VOsterix
p3810
sg15
I1
sasg6
(lp3811
(dp3812
g9
I90
sg10
VC0342649
p3813
sg12
I2
sg13
VVC
p3814
sg15
I1
sa(dp3815
g9
I66
sg10
VC0342649
p3816
sg12
I22
sg13
Vvascular calcification
p3817
sg15
I2
sa(dp3818
g9
I97
sg10
VC0022661
p3819
sg12
I21
sg13
Vchronic renal failure
p3820
sg15
I3
sa(dp3821
g9
I120
sg10
VC0022661
p3822
sg12
I3
sg13
VCRF
p3823
sg15
I1
sasa(dp3824
g2
VHere, we report that inhibition of Src significantly reduced survival of H37Rv as well as multidrug-resistant (MDR) and extremely drug-resistant (XDR) strains of M. tuberculosis in THP-1 macrophages.
p3825
sg4
(lp3826
(dp3827
g9
I35
sg20
VP12931
p3828
sg12
I3
sg13
VSrc
p3829
sg15
I1
sasg6
(lp3830
(dp3831
g9
I165
sg10
VC0041296
p3832
sg12
I12
sg13
Vtuberculosis
p3833
sg15
I1
sasa(dp3834
g2
VSrc inhibition was also effective in controlling M. tuberculosis infection in guinea pigs.
p3835
sg4
(lp3836
(dp3837
g9
I0
sg20
VP12931
p3838
sg12
I3
sg13
VSrc
p3839
sg15
I1
sasg6
(lp3840
(dp3841
g9
I52
sg10
VC0041296
p3842
sg12
I22
sg13
Vtuberculosis infection
p3843
sg15
I2
sasa(dp3844
g2
VIn guinea pigs, reduced M. tuberculosis burden due to Src inhibition also led to a marked decline in the disease pathology.
p3845
sg4
(lp3846
(dp3847
g9
I54
sg20
VP12931
p3848
sg12
I3
sg13
VSrc
p3849
sg15
I1
sasg6
(lp3850
(dp3851
g9
I27
sg10
VC0041296
p3852
sg12
I12
sg13
Vtuberculosis
p3853
sg15
I1
sa(dp3854
g9
I113
sg10
VC0677042
p3855
sg12
I9
sg13
Vpathology
p3856
sg15
I1
sasa(dp3857
g2
VWe propose that Src inhibitors could be developed into effective host-directed anti-TB drugs, which could be indiscriminately used against both drug-sensitive and drug-resistant strains of M. tuberculosis.
p3858
sg4
(lp3859
(dp3860
g9
I16
sg20
VP12931
p3861
sg12
I3
sg13
VSrc
p3862
sg15
I1
sasg6
(lp3863
(dp3864
g9
I192
sg10
VC0041296
p3865
sg12
I12
sg13
Vtuberculosis
p3866
sg15
I1
sasa(dp3867
g2
VWe explored tyrosine kinase Src as a host factor exploited by virulent M. tuberculosis for intracellular survival.
p3868
sg4
(lp3869
(dp3870
g9
I12
sg20
VP29401
p3871
sg12
I19
sg13
Vtyrosine kinase Src
p3872
sg15
I3
sasg6
(lp3873
(dp3874
g9
I74
sg10
VC0041296
p3875
sg12
I12
sg13
Vtuberculosis
p3876
sg15
I1
sasa(dp3877
g2
VWe show that Src inhibition can effectively control tuberculosis in infected guinea pigs.
p3878
sg4
(lp3879
(dp3880
g9
I13
sg20
VP12931
p3881
sg12
I3
sg13
VSrc
p3882
sg15
I1
sasg6
(lp3883
(dp3884
g9
I52
sg10
VC0041296
p3885
sg12
I12
sg13
Vtuberculosis
p3886
sg15
I1
sasa(dp3887
g2
VIn the current study we aimed to find out the impact of cytokine-inducible Src homology 2 domain protein (CISH) gene polymorphisms on the risk of pulmonary tuberculosis (PTB) in a sample of Iranian population.
p3888
sg4
(lp3889
(dp3890
g9
I56
sg20
g21
sg12
I48
sg13
Vcytokine-inducible Src homology 2 domain protein
p3891
sg15
I6
sa(dp3892
g9
I106
sg20
g21
sg12
I4
sg13
VCISH
p3893
sg15
I1
sasg6
(lp3894
(dp3895
g9
I170
sg10
VC0041327
p3896
sg12
I3
sg13
VPTB
p3897
sg15
I1
sa(dp3898
g9
I146
sg10
VC0041327
p3899
sg12
I22
sg13
Vpulmonary tuberculosis
p3900
sg15
I2
sasa(dp3901
g2
VA recent multi-center case-control study identified several single nucleotide polymorphisms (SNPs) within the cytokine-inducible SRC homology 2 domain (CISH) gene that are associated with susceptibility to tuberculosis (TB) in both African and Asian populations.
p3902
sg4
(lp3903
(dp3904
g9
I152
sg20
g21
sg12
I4
sg13
VCISH
p3905
sg15
I1
sa(dp3906
g9
I110
sg20
g21
sg12
I40
sg13
Vcytokine-inducible SRC homology 2 domain
p3907
sg15
I5
sasg6
(lp3908
(dp3909
g9
I220
sg10
VC0041296
p3910
sg12
I2
sg13
VTB
p3911
sg15
I1
sa(dp3912
g9
I206
sg10
VC0041296
p3913
sg12
I12
sg13
Vtuberculosis
p3914
sg15
I1
sasa(dp3915
g2
VAmong them, the human Cytokine-inducible Src homology 2(SH2) domain protein (CISH) gene has been very recently reported to be involved in T cell activation and differentiation in response to Mycobacterium tuberculosis infection.
p3916
sg4
(lp3917
(dp3918
g9
I41
sg20
VP12931
p3919
sg12
I14
sg13
VSrc homology 2
p3920
sg15
I3
sasg6
(lp3921
(dp3922
g9
I205
sg10
VC0041296
p3923
sg12
I22
sg13
Vtuberculosis infection
p3924
sg15
I2
sasa(dp3925
g2
VFor the first time, we report different genetic anomalies between adult and paediatric BLs, suggesting age-related heterogeneity in Burkitt lymphomagenesis.
p3926
sg4
(lp3927
sg6
(lp3928
(dp3929
g9
I87
sg10
VC0005859
p3930
sg12
I3
sg13
VBLs
p3931
sg15
I1
sa(dp3932
g9
I140
sg10
VC0598766
p3933
sg12
I15
sg13
Vlymphomagenesis
p3934
sg15
I1
sasa(dp3935
g2
VAlthough there are conflicting data regarding prognostic implications of isolated MYC aberrancy in these non-BLs, the co-occurrence of MYC rearrangements and either the antiapoptotic gene B-cell chronic lymphocytic leukemia/lymphoma 2 (BCL2) or the transcriptional repressor BCL6 leads to an entity termed double-hit B-cell lymphoma (DHL) (or triple-hit if all 3 abnormalities are observed) with a particularly poor prognosis and no established treatment paradigms.
p3936
sg4
(lp3937
(dp3938
g9
I275
sg20
VP41182
p3939
sg12
I4
sg13
VBCL6
p3940
sg15
I1
sa(dp3941
g9
I236
sg20
VP10415
p3942
sg12
I4
sg13
VBCL2
p3943
sg15
I1
sa(dp3944
g9
I82
sg20
VP12524
p3945
sg12
I3
sg13
VMYC
p3946
sg15
I1
sa(dp3947
g9
I188
sg20
VP10415
p3948
sg12
I46
sg13
VB-cell chronic lymphocytic leukemia/lymphoma 2
p3949
sg15
I5
sasg6
(lp3950
(dp3951
g9
I317
sg10
VC0079731
p3952
sg12
I15
sg13
VB-cell lymphoma
p3953
sg15
I2
sa(dp3954
g9
I188
sg10
VC1868683
p3955
sg12
I35
sg13
VB-cell chronic lymphocytic leukemia
p3956
sg15
I4
sa(dp3957
g9
I109
sg10
VC0005859
p3958
sg12
I3
sg13
VBLs
p3959
sg15
I1
sa(dp3960
g9
I224
sg10
VC0024299
p3961
sg12
I8
sg13
Vlymphoma
p3962
sg15
I1
sasa(dp3963
g2
VThe clinicopathologic findings in Burkitt lymphoma (BL) and diffuse large B-cell lymphoma (DLBCL) may show significant overlap, and MYC abnormalities, found in all BLs, also occur in a subset of DLBCL.
p3964
sg4
(lp3965
(dp3966
g9
I132
sg20
VP12524
p3967
sg12
I3
sg13
VMYC
p3968
sg15
I1
sasg6
(lp3969
(dp3970
g9
I34
sg10
VC0006413
p3971
sg12
I16
sg13
VBurkitt lymphoma
p3972
sg15
I2
sa(dp3973
g9
I91
sg10
VC0079744
p3974
sg12
I5
sg13
VDLBCL
p3975
sg15
I1
sa(dp3976
g9
I91
sg10
VC0079744
p3977
sg12
I5
sg13
VDLBCL
p3978
sg15
I1
sa(dp3979
g9
I60
sg10
VC0079744
p3980
sg12
I29
sg13
Vdiffuse large B-cell lymphoma
p3981
sg15
I4
sa(dp3982
g9
I52
sg10
VC0006413
p3983
sg12
I2
sg13
VBL
p3984
sg15
I1
sa(dp3985
g9
I164
sg10
VC0005859
p3986
sg12
I3
sg13
VBLs
p3987
sg15
I1
sasa(dp3988
g2
VDouble negative cases were absent in the group of BLs but could be found in approximately one third of the remaining cases of mature aggressive B-cell lymphomas.
p3989
sg4
(lp3990
sg6
(lp3991
(dp3992
g9
I133
sg10
VC0001807
p3993
sg12
I10
sg13
Vaggressive
p3994
sg15
I1
sa(dp3995
g9
I50
sg10
VC0005859
p3996
sg12
I3
sg13
VBLs
p3997
sg15
I1
sa(dp3998
g9
I144
sg10
VC0079731
p3999
sg12
I16
sg13
VB-cell lymphomas
p4000
sg15
I2
sasa(dp4001
g2
VIn particular, we determined the expression and production of several angiogenic factors including tissue inhibitor of matrix metalloproteinases-1 (TIMP-1), Leptin, connective tissue growth factor (CTGF), meningioma-associated complimentary DNA (Mac25), basic fibroblast growth factor (bFGF), and Midkine.
p4002
sg4
(lp4003
(dp4004
g9
I70
sg20
VP19883
p4005
sg12
I76
sg13
Vangiogenic factors including tissue inhibitor of matrix metalloproteinases-1
p4006
sg15
I8
sa(dp4007
g9
I254
sg20
VP53370
p4008
sg12
I30
sg13
Vbasic fibroblast growth factor
p4009
sg15
I4
sa(dp4010
g9
I148
sg20
VP01033
p4011
sg12
I6
sg13
VTIMP-1
p4012
sg15
I1
sa(dp4013
g9
I286
sg20
VP53370
p4014
sg12
I4
sg13
VbFGF
p4015
sg15
I1
sa(dp4016
g9
I198
sg20
VP29279
p4017
sg12
I4
sg13
VCTGF
p4018
sg15
I1
sa(dp4019
g9
I165
sg20
VP29279
p4020
sg12
I31
sg13
Vconnective tissue growth factor
p4021
sg15
I4
sa(dp4022
g9
I157
sg20
VP41159
p4023
sg12
I6
sg13
VLeptin
p4024
sg15
I1
sasg6
(lp4025
(dp4026
g9
I205
sg10
VC0025286
p4027
sg12
I10
sg13
Vmeningioma
p4028
sg15
I1
sasa(dp4029
g2
VAltered expression levels of several genes identified in this study have been previously noted in meningiomas (eg, growth hormone receptor, IGFBP-7, endothelin receptor A, IGF2).
p4030
sg4
(lp4031
(dp4032
g9
I149
sg20
g21
sg12
I21
sg13
Vendothelin receptor A
p4033
sg15
I3
sa(dp4034
g9
I172
sg20
VP01344
p4035
sg12
I4
sg13
VIGF2
p4036
sg15
I1
sa(dp4037
g9
I115
sg20
VP10912
p4038
sg12
I23
sg13
Vgrowth hormone receptor
p4039
sg15
I3
sasg6
(lp4040
(dp4041
g9
I98
sg10
VC0025286
p4042
sg12
I11
sg13
Vmeningiomas
p4043
sg15
I1
sasa(dp4044
g2
Vmac25, a retinoic acid-inducible gene that is expressed at high levels in senescent epithelial cells, was initially cloned as a gene that is differentially expressed in meningioma.
p4045
sg4
(lp4046
(dp4047
g9
I0
sg20
g21
sg12
I5
sg13
Vmac25
p4048
sg15
I1
sasg6
(lp4049
(dp4050
g9
I169
sg10
VC0025286
p4051
sg12
I10
sg13
Vmeningioma
p4052
sg15
I1
sasa(dp4053
g2
Vmac25 had previously been cloned as a discrete gene, preferentially expressed in normal, leptomeningial cells compared with meningioma tumors.
p4054
sg4
(lp4055
(dp4056
g9
I0
sg20
g21
sg12
I5
sg13
Vmac25
p4057
sg15
I1
sasg6
(lp4058
(dp4059
g9
I135
sg10
VC0027651
p4060
sg12
I6
sg13
Vtumors
p4061
sg15
I1
sa(dp4062
g9
I124
sg10
VC0025286
p4063
sg12
I10
sg13
Vmeningioma
p4064
sg15
I1
sasa(dp4065
g2
VOutcome assessments included the Sheehan Panic Disorder Scale (SPS), Panic Disorder Severity Scale (PDSS), Bandelow Panic and Agoraphobia Scale (PAS), Hamilton Rating Scale for Anxiety (HAM-A), 21-point Clinician Global Improvement Scale (CGI-21), 21-point Patient Global Improvement (PGI-21) and the Sheehan Disability Scale (SDS).
p4066
sg4
(lp4067
sg6
(lp4068
(dp4069
g9
I327
sg10
VC0272170
p4070
sg12
I3
sg13
VSDS
p4071
sg15
I1
sa(dp4072
g9
I186
sg10
VC0030481
p4073
sg12
I3
sg13
VHAM
p4074
sg15
I1
sa(dp4075
g9
I33
sg10
VC0085292
p4076
sg12
I28
sg13
VSheehan Panic Disorder Scale
p4077
sg15
I4
sa(dp4078
g9
I126
sg10
VC0001818
p4079
sg12
I11
sg13
VAgoraphobia
p4080
sg15
I1
sa(dp4081
g9
I63
sg10
VC0085292
p4082
sg12
I3
sg13
VSPS
p4083
sg15
I1
sa(dp4084
g9
I301
sg10
VC0272170
p4085
sg12
I24
sg13
VSheehan Disability Scale
p4086
sg15
I3
sa(dp4087
g9
I41
sg10
VC1868649
p4088
sg12
I14
sg13
VPanic Disorder
p4089
sg15
I2
sasa(dp4090
g2
VTaken together, the results of the present study concluded that human FAT2 may function as a key molecule that governs not only PCP, but also NF2-Hpo signaling in arachnoid cells; thus, a mutation in this gene may result in spinal meningioma.
p4091
sg4
(lp4092
(dp4093
g9
I146
sg20
VP55789
p4094
sg12
I3
sg13
VHpo
p4095
sg15
I1
sa(dp4096
g9
I70
sg20
g21
sg12
I4
sg13
VFAT2
p4097
sg15
I1
sa(dp4098
g9
I128
sg20
VP42785
p4099
sg12
I3
sg13
VPCP
p4100
sg15
I1
sasg6
(lp4101
(dp4102
g9
I142
sg10
VC0027832
p4103
sg12
I3
sg13
VNF2
p4104
sg15
I1
sa(dp4105
g9
I128
sg10
VC2919094
p4106
sg12
I3
sg13
VPCP
p4107
sg15
I1
sa(dp4108
g9
I224
sg10
VC0347515
p4109
sg12
I17
sg13
Vspinal meningioma
p4110
sg15
I2
sasa(dp4111
g2
VEight human STS cell lines were used: fibrosarcoma (HT1080), liposarcoma (SW872, T778, MLS-402), synovial sarcoma (SW982, SYO1, 1273), and malignant fibrous histiocytoma (U2197).
p4112
sg4
(lp4113
sg6
(lp4114
(dp4115
g9
I139
sg10
VC0334463
p4116
sg12
I30
sg13
Vmalignant fibrous histiocytoma
p4117
sg15
I3
sa(dp4118
g9
I87
sg10
VC0796070
p4119
sg12
I3
sg13
VMLS
p4120
sg15
I1
sa(dp4121
g9
I12
sg10
VC0079588
p4122
sg12
I3
sg13
VSTS
p4123
sg15
I1
sa(dp4124
g9
I38
sg10
VC0016057
p4125
sg12
I12
sg13
Vfibrosarcoma
p4126
sg15
I1
sa(dp4127
g9
I61
sg10
VC0023827
p4128
sg12
I11
sg13
Vliposarcoma
p4129
sg15
I1
sa(dp4130
g9
I97
sg10
VC0039101
p4131
sg12
I16
sg13
Vsynovial sarcoma
p4132
sg15
I2
sasa(dp4133
g2
VVAE diminished the CI in most of the synovial sarcoma (SW982, SYO1) and liposarcoma (SW872, T778) cell lines as well as HT1080.
p4134
sg4
(lp4135
sg6
(lp4136
(dp4137
g9
I72
sg10
VC0023827
p4138
sg12
I11
sg13
Vliposarcoma
p4139
sg15
I1
sa(dp4140
g9
I37
sg10
VC0039101
p4141
sg12
I16
sg13
Vsynovial sarcoma
p4142
sg15
I2
sasa(dp4143
g2
VA total of eight different human STS cell lines were used in the study: Fibrosarcoma (HT1080), liposarcoma (SW872, T778 and MLS-402), synovial sarcoma (SW982, SYO1 and 1273) and pleomorphic sarcoma (U2197).
p4144
sg4
(lp4145
sg6
(lp4146
(dp4147
g9
I33
sg10
VC0079588
p4148
sg12
I3
sg13
VSTS
p4149
sg15
I1
sa(dp4150
g9
I77
sg10
VC1261473
p4151
sg12
I7
sg13
Vsarcoma
p4152
sg15
I1
sa(dp4153
g9
I72
sg10
VC0016057
p4154
sg12
I12
sg13
VFibrosarcoma
p4155
sg15
I1
sa(dp4156
g9
I124
sg10
VC0796070
p4157
sg12
I3
sg13
VMLS
p4158
sg15
I1
sa(dp4159
g9
I95
sg10
VC0023827
p4160
sg12
I11
sg13
Vliposarcoma
p4161
sg15
I1
sa(dp4162
g9
I134
sg10
VC0039101
p4163
sg12
I16
sg13
Vsynovial sarcoma
p4164
sg15
I2
sasa(dp4165
g2
VIn SYO-1 synovial sarcoma xenografts, administration of small molecule Tcf/Beta-catenin complex inhibitors significantly reduced tumor growth, associated with diminished AXIN2 protein levels.
p4166
sg4
(lp4167
(dp4168
g9
I170
sg20
g21
sg12
I13
sg13
VAXIN2 protein
p4169
sg15
I2
sasg6
(lp4170
(dp4171
g9
I9
sg10
VC0039101
p4172
sg12
I16
sg13
Vsynovial sarcoma
p4173
sg15
I2
sa(dp4174
g9
I129
sg10
VC0598934
p4175
sg12
I12
sg13
Vtumor growth
p4176
sg15
I2
sasa(dp4177
g2
VThese plasmids were transfected in synovial sarcoma SYO-1 cells and we observed the expression of these proteins using a fluorescence microscope.
p4178
sg4
(lp4179
sg6
(lp4180
(dp4181
g9
I35
sg10
VC0039101
p4182
sg12
I16
sg13
Vsynovial sarcoma
p4183
sg15
I2
sasa(dp4184
g2
VFurthermore, cell proliferation and colony formation of synovial sarcoma SYO-1 and YaFuSS cells were suppressed by exogenous tSSX expression.
p4185
sg4
(lp4186
sg6
(lp4187
(dp4188
g9
I18
sg10
VC0334094
p4189
sg12
I13
sg13
Vproliferation
p4190
sg15
I1
sa(dp4191
g9
I56
sg10
VC0039101
p4192
sg12
I16
sg13
Vsynovial sarcoma
p4193
sg15
I2
sasa(dp4194
g2
VPsoriasis area and severity index (PASI), serum P-selectin and interleukin (IL)-6 were monitored throughout the treatment.
p4195
sg4
(lp4196
(dp4197
g9
I42
sg20
VP16109
p4198
sg12
I16
sg13
Vserum P-selectin
p4199
sg15
I2
sa(dp4200
g9
I63
sg20
VP60568
p4201
sg12
I18
sg13
Vinterleukin (IL)-6
p4202
sg15
I2
sasg6
(lp4203
(dp4204
g9
I0
sg10
VC0033860
p4205
sg12
I9
sg13
VPsoriasis
p4206
sg15
I1
sasa(dp4207
g2
VWe aimed to study the association of the endothelial activation biomarkers monocyte chemoattractant protein 1 (MCP-1), soluble (s) E-selectin and P-selectin with disease activity and severity in psoriasis patients treated with anti-TNF-Alfa therapy.
p4208
sg4
(lp4209
(dp4210
g9
I41
sg20
VP14222
p4211
sg12
I68
sg13
Vendothelial activation biomarkers monocyte chemoattractant protein 1
p4212
sg15
I7
sa(dp4213
g9
I227
sg20
VP01375
p4214
sg12
I13
sg13
Vanti-TNF-Alfa
p4215
sg15
I1
sa(dp4216
g9
I146
sg20
VP16109
p4217
sg12
I10
sg13
VP-selectin
p4218
sg15
I1
sasg6
(lp4219
(dp4220
g9
I195
sg10
VC0033860
p4221
sg12
I9
sg13
Vpsoriasis
p4222
sg15
I1
sasa(dp4223
g2
VPlasma soluble P-selectin concentrations, PDMP and platelet aggregation were significantly elevated in patients with psoriasis, as compared to controls.
p4224
sg4
(lp4225
(dp4226
g9
I0
sg20
VP16109
p4227
sg12
I25
sg13
VPlasma soluble P-selectin
p4228
sg15
I3
sasg6
(lp4229
(dp4230
g9
I117
sg10
VC0033860
p4231
sg12
I9
sg13
Vpsoriasis
p4232
sg15
I1
sasa(dp4233
g2
VMost efficient among them is the newly identified SOXN (neuroblastoma-derived sulfhydryl oxidase), which comprises 12 exons and maps to 9q34.3.
p4234
sg4
(lp4235
sg6
(lp4236
(dp4237
g9
I56
sg10
VC0027819
p4238
sg12
I13
sg13
Vneuroblastoma
p4239
sg15
I1
sasa(dp4240
g2
VThese results identify SOXN as a major player in regulating the sensitization of neuroblastoma cells for IFN-gamma-induced apoptosis.
p4241
sg4
(lp4242
(dp4243
g9
I105
sg20
VP01579
p4244
sg12
I9
sg13
VIFN-gamma
p4245
sg15
I1
sa(dp4246
g9
I23
sg20
g21
sg12
I4
sg13
VSOXN
p4247
sg15
I1
sasg6
(lp4248
(dp4249
g9
I81
sg10
VC0027819
p4250
sg12
I13
sg13
Vneuroblastoma
p4251
sg15
I1
sasa(dp4252
g2
VThe cartilage proteins melanoma inhibitory activity (MIA) and human cartilage gp-39 (HC gp-39) are candidate autoantigens in rheumatoid arthritis (RA).
p4253
sg4
(lp4254
sg6
(lp4255
(dp4256
g9
I125
sg10
VC0003873
p4257
sg12
I20
sg13
Vrheumatoid arthritis
p4258
sg15
I2
sa(dp4259
g9
I23
sg10
VC0025202
p4260
sg12
I8
sg13
Vmelanoma
p4261
sg15
I1
sa(dp4262
g9
I147
sg10
VC0003873
p4263
sg12
I2
sg13
VRA
p4264
sg15
I1
sasa(dp4265
g2
VThe presented results confirm expression of CDRAP by normal and osteoarthritic articular chondrocytes, but indicate that increased expression levels by chondrocytes are not the cause of the increased levels of CDRAP in the synovial fluid of patients with osteoarthritis.
p4266
sg4
(lp4267
(dp4268
g9
I44
sg20
g21
sg12
I5
sg13
VCDRAP
p4269
sg15
I1
sa(dp4270
g9
I44
sg20
g21
sg12
I5
sg13
VCDRAP
p4271
sg15
I1
sasg6
(lp4272
(dp4273
g9
I255
sg10
VC0029408
p4274
sg12
I14
sg13
Vosteoarthritis
p4275
sg15
I1
sasa(dp4276
g2
VWe have measured the concentration of cartilage-derived retinoic-acid-sensitive protein (CD-RAP) in synovial fluid (SF) from the knees of 49 patients with osteoarthritis (OA) and 79 with rheumatoid arthritis (RA) in order to investigate the correlation between the type of joint disease and level of CD-RAP.
p4277
sg4
(lp4278
sg6
(lp4279
(dp4280
g9
I92
sg10
VC0003873
p4281
sg12
I2
sg13
VRA
p4282
sg15
I1
sa(dp4283
g9
I171
sg10
VC0029408
p4284
sg12
I2
sg13
VOA
p4285
sg15
I1
sa(dp4286
g9
I155
sg10
VC0029408
p4287
sg12
I14
sg13
Vosteoarthritis
p4288
sg15
I1
sa(dp4289
g9
I187
sg10
VC0003873
p4290
sg12
I20
sg13
Vrheumatoid arthritis
p4291
sg15
I2
sa(dp4292
g9
I273
sg10
VC0022408
p4293
sg12
I13
sg13
Vjoint disease
p4294
sg15
I2
sasa(dp4295
g2
VIn this study, we demonstrated that osteopontin (OPN) was dramatically reduced by loss of TSC1/TSC2 complex in Tsc2-null mouse embryonic fibroblasts (MEFs), rat uterine leiomyoma-derived Tsc2-deficient cells, genetically modified mouse TSC models, and clinical samples.
p4296
sg4
(lp4297
(dp4298
g9
I111
sg20
VP49815
p4299
sg12
I4
sg13
VTsc2
p4300
sg15
I1
sa(dp4301
g9
I49
sg20
VP10451
p4302
sg12
I3
sg13
VOPN
p4303
sg15
I1
sa(dp4304
g9
I90
sg20
g21
sg12
I4
sg13
VTSC1
p4305
sg15
I1
sa(dp4306
g9
I36
sg20
VP10451
p4307
sg12
I11
sg13
Vosteopontin
p4308
sg15
I1
sa(dp4309
g9
I111
sg20
VP49815
p4310
sg12
I4
sg13
VTsc2
p4311
sg15
I1
sa(dp4312
g9
I95
sg20
VP49815
p4313
sg12
I4
sg13
VTSC2
p4314
sg15
I1
sasg6
(lp4315
(dp4316
g9
I111
sg10
VC1860707
p4317
sg12
I4
sg13
VTsc2
p4318
sg15
I1
sa(dp4319
g9
I161
sg10
VC0042133
p4320
sg12
I17
sg13
Vuterine leiomyoma
p4321
sg15
I2
sa(dp4322
g9
I90
sg10
VC1854465
p4323
sg12
I4
sg13
VTSC1
p4324
sg15
I1
sa(dp4325
g9
I90
sg10
VC0041341
p4326
sg12
I3
sg13
VTSC
p4327
sg15
I1
sa(dp4328
g9
I111
sg10
VC1860707
p4329
sg12
I4
sg13
VTsc2
p4330
sg15
I1
sa(dp4331
g9
I95
sg10
VC1860707
p4332
sg12
I4
sg13
VTSC2
p4333
sg15
I1
sasa(dp4334
g2
VTSC2-deficient Eker rat uterine leiomyoma ELT3 cells were stably transfected with empty vector or plasmid for the expression of TSC2.
p4335
sg4
(lp4336
(dp4337
g9
I0
sg20
VP49815
p4338
sg12
I4
sg13
VTSC2
p4339
sg15
I1
sa(dp4340
g9
I0
sg20
VP49815
p4341
sg12
I4
sg13
VTSC2
p4342
sg15
I1
sasg6
(lp4343
(dp4344
g9
I0
sg10
VC1860707
p4345
sg12
I4
sg13
VTSC2
p4346
sg15
I1
sa(dp4347
g9
I24
sg10
VC0042133
p4348
sg12
I17
sg13
Vuterine leiomyoma
p4349
sg15
I2
sa(dp4350
g9
I0
sg10
VC1860707
p4351
sg12
I4
sg13
VTSC2
p4352
sg15
I1
sasa(dp4353
g2
VBy analyzing Tsc2-null mouse embryonic fibroblasts (MEFs) and rat uterine leiomyoma-derived Tsc2-null ELT3 cells, we detected evidence for the involvement of cyclooxygenase 2 (COX2) as a downstream target of mTORC1 in the development of TSC tumors.
p4354
sg4
(lp4355
(dp4356
g9
I13
sg20
VP49815
p4357
sg12
I4
sg13
VTsc2
p4358
sg15
I1
sa(dp4359
g9
I13
sg20
VP49815
p4360
sg12
I4
sg13
VTsc2
p4361
sg15
I1
sa(dp4362
g9
I176
sg20
VP35354
p4363
sg12
I4
sg13
VCOX2
p4364
sg15
I1
sa(dp4365
g9
I158
sg20
VP35354
p4366
sg12
I16
sg13
Vcyclooxygenase 2
p4367
sg15
I2
sasg6
(lp4368
(dp4369
g9
I66
sg10
VC0042133
p4370
sg12
I17
sg13
Vuterine leiomyoma
p4371
sg15
I2
sa(dp4372
g9
I237
sg10
VC0041341
p4373
sg12
I3
sg13
VTSC
p4374
sg15
I1
sa(dp4375
g9
I13
sg10
VC1860707
p4376
sg12
I4
sg13
VTsc2
p4377
sg15
I1
sa(dp4378
g9
I13
sg10
VC1860707
p4379
sg12
I4
sg13
VTsc2
p4380
sg15
I1
sa(dp4381
g9
I241
sg10
VC0027651
p4382
sg12
I6
sg13
Vtumors
p4383
sg15
I1
sasa(dp4384
g2
VTSC2-positive and TSC2-negative mouse embryonic fibroblasts (MEF), 323-TSC2-positive and 323-TSC2-null MEF and Eker rat uterine leiomyoma (ELT3) cells were treated with doxycycline or rapamycin alone, or in combination.
p4385
sg4
(lp4386
(dp4387
g9
I0
sg20
VP49815
p4388
sg12
I4
sg13
VTSC2
p4389
sg15
I1
sa(dp4390
g9
I0
sg20
VP49815
p4391
sg12
I4
sg13
VTSC2
p4392
sg15
I1
sa(dp4393
g9
I0
sg20
VP49815
p4394
sg12
I4
sg13
VTSC2
p4395
sg15
I1
sa(dp4396
g9
I0
sg20
VP49815
p4397
sg12
I4
sg13
VTSC2
p4398
sg15
I1
sasg6
(lp4399
(dp4400
g9
I0
sg10
VC1860707
p4401
sg12
I4
sg13
VTSC2
p4402
sg15
I1
sa(dp4403
g9
I0
sg10
VC1860707
p4404
sg12
I4
sg13
VTSC2
p4405
sg15
I1
sa(dp4406
g9
I0
sg10
VC1860707
p4407
sg12
I4
sg13
VTSC2
p4408
sg15
I1
sa(dp4409
g9
I120
sg10
VC0042133
p4410
sg12
I17
sg13
Vuterine leiomyoma
p4411
sg15
I2
sa(dp4412
g9
I0
sg10
VC1860707
p4413
sg12
I4
sg13
VTSC2
p4414
sg15
I1
sasa(dp4415
g2
VImportantly, rapamycin treatment did not affect the expression of AdPLA2 and the production of PGE2 by TSC2-deficient mouse embryonic fibroblast (Tsc2-/-MEFs), rat uterine leiomyoma-derived ELT3 cells, and LAM patient-associated renal angiomyolipoma-derived "mesenchymal" cells.
p4416
sg4
(lp4417
(dp4418
g9
I146
sg20
VP49815
p4419
sg12
I11
sg13
VTsc2-/-MEFs
p4420
sg15
I1
sa(dp4421
g9
I103
sg20
VP49815
p4422
sg12
I41
sg13
VTSC2-deficient mouse embryonic fibroblast
p4423
sg15
I4
sasg6
(lp4424
(dp4425
g9
I229
sg10
VC0241961
p4426
sg12
I20
sg13
Vrenal angiomyolipoma
p4427
sg15
I2
sa(dp4428
g9
I206
sg10
VC0751674
p4429
sg12
I3
sg13
VLAM
p4430
sg15
I1
sa(dp4431
g9
I164
sg10
VC0042133
p4432
sg12
I17
sg13
Vuterine leiomyoma
p4433
sg15
I2
sa(dp4434
g9
I103
sg10
VC1860707
p4435
sg12
I4
sg13
VTSC2
p4436
sg15
I1
sa(dp4437
g9
I146
sg10
VC1860707
p4438
sg12
I4
sg13
VTsc2
p4439
sg15
I1
sasa(dp4440
g2
VLoss of the Tuberous Sclerosis 2 (TSC2) tumor suppressor has been proposed as a mechanism important for the etiology of uterine leiomyomata based on the Eker rat model.
p4441
sg4
(lp4442
(dp4443
g9
I34
sg20
VP49815
p4444
sg12
I4
sg13
VTSC2
p4445
sg15
I1
sa(dp4446
g9
I12
sg20
VP49815
p4447
sg12
I20
sg13
VTuberous Sclerosis 2
p4448
sg15
I3
sasg6
(lp4449
(dp4450
g9
I120
sg10
VC0042133
p4451
sg12
I19
sg13
Vuterine leiomyomata
p4452
sg15
I2
sa(dp4453
g9
I34
sg10
VC1860707
p4454
sg12
I4
sg13
VTSC2
p4455
sg15
I1
sa(dp4456
g9
I12
sg10
VC1860707
p4457
sg12
I20
sg13
VTuberous Sclerosis 2
p4458
sg15
I3
sa(dp4459
g9
I40
sg10
VC0027651
p4460
sg12
I5
sg13
Vtumor
p4461
sg15
I1
sasa(dp4462
g2
VHowever, conflicting evidence showing increased TSC2 expression has been reported in human uterine leiomyomata, suggesting that TSC2 might not be involved in the pathogenesis of this disorder.
p4463
sg4
(lp4464
(dp4465
g9
I48
sg20
VP49815
p4466
sg12
I4
sg13
VTSC2
p4467
sg15
I1
sa(dp4468
g9
I48
sg20
VP49815
p4469
sg12
I4
sg13
VTSC2
p4470
sg15
I1
sasg6
(lp4471
(dp4472
g9
I162
sg10
VC0699748
p4473
sg12
I12
sg13
Vpathogenesis
p4474
sg15
I1
sa(dp4475
g9
I91
sg10
VC0042133
p4476
sg12
I19
sg13
Vuterine leiomyomata
p4477
sg15
I2
sa(dp4478
g9
I48
sg10
VC1860707
p4479
sg12
I4
sg13
VTSC2
p4480
sg15
I1
sa(dp4481
g9
I48
sg10
VC1860707
p4482
sg12
I4
sg13
VTSC2
p4483
sg15
I1
sasa(dp4484
g2
VIn cell culture models of TSC2-deficient LAM patient-derived and rat uterine leiomyoma-derived cells, we found that progesterone treatment or progesterone plus estradiol resulted in increased phosphorylation of Protein Kinase B (Akt) and Extracellular signal-regulated kinases1/2 (ERK1/2), induced the proliferation, and enhanced the migration and invasiveness.
p4485
sg4
(lp4486
(dp4487
g9
I211
sg20
VP31749
p4488
sg12
I16
sg13
VProtein Kinase B
p4489
sg15
I3
sa(dp4490
g9
I26
sg20
VP49815
p4491
sg12
I4
sg13
VTSC2
p4492
sg15
I1
sa(dp4493
g9
I238
sg20
VP35555
p4494
sg12
I41
sg13
VExtracellular signal-regulated kinases1/2
p4495
sg15
I3
sa(dp4496
g9
I229
sg20
g21
sg12
I3
sg13
VAkt
p4497
sg15
I1
sa(dp4498
g9
I281
sg20
VP27361
p4499
sg12
I6
sg13
VERK1/2
p4500
sg15
I1
sasg6
(lp4501
(dp4502
g9
I41
sg10
VC0751674
p4503
sg12
I3
sg13
VLAM
p4504
sg15
I1
sa(dp4505
g9
I302
sg10
VC0334094
p4506
sg12
I13
sg13
Vproliferation
p4507
sg15
I1
sa(dp4508
g9
I26
sg10
VC1860707
p4509
sg12
I4
sg13
VTSC2
p4510
sg15
I1
sa(dp4511
g9
I69
sg10
VC0042133
p4512
sg12
I17
sg13
Vuterine leiomyoma
p4513
sg15
I2
sasa(dp4514
g2
VWe report here that expression of AlfaB-crystallin was upregulated in Tsc1-/- or Tsc2-/- mouse embryonic fibroblasts, Eker rat uterine leiomyoma-derived Tsc2-deficient ELT3 cells, mutant Tsc2-associated mouse kidney tumors, and human lung lymphangioleiomyomatosis nodules.
p4515
sg4
(lp4516
(dp4517
g9
I81
sg20
VP49815
p4518
sg12
I4
sg13
VTsc2
p4519
sg15
I1
sa(dp4520
g9
I34
sg20
VP22914
p4521
sg12
I16
sg13
VAlfaB-crystallin
p4522
sg15
I1
sa(dp4523
g9
I81
sg20
VP49815
p4524
sg12
I4
sg13
VTsc2
p4525
sg15
I1
sa(dp4526
g9
I81
sg20
VP49815
p4527
sg12
I4
sg13
VTsc2
p4528
sg15
I1
sa(dp4529
g9
I70
sg20
g21
sg12
I4
sg13
VTsc1
p4530
sg15
I1
sasg6
(lp4531
(dp4532
g9
I81
sg10
VC1860707
p4533
sg12
I4
sg13
VTsc2
p4534
sg15
I1
sa(dp4535
g9
I70
sg10
VC1854465
p4536
sg12
I4
sg13
VTsc1
p4537
sg15
I1
sa(dp4538
g9
I209
sg10
VC0022665
p4539
sg12
I13
sg13
Vkidney tumors
p4540
sg15
I2
sa(dp4541
g9
I81
sg10
VC1860707
p4542
sg12
I4
sg13
VTsc2
p4543
sg15
I1
sa(dp4544
g9
I264
sg10
VC0028259
p4545
sg12
I7
sg13
Vnodules
p4546
sg15
I1
sa(dp4547
g9
I127
sg10
VC0042133
p4548
sg12
I17
sg13
Vuterine leiomyoma
p4549
sg15
I2
sa(dp4550
g9
I81
sg10
VC1860707
p4551
sg12
I4
sg13
VTsc2
p4552
sg15
I1
sa(dp4553
g9
I180
sg10
VC0596988
p4554
sg12
I6
sg13
Vmutant
p4555
sg15
I1
sa(dp4556
g9
I234
sg10
VC0349649
p4557
sg12
I29
sg13
Vlung lymphangioleiomyomatosis
p4558
sg15
I2
sasa(dp4559
g2
VFemale Eker rats harboring an insertional deletion in one copy of the tuberous sclerosis complex 2 (Tsc2) gene develop uterine leiomyoma, but the underlying mechanism of human uterine leiomyoma is not completely understood.
p4560
sg4
(lp4561
(dp4562
g9
I100
sg20
VP49815
p4563
sg12
I4
sg13
VTsc2
p4564
sg15
I1
sa(dp4565
g9
I70
sg20
VP49815
p4566
sg12
I28
sg13
Vtuberous sclerosis complex 2
p4567
sg15
I4
sasg6
(lp4568
(dp4569
g9
I119
sg10
VC0042133
p4570
sg12
I17
sg13
Vuterine leiomyoma
p4571
sg15
I2
sa(dp4572
g9
I100
sg10
VC1860707
p4573
sg12
I4
sg13
VTsc2
p4574
sg15
I1
sa(dp4575
g9
I70
sg10
VC1860707
p4576
sg12
I28
sg13
Vtuberous sclerosis complex 2
p4577
sg15
I4
sa(dp4578
g9
I119
sg10
VC0042133
p4579
sg12
I17
sg13
Vuterine leiomyoma
p4580
sg15
I2
sasa(dp4581
g2
VTo examine whether down-regulation of tuberin, a TSC2 gene product, is present in human uterine leiomyoma, we analyzed leiomyoma and matched myometrium tissues from 22 Chinese patients with Western blotting and real-time polymerase chain reaction analyses, and found that the expression of tuberin was significantly increased in leiomyoma tissues compared with matched myometrium tissues with inhibition of both the mammalian target of rapacmycin pathway and mitogen-activated protein kinase pathways.
p4582
sg4
(lp4583
(dp4584
g9
I38
sg20
VP49815
p4585
sg12
I7
sg13
Vtuberin
p4586
sg15
I1
sa(dp4587
g9
I49
sg20
VP49815
p4588
sg12
I17
sg13
VTSC2 gene product
p4589
sg15
I3
sa(dp4590
g9
I38
sg20
VP49815
p4591
sg12
I7
sg13
Vtuberin
p4592
sg15
I1
sa(dp4593
g9
I459
sg20
VP53779
p4594
sg12
I32
sg13
Vmitogen-activated protein kinase
p4595
sg15
I3
sasg6
(lp4596
(dp4597
g9
I96
sg10
VC0042133
p4598
sg12
I9
sg13
Vleiomyoma
p4599
sg15
I1
sa(dp4600
g9
I88
sg10
VC0042133
p4601
sg12
I17
sg13
Vuterine leiomyoma
p4602
sg15
I2
sa(dp4603
g9
I96
sg10
VC0042133
p4604
sg12
I9
sg13
Vleiomyoma
p4605
sg15
I1
sa(dp4606
g9
I49
sg10
VC1860707
p4607
sg12
I4
sg13
VTSC2
p4608
sg15
I1
sasa(dp4609
g2
VCells derived from an Eker rat uterine leiomyoma (ELT3 cells) are Tsc2-null and these have been used in a rodent cell models for LAM.
p4610
sg4
(lp4611
(dp4612
g9
I66
sg20
VP49815
p4613
sg12
I9
sg13
VTsc2-null
p4614
sg15
I1
sasg6
(lp4615
(dp4616
g9
I129
sg10
VC0751674
p4617
sg12
I3
sg13
VLAM
p4618
sg15
I1
sa(dp4619
g9
I31
sg10
VC0042133
p4620
sg12
I17
sg13
Vuterine leiomyoma
p4621
sg15
I2
sa(dp4622
g9
I66
sg10
VC1860707
p4623
sg12
I4
sg13
VTsc2
p4624
sg15
I1
sasa(dp4625
g2
VIn patients with rheumatoid arthritis, furin is reported to be highly expressed in the synovial pannus compared with healthy persons.
p4626
sg4
(lp4627
(dp4628
g9
I39
sg20
VP09958
p4629
sg12
I5
sg13
Vfurin
p4630
sg15
I1
sasg6
(lp4631
(dp4632
g9
I96
sg10
VC0155094
p4633
sg12
I6
sg13
Vpannus
p4634
sg15
I1
sa(dp4635
g9
I17
sg10
VC0003873
p4636
sg12
I20
sg13
Vrheumatoid arthritis
p4637
sg15
I2
sasa(dp4638
g2
VInhibition of furin enhances invasive phenotype of synoviocytes from patients with rheumatoid arthritis, implying a protective role of furin.
p4639
sg4
(lp4640
(dp4641
g9
I14
sg20
VP09958
p4642
sg12
I5
sg13
Vfurin
p4643
sg15
I1
sa(dp4644
g9
I14
sg20
VP09958
p4645
sg12
I5
sg13
Vfurin
p4646
sg15
I1
sasg6
(lp4647
(dp4648
g9
I83
sg10
VC0003873
p4649
sg12
I20
sg13
Vrheumatoid arthritis
p4650
sg15
I2
sasa(dp4651
g2
VAgents targeting upregulation of furin may have therapeutic potential for rheumatoid arthritis.
p4652
sg4
(lp4653
(dp4654
g9
I33
sg20
VP09958
p4655
sg12
I5
sg13
Vfurin
p4656
sg15
I1
sasg6
(lp4657
(dp4658
g9
I74
sg10
VC0003873
p4659
sg12
I20
sg13
Vrheumatoid arthritis
p4660
sg15
I2
sasa(dp4661
g2
VThe effect of furin and its inhibitor Alfa1-PDX was tested in mice with collagen-induced arthritis (CIA).
p4662
sg4
(lp4663
(dp4664
g9
I14
sg20
VP09958
p4665
sg12
I5
sg13
Vfurin
p4666
sg15
I1
sasg6
(lp4667
(dp4668
g9
I89
sg10
VC0003864
p4669
sg12
I9
sg13
Varthritis
p4670
sg15
I1
sasa(dp4671
g2
VSystemic administration of furin prevented increases in the arthritis score, joint destruction, and bone loss, in contrast to systemic administration of the furin inhibitor Alfa1-PDX, which enhanced these parameters.
p4672
sg4
(lp4673
(dp4674
g9
I27
sg20
VP09958
p4675
sg12
I5
sg13
Vfurin
p4676
sg15
I1
sa(dp4677
g9
I27
sg20
VP09958
p4678
sg12
I5
sg13
Vfurin
p4679
sg15
I1
sasg6
(lp4680
(dp4681
g9
I60
sg10
VC0003864
p4682
sg12
I9
sg13
Varthritis
p4683
sg15
I1
sa(dp4684
g9
I100
sg10
VC0029453
p4685
sg12
I9
sg13
Vbone loss
p4686
sg15
I2
sasa(dp4687
g2
VThey also suggest that Adamts5 induction in joint components other than cartilage, and its post-translational activation by PACE4 and/or furin may be important in the pathophysiology of arthritis.
p4688
sg4
(lp4689
(dp4690
g9
I23
sg20
g21
sg12
I7
sg13
VAdamts5
p4691
sg15
I1
sa(dp4692
g9
I137
sg20
VP09958
p4693
sg12
I5
sg13
Vfurin
p4694
sg15
I1
sasg6
(lp4695
(dp4696
g9
I186
sg10
VC0003864
p4697
sg12
I9
sg13
Varthritis
p4698
sg15
I1
sasa(dp4699
g2
VWhen comparing the chorioamniotic membranes from women in spontaneous preterm labor with acute histologic chorioamnionitis to those without this placental lesion, we found that (1) the mRNA of NLR family pyrin domain-containing protein ( NLRP) 1, NLRP3, NLR family CARD domain-containing protein 4 ( NLRC4), and NOD2 were higher; (2) the NLRP3 protein was increased; (3) the mRNA and active form (p10) of CASP-1 were greater; (4) the mRNA and active form of CASP-4 were increased; (5) the mRNA and mature form of IL-1Beta were higher; (6) the mature form of IL-18 was elevated; and (7) ASC/CASP-1 complex formation was increased.
p4700
sg4
(lp4701
(dp4702
g9
I193
sg20
g21
sg12
I52
sg13
VNLR family pyrin domain-containing protein ( NLRP) 1
p4703
sg15
I8
sa(dp4704
g9
I513
sg20
VP01584
p4705
sg12
I8
sg13
VIL-1Beta
p4706
sg15
I1
sa(dp4707
g9
I300
sg20
g21
sg12
I5
sg13
VNLRC4
p4708
sg15
I1
sa(dp4709
g9
I254
sg20
g21
sg12
I43
sg13
VNLR family CARD domain-containing protein 4
p4710
sg15
I6
sa(dp4711
g9
I458
sg20
VP39880
p4712
sg12
I6
sg13
VCASP-4
p4713
sg15
I1
sa(dp4714
g9
I405
sg20
VP39880
p4715
sg12
I6
sg13
VCASP-1
p4716
sg15
I1
sa(dp4717
g9
I312
sg20
VP22301
p4718
sg12
I4
sg13
VNOD2
p4719
sg15
I1
sa(dp4720
g9
I397
sg20
VP60903
p4721
sg12
I3
sg13
Vp10
p4722
sg15
I1
sasg6
(lp4723
(dp4724
g9
I106
sg10
VC0008495
p4725
sg12
I16
sg13
Vchorioamnionitis
p4726
sg15
I1
sa(dp4727
g9
I70
sg10
VC0022876
p4728
sg12
I13
sg13
Vpreterm labor
p4729
sg15
I2
sasa(dp4730
g2
VWhen comparing the chorioamniotic membranes from women in spontaneous labor at term with acute histologic chorioamnionitis to those without this placental lesion, we found that (1) the messenger RNA (mRNA) abundance of NLR family pyrin domain containing 3 ( NLRP3), NLR family CARD domain containing 4 ( NLRC4), absent in melanoma 2 ( AIM2), and nucleotide binding oligomerization domain 2 ( NOD2) was higher; (2) the NLRP3 and NLRC4 protein quantities were increased; (3) the mRNA and protein expressions of CASP-1 and its active forms were greater; (4) CASP-4 was increased at the mRNA level only; (5) the mRNA and protein expressions of IL-1Beta and its mature form were higher; and (6) a modest increase in the total protein concentration and abundance of the mature form of IL-18 was observed.
p4731
sg4
(lp4732
(dp4733
g9
I335
sg20
g21
sg12
I4
sg13
VAIM2
p4734
sg15
I1
sa(dp4735
g9
I266
sg20
g21
sg12
I35
sg13
VNLR family CARD domain containing 4
p4736
sg15
I6
sa(dp4737
g9
I640
sg20
VP01584
p4738
sg12
I8
sg13
VIL-1Beta
p4739
sg15
I1
sa(dp4740
g9
I304
sg20
g21
sg12
I5
sg13
VNLRC4
p4741
sg15
I1
sa(dp4742
g9
I509
sg20
VP39880
p4743
sg12
I6
sg13
VCASP-1
p4744
sg15
I1
sa(dp4745
g9
I219
sg20
g21
sg12
I36
sg13
VNLR family pyrin domain containing 3
p4746
sg15
I6
sa(dp4747
g9
I346
sg20
VP63244
p4748
sg12
I43
sg13
Vnucleotide binding oligomerization domain 2
p4749
sg15
I5
sa(dp4750
g9
I428
sg20
g21
sg12
I13
sg13
VNLRC4 protein
p4751
sg15
I2
sa(dp4752
g9
I392
sg20
VP22301
p4753
sg12
I4
sg13
VNOD2
p4754
sg15
I1
sasg6
(lp4755
(dp4756
g9
I106
sg10
VC0008495
p4757
sg12
I16
sg13
Vchorioamnionitis
p4758
sg15
I1
sa(dp4759
g9
I322
sg10
VC0025202
p4760
sg12
I8
sg13
Vmelanoma
p4761
sg15
I1
sasa(dp4762
g2
VMutations in NLRP7 (NOD-like-receptor family, pyrin domain containing 7) are responsible for a type of recurrent pregnancy loss known as recurrent hydatidiform mole (HYDM1).
p4763
sg4
(lp4764
(dp4765
g9
I20
sg20
VP54259
p4766
sg12
I24
sg13
VNOD-like-receptor family
p4767
sg15
I2
sa(dp4768
g9
I13
sg20
g21
sg12
I5
sg13
VNLRP7
p4769
sg15
I1
sa(dp4770
g9
I46
sg20
g21
sg12
I25
sg13
Vpyrin domain containing 7
p4771
sg15
I4
sasg6
(lp4772
(dp4773
g9
I20
sg10
VC0751781
p4774
sg12
I3
sg13
VNOD
p4775
sg15
I1
sa(dp4776
g9
I103
sg10
VC2921106
p4777
sg12
I24
sg13
Vrecurrent pregnancy loss
p4778
sg15
I3
sa(dp4779
g9
I147
sg10
VC0020217
p4780
sg12
I17
sg13
Vhydatidiform mole
p4781
sg15
I2
sa(dp4782
g9
I166
sg10
VC3463897
p4783
sg12
I5
sg13
VHYDM1
p4784
sg15
I1
sasa(dp4785
g2
VNRG1 fusion-positive lung cancers have emerged as potentially actionable events in lung cancer but clinical support is currently limited and no evidence of efficacy of this approach in cancers beyond lung has been shown.
p4786
sg4
(lp4787
sg6
(lp4788
(dp4789
g9
I26
sg10
VC0006826
p4790
sg12
I7
sg13
Vcancers
p4791
sg15
I1
sa(dp4792
g9
I21
sg10
VC0242379
p4793
sg12
I12
sg13
Vlung cancers
p4794
sg15
I2
sa(dp4795
g9
I21
sg10
VC0242379
p4796
sg12
I11
sg13
Vlung cancer
p4797
sg15
I2
sasa(dp4798
g2
VIn patient 1 an SDC4-NRG1 gene fusion was detected, similar gene fusions having been described in lung cancers previously.
p4799
sg4
(lp4800
(dp4801
g9
I60
sg20
VP35637
p4802
sg12
I12
sg13
Vgene fusions
p4803
sg15
I2
sa(dp4804
g9
I16
sg20
VP31431
p4805
sg12
I4
sg13
VSDC4
p4806
sg15
I1
sasg6
(lp4807
(dp4808
g9
I26
sg10
VC1705736
p4809
sg12
I11
sg13
Vgene fusion
p4810
sg15
I2
sa(dp4811
g9
I98
sg10
VC0242379
p4812
sg12
I12
sg13
Vlung cancers
p4813
sg15
I2
sasa(dp4814
g2
VUnexpected molecular lesions of the NRG1 gene followed by an aberrant ErbB signaling were recently described as a new molecular features of non-small cell lung cancer, but it has been also sporadically reported in other tumors.
p4815
sg4
(lp4816
(dp4817
g9
I70
sg20
g21
sg12
I4
sg13
VErbB
p4818
sg15
I1
sasg6
(lp4819
(dp4820
g9
I220
sg10
VC0027651
p4821
sg12
I6
sg13
Vtumors
p4822
sg15
I1
sa(dp4823
g9
I140
sg10
VC0007131
p4824
sg12
I26
sg13
Vnon-small cell lung cancer
p4825
sg15
I4
sasa(dp4826
g2
VWe highlight the current knowledge about the ErbB network and NRG1 deregulation in lung cancer and their merger into the ErbB/PI3K-AKT axis modulation and current therapeutic strategies.
p4827
sg4
(lp4828
(dp4829
g9
I45
sg20
g21
sg12
I4
sg13
VErbB
p4830
sg15
I1
sa(dp4831
g9
I131
sg20
g21
sg12
I3
sg13
VAKT
p4832
sg15
I1
sa(dp4833
g9
I126
sg20
VP42336
p4834
sg12
I4
sg13
VPI3K
p4835
sg15
I1
sa(dp4836
g9
I45
sg20
g21
sg12
I12
sg13
VErbB network
p4837
sg15
I2
sasg6
(lp4838
(dp4839
g9
I83
sg10
VC0684249
p4840
sg12
I11
sg13
Vlung cancer
p4841
sg15
I2
sasa(dp4842
g2
VMore advances in knowledge of crosstalk between NRG1, ErbB3 and PI3K-AKT pathways may increase and strongly support the therapeutic choice for lung cancer patients.
p4843
sg4
(lp4844
(dp4845
g9
I64
sg20
VP42336
p4846
sg12
I4
sg13
VPI3K
p4847
sg15
I1
sa(dp4848
g9
I54
sg20
VP21860
p4849
sg12
I5
sg13
VErbB3
p4850
sg15
I1
sa(dp4851
g9
I69
sg20
g21
sg12
I3
sg13
VAKT
p4852
sg15
I1
sasg6
(lp4853
(dp4854
g9
I143
sg10
VC0684249
p4855
sg12
I11
sg13
Vlung cancer
p4856
sg15
I2
sasa(dp4857
g2
VAll coding exons of SCN1B, GABRG2, and CACNB4 genes were screened for mutations in 38 SCN1A-mutation-positive SMEI probands.
p4858
sg4
(lp4859
(dp4860
g9
I86
sg20
VP35498
p4861
sg12
I5
sg13
VSCN1A
p4862
sg15
I1
sa(dp4863
g9
I20
sg20
g21
sg12
I5
sg13
VSCN1B
p4864
sg15
I1
sa(dp4865
g9
I39
sg20
g21
sg12
I12
sg13
VCACNB4 genes
p4866
sg15
I2
sa(dp4867
g9
I27
sg20
VP18507
p4868
sg12
I6
sg13
VGABRG2
p4869
sg15
I1
sasg6
(lp4870
(dp4871
g9
I110
sg10
VC0751122
p4872
sg12
I4
sg13
VSMEI
p4873
sg15
I1
sasa(dp4874
g2
VFollowing the univariate analysis, high expressions of nuclear Beta-arrestin1 and p300 were classed as poor prognostic factors for both OS (P = .016) and DFS (P = .025).The expression of Beta-arrestin1 in the nucleus is associated with increased malignant tendency of lung adenocarcinoma, and the predictive value of Beta-arrestin1 may be optimized by combining information about the expression of p300 acetyltransferase.
p4875
sg4
(lp4876
(dp4877
g9
I82
sg20
g21
sg12
I4
sg13
Vp300
p4878
sg15
I1
sa(dp4879
g9
I398
sg20
g21
sg12
I22
sg13
Vp300 acetyltransferase
p4880
sg15
I2
sasg6
(lp4881
(dp4882
g9
I268
sg10
VC0152013
p4883
sg12
I19
sg13
Vlung adenocarcinoma
p4884
sg15
I2
sasa(dp4885
g2
VFurthermore, we demonstrated that the activation of COX-2 expression by hnRNPA2/B1 was mediated through the cooperation with p300, a transcriptional co-activator, in NSCLC cells.
p4886
sg4
(lp4887
(dp4888
g9
I72
sg20
VP22626
p4889
sg12
I7
sg13
VhnRNPA2
p4890
sg15
I1
sa(dp4891
g9
I52
sg20
VP35354
p4892
sg12
I5
sg13
VCOX-2
p4893
sg15
I1
sa(dp4894
g9
I125
sg20
g21
sg12
I4
sg13
Vp300
p4895
sg15
I1
sasg6
(lp4896
(dp4897
g9
I166
sg10
VC0007131
p4898
sg12
I5
sg13
VNSCLC
p4899
sg15
I1
sasa(dp4900
g2
VPPARGC1A and PPARGC1B) are key agents in the development and pathophysiology of type 2 diabetes mellitus (T2DM).
p4901
sg4
(lp4902
(dp4903
g9
I0
sg20
g21
sg12
I8
sg13
VPPARGC1A
p4904
sg15
I1
sasg6
(lp4905
(dp4906
g9
I106
sg10
VC0011860
p4907
sg12
I4
sg13
VT2DM
p4908
sg15
I1
sa(dp4909
g9
I80
sg10
VC0011860
p4910
sg12
I24
sg13
Vtype 2 diabetes mellitus
p4911
sg15
I4
sasa(dp4912
g2
VFurthermore, eight of the 17 CpG sites reside in genes (FSTL1, SORCS2, NRF1, DLC1, PPARGC1B, CHN2, NXPH1) that have prior known associations with obesity, diabetes, and the insulin pathway.
p4913
sg4
(lp4914
(dp4915
g9
I63
sg20
g21
sg12
I6
sg13
VSORCS2
p4916
sg15
I1
sa(dp4917
g9
I93
sg20
VP52757
p4918
sg12
I4
sg13
VCHN2
p4919
sg15
I1
sa(dp4920
g9
I71
sg20
g21
sg12
I4
sg13
VNRF1
p4921
sg15
I1
sa(dp4922
g9
I56
sg20
g21
sg12
I5
sg13
VFSTL1
p4923
sg15
I1
sa(dp4924
g9
I77
sg20
VP63167
p4925
sg12
I4
sg13
VDLC1
p4926
sg15
I1
sa(dp4927
g9
I173
sg20
VP01308
p4928
sg12
I7
sg13
Vinsulin
p4929
sg15
I1
sa(dp4930
g9
I99
sg20
VP58417
p4931
sg12
I5
sg13
VNXPH1
p4932
sg15
I1
sasg6
(lp4933
(dp4934
g9
I155
sg10
VC0011849
p4935
sg12
I8
sg13
Vdiabetes
p4936
sg15
I1
sa(dp4937
g9
I146
sg10
VC0028754
p4938
sg12
I7
sg13
Vobesity
p4939
sg15
I1
sasa(dp4940
g2
VNo significant associations were found, although the top significant CpGs in boys were located in the LRPAP1, HAGH, PPARGC1B, KCNQ1 and KCNQ1DN genes, previously associated to birth weight, Type 2 diabetes, obesity or steroid hormone signaling.
p4941
sg4
(lp4942
(dp4943
g9
I136
sg20
g21
sg12
I13
sg13
VKCNQ1DN genes
p4944
sg15
I2
sa(dp4945
g9
I126
sg20
VP51787
p4946
sg12
I5
sg13
VKCNQ1
p4947
sg15
I1
sa(dp4948
g9
I102
sg20
VP30533
p4949
sg12
I6
sg13
VLRPAP1
p4950
sg15
I1
sa(dp4951
g9
I110
sg20
g21
sg12
I4
sg13
VHAGH
p4952
sg15
I1
sasg6
(lp4953
(dp4954
g9
I190
sg10
VC0011860
p4955
sg12
I15
sg13
VType 2 diabetes
p4956
sg15
I3
sa(dp4957
g9
I207
sg10
VC0028754
p4958
sg12
I7
sg13
Vobesity
p4959
sg15
I1
sasa(dp4960
g2
VWe used a two-stage study design to evaluate whether variations in the peroxisome proliferator-activated receptors (PPAR) and the PPAR gamma co-activator 1 (PGC1) gene families (PPARA, PPARG, PPARD, PPARGC1A, and PPARGC1B) are associated with type 2 diabetes (T2D) risk.
p4961
sg4
(lp4962
(dp4963
g9
I163
sg20
VP19883
p4964
sg12
I13
sg13
Vgene families
p4965
sg15
I2
sa(dp4966
g9
I157
sg20
g21
sg12
I4
sg13
VPGC1
p4967
sg15
I1
sa(dp4968
g9
I199
sg20
g21
sg12
I8
sg13
VPPARGC1A
p4969
sg15
I1
sa(dp4970
g9
I116
sg20
g21
sg12
I4
sg13
VPPAR
p4971
sg15
I1
sa(dp4972
g9
I71
sg20
g21
sg12
I43
sg13
Vperoxisome proliferator-activated receptors
p4973
sg15
I3
sa(dp4974
g9
I130
sg20
g21
sg12
I25
sg13
VPPAR gamma co-activator 1
p4975
sg15
I4
sa(dp4976
g9
I185
sg20
g21
sg12
I5
sg13
VPPARG
p4977
sg15
I1
sa(dp4978
g9
I192
sg20
g21
sg12
I5
sg13
VPPARD
p4979
sg15
I1
sa(dp4980
g9
I178
sg20
g21
sg12
I5
sg13
VPPARA
p4981
sg15
I1
sasg6
(lp4982
(dp4983
g9
I260
sg10
VC0011860
p4984
sg12
I3
sg13
VT2D
p4985
sg15
I1
sa(dp4986
g9
I243
sg10
VC0011860
p4987
sg12
I15
sg13
Vtype 2 diabetes
p4988
sg15
I3
sasa(dp4989
g2
VA recently identified muscular dystrophy gene TOR1AIP1 was detected as a hub gene in dysferlinopathy.
p4990
sg4
(lp4991
(dp4992
g9
I73
sg20
g21
sg12
I8
sg13
Vhub gene
p4993
sg15
I2
sa(dp4994
g9
I22
sg20
VP43034
p4995
sg12
I32
sg13
Vmuscular dystrophy gene TOR1AIP1
p4996
sg15
I4
sasg6
(lp4997
(dp4998
g9
I22
sg10
VC0026850
p4999
sg12
I18
sg13
Vmuscular dystrophy
p5000
sg15
I2
sa(dp5001
g9
I85
sg10
VC2931687
p5002
sg12
I15
sg13
Vdysferlinopathy
p5003
sg15
I1
sasa(dp5004
g2
VTorsinA-interacting protein 1 (TOR1AIP1) gene is a novel gene that has recently been described to cause limb-girdle muscular dystrophy (LGMD) with mild dilated cardiomyopathy.
p5005
sg4
(lp5006
(dp5007
g9
I0
sg20
VP14222
p5008
sg12
I29
sg13
VTorsinA-interacting protein 1
p5009
sg15
I3
sasg6
(lp5010
(dp5011
g9
I152
sg10
VC0007193
p5012
sg12
I22
sg13
Vdilated cardiomyopathy
p5013
sg15
I2
sa(dp5014
g9
I104
sg10
VC0686353
p5015
sg12
I30
sg13
Vlimb-girdle muscular dystrophy
p5016
sg15
I3
sa(dp5017
g9
I136
sg10
VC0686353
p5018
sg12
I4
sg13
VLGMD
p5019
sg15
I1
sasa(dp5020
g2
VWe report a family with mutations in TOR1AIP1 where the striking clinical feature is severe cardiac failure requiring cardiac transplant in two siblings, in addition to musculoskeletal weakness and muscular dystrophy.
p5021
sg4
(lp5022
sg6
(lp5023
(dp5024
g9
I92
sg10
VC0018801
p5025
sg12
I15
sg13
Vcardiac failure
p5026
sg15
I2
sa(dp5027
g9
I198
sg10
VC0026850
p5028
sg12
I18
sg13
Vmuscular dystrophy
p5029
sg15
I2
sa(dp5030
g9
I185
sg10
VC1883552
p5031
sg12
I8
sg13
Vweakness
p5032
sg15
I1
sasa(dp5033
g2
VThese scientific contributions strengthen the role of LAP1 in DYT1 dystonia and muscular dystrophy.
p5034
sg4
(lp5035
(dp5036
g9
I62
sg20
g21
sg12
I13
sg13
VDYT1 dystonia
p5037
sg15
I2
sa(dp5038
g9
I54
sg20
VP15144
p5039
sg12
I4
sg13
VLAP1
p5040
sg15
I1
sasg6
(lp5041
(dp5042
g9
I62
sg10
VC1851945
p5043
sg12
I4
sg13
VDYT1
p5044
sg15
I1
sa(dp5045
g9
I67
sg10
VC0393593
p5046
sg12
I8
sg13
Vdystonia
p5047
sg15
I1
sa(dp5048
g9
I80
sg10
VC0026850
p5049
sg12
I18
sg13
Vmuscular dystrophy
p5050
sg15
I2
sasa(dp5051
g2
VMoreover, LAP1 also interacts with torsinA and emerin, proteins involved in DYT1 dystonia and X-linked Emery-Dreifuss muscular dystrophy disorder, respectively.
p5052
sg4
(lp5053
(dp5054
g9
I76
sg20
g21
sg12
I4
sg13
VDYT1
p5055
sg15
I1
sa(dp5056
g9
I47
sg20
VP50402
p5057
sg12
I6
sg13
Vemerin
p5058
sg15
I1
sa(dp5059
g9
I35
sg20
g21
sg12
I7
sg13
VtorsinA
p5060
sg15
I1
sa(dp5061
g9
I10
sg20
VP15144
p5062
sg12
I4
sg13
VLAP1
p5063
sg15
I1
sasg6
(lp5064
(dp5065
g9
I76
sg10
VC1851945
p5066
sg12
I4
sg13
VDYT1
p5067
sg15
I1
sa(dp5068
g9
I94
sg10
VC0751337
p5069
sg12
I42
sg13
VX-linked Emery-Dreifuss muscular dystrophy
p5070
sg15
I4
sa(dp5071
g9
I81
sg10
VC0393593
p5072
sg12
I8
sg13
Vdystonia
p5073
sg15
I1
sasa(dp5074
g2
VDeletions encompassing TAK1-binding protein 2 (TAB2) associated with isolated and syndromic congenital heart defects.
p5075
sg4
(lp5076
(dp5077
g9
I23
sg20
g21
sg12
I22
sg13
VTAK1-binding protein 2
p5078
sg15
I3
sa(dp5079
g9
I47
sg20
g21
sg12
I4
sg13
VTAB2
p5080
sg15
I1
sasg6
(lp5081
(dp5082
g9
I92
sg10
VC0018798
p5083
sg12
I24
sg13
Vcongenital heart defects
p5084
sg15
I3
sasa(dp5085
g2
VHaploinsufficiency of TAB2 was recently implicated as a cause for a variety of congenital heart defects.
p5086
sg4
(lp5087
(dp5088
g9
I22
sg20
g21
sg12
I4
sg13
VTAB2
p5089
sg15
I1
sasg6
(lp5090
(dp5091
g9
I79
sg10
VC0018798
p5092
sg12
I24
sg13
Vcongenital heart defects
p5093
sg15
I3
sasa(dp5094
g2
VThis is the smallest reported deletion involving TAB2 that segregates with congenital heart defects.
p5095
sg4
(lp5096
(dp5097
g9
I49
sg20
g21
sg12
I4
sg13
VTAB2
p5098
sg15
I1
sasg6
(lp5099
(dp5100
g9
I75
sg10
VC0018798
p5101
sg12
I24
sg13
Vcongenital heart defects
p5102
sg15
I3
sasa(dp5103
g2
VFindings from this family support a key role of TAB2 haploinsufficiency in congenital heart defects and expand the phenotypic spectrum of TAB2-microdeletion syndrome.
p5104
sg4
(lp5105
(dp5106
g9
I48
sg20
g21
sg12
I4
sg13
VTAB2
p5107
sg15
I1
sa(dp5108
g9
I48
sg20
g21
sg12
I4
sg13
VTAB2
p5109
sg15
I1
sasg6
(lp5110
(dp5111
g9
I157
sg10
VC0039082
p5112
sg12
I8
sg13
Vsyndrome
p5113
sg15
I1
sa(dp5114
g9
I75
sg10
VC0018798
p5115
sg12
I24
sg13
Vcongenital heart defects
p5116
sg15
I3
sasa(dp5117
g2
VIn addition, the present deletion is the smallest so far recorded in the 6q25 region encompassing eight known genes [vs. 41 of Bisgaard et al., and 23 of Caselli et al.,], including the TAB2 (likely responsible for the girl's congenital heart defect), LATS1 gene, and the UST gene (a regulator of the homeostasis of proteoglycans, which could have played a role in the abnormal dermal and cartilage elasticity).
p5118
sg4
(lp5119
(dp5120
g9
I272
sg20
g21
sg12
I8
sg13
VUST gene
p5121
sg15
I2
sa(dp5122
g9
I252
sg20
g21
sg12
I10
sg13
VLATS1 gene
p5123
sg15
I2
sa(dp5124
g9
I186
sg20
g21
sg12
I4
sg13
VTAB2
p5125
sg15
I1
sasg6
(lp5126
(dp5127
g9
I226
sg10
VC0018798
p5128
sg12
I23
sg13
Vcongenital heart defect
p5129
sg15
I3
sasa(dp5130
g2
VThe isozymes hPAD2 and hPAD4 have been implicated in the development and progression of several autoimmune diseases, including rheumatoid arthritis and multiple sclerosis.
p5131
sg4
(lp5132
sg6
(lp5133
(dp5134
g9
I96
sg10
VC0004364
p5135
sg12
I19
sg13
Vautoimmune diseases
p5136
sg15
I2
sa(dp5137
g9
I127
sg10
VC0003873
p5138
sg12
I20
sg13
Vrheumatoid arthritis
p5139
sg15
I2
sa(dp5140
g9
I152
sg10
VC0026769
p5141
sg12
I18
sg13
Vmultiple sclerosis
p5142
sg15
I2
sasa(dp5143
g2
VProtein arginine deiminase 2 (PAD2) plays a key role in the onset and progression of multiple sclerosis, rheumatoid arthritis, and breast cancer.
p5144
sg4
(lp5145
(dp5146
g9
I0
sg20
g21
sg12
I28
sg13
VProtein arginine deiminase 2
p5147
sg15
I4
sa(dp5148
g9
I30
sg20
g21
sg12
I4
sg13
VPAD2
p5149
sg15
I1
sasg6
(lp5150
(dp5151
g9
I105
sg10
VC0003873
p5152
sg12
I20
sg13
Vrheumatoid arthritis
p5153
sg15
I2
sa(dp5154
g9
I131
sg10
VC0678222
p5155
sg12
I13
sg13
Vbreast cancer
p5156
sg15
I2
sa(dp5157
g9
I85
sg10
VC0026769
p5158
sg12
I18
sg13
Vmultiple sclerosis
p5159
sg15
I2
sasa(dp5160
g2
VThe enzyme peptidylarginine deiminase 2 (PAD2) has been associated with inflammatory diseases, such as rheumatoid arthritis and neurodegenerative diseases including multiple sclerosis.
p5161
sg4
(lp5162
(dp5163
g9
I11
sg20
g21
sg12
I28
sg13
Vpeptidylarginine deiminase 2
p5164
sg15
I3
sa(dp5165
g9
I41
sg20
g21
sg12
I4
sg13
VPAD2
p5166
sg15
I1
sasg6
(lp5167
(dp5168
g9
I103
sg10
VC0003873
p5169
sg12
I20
sg13
Vrheumatoid arthritis
p5170
sg15
I2
sa(dp5171
g9
I128
sg10
VC0524851
p5172
sg12
I26
sg13
Vneurodegenerative diseases
p5173
sg15
I2
sa(dp5174
g9
I165
sg10
VC0026769
p5175
sg12
I18
sg13
Vmultiple sclerosis
p5176
sg15
I2
sasa(dp5177
g2
VPeptidylarginine deiminase 2 (PAD2) and peptidylarginine deiminase 4 (PAD4) are two members of PAD family which are over-expressed in the multiple sclerosis (MS) brain.
p5178
sg4
(lp5179
(dp5180
g9
I95
sg20
g21
sg12
I10
sg13
VPAD family
p5181
sg15
I2
sa(dp5182
g9
I70
sg20
g21
sg12
I4
sg13
VPAD4
p5183
sg15
I1
sa(dp5184
g9
I40
sg20
g21
sg12
I28
sg13
Vpeptidylarginine deiminase 4
p5185
sg15
I3
sa(dp5186
g9
I0
sg20
g21
sg12
I28
sg13
VPeptidylarginine deiminase 2
p5187
sg15
I3
sa(dp5188
g9
I30
sg20
g21
sg12
I4
sg13
VPAD2
p5189
sg15
I1
sasg6
(lp5190
(dp5191
g9
I138
sg10
VC0026769
p5192
sg12
I18
sg13
Vmultiple sclerosis
p5193
sg15
I2
sa(dp5194
g9
I158
sg10
VC0026769
p5195
sg12
I2
sg13
VMS
p5196
sg15
I1
sa(dp5197
g9
I30
sg10
VC1704436
p5198
sg12
I3
sg13
VPAD
p5199
sg15
I1
sasa(dp5200
g2
VRecent studies have revealed that abnormal activation of PADI2, the gene for which is expressed throughout the nervous system, is likely to be related to the pathogenesis of neuropsychiatric diseases with neurodegenerative processes, such as Alzheimer's disease and multiple sclerosis.
p5201
sg4
(lp5202
(dp5203
g9
I57
sg20
g21
sg12
I5
sg13
VPADI2
p5204
sg15
I1
sasg6
(lp5205
(dp5206
g9
I158
sg10
VC0699748
p5207
sg12
I12
sg13
Vpathogenesis
p5208
sg15
I1
sa(dp5209
g9
I266
sg10
VC0026769
p5210
sg12
I18
sg13
Vmultiple sclerosis
p5211
sg15
I2
sa(dp5212
g9
I111
sg10
VC0027769
p5213
sg12
I7
sg13
Vnervous
p5214
sg15
I1
sa(dp5215
g9
I242
sg10
VC1521724
p5216
sg12
I19
sg13
VAlzheimer's disease
p5217
sg15
I2
sasa(dp5218
g2
VVEGF-Flt-1 signaling induces osteoclastogenesis in OSCC through two possible ways: 1) VEGF produced from OSCC cells can directly stimulate the Flt-1 pathway in preosteoclasts to induce migration to future bone resorbing area and differentiation into osteoclasts, and 2) VEGF-Flt-1 signaling upregulates RANKL expression in OSCC cells, which indirectly leads to osteoclast differentiation.
p5219
sg4
(lp5220
(dp5221
g9
I0
sg20
VP17948
p5222
sg12
I10
sg13
VVEGF-Flt-1
p5223
sg15
I1
sa(dp5224
g9
I5
sg20
VP17948
p5225
sg12
I5
sg13
VFlt-1
p5226
sg15
I1
sa(dp5227
g9
I303
sg20
g21
sg12
I5
sg13
VRANKL
p5228
sg15
I1
sa(dp5229
g9
I5
sg20
VP17948
p5230
sg12
I5
sg13
VFlt-1
p5231
sg15
I1
sasg6
(lp5232
sa(dp5233
g2
VThus, the transcriptional targets normally activated by RANKL that promote a proliferative response in luminal progenitors can contribute to the susceptibility of mammary epithelial cells to BRCA1-mutated breast cancers as a consequence of DDR-induced NF-kappaB.
p5234
sg4
(lp5235
(dp5236
g9
I191
sg20
VP38398
p5237
sg12
I5
sg13
VBRCA1
p5238
sg15
I1
sa(dp5239
g9
I252
sg20
VP19838
p5240
sg12
I9
sg13
VNF-kappaB
p5241
sg15
I1
sa(dp5242
g9
I56
sg20
g21
sg12
I5
sg13
VRANKL
p5243
sg15
I1
sasg6
(lp5244
(dp5245
g9
I77
sg10
VC0334094
p5246
sg12
I13
sg13
Vproliferative
p5247
sg15
I1
sa(dp5248
g9
I205
sg10
VC0006142
p5249
sg12
I14
sg13
Vbreast cancers
p5250
sg15
I2
sasa(dp5251
g2
VOur finding provides mechanistic support for a breast cancer chemoprevention trial with a RANKL inhibitor among high-risk premenopausal women with dense breasts.
p5252
sg4
(lp5253
(dp5254
g9
I90
sg20
g21
sg12
I5
sg13
VRANKL
p5255
sg15
I1
sasg6
(lp5256
(dp5257
g9
I47
sg10
VC0678222
p5258
sg12
I13
sg13
Vbreast cancer
p5259
sg15
I2
sasa(dp5260
g2
VThe present study examined the effects of brucine on the OPG/RANKL/RANK signaling pathway for exploring the mechanism of brucine suppression of bone metastasis in breast cancer.
p5261
sg4
(lp5262
(dp5263
g9
I61
sg20
g21
sg12
I5
sg13
VRANKL
p5264
sg15
I1
sa(dp5265
g9
I57
sg20
g21
sg12
I3
sg13
VOPG
p5266
sg15
I1
sasg6
(lp5267
(dp5268
g9
I129
sg10
VC0221103
p5269
sg12
I11
sg13
Vsuppression
p5270
sg15
I1
sa(dp5271
g9
I163
sg10
VC0678222
p5272
sg12
I13
sg13
Vbreast cancer
p5273
sg15
I2
sa(dp5274
g9
I144
sg10
VC0153690
p5275
sg12
I15
sg13
Vbone metastasis
p5276
sg15
I2
sasa(dp5277
g2
VIn the present study, we evaluated the clinical usefulness of OPG and sRANKL assessment in bronchoalveolar lavage fluid (BALF) of patients with advanced non-small cell lung cancer (NSCLC).
p5278
sg4
(lp5279
(dp5280
g9
I62
sg20
g21
sg12
I3
sg13
VOPG
p5281
sg15
I1
sasg6
(lp5282
(dp5283
g9
I181
sg10
VC0007131
p5284
sg12
I5
sg13
VNSCLC
p5285
sg15
I1
sa(dp5286
g9
I153
sg10
VC0007131
p5287
sg12
I26
sg13
Vnon-small cell lung cancer
p5288
sg15
I4
sasa(dp5289
g2
VWe measured the concentration of OPG and sRANKL in BALF of 44 NSCLC patients and 15 healthy volunteers taken as control subjects.
p5290
sg4
(lp5291
(dp5292
g9
I33
sg20
g21
sg12
I3
sg13
VOPG
p5293
sg15
I1
sasg6
(lp5294
(dp5295
g9
I62
sg10
VC0007131
p5296
sg12
I5
sg13
VNSCLC
p5297
sg15
I1
sasa(dp5298
g2
VThere were no significant differences in sRANKL content between the NSCLC and control groups [1.22 (0.74-23.00) vs. 1.12 (0.79-4.39) pmol/l; p = 0.67].
p5299
sg4
(lp5300
sg6
(lp5301
(dp5302
g9
I68
sg10
VC0007131
p5303
sg12
I5
sg13
VNSCLC
p5304
sg15
I1
sasa(dp5305
g2
VHowever, we found that the greater the level of sRANKL in NSCLC patients, the shorter the overall survival.
p5306
sg4
(lp5307
sg6
(lp5308
(dp5309
g9
I58
sg10
VC0007131
p5310
sg12
I5
sg13
VNSCLC
p5311
sg15
I1
sasa(dp5312
g2
VWe found a correlation between the content of sRANKL and the percentage of lymphocytes in BALF of NSCLC patients (r = 0.52; p = 0.041).
p5313
sg4
(lp5314
sg6
(lp5315
(dp5316
g9
I98
sg10
VC0007131
p5317
sg12
I5
sg13
VNSCLC
p5318
sg15
I1
sasa(dp5319
g2
VA high level of sRANKL in BALF of NSCLC patients may predict worse survival.
p5320
sg4
(lp5321
sg6
(lp5322
(dp5323
g9
I34
sg10
VC0007131
p5324
sg12
I5
sg13
VNSCLC
p5325
sg15
I1
sasa(dp5326
g2
VThe goal of our study was to assess the prognostic impact of the necroptosis relative protein RIPK1 genetic polymorphism in ischemia-reperfusion injury and survival after hepatectomy in hepatocellular carcinoma (HCC) patients.
p5327
sg4
(lp5328
(dp5329
g9
I94
sg20
g21
sg12
I5
sg13
VRIPK1
p5330
sg15
I1
sasg6
(lp5331
(dp5332
g9
I212
sg10
VC2239176
p5333
sg12
I3
sg13
VHCC
p5334
sg15
I1
sa(dp5335
g9
I186
sg10
VC2239176
p5336
sg12
I24
sg13
Vhepatocellular carcinoma
p5337
sg15
I2
sa(dp5338
g9
I124
sg10
VC0022116
p5339
sg12
I8
sg13
Vischemia
p5340
sg15
I1
sa(dp5341
g9
I65
sg10
VC2610958
p5342
sg12
I11
sg13
Vnecroptosis
p5343
sg15
I1
sasa(dp5344
g2
VHere, we discuss our recent data on RIPK1 in liver injury and hepatocellular carcinoma development and put these into relation to previous experimental findings to underpin that it exerts opposing kinase-dependent and kinase independent functions in liver cells.
p5345
sg4
(lp5346
(dp5347
g9
I36
sg20
g21
sg12
I5
sg13
VRIPK1
p5348
sg15
I1
sasg6
(lp5349
(dp5350
g9
I62
sg10
VC1512411
p5351
sg12
I24
sg13
Vhepatocellular carcinoma
p5352
sg15
I2
sasa(dp5353
g2
VMoreover, loss of both Ripk1 and Traf2 in LPC not only resulted in caspase-8 hyperactivation but also impaired NF-KB activation, promoting the spontaneous development of hepatocellular carcinoma.
p5354
sg4
(lp5355
(dp5356
g9
I23
sg20
g21
sg12
I5
sg13
VRipk1
p5357
sg15
I1
sa(dp5358
g9
I33
sg20
g21
sg12
I5
sg13
VTraf2
p5359
sg15
I1
sa(dp5360
g9
I67
sg20
VP39880
p5361
sg12
I9
sg13
Vcaspase-8
p5362
sg15
I1
sasg6
(lp5363
(dp5364
g9
I170
sg10
VC1512411
p5365
sg12
I24
sg13
Vhepatocellular carcinoma
p5366
sg15
I2
sa(dp5367
g9
I102
sg10
VC0684336
p5368
sg12
I8
sg13
Vimpaired
p5369
sg15
I1
sasa(dp5370
g2
VThe single-stranded DNA cytidine deaminases APOBEC3B, APOBEC3H haplotype I, and APOBEC3A can contribute to cancer through deamination of cytosine to form promutagenic uracil in genomic DNA.
p5371
sg4
(lp5372
(dp5373
g9
I54
sg20
g21
sg12
I20
sg13
VAPOBEC3H haplotype I
p5374
sg15
I3
sa(dp5375
g9
I44
sg20
g21
sg12
I8
sg13
VAPOBEC3B
p5376
sg15
I1
sa(dp5377
g9
I80
sg20
VP31941
p5378
sg12
I8
sg13
VAPOBEC3A
p5379
sg15
I1
sa(dp5380
g9
I4
sg20
VP32320
p5381
sg12
I39
sg13
Vsingle-stranded DNA cytidine deaminases
p5382
sg15
I4
sasg6
(lp5383
(dp5384
g9
I107
sg10
VC0006826
p5385
sg12
I6
sg13
Vcancer
p5386
sg15
I1
sasa(dp5387
g2
VTo study this, we developed a method to purify full length APOBEC3B and characterized it in comparison to APOBEC3A and APOBEC3H on substrates relevant to cancer mutagenesis.
p5388
sg4
(lp5389
(dp5390
g9
I106
sg20
VP31941
p5391
sg12
I8
sg13
VAPOBEC3A
p5392
sg15
I1
sa(dp5393
g9
I119
sg20
g21
sg12
I8
sg13
VAPOBEC3H
p5394
sg15
I1
sasg6
(lp5395
(dp5396
g9
I154
sg10
VC0006826
p5397
sg12
I6
sg13
Vcancer
p5398
sg15
I1
sasa(dp5399
g2
VA3H-I also associates with clonal TCA/T-biased mutations in lung adenocarcinoma suggesting this enzyme makes broader contributions to cancer mutagenesis.
p5400
sg4
(lp5401
sg6
(lp5402
(dp5403
g9
I134
sg10
VC0006826
p5404
sg12
I6
sg13
Vcancer
p5405
sg15
I1
sa(dp5406
g9
I60
sg10
VC0152013
p5407
sg12
I19
sg13
Vlung adenocarcinoma
p5408
sg15
I2
sasa(dp5409
g2
VThese studies combine to suggest that A3B and A3H-I, together, explain the bulk of 'APOBEC signature' mutations in cancer.
p5410
sg4
(lp5411
(dp5412
g9
I38
sg20
g21
sg12
I3
sg13
VA3B
p5413
sg15
I1
sasg6
(lp5414
(dp5415
g9
I115
sg10
VC0006826
p5416
sg12
I6
sg13
Vcancer
p5417
sg15
I1
sasa(dp5418
g2
VTCGA data analyses revealed that expression of APOBEC3D and APOBEC3H also correlates with CD3D across multiple cancer types.
p5419
sg4
(lp5420
(dp5421
g9
I90
sg20
VP04234
p5422
sg12
I4
sg13
VCD3D
p5423
sg15
I1
sa(dp5424
g9
I60
sg20
g21
sg12
I8
sg13
VAPOBEC3H
p5425
sg15
I1
sa(dp5426
g9
I47
sg20
g21
sg12
I8
sg13
VAPOBEC3D
p5427
sg15
I1
sasg6
(lp5428
(dp5429
g9
I102
sg10
VC0346429
p5430
sg12
I15
sg13
Vmultiple cancer
p5431
sg15
I2
sasa(dp5432
g2
VWe found that the T allele of rs139293 in exon 2 of APOBEC3H was significantly associated with decreased risk of lung cancer (odds ratio = 0.76, 95% confidence interval: 0.63-0.91).
p5433
sg4
(lp5434
(dp5435
g9
I52
sg20
g21
sg12
I8
sg13
VAPOBEC3H
p5436
sg15
I1
sasg6
(lp5437
(dp5438
g9
I113
sg10
VC0684249
p5439
sg12
I11
sg13
Vlung cancer
p5440
sg15
I2
sasa(dp5441
g2
VThese results indicate that genetic variants in APOBEC3H may contribute to lung cancer susceptibility in Chinese population.
p5442
sg4
(lp5443
(dp5444
g9
I48
sg20
g21
sg12
I8
sg13
VAPOBEC3H
p5445
sg15
I1
sasg6
(lp5446
(dp5447
g9
I75
sg10
VC0684249
p5448
sg12
I11
sg13
Vlung cancer
p5449
sg15
I2
sasa(dp5450
g2
VA 56-year-old male with cirrhosis presented with acute bleeding from cardiofundal gastroesophageal varices (GOV) and was treated with endoscopic cyanoacrylate glue.
p5451
sg4
(lp5452
sg6
(lp5453
(dp5454
g9
I24
sg10
VC0023890
p5455
sg12
I9
sg13
Vcirrhosis
p5456
sg15
I1
sa(dp5457
g9
I82
sg10
VC2609266
p5458
sg12
I24
sg13
Vgastroesophageal varices
p5459
sg15
I2
sa(dp5460
g9
I108
sg10
VC2609266
p5461
sg12
I3
sg13
VGOV
p5462
sg15
I1
sa(dp5463
g9
I49
sg10
VC0333276
p5464
sg12
I14
sg13
Vacute bleeding
p5465
sg15
I2
sasa(dp5466
g2
VAt that time, he underwent retreatment with balloon-occluded retrograde obliteration (BRTO), with no recurrence at a follow-up of 14 months.Available treatments for bleeding GOV include methods to (a) directly obstruct the varices (endoscopic variceal ligation , sclerotherapy and cyanoacrylate glue, BRTO) or to (b) decrease portal pressure (surgical portacaval shunts; transportal intrahepatic portosystemic shunt).
p5467
sg4
(lp5468
sg6
(lp5469
(dp5470
g9
I101
sg10
VC1458156
p5471
sg12
I10
sg13
Vrecurrence
p5472
sg15
I1
sa(dp5473
g9
I165
sg10
VC0019080
p5474
sg12
I8
sg13
Vbleeding
p5475
sg15
I1
sa(dp5476
g9
I52
sg10
VC0028778
p5477
sg12
I8
sg13
Voccluded
p5478
sg15
I1
sa(dp5479
g9
I223
sg10
VC0042345
p5480
sg12
I7
sg13
Vvarices
p5481
sg15
I1
sasa(dp5482
g2
VGastroesophageal varices (GOV) is a common complication in patients with portal hypertension.
p5483
sg4
(lp5484
sg6
(lp5485
(dp5486
g9
I73
sg10
VC0020541
p5487
sg12
I19
sg13
Vportal hypertension
p5488
sg15
I2
sa(dp5489
g9
I0
sg10
VC2609266
p5490
sg12
I24
sg13
VGastroesophageal varices
p5491
sg15
I2
sa(dp5492
g9
I26
sg10
VC2609266
p5493
sg12
I3
sg13
VGOV
p5494
sg15
I1
sa(dp5495
g9
I43
sg10
VC0009566
p5496
sg12
I12
sg13
Vcomplication
p5497
sg15
I1
sasa(dp5498
g2
VGastric varices were categorized as GOV-1 (3%), GOV-2 (61%), and isolated gastric varices type 1 (36%) per Sarin classification.
p5499
sg4
(lp5500
sg6
(lp5501
(dp5502
g9
I74
sg10
VC0017145
p5503
sg12
I15
sg13
Vgastric varices
p5504
sg15
I2
sa(dp5505
g9
I0
sg10
VC0017145
p5506
sg12
I15
sg13
VGastric varices
p5507
sg15
I2
sasa(dp5508
g2
VOf the 9 children with associated gastroeosophageal varices (GOV), the severity of lesions was reduced in 8 of them.
p5509
sg4
(lp5510
sg6
(lp5511
(dp5512
g9
I52
sg10
VC0042345
p5513
sg12
I7
sg13
Vvarices
p5514
sg15
I1
sasa(dp5515
g2
VHere, we address the contribution of the EP3 receptor in dictating early outcomes after transient cerebral ischemia.
p5516
sg4
(lp5517
(dp5518
g9
I41
sg20
VP43115
p5519
sg12
I12
sg13
VEP3 receptor
p5520
sg15
I2
sasg6
(lp5521
(dp5522
g9
I88
sg10
VC0917805
p5523
sg12
I27
sg13
Vtransient cerebral ischemia
p5524
sg15
I3
sasa(dp5525
g2
VFollowing S1, separate scalp recordings in 4 patients in the epilepsy group displayed EP 3 times in the 'over 300 ms' time window.
p5526
sg4
(lp5527
sg6
(lp5528
(dp5529
g9
I61
sg10
VC0014544
p5530
sg12
I8
sg13
Vepilepsy
p5531
sg15
I1
sasa(dp5532
g2
VConversely, patients with endometriosis had significantly shortened activated partial thromboplastin time (APTT) when compared to controls (1.08 +/- 0.06 and 1.12 +/- 0.19, respectively; P &lt; .01).
p5533
sg4
(lp5534
(dp5535
g9
I86
sg20
VP13726
p5536
sg12
I14
sg13
Vthromboplastin
p5537
sg15
I1
sasg6
(lp5538
(dp5539
g9
I26
sg10
VC0014175
p5540
sg12
I13
sg13
Vendometriosis
p5541
sg15
I1
sasa(dp5542
g2
VActivated partial thromboplastin time is shorter in women with endometriosis but still in the normal range.
p5543
sg4
(lp5544
(dp5545
g9
I18
sg20
VP13726
p5546
sg12
I14
sg13
Vthromboplastin
p5547
sg15
I1
sasg6
(lp5548
(dp5549
g9
I63
sg10
VC0014175
p5550
sg12
I13
sg13
Vendometriosis
p5551
sg15
I1
sasa(dp5552
g2
VAre the levels of total circulating cell-derived microparticles (cMPs) and circulating tissue factor-containing microparticles (cMP-TF) increased in patients with endometriosis?
p5553
sg4
(lp5554
(dp5555
g9
I128
sg20
VP21941
p5556
sg12
I6
sg13
VcMP-TF
p5557
sg15
I1
sasg6
(lp5558
(dp5559
g9
I163
sg10
VC0014175
p5560
sg12
I13
sg13
Vendometriosis
p5561
sg15
I1
sasa(dp5562
g2
VIncreased expression of tissue factor (a transmembrane receptor for Factor VII/VIIa) in eutopic and ectopic endometrium from patients with endometriosis has been described.
p5563
sg4
(lp5564
(dp5565
g9
I68
sg20
VP08709
p5566
sg12
I15
sg13
VFactor VII/VIIa
p5567
sg15
I2
sasg6
(lp5568
(dp5569
g9
I139
sg10
VC0014175
p5570
sg12
I13
sg13
Vendometriosis
p5571
sg15
I1
sasa(dp5572
g2
VTissue factor (TF) expression was elevated in endometriosis and TF concentrations were significantly elevated both in the supernatant of cultured primary endometriotic stromal cells and in peritoneal fluid from women with endometriosis.
p5573
sg4
(lp5574
sg6
(lp5575
(dp5576
g9
I46
sg10
VC0014175
p5577
sg12
I13
sg13
Vendometriosis
p5578
sg15
I1
sa(dp5579
g9
I46
sg10
VC0014175
p5580
sg12
I13
sg13
Vendometriosis
p5581
sg15
I1
sasa(dp5582
g2
VHere, we first determined the value of ALCAM as a marker of recurrence in endometrioid endometrial cancer by conducting a retrospective multicentre study of 174 primary tumours.
p5583
sg4
(lp5584
(dp5585
g9
I39
sg20
g21
sg12
I5
sg13
VALCAM
p5586
sg15
I1
sasg6
(lp5587
(dp5588
g9
I169
sg10
VC0027651
p5589
sg12
I7
sg13
Vtumours
p5590
sg15
I1
sa(dp5591
g9
I60
sg10
VC1458156
p5592
sg12
I10
sg13
Vrecurrence
p5593
sg15
I1
sa(dp5594
g9
I87
sg10
VC0476089
p5595
sg12
I18
sg13
Vendometrial cancer
p5596
sg15
I2
sasa(dp5597
g2
VThen we demonstrated in vitro a role for ALCAM in cell migration and invasion by using a loss-of-function model in two endometrial cancer cell lines.
p5598
sg4
(lp5599
(dp5600
g9
I41
sg20
g21
sg12
I5
sg13
VALCAM
p5601
sg15
I1
sasg6
(lp5602
(dp5603
g9
I69
sg10
VC2699153
p5604
sg12
I8
sg13
Vinvasion
p5605
sg15
I1
sa(dp5606
g9
I119
sg10
VC0476089
p5607
sg12
I18
sg13
Vendometrial cancer
p5608
sg15
I2
sasa(dp5609
g2
VIn conclusion, our results highlight the potential of ALCAM as a recurrent biomarker in early-stage endometrioid endometrial cancer and point to ALCAM as an important molecule in endometrial cancer dissemination by regulating cell migration, invasion, and metastasis.
p5610
sg4
(lp5611
(dp5612
g9
I54
sg20
g21
sg12
I5
sg13
VALCAM
p5613
sg15
I1
sasg6
(lp5614
(dp5615
g9
I113
sg10
VC0476089
p5616
sg12
I18
sg13
Vendometrial cancer
p5617
sg15
I2
sa(dp5618
g9
I242
sg10
VC2699153
p5619
sg12
I8
sg13
Vinvasion
p5620
sg15
I1
sa(dp5621
g9
I256
sg10
VC0027627
p5622
sg12
I10
sg13
Vmetastasis
p5623
sg15
I1
sa(dp5624
g9
I113
sg10
VC0476089
p5625
sg12
I18
sg13
Vendometrial cancer
p5626
sg15
I2
sasa(dp5627
g2
VOverexpressing miR-378 in ovarian cancer cells altered expression of genes associated with angiogenesis (ALCAM, EHD1, ELK3, TLN1), apoptosis (RPN2, HIPK3), and cell cycle regulation (SWAP-70, LSM14A, RDX).
p5628
sg4
(lp5629
(dp5630
g9
I148
sg20
g21
sg12
I5
sg13
VHIPK3
p5631
sg15
I1
sa(dp5632
g9
I15
sg20
g21
sg12
I7
sg13
VmiR-378
p5633
sg15
I1
sa(dp5634
g9
I105
sg20
g21
sg12
I5
sg13
VALCAM
p5635
sg15
I1
sa(dp5636
g9
I192
sg20
g21
sg12
I6
sg13
VLSM14A
p5637
sg15
I1
sa(dp5638
g9
I142
sg20
VP04844
p5639
sg12
I4
sg13
VRPN2
p5640
sg15
I1
sa(dp5641
g9
I200
sg20
VP35241
p5642
sg12
I3
sg13
VRDX
p5643
sg15
I1
sa(dp5644
g9
I183
sg20
g21
sg12
I7
sg13
VSWAP-70
p5645
sg15
I1
sa(dp5646
g9
I118
sg20
VP41970
p5647
sg12
I4
sg13
VELK3
p5648
sg15
I1
sa(dp5649
g9
I124
sg20
g21
sg12
I4
sg13
VTLN1
p5650
sg15
I1
sa(dp5651
g9
I112
sg20
g21
sg12
I4
sg13
VEHD1
p5652
sg15
I1
sasg6
(lp5653
(dp5654
g9
I26
sg10
VC1140680
p5655
sg12
I14
sg13
Vovarian cancer
p5656
sg15
I2
sasa(dp5657
g2
VActivated leukocyte cell adhesion molecule (ALCAM) is expressed at the surface of epithelial ovarian cancer (EOC) cells and is released in a soluble form (sALCAM) by ADAM-17-mediated shedding.
p5658
sg4
(lp5659
(dp5660
g9
I44
sg20
g21
sg12
I5
sg13
VALCAM
p5661
sg15
I1
sa(dp5662
g9
I166
sg20
VP78536
p5663
sg12
I7
sg13
VADAM-17
p5664
sg15
I1
sa(dp5665
g9
I0
sg20
g21
sg12
I42
sg13
VActivated leukocyte cell adhesion molecule
p5666
sg15
I5
sasg6
(lp5667
(dp5668
g9
I109
sg10
VC0677886
p5669
sg12
I3
sg13
VEOC
p5670
sg15
I1
sa(dp5671
g9
I25
sg10
VC0001511
p5672
sg12
I8
sg13
Vadhesion
p5673
sg15
I1
sa(dp5674
g9
I82
sg10
VC0677886
p5675
sg12
I25
sg13
Vepithelial ovarian cancer
p5676
sg15
I3
sasa(dp5677
g2
VHere, we show that serum sALCAM levels were significantly higher in epithelial ovarian cancer (EOC) (p &lt; 0.005) than in controls.
p5678
sg4
(lp5679
(dp5680
g9
I19
sg20
g21
sg12
I12
sg13
Vserum sALCAM
p5681
sg15
I2
sasg6
(lp5682
(dp5683
g9
I95
sg10
VC0677886
p5684
sg12
I3
sg13
VEOC
p5685
sg15
I1
sa(dp5686
g9
I68
sg10
VC0677886
p5687
sg12
I25
sg13
Vepithelial ovarian cancer
p5688
sg15
I3
sasa(dp5689
g2
VTo date there are no data on the role of ALCAM in cervical cancer available.
p5690
sg4
(lp5691
(dp5692
g9
I41
sg20
g21
sg12
I5
sg13
VALCAM
p5693
sg15
I1
sasg6
(lp5694
(dp5695
g9
I50
sg10
VC0302592
p5696
sg12
I15
sg13
Vcervical cancer
p5697
sg15
I2
sasa(dp5698
g2
VIn this study, ALCAM expression was analysed by immunohistochemistry (IHC) in tissue samples of 233 patients with cervical cancer, among them 178 with complete follow-up information.
p5699
sg4
(lp5700
sg6
(lp5701
(dp5702
g9
I114
sg10
VC0302592
p5703
sg12
I15
sg13
Vcervical cancer
p5704
sg15
I2
sasa(dp5705
g2
VALCAM overexpression was detected (immunoreactive score (IRS) 2-12) in 58.4% of the cervical cancer samples.
p5706
sg4
(lp5707
(dp5708
g9
I0
sg20
g21
sg12
I5
sg13
VALCAM
p5709
sg15
I1
sasg6
(lp5710
(dp5711
g9
I84
sg10
VC0302592
p5712
sg12
I15
sg13
Vcervical cancer
p5713
sg15
I2
sasa(dp5714
g2
VESs and USTSs were further separated by CD166 staining, wherein increased expression was associated with ES (P &lt; 0.0001).
p5715
sg4
(lp5716
(dp5717
g9
I40
sg20
g21
sg12
I5
sg13
VCD166
p5718
sg15
I1
sasg6
(lp5719
sa(dp5720
g2
VUSP22 is one of the important targets for inhibiting tumor growth, but clear illustration regarding its effects of telomerase, tumor cell immortality and retinoblastoma cell aging or apoptosis via suppressing TERT/P53 signal pathway remains to be elusive.
p5721
sg4
(lp5722
(dp5723
g9
I209
sg20
g21
sg12
I4
sg13
VTERT
p5724
sg15
I1
sa(dp5725
g9
I0
sg20
g21
sg12
I5
sg13
VUSP22
p5726
sg15
I1
sa(dp5727
g9
I214
sg20
VP42771
p5728
sg12
I3
sg13
VP53
p5729
sg15
I1
sasg6
(lp5730
(dp5731
g9
I53
sg10
VC0027651
p5732
sg12
I5
sg13
Vtumor
p5733
sg15
I1
sa(dp5734
g9
I154
sg10
VC0035335
p5735
sg12
I14
sg13
Vretinoblastoma
p5736
sg15
I1
sa(dp5737
g9
I53
sg10
VC0598934
p5738
sg12
I12
sg13
Vtumor growth
p5739
sg15
I2
sasa(dp5740
g2
VUSP22 played an important role in retinoblastoma cell proliferation/aging and apoptosis.
p5741
sg4
(lp5742
(dp5743
g9
I0
sg20
g21
sg12
I5
sg13
VUSP22
p5744
sg15
I1
sasg6
(lp5745
(dp5746
g9
I34
sg10
VC0035335
p5747
sg12
I14
sg13
Vretinoblastoma
p5748
sg15
I1
sa(dp5749
g9
I54
sg10
VC0334094
p5750
sg12
I13
sg13
Vproliferation
p5751
sg15
I1
sasa(dp5752
g2
VThe reduction of USP22 expression facilitated human retinoblastoma cell aging or apoptosis via suppressing TERT/P53 signal pathway.
p5753
sg4
(lp5754
(dp5755
g9
I17
sg20
g21
sg12
I5
sg13
VUSP22
p5756
sg15
I1
sa(dp5757
g9
I112
sg20
VP42771
p5758
sg12
I3
sg13
VP53
p5759
sg15
I1
sa(dp5760
g9
I107
sg20
g21
sg12
I4
sg13
VTERT
p5761
sg15
I1
sasg6
(lp5762
(dp5763
g9
I52
sg10
VC0035335
p5764
sg12
I14
sg13
Vretinoblastoma
p5765
sg15
I1
sasa(dp5766
g2
VUSP22, thus, may work as a target for treating retinoblastoma.
p5767
sg4
(lp5768
(dp5769
g9
I0
sg20
g21
sg12
I5
sg13
VUSP22
p5770
sg15
I1
sasg6
(lp5771
(dp5772
g9
I47
sg10
VC0035335
p5773
sg12
I14
sg13
Vretinoblastoma
p5774
sg15
I1
sasa(dp5775
g2
VThe present study aimed to investigate the correlation of ubiquitin-specific peptidase 22 (USP22) with acquired resistance to cisplatin in lung adenocarcinoma.
p5776
sg4
(lp5777
(dp5778
g9
I58
sg20
VP62979
p5779
sg12
I31
sg13
Vubiquitin-specific peptidase 22
p5780
sg15
I3
sa(dp5781
g9
I91
sg20
g21
sg12
I5
sg13
VUSP22
p5782
sg15
I1
sasg6
(lp5783
(dp5784
g9
I139
sg10
VC0152013
p5785
sg12
I19
sg13
Vlung adenocarcinoma
p5786
sg15
I2
sasa(dp5787
g2
VUSP22 is a potential target in cisplatin-resistant lung adenocarcinoma and should be considered in future therapeutic practice.
p5788
sg4
(lp5789
(dp5790
g9
I0
sg20
g21
sg12
I5
sg13
VUSP22
p5791
sg15
I1
sasg6
(lp5792
(dp5793
g9
I51
sg10
VC0152013
p5794
sg12
I19
sg13
Vlung adenocarcinoma
p5795
sg15
I2
sasa(dp5796
g2
VUbiquitin specific peptidase 22 (USP22), a putative cancer stem cell marker, is overexpressed in liver metastases of colorectal cancer (CRC).
p5797
sg4
(lp5798
(dp5799
g9
I0
sg20
g21
sg12
I31
sg13
VUbiquitin specific peptidase 22
p5800
sg15
I4
sa(dp5801
g9
I33
sg20
g21
sg12
I5
sg13
VUSP22
p5802
sg15
I1
sasg6
(lp5803
(dp5804
g9
I52
sg10
VC0006826
p5805
sg12
I6
sg13
Vcancer
p5806
sg15
I1
sa(dp5807
g9
I97
sg10
VC0494165
p5808
sg12
I16
sg13
Vliver metastases
p5809
sg15
I2
sa(dp5810
g9
I136
sg10
VC1527249
p5811
sg12
I3
sg13
VCRC
p5812
sg15
I1
sa(dp5813
g9
I117
sg10
VC1527249
p5814
sg12
I17
sg13
Vcolorectal cancer
p5815
sg15
I2
sasa(dp5816
g2
VIn this study, we explored the functional role of USP22 in modulating c-Myc stability and its physiological relevance in breast cancer progression.
p5817
sg4
(lp5818
(dp5819
g9
I70
sg20
VP12524
p5820
sg12
I5
sg13
Vc-Myc
p5821
sg15
I1
sa(dp5822
g9
I50
sg20
g21
sg12
I5
sg13
VUSP22
p5823
sg15
I1
sasg6
(lp5824
(dp5825
g9
I128
sg10
VC0178874
p5826
sg12
I18
sg13
Vcancer progression
p5827
sg15
I2
sasa(dp5828
g2
VWe found that USP22 promotes deubiquitination of c-Myc in several breast cancer cell lines, resulting in increased levels of c-Myc.
p5829
sg4
(lp5830
(dp5831
g9
I49
sg20
VP12524
p5832
sg12
I5
sg13
Vc-Myc
p5833
sg15
I1
sa(dp5834
g9
I14
sg20
g21
sg12
I5
sg13
VUSP22
p5835
sg15
I1
sa(dp5836
g9
I49
sg20
VP12524
p5837
sg12
I5
sg13
Vc-Myc
p5838
sg15
I1
sasg6
(lp5839
(dp5840
g9
I66
sg10
VC0678222
p5841
sg12
I13
sg13
Vbreast cancer
p5842
sg15
I2
sasa(dp5843
g2
VFurthermore, overexpression of USP22 stimulates breast cancer cell growth and colony formation, and increases c-Myc tumorigenic activity.
p5844
sg4
(lp5845
(dp5846
g9
I110
sg20
VP12524
p5847
sg12
I5
sg13
Vc-Myc
p5848
sg15
I1
sa(dp5849
g9
I31
sg20
g21
sg12
I5
sg13
VUSP22
p5850
sg15
I1
sasg6
(lp5851
(dp5852
g9
I55
sg10
VC1516170
p5853
sg12
I18
sg13
Vcancer cell growth
p5854
sg15
I3
sasa(dp5855
g2
VIn conclusion, the present study reveals that USP22 in breast cancer cell lines increases c-Myc stability through c-Myc deubiquitination, which is closely correlated with breast cancer progression.
p5856
sg4
(lp5857
(dp5858
g9
I90
sg20
VP12524
p5859
sg12
I5
sg13
Vc-Myc
p5860
sg15
I1
sa(dp5861
g9
I90
sg20
VP12524
p5862
sg12
I5
sg13
Vc-Myc
p5863
sg15
I1
sa(dp5864
g9
I46
sg20
g21
sg12
I5
sg13
VUSP22
p5865
sg15
I1
sasg6
(lp5866
(dp5867
g9
I178
sg10
VC0178874
p5868
sg12
I18
sg13
Vcancer progression
p5869
sg15
I2
sa(dp5870
g9
I55
sg10
VC0678222
p5871
sg12
I13
sg13
Vbreast cancer
p5872
sg15
I2
sasa(dp5873
g2
VIn this study, we investigated the effects of the deubiquitinating enzyme USP22 on the expression of the drug-resistance genes BMI1 and EZH2 in hepatocellular carcinoma (HCC) and on prognosis.
p5874
sg4
(lp5875
(dp5876
g9
I136
sg20
g21
sg12
I4
sg13
VEZH2
p5877
sg15
I1
sa(dp5878
g9
I74
sg20
g21
sg12
I5
sg13
VUSP22
p5879
sg15
I1
sa(dp5880
g9
I127
sg20
VP35226
p5881
sg12
I4
sg13
VBMI1
p5882
sg15
I1
sasg6
(lp5883
(dp5884
g9
I170
sg10
VC2239176
p5885
sg12
I3
sg13
VHCC
p5886
sg15
I1
sa(dp5887
g9
I144
sg10
VC2239176
p5888
sg12
I24
sg13
Vhepatocellular carcinoma
p5889
sg15
I2
sasa(dp5890
g2
VUbiquitin-specific protease 22 (USP22) aberrance has been implicated in several malignancies; however, whether USP22 plays a role in anaplastic thyroid carcinoma (ATC) remains unclear.
p5891
sg4
(lp5892
(dp5893
g9
I0
sg20
g21
sg12
I30
sg13
VUbiquitin-specific protease 22
p5894
sg15
I3
sa(dp5895
g9
I32
sg20
g21
sg12
I5
sg13
VUSP22
p5896
sg15
I1
sa(dp5897
g9
I32
sg20
g21
sg12
I5
sg13
VUSP22
p5898
sg15
I1
sasg6
(lp5899
(dp5900
g9
I80
sg10
VC0006826
p5901
sg12
I12
sg13
Vmalignancies
p5902
sg15
I1
sa(dp5903
g9
I163
sg10
VC0238461
p5904
sg12
I3
sg13
VATC
p5905
sg15
I1
sa(dp5906
g9
I133
sg10
VC0238461
p5907
sg12
I28
sg13
Vanaplastic thyroid carcinoma
p5908
sg15
I3
sasa(dp5909
g2
VCurcumin might have therapeutic potential in breast cancer through regulating breast cancer-related genes, including SERPINE1, PGAP3, MAP3K1, MAPK1, GSTO2, VIM, SPARC, and FGF2.
p5910
sg4
(lp5911
(dp5912
g9
I161
sg20
VP09486
p5913
sg12
I5
sg13
VSPARC
p5914
sg15
I1
sa(dp5915
g9
I142
sg20
VP28482
p5916
sg12
I5
sg13
VMAPK1
p5917
sg15
I1
sa(dp5918
g9
I134
sg20
g21
sg12
I6
sg13
VMAP3K1
p5919
sg15
I1
sa(dp5920
g9
I78
sg20
VP01893
p5921
sg12
I27
sg13
Vbreast cancer-related genes
p5922
sg15
I3
sa(dp5923
g9
I117
sg20
VP05121
p5924
sg12
I8
sg13
VSERPINE1
p5925
sg15
I1
sa(dp5926
g9
I149
sg20
g21
sg12
I5
sg13
VGSTO2
p5927
sg15
I1
sa(dp5928
g9
I127
sg20
g21
sg12
I5
sg13
VPGAP3
p5929
sg15
I1
sa(dp5930
g9
I172
sg20
g21
sg12
I4
sg13
VFGF2
p5931
sg15
I1
sasg6
(lp5932
(dp5933
g9
I45
sg10
VC0678222
p5934
sg12
I13
sg13
Vbreast cancer
p5935
sg15
I2
sa(dp5936
g9
I45
sg10
VC0678222
p5937
sg12
I13
sg13
Vbreast cancer
p5938
sg15
I2
sasa(dp5939
g2
VOur data showed that the level of CENPE, BAG2, SOD2, GDI2, CORO1C, CFL1, DSTN, CALD1, PHGDH, PDHA1, AKR1B1, TST and TBCA proteins were significantly up-regulated in the fibroblasts co-cultured with ovarian cancer cells, whereas HSPB1, P4HB and VIM were significantly down-regulated.
p5940
sg4
(lp5941
(dp5942
g9
I93
sg20
VP08559
p5943
sg12
I5
sg13
VPDHA1
p5944
sg15
I1
sa(dp5945
g9
I100
sg20
VP15121
p5946
sg12
I6
sg13
VAKR1B1
p5947
sg15
I1
sa(dp5948
g9
I79
sg20
g21
sg12
I5
sg13
VCALD1
p5949
sg15
I1
sa(dp5950
g9
I67
sg20
VP23528
p5951
sg12
I4
sg13
VCFL1
p5952
sg15
I1
sa(dp5953
g9
I59
sg20
g21
sg12
I6
sg13
VCORO1C
p5954
sg15
I1
sa(dp5955
g9
I116
sg20
g21
sg12
I13
sg13
VTBCA proteins
p5956
sg15
I2
sa(dp5957
g9
I73
sg20
VP60981
p5958
sg12
I4
sg13
VDSTN
p5959
sg15
I1
sa(dp5960
g9
I47
sg20
VP04179
p5961
sg12
I4
sg13
VSOD2
p5962
sg15
I1
sa(dp5963
g9
I53
sg20
VP50395
p5964
sg12
I4
sg13
VGDI2
p5965
sg15
I1
sa(dp5966
g9
I235
sg20
VP07237
p5967
sg12
I4
sg13
VP4HB
p5968
sg15
I1
sa(dp5969
g9
I108
sg20
g21
sg12
I3
sg13
VTST
p5970
sg15
I1
sa(dp5971
g9
I41
sg20
g21
sg12
I4
sg13
VBAG2
p5972
sg15
I1
sa(dp5973
g9
I86
sg20
g21
sg12
I5
sg13
VPHGDH
p5974
sg15
I1
sa(dp5975
g9
I34
sg20
g21
sg12
I5
sg13
VCENPE
p5976
sg15
I1
sasg6
(lp5977
(dp5978
g9
I198
sg10
VC1140680
p5979
sg12
I14
sg13
Vovarian cancer
p5980
sg15
I2
sasa(dp5981
g2
VPreviously, using systems biology approach and cancer signaling networks, we identified top-5 highly expressed and connected proteins (HSP90AB1, CSNK2B, TK1, YWHAB and VIM) in the invasive MDA-MB-231 breast cancer cell line.
p5982
sg4
(lp5983
(dp5984
g9
I158
sg20
VP31946
p5985
sg12
I5
sg13
VYWHAB
p5986
sg15
I1
sa(dp5987
g9
I135
sg20
VP08238
p5988
sg12
I8
sg13
VHSP90AB1
p5989
sg15
I1
sa(dp5990
g9
I153
sg20
VP04183
p5991
sg12
I3
sg13
VTK1
p5992
sg15
I1
sa(dp5993
g9
I145
sg20
VP67870
p5994
sg12
I6
sg13
VCSNK2B
p5995
sg15
I1
sasg6
(lp5996
(dp5997
g9
I200
sg10
VC0678222
p5998
sg12
I13
sg13
Vbreast cancer
p5999
sg15
I2
sa(dp6000
g9
I47
sg10
VC0006826
p6001
sg12
I6
sg13
Vcancer
p6002
sg15
I1
sasa(dp6003
g2
VMiR-208b was also upregulated in DCM patients, but not in heart failure patients due to ischemic heart disease or myocarditis.
p6004
sg4
(lp6005
(dp6006
g9
I0
sg20
g21
sg12
I8
sg13
VMiR-208b
p6007
sg15
I1
sasg6
(lp6008
(dp6009
g9
I58
sg10
VC0018802
p6010
sg12
I13
sg13
Vheart failure
p6011
sg15
I2
sa(dp6012
g9
I114
sg10
VC0027059
p6013
sg12
I11
sg13
Vmyocarditis
p6014
sg15
I1
sa(dp6015
g9
I88
sg10
VC0151744
p6016
sg12
I22
sg13
Vischemic heart disease
p6017
sg15
I3
sasa(dp6018
g2
VElevated cAMP levels increased cell size and altered expression levels of cardiac genes and micro-RNAs associated with hypertrophic cardiomyopathy (HCM), including Myh6, Myh7, Myh7b, Tnni3, Anp, Bnp, Gata4, Mef2c, Mef2d, Nfatc1, miR208a, and miR208b.
p6019
sg4
(lp6020
(dp6021
g9
I221
sg20
g21
sg12
I6
sg13
VNfatc1
p6022
sg15
I1
sa(dp6023
g9
I214
sg20
g21
sg12
I5
sg13
VMef2d
p6024
sg15
I1
sa(dp6025
g9
I176
sg20
g21
sg12
I5
sg13
VMyh7b
p6026
sg15
I1
sa(dp6027
g9
I183
sg20
VP19429
p6028
sg12
I5
sg13
VTnni3
p6029
sg15
I1
sa(dp6030
g9
I200
sg20
VP43694
p6031
sg12
I5
sg13
VGata4
p6032
sg15
I1
sa(dp6033
g9
I190
sg20
VP16066
p6034
sg12
I3
sg13
VAnp
p6035
sg15
I1
sa(dp6036
g9
I164
sg20
VP13533
p6037
sg12
I4
sg13
VMyh6
p6038
sg15
I1
sa(dp6039
g9
I195
sg20
VP16860
p6040
sg12
I3
sg13
VBnp
p6041
sg15
I1
sa(dp6042
g9
I207
sg20
g21
sg12
I5
sg13
VMef2c
p6043
sg15
I1
sasg6
(lp6044
(dp6045
g9
I119
sg10
VC0007194
p6046
sg12
I27
sg13
Vhypertrophic cardiomyopathy
p6047
sg15
I2
sa(dp6048
g9
I148
sg10
VC0007194
p6049
sg12
I3
sg13
VHCM
p6050
sg15
I1
sasa(dp6051
g2
VThe aim of this study was to determine whether miR-208, miR-208b, and miR-499 are expressed with MHC mRNA in human dilated cardiomyopathy (DCM), and whether these levels are related to left ventricular (LV) function and to clinical outcomes.
p6052
sg4
(lp6053
(dp6054
g9
I56
sg20
g21
sg12
I8
sg13
VmiR-208b
p6055
sg15
I1
sa(dp6056
g9
I47
sg20
g21
sg12
I7
sg13
VmiR-208
p6057
sg15
I1
sa(dp6058
g9
I70
sg20
g21
sg12
I7
sg13
VmiR-499
p6059
sg15
I1
sa(dp6060
g9
I97
sg20
VP13747
p6061
sg12
I8
sg13
VMHC mRNA
p6062
sg15
I2
sasg6
(lp6063
(dp6064
g9
I139
sg10
VC0007193
p6065
sg12
I3
sg13
VDCM
p6066
sg15
I1
sa(dp6067
g9
I115
sg10
VC0007193
p6068
sg12
I22
sg13
Vdilated cardiomyopathy
p6069
sg15
I2
sasa(dp6070
g2
VThe goal of this study was to examine the long-term effects of maternal postpartum corticosterone (CORT, a model of postpartum depression) and concurrent FLX on hippocampal neurogenesis in male and female offspring.
p6071
sg4
(lp6072
sg6
(lp6073
(dp6074
g9
I116
sg10
VC0221074
p6075
sg12
I21
sg13
Vpostpartum depression
p6076
sg15
I2
sasa(dp6077
g2
VUsing high-resolution magnetic resonance imaging (MRI), the present pilot study examined the relationship between morning serum cortisol, DHEA(S), and HCV in nineteen normal controls and eighteen unmedicated subjects with Major Depressive Disorder (MDD).
p6078
sg4
(lp6079
sg6
(lp6080
(dp6081
g9
I222
sg10
VC1269683
p6082
sg12
I25
sg13
VMajor Depressive Disorder
p6083
sg15
I3
sa(dp6084
g9
I249
sg10
VC1269683
p6085
sg12
I3
sg13
VMDD
p6086
sg15
I1
sasa(dp6087
g2
VTo assess the association of neural development-related genes LIS1and TSNAX with bipolar disorder in a Chinese Han population.
p6088
sg4
(lp6089
(dp6090
g9
I56
sg20
g21
sg12
I19
sg13
Vgenes LIS1and TSNAX
p6091
sg15
I3
sasg6
(lp6092
(dp6093
g9
I81
sg10
VC0005586
p6094
sg12
I16
sg13
Vbipolar disorder
p6095
sg15
I2
sasa(dp6096
g2
VOur results indicated that LIS1 and TSNAX genes are not associated with susceptibility to bipolar I disorder in Chinese Han population.
p6097
sg4
(lp6098
(dp6099
g9
I27
sg20
VP43034
p6100
sg12
I4
sg13
VLIS1
p6101
sg15
I1
sa(dp6102
g9
I36
sg20
g21
sg12
I11
sg13
VTSNAX genes
p6103
sg15
I2
sasg6
(lp6104
(dp6105
g9
I27
sg10
VC1843916
p6106
sg12
I4
sg13
VLIS1
p6107
sg15
I1
sa(dp6108
g9
I90
sg10
VC0853193
p6109
sg12
I18
sg13
Vbipolar I disorder
p6110
sg15
I3
sasa(dp6111
g2
VThe translin-associated factor X gene (TSNAX)/disrupted-in-schizophrenia-1 gene (DISC1) has been associated with psychiatric disorders, including schizophrenia, MDD and bipolar disorder.
p6112
sg4
(lp6113
(dp6114
g9
I4
sg20
g21
sg12
I33
sg13
Vtranslin-associated factor X gene
p6115
sg15
I4
sa(dp6116
g9
I81
sg20
g21
sg12
I5
sg13
VDISC1
p6117
sg15
I1
sa(dp6118
g9
I39
sg20
g21
sg12
I5
sg13
VTSNAX
p6119
sg15
I1
sa(dp6120
g9
I45
sg20
g21
sg12
I34
sg13
V/disrupted-in-schizophrenia-1 gene
p6121
sg15
I2
sasg6
(lp6122
(dp6123
g9
I59
sg10
VC0036341
p6124
sg12
I13
sg13
Vschizophrenia
p6125
sg15
I1
sa(dp6126
g9
I59
sg10
VC0036341
p6127
sg12
I13
sg13
Vschizophrenia
p6128
sg15
I1
sa(dp6129
g9
I161
sg10
VC1269683
p6130
sg12
I3
sg13
VMDD
p6131
sg15
I1
sa(dp6132
g9
I113
sg10
VC0004936
p6133
sg12
I21
sg13
Vpsychiatric disorders
p6134
sg15
I2
sa(dp6135
g9
I169
sg10
VC0005586
p6136
sg12
I16
sg13
Vbipolar disorder
p6137
sg15
I2
sasa(dp6138
g2
VSeveral investigations have reported that the translin-associated factor X gene (TSNAX)/disrupted-in-schizophrenia-1 gene (DISC1) was associated with major psychiatric disorders including schizophrenia, bipolar disorder (BP), and major depressive disorder (MDD).
p6139
sg4
(lp6140
(dp6141
g9
I123
sg20
g21
sg12
I5
sg13
VDISC1
p6142
sg15
I1
sa(dp6143
g9
I87
sg20
g21
sg12
I34
sg13
V/disrupted-in-schizophrenia-1 gene
p6144
sg15
I2
sa(dp6145
g9
I46
sg20
g21
sg12
I33
sg13
Vtranslin-associated factor X gene
p6146
sg15
I4
sa(dp6147
g9
I81
sg20
g21
sg12
I5
sg13
VTSNAX
p6148
sg15
I1
sasg6
(lp6149
(dp6150
g9
I230
sg10
VC1269683
p6151
sg12
I25
sg13
Vmajor depressive disorder
p6152
sg15
I3
sa(dp6153
g9
I101
sg10
VC0036341
p6154
sg12
I13
sg13
Vschizophrenia
p6155
sg15
I1
sa(dp6156
g9
I257
sg10
VC1269683
p6157
sg12
I3
sg13
VMDD
p6158
sg15
I1
sa(dp6159
g9
I156
sg10
VC0004936
p6160
sg12
I21
sg13
Vpsychiatric disorders
p6161
sg15
I2
sa(dp6162
g9
I221
sg10
VC0005586
p6163
sg12
I2
sg13
VBP
p6164
sg15
I1
sa(dp6165
g9
I203
sg10
VC0005586
p6166
sg12
I16
sg13
Vbipolar disorder
p6167
sg15
I2
sa(dp6168
g9
I101
sg10
VC0036341
p6169
sg12
I13
sg13
Vschizophrenia
p6170
sg15
I1
sasa(dp6171
g2
VThe Translin-associated factor X/Disrupted in Schizophrenia 1 (TRAX/DISC) region was first implicated as a susceptibility locus for schizophrenia by analysis of a large Scottish family in which a t(1;11) translocation cosegregates with schizophrenia, bipolar disorder and recurrent major depression.
p6172
sg4
(lp6173
(dp6174
g9
I4
sg20
g21
sg12
I28
sg13
VTranslin-associated factor X
p6175
sg15
I3
sa(dp6176
g9
I46
sg20
VP35462
p6177
sg12
I15
sg13
VSchizophrenia 1
p6178
sg15
I2
sa(dp6179
g9
I63
sg20
g21
sg12
I4
sg13
VTRAX
p6180
sg15
I1
sasg6
(lp6181
(dp6182
g9
I272
sg10
VC0154409
p6183
sg12
I26
sg13
Vrecurrent major depression
p6184
sg15
I3
sa(dp6185
g9
I132
sg10
VC0036341
p6186
sg12
I13
sg13
Vschizophrenia
p6187
sg15
I1
sa(dp6188
g9
I132
sg10
VC0036341
p6189
sg12
I13
sg13
Vschizophrenia
p6190
sg15
I1
sa(dp6191
g9
I204
sg10
VC0040715
p6192
sg12
I13
sg13
Vtranslocation
p6193
sg15
I1
sa(dp6194
g9
I251
sg10
VC0005586
p6195
sg12
I16
sg13
Vbipolar disorder
p6196
sg15
I2
sa(dp6197
g9
I46
sg10
VC0220702
p6198
sg12
I15
sg13
VSchizophrenia 1
p6199
sg15
I2
sasa(dp6200
g2
VTwo further regions, one in TRAX and the second in DISC1, showed weaker evidence for sex-specific associations of individual haplotypes with bipolar disorder in men and women respectively, P&lt;0.01.
p6201
sg4
(lp6202
(dp6203
g9
I51
sg20
g21
sg12
I5
sg13
VDISC1
p6204
sg15
I1
sasg6
(lp6205
(dp6206
g9
I141
sg10
VC0005586
p6207
sg12
I16
sg13
Vbipolar disorder
p6208
sg15
I2
sasa(dp6209
g2
VCompared with non-CKD controls, mice with CKD had downregulated expression of GSTA4 at the mRNA and protein levels, with concomitant increase in 4-HNE in arteries and veins.
p6210
sg4
(lp6211
(dp6212
g9
I78
sg20
g21
sg12
I5
sg13
VGSTA4
p6213
sg15
I1
sasg6
(lp6214
sa(dp6215
g2
VThe data showed age-related upregulation of downstream signaling molecules such as mitogen activated protein kinases (MAPKs), activator protein-1 (AP-1), NF-KB, and COX-2 in a cell culture cell system.Taken together, the results of this study show that the formation of adducts between 4-HNE and Src activates inflammatory signaling pathways in the aged kidney, contributing to age-related nephropathy.
p6216
sg4
(lp6217
(dp6218
g9
I165
sg20
VP35354
p6219
sg12
I5
sg13
VCOX-2
p6220
sg15
I1
sa(dp6221
g9
I296
sg20
VP12931
p6222
sg12
I3
sg13
VSrc
p6223
sg15
I1
sa(dp6224
g9
I147
sg20
VP01100
p6225
sg12
I4
sg13
VAP-1
p6226
sg15
I1
sa(dp6227
g9
I288
sg20
VP08246
p6228
sg12
I3
sg13
VHNE
p6229
sg15
I1
sa(dp6230
g9
I83
sg20
VP17980
p6231
sg12
I62
sg13
Vmitogen activated protein kinases (MAPKs), activator protein-1
p6232
sg15
I7
sasg6
(lp6233
(dp6234
g9
I390
sg10
VC0022658
p6235
sg12
I11
sg13
Vnephropathy
p6236
sg15
I1
sasa(dp6237
g2
VElevated plasma 4-HNE has been associated with renal failure, septic shock and cardiopulmonary bypass surgery.
p6238
sg4
(lp6239
(dp6240
g9
I9
sg20
VP08246
p6241
sg12
I12
sg13
Vplasma 4-HNE
p6242
sg15
I2
sasg6
(lp6243
(dp6244
g9
I62
sg10
VC0036983
p6245
sg12
I12
sg13
Vseptic shock
p6246
sg15
I2
sa(dp6247
g9
I47
sg10
VC0035078
p6248
sg12
I13
sg13
Vrenal failure
p6249
sg15
I2
sasa(dp6250
g2
VAdditionally, the effect of PlGF (inhibition) on IOP was investigated, since aqueous PlGF is known to be upregulated in glaucoma patients.
p6251
sg4
(lp6252
(dp6253
g9
I28
sg20
VP49763
p6254
sg12
I4
sg13
VPlGF
p6255
sg15
I1
sa(dp6256
g9
I28
sg20
VP49763
p6257
sg12
I4
sg13
VPlGF
p6258
sg15
I1
sasg6
(lp6259
(dp6260
g9
I120
sg10
VC0017601
p6261
sg12
I8
sg13
Vglaucoma
p6262
sg15
I1
sasa(dp6263
g2
VInhibition of PlGF also might open alternative perspectives as IOP-lowering strategy for glaucoma patients with increased aqueous PlGF levels.
p6264
sg4
(lp6265
(dp6266
g9
I14
sg20
VP49763
p6267
sg12
I4
sg13
VPlGF
p6268
sg15
I1
sa(dp6269
g9
I14
sg20
VP49763
p6270
sg12
I4
sg13
VPlGF
p6271
sg15
I1
sasg6
(lp6272
(dp6273
g9
I89
sg10
VC0017601
p6274
sg12
I8
sg13
Vglaucoma
p6275
sg15
I1
sasa(dp6276
g2
VTo evaluate changes in the concentrations of placental growth factor (PlGF) and vascular endothelial growth factor-A (VEGF-A) in aqueous humor of patients with neovascular glaucoma (NVG) before and after an intravitreal injection of ranibizumab (IVR) and to determine the underlying correlation between the levels.
p6277
sg4
(lp6278
(dp6279
g9
I80
sg20
g21
sg12
I36
sg13
Vvascular endothelial growth factor-A
p6280
sg15
I4
sa(dp6281
g9
I118
sg20
g21
sg12
I6
sg13
VVEGF-A
p6282
sg15
I1
sa(dp6283
g9
I70
sg20
VP49763
p6284
sg12
I4
sg13
VPlGF
p6285
sg15
I1
sa(dp6286
g9
I45
sg20
VP49763
p6287
sg12
I23
sg13
Vplacental growth factor
p6288
sg15
I3
sasg6
(lp6289
(dp6290
g9
I160
sg10
VC0017609
p6291
sg12
I20
sg13
Vneovascular glaucoma
p6292
sg15
I2
sa(dp6293
g9
I129
sg10
VC0595936
p6294
sg12
I13
sg13
Vaqueous humor
p6295
sg15
I2
sa(dp6296
g9
I182
sg10
VC0017609
p6297
sg12
I3
sg13
VNVG
p6298
sg15
I1
sasa(dp6299
g2
VELISA experiments showed that PlGF levels were significantly increased in aqueous humour of glaucoma patients and after VEGF treatment, which may indicate an important contribution of this growth factor to wound healing after trabeculectomy.
p6300
sg4
(lp6301
(dp6302
g9
I30
sg20
VP49763
p6303
sg12
I4
sg13
VPlGF
p6304
sg15
I1
sasg6
(lp6305
(dp6306
g9
I92
sg10
VC0017601
p6307
sg12
I8
sg13
Vglaucoma
p6308
sg15
I1
sasa(dp6309
g2
VUsing a mouse model of glaucoma filtration surgery, we were able to show that intracameral injection of a previously characterized anti-PlGF antibody (ThromboGenics NV) significantly improved surgical outcome by increasing bleb survival and bleb area.
p6310
sg4
(lp6311
(dp6312
g9
I131
sg20
VP49763
p6313
sg12
I18
sg13
Vanti-PlGF antibody
p6314
sg15
I2
sasg6
(lp6315
(dp6316
g9
I223
sg10
VC0005758
p6317
sg12
I4
sg13
Vbleb
p6318
sg15
I1
sa(dp6319
g9
I223
sg10
VC0005758
p6320
sg12
I4
sg13
Vbleb
p6321
sg15
I1
sa(dp6322
g9
I23
sg10
VC0017601
p6323
sg12
I8
sg13
Vglaucoma
p6324
sg15
I1
sasa(dp6325
g2
VThe 17-phenyl PGF(2Alfa) analogue bimatoprost (10a) is the most efficacious ocular hypotensive agent currently available for the treatment of glaucoma or ocular hypertension.
p6326
sg4
(lp6327
sg6
(lp6328
(dp6329
g9
I154
sg10
VC0028840
p6330
sg12
I19
sg13
Vocular hypertension
p6331
sg15
I2
sa(dp6332
g9
I142
sg10
VC0017601
p6333
sg12
I8
sg13
Vglaucoma
p6334
sg15
I1
sa(dp6335
g9
I83
sg10
VC0857353
p6336
sg12
I11
sg13
Vhypotensive
p6337
sg15
I1
sasa(dp6338
g2
VLatanoprost, a synthetic derivative of the natural prostaglandin F(2a) (PGF(2a)), is a powerful antiglaucoma agent with ocular hypotensive and neuroprotective effects.
p6339
sg4
(lp6340
sg6
(lp6341
(dp6342
g9
I127
sg10
VC0857353
p6343
sg12
I11
sg13
Vhypotensive
p6344
sg15
I1
sasa(dp6345
g2
VEndotoxaemia enhanced early VT occurs in a TLR-4 and ICAM-1 dependent fashion, and is potentiated by neutropenia.
p6346
sg4
(lp6347
(dp6348
g9
I43
sg20
g21
sg12
I5
sg13
VTLR-4
p6349
sg15
I1
sa(dp6350
g9
I53
sg20
VP05362
p6351
sg12
I6
sg13
VICAM-1
p6352
sg15
I1
sasg6
(lp6353
sa(dp6354
g2
VThe aim of this study was to investigate the mannose-binding lectin 2 (MBL-2), interleukin (IL)-4, Toll-like receptor 4 (TLR-4), angiotensin converting enzyme (ACE), chemokine receptor 5 (CCR-5), and IL-1 receptor antagonist (RA) gene polymorphisms (GPs) in acute leukemias (ALs) and to evaluate their roles in febrile neutropenia (FN) resulting from chemotherapy.
p6355
sg4
(lp6356
(dp6357
g9
I45
sg20
VP11226
p6358
sg12
I24
sg13
Vmannose-binding lectin 2
p6359
sg15
I3
sa(dp6360
g9
I71
sg20
VP11226
p6361
sg12
I5
sg13
VMBL-2
p6362
sg15
I1
sa(dp6363
g9
I200
sg20
g21
sg12
I13
sg13
VIL-1 receptor
p6364
sg15
I2
sa(dp6365
g9
I79
sg20
VP60568
p6366
sg12
I18
sg13
Vinterleukin (IL)-4
p6367
sg15
I2
sa(dp6368
g9
I129
sg20
VP12821
p6369
sg12
I29
sg13
Vangiotensin converting enzyme
p6370
sg15
I3
sa(dp6371
g9
I188
sg20
VP61073
p6372
sg12
I5
sg13
VCCR-5
p6373
sg15
I1
sa(dp6374
g9
I121
sg20
g21
sg12
I5
sg13
VTLR-4
p6375
sg15
I1
sa(dp6376
g9
I166
sg20
VP61073
p6377
sg12
I20
sg13
Vchemokine receptor 5
p6378
sg15
I3
sa(dp6379
g9
I99
sg20
g21
sg12
I20
sg13
VToll-like receptor 4
p6380
sg15
I3
sa(dp6381
g9
I160
sg20
VP12821
p6382
sg12
I3
sg13
VACE
p6383
sg15
I1
sasg6
(lp6384
(dp6385
g9
I332
sg10
VC0746883
p6386
sg12
I2
sg13
VFN
p6387
sg15
I1
sa(dp6388
g9
I250
sg10
VC0272302
p6389
sg12
I3
sg13
VGPs
p6390
sg15
I1
sa(dp6391
g9
I230
sg10
VC0272302
p6392
sg12
I18
sg13
Vgene polymorphisms
p6393
sg15
I2
sa(dp6394
g9
I258
sg10
VC0085669
p6395
sg12
I15
sg13
Vacute leukemias
p6396
sg15
I2
sa(dp6397
g9
I275
sg10
VC0002736
p6398
sg12
I3
sg13
VALs
p6399
sg15
I1
sa(dp6400
g9
I311
sg10
VC0746883
p6401
sg12
I19
sg13
Vfebrile neutropenia
p6402
sg15
I2
sasa(dp6403
g2
VIn a multivariate analysis, adjusted for occurrence of graft-versus-host-disease, Cytomegalovirus serostatus and duration of neutropenia, paired presence of the TLR4 1063A&gt;G and IFNG 874T&gt;A single nucleotide polymorphisms showed a trend towards increased susceptibility to invasive aspergillosis (p = 0.04).
p6404
sg4
(lp6405
(dp6406
g9
I181
sg20
VP01579
p6407
sg12
I9
sg13
VIFNG 874T
p6408
sg15
I2
sasg6
(lp6409
(dp6410
g9
I55
sg10
VC0018133
p6411
sg12
I25
sg13
Vgraft-versus-host-disease
p6412
sg15
I1
sa(dp6413
g9
I279
sg10
VC0238013
p6414
sg12
I22
sg13
Vinvasive aspergillosis
p6415
sg15
I2
sasa(dp6416
g2
VFour SNPs in the TLR4 gene (rs10759931, rs11536889, rs1927911 and rs6478317) were associated with an increased risk of developing chemotherapy-induced neutropenia, each sustaining correction for multiple testing.
p6417
sg4
(lp6418
sg6
(lp6419
(dp6420
g9
I130
sg10
VC1827687
p6421
sg12
I32
sg13
Vchemotherapy-induced neutropenia
p6422
sg15
I2
sasa(dp6423
g2
VThe rs1064395 single nucleotide polymorphism, within the gene encoding neurocan (NCAN), is reported to be associated with schizophrenia in European populations and may influence brain structure in patients with schizophrenia.
p6424
sg4
(lp6425
(dp6426
g9
I81
sg20
g21
sg12
I4
sg13
VNCAN
p6427
sg15
I1
sa(dp6428
g9
I57
sg20
g21
sg12
I22
sg13
Vgene encoding neurocan
p6429
sg15
I3
sasg6
(lp6430
(dp6431
g9
I122
sg10
VC0036341
p6432
sg12
I13
sg13
Vschizophrenia
p6433
sg15
I1
sa(dp6434
g9
I122
sg10
VC0036341
p6435
sg12
I13
sg13
Vschizophrenia
p6436
sg15
I1
sasa(dp6437
g2
VIn this study, we aimed to explore whether NCAN rs1064395 confers some risk for schizophrenia and cognitive dysfunction in Han Chinese.
p6438
sg4
(lp6439
(dp6440
g9
I43
sg20
g21
sg12
I14
sg13
VNCAN rs1064395
p6441
sg15
I2
sasg6
(lp6442
(dp6443
g9
I80
sg10
VC0036341
p6444
sg12
I13
sg13
Vschizophrenia
p6445
sg15
I1
sa(dp6446
g9
I98
sg10
VC0338656
p6447
sg12
I21
sg13
Vcognitive dysfunction
p6448
sg15
I2
sasa(dp6449
g2
VThe A allele of the single nucleotide polymorphism (SNP) rs1064395 in the NCAN gene has recently been identified as a susceptibility factor for bipolar disorder and schizophrenia.
p6450
sg4
(lp6451
(dp6452
g9
I74
sg20
g21
sg12
I9
sg13
VNCAN gene
p6453
sg15
I2
sasg6
(lp6454
(dp6455
g9
I144
sg10
VC0005586
p6456
sg12
I16
sg13
Vbipolar disorder
p6457
sg15
I2
sa(dp6458
g9
I165
sg10
VC0036341
p6459
sg12
I13
sg13
Vschizophrenia
p6460
sg15
I1
sasa(dp6461
g2
VRecently, it was shown that some CSPGs members like aggrecan, versican, and neurocan were strongly involved in brain disorders like bipolar disorder (BD), schizophrenia, and ADHD.
p6462
sg4
(lp6463
(dp6464
g9
I52
sg20
VP16112
p6465
sg12
I8
sg13
Vaggrecan
p6466
sg15
I1
sa(dp6467
g9
I174
sg20
g21
sg12
I4
sg13
VADHD
p6468
sg15
I1
sasg6
(lp6469
(dp6470
g9
I174
sg10
VC1263846
p6471
sg12
I4
sg13
VADHD
p6472
sg15
I1
sa(dp6473
g9
I111
sg10
VC0006111
p6474
sg12
I15
sg13
Vbrain disorders
p6475
sg15
I2
sa(dp6476
g9
I132
sg10
VC0005586
p6477
sg12
I16
sg13
Vbipolar disorder
p6478
sg15
I2
sa(dp6479
g9
I150
sg10
VC0005586
p6480
sg12
I2
sg13
VBD
p6481
sg15
I1
sa(dp6482
g9
I155
sg10
VC0036341
p6483
sg12
I13
sg13
Vschizophrenia
p6484
sg15
I1
sasa(dp6485
g2
VRecent studies have provided strong evidence that variation in the gene neurocan (NCAN, rs1064395) is a common risk factor for bipolar disorder (BD) and schizophrenia.
p6486
sg4
(lp6487
(dp6488
g9
I82
sg20
g21
sg12
I4
sg13
VNCAN
p6489
sg15
I1
sa(dp6490
g9
I72
sg20
g21
sg12
I8
sg13
Vneurocan
p6491
sg15
I1
sasg6
(lp6492
(dp6493
g9
I145
sg10
VC0005586
p6494
sg12
I2
sg13
VBD
p6495
sg15
I1
sa(dp6496
g9
I153
sg10
VC0036341
p6497
sg12
I13
sg13
Vschizophrenia
p6498
sg15
I1
sa(dp6499
g9
I127
sg10
VC0005586
p6500
sg12
I16
sg13
Vbipolar disorder
p6501
sg15
I2
sasa(dp6502
g2
VIn this work, authors investigated the association between previously confirmed bipolar disorder genetic risk factor- neurocan with schizophrenia in a population sample of Bosnia and Herzegovina.
p6503
sg4
(lp6504
sg6
(lp6505
(dp6506
g9
I132
sg10
VC0036341
p6507
sg12
I13
sg13
Vschizophrenia
p6508
sg15
I1
sa(dp6509
g9
I80
sg10
VC0005586
p6510
sg12
I16
sg13
Vbipolar disorder
p6511
sg15
I2
sasa(dp6512
g2
VA case-control analysis of common genetic polymorphism within neurocan gene and schizophrenia status in a consecutively sampled patient cohort have been done using Fisher-exact test with odds-ratio calculation.
p6513
sg4
(lp6514
sg6
(lp6515
(dp6516
g9
I80
sg10
VC0036341
p6517
sg12
I13
sg13
Vschizophrenia
p6518
sg15
I1
sasa(dp6519
g2
VOur data suggest that genetic variation in NCAN is a common risk factor for BD and schizophrenia.
p6520
sg4
(lp6521
(dp6522
g9
I43
sg20
g21
sg12
I4
sg13
VNCAN
p6523
sg15
I1
sasg6
(lp6524
(dp6525
g9
I83
sg10
VC0036341
p6526
sg12
I13
sg13
Vschizophrenia
p6527
sg15
I1
sasa(dp6528
g2
VIn contrast, studies have associated primary biliary cirrhosis and primary sclerosing cholangitis with genes encoding major histocompatibility complex proteins and identified loci associated with microbial sensing and immune regulatory pathways outside this region, such as genes encoding IL12, STAT4, IRF5, IL2 and its receptor (IL2R), CD28, and CD80.
p6529
sg4
(lp6530
(dp6531
g9
I308
sg20
VP01589
p6532
sg12
I20
sg13
VIL2 and its receptor
p6533
sg15
I4
sa(dp6534
g9
I330
sg20
VP01589
p6535
sg12
I4
sg13
VIL2R
p6536
sg15
I1
sa(dp6537
g9
I302
sg20
g21
sg12
I4
sg13
VIRF5
p6538
sg15
I1
sa(dp6539
g9
I118
sg20
VP18464
p6540
sg12
I41
sg13
Vmajor histocompatibility complex proteins
p6541
sg15
I4
sa(dp6542
g9
I347
sg20
VP33681
p6543
sg12
I4
sg13
VCD80
p6544
sg15
I1
sa(dp6545
g9
I295
sg20
g21
sg12
I5
sg13
VSTAT4
p6546
sg15
I1
sa(dp6547
g9
I337
sg20
VP33681
p6548
sg12
I4
sg13
VCD28
p6549
sg15
I1
sasg6
(lp6550
(dp6551
g9
I37
sg10
VC0008312
p6552
sg12
I25
sg13
Vprimary biliary cirrhosis
p6553
sg15
I3
sa(dp6554
g9
I67
sg10
VC0566602
p6555
sg12
I30
sg13
Vprimary sclerosing cholangitis
p6556
sg15
I3
sasa(dp6557
g2
VIn this condition, 8CR inhibited edema and myonecrosis induced by the sPLA2 activity of Crotalus durissus terrificus in a dose-dependent manner by decreasing interleukin-1Beta (IL-1Beta), tumor necrosis factor Alfa (TNF-Alfa), prostaglandin E2 (PGE2), and lipid peroxidation.
p6558
sg4
(lp6559
(dp6560
g9
I216
sg20
VP01375
p6561
sg12
I8
sg13
VTNF-Alfa
p6562
sg15
I1
sa(dp6563
g9
I177
sg20
VP01584
p6564
sg12
I8
sg13
VIL-1Beta
p6565
sg15
I1
sa(dp6566
g9
I158
sg20
VP01584
p6567
sg12
I17
sg13
Vinterleukin-1Beta
p6568
sg15
I1
sa(dp6569
g9
I188
sg20
VP01375
p6570
sg12
I26
sg13
Vtumor necrosis factor Alfa
p6571
sg15
I4
sa(dp6572
g9
I70
sg20
VP14555
p6573
sg12
I5
sg13
VsPLA2
p6574
sg15
I1
sasg6
(lp6575
(dp6576
g9
I8
sg10
VC0012634
p6577
sg12
I9
sg13
Vcondition
p6578
sg15
I1
sa(dp6579
g9
I43
sg10
VC0235957
p6580
sg12
I11
sg13
Vmyonecrosis
p6581
sg15
I1
sa(dp6582
g9
I33
sg10
VC0013604
p6583
sg12
I5
sg13
Vedema
p6584
sg15
I1
sa(dp6585
g9
I188
sg10
VC0333516
p6586
sg12
I14
sg13
Vtumor necrosis
p6587
sg15
I2
sasa(dp6588
g2
VIn addition, it was shown that Crotalus durissus terrificus sPLA2 increases cell oxidative stress during edema and myonecrosis, and the antioxidant properties of the polyphenolic compound may be significant in mitigating the pharmacological effect induced by sPLA2 and other snake venom toxins.
p6589
sg4
(lp6590
(dp6591
g9
I60
sg20
VP14555
p6592
sg12
I5
sg13
VsPLA2
p6593
sg15
I1
sasg6
(lp6594
(dp6595
g9
I115
sg10
VC0235957
p6596
sg12
I11
sg13
Vmyonecrosis
p6597
sg15
I1
sa(dp6598
g9
I105
sg10
VC0013604
p6599
sg12
I5
sg13
Vedema
p6600
sg15
I1
sa(dp6601
g9
I81
sg10
VC0242606
p6602
sg12
I16
sg13
Voxidative stress
p6603
sg15
I2
sasa(dp6604
g2
VTherefore, it's necessary to express CssPLA2 in water-soluble form and determine whether the enzymatic activity of CssPLA2 or cell signalling pathways is involved in liver fibrosis caused by clonorchiasis.
p6605
sg4
(lp6606
sg6
(lp6607
(dp6608
g9
I191
sg10
VC0009021
p6609
sg12
I13
sg13
Vclonorchiasis
p6610
sg15
I1
sa(dp6611
g9
I166
sg10
VC0239946
p6612
sg12
I14
sg13
Vliver fibrosis
p6613
sg15
I2
sasa(dp6614
g2
VWe sought to investigate if mast cell activation and increases in secretory sPLA2s are associated with an increase in PAF and occurrence of dengue haemorrhagic fever (DHF).
p6615
sg4
(lp6616
(dp6617
g9
I66
sg20
g21
sg12
I16
sg13
Vsecretory sPLA2s
p6618
sg15
I2
sasg6
(lp6619
(dp6620
g9
I167
sg10
VC0019100
p6621
sg12
I3
sg13
VDHF
p6622
sg15
I1
sa(dp6623
g9
I140
sg10
VC0019100
p6624
sg12
I25
sg13
Vdengue haemorrhagic fever
p6625
sg15
I3
sa(dp6626
g9
I118
sg10
VC0235480
p6627
sg12
I3
sg13
VPAF
p6628
sg15
I1
sasa(dp6629
g2
VThe changes in the levels of mast cell tryptase, PAF and the activity of sPLA2 were determined throughout the course of illness in 13 adult patients with DHF, and 30 patients with dengue fever (DF).
p6630
sg4
(lp6631
(dp6632
g9
I49
sg20
g21
sg12
I3
sg13
VPAF
p6633
sg15
I1
sa(dp6634
g9
I73
sg20
VP14555
p6635
sg12
I5
sg13
VsPLA2
p6636
sg15
I1
sa(dp6637
g9
I29
sg20
VP15157
p6638
sg12
I18
sg13
Vmast cell tryptase
p6639
sg15
I3
sasg6
(lp6640
(dp6641
g9
I49
sg10
VC0235480
p6642
sg12
I3
sg13
VPAF
p6643
sg15
I1
sa(dp6644
g9
I180
sg10
VC0011311
p6645
sg12
I12
sg13
Vdengue fever
p6646
sg15
I2
sa(dp6647
g9
I110
sg10
VC0242656
p6648
sg12
I17
sg13
Vcourse of illness
p6649
sg15
I3
sa(dp6650
g9
I194
sg10
VC0011311
p6651
sg12
I2
sg13
VDF
p6652
sg15
I1
sasa(dp6653
g2
VThe difference in serum levels of PLA2G2A was analyzed among chronic hepatitis B (CHB), LC, and HCC patients.
p6654
sg4
(lp6655
(dp6656
g9
I34
sg20
VP14555
p6657
sg12
I7
sg13
VPLA2G2A
p6658
sg15
I1
sasg6
(lp6659
(dp6660
g9
I82
sg10
VC0151517
p6661
sg12
I3
sg13
VCHB
p6662
sg15
I1
sa(dp6663
g9
I61
sg10
VC0524909
p6664
sg12
I19
sg13
Vchronic hepatitis B
p6665
sg15
I3
sa(dp6666
g9
I96
sg10
VC2239176
p6667
sg12
I3
sg13
VHCC
p6668
sg15
I1
sasa(dp6669
g2
VWe have previously shown that secreted phospholipases A2 (sPLA2s) from animal venoms inhibit the in vitro development of Plasmodium falciparum, the agent of malaria.
p6670
sg4
(lp6671
(dp6672
g9
I58
sg20
g21
sg12
I6
sg13
VsPLA2s
p6673
sg15
I1
sa(dp6674
g9
I39
sg20
VP04054
p6675
sg12
I17
sg13
Vphospholipases A2
p6676
sg15
I2
sasg6
(lp6677
(dp6678
g9
I157
sg10
VC0024530
p6679
sg12
I7
sg13
Vmalaria
p6680
sg15
I1
sasa(dp6681
g2
VIn addition, the inflammatory-type human group IIA (hGIIA) sPLA2 circulates at high levels in the serum of malaria patients.
p6682
sg4
(lp6683
(dp6684
g9
I59
sg20
VP14555
p6685
sg12
I5
sg13
VsPLA2
p6686
sg15
I1
sasg6
(lp6687
(dp6688
g9
I107
sg10
VC0024530
p6689
sg12
I7
sg13
Vmalaria
p6690
sg15
I1
sasa(dp6691
g2
VTogether, our findings indicate that 4 human sPLA2s are active against P. falciparum in vitro and pave the way to future investigations on their in vivo contribution in malaria pathophysiology.
p6692
sg4
(lp6693
sg6
(lp6694
(dp6695
g9
I169
sg10
VC0024530
p6696
sg12
I7
sg13
Vmalaria
p6697
sg15
I1
sasa(dp6698
g2
VTwo subtypes of phospholipases A2 (PLA2s) with the ability to induce myonecrosis, 'Asp49' and 'Lys49' myotoxins, often coexist in viperid snake venoms.
p6699
sg4
(lp6700
(dp6701
g9
I16
sg20
VP04054
p6702
sg12
I17
sg13
Vphospholipases A2
p6703
sg15
I2
sa(dp6704
g9
I35
sg20
VP04054
p6705
sg12
I5
sg13
VPLA2s
p6706
sg15
I1
sasg6
(lp6707
(dp6708
g9
I69
sg10
VC0235957
p6709
sg12
I11
sg13
Vmyonecrosis
p6710
sg15
I1
sasa(dp6711
g2
VIn order to assess the contribution of the IL-18 to susceptibility to Chronic Chagas Disease, we investigated the association between a single nucleotide polymorphism (SNP) located in the IL-18 gene with the risk of developing Chagas cardiomyopathy.
p6712
sg4
(lp6713
sg6
(lp6714
(dp6715
g9
I227
sg10
VC0007930
p6716
sg12
I21
sg13
VChagas cardiomyopathy
p6717
sg15
I2
sa(dp6718
g9
I78
sg10
VC0041234
p6719
sg12
I14
sg13
VChagas Disease
p6720
sg15
I2
sasa(dp6721
g2
VWe analyzed the rs2043055 marker in the IL18 gene in a cohort of Chagas disease cardiomyopathy patients (n=849) and asymptomatic subjects (n=202).
p6722
sg4
(lp6723
(dp6724
g9
I40
sg20
g21
sg12
I9
sg13
VIL18 gene
p6725
sg15
I2
sasg6
(lp6726
(dp6727
g9
I80
sg10
VC0878544
p6728
sg12
I14
sg13
Vcardiomyopathy
p6729
sg15
I1
sa(dp6730
g9
I65
sg10
VC0041234
p6731
sg12
I14
sg13
VChagas disease
p6732
sg15
I2
sasa(dp6733
g2
VTo describe a peculiar flecked-retina phenotype in a young female affected by early-onset retinal dystrophy due to a heterozygous mutation in the cone-rod transcription factor CRX gene.
p6734
sg4
(lp6735
(dp6736
g9
I176
sg20
g21
sg12
I8
sg13
VCRX gene
p6737
sg15
I2
sasg6
(lp6738
(dp6739
g9
I90
sg10
VC0854723
p6740
sg12
I17
sg13
Vretinal dystrophy
p6741
sg15
I2
sasa(dp6742
g2
VWe identified a novel early-onset retinal dystrophy-related heterozygous CRX mutation associated with early and severe rod and cone dysfunction and regressive flecked-retina appearance on ophthalmoscopy.
p6743
sg4
(lp6744
(dp6745
g9
I73
sg20
g21
sg12
I12
sg13
VCRX mutation
p6746
sg15
I2
sasg6
(lp6747
(dp6748
g9
I34
sg10
VC0854723
p6749
sg12
I17
sg13
Vretinal dystrophy
p6750
sg15
I2
sasa(dp6751
g2
VWe found that retinal disease-related genes were efficiently detected in CRX-transduced cells, most of which are crucial to photoreceptor functions.
p6752
sg4
(lp6753
sg6
(lp6754
(dp6755
g9
I14
sg10
VC0035309
p6756
sg12
I15
sg13
Vretinal disease
p6757
sg15
I2
sasa(dp6758
g2
VMoreover, by modification of the culture conditions including additional transduction of RAX1 and NEUROD1, we found a greater variety of retinal disease-related genes than that observed in CRX-transduced PBMCs.
p6759
sg4
(lp6760
(dp6761
g9
I98
sg20
g21
sg12
I7
sg13
VNEUROD1
p6762
sg15
I1
sasg6
(lp6763
(dp6764
g9
I137
sg10
VC0035309
p6765
sg12
I15
sg13
Vretinal disease
p6766
sg15
I2
sasa(dp6767
g2
VThese data suggest that CRX acts as a master control gene for reprogramming PBMCs into photoreceptor-like cells and that our induced photoreceptor-like cells might contribute to individualized drug screening and disease modeling of inherited retinal degeneration.
p6768
sg4
(lp6769
(dp6770
g9
I24
sg20
g21
sg12
I3
sg13
VCRX
p6771
sg15
I1
sasg6
(lp6772
(dp6773
g9
I242
sg10
VC0035304
p6774
sg12
I20
sg13
Vretinal degeneration
p6775
sg15
I2
sasa(dp6776
g2
VFinally, anisomycin was the highest correlation with DEGs.MiR-124a might be involved in the pathogenesis of hypertension via targeting Ebf3 and Rgs7 bp, which possibly represent a novel and effective strategy for treatment of hypertension.
p6777
sg4
(lp6778
(dp6779
g9
I135
sg20
g21
sg12
I4
sg13
VEbf3
p6780
sg15
I1
sa(dp6781
g9
I53
sg20
g21
sg12
I13
sg13
VDEGs.MiR-124a
p6782
sg15
I1
sa(dp6783
g9
I144
sg20
VP49802
p6784
sg12
I4
sg13
VRgs7
p6785
sg15
I1
sasg6
(lp6786
(dp6787
g9
I92
sg10
VC0699748
p6788
sg12
I12
sg13
Vpathogenesis
p6789
sg15
I1
sa(dp6790
g9
I108
sg10
VC0020538
p6791
sg12
I12
sg13
Vhypertension
p6792
sg15
I1
sa(dp6793
g9
I108
sg10
VC0020538
p6794
sg12
I12
sg13
Vhypertension
p6795
sg15
I1
sasa(dp6796
g2
VThe serum miR-124 expression levels in 114 osteosarcoma patients, 40 periostitis patients and 50 normal controls were detected using real-time quantitative polymerase chain reaction (RT-qPCR).
p6797
sg4
(lp6798
(dp6799
g9
I10
sg20
g21
sg12
I7
sg13
VmiR-124
p6800
sg15
I1
sasg6
(lp6801
(dp6802
g9
I43
sg10
VC0029463
p6803
sg12
I12
sg13
Vosteosarcoma
p6804
sg15
I1
sa(dp6805
g9
I69
sg10
VC0031111
p6806
sg12
I11
sg13
Vperiostitis
p6807
sg15
I1
sasa(dp6808
g2
VThe level of serum miR-124 was remarkably decreased in osteosarcoma patients when compared to periostitis patients and healthy controls (both p&lt; 0.05).
p6809
sg4
(lp6810
(dp6811
g9
I13
sg20
g21
sg12
I13
sg13
Vserum miR-124
p6812
sg15
I2
sasg6
(lp6813
(dp6814
g9
I94
sg10
VC0031111
p6815
sg12
I11
sg13
Vperiostitis
p6816
sg15
I1
sa(dp6817
g9
I55
sg10
VC0029463
p6818
sg12
I12
sg13
Vosteosarcoma
p6819
sg15
I1
sasa(dp6820
g2
VMoreover, the Kaplan-Meier method with log-rank test showed that osteosarcoma patients with lower serum miR-124 levels had unfavorable 5 year overall survival and disease free survival rates.
p6821
sg4
(lp6822
sg6
(lp6823
(dp6824
g9
I65
sg10
VC0029463
p6825
sg12
I12
sg13
Vosteosarcoma
p6826
sg15
I1
sasa(dp6827
g2
VIt was also demonstrated that miR-124-3p expression was positively associated with mTOR signaling and this relationship was dependent on the tuberous sclerosis proteins 1/2 complex.
p6828
sg4
(lp6829
(dp6830
g9
I30
sg20
g21
sg12
I10
sg13
VmiR-124-3p
p6831
sg15
I1
sa(dp6832
g9
I83
sg20
VP42345
p6833
sg12
I4
sg13
VmTOR
p6834
sg15
I1
sasg6
(lp6835
(dp6836
g9
I141
sg10
VC0041341
p6837
sg12
I18
sg13
Vtuberous sclerosis
p6838
sg15
I2
sasa(dp6839
g2
VAmong these microRNAs, miR-142-3p/5p and miR-146a expression was found to be significantly increased in MPA-treated lupus CD4(+)T cells compared to untreated controls.
p6840
sg4
(lp6841
(dp6842
g9
I23
sg20
g21
sg12
I13
sg13
VmiR-142-3p/5p
p6843
sg15
I1
sa(dp6844
g9
I41
sg20
g21
sg12
I8
sg13
VmiR-146a
p6845
sg15
I1
sasg6
(lp6846
(dp6847
g9
I116
sg10
VC0024131
p6848
sg12
I5
sg13
Vlupus
p6849
sg15
I1
sasa(dp6850
g2
VTo examine the role of microRNA-142-3p/5p (miR-142-3p/5p) in the development of autoimmunity in patients with systemic lupus erythematosus (SLE).
p6851
sg4
(lp6852
(dp6853
g9
I43
sg20
g21
sg12
I13
sg13
VmiR-142-3p/5p
p6854
sg15
I1
sa(dp6855
g9
I23
sg20
g21
sg12
I18
sg13
VmicroRNA-142-3p/5p
p6856
sg15
I1
sasg6
(lp6857
(dp6858
g9
I110
sg10
VC0024141
p6859
sg12
I28
sg13
Vsystemic lupus erythematosus
p6860
sg15
I3
sa(dp6861
g9
I140
sg10
VC0024141
p6862
sg12
I3
sg13
VSLE
p6863
sg15
I1
sa(dp6864
g9
I80
sg10
VC0004368
p6865
sg12
I12
sg13
Vautoimmunity
p6866
sg15
I1
sasa(dp6867
g2
VTo establish the cytologic and immunocytochemical features of lymphangioleiomyomatosis (LAM) cell clusters (LCCs) and to clarify its diagnostic significance for LAM.
p6868
sg4
(lp6869
sg6
(lp6870
(dp6871
g9
I108
sg10
VC1854664
p6872
sg12
I4
sg13
VLCCs
p6873
sg15
I1
sa(dp6874
g9
I62
sg10
VC0751674
p6875
sg12
I24
sg13
Vlymphangioleiomyomatosis
p6876
sg15
I1
sa(dp6877
g9
I88
sg10
VC0751674
p6878
sg12
I3
sg13
VLAM
p6879
sg15
I1
sa(dp6880
g9
I88
sg10
VC0751674
p6881
sg12
I3
sg13
VLAM
p6882
sg15
I1
sasa(dp6883
g2
VThis study aimed to evaluate fibrosis and elastin destruction in childhood interstitial lung disease (chILD) patients.
p6884
sg4
(lp6885
(dp6886
g9
I42
sg20
VP49918
p6887
sg12
I7
sg13
Velastin
p6888
sg15
I1
sasg6
(lp6889
(dp6890
g9
I75
sg10
VC0206062
p6891
sg12
I25
sg13
Vinterstitial lung disease
p6892
sg15
I3
sa(dp6893
g9
I29
sg10
VC0016059
p6894
sg12
I8
sg13
Vfibrosis
p6895
sg15
I1
sasa(dp6896
g2
VInhibitors of the cGMP-degrading phosphodiesterase (PDE) 5 have achieved blockbuster status in the treatment of penile erectile dysfunction (PED).
p6897
sg4
(lp6898
(dp6899
g9
I52
sg20
VP49419
p6900
sg12
I3
sg13
VPDE
p6901
sg15
I1
sa(dp6902
g9
I18
sg20
VP22413
p6903
sg12
I32
sg13
VcGMP-degrading phosphodiesterase
p6904
sg15
I2
sasg6
(lp6905
(dp6906
g9
I52
sg10
VC1849508
p6907
sg12
I3
sg13
VPDE
p6908
sg15
I1
sa(dp6909
g9
I33
sg10
VC1849508
p6910
sg12
I17
sg13
Vphosphodiesterase
p6911
sg15
I1
sa(dp6912
g9
I119
sg10
VC0242350
p6913
sg12
I20
sg13
Verectile dysfunction
p6914
sg15
I2
sasa(dp6915
g2
VTo compare the effectiveness of the phosphodiesterase type 5 inhibitor (PDE-5i) tadalafil alone and in combination with a biologically active dietary supplement (BADS) NeyroDoz, containing the precursors of serotonin in patients with erectile dysfunction (ED) associated with secondary premature ejaculation (SPE).
p6916
sg4
(lp6917
(dp6918
g9
I36
sg20
VP22413
p6919
sg12
I34
sg13
Vphosphodiesterase type 5 inhibitor
p6920
sg15
I4
sa(dp6921
g9
I72
sg20
VP49419
p6922
sg12
I6
sg13
VPDE-5i
p6923
sg15
I1
sasg6
(lp6924
(dp6925
g9
I72
sg10
VC1849508
p6926
sg12
I3
sg13
VPDE
p6927
sg15
I1
sa(dp6928
g9
I286
sg10
VC0033038
p6929
sg12
I21
sg13
Vpremature ejaculation
p6930
sg15
I2
sa(dp6931
g9
I256
sg10
VC0242350
p6932
sg12
I2
sg13
VED
p6933
sg15
I1
sa(dp6934
g9
I234
sg10
VC0242350
p6935
sg12
I20
sg13
Verectile dysfunction
p6936
sg15
I2
sasa(dp6937
g2
VOf these enzymes, PDE5 has attracted a special attention over the years after its recognition as being the target enzyme in treating erectile dysfunction.
p6938
sg4
(lp6939
(dp6940
g9
I18
sg20
g21
sg12
I4
sg13
VPDE5
p6941
sg15
I1
sasg6
(lp6942
(dp6943
g9
I133
sg10
VC0242350
p6944
sg12
I20
sg13
Verectile dysfunction
p6945
sg15
I2
sasa(dp6946
g2
VPhosphodiesterase (PDE) 5 inhibitor induced muscle relaxation in corporal smooth muscle cells and was used to treat erectile dysfunction by inhibiting cGMP degradation.
p6947
sg4
(lp6948
(dp6949
g9
I0
sg20
VP22413
p6950
sg12
I25
sg13
VPhosphodiesterase (PDE) 5
p6951
sg15
I3
sasg6
(lp6952
(dp6953
g9
I0
sg10
VC1849508
p6954
sg12
I17
sg13
VPhosphodiesterase
p6955
sg15
I1
sa(dp6956
g9
I19
sg10
VC1849508
p6957
sg12
I3
sg13
VPDE
p6958
sg15
I1
sa(dp6959
g9
I44
sg10
VC0700323
p6960
sg12
I17
sg13
Vmuscle relaxation
p6961
sg15
I2
sa(dp6962
g9
I116
sg10
VC0242350
p6963
sg12
I20
sg13
Verectile dysfunction
p6964
sg15
I2
sasa(dp6965
g2
VCyclic guanosine monophosphate (cGMP)-specific phosphodiesterase (PDE) inhibitors are hypothesized to improve cognition in schizophrenia and Alzheimer disease by increasing cGMP levels in certain brain regions.
p6966
sg4
(lp6967
(dp6968
g9
I66
sg20
VP49419
p6969
sg12
I3
sg13
VPDE
p6970
sg15
I1
sa(dp6971
g9
I0
sg20
VP22413
p6972
sg12
I64
sg13
VCyclic guanosine monophosphate (cGMP)-specific phosphodiesterase
p6973
sg15
I5
sasg6
(lp6974
(dp6975
g9
I47
sg10
VC1849508
p6976
sg12
I17
sg13
Vphosphodiesterase
p6977
sg15
I1
sa(dp6978
g9
I141
sg10
VC0002395
p6979
sg12
I17
sg13
VAlzheimer disease
p6980
sg15
I2
sa(dp6981
g9
I123
sg10
VC0036341
p6982
sg12
I13
sg13
Vschizophrenia
p6983
sg15
I1
sa(dp6984
g9
I66
sg10
VC1849508
p6985
sg12
I3
sg13
VPDE
p6986
sg15
I1
sasa(dp6987
g2
VTo find out whether increased spinal nociception represents a premotor feature, experimental pain sensitivity was assessed in idiopathic REM-sleep behavior disorder (IRBD) patients with or without signs of a neurodegenerative disorder compared to early Parkinson's disease (ePD) patients and healthy controls (HC).
p6988
sg4
(lp6989
sg6
(lp6990
(dp6991
g9
I247
sg10
VC1849508
p6992
sg12
I25
sg13
Vearly Parkinson's disease
p6993
sg15
I3
sa(dp6994
g9
I208
sg10
VC0524851
p6995
sg12
I26
sg13
Vneurodegenerative disorder
p6996
sg15
I2
sa(dp6997
g9
I147
sg10
VC0004930
p6998
sg12
I17
sg13
Vbehavior disorder
p6999
sg15
I2
sa(dp7000
g9
I274
sg10
VC1849508
p7001
sg12
I3
sg13
VePD
p7002
sg15
I1
sasa(dp7003
g2
VPhosphodiesterase (PDE) inhibitors are currently under evaluation as agents that may facilitate the improvement of cognitive impairment associated with Alzheimer's disease.
p7004
sg4
(lp7005
(dp7006
g9
I0
sg20
VP22413
p7007
sg12
I23
sg13
VPhosphodiesterase (PDE)
p7008
sg15
I2
sasg6
(lp7009
(dp7010
g9
I0
sg10
VC1849508
p7011
sg12
I17
sg13
VPhosphodiesterase
p7012
sg15
I1
sa(dp7013
g9
I152
sg10
VC1521724
p7014
sg12
I19
sg13
VAlzheimer's disease
p7015
sg15
I2
sa(dp7016
g9
I19
sg10
VC1849508
p7017
sg12
I3
sg13
VPDE
p7018
sg15
I1
sa(dp7019
g9
I115
sg10
VC0338656
p7020
sg12
I20
sg13
Vcognitive impairment
p7021
sg15
I2
sasa(dp7022
g2
VNotably, much experimental and clinical evidence show that PXR senses xenobiotics and triggers the detoxification response to prevent diseases such as diabetes, obesity, intestinal inflammatory diseases and liver fibrosis.
p7023
sg4
(lp7024
sg6
(lp7025
(dp7026
g9
I161
sg10
VC0028754
p7027
sg12
I7
sg13
Vobesity
p7028
sg15
I1
sa(dp7029
g9
I151
sg10
VC0011849
p7030
sg12
I8
sg13
Vdiabetes
p7031
sg15
I1
sa(dp7032
g9
I99
sg10
VC1622680
p7033
sg12
I23
sg13
Vdetoxification response
p7034
sg15
I2
sa(dp7035
g9
I207
sg10
VC0239946
p7036
sg12
I14
sg13
Vliver fibrosis
p7037
sg15
I2
sasa(dp7038
g2
VRescued Tg(INV-Cst6)Cst6ichq/ichq mice survive the neonatal phase, but display severe eye pathology and alopecia after 4 mo.
p7039
sg4
(lp7040
(dp7041
g9
I11
sg20
g21
sg12
I8
sg13
VINV-Cst6
p7042
sg15
I1
sasg6
(lp7043
(dp7044
g9
I90
sg10
VC0677042
p7045
sg12
I9
sg13
Vpathology
p7046
sg15
I1
sasa(dp7047
g2
VIntriguingly, both Cst6(-/-)Ctsl(-/-) and Cst6(-/-)Ctsl(+/-) mice were viable, but the absence of cystatin M/E caused scarring alopecia in adult animals.
p7048
sg4
(lp7049
(dp7050
g9
I19
sg20
VP04080
p7051
sg12
I4
sg13
VCst6
p7052
sg15
I1
sa(dp7053
g9
I19
sg20
VP04080
p7054
sg12
I4
sg13
VCst6
p7055
sg15
I1
sa(dp7056
g9
I98
sg20
g21
sg12
I12
sg13
Vcystatin M/E
p7057
sg15
I2
sasg6
(lp7058
(dp7059
g9
I118
sg10
VC2936846
p7060
sg12
I17
sg13
Vscarring alopecia
p7061
sg15
I2
sasa(dp7062
g2
VTranscription factor 4 (TCF-4) was recently identified as a candidate gene for the cause of type 2 diabetes, although the mechanisms have not been fully elucidated.
p7063
sg4
(lp7064
(dp7065
g9
I0
sg20
VP15884
p7066
sg12
I22
sg13
VTranscription factor 4
p7067
sg15
I3
sa(dp7068
g9
I24
sg20
VP15884
p7069
sg12
I5
sg13
VTCF-4
p7070
sg15
I1
sasg6
(lp7071
(dp7072
g9
I92
sg10
VC0011860
p7073
sg12
I15
sg13
Vtype 2 diabetes
p7074
sg15
I3
sasa(dp7075
g2
VCollectively, these observations demonstrate a disease-promoting role of E2-2 dependent pDCs in the pancreas during autoimmune diabetes in the NOD mouse.
p7076
sg4
(lp7077
(dp7078
g9
I73
sg20
VP15884
p7079
sg12
I4
sg13
VE2-2
p7080
sg15
I1
sasg6
(lp7081
(dp7082
g9
I143
sg10
VC0751781
p7083
sg12
I3
sg13
VNOD
p7084
sg15
I1
sa(dp7085
g9
I116
sg10
VC0205734
p7086
sg12
I19
sg13
Vautoimmune diabetes
p7087
sg15
I2
sasa(dp7088
g2
VFecal incontinence and constipation still remain the major complications after procedures for anorectal malformations (ARMs).
p7089
sg4
(lp7090
sg6
(lp7091
(dp7092
g9
I23
sg10
VC0009806
p7093
sg12
I12
sg13
Vconstipation
p7094
sg15
I1
sa(dp7095
g9
I94
sg10
VC2974527
p7096
sg12
I23
sg13
Vanorectal malformations
p7097
sg15
I2
sa(dp7098
g9
I119
sg10
VC0206655
p7099
sg12
I4
sg13
VARMs
p7100
sg15
I1
sa(dp7101
g9
I0
sg10
VC0015732
p7102
sg12
I18
sg13
VFecal incontinence
p7103
sg15
I2
sasa(dp7104
g2
VNumerous patients with anorectal malformations (ARMs) continue to experience fecal incontinence and constipation following surgical procedures.
p7105
sg4
(lp7106
sg6
(lp7107
(dp7108
g9
I100
sg10
VC0009806
p7109
sg12
I12
sg13
Vconstipation
p7110
sg15
I1
sa(dp7111
g9
I48
sg10
VC0206655
p7112
sg12
I4
sg13
VARMs
p7113
sg15
I1
sa(dp7114
g9
I77
sg10
VC0015732
p7115
sg12
I18
sg13
Vfecal incontinence
p7116
sg15
I2
sa(dp7117
g9
I23
sg10
VC2974527
p7118
sg12
I23
sg13
Vanorectal malformations
p7119
sg15
I2
sasa(dp7120
g2
VOver the last two decades, advances in laparoscopic surgery and minimally invasive techniques have transformed the operative management of neonatal colorectal surgery for conditions such as anorectal malformations (ARMs) and Hirschsprung's disease.
p7121
sg4
(lp7122
sg6
(lp7123
(dp7124
g9
I215
sg10
VC0206655
p7125
sg12
I4
sg13
VARMs
p7126
sg15
I1
sa(dp7127
g9
I190
sg10
VC2974527
p7128
sg12
I23
sg13
Vanorectal malformations
p7129
sg15
I2
sa(dp7130
g9
I225
sg10
VC0019569
p7131
sg12
I22
sg13
VHirschsprung's disease
p7132
sg15
I2
sasa(dp7133
g2
VThis review describes these advances and outlines the main minimally invasive techniques currently used for management of ARMs and Hirschsprung's disease.
p7134
sg4
(lp7135
sg6
(lp7136
(dp7137
g9
I122
sg10
VC0206655
p7138
sg12
I4
sg13
VARMs
p7139
sg15
I1
sa(dp7140
g9
I131
sg10
VC0019569
p7141
sg12
I22
sg13
VHirschsprung's disease
p7142
sg15
I2
sasa(dp7143
g2
VFurther analysis of the PRKAG3 signaling pathway may provide insights into muscle physiology as well as the pathogenesis of noninsulin-dependent diabetes mellitus in humans, a metabolic disorder associated with impaired glycogen synthesis.
p7144
sg4
(lp7145
(dp7146
g9
I24
sg20
g21
sg12
I6
sg13
VPRKAG3
p7147
sg15
I1
sasg6
(lp7148
(dp7149
g9
I211
sg10
VC0684336
p7150
sg12
I8
sg13
Vimpaired
p7151
sg15
I1
sa(dp7152
g9
I124
sg10
VC0011860
p7153
sg12
I38
sg13
Vnoninsulin-dependent diabetes mellitus
p7154
sg15
I3
sa(dp7155
g9
I176
sg10
VC0025517
p7156
sg12
I18
sg13
Vmetabolic disorder
p7157
sg15
I2
sa(dp7158
g9
I108
sg10
VC0699748
p7159
sg12
I12
sg13
Vpathogenesis
p7160
sg15
I1
sasa(dp7161
g2
VIn primates, a PGBD3 element inserted into the Cockayne syndrome group B (CSB) gene over 43 Mya serves as an alternative 3' terminal exon, enabling the CSB gene to generate both full length CSB and a conserved CSB-PGBD3 fusion protein that joins an N-terminal CSB domain to the C-terminal transposase domain.
p7162
sg4
(lp7163
(dp7164
g9
I152
sg20
VP35548
p7165
sg12
I8
sg13
VCSB gene
p7166
sg15
I2
sa(dp7167
g9
I278
sg20
g21
sg12
I29
sg13
VC-terminal transposase domain
p7168
sg15
I3
sa(dp7169
g9
I74
sg20
VP35548
p7170
sg12
I3
sg13
VCSB
p7171
sg15
I1
sa(dp7172
g9
I15
sg20
g21
sg12
I13
sg13
VPGBD3 element
p7173
sg15
I2
sa(dp7174
g9
I15
sg20
g21
sg12
I5
sg13
VPGBD3
p7175
sg15
I1
sa(dp7176
g9
I47
sg20
VP35548
p7177
sg12
I25
sg13
VCockayne syndrome group B
p7178
sg15
I4
sa(dp7179
g9
I74
sg20
VP35548
p7180
sg12
I3
sg13
VCSB
p7181
sg15
I1
sasg6
(lp7182
(dp7183
g9
I74
sg10
VC1858160
p7184
sg12
I3
sg13
VCSB
p7185
sg15
I1
sa(dp7186
g9
I74
sg10
VC1858160
p7187
sg12
I3
sg13
VCSB
p7188
sg15
I1
sa(dp7189
g9
I74
sg10
VC1858160
p7190
sg12
I3
sg13
VCSB
p7191
sg15
I1
sa(dp7192
g9
I47
sg10
VC1858160
p7193
sg12
I25
sg13
VCockayne syndrome group B
p7194
sg15
I4
sa(dp7195
g9
I74
sg10
VC1858160
p7196
sg12
I3
sg13
VCSB
p7197
sg15
I1
sa(dp7198
g9
I74
sg10
VC1858160
p7199
sg12
I3
sg13
VCSB
p7200
sg15
I1
sasa(dp7201
g2
VThe CSB-PGBD3 fusion protein arose more than 43 million years ago when a 2.5-kb piggyBac 3 (PGBD3) transposon inserted into intron 5 of the Cockayne syndrome Group B (CSB) gene in the common ancestor of all higher primates.
p7202
sg4
(lp7203
(dp7204
g9
I4
sg20
VP35548
p7205
sg12
I3
sg13
VCSB
p7206
sg15
I1
sa(dp7207
g9
I8
sg20
g21
sg12
I5
sg13
VPGBD3
p7208
sg15
I1
sa(dp7209
g9
I8
sg20
g21
sg12
I5
sg13
VPGBD3
p7210
sg15
I1
sa(dp7211
g9
I4
sg20
VP35548
p7212
sg12
I3
sg13
VCSB
p7213
sg15
I1
sa(dp7214
g9
I140
sg20
VP35548
p7215
sg12
I25
sg13
VCockayne syndrome Group B
p7216
sg15
I4
sasg6
(lp7217
(dp7218
g9
I4
sg10
VC1858160
p7219
sg12
I3
sg13
VCSB
p7220
sg15
I1
sa(dp7221
g9
I140
sg10
VC1858160
p7222
sg12
I25
sg13
VCockayne syndrome Group B
p7223
sg15
I4
sa(dp7224
g9
I4
sg10
VC1858160
p7225
sg12
I3
sg13
VCSB
p7226
sg15
I1
sasa(dp7227
g2
VOur data suggest that the CSB-PGBD3 fusion protein is important in both health and disease, and could play a role in Cockayne syndrome.
p7228
sg4
(lp7229
(dp7230
g9
I30
sg20
g21
sg12
I5
sg13
VPGBD3
p7231
sg15
I1
sa(dp7232
g9
I26
sg20
VP35548
p7233
sg12
I3
sg13
VCSB
p7234
sg15
I1
sasg6
(lp7235
(dp7236
g9
I117
sg10
VC0009207
p7237
sg12
I17
sg13
VCockayne syndrome
p7238
sg15
I2
sa(dp7239
g9
I26
sg10
VC1858160
p7240
sg12
I3
sg13
VCSB
p7241
sg15
I1
sasa(dp7242
g2
VIn this study, we searched for cerebral MBs in cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), a unique type of small-vessel disease caused by mutations in the Notch3 gene.
p7243
sg4
(lp7244
(dp7245
g9
I214
sg20
g21
sg12
I11
sg13
VNotch3 gene
p7246
sg15
I2
sasg6
(lp7247
(dp7248
g9
I47
sg10
VC0751587
p7249
sg12
I90
sg13
Vcerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy
p7250
sg15
I9
sa(dp7251
g9
I139
sg10
VC0751587
p7252
sg12
I7
sg13
VCADASIL
p7253
sg15
I1
sa(dp7254
g9
I40
sg10
VC0221060
p7255
sg12
I3
sg13
VMBs
p7256
sg15
I1
sasa(dp7257
g2
VOur purposes were (1) to determine the frequency, extent, and pattern of MBs in CADASIL; (2) to analyze the relationship between MBs and T2-hyperintense lesions; and (3) to evaluate the histopathology of brain tissue affected by MBs.
p7258
sg4
(lp7259
(dp7260
g9
I73
sg20
g21
sg12
I3
sg13
VMBs
p7261
sg15
I1
sasg6
(lp7262
(dp7263
g9
I73
sg10
VC0221060
p7264
sg12
I3
sg13
VMBs
p7265
sg15
I1
sa(dp7266
g9
I73
sg10
VC0221060
p7267
sg12
I3
sg13
VMBs
p7268
sg15
I1
sa(dp7269
g9
I73
sg10
VC0221060
p7270
sg12
I3
sg13
VMBs
p7271
sg15
I1
sa(dp7272
g9
I80
sg10
VC0751587
p7273
sg12
I7
sg13
VCADASIL
p7274
sg15
I1
sasa(dp7275
g2
VFocal areas of signal loss on gradient-echo images suggesting past MBs were found in 11 CADASIL individuals (69%) and no control subjects (P&lt;0.001).
p7276
sg4
(lp7277
(dp7278
g9
I67
sg20
g21
sg12
I3
sg13
VMBs
p7279
sg15
I1
sasg6
(lp7280
(dp7281
g9
I67
sg10
VC0221060
p7282
sg12
I3
sg13
VMBs
p7283
sg15
I1
sa(dp7284
g9
I88
sg10
VC0751587
p7285
sg12
I7
sg13
VCADASIL
p7286
sg15
I1
sasa(dp7287
g2
VThe average number of MBs was 5.9+/-7.3 (range, 0 to 22) in individual CADASIL patients.
p7288
sg4
(lp7289
sg6
(lp7290
(dp7291
g9
I22
sg10
VC0221060
p7292
sg12
I3
sg13
VMBs
p7293
sg15
I1
sa(dp7294
g9
I71
sg10
VC0751587
p7295
sg12
I7
sg13
VCADASIL
p7296
sg15
I1
sasa(dp7297
g2
VThis study shows a high frequency and multiplicity of MBs in individuals with CADASIL.
p7298
sg4
(lp7299
sg6
(lp7300
(dp7301
g9
I78
sg10
VC0751587
p7302
sg12
I7
sg13
VCADASIL
p7303
sg15
I1
sa(dp7304
g9
I54
sg10
VC0221060
p7305
sg12
I3
sg13
VMBs
p7306
sg15
I1
sasa(dp7307
g2
VAt stimulation, the tubulovesicles fuse with the apical canaliculi and the HK-ATPase is incorporated into the apical membrane where it actively pumps H ions in exchange for K. Acute infection with Helicobacter pylori results in hypochlorhydria, whereas chronic infection can cause either hypo- or hyperchlorhydria, depending on the distribution of the infection and the degree of corpus gastritis.
p7308
sg4
(lp7309
(dp7310
g9
I75
sg20
VP38606
p7311
sg12
I9
sg13
VHK-ATPase
p7312
sg15
I1
sasg6
(lp7313
(dp7314
g9
I176
sg10
VC0275518
p7315
sg12
I15
sg13
VAcute infection
p7316
sg15
I2
sa(dp7317
g9
I297
sg10
VC0151713
p7318
sg12
I16
sg13
Vhyperchlorhydria
p7319
sg15
I1
sa(dp7320
g9
I253
sg10
VC0151317
p7321
sg12
I17
sg13
Vchronic infection
p7322
sg15
I2
sa(dp7323
g9
I182
sg10
VC0009450
p7324
sg12
I9
sg13
Vinfection
p7325
sg15
I1
sa(dp7326
g9
I387
sg10
VC0017152
p7327
sg12
I9
sg13
Vgastritis
p7328
sg15
I1
sa(dp7329
g9
I228
sg10
VC0079581
p7330
sg12
I15
sg13
Vhypochlorhydria
p7331
sg15
I1
sasa(dp7332
g2
VThe results directly confirm that the gastric H+/K(+)-ATPase is the causative autoantigen in the genesis of autoimmune gastritis.
p7333
sg4
(lp7334
(dp7335
g9
I38
sg20
VP38606
p7336
sg12
I22
sg13
Vgastric H+/K(+)-ATPase
p7337
sg15
I2
sasg6
(lp7338
(dp7339
g9
I108
sg10
VC0017154
p7340
sg12
I20
sg13
Vautoimmune gastritis
p7341
sg15
I2
sasa(dp7342
g2
VWe conclude that the beta subunit of the gastric H/K ATPase is a major T cell target in autoimmune gastritis and that thymic expression of a single autoantigen can abrogate an autoimmune response to multiple autoantigens.
p7343
sg4
(lp7344
(dp7345
g9
I41
sg20
VP38606
p7346
sg12
I18
sg13
Vgastric H/K ATPase
p7347
sg15
I3
sasg6
(lp7348
(dp7349
g9
I176
sg10
VC0004366
p7350
sg12
I19
sg13
Vautoimmune response
p7351
sg15
I2
sa(dp7352
g9
I88
sg10
VC0017154
p7353
sg12
I20
sg13
Vautoimmune gastritis
p7354
sg15
I2
sasa(dp7355
g2
V8 cases of pneumophathia osteoplastica (ppo) of branching type observed at patients having no vascular deformities and one case of a focal ppo at a patient with mitral stenosis are reported.
p7356
sg4
(lp7357
(dp7358
g9
I40
sg20
VP50336
p7359
sg12
I3
sg13
Vppo
p7360
sg15
I1
sasg6
(lp7361
(dp7362
g9
I161
sg10
VC0026269
p7363
sg12
I15
sg13
Vmitral stenosis
p7364
sg15
I2
sa(dp7365
g9
I103
sg10
VC0000768
p7366
sg12
I11
sg13
Vdeformities
p7367
sg15
I1
sasa(dp7368
g2
VCDKN3 is often overexpressed in human cancer, and this overexpression correlates with reduced survival in several types of cancer.
p7369
sg4
(lp7370
sg6
(lp7371
(dp7372
g9
I38
sg10
VC0006826
p7373
sg12
I6
sg13
Vcancer
p7374
sg15
I1
sa(dp7375
g9
I38
sg10
VC0006826
p7376
sg12
I6
sg13
Vcancer
p7377
sg15
I1
sasa(dp7378
g2
VThe mechanism of CDKN3 overexpression and the role of CDKN3 transcript variants in human cancer are not entirely clear.
p7379
sg4
(lp7380
(dp7381
g9
I54
sg20
VP26640
p7382
sg12
I25
sg13
VCDKN3 transcript variants
p7383
sg15
I3
sasg6
(lp7384
(dp7385
g9
I89
sg10
VC0006826
p7386
sg12
I6
sg13
Vcancer
p7387
sg15
I1
sasa(dp7388
g2
VBesides the full-length CDKN3 encoding transcript and a major transcript that skips exon 2 express in normal and cancer cells, minor aberrant transcript variants have been reported.
p7389
sg4
(lp7390
sg6
(lp7391
(dp7392
g9
I113
sg10
VC0006826
p7393
sg12
I6
sg13
Vcancer
p7394
sg15
I1
sasa(dp7395
g2
VAberrant CDKN3 transcripts were postulated to encode dominant-negative inhibitors of CDKN3 as an explanation for overexpression of the perceived tumor suppressor gene in human cancer.
p7396
sg4
(lp7397
sg6
(lp7398
(dp7399
g9
I145
sg10
VC0027651
p7400
sg12
I5
sg13
Vtumor
p7401
sg15
I1
sa(dp7402
g9
I176
sg10
VC0006826
p7403
sg12
I6
sg13
Vcancer
p7404
sg15
I1
sasa(dp7405
g2
VHowever, while CDKN3 is often overexpressed in human cancer, aberrant CDKN3 transcripts occur infrequently and at lower levels.
p7406
sg4
(lp7407
sg6
(lp7408
(dp7409
g9
I53
sg10
VC0006826
p7410
sg12
I6
sg13
Vcancer
p7411
sg15
I1
sasa(dp7412
g2
VCDKN3 mutations and copy number alternation are rare in human cancer, implying that neither loss of CDKN3 activity nor constitutive gain of CDKN3 expression offer an advantage to tumorigenesis.
p7413
sg4
(lp7414
sg6
(lp7415
(dp7416
g9
I179
sg10
VC0007621
p7417
sg12
I13
sg13
Vtumorigenesis
p7418
sg15
I1
sa(dp7419
g9
I62
sg10
VC0006826
p7420
sg12
I6
sg13
Vcancer
p7421
sg15
I1
sa(dp7422
g9
I32
sg10
VC0919661
p7423
sg12
I11
sg13
Valternation
p7424
sg15
I1
sasa(dp7425
g2
VGiven that rapidly growing tumors have more mitotic cells, the high level of mitotic CDKN3 expression is the most plausible mechanism of frequent CDKN3 overexpression in human cancer.
p7426
sg4
(lp7427
sg6
(lp7428
(dp7429
g9
I27
sg10
VC0027651
p7430
sg12
I6
sg13
Vtumors
p7431
sg15
I1
sa(dp7432
g9
I176
sg10
VC0006826
p7433
sg12
I6
sg13
Vcancer
p7434
sg15
I1
sasa(dp7435
g2
VThis finding clarifies the mechanism of CDKN3 overexpression in human cancer and questions the view of CDKN3 as a tumor suppressor.
p7436
sg4
(lp7437
sg6
(lp7438
(dp7439
g9
I70
sg10
VC0006826
p7440
sg12
I6
sg13
Vcancer
p7441
sg15
I1
sa(dp7442
g9
I114
sg10
VC0027651
p7443
sg12
I5
sg13
Vtumor
p7444
sg15
I1
sasa(dp7445
g2
VAbnormal expression of CDKN3 has been found in numerous types of cancer.
p7446
sg4
(lp7447
sg6
(lp7448
(dp7449
g9
I65
sg10
VC0006826
p7450
sg12
I6
sg13
Vcancer
p7451
sg15
I1
sasa(dp7452
g2
VSince it is unclear whether CDKN3 participates in the development of human gastric cancer, this study assessed the association between CDKN3 expression and cell biological function and demonstrated the clinical significance and prognosis of CDKN3 in human gastric cancer.
p7453
sg4
(lp7454
sg6
(lp7455
(dp7456
g9
I75
sg10
VC0024623
p7457
sg12
I14
sg13
Vgastric cancer
p7458
sg15
I2
sa(dp7459
g9
I75
sg10
VC0024623
p7460
sg12
I14
sg13
Vgastric cancer
p7461
sg15
I2
sasa(dp7462
g2
VIn this study, we found that CDKN3 showed a high expression in 35 paired human gastric cancer tissues and was correlated with poor patient survival, AJCC clinical staging, and recurrence.
p7463
sg4
(lp7464
sg6
(lp7465
(dp7466
g9
I79
sg10
VC0024623
p7467
sg12
I14
sg13
Vgastric cancer
p7468
sg15
I2
sa(dp7469
g9
I176
sg10
VC1458156
p7470
sg12
I10
sg13
Vrecurrence
p7471
sg15
I1
sasa(dp7472
g2
VSilencing of CDKN3 in human gastric cancer cells can significantly reduce proliferation, migration, invasion, and adhesion abilities.
p7473
sg4
(lp7474
sg6
(lp7475
(dp7476
g9
I100
sg10
VC2699153
p7477
sg12
I8
sg13
Vinvasion
p7478
sg15
I1
sa(dp7479
g9
I28
sg10
VC0024623
p7480
sg12
I14
sg13
Vgastric cancer
p7481
sg15
I2
sa(dp7482
g9
I74
sg10
VC0334094
p7483
sg12
I13
sg13
Vproliferation
p7484
sg15
I1
sa(dp7485
g9
I114
sg10
VC0001511
p7486
sg12
I8
sg13
Vadhesion
p7487
sg15
I1
sasa(dp7488
g2
VAlso, silencing of CDKN3 in human gastric cancer cells can induce G0-G1 cell cycle arrest and apoptosis.
p7489
sg4
(lp7490
sg6
(lp7491
(dp7492
g9
I34
sg10
VC0024623
p7493
sg12
I14
sg13
Vgastric cancer
p7494
sg15
I2
sasa(dp7495
g2
VDetection of cell cycle marker expression showed that CDKN3 knockdown promotes cell cycle arrest by decreasing the expression of CDK2, CDC25A, CCNB1, and CCNB2 in human gastric cancer cells.
p7496
sg4
(lp7497
(dp7498
g9
I129
sg20
VP24941
p7499
sg12
I4
sg13
VCDK2
p7500
sg15
I1
sa(dp7501
g9
I154
sg20
g21
sg12
I5
sg13
VCCNB2
p7502
sg15
I1
sa(dp7503
g9
I143
sg20
VP14635
p7504
sg12
I5
sg13
VCCNB1
p7505
sg15
I1
sa(dp7506
g9
I135
sg20
VP30304
p7507
sg12
I6
sg13
VCDC25A
p7508
sg15
I1
sasg6
(lp7509
(dp7510
g9
I169
sg10
VC0024623
p7511
sg12
I14
sg13
Vgastric cancer
p7512
sg15
I2
sasa(dp7513
g2
VThe results of this study will help elucidate the oncogene function of CDKN3 in human gastric cancer.
p7514
sg4
(lp7515
sg6
(lp7516
(dp7517
g9
I86
sg10
VC0024623
p7518
sg12
I14
sg13
Vgastric cancer
p7519
sg15
I2
sasa(dp7520
g2
VHowever, whether CDKN3 is a potential therapeutic target for breast cancer remains to be elucidated.
p7521
sg4
(lp7522
sg6
(lp7523
(dp7524
g9
I61
sg10
VC0678222
p7525
sg12
I13
sg13
Vbreast cancer
p7526
sg15
I2
sasa(dp7527
g2
VThe present in vitro study aimed to investigate the potential roles of CDKN3 in breast cancer.
p7528
sg4
(lp7529
sg6
(lp7530
(dp7531
g9
I80
sg10
VC0678222
p7532
sg12
I13
sg13
Vbreast cancer
p7533
sg15
I2
sasa(dp7534
g2
VBreast cancer cell lines were used to detect CDKN3 expression, and CDKN3 expression was silenced to investigate its role in cell apoptosis, cell cycle arrest and migration.
p7535
sg4
(lp7536
sg6
(lp7537
(dp7538
g9
I0
sg10
VC0678222
p7539
sg12
I13
sg13
VBreast cancer
p7540
sg15
I2
sasa(dp7541
g2
VThese results suggest that CDKN3 acts as an oncogene during breast cancer progression.
p7542
sg4
(lp7543
sg6
(lp7544
(dp7545
g9
I67
sg10
VC0178874
p7546
sg12
I18
sg13
Vcancer progression
p7547
sg15
I2
sasa(dp7548
g2
VCDKN3 may therefore be considered a potential target for the treatment of breast cancer.
p7549
sg4
(lp7550
sg6
(lp7551
(dp7552
g9
I74
sg10
VC0678222
p7553
sg12
I13
sg13
Vbreast cancer
p7554
sg15
I2
sasa(dp7555
g2
VParadoxically, CDKN3 is often overexpressed in human cancer.
p7556
sg4
(lp7557
sg6
(lp7558
(dp7559
g9
I53
sg10
VC0006826
p7560
sg12
I6
sg13
Vcancer
p7561
sg15
I1
sasa(dp7562
g2
VWe analysed CDKN3 expression and its association with patient survival in three cohorts of lung adenocarcinoma.
p7563
sg4
(lp7564
sg6
(lp7565
(dp7566
g9
I91
sg10
VC0152013
p7567
sg12
I19
sg13
Vlung adenocarcinoma
p7568
sg15
I2
sasa(dp7569
g2
VWe also examined CDKN3 mutations in the Cancer Genome Atlas (TCGA) and the Moffitt Cancer Center's Total Cancer Care (TCC) projects.
p7570
sg4
(lp7571
sg6
(lp7572
(dp7573
g9
I40
sg10
VC0006826
p7574
sg12
I6
sg13
VCancer
p7575
sg15
I1
sa(dp7576
g9
I118
sg10
VC1861305
p7577
sg12
I3
sg13
VTCC
p7578
sg15
I1
sa(dp7579
g9
I40
sg10
VC0006826
p7580
sg12
I6
sg13
VCancer
p7581
sg15
I1
sa(dp7582
g9
I99
sg10
VC1861305
p7583
sg12
I17
sg13
VTotal Cancer Care
p7584
sg15
I3
sasa(dp7585
g2
VCDKN3 transcripts were further analysed in a panel of cell lines and lung adenocarcinoma tissues.
p7586
sg4
(lp7587
sg6
(lp7588
(dp7589
g9
I69
sg10
VC0152013
p7590
sg12
I19
sg13
Vlung adenocarcinoma
p7591
sg15
I2
sasa(dp7592
g2
VCDKN3 is overexpressed in non small cell lung cancer.
p7593
sg4
(lp7594
sg6
(lp7595
(dp7596
g9
I26
sg10
VC0007131
p7597
sg12
I26
sg13
Vnon small cell lung cancer
p7598
sg15
I5
sasa(dp7599
g2
VHigh CDKN3 expression is associated with poor overall survival in lung adenocarcinoma.
p7600
sg4
(lp7601
sg6
(lp7602
(dp7603
g9
I66
sg10
VC0152013
p7604
sg12
I19
sg13
Vlung adenocarcinoma
p7605
sg15
I2
sasa(dp7606
g2
VCDKN3 overexpression is prognostic of poor overall survival in lung adenocarcinoma.
p7607
sg4
(lp7608
sg6
(lp7609
(dp7610
g9
I63
sg10
VC0152013
p7611
sg12
I19
sg13
Vlung adenocarcinoma
p7612
sg15
I2
sasa(dp7613
g2
VCDKN3 overexpression in lung adenocarcinoma is not attributed to alternative splicing or mutation but is likely due to increased mitotic activity, arguing against CDKN3 as a tumour suppressor.
p7614
sg4
(lp7615
sg6
(lp7616
(dp7617
g9
I174
sg10
VC0027651
p7618
sg12
I6
sg13
Vtumour
p7619
sg15
I1
sa(dp7620
g9
I24
sg10
VC0152013
p7621
sg12
I19
sg13
Vlung adenocarcinoma
p7622
sg15
I2
sasa(dp7623
g2
VThe cyclin-dependent kinase inhibitor 3 (CDKN3) gene, involved in mitosis, is upregulated in cervical cancer (CC).
p7624
sg4
(lp7625
(dp7626
g9
I4
sg20
VP38936
p7627
sg12
I35
sg13
Vcyclin-dependent kinase inhibitor 3
p7628
sg15
I4
sa(dp7629
g9
I41
sg20
VP38936
p7630
sg12
I5
sg13
VCDKN3
p7631
sg15
I1
sasg6
(lp7632
(dp7633
g9
I93
sg10
VC0302592
p7634
sg12
I15
sg13
Vcervical cancer
p7635
sg15
I2
sasa(dp7636
g2
VThe aim of this study is to investigate the possible mechanisms of silence of CDKN3 exerting the suppressive role on epithelial ovarian cancer (EOC).
p7637
sg4
(lp7638
sg6
(lp7639
(dp7640
g9
I144
sg10
VC0677886
p7641
sg12
I3
sg13
VEOC
p7642
sg15
I1
sa(dp7643
g9
I67
sg10
VC0858952
p7644
sg12
I7
sg13
Vsilence
p7645
sg15
I1
sa(dp7646
g9
I117
sg10
VC0677886
p7647
sg12
I25
sg13
Vepithelial ovarian cancer
p7648
sg15
I3
sasa(dp7649
g2
VFunctional studies showed that silence of CDKN3 inhibited cancer cell proliferation by promoting cell cycle progression in G1 phase, decreased cell invasion and promoted EOC cells apoptosis.
p7650
sg4
(lp7651
sg6
(lp7652
(dp7653
g9
I31
sg10
VC0858952
p7654
sg12
I7
sg13
Vsilence
p7655
sg15
I1
sa(dp7656
g9
I58
sg10
VC0006826
p7657
sg12
I6
sg13
Vcancer
p7658
sg15
I1
sa(dp7659
g9
I143
sg10
VC2699153
p7660
sg12
I13
sg13
Vcell invasion
p7661
sg15
I2
sa(dp7662
g9
I70
sg10
VC0334094
p7663
sg12
I13
sg13
Vproliferation
p7664
sg15
I1
sasa(dp7665
g2
VThese findings indicated that CDKN3 might serve as a useful potential target for treatment of ovarian cancer.
p7666
sg4
(lp7667
sg6
(lp7668
(dp7669
g9
I94
sg10
VC1140680
p7670
sg12
I14
sg13
Vovarian cancer
p7671
sg15
I2
sasa(dp7672
g2
VWe first discovered the pro-tumor effect of a controversial cell cycle regulator, cylin-dependent kinase inhibitor 3 (CDKN3), which is highly expressed in colorectal cancer, and the possible related signaling pathways, by bioinformatics tools.
p7673
sg4
(lp7674
(dp7675
g9
I82
sg20
VP19525
p7676
sg12
I34
sg13
Vcylin-dependent kinase inhibitor 3
p7677
sg15
I4
sa(dp7678
g9
I118
sg20
VP19525
p7679
sg12
I5
sg13
VCDKN3
p7680
sg15
I1
sasg6
(lp7681
(dp7682
g9
I28
sg10
VC0027651
p7683
sg12
I5
sg13
Vtumor
p7684
sg15
I1
sa(dp7685
g9
I155
sg10
VC1527249
p7686
sg12
I17
sg13
Vcolorectal cancer
p7687
sg15
I2
sasa(dp7688
g2
VWe found that CDKN3 had remarkable effects in suppressing colorectal cancer cell proliferation and migration, inducing cell cycle arrest and apoptosis in a colorectal cancer cell line, SW480 cells.
p7689
sg4
(lp7690
sg6
(lp7691
(dp7692
g9
I58
sg10
VC1527249
p7693
sg12
I17
sg13
Vcolorectal cancer
p7694
sg15
I2
sa(dp7695
g9
I58
sg10
VC1527249
p7696
sg12
I17
sg13
Vcolorectal cancer
p7697
sg15
I2
sa(dp7698
g9
I81
sg10
VC0334094
p7699
sg12
I13
sg13
Vproliferation
p7700
sg15
I1
sasa(dp7701
g2
VOur study, for the first time, provided consistent evidence showing overexpression of cell cycle regulator CDKN3, in colorectal cancer.
p7702
sg4
(lp7703
sg6
(lp7704
(dp7705
g9
I117
sg10
VC1527249
p7706
sg12
I17
sg13
Vcolorectal cancer
p7707
sg15
I2
sasa(dp7708
g2
VThe in vitro studies in SW480 cells revealed a unique role of CDKN3 in regulating cellular behavior of colorectal cancer cells, and implied the possibility of targeting CDKN3 as a novel treatment for colorectal cancer.
p7709
sg4
(lp7710
sg6
(lp7711
(dp7712
g9
I103
sg10
VC1527249
p7713
sg12
I17
sg13
Vcolorectal cancer
p7714
sg15
I2
sa(dp7715
g9
I103
sg10
VC1527249
p7716
sg12
I17
sg13
Vcolorectal cancer
p7717
sg15
I2
sasa(dp7718
g2
VHowever, the role of CDKN3 in Bcr-Abl-mediated chronic myelogenous leukemia (CML) remains unknown.
p7719
sg4
(lp7720
(dp7721
g9
I30
sg20
VP11274
p7722
sg12
I3
sg13
VBcr
p7723
sg15
I1
sa(dp7724
g9
I34
sg20
VP55157
p7725
sg12
I3
sg13
VAbl
p7726
sg15
I1
sasg6
(lp7727
(dp7728
g9
I47
sg10
VC0023473
p7729
sg12
I28
sg13
Vchronic myelogenous leukemia
p7730
sg15
I3
sa(dp7731
g9
I77
sg10
VC0023473
p7732
sg12
I3
sg13
VCML
p7733
sg15
I1
sa(dp7734
g9
I34
sg10
VC0000744
p7735
sg12
I3
sg13
VAbl
p7736
sg15
I1
sasa(dp7737
g2
VIn contrast, depletion of CDKN3 expression conferred resistance to imatinib-induced apoptosis in the leukemic cells and accelerated the growth of xenograph leukemia in mice.
p7738
sg4
(lp7739
sg6
(lp7740
(dp7741
g9
I156
sg10
VC0023418
p7742
sg12
I8
sg13
Vleukemia
p7743
sg15
I1
sasa(dp7744
g2
VOur results highlight the importance of CDKN3 in Bcr-Abl-mediated leukemogenesis, and provide new insights into diagnostics and therapeutics of the leukemia.
p7745
sg4
(lp7746
(dp7747
g9
I49
sg20
VP11274
p7748
sg12
I3
sg13
VBcr
p7749
sg15
I1
sa(dp7750
g9
I53
sg20
VP55157
p7751
sg12
I3
sg13
VAbl
p7752
sg15
I1
sasg6
(lp7753
(dp7754
g9
I148
sg10
VC0023418
p7755
sg12
I8
sg13
Vleukemia
p7756
sg15
I1
sa(dp7757
g9
I66
sg10
VC0598766
p7758
sg12
I14
sg13
Vleukemogenesis
p7759
sg15
I1
sa(dp7760
g9
I53
sg10
VC0000744
p7761
sg12
I3
sg13
VAbl
p7762
sg15
I1
sasa(dp7763
g2
VUsing in situ hybridization, the expression of key clock genes, including period circadian protein homolog (Per) 1 and 2, cryptochrome 1 (Cry1), circadian locomoter output cycles protein kaput (Clock), brain and muscle ARNT-like protein 1 (Bmal1) and casein kinase 1Epsilon (CK1Epsilon) were retrospectively examined in 51 cases of colorectal carcinoma and 10 cases of adenoma.
p7764
sg4
(lp7765
(dp7766
g9
I219
sg20
VP14222
p7767
sg12
I19
sg13
VARNT-like protein 1
p7768
sg15
I3
sa(dp7769
g9
I275
sg20
VP48729
p7770
sg12
I10
sg13
VCK1Epsilon
p7771
sg15
I1
sa(dp7772
g9
I138
sg20
g21
sg12
I4
sg13
VCry1
p7773
sg15
I1
sa(dp7774
g9
I122
sg20
g21
sg12
I14
sg13
Vcryptochrome 1
p7775
sg15
I2
sa(dp7776
g9
I81
sg20
g21
sg12
I39
sg13
Vcircadian protein homolog (Per) 1 and 2
p7777
sg15
I7
sa(dp7778
g9
I251
sg20
VP48729
p7779
sg12
I22
sg13
Vcasein kinase 1Epsilon
p7780
sg15
I3
sasg6
(lp7781
(dp7782
g9
I369
sg10
VC0001430
p7783
sg12
I7
sg13
Vadenoma
p7784
sg15
I1
sa(dp7785
g9
I332
sg10
VC0009402
p7786
sg12
I20
sg13
Vcolorectal carcinoma
p7787
sg15
I2
sasa(dp7788
g2
VThe present study demonstrated that the protein expression levels of human circadian locomoter output cycles protein kaput (hCLOCK) is significantly increased, while miR-124 is attenuated in high-grade human CRC tissues and in the more invasive colorectal cancer cell lines SW620 and LOVO.
p7789
sg4
(lp7790
(dp7791
g9
I166
sg20
g21
sg12
I7
sg13
VmiR-124
p7792
sg15
I1
sa(dp7793
g9
I124
sg20
g21
sg12
I6
sg13
VhCLOCK
p7794
sg15
I1
sa(dp7795
g9
I69
sg20
g21
sg12
I53
sg13
Vhuman circadian locomoter output cycles protein kaput
p7796
sg15
I7
sasg6
(lp7797
(dp7798
g9
I208
sg10
VC1527249
p7799
sg12
I3
sg13
VCRC
p7800
sg15
I1
sa(dp7801
g9
I245
sg10
VC1527249
p7802
sg12
I17
sg13
Vcolorectal cancer
p7803
sg15
I2
sasa(dp7804
g2
VThe CLOCK gene may be designated as a novel candidate for targeted gene therapy in drug-resistant ovarian cancer.
p7805
sg4
(lp7806
(dp7807
g9
I4
sg20
g21
sg12
I10
sg13
VCLOCK gene
p7808
sg15
I2
sasg6
(lp7809
(dp7810
g9
I98
sg10
VC1140680
p7811
sg12
I14
sg13
Vovarian cancer
p7812
sg15
I2
sasa(dp7813
g2
VStudy distribution by tumor was as follows: breast cancer (n=15), prostate cancer (n=3), pancreatic cancer (n=2), non-Hodgkin's lymphoma (n=2), glioma (n=1), chronic lymphocytic leukemia (n=1), colorectal cancer (n=1), non-small cell lung cancer (n=1) and ovarian cancer (n=1).We identified 10 single nucleotide polymorphisms (SNPs) significantly associated with cancer risk: NPAS2 rs10165970 (mixed and breast cancer shiftworkers), rs895520 (mixed), rs17024869 (breast) and rs7581886 (breast); CLOCK rs3749474 (breast) and rs11943456 (breast); RORA rs7164773 (breast and breast cancer postmenopausal), rs10519097 (breast); RORB rs7867494 (breast cancer postmenopausal), PER3 rs1012477 (breast cancer subgroups) and assessed the level of quality evidence to be intermediate.
p7814
sg4
(lp7815
(dp7816
g9
I495
sg20
g21
sg12
I15
sg13
VCLOCK rs3749474
p7817
sg15
I2
sa(dp7818
g9
I376
sg20
g21
sg12
I16
sg13
VNPAS2 rs10165970
p7819
sg15
I2
sa(dp7820
g9
I671
sg20
VP56645
p7821
sg12
I4
sg13
VPER3
p7822
sg15
I1
sa(dp7823
g9
I624
sg20
g21
sg12
I14
sg13
VRORB rs7867494
p7824
sg15
I2
sasg6
(lp7825
(dp7826
g9
I219
sg10
VC0007131
p7827
sg12
I26
sg13
Vnon-small cell lung cancer
p7828
sg15
I4
sa(dp7829
g9
I144
sg10
VC0017638
p7830
sg12
I6
sg13
Vglioma
p7831
sg15
I1
sa(dp7832
g9
I22
sg10
VC0027651
p7833
sg12
I5
sg13
Vtumor
p7834
sg15
I1
sa(dp7835
g9
I44
sg10
VC0678222
p7836
sg12
I13
sg13
Vbreast cancer
p7837
sg15
I2
sa(dp7838
g9
I44
sg10
VC0678222
p7839
sg12
I13
sg13
Vbreast cancer
p7840
sg15
I2
sa(dp7841
g9
I44
sg10
VC0678222
p7842
sg12
I13
sg13
Vbreast cancer
p7843
sg15
I2
sa(dp7844
g9
I51
sg10
VC0006826
p7845
sg12
I6
sg13
Vcancer
p7846
sg15
I1
sa(dp7847
g9
I89
sg10
VC0235974
p7848
sg12
I17
sg13
Vpancreatic cancer
p7849
sg15
I2
sa(dp7850
g9
I256
sg10
VC1140680
p7851
sg12
I14
sg13
Vovarian cancer
p7852
sg15
I2
sa(dp7853
g9
I44
sg10
VC0678222
p7854
sg12
I13
sg13
Vbreast cancer
p7855
sg15
I2
sa(dp7856
g9
I44
sg10
VC0678222
p7857
sg12
I13
sg13
Vbreast cancer
p7858
sg15
I2
sa(dp7859
g9
I158
sg10
VC0023434
p7860
sg12
I28
sg13
Vchronic lymphocytic leukemia
p7861
sg15
I3
sa(dp7862
g9
I114
sg10
VC0024305
p7863
sg12
I22
sg13
Vnon-Hodgkin's lymphoma
p7864
sg15
I2
sa(dp7865
g9
I66
sg10
VC0600139
p7866
sg12
I15
sg13
Vprostate cancer
p7867
sg15
I2
sa(dp7868
g9
I194
sg10
VC1527249
p7869
sg12
I17
sg13
Vcolorectal cancer
p7870
sg15
I2
sasa(dp7871
g2
VWe summarize fifteen epidemiological studies, including five studies on shift work that have indicated BMAL1, BMAL2, CLOCK, NPAS2, CRY1, CRY2, PER1, PER3 and TIMELESS as a candidate breast cancer risk variants.
p7872
sg4
(lp7873
(dp7874
g9
I149
sg20
VP56645
p7875
sg12
I4
sg13
VPER3
p7876
sg15
I1
sa(dp7877
g9
I131
sg20
g21
sg12
I4
sg13
VCRY1
p7878
sg15
I1
sa(dp7879
g9
I124
sg20
g21
sg12
I5
sg13
VNPAS2
p7880
sg15
I1
sa(dp7881
g9
I158
sg20
VP60174
p7882
sg12
I8
sg13
VTIMELESS
p7883
sg15
I1
sa(dp7884
g9
I143
sg20
g21
sg12
I4
sg13
VPER1
p7885
sg15
I1
sa(dp7886
g9
I117
sg20
g21
sg12
I5
sg13
VCLOCK
p7887
sg15
I1
sa(dp7888
g9
I137
sg20
g21
sg12
I4
sg13
VCRY2
p7889
sg15
I1
sasg6
(lp7890
(dp7891
g9
I182
sg10
VC0678222
p7892
sg12
I13
sg13
Vbreast cancer
p7893
sg15
I2
sasa(dp7894
g2
VThis study sought to determine TANK (rs1921310, rs3820998) gene polymorphism in patients suffering from chronic periodontitis and peri-implantitis among an Iranian population.
p7895
sg4
(lp7896
(dp7897
g9
I31
sg20
g21
sg12
I4
sg13
VTANK
p7898
sg15
I1
sasg6
(lp7899
(dp7900
g9
I89
sg10
VC0683278
p7901
sg12
I9
sg13
Vsuffering
p7902
sg15
I1
sa(dp7903
g9
I104
sg10
VC0266929
p7904
sg12
I21
sg13
Vchronic periodontitis
p7905
sg15
I2
sa(dp7906
g9
I130
sg10
VC2936258
p7907
sg12
I16
sg13
Vperi-implantitis
p7908
sg15
I1
sasa(dp7909
g2
VThe tumor necrosis factor receptor-associated factor family member-associated nuclear factor-KB (NF-KB) activator (TANK) takes part in the tumor necrosis factor-Alfa (TNF-Alfa)-mediated NF-KB signaling pathway and the interferon (IFN)-induction pathways that have relevance to HBV-related liver disease.
p7910
sg4
(lp7911
(dp7912
g9
I4
sg20
VP01375
p7913
sg12
I91
sg13
Vtumor necrosis factor receptor-associated factor family member-associated nuclear factor-KB
p7914
sg15
I9
sa(dp7915
g9
I218
sg20
VP01563
p7916
sg12
I10
sg13
Vinterferon
p7917
sg15
I1
sa(dp7918
g9
I115
sg20
g21
sg12
I4
sg13
VTANK
p7919
sg15
I1
sa(dp7920
g9
I139
sg20
VP01375
p7921
sg12
I26
sg13
Vtumor necrosis factor-Alfa
p7922
sg15
I3
sa(dp7923
g9
I167
sg20
VP01375
p7924
sg12
I8
sg13
VTNF-Alfa
p7925
sg15
I1
sa(dp7926
g9
I230
sg20
VP01562
p7927
sg12
I3
sg13
VIFN
p7928
sg15
I1
sasg6
(lp7929
(dp7930
g9
I4
sg10
VC0333516
p7931
sg12
I14
sg13
Vtumor necrosis
p7932
sg15
I2
sa(dp7933
g9
I289
sg10
VC0023895
p7934
sg12
I13
sg13
Vliver disease
p7935
sg15
I2
sa(dp7936
g9
I4
sg10
VC0333516
p7937
sg12
I14
sg13
Vtumor necrosis
p7938
sg15
I2
sa(dp7939
g9
I277
sg10
VC0019163
p7940
sg12
I3
sg13
VHBV
p7941
sg15
I1
sasa(dp7942
g2
VThese results indicate that treatment with TUDCA may be helpful to counteract obesity-induced hyperinsulinemia through increasing insulin clearance, likely through enhanced liver IDE expression in a mechanism dependent on S1PR2-Insulin pathway activation.
p7943
sg4
(lp7944
(dp7945
g9
I228
sg20
VP01308
p7946
sg12
I7
sg13
VInsulin
p7947
sg15
I1
sa(dp7948
g9
I99
sg20
VP01308
p7949
sg12
I7
sg13
Vinsulin
p7950
sg15
I1
sa(dp7951
g9
I179
sg20
VP14735
p7952
sg12
I3
sg13
VIDE
p7953
sg15
I1
sa(dp7954
g9
I222
sg20
g21
sg12
I5
sg13
VS1PR2
p7955
sg15
I1
sasg6
(lp7956
(dp7957
g9
I78
sg10
VC0028754
p7958
sg12
I7
sg13
Vobesity
p7959
sg15
I1
sa(dp7960
g9
I119
sg10
VC0020459
p7961
sg12
I18
sg13
Vincreasing insulin
p7962
sg15
I2
sa(dp7963
g9
I94
sg10
VC0020459
p7964
sg12
I16
sg13
Vhyperinsulinemia
p7965
sg15
I1
sasa(dp7966
g2
VInsulin-degrading enzyme (IDE) is a ubiquitous zinc peptidase of the inverzincin family, which has been initially discovered as the enzyme responsible for insulin catabolism; therefore, its involvement in the onset of diabetes has been largely investigated.
p7967
sg4
(lp7968
(dp7969
g9
I0
sg20
VP14735
p7970
sg12
I24
sg13
VInsulin-degrading enzyme
p7971
sg15
I2
sa(dp7972
g9
I47
sg20
g21
sg12
I14
sg13
Vzinc peptidase
p7973
sg15
I2
sa(dp7974
g9
I26
sg20
VP14735
p7975
sg12
I3
sg13
VIDE
p7976
sg15
I1
sa(dp7977
g9
I155
sg20
VP01308
p7978
sg12
I7
sg13
Vinsulin
p7979
sg15
I1
sasg6
(lp7980
(dp7981
g9
I218
sg10
VC0011849
p7982
sg12
I8
sg13
Vdiabetes
p7983
sg15
I1
sasa(dp7984
g2
VImpairment of the insulin-degrading enzyme (IDE) is associated with obesity and type 2 diabetes mellitus (T2DM).
p7985
sg4
(lp7986
(dp7987
g9
I18
sg20
VP14735
p7988
sg12
I24
sg13
Vinsulin-degrading enzyme
p7989
sg15
I2
sa(dp7990
g9
I44
sg20
VP14735
p7991
sg12
I3
sg13
VIDE
p7992
sg15
I1
sasg6
(lp7993
(dp7994
g9
I106
sg10
VC0011860
p7995
sg12
I4
sg13
VT2DM
p7996
sg15
I1
sa(dp7997
g9
I80
sg10
VC0011860
p7998
sg12
I24
sg13
Vtype 2 diabetes mellitus
p7999
sg15
I4
sa(dp8000
g9
I0
sg10
VC0684336
p8001
sg12
I10
sg13
VImpairment
p8002
sg15
I1
sa(dp8003
g9
I68
sg10
VC0028754
p8004
sg12
I7
sg13
Vobesity
p8005
sg15
I1
sasa(dp8006
g2
VSeveral mechanisms have been reported underlying the association of the two disorders, diabetes and dementia, one among which is the insulin-degrading enzyme (IDE) which is known to degrade insulin as well beta-amyloid peptides.
p8007
sg4
(lp8008
(dp8009
g9
I159
sg20
VP14735
p8010
sg12
I3
sg13
VIDE
p8011
sg15
I1
sa(dp8012
g9
I133
sg20
VP14735
p8013
sg12
I24
sg13
Vinsulin-degrading enzyme
p8014
sg15
I2
sa(dp8015
g9
I133
sg20
VP01308
p8016
sg12
I7
sg13
Vinsulin
p8017
sg15
I1
sasg6
(lp8018
(dp8019
g9
I100
sg10
VC0497327
p8020
sg12
I8
sg13
Vdementia
p8021
sg15
I1
sa(dp8022
g9
I211
sg10
VC0011560
p8023
sg12
I7
sg13
Vamyloid
p8024
sg15
I1
sa(dp8025
g9
I87
sg10
VC0011849
p8026
sg12
I8
sg13
Vdiabetes
p8027
sg15
I1
sasa(dp8028
g2
VWe concluded that vitamin D3 ameliorated insulin resistance and hyperinsulinemia in diabetic rat model received HFW through reduction of IDE and activation of insulin receptor phosphorylation.
p8029
sg4
(lp8030
(dp8031
g9
I41
sg20
VP01308
p8032
sg12
I7
sg13
Vinsulin
p8033
sg15
I1
sa(dp8034
g9
I159
sg20
VP01308
p8035
sg12
I16
sg13
Vinsulin receptor
p8036
sg15
I2
sasg6
(lp8037
(dp8038
g9
I64
sg10
VC0020459
p8039
sg12
I16
sg13
Vhyperinsulinemia
p8040
sg15
I1
sa(dp8041
g9
I41
sg10
VC0021655
p8042
sg12
I18
sg13
Vinsulin resistance
p8043
sg15
I2
sasa(dp8044
g2
VIndependently, the same approach identified a second homozygous truncating GZF1 variant in another multiplex consanguineous family affected by severe myopia, retinal detachment, and milder skeletal involvement.
p8045
sg4
(lp8046
(dp8047
g9
I64
sg20
g21
sg12
I23
sg13
Vtruncating GZF1 variant
p8048
sg15
I3
sasg6
(lp8049
(dp8050
g9
I158
sg10
VC0035305
p8051
sg12
I18
sg13
Vretinal detachment
p8052
sg15
I2
sa(dp8053
g9
I143
sg10
VC0271183
p8054
sg12
I13
sg13
Vsevere myopia
p8055
sg15
I2
sasa(dp8056
g2
VSubgroup analyses found that the IL4RA I50V polymorphism was significantly associated with asthma risk in Asians (OR = 1.72, 95% CI 1.31-2.25, P&lt;0.0001), pediatric asthma risk (OR = 1.50, 95% CI 1.13-1.99, P = 0.005), and atopic asthma risk (OR = 1.88, 95% CI 1.27-2.79, P = 0.002).
p8057
sg4
(lp8058
sg6
(lp8059
(dp8060
g9
I225
sg10
VC0155877
p8061
sg12
I13
sg13
Vatopic asthma
p8062
sg15
I2
sa(dp8063
g9
I91
sg10
VC0004096
p8064
sg12
I6
sg13
Vasthma
p8065
sg15
I1
sa(dp8066
g9
I91
sg10
VC0004096
p8067
sg12
I6
sg13
Vasthma
p8068
sg15
I1
sasa(dp8069
g2
VTo verify the association of transforming growth factor-beta1(TGF-beta1) (C-509T and T869C), CD14 (C-159T), IL-4 (C-590T), IL-4R (ILe50Val) and ADAM33 (S_2) gene polymorphisms with asthma severity in a sample of patients with mild, moderate and severe persistent atopic asthma.
p8070
sg4
(lp8071
(dp8072
g9
I108
sg20
VP05112
p8073
sg12
I4
sg13
VIL-4
p8074
sg15
I1
sa(dp8075
g9
I29
sg20
VP01137
p8076
sg12
I32
sg13
Vtransforming growth factor-beta1
p8077
sg15
I3
sa(dp8078
g9
I144
sg20
g21
sg12
I6
sg13
VADAM33
p8079
sg15
I1
sa(dp8080
g9
I62
sg20
VP01137
p8081
sg12
I9
sg13
VTGF-beta1
p8082
sg15
I1
sa(dp8083
g9
I93
sg20
VP08571
p8084
sg12
I4
sg13
VCD14
p8085
sg15
I1
sasg6
(lp8086
(dp8087
g9
I263
sg10
VC0155877
p8088
sg12
I13
sg13
Vatopic asthma
p8089
sg15
I2
sa(dp8090
g9
I181
sg10
VC0004096
p8091
sg12
I6
sg13
Vasthma
p8092
sg15
I1
sasa(dp8093
g2
VTo investigate the correlation between Chlamydia pneumonia (Cpn) infection and chronic obstructive pulmonary disease (COPD).
p8094
sg4
(lp8095
sg6
(lp8096
(dp8097
g9
I79
sg10
VC0024117
p8098
sg12
I37
sg13
Vchronic obstructive pulmonary disease
p8099
sg15
I4
sa(dp8100
g9
I118
sg10
VC0024117
p8101
sg12
I4
sg13
VCOPD
p8102
sg15
I1
sa(dp8103
g9
I49
sg10
VC0032285
p8104
sg12
I9
sg13
Vpneumonia
p8105
sg15
I1
sa(dp8106
g9
I65
sg10
VC0009450
p8107
sg12
I9
sg13
Vinfection
p8108
sg15
I1
sasa(dp8109
g2
VChlamydia pneumoniae (Cpn) infection may play a role in the pathogenesis of chronic obstructive pulmonary disease (COPD).
p8110
sg4
(lp8111
(dp8112
g9
I0
sg20
VP15169
p8113
sg12
I20
sg13
VChlamydia pneumoniae
p8114
sg15
I2
sa(dp8115
g9
I22
sg20
VP15169
p8116
sg12
I3
sg13
VCpn
p8117
sg15
I1
sasg6
(lp8118
(dp8119
g9
I27
sg10
VC0009450
p8120
sg12
I9
sg13
Vinfection
p8121
sg15
I1
sa(dp8122
g9
I115
sg10
VC0024117
p8123
sg12
I4
sg13
VCOPD
p8124
sg15
I1
sa(dp8125
g9
I76
sg10
VC0024117
p8126
sg12
I37
sg13
Vchronic obstructive pulmonary disease
p8127
sg15
I4
sa(dp8128
g9
I60
sg10
VC0699748
p8129
sg12
I12
sg13
Vpathogenesis
p8130
sg15
I1
sasa(dp8131
g2
VTo determine the possible association between Chlamydiae pneumoniae (Cpn) infection and chronic obstructive pulmonary disease (COPD).
p8132
sg4
(lp8133
(dp8134
g9
I46
sg20
VP15169
p8135
sg12
I21
sg13
VChlamydiae pneumoniae
p8136
sg15
I2
sa(dp8137
g9
I69
sg20
VP15169
p8138
sg12
I3
sg13
VCpn
p8139
sg15
I1
sasg6
(lp8140
(dp8141
g9
I127
sg10
VC0024117
p8142
sg12
I4
sg13
VCOPD
p8143
sg15
I1
sa(dp8144
g9
I88
sg10
VC0024117
p8145
sg12
I37
sg13
Vchronic obstructive pulmonary disease
p8146
sg15
I4
sa(dp8147
g9
I74
sg10
VC0009450
p8148
sg12
I9
sg13
Vinfection
p8149
sg15
I1
sasa(dp8150
g2
VThe objective of the study was to investigate the possible association of Chlamydia pneumoniae (Cpn) in acute exacerbations of chronic obstructive pulmonary disease (COPD) patients.
p8151
sg4
(lp8152
(dp8153
g9
I96
sg20
VP15169
p8154
sg12
I3
sg13
VCpn
p8155
sg15
I1
sa(dp8156
g9
I74
sg20
VP15169
p8157
sg12
I20
sg13
VChlamydia pneumoniae
p8158
sg15
I2
sasg6
(lp8159
(dp8160
g9
I127
sg10
VC0024117
p8161
sg12
I37
sg13
Vchronic obstructive pulmonary disease
p8162
sg15
I4
sa(dp8163
g9
I166
sg10
VC0024117
p8164
sg12
I4
sg13
VCOPD
p8165
sg15
I1
sasa(dp8166
g2
VReading this article will familiarize the reader with (1) the unique chlamydial intracellular life cycle and the propensity for human chlamydial infections to become persistent and to result in immunopathologic (inflammatory) damage in target organs and (2) current evidence linking Chlamydia pneumoniae (Cpn) infection to obstructive lung diseases (asthma and chronic obstructive pulmonary disease, COPD).
p8167
sg4
(lp8168
(dp8169
g9
I305
sg20
VP15169
p8170
sg12
I3
sg13
VCpn
p8171
sg15
I1
sa(dp8172
g9
I283
sg20
VP15169
p8173
sg12
I20
sg13
VChlamydia pneumoniae
p8174
sg15
I2
sasg6
(lp8175
(dp8176
g9
I400
sg10
VC0024117
p8177
sg12
I4
sg13
VCOPD
p8178
sg15
I1
sa(dp8179
g9
I145
sg10
VC0009450
p8180
sg12
I9
sg13
Vinfection
p8181
sg15
I1
sa(dp8182
g9
I323
sg10
VC0600260
p8183
sg12
I25
sg13
Vobstructive lung diseases
p8184
sg15
I3
sa(dp8185
g9
I134
sg10
VC0008149
p8186
sg12
I21
sg13
Vchlamydial infections
p8187
sg15
I2
sa(dp8188
g9
I361
sg10
VC0024117
p8189
sg12
I37
sg13
Vchronic obstructive pulmonary disease
p8190
sg15
I4
sa(dp8191
g9
I350
sg10
VC0004096
p8192
sg12
I6
sg13
Vasthma
p8193
sg15
I1
sasa(dp8194
g2
VAlthough the full clinical significance of these Cpn-obstructive lung disease associations remains to be established, reports of asthma improvement after treatment of Cpn infection deserve further investigation.
p8195
sg4
(lp8196
sg6
(lp8197
(dp8198
g9
I53
sg10
VC0600260
p8199
sg12
I24
sg13
Vobstructive lung disease
p8200
sg15
I3
sa(dp8201
g9
I129
sg10
VC0004096
p8202
sg12
I6
sg13
Vasthma
p8203
sg15
I1
sa(dp8204
g9
I171
sg10
VC0009450
p8205
sg12
I9
sg13
Vinfection
p8206
sg15
I1
sasa(dp8207
g2
VTaken together, we conclude that EGFR TKIs enhance the sensitivity of NSCLC cells to vATPase inhibitors by decreasing Hif-1Alfa/Bnip3 expression.
p8208
sg4
(lp8209
(dp8210
g9
I128
sg20
g21
sg12
I5
sg13
VBnip3
p8211
sg15
I1
sasg6
(lp8212
(dp8213
g9
I70
sg10
VC0007131
p8214
sg12
I5
sg13
VNSCLC
p8215
sg15
I1
sasa(dp8216
g2
VWe found a significant upregulation of BNIP3 in human lung cancer datasets, and we identified a direct association between BNIP3 expression and survival rate of lung cancer patients.
p8217
sg4
(lp8218
(dp8219
g9
I39
sg20
g21
sg12
I5
sg13
VBNIP3
p8220
sg15
I1
sa(dp8221
g9
I39
sg20
g21
sg12
I5
sg13
VBNIP3
p8222
sg15
I1
sasg6
(lp8223
(dp8224
g9
I54
sg10
VC0684249
p8225
sg12
I11
sg13
Vlung cancer
p8226
sg15
I2
sa(dp8227
g9
I54
sg10
VC0684249
p8228
sg12
I11
sg13
Vlung cancer
p8229
sg15
I2
sasa(dp8230
g2
VIn this study we used 115 NSCLC tissues to examine the immunohistochemical expression of four distinct molecules - the major regulator of autophagy Beclin 1, the anti-apoptotic and anti-autophagic protein Bcl-2, the pro-apoptotic and pro-autophagic protein BNIP3, and a marker of hypoxia and glucolysis, the glucose transporter Glut 1.
p8231
sg4
(lp8232
(dp8233
g9
I138
sg20
g21
sg12
I18
sg13
Vautophagy Beclin 1
p8234
sg15
I3
sa(dp8235
g9
I181
sg20
VP10415
p8236
sg12
I29
sg13
Vanti-autophagic protein Bcl-2
p8237
sg15
I3
sa(dp8238
g9
I234
sg20
g21
sg12
I28
sg13
Vpro-autophagic protein BNIP3
p8239
sg15
I3
sasg6
(lp8240
(dp8241
g9
I280
sg10
VC0242184
p8242
sg12
I7
sg13
Vhypoxia
p8243
sg15
I1
sa(dp8244
g9
I26
sg10
VC0007131
p8245
sg12
I5
sg13
VNSCLC
p8246
sg15
I1
sasa(dp8247
g2
VIn conclusion, the accelerated autophagic status in NSCLC is unrelated to Beclin 1 and BNIP3 expression, but does show significant association with Bcl-2 reactivity.
p8248
sg4
(lp8249
(dp8250
g9
I74
sg20
g21
sg12
I8
sg13
VBeclin 1
p8251
sg15
I2
sa(dp8252
g9
I87
sg20
g21
sg12
I5
sg13
VBNIP3
p8253
sg15
I1
sa(dp8254
g9
I148
sg20
VP10415
p8255
sg12
I5
sg13
VBcl-2
p8256
sg15
I1
sasg6
(lp8257
(dp8258
g9
I52
sg10
VC0007131
p8259
sg12
I5
sg13
VNSCLC
p8260
sg15
I1
sasa(dp8261
g2
VThis study was designed to determine the pattern and correlation between expression of the HIF-1Alfa transcriptional targets TGM2 and BNIP3 in laryngeal cancer, and investigate the association of BNIP3 and TGM2 with clinical outcome in laryngeal squamous cell carcinoma (SCC) patients receiving postoperative radiotherapy.
p8262
sg4
(lp8263
(dp8264
g9
I134
sg20
g21
sg12
I5
sg13
VBNIP3
p8265
sg15
I1
sa(dp8266
g9
I125
sg20
VP21980
p8267
sg12
I4
sg13
VTGM2
p8268
sg15
I1
sa(dp8269
g9
I125
sg20
VP21980
p8270
sg12
I4
sg13
VTGM2
p8271
sg15
I1
sa(dp8272
g9
I134
sg20
g21
sg12
I5
sg13
VBNIP3
p8273
sg15
I1
sasg6
(lp8274
(dp8275
g9
I236
sg10
VC0280324
p8276
sg12
I33
sg13
Vlaryngeal squamous cell carcinoma
p8277
sg15
I4
sa(dp8278
g9
I143
sg10
VC0595989
p8279
sg12
I16
sg13
Vlaryngeal cancer
p8280
sg15
I2
sasa(dp8281
g2
VConsidering tumors with telomere shortening, expression for BNIP3, DAPK1, NDRG1, EGFR, and CDKN2A was significantly higher in NSCLC than in CRC, whereas TP53 was overexpressed in CRC with respect to NSCLC.
p8282
sg4
(lp8283
(dp8284
g9
I140
sg20
VP31749
p8285
sg12
I17
sg13
VCRC, whereas TP53
p8286
sg15
I3
sa(dp8287
g9
I91
sg20
VP42771
p8288
sg12
I6
sg13
VCDKN2A
p8289
sg15
I1
sa(dp8290
g9
I67
sg20
VP53355
p8291
sg12
I5
sg13
VDAPK1
p8292
sg15
I1
sa(dp8293
g9
I140
sg20
VP31749
p8294
sg12
I3
sg13
VCRC
p8295
sg15
I1
sa(dp8296
g9
I74
sg20
g21
sg12
I5
sg13
VNDRG1
p8297
sg15
I1
sa(dp8298
g9
I60
sg20
g21
sg12
I5
sg13
VBNIP3
p8299
sg15
I1
sasg6
(lp8300
(dp8301
g9
I24
sg10
VC1515263
p8302
sg12
I19
sg13
Vtelomere shortening
p8303
sg15
I2
sa(dp8304
g9
I140
sg10
VC1527249
p8305
sg12
I3
sg13
VCRC
p8306
sg15
I1
sa(dp8307
g9
I12
sg10
VC0027651
p8308
sg12
I6
sg13
Vtumors
p8309
sg15
I1
sa(dp8310
g9
I126
sg10
VC0007131
p8311
sg12
I5
sg13
VNSCLC
p8312
sg15
I1
sa(dp8313
g9
I140
sg10
VC1527249
p8314
sg12
I3
sg13
VCRC
p8315
sg15
I1
sa(dp8316
g9
I126
sg10
VC0007131
p8317
sg12
I5
sg13
VNSCLC
p8318
sg15
I1
sasa(dp8319
g2
VKIAA0513 was previously identified as upregulated in the dorsolateral prefrontal cortex of subjects with schizophrenia by microarray analysis.
p8320
sg4
(lp8321
sg6
(lp8322
(dp8323
g9
I105
sg10
VC0036341
p8324
sg12
I13
sg13
Vschizophrenia
p8325
sg15
I1
sasa(dp8326
g2
VHigher fasting glucose levels may amplify obesity-risk in FTO carriers and lead to an exaggerated weight gain over time.
p8327
sg4
(lp8328
sg6
(lp8329
(dp8330
g9
I42
sg10
VC0028754
p8331
sg12
I7
sg13
Vobesity
p8332
sg15
I1
sasa(dp8333
g2
VType 2 diabetes-associated genes TCF7L2 and FTO; and a miRNA, miR21 were further investigated in another B12-supplementation cohort.
p8334
sg4
(lp8335
(dp8336
g9
I44
sg20
g21
sg12
I3
sg13
VFTO
p8337
sg15
I1
sasg6
(lp8338
(dp8339
g9
I0
sg10
VC0011860
p8340
sg12
I15
sg13
VType 2 diabetes
p8341
sg15
I3
sasa(dp8342
g2
VRecent studies show that FTO single nucleotide polymorphisms (SNPs) are associated with obesity and type 2 diabetes mellitus (T2DM).
p8343
sg4
(lp8344
sg6
(lp8345
(dp8346
g9
I88
sg10
VC0028754
p8347
sg12
I7
sg13
Vobesity
p8348
sg15
I1
sa(dp8349
g9
I126
sg10
VC0011860
p8350
sg12
I4
sg13
VT2DM
p8351
sg15
I1
sa(dp8352
g9
I100
sg10
VC0011860
p8353
sg12
I24
sg13
Vtype 2 diabetes mellitus
p8354
sg15
I4
sasa(dp8355
g2
VThe FTO gene is associated with type-2 diabetes (T2D) and increased fat mass.
p8356
sg4
(lp8357
(dp8358
g9
I4
sg20
g21
sg12
I8
sg13
VFTO gene
p8359
sg15
I2
sasg6
(lp8360
(dp8361
g9
I32
sg10
VC0011860
p8362
sg12
I15
sg13
Vtype-2 diabetes
p8363
sg15
I2
sa(dp8364
g9
I49
sg10
VC0011860
p8365
sg12
I3
sg13
VT2D
p8366
sg15
I1
sasa(dp8367
g2
VA significant association was found between the perilipin rs1052700 polymorphism and T2D, and between the FTO rs3751812 polymorphism and obesity (P = 0.03 and 0.003, respectively); however, no significant relationship was found between rs3751812 and T2D.
p8368
sg4
(lp8369
(dp8370
g9
I48
sg20
g21
sg12
I19
sg13
Vperilipin rs1052700
p8371
sg15
I2
sasg6
(lp8372
(dp8373
g9
I85
sg10
VC0011860
p8374
sg12
I3
sg13
VT2D
p8375
sg15
I1
sa(dp8376
g9
I85
sg10
VC0011860
p8377
sg12
I3
sg13
VT2D
p8378
sg15
I1
sa(dp8379
g9
I137
sg10
VC0028754
p8380
sg12
I7
sg13
Vobesity
p8381
sg15
I1
sasa(dp8382
g2
VThe FTO rs3751812 polymorphism is a major genetic determinant of obesity, but not T2D.
p8383
sg4
(lp8384
sg6
(lp8385
(dp8386
g9
I65
sg10
VC0028754
p8387
sg12
I7
sg13
Vobesity
p8388
sg15
I1
sa(dp8389
g9
I82
sg10
VC0011860
p8390
sg12
I3
sg13
VT2D
p8391
sg15
I1
sasa(dp8392
g2
VRecent studies have implicated the FTO gene in child and adult obesity.
p8393
sg4
(lp8394
(dp8395
g9
I35
sg20
g21
sg12
I8
sg13
VFTO gene
p8396
sg15
I2
sasg6
(lp8397
(dp8398
g9
I63
sg10
VC0028754
p8399
sg12
I7
sg13
Vobesity
p8400
sg15
I1
sasa(dp8401
g2
VVariants (rs1558902, rs1121980, rs9939609, and rs9941349) in the fat mass and obesity-associated (FTO) gene exhibited strong but ethnicity-independent association with obesity.
p8402
sg4
(lp8403
sg6
(lp8404
(dp8405
g9
I78
sg10
VC0028754
p8406
sg12
I7
sg13
Vobesity
p8407
sg15
I1
sa(dp8408
g9
I78
sg10
VC0028754
p8409
sg12
I7
sg13
Vobesity
p8410
sg15
I1
sasa(dp8411
g2
VThere is increasing interest of which dietary patterns can modify the association of fat mass and obesity associated (FTO) variants with obesity.
p8412
sg4
(lp8413
sg6
(lp8414
(dp8415
g9
I98
sg10
VC0028754
p8416
sg12
I7
sg13
Vobesity
p8417
sg15
I1
sa(dp8418
g9
I98
sg10
VC0028754
p8419
sg12
I7
sg13
Vobesity
p8420
sg15
I1
sasa(dp8421
g2
VThis study was aimed at investigating the interaction of the Mediterranean dietary pattern (Med Diet) with FTO polymorphisms in relation to obesity phenotypes.
p8422
sg4
(lp8423
sg6
(lp8424
(dp8425
g9
I140
sg10
VC0028754
p8426
sg12
I7
sg13
Vobesity
p8427
sg15
I1
sasa(dp8428
g2
VObesity is a heritable disorder, and some of the many obesity susceptible genes are fat mass and obesity (FTO), leptin, and Melanocortin-4 receptor (MC4R).
p8429
sg4
(lp8430
(dp8431
g9
I124
sg20
VP32245
p8432
sg12
I23
sg13
VMelanocortin-4 receptor
p8433
sg15
I2
sa(dp8434
g9
I149
sg20
VP32245
p8435
sg12
I4
sg13
VMC4R
p8436
sg15
I1
sa(dp8437
g9
I112
sg20
VP41159
p8438
sg12
I6
sg13
Vleptin
p8439
sg15
I1
sasg6
(lp8440
(dp8441
g9
I0
sg10
VC0028754
p8442
sg12
I7
sg13
VObesity
p8443
sg15
I1
sa(dp8444
g9
I54
sg10
VC0028754
p8445
sg12
I7
sg13
Vobesity
p8446
sg15
I1
sa(dp8447
g9
I54
sg10
VC0028754
p8448
sg12
I7
sg13
Vobesity
p8449
sg15
I1
sasa(dp8450
g2
VWe showed that: (1) there was a significant association between the biased usage of IGHV4-34 (binds to the carbohydrate I/i antigens) and inactivating mutation of TNFAIP3 [encoding a global negative regulator of the canonical nuclear factor-KB (NF-KB) pathway] in ocular adnexal MALT lymphoma; (2) IGHV1-69 was significantly overrepresented (54%) in MALT lymphoma of the salivary gland, but was not associated with mutation in any of the 17 genes investigated; and (3) MALT lymphoma lacked mutations that are frequently seen in other B-cell lymphomas characterized by constitutive NF-KB activities, including mutations in CD79B, CARD11, MYD88, TNFRSF11A, and TRAF3.
p8451
sg4
(lp8452
(dp8453
g9
I637
sg20
g21
sg12
I5
sg13
VMYD88
p8454
sg15
I1
sa(dp8455
g9
I644
sg20
g21
sg12
I9
sg13
VTNFRSF11A
p8456
sg15
I1
sa(dp8457
g9
I226
sg20
VP01160
p8458
sg12
I17
sg13
Vnuclear factor-KB
p8459
sg15
I2
sa(dp8460
g9
I629
sg20
g21
sg12
I6
sg13
VCARD11
p8461
sg15
I1
sa(dp8462
g9
I245
sg20
VP01160
p8463
sg12
I5
sg13
VNF-KB
p8464
sg15
I1
sa(dp8465
g9
I659
sg20
g21
sg12
I5
sg13
VTRAF3
p8466
sg15
I1
sa(dp8467
g9
I245
sg20
VP01160
p8468
sg12
I5
sg13
VNF-KB
p8469
sg15
I1
sa(dp8470
g9
I107
sg20
g21
sg12
I25
sg13
Vcarbohydrate I/i antigens
p8471
sg15
I3
sa(dp8472
g9
I163
sg20
VP21580
p8473
sg12
I7
sg13
VTNFAIP3
p8474
sg15
I1
sa(dp8475
g9
I622
sg20
VP40259
p8476
sg12
I5
sg13
VCD79B
p8477
sg15
I1
sasg6
(lp8478
(dp8479
g9
I279
sg10
VC0242647
p8480
sg12
I13
sg13
VMALT lymphoma
p8481
sg15
I2
sa(dp8482
g9
I534
sg10
VC0079731
p8483
sg12
I16
sg13
VB-cell lymphomas
p8484
sg15
I2
sa(dp8485
g9
I264
sg10
VC1335103
p8486
sg12
I28
sg13
Vocular adnexal MALT lymphoma
p8487
sg15
I4
sa(dp8488
g9
I279
sg10
VC0242647
p8489
sg12
I13
sg13
VMALT lymphoma
p8490
sg15
I2
sasa(dp8491
g2
VTherefore, we aim to assess the correlation of endothelin-1 concentrations with the development and severity of knee osteoarthritis (OA).
p8492
sg4
(lp8493
(dp8494
g9
I47
sg20
VP20800
p8495
sg12
I12
sg13
Vendothelin-1
p8496
sg15
I1
sasg6
(lp8497
(dp8498
g9
I112
sg10
VC0409959
p8499
sg12
I19
sg13
Vknee osteoarthritis
p8500
sg15
I2
sasa(dp8501
g2
VTogether, the results here demonstrate that the febrile response in zymosan-induced arthritis in rats depends on the centrally acting pyrogenic cytokines TNF-Alfa, IL-1Beta, and IL-6, but does not depend on either CRF or ET-1.
p8502
sg4
(lp8503
(dp8504
g9
I221
sg20
VP05305
p8505
sg12
I4
sg13
VET-1
p8506
sg15
I1
sa(dp8507
g9
I178
sg20
VP05231
p8508
sg12
I4
sg13
VIL-6
p8509
sg15
I1
sa(dp8510
g9
I164
sg20
VP01584
p8511
sg12
I8
sg13
VIL-1Beta
p8512
sg15
I1
sa(dp8513
g9
I214
sg20
VP06850
p8514
sg12
I3
sg13
VCRF
p8515
sg15
I1
sa(dp8516
g9
I144
sg20
VP01375
p8517
sg12
I18
sg13
Vcytokines TNF-Alfa
p8518
sg15
I2
sasg6
(lp8519
(dp8520
g9
I84
sg10
VC0003864
p8521
sg12
I9
sg13
Varthritis
p8522
sg15
I1
sa(dp8523
g9
I214
sg10
VC0022661
p8524
sg12
I3
sg13
VCRF
p8525
sg15
I1
sasa(dp8526
g2
VAntibodies to AQP4 and AQP1 are detected in neuromyelitis optica and are believed to play a pathogenic role.
p8527
sg4
(lp8528
(dp8529
g9
I14
sg20
VP55087
p8530
sg12
I4
sg13
VAQP4
p8531
sg15
I1
sa(dp8532
g9
I23
sg20
VP29972
p8533
sg12
I4
sg13
VAQP1
p8534
sg15
I1
sasg6
(lp8535
(dp8536
g9
I44
sg10
VC0027873
p8537
sg12
I20
sg13
Vneuromyelitis optica
p8538
sg15
I2
sasa(dp8539
g2
VAmong thirteen different mammalian AQPs, AQP1 and AQP4 have been mainly studied in the CNS and evidence has been presented that they play important roles in the pathogenesis of CNS injury, edema and multiple diseases such as multiple sclerosis, neuromyelitis optica spectrum disorders, amyotrophic lateral sclerosis, glioblastoma multiforme, Alzheimer's disease and Parkinson's disease.
p8540
sg4
(lp8541
(dp8542
g9
I50
sg20
VP55087
p8543
sg12
I4
sg13
VAQP4
p8544
sg15
I1
sa(dp8545
g9
I41
sg20
VP29972
p8546
sg12
I4
sg13
VAQP1
p8547
sg15
I1
sasg6
(lp8548
(dp8549
g9
I161
sg10
VC0699748
p8550
sg12
I12
sg13
Vpathogenesis
p8551
sg15
I1
sa(dp8552
g9
I366
sg10
VC0030567
p8553
sg12
I19
sg13
VParkinson's disease
p8554
sg15
I2
sa(dp8555
g9
I317
sg10
VC1621958
p8556
sg12
I23
sg13
Vglioblastoma multiforme
p8557
sg15
I2
sa(dp8558
g9
I286
sg10
VC0002736
p8559
sg12
I29
sg13
Vamyotrophic lateral sclerosis
p8560
sg15
I3
sa(dp8561
g9
I245
sg10
VC0027873
p8562
sg12
I20
sg13
Vneuromyelitis optica
p8563
sg15
I2
sa(dp8564
g9
I342
sg10
VC1521724
p8565
sg12
I19
sg13
VAlzheimer's disease
p8566
sg15
I2
sa(dp8567
g9
I225
sg10
VC0026769
p8568
sg12
I18
sg13
Vmultiple sclerosis
p8569
sg15
I2
sa(dp8570
g9
I189
sg10
VC0013604
p8571
sg12
I5
sg13
Vedema
p8572
sg15
I1
sasa(dp8573
g2
VICOSL knockout (ICOSL-KO) mice and wild-type C57BL/6J mice were used as experimental Schistosomiasis model infected with Schistosoma japonicum.
p8574
sg4
(lp8575
sg6
(lp8576
(dp8577
g9
I85
sg10
VC0036323
p8578
sg12
I15
sg13
VSchistosomiasis
p8579
sg15
I1
sasa(dp8580
g2
VThe ICOS-ICOSL signaling has a regulatory effect on CD154-CD40 signaling pathway, and may play an important role in the hepatic egg granuloma formation of Schistosomiasis.
p8581
sg4
(lp8582
(dp8583
g9
I52
sg20
VP29965
p8584
sg12
I5
sg13
VCD154
p8585
sg15
I1
sa(dp8586
g9
I58
sg20
VP25942
p8587
sg12
I4
sg13
VCD40
p8588
sg15
I1
sa(dp8589
g9
I4
sg20
VP16410
p8590
sg12
I10
sg13
VICOS-ICOSL
p8591
sg15
I1
sasg6
(lp8592
(dp8593
g9
I132
sg10
VC0018188
p8594
sg12
I9
sg13
Vgranuloma
p8595
sg15
I1
sa(dp8596
g9
I155
sg10
VC0036323
p8597
sg12
I15
sg13
VSchistosomiasis
p8598
sg15
I1
sasa(dp8599
g2
VUsing models of schistosomiasis in ICOSL KO and the C57BL/6 WT mice, we studied the role of the ICOSL/ICOS interaction in the mediation of the Th17 response in host granulomatous inflammation, particularly in liver fibrosis during S. japonicum infection, and investigated the immune responses and pathology of ICOSL KO mice in these models.
p8600
sg4
(lp8601
(dp8602
g9
I35
sg20
g21
sg12
I8
sg13
VICOSL KO
p8603
sg15
I2
sa(dp8604
g9
I35
sg20
VP16410
p8605
sg12
I4
sg13
VICOS
p8606
sg15
I1
sa(dp8607
g9
I35
sg20
g21
sg12
I8
sg13
VICOSL KO
p8608
sg15
I2
sa(dp8609
g9
I35
sg20
g21
sg12
I5
sg13
VICOSL
p8610
sg15
I1
sasg6
(lp8611
(dp8612
g9
I16
sg10
VC0036323
p8613
sg12
I15
sg13
Vschistosomiasis
p8614
sg15
I1
sa(dp8615
g9
I209
sg10
VC0239946
p8616
sg12
I14
sg13
Vliver fibrosis
p8617
sg15
I2
sa(dp8618
g9
I244
sg10
VC0009450
p8619
sg12
I9
sg13
Vinfection
p8620
sg15
I1
sa(dp8621
g9
I165
sg10
VC0553697
p8622
sg12
I26
sg13
Vgranulomatous inflammation
p8623
sg15
I2
sa(dp8624
g9
I297
sg10
VC0677042
p8625
sg12
I9
sg13
Vpathology
p8626
sg15
I1
sasa(dp8627
g2
VImportantly, there was a clearly positive correlation between the presence of IL-17-producing cells and ICOS expression in ICOSL KO mice, and additional results indicated that Th17 was involved in the pathological tissue remodeling in liver fibrosis induced by schistosomiasis.
p8628
sg4
(lp8629
(dp8630
g9
I123
sg20
g21
sg12
I8
sg13
VICOSL KO
p8631
sg15
I2
sasg6
(lp8632
(dp8633
g9
I235
sg10
VC0239946
p8634
sg12
I14
sg13
Vliver fibrosis
p8635
sg15
I2
sa(dp8636
g9
I261
sg10
VC0036323
p8637
sg12
I15
sg13
Vschistosomiasis
p8638
sg15
I1
sasa(dp8639
g2
VLncRNA ZEB1 Antisense 1 (ZEB1-AS1) has been suggested to be an oncogenic role in human hepatocellular carcinoma, osteosarcoma, glioma and esophageal carcinoma progression.
p8640
sg4
(lp8641
(dp8642
g9
I7
sg20
VP37275
p8643
sg12
I4
sg13
VZEB1
p8644
sg15
I1
sa(dp8645
g9
I30
sg20
g21
sg12
I3
sg13
VAS1
p8646
sg15
I1
sa(dp8647
g9
I0
sg20
VP37275
p8648
sg12
I23
sg13
VLncRNA ZEB1 Antisense 1
p8649
sg15
I4
sasg6
(lp8650
(dp8651
g9
I87
sg10
VC1512411
p8652
sg12
I24
sg13
Vhepatocellular carcinoma
p8653
sg15
I2
sa(dp8654
g9
I138
sg10
VC0152018
p8655
sg12
I20
sg13
Vesophageal carcinoma
p8656
sg15
I2
sa(dp8657
g9
I30
sg10
VC1846534
p8658
sg12
I3
sg13
VAS1
p8659
sg15
I1
sa(dp8660
g9
I113
sg10
VC0029463
p8661
sg12
I12
sg13
Vosteosarcoma
p8662
sg15
I1
sa(dp8663
g9
I127
sg10
VC0017638
p8664
sg12
I6
sg13
Vglioma
p8665
sg15
I1
sasa(dp8666
g2
VZEB1-AS1 acts as an oncogene in hepatocellular carcinoma, accelerating tumor growth and promoting metastasis.
p8667
sg4
(lp8668
(dp8669
g9
I0
sg20
VP37275
p8670
sg12
I4
sg13
VZEB1
p8671
sg15
I1
sa(dp8672
g9
I5
sg20
g21
sg12
I3
sg13
VAS1
p8673
sg15
I1
sasg6
(lp8674
(dp8675
g9
I32
sg10
VC1512411
p8676
sg12
I24
sg13
Vhepatocellular carcinoma
p8677
sg15
I2
sa(dp8678
g9
I98
sg10
VC0027627
p8679
sg12
I10
sg13
Vmetastasis
p8680
sg15
I1
sa(dp8681
g9
I5
sg10
VC1846534
p8682
sg12
I3
sg13
VAS1
p8683
sg15
I1
sa(dp8684
g9
I71
sg10
VC0598934
p8685
sg12
I12
sg13
Vtumor growth
p8686
sg15
I2
sasa(dp8687
g2
VLncRNA ZEB1-AS1 has been identified as a tumor oncogene in hepatocellular carcinoma.
p8688
sg4
(lp8689
(dp8690
g9
I12
sg20
g21
sg12
I3
sg13
VAS1
p8691
sg15
I1
sa(dp8692
g9
I7
sg20
VP37275
p8693
sg12
I4
sg13
VZEB1
p8694
sg15
I1
sasg6
(lp8695
(dp8696
g9
I12
sg10
VC1846534
p8697
sg12
I3
sg13
VAS1
p8698
sg15
I1
sa(dp8699
g9
I59
sg10
VC1512411
p8700
sg12
I24
sg13
Vhepatocellular carcinoma
p8701
sg15
I2
sa(dp8702
g9
I41
sg10
VC0027651
p8703
sg12
I5
sg13
Vtumor
p8704
sg15
I1
sasa(dp8705
g2
VWe analyzed the outcome of allo-SCT in a population of FLT3-positive AML patients according to molecular MRD at the pretransplantation workup, assessed by the quantitative expression evaluation of the panleukemic marker Wilms' tumor (WT1) gene.
p8706
sg4
(lp8707
(dp8708
g9
I55
sg20
VP36888
p8709
sg12
I4
sg13
VFLT3
p8710
sg15
I1
sasg6
(lp8711
(dp8712
g9
I220
sg10
VC0027708
p8713
sg12
I12
sg13
VWilms' tumor
p8714
sg15
I2
sa(dp8715
g9
I32
sg10
VC1848934
p8716
sg12
I3
sg13
VSCT
p8717
sg15
I1
sa(dp8718
g9
I105
sg10
VC1840451
p8719
sg12
I3
sg13
VMRD
p8720
sg15
I1
sa(dp8721
g9
I234
sg10
VC0027708
p8722
sg12
I3
sg13
VWT1
p8723
sg15
I1
sa(dp8724
g9
I69
sg10
VC0023467
p8725
sg12
I3
sg13
VAML
p8726
sg15
I1
sasa(dp8727
g2
VTo determine the chemokine receptor expression profile in gastric mucosa-associated lymphoid tissue (MALT) lymphoma, we performed an expression analysis of 19 chemokine receptors at mRNA levels by using real-time RT-PCR, as well as of five chemokine receptors--CCR8, CCR9, CXCR4, CXCR6 and CXCR7--by immunohistochemistry on human tissue samples of Helicobacter pylori-associated gastritis, gastric MALT lymphoma and gastric extranodal diffuse large B-cell lymphoma originating from MALT lymphoma (transformed MALT lymphoma).
p8728
sg4
(lp8729
(dp8730
g9
I261
sg20
VP51685
p8731
sg12
I4
sg13
VCCR8
p8732
sg15
I1
sa(dp8733
g9
I267
sg20
VP51686
p8734
sg12
I4
sg13
VCCR9
p8735
sg15
I1
sa(dp8736
g9
I273
sg20
VP61073
p8737
sg12
I5
sg13
VCXCR4
p8738
sg15
I1
sa(dp8739
g9
I290
sg20
VP25106
p8740
sg12
I5
sg13
VCXCR7
p8741
sg15
I1
sa(dp8742
g9
I280
sg20
g21
sg12
I5
sg13
VCXCR6
p8743
sg15
I1
sasg6
(lp8744
(dp8745
g9
I398
sg10
VC0242647
p8746
sg12
I13
sg13
VMALT lymphoma
p8747
sg15
I2
sa(dp8748
g9
I107
sg10
VC0024299
p8749
sg12
I8
sg13
Vlymphoma
p8750
sg15
I1
sa(dp8751
g9
I435
sg10
VC0079744
p8752
sg12
I29
sg13
Vdiffuse large B-cell lymphoma
p8753
sg15
I4
sa(dp8754
g9
I398
sg10
VC0242647
p8755
sg12
I13
sg13
VMALT lymphoma
p8756
sg15
I2
sa(dp8757
g9
I390
sg10
VC1333782
p8758
sg12
I21
sg13
Vgastric MALT lymphoma
p8759
sg15
I3
sa(dp8760
g9
I348
sg10
VC0343378
p8761
sg12
I40
sg13
VHelicobacter pylori-associated gastritis
p8762
sg15
I3
sasa(dp8763
g2
VThe transformation of gastric MALT lymphomas to gastric extranodal diffuse large B-cell lymphoma was accompanied by upregulation of CCR1, CCR5, CCR7, CCR8, CCR9, CXCR3, CXCR6, CXCR7 and XCR1.
p8764
sg4
(lp8765
(dp8766
g9
I162
sg20
VP49682
p8767
sg12
I5
sg13
VCXCR3
p8768
sg15
I1
sa(dp8769
g9
I169
sg20
g21
sg12
I5
sg13
VCXCR6
p8770
sg15
I1
sa(dp8771
g9
I138
sg20
VP32302
p8772
sg12
I4
sg13
VCCR5
p8773
sg15
I1
sa(dp8774
g9
I132
sg20
VP32246
p8775
sg12
I4
sg13
VCCR1
p8776
sg15
I1
sa(dp8777
g9
I176
sg20
VP25106
p8778
sg12
I5
sg13
VCXCR7
p8779
sg15
I1
sa(dp8780
g9
I156
sg20
VP51686
p8781
sg12
I4
sg13
VCCR9
p8782
sg15
I1
sa(dp8783
g9
I150
sg20
VP51685
p8784
sg12
I4
sg13
VCCR8
p8785
sg15
I1
sa(dp8786
g9
I186
sg20
VP46094
p8787
sg12
I4
sg13
VXCR1
p8788
sg15
I1
sa(dp8789
g9
I144
sg20
VP32248
p8790
sg12
I4
sg13
VCCR7
p8791
sg15
I1
sasg6
(lp8792
(dp8793
g9
I67
sg10
VC0079744
p8794
sg12
I29
sg13
Vdiffuse large B-cell lymphoma
p8795
sg15
I4
sa(dp8796
g9
I4
sg10
VC1510411
p8797
sg12
I14
sg13
Vtransformation
p8798
sg15
I1
sa(dp8799
g9
I30
sg10
VC0242647
p8800
sg12
I14
sg13
VMALT lymphomas
p8801
sg15
I2
sasa(dp8802
g2
VFeline leukemia virus (FeLV) p27 or gp70 antigen was detected in 21 lymphomas (54%).
p8803
sg4
(lp8804
(dp8805
g9
I29
sg20
VP40305
p8806
sg12
I3
sg13
Vp27
p8807
sg15
I1
sa(dp8808
g9
I36
sg20
g21
sg12
I12
sg13
Vgp70 antigen
p8809
sg15
I2
sasg6
(lp8810
(dp8811
g9
I68
sg10
VC0024299
p8812
sg12
I9
sg13
Vlymphomas
p8813
sg15
I1
sa(dp8814
g9
I0
sg10
VC0085164
p8815
sg12
I15
sg13
VFeline leukemia
p8816
sg15
I2
sasa(dp8817
g2
VVaccines to large B cell lymphoma were made by the covalent attachment of an epitope from the gp70 glycoprotein (SSWDFITV) to the N-termini of the conformationally biased, response-selective C5a agonists EP54 (YSFKPMPLaR) and EP67 (YSFKDMP(MeL)aR).
p8818
sg4
(lp8819
(dp8820
g9
I94
sg20
g21
sg12
I17
sg13
Vgp70 glycoprotein
p8821
sg15
I2
sa(dp8822
g9
I191
sg20
VP21730
p8823
sg12
I3
sg13
VC5a
p8824
sg15
I1
sa(dp8825
g9
I240
sg20
VP61006
p8826
sg12
I3
sg13
VMeL
p8827
sg15
I1
sasg6
(lp8828
(dp8829
g9
I18
sg10
VC0079731
p8830
sg12
I15
sg13
VB cell lymphoma
p8831
sg15
I3
sa(dp8832
g9
I240
sg10
VC3149631
p8833
sg12
I3
sg13
VMeL
p8834
sg15
I1
sasa(dp8835
g2
VSyngeneic Balb/c mice were immunized with these EP54/EP67-containing vaccines and challenged with a lethal dose of the highly liver metastatic and gp70-expressing lymphoma cell line RAW117-H10 to evaluate the ability of these vaccines to induce protective immune outcomes.
p8836
sg4
(lp8837
(dp8838
g9
I147
sg20
g21
sg12
I4
sg13
Vgp70
p8839
sg15
I1
sasg6
(lp8840
(dp8841
g9
I163
sg10
VC0024299
p8842
sg12
I8
sg13
Vlymphoma
p8843
sg15
I1
sasa(dp8844
g2
VCD8(+) T lymphocytes activated in response to Vaccines 2 and 3 express cytotoxic specificity for gp70-expressing RAW117-H10 lymphoma cells, but not antigen-irrelevant MDA-MB231A human breast cancer cells.
p8845
sg4
(lp8846
(dp8847
g9
I0
sg20
VP01732
p8848
sg12
I3
sg13
VCD8
p8849
sg15
I1
sa(dp8850
g9
I97
sg20
g21
sg12
I4
sg13
Vgp70
p8851
sg15
I1
sasg6
(lp8852
(dp8853
g9
I124
sg10
VC0024299
p8854
sg12
I8
sg13
Vlymphoma
p8855
sg15
I1
sa(dp8856
g9
I184
sg10
VC0678222
p8857
sg12
I13
sg13
Vbreast cancer
p8858
sg15
I2
sasa(dp8859
g2
VOur strategy relies on the fact that feline leukemia virus subgroup B (FeLV-B) and amphotropic murine leukemia virus (A-MLV) have closely related gp70 surface envelope glycoproteins and use related Na(+)-dependent phosphate symporters, Pit1 and Pit2, respectively, as their receptors.
p8860
sg4
(lp8861
(dp8862
g9
I245
sg20
g21
sg12
I4
sg13
VPit2
p8863
sg15
I1
sa(dp8864
g9
I236
sg20
VP28069
p8865
sg12
I4
sg13
VPit1
p8866
sg15
I1
sa(dp8867
g9
I146
sg20
g21
sg12
I35
sg13
Vgp70 surface envelope glycoproteins
p8868
sg15
I4
sa(dp8869
g9
I198
sg20
VP19525
p8870
sg12
I36
sg13
VNa(+)-dependent phosphate symporters
p8871
sg15
I3
sasg6
(lp8872
(dp8873
g9
I37
sg10
VC0085164
p8874
sg12
I15
sg13
Vfeline leukemia
p8875
sg15
I2
sa(dp8876
g9
I44
sg10
VC0023418
p8877
sg12
I8
sg13
Vleukemia
p8878
sg15
I1
sasa(dp8879
g2
VNumerous studies have investigated the utility of serum intestinal fatty-acid binding protein (I-FABP) in differentiating acute intestinal ischemia from acute abdomen.
p8880
sg4
(lp8881
(dp8882
g9
I56
sg20
VP12104
p8883
sg12
I37
sg13
Vintestinal fatty-acid binding protein
p8884
sg15
I4
sa(dp8885
g9
I95
sg20
VP12104
p8886
sg12
I6
sg13
VI-FABP
p8887
sg15
I1
sasg6
(lp8888
(dp8889
g9
I122
sg10
VC0001363
p8890
sg12
I25
sg13
Vacute intestinal ischemia
p8891
sg15
I3
sa(dp8892
g9
I153
sg10
VC0000727
p8893
sg12
I13
sg13
Vacute abdomen
p8894
sg15
I2
sasa(dp8895
g2
VThe aim of this meta-analysis is to determine the overall accuracy of serum I-FABP in the diagnosis of acute intestinal ischemia.
p8896
sg4
(lp8897
(dp8898
g9
I70
sg20
VP12104
p8899
sg12
I12
sg13
Vserum I-FABP
p8900
sg15
I2
sasg6
(lp8901
(dp8902
g9
I103
sg10
VC0001363
p8903
sg12
I25
sg13
Vacute intestinal ischemia
p8904
sg15
I3
sasa(dp8905
g2
VThe meta-analysis carried out in this report suggests that the I-FABP may be a useful diagnostic tool to confirm acute intestinal ischemia in acute abdomen, but better-designed trials are still required to confirm our findings.
p8906
sg4
(lp8907
(dp8908
g9
I63
sg20
VP12104
p8909
sg12
I6
sg13
VI-FABP
p8910
sg15
I1
sasg6
(lp8911
(dp8912
g9
I142
sg10
VC0000727
p8913
sg12
I13
sg13
Vacute abdomen
p8914
sg15
I2
sa(dp8915
g9
I113
sg10
VC0001363
p8916
sg12
I25
sg13
Vacute intestinal ischemia
p8917
sg15
I3
sasa(dp8918
g2
VThe aim of the present study was to evaluate whether I-FABP can predict active disease or remission in Crohn's disease (CD) and ulcerative colitis (UC) in a real-life IBD cohort.
p8919
sg4
(lp8920
sg6
(lp8921
(dp8922
g9
I120
sg10
VC0010346
p8923
sg12
I2
sg13
VCD
p8924
sg15
I1
sa(dp8925
g9
I167
sg10
VC0021390
p8926
sg12
I3
sg13
VIBD
p8927
sg15
I1
sa(dp8928
g9
I90
sg10
VC0687702
p8929
sg12
I9
sg13
Vremission
p8930
sg15
I1
sa(dp8931
g9
I148
sg10
VC0009324
p8932
sg12
I2
sg13
VUC
p8933
sg15
I1
sa(dp8934
g9
I103
sg10
VC0010346
p8935
sg12
I15
sg13
VCrohn's disease
p8936
sg15
I2
sa(dp8937
g9
I128
sg10
VC0009324
p8938
sg12
I18
sg13
Vulcerative colitis
p8939
sg15
I2
sasa(dp8940
g2
VIn our study, we found the expression of EWSAT1 was upregulated in ovarian cancer cell lines and samples.
p8941
sg4
(lp8942
sg6
(lp8943
(dp8944
g9
I67
sg10
VC1140680
p8945
sg12
I14
sg13
Vovarian cancer
p8946
sg15
I2
sasa(dp8947
g2
VEcoptic expression of EWSAT1 suppressed miR-330-5p expression in ovarian cancer cell.
p8948
sg4
(lp8949
(dp8950
g9
I40
sg20
g21
sg12
I10
sg13
VmiR-330-5p
p8951
sg15
I1
sasg6
(lp8952
(dp8953
g9
I65
sg10
VC1140680
p8954
sg12
I14
sg13
Vovarian cancer
p8955
sg15
I2
sasa(dp8956
g2
VMoreover, the expression of miR-330-5p was negatively related with the expression of EWSAT1 in ovarian cancer samples.
p8957
sg4
(lp8958
(dp8959
g9
I28
sg20
g21
sg12
I10
sg13
VmiR-330-5p
p8960
sg15
I1
sasg6
(lp8961
(dp8962
g9
I95
sg10
VC1140680
p8963
sg12
I14
sg13
Vovarian cancer
p8964
sg15
I2
sasa(dp8965
g2
VEcoptic expression of miR-330-5p suppressed Pdia3 expression and overexpression of EWSAT1 promoted Pdia3 expression in ovarian cancer cell.
p8966
sg4
(lp8967
(dp8968
g9
I22
sg20
g21
sg12
I10
sg13
VmiR-330-5p
p8969
sg15
I1
sa(dp8970
g9
I44
sg20
VP30101
p8971
sg12
I5
sg13
VPdia3
p8972
sg15
I1
sa(dp8973
g9
I44
sg20
VP30101
p8974
sg12
I5
sg13
VPdia3
p8975
sg15
I1
sasg6
(lp8976
(dp8977
g9
I119
sg10
VC1140680
p8978
sg12
I14
sg13
Vovarian cancer
p8979
sg15
I2
sasa(dp8980
g2
VOverexpression of EWSAT1 increased ovarian cancer cell proliferation, colony formation and invasion through targeting miR-330-5p.
p8981
sg4
(lp8982
(dp8983
g9
I118
sg20
g21
sg12
I10
sg13
VmiR-330-5p
p8984
sg15
I1
sasg6
(lp8985
(dp8986
g9
I55
sg10
VC0334094
p8987
sg12
I13
sg13
Vproliferation
p8988
sg15
I1
sa(dp8989
g9
I91
sg10
VC2699153
p8990
sg12
I8
sg13
Vinvasion
p8991
sg15
I1
sa(dp8992
g9
I35
sg10
VC1140680
p8993
sg12
I14
sg13
Vovarian cancer
p8994
sg15
I2
sasa(dp8995
g2
VThese data suggested that EWSAT1 might act as an oncogene in the development of ovarian cancer partly through inhibiting miR-330-5p expression.
p8996
sg4
(lp8997
(dp8998
g9
I121
sg20
g21
sg12
I10
sg13
VmiR-330-5p
p8999
sg15
I1
sasg6
(lp9000
(dp9001
g9
I80
sg10
VC1140680
p9002
sg12
I14
sg13
Vovarian cancer
p9003
sg15
I2
sasa(dp9004
g2
VRecently, lncRNA Ewing sarcoma-associated transcript 1 (EWSAT1) was functionally identified in Ewing sarcoma, a highly aggressive primary pediatric bone tumor.
p9005
sg4
(lp9006
(dp9007
g9
I10
sg20
VP11308
p9008
sg12
I44
sg13
VlncRNA Ewing sarcoma-associated transcript 1
p9009
sg15
I5
sasg6
(lp9010
(dp9011
g9
I148
sg10
VC0005967
p9012
sg12
I10
sg13
Vbone tumor
p9013
sg15
I2
sa(dp9014
g9
I17
sg10
VC0553580
p9015
sg12
I13
sg13
VEwing sarcoma
p9016
sg15
I2
sa(dp9017
g9
I119
sg10
VC0001807
p9018
sg12
I10
sg13
Vaggressive
p9019
sg15
I1
sa(dp9020
g9
I17
sg10
VC0553580
p9021
sg12
I13
sg13
VEwing sarcoma
p9022
sg15
I2
sasa(dp9023
g2
VLong non-coding RNA (lncRNA) Ewing sarcoma associated transcript 1 (EWSAT1) has been identified as an oncogene, and its dysregulation is closed corrected with tumor progression in Ewing sarcoma.
p9024
sg4
(lp9025
sg6
(lp9026
(dp9027
g9
I29
sg10
VC0553580
p9028
sg12
I13
sg13
VEwing sarcoma
p9029
sg15
I2
sa(dp9030
g9
I159
sg10
VC0178874
p9031
sg12
I17
sg13
Vtumor progression
p9032
sg15
I2
sa(dp9033
g9
I29
sg10
VC0553580
p9034
sg12
I13
sg13
VEwing sarcoma
p9035
sg15
I2
sasa(dp9036
g2
VRecently, high-through put analysis reveals that EWSAT1 is also highly expressed in human nasopharyngeal carcinoma (NPC).
p9037
sg4
(lp9038
sg6
(lp9039
(dp9040
g9
I90
sg10
VC2931822
p9041
sg12
I24
sg13
Vnasopharyngeal carcinoma
p9042
sg15
I2
sa(dp9043
g9
I116
sg10
VC2931822
p9044
sg12
I3
sg13
VNPC
p9045
sg15
I1
sasa(dp9046
g2
VWe determined that long noncoding RNA-277 (Ewing sarcoma-associated transcript 1 [EWSAT1]) is upregulated by EWS-FLI1 in pMPCs.
p9047
sg4
(lp9048
(dp9049
g9
I82
sg20
g21
sg12
I3
sg13
VEWS
p9050
sg15
I1
sa(dp9051
g9
I113
sg20
g21
sg12
I4
sg13
VFLI1
p9052
sg15
I1
sasg6
(lp9053
(dp9054
g9
I43
sg10
VC0553580
p9055
sg12
I13
sg13
VEwing sarcoma
p9056
sg15
I2
sasa(dp9057
g2
VInhibition of EWSAT1 expression diminished the ability of Ewing sarcoma cell lines to proliferate and form colonies in soft agar, whereas EWSAT1 inhibition had no effect on other cell types tested.
p9058
sg4
(lp9059
sg6
(lp9060
(dp9061
g9
I58
sg10
VC0553580
p9062
sg12
I13
sg13
VEwing sarcoma
p9063
sg15
I2
sasa(dp9064
g2
VAnalysis of RNAseq data from primary human Ewing sarcoma further supported a role for EWSAT1 in mediating gene repression.
p9065
sg4
(lp9066
sg6
(lp9067
(dp9068
g9
I43
sg10
VC0553580
p9069
sg12
I13
sg13
VEwing sarcoma
p9070
sg15
I2
sasa(dp9071
g2
VTogether, our data reveal that EWSAT1 is a downstream target of EWS-FLI1 that facilitates the development of Ewing sarcoma via the repression of target genes.
p9072
sg4
(lp9073
(dp9074
g9
I31
sg20
g21
sg12
I3
sg13
VEWS
p9075
sg15
I1
sa(dp9076
g9
I68
sg20
g21
sg12
I4
sg13
VFLI1
p9077
sg15
I1
sasg6
(lp9078
(dp9079
g9
I109
sg10
VC0553580
p9080
sg12
I13
sg13
VEwing sarcoma
p9081
sg15
I2
sasa(dp9082
g2
VResults: The data show that the expression of MZF-1/Elk-1 is correlated with that of PKCAlfa in hepatocellular carcinoma (HCC), but not in bladder and lung cancers.
p9083
sg4
(lp9084
(dp9085
g9
I52
sg20
VP54762
p9086
sg12
I5
sg13
VElk-1
p9087
sg15
I1
sa(dp9088
g9
I46
sg20
VP28698
p9089
sg12
I5
sg13
VMZF-1
p9090
sg15
I1
sasg6
(lp9091
(dp9092
g9
I122
sg10
VC2239176
p9093
sg12
I3
sg13
VHCC
p9094
sg15
I1
sa(dp9095
g9
I151
sg10
VC0242379
p9096
sg12
I12
sg13
Vlung cancers
p9097
sg15
I2
sa(dp9098
g9
I96
sg10
VC2239176
p9099
sg12
I24
sg13
Vhepatocellular carcinoma
p9100
sg15
I2
sasa(dp9101
g2
VHere, using PEI-Mn0.5Zn0.5Fe2O4 nanoparticles (PEI-MZF-NPs) as magnetic media for MFH (magnetic fluid hyperthermia) and gene transfer vector for gene-therapy, a combined therapy, pHRE-Egr1-HSV-TK/(131)I-antiAFPMcAb-GCV/MFH, for hepatoma is developed.
p9102
sg4
(lp9103
(dp9104
g9
I179
sg20
VP29401
p9105
sg12
I16
sg13
VpHRE-Egr1-HSV-TK
p9106
sg15
I1
sa(dp9107
g9
I12
sg20
g21
sg12
I33
sg13
VPEI-Mn0.5Zn0.5Fe2O4 nanoparticles
p9108
sg15
I2
sa(dp9109
g9
I47
sg20
VP28698
p9110
sg12
I11
sg13
VPEI-MZF-NPs
p9111
sg15
I1
sasg6
(lp9112
(dp9113
g9
I228
sg10
VC0023903
p9114
sg12
I8
sg13
Vhepatoma
p9115
sg15
I1
sa(dp9116
g9
I55
sg10
VC0027341
p9117
sg12
I3
sg13
VNPs
p9118
sg15
I1
sasa(dp9119
g2
VTo explore a new combination of thermal treatment and gene therapy for hepatoma, a heat-inducible herpes simplex virus thymidine kinase/ganciclovir (HSV-TK/GCV) gene therapy system was developed in which thermal energy generated by Mn0.5Zn0.5Fe2O4 nanoparticles (MZF-NPs) under an alternating magnetic field was used to activate gene expression.
p9120
sg4
(lp9121
(dp9122
g9
I232
sg20
g21
sg12
I29
sg13
VMn0.5Zn0.5Fe2O4 nanoparticles
p9123
sg15
I2
sa(dp9124
g9
I156
sg20
VP23434
p9125
sg12
I3
sg13
VGCV
p9126
sg15
I1
sa(dp9127
g9
I153
sg20
VP29401
p9128
sg12
I2
sg13
VTK
p9129
sg15
I1
sa(dp9130
g9
I263
sg20
VP28698
p9131
sg12
I7
sg13
VMZF-NPs
p9132
sg15
I1
sasg6
(lp9133
(dp9134
g9
I71
sg10
VC0023903
p9135
sg12
I8
sg13
Vhepatoma
p9136
sg15
I1
sa(dp9137
g9
I98
sg10
VC0019348
p9138
sg12
I14
sg13
Vherpes simplex
p9139
sg15
I2
sa(dp9140
g9
I267
sg10
VC0027341
p9141
sg12
I3
sg13
VNPs
p9142
sg15
I1
sasa(dp9143
g2
VMagnet-induced heating was then applied to cells to assess the antihepatoma effects of the polyethylenimine (PEI)-MZF-NPs/pHsp 70-HSV-TK/GCV complex, in vitro and in vivo.
p9144
sg4
(lp9145
(dp9146
g9
I137
sg20
VP23434
p9147
sg12
I3
sg13
VGCV
p9148
sg15
I1
sa(dp9149
g9
I118
sg20
VP0C0P6
p9150
sg12
I3
sg13
VNPs
p9151
sg15
I1
sa(dp9152
g9
I114
sg20
VP28698
p9153
sg12
I3
sg13
VMZF
p9154
sg15
I1
sa(dp9155
g9
I134
sg20
VP29401
p9156
sg12
I2
sg13
VTK
p9157
sg15
I1
sasg6
(lp9158
(dp9159
g9
I118
sg10
VC0027341
p9160
sg12
I3
sg13
VNPs
p9161
sg15
I1
sasa(dp9162
g2
VIn this study, the molecular mechanism of protein kinase C alpha (PKCAlfa) gene regulation in hepatocellular carcinoma (HCC) involving Ets-like protein-1 (Elk-1) and myeloid zinc finger-1 (MZF-1) was investigated.
p9163
sg4
(lp9164
(dp9165
g9
I166
sg20
VP28698
p9166
sg12
I21
sg13
Vmyeloid zinc finger-1
p9167
sg15
I3
sa(dp9168
g9
I155
sg20
VP54762
p9169
sg12
I5
sg13
VElk-1
p9170
sg15
I1
sa(dp9171
g9
I135
sg20
VP17980
p9172
sg12
I18
sg13
VEts-like protein-1
p9173
sg15
I2
sa(dp9174
g9
I42
sg20
VP17252
p9175
sg12
I22
sg13
Vprotein kinase C alpha
p9176
sg15
I4
sa(dp9177
g9
I189
sg20
VP28698
p9178
sg12
I5
sg13
VMZF-1
p9179
sg15
I1
sasg6
(lp9180
(dp9181
g9
I120
sg10
VC2239176
p9182
sg12
I3
sg13
VHCC
p9183
sg15
I1
sa(dp9184
g9
I94
sg10
VC2239176
p9185
sg12
I24
sg13
Vhepatocellular carcinoma
p9186
sg15
I2
sasa(dp9187
g2
VBesides, PEI-MZF-NPs were used as magnetic media for thermotherapy to treat hepatoma by magnet-induced heating, combined with radiation-gene therapy.
p9188
sg4
(lp9189
(dp9190
g9
I9
sg20
VP28698
p9191
sg12
I11
sg13
VPEI-MZF-NPs
p9192
sg15
I1
sasg6
(lp9193
(dp9194
g9
I17
sg10
VC0027341
p9195
sg12
I3
sg13
VNPs
p9196
sg15
I1
sa(dp9197
g9
I76
sg10
VC0023903
p9198
sg12
I8
sg13
Vhepatoma
p9199
sg15
I1
sasa(dp9200
g2
VIn a recent study on hepatocellular carcinoma (HCC), we have shown that the transcription factors Myeloid Zinc Finger-1 (MZF-1) and Ets-like-protein 1 (Elk-1) are significantly related to protein kinase C alpha (PKCAlfa) expression.
p9201
sg4
(lp9202
(dp9203
g9
I121
sg20
VP28698
p9204
sg12
I5
sg13
VMZF-1
p9205
sg15
I1
sa(dp9206
g9
I132
sg20
VP14222
p9207
sg12
I18
sg13
VEts-like-protein 1
p9208
sg15
I2
sa(dp9209
g9
I188
sg20
VP17252
p9210
sg12
I22
sg13
Vprotein kinase C alpha
p9211
sg15
I4
sa(dp9212
g9
I98
sg20
VP28698
p9213
sg12
I21
sg13
VMyeloid Zinc Finger-1
p9214
sg15
I3
sa(dp9215
g9
I152
sg20
VP54762
p9216
sg12
I5
sg13
VElk-1
p9217
sg15
I1
sasg6
(lp9218
(dp9219
g9
I21
sg10
VC2239176
p9220
sg12
I24
sg13
Vhepatocellular carcinoma
p9221
sg15
I2
sa(dp9222
g9
I47
sg10
VC2239176
p9223
sg12
I3
sg13
VHCC
p9224
sg15
I1
sasa(dp9225
g2
VRecently, our research into hepatocellular carcinoma (HCC) has shown that the transcription factors Myeloid Zinc Finger-1 (MZF-1) and Ets-like-protein 1 are related to protein kinase C alpha (PKCAlfa) expression.
p9226
sg4
(lp9227
(dp9228
g9
I100
sg20
VP28698
p9229
sg12
I21
sg13
VMyeloid Zinc Finger-1
p9230
sg15
I3
sa(dp9231
g9
I123
sg20
VP28698
p9232
sg12
I5
sg13
VMZF-1
p9233
sg15
I1
sa(dp9234
g9
I168
sg20
VP17252
p9235
sg12
I22
sg13
Vprotein kinase C alpha
p9236
sg15
I4
sa(dp9237
g9
I134
sg20
VP14222
p9238
sg12
I18
sg13
VEts-like-protein 1
p9239
sg15
I2
sasg6
(lp9240
(dp9241
g9
I54
sg10
VC2239176
p9242
sg12
I3
sg13
VHCC
p9243
sg15
I1
sa(dp9244
g9
I28
sg10
VC2239176
p9245
sg12
I24
sg13
Vhepatocellular carcinoma
p9246
sg15
I2
sasa(dp9247
g2
VUsing immunocytochemistry, we investigated the distribution of chromogranin A, chromogranin B, secretoneurin, and, for comparison, dynorphin in hippocampal specimens removed at routine surgery from patients with drug-resistant mesial temporal lobe epilepsy and in autopsy tissues from nonneurologically deceased subjects.
p9248
sg4
(lp9249
(dp9250
g9
I79
sg20
VP08311
p9251
sg12
I14
sg13
Vchromogranin B
p9252
sg15
I2
sa(dp9253
g9
I131
sg20
VP01213
p9254
sg12
I9
sg13
Vdynorphin
p9255
sg15
I1
sa(dp9256
g9
I95
sg20
VP13521
p9257
sg12
I13
sg13
Vsecretoneurin
p9258
sg15
I1
sa(dp9259
g9
I63
sg20
VP10645
p9260
sg12
I14
sg13
Vchromogranin A
p9261
sg15
I2
sasg6
(lp9262
(dp9263
g9
I234
sg10
VC0014556
p9264
sg12
I22
sg13
Vtemporal lobe epilepsy
p9265
sg15
I3
sasa(dp9266
g2
VThe most intriguing change seen in human temporal lobe epilepsy specimens and in the kainic acid model of the rat was the prominent staining of the inner molecular layer, indicating storage of chromogranins A and B and secretoneurin in terminals of reorganized mossy fibers, from which they may be released upon nerve stimulation.
p9267
sg4
(lp9268
(dp9269
g9
I193
sg20
VP08311
p9270
sg12
I39
sg13
Vchromogranins A and B and secretoneurin
p9271
sg15
I6
sasg6
(lp9272
(dp9273
g9
I41
sg10
VC0014556
p9274
sg12
I22
sg13
Vtemporal lobe epilepsy
p9275
sg15
I3
sasa(dp9276
g2
VTransition of control prediabetic ZDF rats to diabetes was associated with reduced plasma insulin levels, reduced islet insulin content and GSIS, reduced stearoyl-CoA desaturase 2 (SCD 2) expression, and increased islet TAG, diacylglyceride (DAG) and ceramides species containing saturated FA.
p9277
sg4
(lp9278
(dp9279
g9
I114
sg20
VP01308
p9280
sg12
I13
sg13
Vislet insulin
p9281
sg15
I2
sa(dp9282
g9
I154
sg20
g21
sg12
I25
sg13
Vstearoyl-CoA desaturase 2
p9283
sg15
I3
sa(dp9284
g9
I83
sg20
VP01308
p9285
sg12
I14
sg13
Vplasma insulin
p9286
sg15
I2
sa(dp9287
g9
I181
sg20
g21
sg12
I5
sg13
VSCD 2
p9288
sg15
I2
sasg6
(lp9289
(dp9290
g9
I46
sg10
VC0011849
p9291
sg12
I8
sg13
Vdiabetes
p9292
sg15
I1
sa(dp9293
g9
I0
sg10
VC0599156
p9294
sg12
I10
sg13
VTransition
p9295
sg15
I1
sa(dp9296
g9
I163
sg10
VC2678439
p9297
sg12
I3
sg13
VCoA
p9298
sg15
I1
sa(dp9299
g9
I220
sg10
VC0037293
p9300
sg12
I3
sg13
VTAG
p9301
sg15
I1
sa(dp9302
g9
I181
sg10
VC0002895
p9303
sg12
I3
sg13
VSCD
p9304
sg15
I1
sasa(dp9305
g2
VIn this research, we have found that lycorine significantly induces the apoptotic and autophagic capacities of hepatocellular carcinoma (HCC) cells in vitro and in vivo Treatment with specific autophagy inhibitor (3-methyladenine/Bafilomycin A1) or knockdown of LC-3B/Atg5 by siRNA drastically enhances the apoptotic cell death effect by facilitating the switch from autophagy to apoptosis.
p9306
sg4
(lp9307
(dp9308
g9
I268
sg20
g21
sg12
I4
sg13
VAtg5
p9309
sg15
I1
sasg6
(lp9310
(dp9311
g9
I137
sg10
VC2239176
p9312
sg12
I3
sg13
VHCC
p9313
sg15
I1
sa(dp9314
g9
I111
sg10
VC2239176
p9315
sg12
I24
sg13
Vhepatocellular carcinoma
p9316
sg15
I2
sasa(dp9317
g2
VThe differential expression of 10 miRNAs were validated by RT-qPCR (let-7a, let-7d, let-7f and miR-16 were downregulated while miR-29b, miR-142-3p, miR-144, miR-203, and miR-223 were upregulated in OSCC; the expression of miR-1275 was variable in tumours, with high levels associated to regional lymph node invasion; additionally, miR-223 exhibited an association with advanced tumour stage/size).
p9318
sg4
(lp9319
(dp9320
g9
I136
sg20
g21
sg12
I10
sg13
VmiR-142-3p
p9321
sg15
I1
sa(dp9322
g9
I157
sg20
g21
sg12
I7
sg13
VmiR-203
p9323
sg15
I1
sa(dp9324
g9
I127
sg20
g21
sg12
I7
sg13
VmiR-29b
p9325
sg15
I1
sa(dp9326
g9
I148
sg20
g21
sg12
I7
sg13
VmiR-144
p9327
sg15
I1
sa(dp9328
g9
I95
sg20
g21
sg12
I6
sg13
VmiR-16
p9329
sg15
I1
sasg6
(lp9330
(dp9331
g9
I247
sg10
VC0027651
p9332
sg12
I6
sg13
Vtumour
p9333
sg15
I1
sa(dp9334
g9
I247
sg10
VC0027651
p9335
sg12
I7
sg13
Vtumours
p9336
sg15
I1
sa(dp9337
g9
I307
sg10
VC2699153
p9338
sg12
I8
sg13
Vinvasion
p9339
sg15
I1
sasa(dp9340
g2
VTo the best of our knowledge, this is the first report to show the association of miR-1275 with nodal invasion and the upregulation of miR-144 in OSCC.
p9341
sg4
(lp9342
(dp9343
g9
I82
sg20
g21
sg12
I8
sg13
VmiR-1275
p9344
sg15
I1
sasg6
(lp9345
(dp9346
g9
I102
sg10
VC2699153
p9347
sg12
I8
sg13
Vinvasion
p9348
sg15
I1
sasa(dp9349
g2
VIn the subgroup of non-vomiting drinkers with Wernicke's encephalopathy (WE), the slope of the linear regression of AETK on ETK was 1.21, so that apoTK decreased as ETK decreased.
p9350
sg4
(lp9351
(dp9352
g9
I117
sg20
VP51813
p9353
sg12
I3
sg13
VETK
p9354
sg15
I1
sa(dp9355
g9
I117
sg20
VP51813
p9356
sg12
I3
sg13
VETK
p9357
sg15
I1
sasg6
(lp9358
(dp9359
g9
I46
sg10
VC0043121
p9360
sg12
I25
sg13
VWernicke's encephalopathy
p9361
sg15
I2
sa(dp9362
g9
I23
sg10
VC0042963
p9363
sg12
I8
sg13
Vvomiting
p9364
sg15
I1
sa(dp9365
g9
I73
sg10
VC0043121
p9366
sg12
I2
sg13
VWE
p9367
sg15
I1
sasa(dp9368
g2
VIn pancreatic ductal adenocarcinoma, the CCL2-CCR2 chemokine axis is used to recruit tumour-associated macrophages for construction of an immunosuppressive tumour microenvironment.
p9369
sg4
(lp9370
(dp9371
g9
I41
sg20
VP13500
p9372
sg12
I4
sg13
VCCL2
p9373
sg15
I1
sa(dp9374
g9
I46
sg20
VP41597
p9375
sg12
I4
sg13
VCCR2
p9376
sg15
I1
sasg6
(lp9377
(dp9378
g9
I3
sg10
VC1335302
p9379
sg12
I32
sg13
Vpancreatic ductal adenocarcinoma
p9380
sg15
I3
sa(dp9381
g9
I85
sg10
VC0027651
p9382
sg12
I6
sg13
Vtumour
p9383
sg15
I1
sa(dp9384
g9
I85
sg10
VC0027651
p9385
sg12
I6
sg13
Vtumour
p9386
sg15
I1
sasa(dp9387
g2
VThis pathway has prognostic implications in pancreatic cancer, and blockade of CCR2 restores anti-tumour immunity in preclinical models.
p9388
sg4
(lp9389
(dp9390
g9
I79
sg20
VP41597
p9391
sg12
I4
sg13
VCCR2
p9392
sg15
I1
sasg6
(lp9393
(dp9394
g9
I44
sg10
VC0235974
p9395
sg12
I17
sg13
Vpancreatic cancer
p9396
sg15
I2
sa(dp9397
g9
I98
sg10
VC0027651
p9398
sg12
I6
sg13
Vtumour
p9399
sg15
I1
sasa(dp9400
g2
VTo determine the role of the CCL2/CCR2 axis and inflammatory monocytes (CCR2(+)/CD14(+)) as immunotherapeutic targets in the treatment of pancreatic cancer.
p9401
sg4
(lp9402
(dp9403
g9
I29
sg20
VP13500
p9404
sg12
I4
sg13
VCCL2
p9405
sg15
I1
sa(dp9406
g9
I34
sg20
VP41597
p9407
sg12
I4
sg13
VCCR2
p9408
sg15
I1
sa(dp9409
g9
I34
sg20
VP41597
p9410
sg12
I4
sg13
VCCR2
p9411
sg15
I1
sa(dp9412
g9
I80
sg20
VP08571
p9413
sg12
I4
sg13
VCD14
p9414
sg15
I1
sasg6
(lp9415
(dp9416
g9
I138
sg10
VC0235974
p9417
sg12
I17
sg13
Vpancreatic cancer
p9418
sg15
I2
sasa(dp9419
g2
VA novel CCR2 inhibitor (PF-04136309) was tested in an orthotopic model of murine pancreatic cancer.
p9420
sg4
(lp9421
(dp9422
g9
I8
sg20
VP41597
p9423
sg12
I4
sg13
VCCR2
p9424
sg15
I1
sasg6
(lp9425
(dp9426
g9
I81
sg10
VC0235974
p9427
sg12
I17
sg13
Vpancreatic cancer
p9428
sg15
I2
sasa(dp9429
g2
VHuman pancreatic cancer produces CCL2, and immunosuppressive CCR2(+) macrophages infiltrate these tumors.
p9430
sg4
(lp9431
(dp9432
g9
I33
sg20
VP13500
p9433
sg12
I4
sg13
VCCL2
p9434
sg15
I1
sasg6
(lp9435
(dp9436
g9
I6
sg10
VC0235974
p9437
sg12
I17
sg13
Vpancreatic cancer
p9438
sg15
I2
sa(dp9439
g9
I98
sg10
VC0027651
p9440
sg12
I6
sg13
Vtumors
p9441
sg15
I1
sa(dp9442
g9
I81
sg10
VC0332448
p9443
sg12
I10
sg13
Vinfiltrate
p9444
sg15
I1
sasa(dp9445
g2
VInflammatory monocyte recruitment is critical to pancreatic cancer progression, and targeting CCR2 may be an effective immunotherapeutic strategy in this disease.
p9446
sg4
(lp9447
(dp9448
g9
I94
sg20
VP41597
p9449
sg12
I4
sg13
VCCR2
p9450
sg15
I1
sasg6
(lp9451
(dp9452
g9
I22
sg10
VC0271510
p9453
sg12
I11
sg13
Vrecruitment
p9454
sg15
I1
sa(dp9455
g9
I60
sg10
VC0178874
p9456
sg12
I18
sg13
Vcancer progression
p9457
sg15
I2
sasa(dp9458
g2
VWeaver syndrome (WS) is a rare congenital overgrowth disorder caused by heterozygous mutations in EZH2 (enhancer of zeste homolog 2) or EED (embryonic ectoderm development).
p9459
sg4
(lp9460
sg6
(lp9461
(dp9462
g9
I17
sg10
VC0265210
p9463
sg12
I2
sg13
VWS
p9464
sg15
I1
sa(dp9465
g9
I0
sg10
VC0265210
p9466
sg12
I15
sg13
VWeaver syndrome
p9467
sg15
I2
sa(dp9468
g9
I31
sg10
VC0332887
p9469
sg12
I21
sg13
Vcongenital overgrowth
p9470
sg15
I2
sasa(dp9471
g2
VWe evaluated the associations of six nonsynonymous SNPs in the MMP3, MMP8, and MMP9 genes with skin cancer risk in a nested case-control study of Caucasians within the Nurses' Health Study among 218 melanoma cases, 285 squamous cell carcinoma (SCC) cases, 300 basal cell carcinoma (BCC) cases, and 870 normal controls.
p9472
sg4
(lp9473
(dp9474
g9
I79
sg20
VP14780
p9475
sg12
I10
sg13
VMMP9 genes
p9476
sg15
I2
sa(dp9477
g9
I63
sg20
VP08254
p9478
sg12
I4
sg13
VMMP3
p9479
sg15
I1
sa(dp9480
g9
I69
sg20
VP22894
p9481
sg12
I4
sg13
VMMP8
p9482
sg15
I1
sasg6
(lp9483
(dp9484
g9
I199
sg10
VC0025202
p9485
sg12
I8
sg13
Vmelanoma
p9486
sg15
I1
sa(dp9487
g9
I244
sg10
VC0007137
p9488
sg12
I3
sg13
VSCC
p9489
sg15
I1
sa(dp9490
g9
I95
sg10
VC0007114
p9491
sg12
I11
sg13
Vskin cancer
p9492
sg15
I2
sa(dp9493
g9
I219
sg10
VC0007137
p9494
sg12
I23
sg13
Vsquamous cell carcinoma
p9495
sg15
I3
sa(dp9496
g9
I282
sg10
VC0007117
p9497
sg12
I3
sg13
VBCC
p9498
sg15
I1
sa(dp9499
g9
I260
sg10
VC0007117
p9500
sg12
I20
sg13
Vbasal cell carcinoma
p9501
sg15
I3
sasa(dp9502
g2
VNinety-four cases of squamous cell carcinoma and 108 cases of basal cell carcinoma using tissue array in order to determine correlations between the expression of Ki-67, p53, EGFR, CD44v6, MMP-1 and MMP-3, invasiveness and histologic differentiation.
p9503
sg4
(lp9504
(dp9505
g9
I199
sg20
VP08254
p9506
sg12
I5
sg13
VMMP-3
p9507
sg15
I1
sa(dp9508
g9
I189
sg20
VP03956
p9509
sg12
I5
sg13
VMMP-1
p9510
sg15
I1
sa(dp9511
g9
I170
sg20
VP42771
p9512
sg12
I3
sg13
Vp53
p9513
sg15
I1
sa(dp9514
g9
I163
sg20
VP46013
p9515
sg12
I5
sg13
VKi-67
p9516
sg15
I1
sasg6
(lp9517
(dp9518
g9
I21
sg10
VC0007137
p9519
sg12
I23
sg13
Vsquamous cell carcinoma
p9520
sg15
I3
sa(dp9521
g9
I62
sg10
VC0007117
p9522
sg12
I20
sg13
Vbasal cell carcinoma
p9523
sg15
I3
sasa(dp9524
g2
VA novel zinc oxide-binding peptide (ZBP), FPYPGGDA, with high affinity to ZNP (K a  = 2.26 x 106 M-1) was isolated from a random peptide library and fused with a bacterial antigen, ScaA of Orientia tsutsugamushi, the causative agent of scrub typhus.
p9525
sg4
(lp9526
(dp9527
g9
I36
sg20
g21
sg12
I3
sg13
VZBP
p9528
sg15
I1
sa(dp9529
g9
I8
sg20
VP10070
p9530
sg12
I26
sg13
Vzinc oxide-binding peptide
p9531
sg15
I3
sa(dp9532
g9
I162
sg20
g21
sg12
I17
sg13
Vbacterial antigen
p9533
sg15
I2
sasg6
(lp9534
(dp9535
g9
I198
sg10
VC0036472
p9536
sg12
I13
sg13
Vtsutsugamushi
p9537
sg15
I1
sa(dp9538
g9
I236
sg10
VC0036472
p9539
sg12
I12
sg13
Vscrub typhus
p9540
sg15
I2
sasa(dp9541
g2
VThe results show that the main latex allergen, a glycine-rich protein molecule, can cause cutaneous, inhalant and systemic hypersensitivity reactions.
p9542
sg4
(lp9543
(dp9544
g9
I49
sg20
g21
sg12
I29
sg13
Vglycine-rich protein molecule
p9545
sg15
I3
sasg6
(lp9546
(dp9547
g9
I123
sg10
VC0020517
p9548
sg12
I26
sg13
Vhypersensitivity reactions
p9549
sg15
I2
sasa(dp9550
g2
VOne hundred and one consecutive patients of Han nationality with rheumatic heart disease undergoing valve surgery were enrolled and randomly assigned to an experimental group (n=50, based on CYP2C9 and VKORC1 genotypes, pharmacogenetic-based "predicted warfarin dose" for 3 days and then was adjusted to INR until stable warfarin maintenance dose) or a control group (n=51, 2.5mg/d for 3 days and then was adjusted to INR until stable warfarin maintenance dose).
p9551
sg4
(lp9552
(dp9553
g9
I191
sg20
VP11712
p9554
sg12
I6
sg13
VCYP2C9
p9555
sg15
I1
sa(dp9556
g9
I202
sg20
g21
sg12
I6
sg13
VVKORC1
p9557
sg15
I1
sasg6
(lp9558
(dp9559
g9
I65
sg10
VC0035439
p9560
sg12
I23
sg13
Vrheumatic heart disease
p9561
sg15
I3
sasa(dp9562
g2
VRNF216) have recently been identified in patients suffering from Gordon Holmes syndrome (GHS), characterized by cognitive decline, dementia, and movement disorders.
p9563
sg4
(lp9564
(dp9565
g9
I0
sg20
g21
sg12
I6
sg13
VRNF216
p9566
sg15
I1
sasg6
(lp9567
(dp9568
g9
I131
sg10
VC0497327
p9569
sg12
I8
sg13
Vdementia
p9570
sg15
I1
sa(dp9571
g9
I89
sg10
VC1859305
p9572
sg12
I3
sg13
VGHS
p9573
sg15
I1
sa(dp9574
g9
I50
sg10
VC0683278
p9575
sg12
I9
sg13
Vsuffering
p9576
sg15
I1
sa(dp9577
g9
I145
sg10
VC0026650
p9578
sg12
I18
sg13
Vmovement disorders
p9579
sg15
I2
sa(dp9580
g9
I65
sg10
VC1859305
p9581
sg12
I22
sg13
VGordon Holmes syndrome
p9582
sg15
I3
sa(dp9583
g9
I112
sg10
VC0338656
p9584
sg12
I17
sg13
Vcognitive decline
p9585
sg15
I2
sasa(dp9586
g2
VOur current findings of Arc misregulation by TRIAD3A variants suggest that loss-of-function mutations in TRIAD3A may contribute to dementia observed in patients with GHS driven by dysfunctional UPS components, leading to cognitive impairments through the synaptic protein Arc.
p9587
sg4
(lp9588
(dp9589
g9
I24
sg20
g21
sg12
I3
sg13
VArc
p9590
sg15
I1
sa(dp9591
g9
I255
sg20
g21
sg12
I20
sg13
Vsynaptic protein Arc
p9592
sg15
I3
sa(dp9593
g9
I45
sg20
g21
sg12
I16
sg13
VTRIAD3A variants
p9594
sg15
I2
sa(dp9595
g9
I45
sg20
g21
sg12
I7
sg13
VTRIAD3A
p9596
sg15
I1
sasg6
(lp9597
(dp9598
g9
I24
sg10
VC0001857
p9599
sg12
I3
sg13
VArc
p9600
sg15
I1
sa(dp9601
g9
I221
sg10
VC0338656
p9602
sg12
I21
sg13
Vcognitive impairments
p9603
sg15
I2
sa(dp9604
g9
I24
sg10
VC0001857
p9605
sg12
I3
sg13
VArc
p9606
sg15
I1
sa(dp9607
g9
I131
sg10
VC0497327
p9608
sg12
I8
sg13
Vdementia
p9609
sg15
I1
sasa(dp9610
g2
VGordon Holmes syndrome (GHS) is a distinct phenotype of autosomal recessive cerebellar ataxia, characterized by ataxia, dementia, reproductive defects and hypogonadism; it has been recently found to be associated with RNF216 mutation.
p9611
sg4
(lp9612
(dp9613
g9
I218
sg20
g21
sg12
I15
sg13
VRNF216 mutation
p9614
sg15
I2
sasg6
(lp9615
(dp9616
g9
I87
sg10
VC0004134
p9617
sg12
I6
sg13
Vataxia
p9618
sg15
I1
sa(dp9619
g9
I120
sg10
VC0497327
p9620
sg12
I8
sg13
Vdementia
p9621
sg15
I1
sa(dp9622
g9
I155
sg10
VC0020619
p9623
sg12
I12
sg13
Vhypogonadism
p9624
sg15
I1
sa(dp9625
g9
I0
sg10
VC1859305
p9626
sg12
I22
sg13
VGordon Holmes syndrome
p9627
sg15
I3
sa(dp9628
g9
I76
sg10
VC0007758
p9629
sg12
I17
sg13
Vcerebellar ataxia
p9630
sg15
I2
sa(dp9631
g9
I24
sg10
VC1859305
p9632
sg12
I3
sg13
VGHS
p9633
sg15
I1
sasa(dp9634
g2
VThe syndrome of hypogonadotropic hypogonadism, ataxia, and dementia can be caused by inactivating mutations in RNF216 or by the combination of mutations in RNF216 and OTUD4.
p9635
sg4
(lp9636
(dp9637
g9
I111
sg20
g21
sg12
I6
sg13
VRNF216
p9638
sg15
I1
sa(dp9639
g9
I167
sg20
g21
sg12
I5
sg13
VOTUD4
p9640
sg15
I1
sa(dp9641
g9
I111
sg20
g21
sg12
I6
sg13
VRNF216
p9642
sg15
I1
sasg6
(lp9643
(dp9644
g9
I16
sg10
VC0022735
p9645
sg12
I29
sg13
Vhypogonadotropic hypogonadism
p9646
sg15
I2
sa(dp9647
g9
I59
sg10
VC0497327
p9648
sg12
I8
sg13
Vdementia
p9649
sg15
I1
sa(dp9650
g9
I47
sg10
VC0004134
p9651
sg12
I6
sg13
Vataxia
p9652
sg15
I1
sa(dp9653
g9
I4
sg10
VC0039082
p9654
sg12
I8
sg13
Vsyndrome
p9655
sg15
I1
sasa(dp9656
g2
Vto investigate the molecular mechanisms and morphological substrate of reduced uterine leiomyoma in patients receiving the selective progesterone receptor modulator (SPRM) ulipristal acetate for 3 months, by estimating the immunohistochemical expression of the markers steroid receptor coactivator 1 (SRC-1), nuclear receptor corepressor 1 (NCoR-1), ER, PgR, Ki-67, p16, TGF-Beta, and VEGF in tumor tissue.
p9657
sg4
(lp9658
(dp9659
g9
I371
sg20
VP18075
p9660
sg12
I8
sg13
VTGF-Beta
p9661
sg15
I1
sa(dp9662
g9
I354
sg20
VP06401
p9663
sg12
I3
sg13
VPgR
p9664
sg15
I1
sa(dp9665
g9
I301
sg20
VP12931
p9666
sg12
I5
sg13
VSRC-1
p9667
sg15
I1
sa(dp9668
g9
I341
sg20
g21
sg12
I6
sg13
VNCoR-1
p9669
sg15
I1
sa(dp9670
g9
I366
sg20
VP42771
p9671
sg12
I3
sg13
Vp16
p9672
sg15
I1
sa(dp9673
g9
I309
sg20
g21
sg12
I30
sg13
Vnuclear receptor corepressor 1
p9674
sg15
I4
sa(dp9675
g9
I359
sg20
VP46013
p9676
sg12
I5
sg13
VKi-67
p9677
sg15
I1
sa(dp9678
g9
I269
sg20
g21
sg12
I30
sg13
Vsteroid receptor coactivator 1
p9679
sg15
I4
sa(dp9680
g9
I133
sg20
VP06401
p9681
sg12
I21
sg13
Vprogesterone receptor
p9682
sg15
I2
sasg6
(lp9683
(dp9684
g9
I79
sg10
VC0042133
p9685
sg12
I17
sg13
Vuterine leiomyoma
p9686
sg15
I2
sa(dp9687
g9
I393
sg10
VC0027651
p9688
sg12
I5
sg13
Vtumor
p9689
sg15
I1
sasa(dp9690
g2
VThe morphological substrate of partial leiomyoma reduction was leiomyocyte apoptosis and dystrophy, tumor stroma sclerosis and hyalinosis with diminished Ki-67 expression and elevated p16 in the smooth muscle cells, trophic nodular tissue disorders exhibited by vascular wall sclerosis and lower VEGF and TGF-Beta expression, and leiomyocyte hormonal reception dysregulation that made itself evident through the reduced expression of SRC-1 with the unchanged expression of PR and ER and the maintained level of NCoR-1.
p9691
sg4
(lp9692
(dp9693
g9
I305
sg20
VP18075
p9694
sg12
I8
sg13
VTGF-Beta
p9695
sg15
I1
sa(dp9696
g9
I511
sg20
g21
sg12
I6
sg13
VNCoR-1
p9697
sg15
I1
sa(dp9698
g9
I184
sg20
VP42771
p9699
sg12
I3
sg13
Vp16
p9700
sg15
I1
sa(dp9701
g9
I434
sg20
VP12931
p9702
sg12
I5
sg13
VSRC-1
p9703
sg15
I1
sasg6
(lp9704
(dp9705
g9
I113
sg10
VC0036429
p9706
sg12
I9
sg13
Vsclerosis
p9707
sg15
I1
sa(dp9708
g9
I89
sg10
VC0333606
p9709
sg12
I9
sg13
Vdystrophy
p9710
sg15
I1
sa(dp9711
g9
I100
sg10
VC0027651
p9712
sg12
I5
sg13
Vtumor
p9713
sg15
I1
sa(dp9714
g9
I39
sg10
VC0023267
p9715
sg12
I9
sg13
Vleiomyoma
p9716
sg15
I1
sa(dp9717
g9
I127
sg10
VC0333438
p9718
sg12
I10
sg13
Vhyalinosis
p9719
sg15
I1
sa(dp9720
g9
I113
sg10
VC0036429
p9721
sg12
I9
sg13
Vsclerosis
p9722
sg15
I1
sasa(dp9723
g2
VUenb - N3y4NTb MoneKynRpHble MexaHN3Mbl N MopoonorN4ecKNN cybcTpaT peAyKmyNN neNoMNoMbl MaTKN y namyNeHToK, nony4aBwNx ceneKTNBHblN MoAynRTop nporecTepoHoBblx pemyenTopoB ynNnpNcTana amyeTaT B Te4eHNe 3 Mec, Ha ocHoBaHNN omyeHKN NMMyHorNcToxNMN4ecKoN EKcnpeccNN SRC-1, NCoR-1, ER, PGR, Ki-67, p16, TGF-Beta, VEGF B TKaHN onyxonN.
p9724
sg4
(lp9725
(dp9726
g9
I208
sg20
VP12931
p9727
sg12
I59
sg13
VHa ocHoBaHNN omyeHKN NMMyHorNcToxNMN4ecKoN EKcnpeccNN SRC-1
p9728
sg15
I6
sa(dp9729
g9
I269
sg20
g21
sg12
I6
sg13
VNCoR-1
p9730
sg15
I1
sa(dp9731
g9
I293
sg20
VP42771
p9732
sg12
I3
sg13
Vp16
p9733
sg15
I1
sa(dp9734
g9
I281
sg20
VP06401
p9735
sg12
I3
sg13
VPGR
p9736
sg15
I1
sa(dp9737
g9
I0
sg20
g21
sg12
I206
sg13
VUenb - N3y4NTb MoneKynRpHble MexaHN3Mbl N MopoonorN4ecKNN cybcTpaT peAyKmyNN neNoMNoMbl MaTKN y namyNeHToK, nony4aBwNx ceneKTNBHblN MoAynRTop nporecTepoHoBblx pemyenTopoB ynNnpNcTana amyeTaT B Te4eHNe 3 Mec
p9738
sg15
I24
sa(dp9739
g9
I308
sg20
VP49765
p9740
sg12
I20
sg13
VVEGF B TKaHN onyxonN
p9741
sg15
I4
sa(dp9742
g9
I286
sg20
VP46013
p9743
sg12
I5
sg13
VKi-67
p9744
sg15
I1
sa(dp9745
g9
I298
sg20
VP18075
p9746
sg12
I8
sg13
VTGF-Beta
p9747
sg15
I1
sasg6
(lp9748
sa(dp9749
g2
VWe find that AML1-ETO and corepressor NCoR co-occupy the miR-29a/b-1 locus and downregulate its expression in leukemia cells.
p9750
sg4
(lp9751
(dp9752
g9
I57
sg20
g21
sg12
I17
sg13
VmiR-29a/b-1 locus
p9753
sg15
I2
sa(dp9754
g9
I38
sg20
g21
sg12
I4
sg13
VNCoR
p9755
sg15
I1
sasg6
(lp9756
(dp9757
g9
I110
sg10
VC0023418
p9758
sg12
I8
sg13
Vleukemia
p9759
sg15
I1
sasa(dp9760
g2
VAuthors present the history of a patient with extra-adrenal pheochromocytoma who represents in Hungary the first genetically confirmed case of hereditary paraganglioma/pheochromocytoma syndrome due to disease-causing mutation of the SDHD gene.
p9761
sg4
(lp9762
(dp9763
g9
I233
sg20
g21
sg12
I9
sg13
VSDHD gene
p9764
sg15
I2
sasg6
(lp9765
(dp9766
g9
I46
sg10
VC1257877
p9767
sg12
I30
sg13
Vextra-adrenal pheochromocytoma
p9768
sg15
I2
sa(dp9769
g9
I168
sg10
VC0031511
p9770
sg12
I25
sg13
Vpheochromocytoma syndrome
p9771
sg15
I2
sa(dp9772
g9
I143
sg10
VC1333993
p9773
sg12
I24
sg13
Vhereditary paraganglioma
p9774
sg15
I2
sa(dp9775
g9
I201
sg10
VC2985434
p9776
sg12
I24
sg13
Vdisease-causing mutation
p9777
sg15
I2
sasa(dp9778
g2
VWhile SDHD has been more frequently associated with the pathogenesis of head and neck paragangliomas, SDHB mutations were mainly associated with malignant and/or extra-adrenal pheochromocytoma/paraganglioma.
p9779
sg4
(lp9780
(dp9781
g9
I102
sg20
VP21912
p9782
sg12
I14
sg13
VSDHB mutations
p9783
sg15
I2
sa(dp9784
g9
I6
sg20
g21
sg12
I4
sg13
VSDHD
p9785
sg15
I1
sasg6
(lp9786
(dp9787
g9
I56
sg10
VC0699748
p9788
sg12
I12
sg13
Vpathogenesis
p9789
sg15
I1
sa(dp9790
g9
I162
sg10
VC1257877
p9791
sg12
I30
sg13
Vextra-adrenal pheochromocytoma
p9792
sg15
I2
sa(dp9793
g9
I86
sg10
VC0030421
p9794
sg12
I13
sg13
Vparaganglioma
p9795
sg15
I1
sa(dp9796
g9
I86
sg10
VC0030421
p9797
sg12
I14
sg13
Vparagangliomas
p9798
sg15
I1
sasa(dp9799
g2
VSDHB mutation carriers were more likely than SDHD mutation carriers to develop extraadrenal pheochromocytomas and malignant disease, whereas SDHD mutation carriers had a greater propensity to develop head and neck paragangliomas and multiple tumors.
p9800
sg4
(lp9801
(dp9802
g9
I45
sg20
g21
sg12
I4
sg13
VSDHD
p9803
sg15
I1
sa(dp9804
g9
I45
sg20
g21
sg12
I13
sg13
VSDHD mutation
p9805
sg15
I2
sa(dp9806
g9
I0
sg20
VP21912
p9807
sg12
I4
sg13
VSDHB
p9808
sg15
I1
sasg6
(lp9809
(dp9810
g9
I92
sg10
VC0031511
p9811
sg12
I17
sg13
Vpheochromocytomas
p9812
sg15
I1
sa(dp9813
g9
I233
sg10
VC0260037
p9814
sg12
I15
sg13
Vmultiple tumors
p9815
sg15
I2
sa(dp9816
g9
I114
sg10
VC0442867
p9817
sg12
I17
sg13
Vmalignant disease
p9818
sg15
I2
sa(dp9819
g9
I214
sg10
VC0030421
p9820
sg12
I14
sg13
Vparagangliomas
p9821
sg15
I1
sasa(dp9822
g2
VIn contrast, SDHD mutation carriers, in addition to head and neck paragangliomas, should be observed for multifocal tumors, infrequent malignancy, and the possibility of extraadrenal pheochromocytoma.
p9823
sg4
(lp9824
(dp9825
g9
I13
sg20
g21
sg12
I4
sg13
VSDHD
p9826
sg15
I1
sasg6
(lp9827
(dp9828
g9
I170
sg10
VC1257877
p9829
sg12
I29
sg13
Vextraadrenal pheochromocytoma
p9830
sg15
I2
sa(dp9831
g9
I116
sg10
VC0027651
p9832
sg12
I6
sg13
Vtumors
p9833
sg15
I1
sa(dp9834
g9
I135
sg10
VC0006826
p9835
sg12
I10
sg13
Vmalignancy
p9836
sg15
I1
sa(dp9837
g9
I66
sg10
VC0030421
p9838
sg12
I14
sg13
Vparagangliomas
p9839
sg15
I1
sasa(dp9840
g2
VHowever, in the presence of extra-adrenal pheochromocytoma, it may be more useful to screen for VHL, SDHD and SDHB mutations.
p9841
sg4
(lp9842
(dp9843
g9
I110
sg20
VP21912
p9844
sg12
I4
sg13
VSDHB
p9845
sg15
I1
sa(dp9846
g9
I96
sg20
VP40337
p9847
sg12
I3
sg13
VVHL
p9848
sg15
I1
sa(dp9849
g9
I101
sg20
g21
sg12
I4
sg13
VSDHD
p9850
sg15
I1
sasg6
(lp9851
(dp9852
g9
I28
sg10
VC1257877
p9853
sg12
I30
sg13
Vextra-adrenal pheochromocytoma
p9854
sg15
I2
sa(dp9855
g9
I96
sg10
VC0019562
p9856
sg12
I3
sg13
VVHL
p9857
sg15
I1
sasa(dp9858
g2
VHere we show, using two different techniques, FISH and quantitative PCR that SHFM3 is caused by a minimal 325 kb duplication containing only two genes (BTRC and POLL).
p9859
sg4
(lp9860
(dp9861
g9
I161
sg20
g21
sg12
I4
sg13
VPOLL
p9862
sg15
I1
sa(dp9863
g9
I152
sg20
g21
sg12
I4
sg13
VBTRC
p9864
sg15
I1
sa(dp9865
g9
I77
sg20
VP57775
p9866
sg12
I5
sg13
VSHFM3
p9867
sg15
I1
sasg6
(lp9868
(dp9869
g9
I77
sg10
VC1838652
p9870
sg12
I5
sg13
VSHFM3
p9871
sg15
I1
sa(dp9872
g9
I113
sg10
VC1705960
p9873
sg12
I11
sg13
Vduplication
p9874
sg15
I1
sasa(dp9875
g2
VThe smaller duplication in the second patient contained the LBX1, BTRC, POLL, and DPCD genes and a disrupted extra copy of the dactylin gene, and was nearly identical to the smallest known duplicated region of SHFM3.
p9876
sg4
(lp9877
(dp9878
g9
I82
sg20
g21
sg12
I10
sg13
VDPCD genes
p9879
sg15
I2
sa(dp9880
g9
I127
sg20
VP57775
p9881
sg12
I13
sg13
Vdactylin gene
p9882
sg15
I2
sa(dp9883
g9
I72
sg20
g21
sg12
I4
sg13
VPOLL
p9884
sg15
I1
sa(dp9885
g9
I210
sg20
VP57775
p9886
sg12
I5
sg13
VSHFM3
p9887
sg15
I1
sa(dp9888
g9
I60
sg20
VP52954
p9889
sg12
I4
sg13
VLBX1
p9890
sg15
I1
sa(dp9891
g9
I66
sg20
g21
sg12
I4
sg13
VBTRC
p9892
sg15
I1
sasg6
(lp9893
(dp9894
g9
I210
sg10
VC1838652
p9895
sg12
I5
sg13
VSHFM3
p9896
sg15
I1
sa(dp9897
g9
I12
sg10
VC1705960
p9898
sg12
I11
sg13
Vduplication
p9899
sg15
I1
sasa(dp9900
g2
VIn the diagnostic work-up of alcoholic cardiomyopathy, the confirmation of alcohol abuse by carbohydrate deficient transferrin (CDT) and increased liver enzymes, and the involvement of the heart by markers of heart failure (e.g., NT-proBNP) and of necrosis (e.g., troponins or CKMb) is mandatory.
p9901
sg4
(lp9902
(dp9903
g9
I92
sg20
g21
sg12
I34
sg13
Vcarbohydrate deficient transferrin
p9904
sg15
I3
sa(dp9905
g9
I128
sg20
g21
sg12
I3
sg13
VCDT
p9906
sg15
I1
sasg6
(lp9907
(dp9908
g9
I209
sg10
VC0018802
p9909
sg12
I13
sg13
Vheart failure
p9910
sg15
I2
sa(dp9911
g9
I92
sg10
VC1846385
p9912
sg12
I34
sg13
Vcarbohydrate deficient transferrin
p9913
sg15
I3
sa(dp9914
g9
I75
sg10
VC0085762
p9915
sg12
I13
sg13
Valcohol abuse
p9916
sg15
I2
sa(dp9917
g9
I128
sg10
VC1846385
p9918
sg12
I3
sg13
VCDT
p9919
sg15
I1
sa(dp9920
g9
I29
sg10
VC0007192
p9921
sg12
I24
sg13
Valcoholic cardiomyopathy
p9922
sg15
I2
sasa(dp9923
g2
VEach 10 myg/m(3) increment in daily mean concentration at lag 2 day was associated with a 0.61% (95% CI: 0.19%, 1.03%) increase in overall respiratory mortality and a 0.67% (95% CI: 0.14%, 1.21%) increase in pneumonia mortality.
p9924
sg4
(lp9925
sg6
(lp9926
(dp9927
g9
I208
sg10
VC0032285
p9928
sg12
I9
sg13
Vpneumonia
p9929
sg15
I1
sasa(dp9930
g2
VThe values of the relative risks for hospitalization for pneumonia and asthma were significant for lag 0 (RR=1.051, 95%CI; 1.016 to 1.088); lag 2 (RR=1.066, 95%CI: 1.023 to 1.113); lag 3 (RR=1.053, 95%CI: 1.015 to 1.092); lag 4 (RR=1.043, 95%CI: 1.004 to 1.088) and lag 5 (RR=1.061, 95%CI: 1.018 to 1.106).
p9931
sg4
(lp9932
(dp9933
g9
I140
sg20
VP16949
p9934
sg12
I5
sg13
Vlag 2
p9935
sg15
I2
sa(dp9936
g9
I266
sg20
VP16949
p9937
sg12
I5
sg13
Vlag 5
p9938
sg15
I2
sa(dp9939
g9
I181
sg20
VP16949
p9940
sg12
I5
sg13
Vlag 3
p9941
sg15
I2
sa(dp9942
g9
I99
sg20
VP16949
p9943
sg12
I5
sg13
Vlag 0
p9944
sg15
I2
sa(dp9945
g9
I222
sg20
VP16949
p9946
sg12
I5
sg13
Vlag 4
p9947
sg15
I2
sasg6
(lp9948
(dp9949
g9
I57
sg10
VC0032285
p9950
sg12
I9
sg13
Vpneumonia
p9951
sg15
I1
sa(dp9952
g9
I71
sg10
VC0004096
p9953
sg12
I6
sg13
Vasthma
p9954
sg15
I1
sasa(dp9955
g2
VA 10 microg/m increase in bushfire PM10 was associated with a 1.24% (95% confidence interval = 0.22% to 2.27%) increase in all respiratory disease admissions (at lag 0), a 3.80% (1.40% to 6.26%) increase in chronic obstructive pulmonary disease admissions (at lag 2), and a 5.02% (1.77% to 8.37%) increase in adult asthma admissions (at lag 0).
p9956
sg4
(lp9957
(dp9958
g9
I260
sg20
VP16949
p9959
sg12
I5
sg13
Vlag 2
p9960
sg15
I2
sasg6
(lp9961
(dp9962
g9
I315
sg10
VC0004096
p9963
sg12
I6
sg13
Vasthma
p9964
sg15
I1
sa(dp9965
g9
I127
sg10
VC0035242
p9966
sg12
I19
sg13
Vrespiratory disease
p9967
sg15
I2
sa(dp9968
g9
I207
sg10
VC0024117
p9969
sg12
I37
sg13
Vchronic obstructive pulmonary disease
p9970
sg15
I4
sasa(dp9971
g2
VWe confirmed that inhibition of TREM-1 attenuates the severity of colitis at clinically, endoscopically and histologically levels.
p9972
sg4
(lp9973
(dp9974
g9
I32
sg20
g21
sg12
I6
sg13
VTREM-1
p9975
sg15
I1
sasg6
(lp9976
(dp9977
g9
I66
sg10
VC0009319
p9978
sg12
I7
sg13
Vcolitis
p9979
sg15
I1
sasa(dp9980
g2
VIndeed, TREM-1 receptor and its signaling pathways contribute to the pathology of several non-infectious acute and chronic inflammatory diseases, including atherosclerosis, ischemia reperfusion-induced tissue injury, colitis, fibrosis and cancer.
p9981
sg4
(lp9982
(dp9983
g9
I8
sg20
g21
sg12
I15
sg13
VTREM-1 receptor
p9984
sg15
I2
sasg6
(lp9985
(dp9986
g9
I217
sg10
VC0009319
p9987
sg12
I7
sg13
Vcolitis
p9988
sg15
I1
sa(dp9989
g9
I173
sg10
VC0022116
p9990
sg12
I8
sg13
Vischemia
p9991
sg15
I1
sa(dp9992
g9
I156
sg10
VC0004153
p9993
sg12
I15
sg13
Vatherosclerosis
p9994
sg15
I1
sa(dp9995
g9
I239
sg10
VC0006826
p9996
sg12
I6
sg13
Vcancer
p9997
sg15
I1
sa(dp9998
g9
I226
sg10
VC0016059
p9999
sg12
I8
sg13
Vfibrosis
p10000
sg15
I1
sa(dp10001
g9
I69
sg10
VC0677042
p10002
sg12
I9
sg13
Vpathology
p10003
sg15
I1
sa(dp10004
g9
I94
sg10
VC0009450
p10005
sg12
I10
sg13
Vinfectious
p10006
sg15
I1
sasa(dp10007
g2
VIn CD4(+) T cell- and dextran sodium sulfate-induced models of colitis, Trem1(-/-) mice displayed significantly attenuated disease that was associated with reduced inflammatory infiltrates and diminished expression of pro-inflammatory cytokines.
p10008
sg4
(lp10009
(dp10010
g9
I3
sg20
VP01730
p10011
sg12
I3
sg13
VCD4
p10012
sg15
I1
sa(dp10013
g9
I72
sg20
g21
sg12
I5
sg13
VTrem1
p10014
sg15
I1
sasg6
(lp10015
(dp10016
g9
I63
sg10
VC0009319
p10017
sg12
I7
sg13
Vcolitis
p10018
sg15
I1
sa(dp10019
g9
I177
sg10
VC0332448
p10020
sg12
I11
sg13
Vinfiltrates
p10021
sg15
I1
sasa(dp10022
g2
VIn vivo, the treatment with the TREM-1 antagonist LP17 or control peptide was initiated at the beginning of or after induction of experimental colitis or colitis-associated tumorigenesis.
p10023
sg4
(lp10024
(dp10025
g9
I32
sg20
g21
sg12
I6
sg13
VTREM-1
p10026
sg15
I1
sasg6
(lp10027
(dp10028
g9
I143
sg10
VC0009319
p10029
sg12
I7
sg13
Vcolitis
p10030
sg15
I1
sa(dp10031
g9
I143
sg10
VC0009319
p10032
sg12
I7
sg13
Vcolitis
p10033
sg15
I1
sa(dp10034
g9
I173
sg10
VC0007621
p10035
sg12
I13
sg13
Vtumorigenesis
p10036
sg15
I1
sasa(dp10037
g2
VIn ulcerative colitis, sTREM-1 level was correlated more strongly with the endoscopic activity (r=0.498) than the C-reactive protein level (r=0.386) or erythrocyte sedimentation rate (r=0.272), although not superior to the partial Mayo score (r=0.611).
p10038
sg4
(lp10039
(dp10040
g9
I114
sg20
VP02741
p10041
sg12
I18
sg13
VC-reactive protein
p10042
sg15
I2
sasg6
(lp10043
(dp10044
g9
I3
sg10
VC0009324
p10045
sg12
I18
sg13
Vulcerative colitis
p10046
sg15
I2
sasa(dp10047
g2
VIn ulcerative colitis, sTREM-1 level was correlated most closely with the endoscopic disease activity among serum biomarkers, but was not superior to the clinical activity index.
p10048
sg4
(lp10049
sg6
(lp10050
(dp10051
g9
I3
sg10
VC0009324
p10052
sg12
I18
sg13
Vulcerative colitis
p10053
sg15
I2
sasa(dp10054
g2
VOur results suggest that sTREM-1 level may represent a complementary marker for the assessment of endoscopic activity in ulcerative colitis, but not in Crohn's disease.
p10055
sg4
(lp10056
sg6
(lp10057
(dp10058
g9
I152
sg10
VC0010346
p10059
sg12
I15
sg13
VCrohn's disease
p10060
sg15
I2
sa(dp10061
g9
I121
sg10
VC0009324
p10062
sg12
I18
sg13
Vulcerative colitis
p10063
sg15
I2
sasa(dp10064
g2
VIntestinal biopsies and concurrently collected sera from patients with Crohn's disease (CD) and Ulcerative colitis (UC) enrolled in the Swiss IBD cohort study were analyzed for intestinal TREM-1 mRNA and serum sTREM-1 expression.
p10065
sg4
(lp10066
(dp10067
g9
I204
sg20
g21
sg12
I13
sg13
Vserum sTREM-1
p10068
sg15
I2
sa(dp10069
g9
I188
sg20
g21
sg12
I11
sg13
VTREM-1 mRNA
p10070
sg15
I2
sasg6
(lp10071
(dp10072
g9
I96
sg10
VC0009324
p10073
sg12
I18
sg13
VUlcerative colitis
p10074
sg15
I2
sa(dp10075
g9
I71
sg10
VC0010346
p10076
sg12
I15
sg13
VCrohn's disease
p10077
sg15
I2
sa(dp10078
g9
I142
sg10
VC0021390
p10079
sg12
I3
sg13
VIBD
p10080
sg15
I1
sa(dp10081
g9
I116
sg10
VC0009324
p10082
sg12
I2
sg13
VUC
p10083
sg15
I1
sa(dp10084
g9
I88
sg10
VC0010346
p10085
sg12
I2
sg13
VCD
p10086
sg15
I1
sasa(dp10087
g2
VSerum sTREM-1 and TREM-1 mRNA expression levels were further determined in sera and colonic tissues collected at various time-points post disease induction in an experimental mouse model of colitis and correlated with disease activity.
p10088
sg4
(lp10089
(dp10090
g9
I18
sg20
g21
sg12
I11
sg13
VTREM-1 mRNA
p10091
sg15
I2
sasg6
(lp10092
(dp10093
g9
I190
sg10
VC0009319
p10094
sg12
I7
sg13
Vcolitis
p10095
sg15
I1
sasa(dp10096
g2
VThree TREM-1 single nucleotide polymorphisms (SNPs, rs2234237, rs3789205, and rs9471535) were genotyped by Taqman technology on 202 Crohn's disease (CD), 265 ulcerative colitis (UC), 138 with intestinal Behcet's disease (BD), and 234 healthy controls and the relationships between these SNPs and IBD development and phenotypes were evaluated.
p10097
sg4
(lp10098
sg6
(lp10099
(dp10100
g9
I203
sg10
VC0004943
p10101
sg12
I16
sg13
VBehcet's disease
p10102
sg15
I2
sa(dp10103
g9
I149
sg10
VC0010346
p10104
sg12
I2
sg13
VCD
p10105
sg15
I1
sa(dp10106
g9
I221
sg10
VC0004943
p10107
sg12
I2
sg13
VBD
p10108
sg15
I1
sa(dp10109
g9
I132
sg10
VC0010346
p10110
sg12
I15
sg13
VCrohn's disease
p10111
sg15
I2
sa(dp10112
g9
I158
sg10
VC0009324
p10113
sg12
I18
sg13
Vulcerative colitis
p10114
sg15
I2
sa(dp10115
g9
I178
sg10
VC0009324
p10116
sg12
I2
sg13
VUC
p10117
sg15
I1
sa(dp10118
g9
I296
sg10
VC0021390
p10119
sg12
I3
sg13
VIBD
p10120
sg15
I1
sasa(dp10121
g2
VHowever, TREM-1 SNPs were not significantly associated with the development of Crohn's disease or ulcerative colitis.
p10122
sg4
(lp10123
(dp10124
g9
I9
sg20
g21
sg12
I11
sg13
VTREM-1 SNPs
p10125
sg15
I2
sasg6
(lp10126
(dp10127
g9
I79
sg10
VC0010346
p10128
sg12
I15
sg13
VCrohn's disease
p10129
sg15
I2
sa(dp10130
g9
I98
sg10
VC0009324
p10131
sg12
I18
sg13
Vulcerative colitis
p10132
sg15
I2
sasa(dp10133
g2
VStable expression of miR-124 in diffuse large B cell lymphoma (DLBCL) cell lines diminished PDE4B expression.
p10134
sg4
(lp10135
(dp10136
g9
I92
sg20
g21
sg12
I5
sg13
VPDE4B
p10137
sg15
I1
sa(dp10138
g9
I21
sg20
g21
sg12
I7
sg13
VmiR-124
p10139
sg15
I1
sasg6
(lp10140
(dp10141
g9
I63
sg10
VC0079744
p10142
sg12
I5
sg13
VDLBCL
p10143
sg15
I1
sa(dp10144
g9
I32
sg10
VC0079744
p10145
sg12
I29
sg13
Vdiffuse large B cell lymphoma
p10146
sg15
I5
sasa(dp10147
g2
VStarting from the GSEA, we found that overexpression of the PDE4B in diffuse large B-cell lymphoma (DLBCL) impinge on the same genes/pathways that are abnormally active in GC-resistant tumors.
p10148
sg4
(lp10149
(dp10150
g9
I60
sg20
g21
sg12
I5
sg13
VPDE4B
p10151
sg15
I1
sasg6
(lp10152
(dp10153
g9
I69
sg10
VC0079744
p10154
sg12
I29
sg13
Vdiffuse large B-cell lymphoma
p10155
sg15
I4
sa(dp10156
g9
I185
sg10
VC0027651
p10157
sg12
I6
sg13
Vtumors
p10158
sg15
I1
sa(dp10159
g9
I100
sg10
VC0079744
p10160
sg12
I5
sg13
VDLBCL
p10161
sg15
I1
sasa(dp10162
g2
VOn the basis of biopsies of the masses in the pharynx and finger, he was diagnosed with extramedullary plasmablastic plasmacytoma, with somewhat immature CD45(+), MPC-1(-), and CD49e(-).
p10163
sg4
(lp10164
(dp10165
g9
I177
sg20
VP08648
p10166
sg12
I5
sg13
VCD49e
p10167
sg15
I1
sa(dp10168
g9
I154
sg20
VP08575
p10169
sg12
I7
sg13
VCD45(+)
p10170
sg15
I1
sa(dp10171
g9
I163
sg20
VP28062
p10172
sg12
I5
sg13
VMPC-1
p10173
sg15
I1
sasg6
(lp10174
(dp10175
g9
I117
sg10
VC0032131
p10176
sg12
I12
sg13
Vplasmacytoma
p10177
sg15
I1
sasa(dp10178
g2
VChanges to CD45 negativity and MPC-1 partial positivity were seen, while CD49e negativity persisted, suggesting that the plasmablastic plasmacytoma had reverted to a more immature state.
p10179
sg4
(lp10180
(dp10181
g9
I31
sg20
VP28062
p10182
sg12
I5
sg13
VMPC-1
p10183
sg15
I1
sa(dp10184
g9
I73
sg20
VP08648
p10185
sg12
I5
sg13
VCD49e
p10186
sg15
I1
sa(dp10187
g9
I11
sg20
VP08575
p10188
sg12
I15
sg13
VCD45 negativity
p10189
sg15
I2
sasg6
(lp10190
(dp10191
g9
I135
sg10
VC0032131
p10192
sg12
I12
sg13
Vplasmacytoma
p10193
sg15
I1
sasa(dp10194
g2
VHe had the following poor prognostic factors: 1) multiple extramedullary plasmacytomas, 2) massive myelomatous effusion, 3) increasing immature myeloma cells with plasmablastic morphology, and 4) predominance of MPC1-CD49e-CD45+ phenotype immature myeloma cells.
p10195
sg4
(lp10196
(dp10197
g9
I212
sg20
VP28062
p10198
sg12
I4
sg13
VMPC1
p10199
sg15
I1
sa(dp10200
g9
I223
sg20
VP08575
p10201
sg12
I5
sg13
VCD45+
p10202
sg15
I1
sa(dp10203
g9
I217
sg20
VP08648
p10204
sg12
I5
sg13
VCD49e
p10205
sg15
I1
sasg6
(lp10206
(dp10207
g9
I99
sg10
VC0026764
p10208
sg12
I7
sg13
Vmyeloma
p10209
sg15
I1
sa(dp10210
g9
I111
sg10
VC0013687
p10211
sg12
I8
sg13
Veffusion
p10212
sg15
I1
sa(dp10213
g9
I99
sg10
VC0026764
p10214
sg12
I7
sg13
Vmyeloma
p10215
sg15
I1
sa(dp10216
g9
I73
sg10
VC0032131
p10217
sg12
I13
sg13
Vplasmacytomas
p10218
sg15
I1
sasa(dp10219
g2
VInterestingly, the proportions of MPC-1(-) and MPC-1(-)CD45(+) immature monoclonal plasma cells also increased in the 7 progressive cases of MGUS.
p10220
sg4
(lp10221
(dp10222
g9
I47
sg20
VP28062
p10223
sg12
I15
sg13
VMPC-1(-)CD45(+)
p10224
sg15
I1
sa(dp10225
g9
I34
sg20
VP28062
p10226
sg12
I5
sg13
VMPC-1
p10227
sg15
I1
sasg6
(lp10228
(dp10229
g9
I141
sg10
VC0026470
p10230
sg12
I4
sg13
VMGUS
p10231
sg15
I1
sasa(dp10232
g2
VThe main hereditary LMNSs in adulthood are Kennedy's disease, late-onset spinal muscular atrophy and distal hereditary motor neuropathies.
p10233
sg4
(lp10234
sg6
(lp10235
(dp10236
g9
I125
sg10
VC0442874
p10237
sg12
I12
sg13
Vneuropathies
p10238
sg15
I1
sa(dp10239
g9
I73
sg10
VC0026847
p10240
sg12
I23
sg13
Vspinal muscular atrophy
p10241
sg15
I3
sa(dp10242
g9
I43
sg10
VC1839259
p10243
sg12
I17
sg13
VKennedy's disease
p10244
sg15
I2
sasa(dp10245
g2
VIn contrast, spinal muscular atrophy (SMA) involves the specific degeneration of LMNs, with symmetrical muscle weakness and atrophy.
p10246
sg4
(lp10247
sg6
(lp10248
(dp10249
g9
I38
sg10
VC0026847
p10250
sg12
I3
sg13
VSMA
p10251
sg15
I1
sa(dp10252
g9
I65
sg10
VC0011164
p10253
sg12
I12
sg13
Vdegeneration
p10254
sg15
I1
sa(dp10255
g9
I13
sg10
VC0026847
p10256
sg12
I23
sg13
Vspinal muscular atrophy
p10257
sg15
I3
sa(dp10258
g9
I104
sg10
VC0030552
p10259
sg12
I15
sg13
Vmuscle weakness
p10260
sg15
I2
sa(dp10261
g9
I29
sg10
VC0333641
p10262
sg12
I7
sg13
Vatrophy
p10263
sg15
I1
sasa(dp10264
g2
VTargeting lower motor neurons (LMNs) for gene delivery could be useful for disorders such as spinal muscular atrophy and amyotrophic lateral sclerosis.
p10265
sg4
(lp10266
sg6
(lp10267
(dp10268
g9
I93
sg10
VC0026847
p10269
sg12
I23
sg13
Vspinal muscular atrophy
p10270
sg15
I3
sa(dp10271
g9
I121
sg10
VC0002736
p10272
sg12
I29
sg13
Vamyotrophic lateral sclerosis
p10273
sg15
I3
sasa(dp10274
g2
VOur previous study showed that reduction of KCa3.1 channel expression by lyso-globotriaosylceramide (lyso-Gb3) inhibits differentiation into myofibroblasts and collagen synthesis, which might lead to development of ascending thoracic aortic aneurysm secondary to Fabry disease.
p10275
sg4
(lp10276
sg6
(lp10277
(dp10278
g9
I225
sg10
VC0162872
p10279
sg12
I24
sg13
Vthoracic aortic aneurysm
p10280
sg15
I3
sa(dp10281
g9
I263
sg10
VC0002986
p10282
sg12
I13
sg13
VFabry disease
p10283
sg15
I2
sasa(dp10284
g2
VMoreover, lyso-Gb3 suppressed expression of class II phosphatidylinositol 3-kinase C2Beta (PI3KC2Beta) by PKA activation, which reduces the production of phosphatidylinositol 3-phosphate [PI(3)P], and the reduced membrane surface expression of KCa3.1 channel was recovered by increasing the intracellular levels of PI(3)P. Consequently, our findings that lyso-Gb3 inhibited both KCa3.1 channel synthesis and surface expression by increasing intracellular cAMP, and controlled surface expression through changes in PI3KC2Beta-mediated PI(3)P production, suggest that modulation of PKA and PI3KC2Beta activity to control of KCa3.1 channel expression can be an alternative important target to attenuate ascending thoracic aortic aneurysms in Fabry disease.
p10285
sg4
(lp10286
(dp10287
g9
I244
sg20
g21
sg12
I6
sg13
VKCa3.1
p10288
sg15
I1
sa(dp10289
g9
I44
sg20
g21
sg12
I45
sg13
Vclass II phosphatidylinositol 3-kinase C2Beta
p10290
sg15
I5
sa(dp10291
g9
I244
sg20
g21
sg12
I6
sg13
VKCa3.1
p10292
sg15
I1
sa(dp10293
g9
I244
sg20
g21
sg12
I6
sg13
VKCa3.1
p10294
sg15
I1
sa(dp10295
g9
I106
sg20
VP17612
p10296
sg12
I3
sg13
VPKA
p10297
sg15
I1
sa(dp10298
g9
I154
sg20
VP48426
p10299
sg12
I41
sg13
Vphosphatidylinositol 3-phosphate [PI(3)P]
p10300
sg15
I3
sa(dp10301
g9
I106
sg20
VP17612
p10302
sg12
I3
sg13
VPKA
p10303
sg15
I1
sasg6
(lp10304
(dp10305
g9
I739
sg10
VC0002986
p10306
sg12
I13
sg13
VFabry disease
p10307
sg15
I2
sa(dp10308
g9
I710
sg10
VC0162872
p10309
sg12
I25
sg13
Vthoracic aortic aneurysms
p10310
sg15
I3
sasa(dp10311
g2
VThese findings suggest that the KCa3.1 channel can serve as a new target to attenuate and prevent development of ascending thoracic aortic aneurysm in Fabry disease.
p10312
sg4
(lp10313
(dp10314
g9
I32
sg20
g21
sg12
I14
sg13
VKCa3.1 channel
p10315
sg15
I2
sasg6
(lp10316
(dp10317
g9
I151
sg10
VC0002986
p10318
sg12
I13
sg13
VFabry disease
p10319
sg15
I2
sa(dp10320
g9
I123
sg10
VC0162872
p10321
sg12
I24
sg13
Vthoracic aortic aneurysm
p10322
sg15
I3
sasa(dp10323
g2
VWe sequenced BCAs in patients with autism or related NDDs, revealing disruption of 33 loci in four general categories: (1) genes previously associated with abnormal neurodevelopment (e.g., AUTS2, FOXP1, and CDKL5), (2) single-gene contributors to microdeletion syndromes (MBD5, SATB2, EHMT1, and SNURF-SNRPN), (3) novel risk loci (e.g., CHD8, KIRREL3, and ZNF507), and (4) genes associated with later-onset psychiatric disorders (e.g., TCF4, ZNF804A, PDE10A, GRIN2B, and ANK3).
p10324
sg4
(lp10325
(dp10326
g9
I436
sg20
VP15884
p10327
sg12
I4
sg13
VTCF4
p10328
sg15
I1
sa(dp10329
g9
I459
sg20
g21
sg12
I6
sg13
VGRIN2B
p10330
sg15
I1
sa(dp10331
g9
I189
sg20
g21
sg12
I5
sg13
VAUTS2
p10332
sg15
I1
sa(dp10333
g9
I296
sg20
VP63162
p10334
sg12
I11
sg13
VSNURF-SNRPN
p10335
sg15
I1
sa(dp10336
g9
I196
sg20
g21
sg12
I5
sg13
VFOXP1
p10337
sg15
I1
sa(dp10338
g9
I471
sg20
g21
sg12
I4
sg13
VANK3
p10339
sg15
I1
sa(dp10340
g9
I278
sg20
g21
sg12
I5
sg13
VSATB2
p10341
sg15
I1
sa(dp10342
g9
I356
sg20
g21
sg12
I6
sg13
VZNF507
p10343
sg15
I1
sa(dp10344
g9
I207
sg20
g21
sg12
I5
sg13
VCDKL5
p10345
sg15
I1
sa(dp10346
g9
I285
sg20
g21
sg12
I5
sg13
VEHMT1
p10347
sg15
I1
sa(dp10348
g9
I272
sg20
g21
sg12
I4
sg13
VMBD5
p10349
sg15
I1
sa(dp10350
g9
I343
sg20
g21
sg12
I7
sg13
VKIRREL3
p10351
sg15
I1
sa(dp10352
g9
I442
sg20
g21
sg12
I7
sg13
VZNF804A
p10353
sg15
I1
sa(dp10354
g9
I451
sg20
g21
sg12
I6
sg13
VPDE10A
p10355
sg15
I1
sasg6
(lp10356
(dp10357
g9
I35
sg10
VC0004352
p10358
sg12
I6
sg13
Vautism
p10359
sg15
I1
sa(dp10360
g9
I407
sg10
VC0004936
p10361
sg12
I21
sg13
Vpsychiatric disorders
p10362
sg15
I2
sa(dp10363
g9
I261
sg10
VC0039082
p10364
sg12
I9
sg13
Vsyndromes
p10365
sg15
I1
sasa(dp10366
g2
VTheir protein products listed below immediately suggest cell signalling pathways/processes worthy of further investigation in elucidating the mechanism of CpG 5mer activity: caspase 2, the transcription factors Atf4, Hic, HoxB3 and Rqcd1, the splicing factors Rbmx, Sfrs5 and Sfrs7, the DNA replication factors Mcm5 and Brd4, phosphoinositide-3-kinase, annexin A1, mucosa-associated lymphoid tissue lymphoma translocation 1 and three enzymes involved in protein ubiquitylation, Siah1, Gsa7 and Nin283.
p10367
sg4
(lp10368
(dp10369
g9
I266
sg20
g21
sg12
I5
sg13
VSfrs5
p10370
sg15
I1
sa(dp10371
g9
I211
sg20
VP18848
p10372
sg12
I4
sg13
VAtf4
p10373
sg15
I1
sa(dp10374
g9
I276
sg20
g21
sg12
I5
sg13
VSfrs7
p10375
sg15
I1
sa(dp10376
g9
I232
sg20
g21
sg12
I5
sg13
VRqcd1
p10377
sg15
I1
sa(dp10378
g9
I485
sg20
g21
sg12
I4
sg13
VGsa7
p10379
sg15
I1
sa(dp10380
g9
I217
sg20
VP18136
p10381
sg12
I3
sg13
VHic
p10382
sg15
I1
sa(dp10383
g9
I311
sg20
VP33992
p10384
sg12
I4
sg13
VMcm5
p10385
sg15
I1
sa(dp10386
g9
I222
sg20
VP14651
p10387
sg12
I5
sg13
VHoxB3
p10388
sg15
I1
sa(dp10389
g9
I320
sg20
g21
sg12
I4
sg13
VBrd4
p10390
sg15
I1
sa(dp10391
g9
I494
sg20
g21
sg12
I6
sg13
VNin283
p10392
sg15
I1
sa(dp10393
g9
I353
sg20
VP04083
p10394
sg12
I10
sg13
Vannexin A1
p10395
sg15
I2
sa(dp10396
g9
I260
sg20
VP38159
p10397
sg12
I4
sg13
VRbmx
p10398
sg15
I1
sa(dp10399
g9
I478
sg20
g21
sg12
I5
sg13
VSiah1
p10400
sg15
I1
sa(dp10401
g9
I174
sg20
VP42575
p10402
sg12
I9
sg13
Vcaspase 2
p10403
sg15
I2
sa(dp10404
g9
I326
sg20
VP33981
p10405
sg12
I25
sg13
Vphosphoinositide-3-kinase
p10406
sg15
I1
sasg6
(lp10407
(dp10408
g9
I365
sg10
VC0242647
p10409
sg12
I42
sg13
Vmucosa-associated lymphoid tissue lymphoma
p10410
sg15
I4
sa(dp10411
g9
I408
sg10
VC0040715
p10412
sg12
I13
sg13
Vtranslocation
p10413
sg15
I1
sasa(dp10414
g2
VMultiple cylindromas can have a syndromic association as seen in Brooke-Spiegler syndrome and familial cylindromatosis.
p10415
sg4
(lp10416
sg6
(lp10417
(dp10418
g9
I9
sg10
VC0010606
p10419
sg12
I11
sg13
Vcylindromas
p10420
sg15
I1
sa(dp10421
g9
I94
sg10
VC1851526
p10422
sg12
I24
sg13
Vfamilial cylindromatosis
p10423
sg15
I2
sa(dp10424
g9
I65
sg10
VC1857941
p10425
sg12
I24
sg13
VBrooke-Spiegler syndrome
p10426
sg15
I2
sasa(dp10427
g2
VA predisposition to multiple cylindromas is seen in patients with Brooke-Spiegler syndrome, who carry germline mutations in the tumour suppressor gene CYLD.
p10428
sg4
(lp10429
(dp10430
g9
I146
sg20
g21
sg12
I9
sg13
Vgene CYLD
p10431
sg15
I2
sasg6
(lp10432
(dp10433
g9
I29
sg10
VC0010606
p10434
sg12
I11
sg13
Vcylindromas
p10435
sg15
I1
sa(dp10436
g9
I66
sg10
VC1857941
p10437
sg12
I24
sg13
VBrooke-Spiegler syndrome
p10438
sg15
I2
sa(dp10439
g9
I128
sg10
VC0027651
p10440
sg12
I6
sg13
Vtumour
p10441
sg15
I1
sasa(dp10442
g2
VPrevious studies of inherited cylindromas have highlighted the frequent presence of bi-allelic truncating CYLD mutations as a recurrent driver mutation.
p10443
sg4
(lp10444
(dp10445
g9
I106
sg20
g21
sg12
I14
sg13
VCYLD mutations
p10446
sg15
I2
sasg6
(lp10447
(dp10448
g9
I30
sg10
VC0010606
p10449
sg12
I11
sg13
Vcylindromas
p10450
sg15
I1
sasa(dp10451
g2
VHere, we investigated inherited cylindromas from several families with germline CYLD mutations for the presence of MYB activation.
p10452
sg4
(lp10453
(dp10454
g9
I115
sg20
VP10243
p10455
sg12
I3
sg13
VMYB
p10456
sg15
I1
sa(dp10457
g9
I80
sg20
g21
sg12
I4
sg13
VCYLD
p10458
sg15
I1
sasg6
(lp10459
(dp10460
g9
I32
sg10
VC0010606
p10461
sg12
I11
sg13
Vcylindromas
p10462
sg15
I1
sasa(dp10463
g2
VCylindroma is a rare skin tumour that is inherited in several skin-tumour syndromes caused by germline mutations in the tumour suppressor gene, CYLD.
p10464
sg4
(lp10465
(dp10466
g9
I144
sg20
g21
sg12
I4
sg13
VCYLD
p10467
sg15
I1
sasg6
(lp10468
(dp10469
g9
I0
sg10
VC0010606
p10470
sg12
I10
sg13
VCylindroma
p10471
sg15
I1
sa(dp10472
g9
I26
sg10
VC0027651
p10473
sg12
I6
sg13
Vtumour
p10474
sg15
I1
sa(dp10475
g9
I26
sg10
VC0027651
p10476
sg12
I6
sg13
Vtumour
p10477
sg15
I1
sa(dp10478
g9
I74
sg10
VC0039082
p10479
sg12
I9
sg13
Vsyndromes
p10480
sg15
I1
sa(dp10481
g9
I21
sg10
VC0037286
p10482
sg12
I11
sg13
Vskin tumour
p10483
sg15
I2
sasa(dp10484
g2
VThe aims of this study were to perform a whole-exome sequencing analysis of a breast cylindroma and to investigate the role of molecular analyses in the differentiation between breast cylindroma, a benign tumour that displays MYB expression, and CYLD gene mutations, and its main differential diagnosis, the breast solid-basaloid adenoid cystic carcinoma, a malignant tumour that is characterized by the presence of the MYB-NFIB fusion gene and MYB overexpression.
p10485
sg4
(lp10486
(dp10487
g9
I424
sg20
g21
sg12
I16
sg13
VNFIB fusion gene
p10488
sg15
I3
sa(dp10489
g9
I226
sg20
VP10243
p10490
sg12
I3
sg13
VMYB
p10491
sg15
I1
sa(dp10492
g9
I226
sg20
VP10243
p10493
sg12
I3
sg13
VMYB
p10494
sg15
I1
sa(dp10495
g9
I246
sg20
g21
sg12
I9
sg13
VCYLD gene
p10496
sg15
I2
sa(dp10497
g9
I226
sg20
VP10243
p10498
sg12
I3
sg13
VMYB
p10499
sg15
I1
sasg6
(lp10500
(dp10501
g9
I330
sg10
VC0010606
p10502
sg12
I24
sg13
Vadenoid cystic carcinoma
p10503
sg15
I3
sa(dp10504
g9
I358
sg10
VC0006826
p10505
sg12
I16
sg13
Vmalignant tumour
p10506
sg15
I2
sa(dp10507
g9
I85
sg10
VC0010606
p10508
sg12
I10
sg13
Vcylindroma
p10509
sg15
I1
sa(dp10510
g9
I198
sg10
VC0086692
p10511
sg12
I13
sg13
Vbenign tumour
p10512
sg15
I2
sa(dp10513
g9
I85
sg10
VC0010606
p10514
sg12
I10
sg13
Vcylindroma
p10515
sg15
I1
sasa(dp10516
g2
VThe clinical presentation of multiple, rare, skin appendage tumours called cylindromas has been attributed to germline mutations in the tumour suppressor gene CYLD (OMIM 605018).
p10517
sg4
(lp10518
(dp10519
g9
I159
sg20
g21
sg12
I4
sg13
VCYLD
p10520
sg15
I1
sasg6
(lp10521
(dp10522
g9
I75
sg10
VC0010606
p10523
sg12
I11
sg13
Vcylindromas
p10524
sg15
I1
sa(dp10525
g9
I60
sg10
VC0027651
p10526
sg12
I6
sg13
Vtumour
p10527
sg15
I1
sa(dp10528
g9
I60
sg10
VC0027651
p10529
sg12
I7
sg13
Vtumours
p10530
sg15
I1
sasa(dp10531
g2
VBrooke-Spiegler Syndrome (BSS), familial cylindromatosis (FC) and multiple familial trichoepitheliomas (MFT) (OMIM #605041, #132700, #601606 respectively) differ due to the types of other skin appendage tumour seen together with cylindroma, such as spiradenoma and trichoepithelioma.
p10532
sg4
(lp10533
sg6
(lp10534
(dp10535
g9
I84
sg10
VC0349658
p10536
sg12
I17
sg13
Vtrichoepithelioma
p10537
sg15
I1
sa(dp10538
g9
I84
sg10
VC0349658
p10539
sg12
I18
sg13
Vtrichoepitheliomas
p10540
sg15
I1
sa(dp10541
g9
I41
sg10
VC0010606
p10542
sg12
I10
sg13
Vcylindroma
p10543
sg15
I1
sa(dp10544
g9
I188
sg10
VC0345988
p10545
sg12
I21
sg13
Vskin appendage tumour
p10546
sg15
I3
sa(dp10547
g9
I32
sg10
VC1851526
p10548
sg12
I24
sg13
Vfamilial cylindromatosis
p10549
sg15
I2
sa(dp10550
g9
I58
sg10
VC1851526
p10551
sg12
I2
sg13
VFC
p10552
sg15
I1
sa(dp10553
g9
I249
sg10
VC0334347
p10554
sg12
I11
sg13
Vspiradenoma
p10555
sg15
I1
sa(dp10556
g9
I0
sg10
VC1857941
p10557
sg12
I24
sg13
VBrooke-Spiegler Syndrome
p10558
sg15
I2
sa(dp10559
g9
I26
sg10
VC1857941
p10560
sg12
I3
sg13
VBSS
p10561
sg15
I1
sasa(dp10562
g2
VUnique tumors included a cutaneous cylindroma invasive of skull convexity occurring in familial cylindromatosis and a ganglioneuroma of the middle ear with massive bilateral skull base extension.
p10563
sg4
(lp10564
sg6
(lp10565
(dp10566
g9
I118
sg10
VC0017075
p10567
sg12
I14
sg13
Vganglioneuroma
p10568
sg15
I1
sa(dp10569
g9
I87
sg10
VC1851526
p10570
sg12
I24
sg13
Vfamilial cylindromatosis
p10571
sg15
I2
sa(dp10572
g9
I35
sg10
VC0010606
p10573
sg12
I10
sg13
Vcylindroma
p10574
sg15
I1
sa(dp10575
g9
I7
sg10
VC0027651
p10576
sg12
I6
sg13
Vtumors
p10577
sg15
I1
sasa(dp10578
g2
VThis review will examine and extrapolate from the recent literature to build support for the use of AXT in mitigating neuropathy in normal aging and neurodegenerative disease.
p10579
sg4
(lp10580
(dp10581
g9
I100
sg20
g21
sg12
I3
sg13
VAXT
p10582
sg15
I1
sasg6
(lp10583
(dp10584
g9
I149
sg10
VC0524851
p10585
sg12
I25
sg13
Vneurodegenerative disease
p10586
sg15
I2
sa(dp10587
g9
I118
sg10
VC0442874
p10588
sg12
I10
sg13
Vneuropathy
p10589
sg15
I1
sasa(dp10590
g2
VWe investigated frequencies of single nucleotide polymorphisms (SNPs) in the candidate genes protein tyrosine phosphatase, non-receptor type 22 (PTPN22), B-cell scaffold protein with ankyrin repeats (BANK1), B lymphocyte kinase (Blk), and Fc gamma receptor class IIB (FCGR2B), which have been found to be associated with other autoimmune diseases, CD1A and CD1E, important for antigen presentation of glycolipids, and transient axonal glycoprotein 1 (TAG-1), which is associated with responsiveness to intravenous immunoglobulin in patients with chronic inflammatory demyelinating polyneuropathy.
p10591
sg4
(lp10592
(dp10593
g9
I348
sg20
VP15813
p10594
sg12
I4
sg13
VCD1A
p10595
sg15
I1
sa(dp10596
g9
I200
sg20
g21
sg12
I5
sg13
VBANK1
p10597
sg15
I1
sa(dp10598
g9
I514
sg20
g21
sg12
I14
sg13
Vimmunoglobulin
p10599
sg15
I1
sa(dp10600
g9
I208
sg20
VP51451
p10601
sg12
I19
sg13
VB lymphocyte kinase
p10602
sg15
I3
sa(dp10603
g9
I87
sg20
VP60484
p10604
sg12
I34
sg13
Vgenes protein tyrosine phosphatase
p10605
sg15
I4
sa(dp10606
g9
I418
sg20
g21
sg12
I31
sg13
Vtransient axonal glycoprotein 1
p10607
sg15
I4
sa(dp10608
g9
I268
sg20
VP31995
p10609
sg12
I6
sg13
VFCGR2B
p10610
sg15
I1
sa(dp10611
g9
I239
sg20
VP12314
p10612
sg12
I27
sg13
VFc gamma receptor class IIB
p10613
sg15
I5
sa(dp10614
g9
I145
sg20
g21
sg12
I6
sg13
VPTPN22
p10615
sg15
I1
sa(dp10616
g9
I183
sg20
VP16157
p10617
sg12
I7
sg13
Vankyrin
p10618
sg15
I1
sa(dp10619
g9
I451
sg20
g21
sg12
I5
sg13
VTAG-1
p10620
sg15
I1
sa(dp10621
g9
I229
sg20
VP51451
p10622
sg12
I3
sg13
VBlk
p10623
sg15
I1
sa(dp10624
g9
I123
sg20
g21
sg12
I20
sg13
Vnon-receptor type 22
p10625
sg15
I3
sasg6
(lp10626
(dp10627
g9
I546
sg10
VC0393819
p10628
sg12
I49
sg13
Vchronic inflammatory demyelinating polyneuropathy
p10629
sg15
I4
sa(dp10630
g9
I451
sg10
VC0037293
p10631
sg12
I3
sg13
VTAG
p10632
sg15
I1
sa(dp10633
g9
I327
sg10
VC0004364
p10634
sg12
I19
sg13
Vautoimmune diseases
p10635
sg15
I2
sasa(dp10636
g2
VTo investigate the clinical features of A-pattern exotropia and to evaluate the efficacy of surgical treatment for the correction of A-pattern exotropia (A-XT).
p10637
sg4
(lp10638
sg6
(lp10639
(dp10640
g9
I50
sg10
VC0015310
p10641
sg12
I9
sg13
Vexotropia
p10642
sg15
I1
sa(dp10643
g9
I50
sg10
VC0015310
p10644
sg12
I9
sg13
Vexotropia
p10645
sg15
I1
sasa(dp10646
g2
VWe identified 10 patients from three CA and from two GMS families with WDR73 mutations including the original family described with CA, mental retardation, optic atrophy, and skin abnormalities (CAMOS).
p10647
sg4
(lp10648
(dp10649
g9
I71
sg20
g21
sg12
I5
sg13
VWDR73
p10650
sg15
I1
sasg6
(lp10651
(dp10652
g9
I136
sg10
VC0025362
p10653
sg12
I18
sg13
Vmental retardation
p10654
sg15
I2
sa(dp10655
g9
I156
sg10
VC0029124
p10656
sg12
I13
sg13
Voptic atrophy
p10657
sg15
I2
sa(dp10658
g9
I175
sg10
VC0037268
p10659
sg12
I18
sg13
Vskin abnormalities
p10660
sg15
I2
sa(dp10661
g9
I195
sg10
VC1847114
p10662
sg12
I5
sg13
VCAMOS
p10663
sg15
I1
sasa(dp10664
g2
VCAMOS (Cerebellar Ataxia with Mental retardation, Optic atrophy and Skin abnormalities) is a rare autosomal recessive syndrome characterized by a nonprogressive congenital cerebellar ataxia associated with mental retardation, optic atrophy, and skin abnormalities.
p10665
sg4
(lp10666
sg6
(lp10667
(dp10668
g9
I161
sg10
VC0852975
p10669
sg12
I28
sg13
Vcongenital cerebellar ataxia
p10670
sg15
I3
sa(dp10671
g9
I206
sg10
VC0025362
p10672
sg12
I18
sg13
Vmental retardation
p10673
sg15
I2
sa(dp10674
g9
I118
sg10
VC0039082
p10675
sg12
I8
sg13
Vsyndrome
p10676
sg15
I1
sa(dp10677
g9
I0
sg10
VC1847114
p10678
sg12
I5
sg13
VCAMOS
p10679
sg15
I1
sa(dp10680
g9
I30
sg10
VC0025362
p10681
sg12
I18
sg13
VMental retardation
p10682
sg15
I2
sa(dp10683
g9
I226
sg10
VC0029124
p10684
sg12
I13
sg13
Voptic atrophy
p10685
sg15
I2
sa(dp10686
g9
I7
sg10
VC0007758
p10687
sg12
I17
sg13
VCerebellar Ataxia
p10688
sg15
I2
sa(dp10689
g9
I68
sg10
VC0037268
p10690
sg12
I18
sg13
VSkin abnormalities
p10691
sg15
I2
sa(dp10692
g9
I50
sg10
VC0029124
p10693
sg12
I13
sg13
VOptic atrophy
p10694
sg15
I2
sa(dp10695
g9
I245
sg10
VC0037268
p10696
sg12
I18
sg13
Vskin abnormalities
p10697
sg15
I2
sasa(dp10698
g2
VEyes with laser-treated threshold ROP had significant myopia at both ages (mean spherical equivalent [MSE] in right eye at both refractions -0.72, -1.21 diopters [D]), astigmatism (MSE -1.62, -1.80 D), and anisometropia (MSE 0.82, 1.02 D; ANOVA p &lt; 0.05), and increased refractive errors across ages (paired t test p &lt; 0.05).
p10699
sg4
(lp10700
sg6
(lp10701
(dp10702
g9
I54
sg10
VC0027092
p10703
sg12
I6
sg13
Vmyopia
p10704
sg15
I1
sa(dp10705
g9
I206
sg10
VC0003081
p10706
sg12
I13
sg13
Vanisometropia
p10707
sg15
I1
sa(dp10708
g9
I168
sg10
VC0004106
p10709
sg12
I11
sg13
Vastigmatism
p10710
sg15
I1
sa(dp10711
g9
I273
sg10
VC0034951
p10712
sg12
I17
sg13
Vrefractive errors
p10713
sg15
I2
sa(dp10714
g9
I34
sg10
VC0035344
p10715
sg12
I3
sg13
VROP
p10716
sg15
I1
sasa(dp10717
g2
VMonocular deprivation does affect the binding parameters (KD and Bmax) of GluRs, which may be a molecular mechanism of the development of amblyopia.
p10718
sg4
(lp10719
sg6
(lp10720
sa(dp10721
g2
VExpressions of GluRs and CaBPs (i.e., parvalbumin and calbindin D-28k) were observed to be increased in the retinal ganglion cell layer (GCL) and inner nuclear layer (INL) at 3 days and 1 week after the onset of glaucoma.
p10722
sg4
(lp10723
(dp10724
g9
I38
sg20
VP20472
p10725
sg12
I11
sg13
Vparvalbumin
p10726
sg15
I1
sa(dp10727
g9
I54
sg20
VP05937
p10728
sg12
I15
sg13
Vcalbindin D-28k
p10729
sg15
I2
sasg6
(lp10730
(dp10731
g9
I116
sg10
VC0023521
p10732
sg12
I19
sg13
Vganglion cell layer
p10733
sg15
I3
sa(dp10734
g9
I212
sg10
VC0017601
p10735
sg12
I8
sg13
Vglaucoma
p10736
sg15
I1
sa(dp10737
g9
I137
sg10
VC0023521
p10738
sg12
I3
sg13
VGCL
p10739
sg15
I1
sasa(dp10740
g2
VThe finding that both NMDA and non-NMDA GluRs were involved in glutamate-induced excitotoxicity suggests that isolated pig RGCs provide a good model for glaucoma.
p10741
sg4
(lp10742
sg6
(lp10743
(dp10744
g9
I153
sg10
VC0017601
p10745
sg12
I8
sg13
Vglaucoma
p10746
sg15
I1
sasa(dp10747
g2
VUSP45 associates with ERCC1, a subunit of the DNA repair endonuclease XPF-ERCC1, via a short acidic motif outside of the USP45 catalytic domain.
p10748
sg4
(lp10749
(dp10750
g9
I22
sg20
VP07992
p10751
sg12
I5
sg13
VERCC1
p10752
sg15
I1
sa(dp10753
g9
I46
sg20
g21
sg12
I27
sg13
VDNA repair endonuclease XPF
p10754
sg15
I4
sa(dp10755
g9
I22
sg20
VP07992
p10756
sg12
I5
sg13
VERCC1
p10757
sg15
I1
sa(dp10758
g9
I0
sg20
g21
sg12
I5
sg13
VUSP45
p10759
sg15
I1
sa(dp10760
g9
I121
sg20
g21
sg12
I22
sg13
VUSP45 catalytic domain
p10761
sg15
I3
sasg6
(lp10762
(dp10763
g9
I70
sg10
VC0268140
p10764
sg12
I3
sg13
VXPF
p10765
sg15
I1
sasa(dp10766
g2
VFinally, USP45 localises to sites of DNA damage in a manner dependent on its deubiquitylase activity, but independent of its ability to bind ERCC1-XPF.
p10767
sg4
(lp10768
(dp10769
g9
I147
sg20
g21
sg12
I3
sg13
VXPF
p10770
sg15
I1
sa(dp10771
g9
I141
sg20
VP07992
p10772
sg12
I5
sg13
VERCC1
p10773
sg15
I1
sa(dp10774
g9
I9
sg20
g21
sg12
I5
sg13
VUSP45
p10775
sg15
I1
sasg6
(lp10776
(dp10777
g9
I37
sg10
VC0012860
p10778
sg12
I10
sg13
VDNA damage
p10779
sg15
I2
sa(dp10780
g9
I147
sg10
VC0268140
p10781
sg12
I3
sg13
VXPF
p10782
sg15
I1
sasa(dp10783
g2
VTogether, these results establish USP45 as a new regulator of XPF-ERCC1 crucial for efficient DNA repair.
p10784
sg4
(lp10785
(dp10786
g9
I34
sg20
g21
sg12
I5
sg13
VUSP45
p10787
sg15
I1
sa(dp10788
g9
I62
sg20
g21
sg12
I9
sg13
VXPF-ERCC1
p10789
sg15
I1
sasg6
(lp10790
(dp10791
g9
I62
sg10
VC0268140
p10792
sg12
I3
sg13
VXPF
p10793
sg15
I1
sasa(dp10794
g2
VWe used a polycistronic lentiviral vector (hSTEMCCA-loxP) encoding OCT4, SOX2, KLF4, and cMYC genes and containing loxP sites, excisible by Cre recombinase, to reprogram patient-specific fetal cells derived from prenatal diagnosis for several genetic disorders, such as myotonic dystrophy type 1 (DM1), Beta-thalassemia (Beta-Thal), lymphedema-distichiasis syndrome (LDS), spinal muscular atrophy (SMA), cystic fibrosis (CF), as well as from wild-type (WT) fetal cells.
p10795
sg4
(lp10796
(dp10797
g9
I297
sg20
g21
sg12
I3
sg13
VDM1
p10798
sg15
I1
sa(dp10799
g9
I140
sg20
g21
sg12
I15
sg13
VCre recombinase
p10800
sg15
I2
sa(dp10801
g9
I79
sg20
g21
sg12
I4
sg13
VKLF4
p10802
sg15
I1
sa(dp10803
g9
I270
sg20
g21
sg12
I25
sg13
Vmyotonic dystrophy type 1
p10804
sg15
I4
sa(dp10805
g9
I89
sg20
VP01893
p10806
sg12
I10
sg13
VcMYC genes
p10807
sg15
I2
sa(dp10808
g9
I73
sg20
VP48431
p10809
sg12
I4
sg13
VSOX2
p10810
sg15
I1
sasg6
(lp10811
(dp10812
g9
I333
sg10
VC0265345
p10813
sg12
I32
sg13
Vlymphedema-distichiasis syndrome
p10814
sg15
I2
sa(dp10815
g9
I421
sg10
VC0010674
p10816
sg12
I2
sg13
VCF
p10817
sg15
I1
sa(dp10818
g9
I270
sg10
VC0027126
p10819
sg12
I18
sg13
Vmyotonic dystrophy
p10820
sg15
I2
sa(dp10821
g9
I404
sg10
VC0010674
p10822
sg12
I15
sg13
Vcystic fibrosis
p10823
sg15
I2
sa(dp10824
g9
I243
sg10
VC0019247
p10825
sg12
I17
sg13
Vgenetic disorders
p10826
sg15
I2
sa(dp10827
g9
I297
sg10
VC2931688
p10828
sg12
I3
sg13
VDM1
p10829
sg15
I1
sa(dp10830
g9
I303
sg10
VC0005283
p10831
sg12
I16
sg13
VBeta-thalassemia
p10832
sg15
I1
sa(dp10833
g9
I398
sg10
VC0026847
p10834
sg12
I3
sg13
VSMA
p10835
sg15
I1
sa(dp10836
g9
I373
sg10
VC0026847
p10837
sg12
I23
sg13
Vspinal muscular atrophy
p10838
sg15
I3
sa(dp10839
g9
I367
sg10
VC0265345
p10840
sg12
I3
sg13
VLDS
p10841
sg15
I1
sa(dp10842
g9
I321
sg10
VC0005283
p10843
sg12
I9
sg13
VBeta-Thal
p10844
sg15
I1
sasa(dp10845
g2
VTwelve CpG loci (11 genes) showed greater than 10% comparative difference in DNA methylation, including hyper-methylated loci of FAM181A, MRI1, PIWIL1, CHFR, DEFA1, MRPL28, AURKA, and hypo-methylated loci of NALP1L5, MAP8KIP3, ACAT2, and PM20D1 in maternal asthma.
p10846
sg4
(lp10847
(dp10848
g9
I173
sg20
VP17038
p10849
sg12
I5
sg13
VAURKA
p10850
sg15
I1
sa(dp10851
g9
I138
sg20
g21
sg12
I4
sg13
VMRI1
p10852
sg15
I1
sa(dp10853
g9
I129
sg20
g21
sg12
I7
sg13
VFAM181A
p10854
sg15
I1
sa(dp10855
g9
I144
sg20
g21
sg12
I6
sg13
VPIWIL1
p10856
sg15
I1
sa(dp10857
g9
I165
sg20
g21
sg12
I6
sg13
VMRPL28
p10858
sg15
I1
sa(dp10859
g9
I152
sg20
g21
sg12
I4
sg13
VCHFR
p10860
sg15
I1
sa(dp10861
g9
I238
sg20
g21
sg12
I6
sg13
VPM20D1
p10862
sg15
I1
sa(dp10863
g9
I158
sg20
VP59665
p10864
sg12
I5
sg13
VDEFA1
p10865
sg15
I1
sa(dp10866
g9
I227
sg20
g21
sg12
I5
sg13
VACAT2
p10867
sg15
I1
sasg6
(lp10868
(dp10869
g9
I257
sg10
VC0004096
p10870
sg12
I6
sg13
Vasthma
p10871
sg15
I1
sasa(dp10872
g2
VSystemic expression of DEFA1,1B,3,4,CTSG and ELA2 was significantly higher in the neutrophilic asthma (NA) phenotype.
p10873
sg4
(lp10874
(dp10875
g9
I45
sg20
VP08246
p10876
sg12
I4
sg13
VELA2
p10877
sg15
I1
sa(dp10878
g9
I23
sg20
VP59665
p10879
sg12
I5
sg13
VDEFA1
p10880
sg15
I1
sa(dp10881
g9
I36
sg20
VP08311
p10882
sg12
I4
sg13
VCTSG
p10883
sg15
I1
sasg6
(lp10884
(dp10885
g9
I103
sg10
VC2363774
p10886
sg12
I2
sg13
VNA
p10887
sg15
I1
sa(dp10888
g9
I82
sg10
VC2363774
p10889
sg12
I19
sg13
Vneutrophilic asthma
p10890
sg15
I2
sasa(dp10891
g2
VThe objective of this study was to determine the combined influence of alpha thalassemia, fetal hemoglobin, and the UGT1A1 polymorphism on serum bilirubin levels and cholelithiasis in patients with sickle cell disease.
p10892
sg4
(lp10893
(dp10894
g9
I90
sg20
VP14207
p10895
sg12
I16
sg13
Vfetal hemoglobin
p10896
sg15
I2
sa(dp10897
g9
I116
sg20
VP35504
p10898
sg12
I6
sg13
VUGT1A1
p10899
sg15
I1
sasg6
(lp10900
(dp10901
g9
I198
sg10
VC0002895
p10902
sg12
I19
sg13
Vsickle cell disease
p10903
sg15
I3
sa(dp10904
g9
I166
sg10
VC0008350
p10905
sg12
I14
sg13
Vcholelithiasis
p10906
sg15
I1
sa(dp10907
g9
I71
sg10
VC0002312
p10908
sg12
I17
sg13
Valpha thalassemia
p10909
sg15
I2
sasa(dp10910
g2
VThe present study investigated the role of several genetic factors (UGT1A1 promoter (TA)n repeat polymorphism, alpha-globin status), hematological parameters, clinical severity, and hydroxyurea (HU) therapy on the occurrence of cholelithiasis in SCD.
p10911
sg4
(lp10912
(dp10913
g9
I111
sg20
VP69905
p10914
sg12
I12
sg13
Valpha-globin
p10915
sg15
I1
sasg6
(lp10916
(dp10917
g9
I246
sg10
VC0002895
p10918
sg12
I3
sg13
VSCD
p10919
sg15
I1
sa(dp10920
g9
I228
sg10
VC0008350
p10921
sg12
I14
sg13
Vcholelithiasis
p10922
sg15
I1
sasa(dp10923
g2
VWe confirmed that alpha-thalassemia and low basal reticulocyte (RET) count were independent protective factors for cholelithiasis while 7/7, 8/8 and 7/8 UGT1A1 (TA)n genotypes were independent predisposing factors for this complication.
p10924
sg4
(lp10925
sg6
(lp10926
(dp10927
g9
I18
sg10
VC0002312
p10928
sg12
I17
sg13
Valpha-thalassemia
p10929
sg15
I1
sa(dp10930
g9
I115
sg10
VC0008350
p10931
sg12
I14
sg13
Vcholelithiasis
p10932
sg15
I1
sa(dp10933
g9
I223
sg10
VC0009566
p10934
sg12
I12
sg13
Vcomplication
p10935
sg15
I1
sasa(dp10936
g2
VWe explored the potential relationship between steady state serum bilirubin levels and the incidence of cholelithiasis in the context of UGT1A1 gene A(TA)nTAA promoter polymorphism in Omani sickle cell anemia (SCA) patients, homozygotes for African (Benin and Bantu) and Arab-Indian Beta(S) haplotypes, but sharing the same microgeographical environment and comparable life style factors.
p10937
sg4
(lp10938
(dp10939
g9
I137
sg20
VP35504
p10940
sg12
I13
sg13
VUGT1A1 gene A
p10941
sg15
I3
sasg6
(lp10942
(dp10943
g9
I210
sg10
VC0002895
p10944
sg12
I3
sg13
VSCA
p10945
sg15
I1
sa(dp10946
g9
I190
sg10
VC0002895
p10947
sg12
I18
sg13
Vsickle cell anemia
p10948
sg15
I3
sa(dp10949
g9
I104
sg10
VC0008350
p10950
sg12
I14
sg13
Vcholelithiasis
p10951
sg15
I1
sasa(dp10952
g2
VThus, not cholelithiasis but total serum bilirubin was influenced by UGT1A1 polymorphism in this SCA cohort.
p10953
sg4
(lp10954
(dp10955
g9
I69
sg20
VP35504
p10956
sg12
I6
sg13
VUGT1A1
p10957
sg15
I1
sasg6
(lp10958
(dp10959
g9
I10
sg10
VC0008350
p10960
sg12
I14
sg13
Vcholelithiasis
p10961
sg15
I1
sasa(dp10962
g2
VAltogether our data provide the implication of UGT1A1 and SLCO1A2 in sickle cell anemia-related cholelithiasis.
p10963
sg4
(lp10964
(dp10965
g9
I58
sg20
VP46721
p10966
sg12
I7
sg13
VSLCO1A2
p10967
sg15
I1
sa(dp10968
g9
I47
sg20
VP35504
p10969
sg12
I6
sg13
VUGT1A1
p10970
sg15
I1
sasg6
(lp10971
(dp10972
g9
I69
sg10
VC0002895
p10973
sg12
I18
sg13
Vsickle cell anemia
p10974
sg15
I3
sa(dp10975
g9
I96
sg10
VC0008350
p10976
sg12
I14
sg13
Vcholelithiasis
p10977
sg15
I1
sasa(dp10978
g2
VPresent study was aimed to explore the effect of (TA)n UGT1A1 gene promoter polymorphism on bilirubin metabolism, bilirubinaemia, predisposition to cholelithiasis and subsequent cholecystectomy, in Sickle-Cell Anemia (SCA) and beta-Thalasemia major (bTH) in Kuwaiti subjects compared to other population.
p10979
sg4
(lp10980
(dp10981
g9
I55
sg20
VP35504
p10982
sg12
I20
sg13
VUGT1A1 gene promoter
p10983
sg15
I3
sasg6
(lp10984
(dp10985
g9
I198
sg10
VC0002895
p10986
sg12
I18
sg13
VSickle-Cell Anemia
p10987
sg15
I2
sa(dp10988
g9
I114
sg10
VC0020433
p10989
sg12
I14
sg13
Vbilirubinaemia
p10990
sg15
I1
sa(dp10991
g9
I148
sg10
VC0008350
p10992
sg12
I14
sg13
Vcholelithiasis
p10993
sg15
I1
sa(dp10994
g9
I218
sg10
VC0002895
p10995
sg12
I3
sg13
VSCA
p10996
sg15
I1
sasa(dp10997
g2
VOur results confirm UGT1A1 (TA)7 allele as one of the factors accounting for the hyperbilirubinemia and cholelithiasis observed in SCA and bTH.
p10998
sg4
(lp10999
(dp11000
g9
I20
sg20
VP35504
p11001
sg12
I6
sg13
VUGT1A1
p11002
sg15
I1
sasg6
(lp11003
(dp11004
g9
I81
sg10
VC0020433
p11005
sg12
I18
sg13
Vhyperbilirubinemia
p11006
sg15
I1
sa(dp11007
g9
I104
sg10
VC0008350
p11008
sg12
I14
sg13
Vcholelithiasis
p11009
sg15
I1
sasa(dp11010
g2
VWe analyzed the polymorphism A(TA)nTAA at the UGT1A1 promoter and the relationships between the various A(TA)nTAA genotypes and alleles and bilirubin levels and occurrence of cholelithiasis.
p11011
sg4
(lp11012
(dp11013
g9
I46
sg20
VP35504
p11014
sg12
I15
sg13
VUGT1A1 promoter
p11015
sg15
I2
sasg6
(lp11016
(dp11017
g9
I175
sg10
VC0008350
p11018
sg12
I14
sg13
Vcholelithiasis
p11019
sg15
I1
sasa(dp11020
g2
VWe analyzed the polymorphism A(TA)&lt;formula&gt;_{n}&lt;/formula&gt; TAA at the UGT1A1 promoter and the relationships between the various A(TA)&lt;formula&gt;_{n}&lt;/formula&gt; TAA genotypes and alleles and bilirubin levels and occurrence of cholelithiasis.
p11021
sg4
(lp11022
(dp11023
g9
I81
sg20
VP35504
p11024
sg12
I15
sg13
VUGT1A1 promoter
p11025
sg15
I2
sasg6
(lp11026
(dp11027
g9
I245
sg10
VC0008350
p11028
sg12
I14
sg13
Vcholelithiasis
p11029
sg15
I1
sa(dp11030
g9
I70
sg10
VC0162872
p11031
sg12
I3
sg13
VTAA
p11032
sg15
I1
sa(dp11033
g9
I70
sg10
VC0162872
p11034
sg12
I3
sg13
VTAA
p11035
sg15
I1
sasa(dp11036
g2
VThe ADP-ribosyltransferase 3 gene (ART3) has been reported to be associated with non-obstructive azoospermia (NOA) in the Japanese population.
p11037
sg4
(lp11038
(dp11039
g9
I35
sg20
g21
sg12
I4
sg13
VART3
p11040
sg15
I1
sa(dp11041
g9
I4
sg20
g21
sg12
I29
sg13
VADP-ribosyltransferase 3 gene
p11042
sg15
I3
sasg6
(lp11043
(dp11044
g9
I97
sg10
VC1321542
p11045
sg12
I11
sg13
Vazoospermia
p11046
sg15
I1
sasa(dp11047
g2
VA recent Japanese study provided evidence that the rs6836703: G&gt;A single-nucleotide polymorphism (SNP) from the ADP-ribosyltransferase 3 (ART3) gene is significantly associated with non-obstructive azoospermia.
p11048
sg4
(lp11049
(dp11050
g9
I115
sg20
g21
sg12
I24
sg13
VADP-ribosyltransferase 3
p11051
sg15
I2
sa(dp11052
g9
I141
sg20
g21
sg12
I4
sg13
VART3
p11053
sg15
I1
sasg6
(lp11054
(dp11055
g9
I201
sg10
VC1321542
p11056
sg12
I11
sg13
Vazoospermia
p11057
sg15
I1
sasa(dp11058
g2
VThe analysis of genes involved in hereditary spherocytosis, by next-generation sequencing in two patients with clinical diagnosis of the disease, showed the presence of the c.1795+1G&gt;A mutation in the SPTB gene.
p11059
sg4
(lp11060
(dp11061
g9
I204
sg20
g21
sg12
I9
sg13
VSPTB gene
p11062
sg15
I2
sasg6
(lp11063
(dp11064
g9
I34
sg10
VC0037889
p11065
sg12
I24
sg13
Vhereditary spherocytosis
p11066
sg15
I2
sasa(dp11067
g2
VHereditary spherocytosis stems from mutations in one of the genes encoding ankyrin-1 (ANKI), alpha spectrin (SPTA1) and beta spectrin (SPTB), the anion exchanger 1 (SLC4A 1), and protein 4.2 (EPB42).
p11068
sg4
(lp11069
(dp11070
g9
I120
sg20
VP11277
p11071
sg12
I13
sg13
Vbeta spectrin
p11072
sg15
I2
sa(dp11073
g9
I93
sg20
VP02549
p11074
sg12
I14
sg13
Valpha spectrin
p11075
sg15
I2
sa(dp11076
g9
I192
sg20
VP16452
p11077
sg12
I5
sg13
VEPB42
p11078
sg15
I1
sa(dp11079
g9
I86
sg20
VP16157
p11080
sg12
I4
sg13
VANKI
p11081
sg15
I1
sa(dp11082
g9
I135
sg20
g21
sg12
I4
sg13
VSPTB
p11083
sg15
I1
sa(dp11084
g9
I109
sg20
VP02549
p11085
sg12
I5
sg13
VSPTA1
p11086
sg15
I1
sa(dp11087
g9
I75
sg20
VP16157
p11088
sg12
I9
sg13
Vankyrin-1
p11089
sg15
I1
sa(dp11090
g9
I179
sg20
VP01031
p11091
sg12
I11
sg13
Vprotein 4.2
p11092
sg15
I2
sa(dp11093
g9
I146
sg20
VP02730
p11094
sg12
I17
sg13
Vanion exchanger 1
p11095
sg15
I3
sasg6
(lp11096
(dp11097
g9
I0
sg10
VC0037889
p11098
sg12
I24
sg13
VHereditary spherocytosis
p11099
sg15
I2
sasa(dp11100
g2
VWe also investigated methylation profiles in peripheral blood mononuclear cells from patients with red cell membrane diseases, such as complete protein 4.2 deficiency due to ELB42 mutations, hereditary spherocytosis with EPB3 mutations, and hereditary elliptocytosis with SPTB mutations.
p11101
sg4
(lp11102
(dp11103
g9
I221
sg20
VP02730
p11104
sg12
I14
sg13
VEPB3 mutations
p11105
sg15
I2
sa(dp11106
g9
I272
sg20
g21
sg12
I4
sg13
VSPTB
p11107
sg15
I1
sa(dp11108
g9
I144
sg20
VP01031
p11109
sg12
I11
sg13
Vprotein 4.2
p11110
sg15
I2
sasg6
(lp11111
(dp11112
g9
I241
sg10
VC0013902
p11113
sg12
I25
sg13
Vhereditary elliptocytosis
p11114
sg15
I2
sa(dp11115
g9
I191
sg10
VC0037889
p11116
sg12
I24
sg13
Vhereditary spherocytosis
p11117
sg15
I2
sasa(dp11118
g2
VThe mutations of most cases of hereditary spherocytosis (HS) are located in the following genes: ANK1, SPTB, SLC4A1, EPB42 and SPTA1, which encode ankyrin, spectrin beta-chain, the anion exchanger 1 (band 3), protein 4.2 and spectrin alpha-chain, respectively.
p11119
sg4
(lp11120
(dp11121
g9
I97
sg20
VP16157
p11122
sg12
I4
sg13
VANK1
p11123
sg15
I1
sa(dp11124
g9
I156
sg20
g21
sg12
I19
sg13
Vspectrin beta-chain
p11125
sg15
I2
sa(dp11126
g9
I109
sg20
VP02730
p11127
sg12
I6
sg13
VSLC4A1
p11128
sg15
I1
sa(dp11129
g9
I209
sg20
VP01031
p11130
sg12
I11
sg13
Vprotein 4.2
p11131
sg15
I2
sa(dp11132
g9
I117
sg20
VP16452
p11133
sg12
I5
sg13
VEPB42
p11134
sg15
I1
sa(dp11135
g9
I225
sg20
VP55899
p11136
sg12
I20
sg13
Vspectrin alpha-chain
p11137
sg15
I2
sa(dp11138
g9
I127
sg20
VP02549
p11139
sg12
I5
sg13
VSPTA1
p11140
sg15
I1
sa(dp11141
g9
I147
sg20
VP16157
p11142
sg12
I7
sg13
Vankyrin
p11143
sg15
I1
sa(dp11144
g9
I103
sg20
g21
sg12
I4
sg13
VSPTB
p11145
sg15
I1
sasg6
(lp11146
(dp11147
g9
I31
sg10
VC0037889
p11148
sg12
I24
sg13
Vhereditary spherocytosis
p11149
sg15
I2
sa(dp11150
g9
I57
sg10
VC0037889
p11151
sg12
I2
sg13
VHS
p11152
sg15
I1
sasa(dp11153
g2
VMutations in bone morphogenetic protein 1 (BMP1) in humans or deletion of BMP1 and related protease tolloid like 1 (TLL1) in mice lead to osteogenesis imperfecta (OI).
p11154
sg4
(lp11155
(dp11156
g9
I43
sg20
VP14222
p11157
sg12
I4
sg13
VBMP1
p11158
sg15
I1
sa(dp11159
g9
I100
sg20
g21
sg12
I14
sg13
Vtolloid like 1
p11160
sg15
I3
sa(dp11161
g9
I116
sg20
g21
sg12
I4
sg13
VTLL1
p11162
sg15
I1
sa(dp11163
g9
I74
sg20
VP63123
p11164
sg12
I25
sg13
VBMP1 and related protease
p11165
sg15
I4
sa(dp11166
g9
I13
sg20
VP14222
p11167
sg12
I28
sg13
Vbone morphogenetic protein 1
p11168
sg15
I4
sasg6
(lp11169
(dp11170
g9
I163
sg10
VC0029434
p11171
sg12
I2
sg13
VOI
p11172
sg15
I1
sa(dp11173
g9
I138
sg10
VC0029434
p11174
sg12
I23
sg13
Vosteogenesis imperfecta
p11175
sg15
I2
sasa(dp11176
g2
VMutations in the proteinase bone morphogenetic protein-1 (BMP1) were recently identified in patients with osteogenesis imperfecta, which can be associated with type 1 dentinogenesis imperfecta.
p11177
sg4
(lp11178
(dp11179
g9
I17
sg20
VP63123
p11180
sg12
I39
sg13
Vproteinase bone morphogenetic protein-1
p11181
sg15
I4
sasg6
(lp11182
(dp11183
g9
I167
sg10
VC0011436
p11184
sg12
I25
sg13
Vdentinogenesis imperfecta
p11185
sg15
I2
sa(dp11186
g9
I106
sg10
VC0029434
p11187
sg12
I23
sg13
Vosteogenesis imperfecta
p11188
sg15
I2
sasa(dp11189
g2
VWe previously showed these mice to have a skeletal phenotype that includes elements of osteogenesis imperfecta (OI), osteomalacia, and deficient osteocyte maturation, observations validated by the finding of BMP1 mutations in a subset of human patients with OI-like phenotypes.
p11190
sg4
(lp11191
sg6
(lp11192
(dp11193
g9
I112
sg10
VC0029434
p11194
sg12
I2
sg13
VOI
p11195
sg15
I1
sa(dp11196
g9
I87
sg10
VC0029434
p11197
sg12
I23
sg13
Vosteogenesis imperfecta
p11198
sg15
I2
sa(dp11199
g9
I112
sg10
VC0029434
p11200
sg12
I2
sg13
VOI
p11201
sg15
I1
sa(dp11202
g9
I117
sg10
VC0029442
p11203
sg12
I12
sg13
Vosteomalacia
p11204
sg15
I1
sasa(dp11205
g2
VAutosomal recessive osteogenesis imperfecta (OI) accounts for 10% of all OI cases, and, currently, mutations in 10 genes (CRTAP, LEPRE1, PPIB, SERPINH1, FKBP10, SERPINF1, SP7, BMP1, TMEM38B, and WNT1) are known to be responsible for this form of the disease.
p11206
sg4
(lp11207
(dp11208
g9
I171
sg20
g21
sg12
I3
sg13
VSP7
p11209
sg15
I1
sa(dp11210
g9
I182
sg20
g21
sg12
I7
sg13
VTMEM38B
p11211
sg15
I1
sa(dp11212
g9
I122
sg20
g21
sg12
I5
sg13
VCRTAP
p11213
sg15
I1
sa(dp11214
g9
I137
sg20
VP23284
p11215
sg12
I4
sg13
VPPIB
p11216
sg15
I1
sa(dp11217
g9
I143
sg20
VP50454
p11218
sg12
I8
sg13
VSERPINH1
p11219
sg15
I1
sa(dp11220
g9
I153
sg20
g21
sg12
I6
sg13
VFKBP10
p11221
sg15
I1
sa(dp11222
g9
I161
sg20
VP36955
p11223
sg12
I8
sg13
VSERPINF1
p11224
sg15
I1
sa(dp11225
g9
I195
sg20
VP04628
p11226
sg12
I4
sg13
VWNT1
p11227
sg15
I1
sasg6
(lp11228
(dp11229
g9
I20
sg10
VC0029434
p11230
sg12
I23
sg13
Vosteogenesis imperfecta
p11231
sg15
I2
sa(dp11232
g9
I45
sg10
VC0029434
p11233
sg12
I2
sg13
VOI
p11234
sg15
I1
sa(dp11235
g9
I45
sg10
VC0029434
p11236
sg12
I2
sg13
VOI
p11237
sg15
I1
sasa(dp11238
g2
VIsolated 3-methylcrotonyl-CoA carboxylase deficiency (3MCCD) is an autosomal recessive disorder of leucine metabolism biochemically characterized by accumulation of 3-methylcrotonylglycine (3MCG), 3-methylcrotonic acid (3MCA) and 3-hydroxyisovaleric acid.
p11239
sg4
(lp11240
(dp11241
g9
I0
sg20
g21
sg12
I41
sg13
VIsolated 3-methylcrotonyl-CoA carboxylase
p11242
sg15
I3
sasg6
(lp11243
(dp11244
g9
I54
sg10
VC0268600
p11245
sg12
I5
sg13
V3MCCD
p11246
sg15
I1
sa(dp11247
g9
I9
sg10
VC0268600
p11248
sg12
I43
sg13
V3-methylcrotonyl-CoA carboxylase deficiency
p11249
sg15
I3
sasa(dp11250
g2
VIsolated 3-methylcrotonyl-CoA carboxylase (MCC) deficiency is an autosomal recessive disorder of leucine metabolism caused by mutations in MCCC1 or MCCC2 encoding the Alfa and Beta subunit of MCC, respectively.
p11251
sg4
(lp11252
(dp11253
g9
I0
sg20
g21
sg12
I41
sg13
VIsolated 3-methylcrotonyl-CoA carboxylase
p11254
sg15
I3
sa(dp11255
g9
I43
sg20
VP23508
p11256
sg12
I3
sg13
VMCC
p11257
sg15
I1
sa(dp11258
g9
I139
sg20
g21
sg12
I5
sg13
VMCCC1
p11259
sg15
I1
sa(dp11260
g9
I148
sg20
g21
sg12
I5
sg13
VMCCC2
p11261
sg15
I1
sa(dp11262
g9
I43
sg20
VP23508
p11263
sg12
I3
sg13
VMCC
p11264
sg15
I1
sasg6
(lp11265
(dp11266
g9
I43
sg10
VC0007129
p11267
sg12
I3
sg13
VMCC
p11268
sg15
I1
sa(dp11269
g9
I43
sg10
VC0007129
p11270
sg12
I3
sg13
VMCC
p11271
sg15
I1
sa(dp11272
g9
I9
sg10
VC0007129
p11273
sg12
I32
sg13
V3-methylcrotonyl-CoA carboxylase
p11274
sg15
I2
sasa(dp11275
g2
VWe performed mutational analysis in the four main HPE causing genes (SHH, SIX3, TGIF, and ZIC2) and GLI3, a gene associated with polydactyly as well as fluorescent in situ hybridization (FISH) to search for microdeletions in these genes and two candidate HPE genes (DISP1 and FOXA2).
p11276
sg4
(lp11277
(dp11278
g9
I90
sg20
g21
sg12
I4
sg13
VZIC2
p11279
sg15
I1
sa(dp11280
g9
I69
sg20
g21
sg12
I3
sg13
VSHH
p11281
sg15
I1
sa(dp11282
g9
I276
sg20
g21
sg12
I5
sg13
VFOXA2
p11283
sg15
I1
sa(dp11284
g9
I255
sg20
VP01893
p11285
sg12
I9
sg13
VHPE genes
p11286
sg15
I2
sa(dp11287
g9
I100
sg20
VP10071
p11288
sg12
I4
sg13
VGLI3
p11289
sg15
I1
sa(dp11290
g9
I266
sg20
g21
sg12
I5
sg13
VDISP1
p11291
sg15
I1
sa(dp11292
g9
I74
sg20
g21
sg12
I4
sg13
VSIX3
p11293
sg15
I1
sa(dp11294
g9
I80
sg20
VP22301
p11295
sg12
I4
sg13
VTGIF
p11296
sg15
I1
sasg6
(lp11297
(dp11298
g9
I129
sg10
VC0152427
p11299
sg12
I11
sg13
Vpolydactyly
p11300
sg15
I1
sasa(dp11301
g2
VAlthough the CCK-1 receptor has been shown to be highly expressed in resected human pancreatic cancer samples, its role is less clear.
p11302
sg4
(lp11303
(dp11304
g9
I13
sg20
VP06307
p11305
sg12
I14
sg13
VCCK-1 receptor
p11306
sg15
I2
sasg6
(lp11307
(dp11308
g9
I84
sg10
VC0235974
p11309
sg12
I17
sg13
Vpancreatic cancer
p11310
sg15
I2
sasa(dp11311
g2
VThe aim of this in vitro study was to investigate the CCK-1 receptor expression and the function of the CCK-CCK-1 receptor pathway in the human pancreatic adenocarcinoma cell line, Mia PaCa-2.
p11312
sg4
(lp11313
(dp11314
g9
I54
sg20
VP06307
p11315
sg12
I14
sg13
VCCK-1 receptor
p11316
sg15
I2
sa(dp11317
g9
I104
sg20
VP06307
p11318
sg12
I18
sg13
VCCK-CCK-1 receptor
p11319
sg15
I2
sa(dp11320
g9
I181
sg20
g21
sg12
I10
sg13
VMia PaCa-2
p11321
sg15
I2
sasg6
(lp11322
(dp11323
g9
I185
sg10
VC1836780
p11324
sg12
I4
sg13
VPaCa
p11325
sg15
I1
sa(dp11326
g9
I144
sg10
VC0281361
p11327
sg12
I25
sg13
Vpancreatic adenocarcinoma
p11328
sg15
I2
sasa(dp11329
g2
VHowever, the main source of CCK receptors in the pancreatic tumor samples consisted of CCK2-expressing islets and/or CCK1-expressing nerves rather than neoplastic tissue.
p11330
sg4
(lp11331
(dp11332
g9
I28
sg20
VP06307
p11333
sg12
I13
sg13
VCCK receptors
p11334
sg15
I2
sa(dp11335
g9
I117
sg20
g21
sg12
I4
sg13
VCCK1
p11336
sg15
I1
sasg6
(lp11337
(dp11338
g9
I49
sg10
VC0030297
p11339
sg12
I16
sg13
Vpancreatic tumor
p11340
sg15
I2
sasa(dp11341
g2
VThese data indicate that the presence of CCK receptors in human ductal pancreatic tumor samples is mainly due to CCK2 expression in residual pancreatic islets and CCK1 in pancreatic nerves.
p11342
sg4
(lp11343
(dp11344
g9
I41
sg20
VP06307
p11345
sg12
I13
sg13
VCCK receptors
p11346
sg15
I2
sa(dp11347
g9
I163
sg20
g21
sg12
I4
sg13
VCCK1
p11348
sg15
I1
sasg6
(lp11349
(dp11350
g9
I71
sg10
VC0030297
p11351
sg12
I16
sg13
Vpancreatic tumor
p11352
sg15
I2
sasa(dp11353
g2
VThe aim of this study was to evaluate the association of the polymorphisms in TCN2 (rs1801198) gene and in MTRR (rs1801394) gene with nonsyndromic cleft lip and/or palate (NSCL/P) in a Brazilian population.
p11354
sg4
(lp11355
(dp11356
g9
I78
sg20
VP20062
p11357
sg12
I21
sg13
VTCN2 (rs1801198) gene
p11358
sg15
I3
sasg6
(lp11359
(dp11360
g9
I147
sg10
VC0008924
p11361
sg12
I9
sg13
Vcleft lip
p11362
sg15
I2
sasa(dp11363
g2
VWhile the roles of the GluN2A and GluN2B subunit in ischemic stroke have been well developed, the role of the GluN2C subunit in ischemia is not well understood.
p11364
sg4
(lp11365
sg6
(lp11366
(dp11367
g9
I128
sg10
VC0022116
p11368
sg12
I8
sg13
Vischemia
p11369
sg15
I1
sa(dp11370
g9
I52
sg10
VC3272363
p11371
sg12
I15
sg13
Vischemic stroke
p11372
sg15
I2
sasa(dp11373
g2
VIn the Western blotting assay, clonidine treatment led to significant up-regulation of the expression level of NR2B and Phospho-NR2B in the hippocampus of the rats when compared with the cerebral ischemia group.
p11374
sg4
(lp11375
(dp11376
g9
I120
sg20
g21
sg12
I12
sg13
VPhospho-NR2B
p11377
sg15
I1
sa(dp11378
g9
I111
sg20
g21
sg12
I4
sg13
VNR2B
p11379
sg15
I1
sasg6
(lp11380
(dp11381
g9
I187
sg10
VC0917798
p11382
sg12
I17
sg13
Vcerebral ischemia
p11383
sg15
I2
sasa(dp11384
g2
VIn conclusion, clonidine could improve the learning and memory ability of rats with cerebral ischemia, and NR2B, ERK1/2, CREB, NF-KB were involved in this effect.
p11385
sg4
(lp11386
(dp11387
g9
I121
sg20
VP16220
p11388
sg12
I4
sg13
VCREB
p11389
sg15
I1
sa(dp11390
g9
I113
sg20
VP27361
p11391
sg12
I6
sg13
VERK1/2
p11392
sg15
I1
sa(dp11393
g9
I107
sg20
g21
sg12
I4
sg13
VNR2B
p11394
sg15
I1
sasg6
(lp11395
(dp11396
g9
I84
sg10
VC0917798
p11397
sg12
I17
sg13
Vcerebral ischemia
p11398
sg15
I2
sasa(dp11399
g2
VDWEYS-IgG cross-reactive with DNA and the N-methyl-D-aspartate receptor subunits GluN2A/GluN2B has been associated with neuropsychiatric systemic lupus erythematosus (NPSLE).
p11400
sg4
(lp11401
(dp11402
g9
I42
sg20
g21
sg12
I52
sg13
VN-methyl-D-aspartate receptor subunits GluN2A/GluN2B
p11403
sg15
I4
sasg6
(lp11404
(dp11405
g9
I167
sg10
VC0752335
p11406
sg12
I5
sg13
VNPSLE
p11407
sg15
I1
sa(dp11408
g9
I120
sg10
VC0752335
p11409
sg12
I45
sg13
Vneuropsychiatric systemic lupus erythematosus
p11410
sg15
I4
sasa(dp11411
g2
VTherefore, NMDAR antagonists, especially NR2B-selective ones, combined with IGF-1 may serve as an alternative therapeutic agent for oxidative stress related neurodegenerative disease.
p11412
sg4
(lp11413
(dp11414
g9
I41
sg20
g21
sg12
I4
sg13
VNR2B
p11415
sg15
I1
sa(dp11416
g9
I76
sg20
VP01343
p11417
sg12
I5
sg13
VIGF-1
p11418
sg15
I1
sasg6
(lp11419
(dp11420
g9
I157
sg10
VC0524851
p11421
sg12
I25
sg13
Vneurodegenerative disease
p11422
sg15
I2
sa(dp11423
g9
I132
sg10
VC0242606
p11424
sg12
I16
sg13
Voxidative stress
p11425
sg15
I2
sasa(dp11426
g2
VTaken together, our results demonstrated that LBP is neuroprotective against ischemic injury by its dual roles in activation of NR2A and inhibition of NR2B signaling pathways, which suggests that LBP may be a superior therapeutic candidate for targeting glutamate excitotoxicity for the treatment of ischemic stroke.
p11427
sg4
(lp11428
(dp11429
g9
I151
sg20
g21
sg12
I4
sg13
VNR2B
p11430
sg15
I1
sa(dp11431
g9
I128
sg20
g21
sg12
I4
sg13
VNR2A
p11432
sg15
I1
sa(dp11433
g9
I46
sg20
VP18428
p11434
sg12
I3
sg13
VLBP
p11435
sg15
I1
sa(dp11436
g9
I46
sg20
VP18428
p11437
sg12
I3
sg13
VLBP
p11438
sg15
I1
sasg6
(lp11439
(dp11440
g9
I300
sg10
VC3272363
p11441
sg12
I15
sg13
Vischemic stroke
p11442
sg15
I2
sa(dp11443
g9
I46
sg10
VC0024031
p11444
sg12
I3
sg13
VLBP
p11445
sg15
I1
sa(dp11446
g9
I46
sg10
VC0024031
p11447
sg12
I3
sg13
VLBP
p11448
sg15
I1
sasa(dp11449
g2
VThe obesity-induced changes in adipose tissue macrophage numbers are mainly due to increases in the triple-positive CD11b+ F4/80+ CD11c+ adipose tissue macrophage subpopulation.
p11450
sg4
(lp11451
(dp11452
g9
I116
sg20
VP11215
p11453
sg12
I20
sg13
VCD11b+ F4/80+ CD11c+
p11454
sg15
I3
sasg6
(lp11455
(dp11456
g9
I4
sg10
VC0028754
p11457
sg12
I7
sg13
Vobesity
p11458
sg15
I1
sasa(dp11459
g2
VContrary to our hypothesis that obesity-mediated white AT inflammation is Nlrp3-dependent, we found that Western diet-induced expression of AT inflammatory markers (i.e., Cd68, Cd11c, Emr1, Itgam, Lgals, Il18, Mcp1, Tnf, Ccr2, Ccl5 mRNAs, and Mac-2 protein) were not accompanied by increased caspase-1 cleavage, a hallmark feature of NLRP3 inflammasome activation.
p11460
sg4
(lp11461
(dp11462
g9
I227
sg20
VP13501
p11463
sg12
I10
sg13
VCcl5 mRNAs
p11464
sg15
I2
sa(dp11465
g9
I292
sg20
VP29466
p11466
sg12
I9
sg13
Vcaspase-1
p11467
sg15
I1
sa(dp11468
g9
I221
sg20
VP41597
p11469
sg12
I4
sg13
VCcr2
p11470
sg15
I1
sa(dp11471
g9
I210
sg20
VP13500
p11472
sg12
I4
sg13
VMcp1
p11473
sg15
I1
sa(dp11474
g9
I190
sg20
VP11215
p11475
sg12
I5
sg13
VItgam
p11476
sg15
I1
sa(dp11477
g9
I243
sg20
VP17931
p11478
sg12
I13
sg13
VMac-2 protein
p11479
sg15
I2
sa(dp11480
g9
I216
sg20
VP01375
p11481
sg12
I3
sg13
VTnf
p11482
sg15
I1
sa(dp11483
g9
I184
sg20
g21
sg12
I4
sg13
VEmr1
p11484
sg15
I1
sa(dp11485
g9
I171
sg20
VP34810
p11486
sg12
I4
sg13
VCd68
p11487
sg15
I1
sa(dp11488
g9
I177
sg20
VP20702
p11489
sg12
I5
sg13
VCd11c
p11490
sg15
I1
sa(dp11491
g9
I204
sg20
g21
sg12
I4
sg13
VIl18
p11492
sg15
I1
sasg6
(lp11493
(dp11494
g9
I32
sg10
VC0028754
p11495
sg12
I7
sg13
Vobesity
p11496
sg15
I1
sa(dp11497
g9
I58
sg10
VC0021368
p11498
sg12
I12
sg13
Vinflammation
p11499
sg15
I1
sasa(dp11500
g2
VIn current practice, an antibody cocktail comprising p63, CK903, and AMACR (PIN-4 cocktail) is frequently utilized to evaluate foci suspicious for prostatic adenocarcinoma.
p11501
sg4
(lp11502
(dp11503
g9
I53
sg20
g21
sg12
I3
sg13
Vp63
p11504
sg15
I1
sasg6
(lp11505
(dp11506
g9
I76
sg10
VC0282612
p11507
sg12
I3
sg13
VPIN
p11508
sg15
I1
sa(dp11509
g9
I147
sg10
VC0007112
p11510
sg12
I24
sg13
Vprostatic adenocarcinoma
p11511
sg15
I2
sasa(dp11512
g2
VOnly 2 NA cases displayed an overall PIN-4 staining pattern compatible with prostate cancer.
p11513
sg4
(lp11514
sg6
(lp11515
(dp11516
g9
I76
sg10
VC0600139
p11517
sg12
I15
sg13
Vprostate cancer
p11518
sg15
I2
sa(dp11519
g9
I37
sg10
VC0282612
p11520
sg12
I3
sg13
VPIN
p11521
sg15
I1
sasa(dp11522
g2
VAlthough heterogenous staining patterns were seen within individual cases, use of the PIN-4 cocktail effectively discriminates NA from prostate cancer because of the high frequency of coexpression of AMACR and CK903 within NA.
p11523
sg4
(lp11524
(dp11525
g9
I86
sg20
VP63167
p11526
sg12
I5
sg13
VPIN-4
p11527
sg15
I1
sasg6
(lp11528
(dp11529
g9
I86
sg10
VC0282612
p11530
sg12
I3
sg13
VPIN
p11531
sg15
I1
sa(dp11532
g9
I135
sg10
VC0600139
p11533
sg12
I15
sg13
Vprostate cancer
p11534
sg15
I2
sasa(dp11535
g2
VKidney and prostate cancer tumor and benign biopsies were stained with hemotoxylin and eosin and prostate biopsies were subjected to PIN-4 immunohistochemistry.
p11536
sg4
(lp11537
(dp11538
g9
I133
sg20
VP63167
p11539
sg12
I5
sg13
VPIN-4
p11540
sg15
I1
sasg6
(lp11541
(dp11542
g9
I11
sg10
VC0600139
p11543
sg12
I15
sg13
Vprostate cancer
p11544
sg15
I2
sa(dp11545
g9
I133
sg10
VC0282612
p11546
sg12
I3
sg13
VPIN
p11547
sg15
I1
sa(dp11548
g9
I27
sg10
VC0027651
p11549
sg12
I5
sg13
Vtumor
p11550
sg15
I1
sasa(dp11551
g2
VA subset of biopsy sections was analyzed by IHC, and cancerous and non-cancerous regions could be readily visualized by PIN4 staining.
p11552
sg4
(lp11553
(dp11554
g9
I120
sg20
g21
sg12
I4
sg13
VPIN4
p11555
sg15
I1
sasg6
(lp11556
sa(dp11557
g2
VElevated serum levels of Ang-2 and high values for the Ang-2/Ang-1 ratio may potentially be used as predictors of worst-case prognoses for P. vivax malaria, especially in patients with thrombocytopenia.
p11558
sg4
(lp11559
(dp11560
g9
I25
sg20
VP03950
p11561
sg12
I5
sg13
VAng-2
p11562
sg15
I1
sa(dp11563
g9
I25
sg20
VP03950
p11564
sg12
I5
sg13
VAng-2
p11565
sg15
I1
sa(dp11566
g9
I61
sg20
VP03950
p11567
sg12
I5
sg13
VAng-1
p11568
sg15
I1
sasg6
(lp11569
(dp11570
g9
I142
sg10
VC0024537
p11571
sg12
I13
sg13
Vvivax malaria
p11572
sg15
I2
sasa(dp11573
g2
VDengue-associated thrombocytopenia and endothelial activation are associated with an imbalance in angiopoietin-2: angiopoietin-1 plasma levels.
p11574
sg4
(lp11575
(dp11576
g9
I114
sg20
g21
sg12
I14
sg13
Vangiopoietin-1
p11577
sg15
I1
sa(dp11578
g9
I98
sg20
g21
sg12
I14
sg13
Vangiopoietin-2
p11579
sg15
I1
sasg6
(lp11580
(dp11581
g9
I85
sg10
VC1397014
p11582
sg12
I9
sg13
Vimbalance
p11583
sg15
I1
sa(dp11584
g9
I0
sg10
VC0011311
p11585
sg12
I6
sg13
VDengue
p11586
sg15
I1
sasa(dp11587
g2
VIt has been previously reported that mutations in retinal G protein coupled receptor (RGR) are associated with retinitis pigmentosa.
p11588
sg4
(lp11589
(dp11590
g9
I86
sg20
VP47804
p11591
sg12
I3
sg13
VRGR
p11592
sg15
I1
sa(dp11593
g9
I50
sg20
VP47804
p11594
sg12
I34
sg13
Vretinal G protein coupled receptor
p11595
sg15
I5
sasg6
(lp11596
(dp11597
g9
I111
sg10
VC0035334
p11598
sg12
I20
sg13
Vretinitis pigmentosa
p11599
sg15
I2
sasa(dp11600
g2
VThe present study aims to systemically analyze the potential role of variants of RGR in retinal diseases.
p11601
sg4
(lp11602
(dp11603
g9
I81
sg20
VP47804
p11604
sg12
I3
sg13
VRGR
p11605
sg15
I1
sasg6
(lp11606
(dp11607
g9
I88
sg10
VC0035309
p11608
sg12
I16
sg13
Vretinal diseases
p11609
sg15
I2
sasa(dp11610
g2
VThese data suggest that the recessive retinal disorder previously reported to be due to homozygous mutation in RGR is, at least in part, due to variants in CDHR1 and that the true consequences of RGR knock-out on human retinal structure and function are yet to be determined.
p11611
sg4
(lp11612
(dp11613
g9
I111
sg20
VP47804
p11614
sg12
I3
sg13
VRGR
p11615
sg15
I1
sa(dp11616
g9
I196
sg20
VP47804
p11617
sg12
I13
sg13
VRGR knock-out
p11618
sg15
I2
sa(dp11619
g9
I156
sg20
g21
sg12
I5
sg13
VCDHR1
p11620
sg15
I1
sasg6
(lp11621
(dp11622
g9
I38
sg10
VC0035309
p11623
sg12
I16
sg13
Vretinal disorder
p11624
sg15
I2
sasa(dp11625
g2
VRare mutations in the human RGR gene lead to autosomal recessive retinitis pigmentosa or dominantly inherited peripapillary choroidal atrophy.
p11626
sg4
(lp11627
(dp11628
g9
I22
sg20
VP47804
p11629
sg12
I14
sg13
Vhuman RGR gene
p11630
sg15
I3
sasg6
(lp11631
(dp11632
g9
I134
sg10
VC0333641
p11633
sg12
I7
sg13
Vatrophy
p11634
sg15
I1
sa(dp11635
g9
I45
sg10
VC0339526
p11636
sg12
I40
sg13
Vautosomal recessive retinitis pigmentosa
p11637
sg15
I4
sasa(dp11638
g2
VIn Western blot assays, the RGR-d protein was detected in retinas of a large proportion ( approximately 53%) of individual donors, including patients with age-related macular degeneration (AMD).
p11639
sg4
(lp11640
(dp11641
g9
I28
sg20
VP47804
p11642
sg12
I13
sg13
VRGR-d protein
p11643
sg15
I2
sasg6
(lp11644
(dp11645
g9
I155
sg10
VC0242383
p11646
sg12
I32
sg13
Vage-related macular degeneration
p11647
sg15
I3
sa(dp11648
g9
I189
sg10
VC0242383
p11649
sg12
I3
sg13
VAMD
p11650
sg15
I1
sasa(dp11651
g2
VMutations in the human gene encoding RGR are associated with retinitis pigmentosa.
p11652
sg4
(lp11653
(dp11654
g9
I17
sg20
VP47804
p11655
sg12
I23
sg13
Vhuman gene encoding RGR
p11656
sg15
I4
sasg6
(lp11657
(dp11658
g9
I61
sg10
VC0035334
p11659
sg12
I20
sg13
Vretinitis pigmentosa
p11660
sg15
I2
sasa(dp11661
g2
VIn recognition of the clinical significance of AML MRD, the European LeukemiaNet (ELN) recently recommended the establishment of CR-MRDNegative as a separate category of treatment response.
p11662
sg4
(lp11663
sg6
(lp11664
(dp11665
g9
I51
sg10
VC1840451
p11666
sg12
I3
sg13
VMRD
p11667
sg15
I1
sa(dp11668
g9
I47
sg10
VC0023467
p11669
sg12
I3
sg13
VAML
p11670
sg15
I1
sasa(dp11671
g2
VThe distribution according to the European LeukemiaNet (ELN) risk categorization from 2010 was 20% favorable, 31% intermediate-1, 28% intermediate-2, and 21% adverse.
p11672
sg4
(lp11673
sg6
(lp11674
sa(dp11675
g2
VPatients were stratified using the ELN European Leukemia Net classification.
p11676
sg4
(lp11677
sg6
(lp11678
(dp11679
g9
I48
sg10
VC0023418
p11680
sg12
I8
sg13
VLeukemia
p11681
sg15
I1
sasa(dp11682
g2
VoH(E)mT-DCN treatment also attenuated the expression of major ECM components, such as collagen I/III, elastin and fibronectin and induced tumor cell apoptosis, leading to extensive viral dispersion within orthotopic pancreatic tumors and pancreatic cancer patient-derived tumor spheroids.
p11683
sg4
(lp11684
(dp11685
g9
I102
sg20
VP49918
p11686
sg12
I7
sg13
Velastin
p11687
sg15
I1
sasg6
(lp11688
(dp11689
g9
I138
sg10
VC0027651
p11690
sg12
I5
sg13
Vtumor
p11691
sg15
I1
sa(dp11692
g9
I138
sg10
VC0027651
p11693
sg12
I5
sg13
Vtumor
p11694
sg15
I1
sa(dp11695
g9
I238
sg10
VC0235974
p11696
sg12
I17
sg13
Vpancreatic cancer
p11697
sg15
I2
sa(dp11698
g9
I216
sg10
VC0030297
p11699
sg12
I17
sg13
Vpancreatic tumors
p11700
sg15
I2
sasa(dp11701
g2
VIn this study, we firstly examined neuroprotective effects of pre- or post-treatment with 15 and 30 mg/kg ATX against ischemic damage in the gerbil hippocampal cornus ammonis 1 (CA1) region subjected to 5 min of transient cerebral ischemia using cresyl violet staining, neuronal nuclei immunohistochemistry and Fluoro-J B histofluorescence staining.
p11702
sg4
(lp11703
sg6
(lp11704
(dp11705
g9
I212
sg10
VC0917805
p11706
sg12
I27
sg13
Vtransient cerebral ischemia
p11707
sg15
I3
sasa(dp11708
g2
VDysregulation of cysteinyl cathepsins and their inhibitors, cystatins (stefins), were implied in progression of tumorgenesis; nevertheless, their role in sinonasal inverted papilloma (IP) is still unrecognized.
p11709
sg4
(lp11710
(dp11711
g9
I17
sg20
VP25774
p11712
sg12
I20
sg13
Vcysteinyl cathepsins
p11713
sg15
I2
sasg6
(lp11714
(dp11715
g9
I184
sg10
VC1881254
p11716
sg12
I2
sg13
VIP
p11717
sg15
I1
sa(dp11718
g9
I164
sg10
VC1881254
p11719
sg12
I18
sg13
Vinverted papilloma
p11720
sg15
I2
sasa(dp11721
g2
VDespite fundamental limitations applying to these models, such as the distinct immune system and the different metabolism regulating liver homeostasis in rodents when compared to humans, multiple approaches, such as surgery (bile duct ligation), chemical-induced (3,5-diethoxycarbonyl-1,4-dihydrocollidine, DDC, Alfa-naphthylisothiocyanate, ANIT), viral infections (Rhesus rotavirustype A, RRV-A), and genetic manipulation (Mdr2, Cftr, Pkd1, Pkd2, Prkcsh, Sec63, Pkhd1) have been developed.
p11722
sg4
(lp11723
(dp11724
g9
I424
sg20
VP21439
p11725
sg12
I4
sg13
VMdr2
p11726
sg15
I1
sa(dp11727
g9
I442
sg20
g21
sg12
I4
sg13
VPkd2
p11728
sg15
I1
sa(dp11729
g9
I463
sg20
VP08F94
p11730
sg12
I5
sg13
VPkhd1
p11731
sg15
I1
sa(dp11732
g9
I436
sg20
VP98161
p11733
sg12
I4
sg13
VPkd1
p11734
sg15
I1
sa(dp11735
g9
I456
sg20
g21
sg12
I5
sg13
VSec63
p11736
sg15
I1
sa(dp11737
g9
I430
sg20
VP13569
p11738
sg12
I4
sg13
VCftr
p11739
sg15
I1
sa(dp11740
g9
I448
sg20
VP14314
p11741
sg12
I6
sg13
VPrkcsh
p11742
sg15
I1
sasg6
(lp11743
(dp11744
g9
I442
sg10
VC2751306
p11745
sg12
I4
sg13
VPkd2
p11746
sg15
I1
sa(dp11747
g9
I463
sg10
VC0085548
p11748
sg12
I5
sg13
VPkhd1
p11749
sg15
I1
sa(dp11750
g9
I348
sg10
VC0042769
p11751
sg12
I16
sg13
Vviral infections
p11752
sg15
I2
sa(dp11753
g9
I436
sg10
VC3149841
p11754
sg12
I4
sg13
VPkd1
p11755
sg15
I1
sasa(dp11756
g2
VProgressive familial intrahepatic cholestasis type 3 (PFIC3) is an autosomal recessive disorder of cholestasis of hepatocellular origin, typically seen in infancy or childhood caused by a defect in the ABCB4 located on chromosome 7.
p11757
sg4
(lp11758
(dp11759
g9
I54
sg20
VP21439
p11760
sg12
I5
sg13
VPFIC3
p11761
sg15
I1
sa(dp11762
g9
I0
sg20
VP21439
p11763
sg12
I52
sg13
VProgressive familial intrahepatic cholestasis type 3
p11764
sg15
I6
sa(dp11765
g9
I202
sg20
VP21439
p11766
sg12
I5
sg13
VABCB4
p11767
sg15
I1
sasg6
(lp11768
(dp11769
g9
I54
sg10
VC1865643
p11770
sg12
I5
sg13
VPFIC3
p11771
sg15
I1
sa(dp11772
g9
I34
sg10
VC0008370
p11773
sg12
I11
sg13
Vcholestasis
p11774
sg15
I1
sa(dp11775
g9
I0
sg10
VC1865643
p11776
sg12
I52
sg13
VProgressive familial intrahepatic cholestasis type 3
p11777
sg15
I6
sasa(dp11778
g2
VFor example, mutations in ABCA1 cause Tangier disease associated with defective efflux of cholesterol and phosphatidylcholine from the plasma membrane to the lipid acceptor protein apoA1 (apolipoprotein AI), mutations in ABCA3 cause neonatal surfactant deficiency associated with a loss in secretion of the lipid pulmonary surfactants from lungs of newborns, mutations in ABCA4 cause Stargardt macular degeneration, a retinal degenerative disease linked to the reduced clearance of retinoid compounds from photoreceptor cells, mutations in ABCA12 cause harlequin and lamellar ichthyosis, skin diseases associated with defective lipid trafficking in keratinocytes, and mutations in ABCB4 and ABCG5/ABCG8 are responsible for progressive intrafamilial hepatic disease and sitosterolaemia associated with defective phospholipid and sterol transport respectively.
p11779
sg4
(lp11780
(dp11781
g9
I188
sg20
VP02656
p11782
sg12
I17
sg13
Vapolipoprotein AI
p11783
sg15
I2
sa(dp11784
g9
I181
sg20
VP02647
p11785
sg12
I5
sg13
VapoA1
p11786
sg15
I1
sa(dp11787
g9
I372
sg20
VP78363
p11788
sg12
I5
sg13
VABCA4
p11789
sg15
I1
sa(dp11790
g9
I221
sg20
g21
sg12
I5
sg13
VABCA3
p11791
sg15
I1
sa(dp11792
g9
I540
sg20
g21
sg12
I6
sg13
VABCA12
p11793
sg15
I1
sa(dp11794
g9
I681
sg20
VP21439
p11795
sg12
I5
sg13
VABCB4
p11796
sg15
I1
sa(dp11797
g9
I697
sg20
g21
sg12
I5
sg13
VABCG8
p11798
sg15
I1
sa(dp11799
g9
I691
sg20
g21
sg12
I5
sg13
VABCG5
p11800
sg15
I1
sasg6
(lp11801
(dp11802
g9
I38
sg10
VC0039292
p11803
sg12
I15
sg13
VTangier disease
p11804
sg15
I2
sa(dp11805
g9
I588
sg10
VC0037274
p11806
sg12
I13
sg13
Vskin diseases
p11807
sg15
I2
sa(dp11808
g9
I426
sg10
VC1285162
p11809
sg12
I20
sg13
Vdegenerative disease
p11810
sg15
I2
sa(dp11811
g9
I394
sg10
VC0242383
p11812
sg12
I20
sg13
Vmacular degeneration
p11813
sg15
I2
sa(dp11814
g9
I749
sg10
VC0023895
p11815
sg12
I15
sg13
Vhepatic disease
p11816
sg15
I2
sa(dp11817
g9
I567
sg10
VC0020758
p11818
sg12
I19
sg13
Vlamellar ichthyosis
p11819
sg15
I2
sa(dp11820
g9
I769
sg10
VC0342907
p11821
sg12
I15
sg13
Vsitosterolaemia
p11822
sg15
I1
sasa(dp11823
g2
VWe further analyze two independent breast cancer datasets and find that specific isoforms of IGF2BP2, NECTIN4, ITGB6, and KLHDC9 are significantly associated with AZD6244, lapatinib, erlotinib, and paclitaxel, respectively.
p11824
sg4
(lp11825
(dp11826
g9
I122
sg20
g21
sg12
I6
sg13
VKLHDC9
p11827
sg15
I1
sa(dp11828
g9
I93
sg20
g21
sg12
I7
sg13
VIGF2BP2
p11829
sg15
I1
sa(dp11830
g9
I111
sg20
VP18564
p11831
sg12
I5
sg13
VITGB6
p11832
sg15
I1
sa(dp11833
g9
I102
sg20
g21
sg12
I7
sg13
VNECTIN4
p11834
sg15
I1
sasg6
(lp11835
(dp11836
g9
I35
sg10
VC0678222
p11837
sg12
I13
sg13
Vbreast cancer
p11838
sg15
I2
sasa(dp11839
g2
VRT-qPCR and Spearman's correlation analysis were then performed to measure IGF2BP2 mRNA expression in clinical glioma tissues and its correlation with miR-188 expression.
p11840
sg4
(lp11841
(dp11842
g9
I75
sg20
g21
sg12
I12
sg13
VIGF2BP2 mRNA
p11843
sg15
I2
sasg6
(lp11844
(dp11845
g9
I111
sg10
VC0017638
p11846
sg12
I6
sg13
Vglioma
p11847
sg15
I1
sasa(dp11848
g2
VFinally, the biological roles of IGF2BP2 in glioma cells were assessed.
p11849
sg4
(lp11850
(dp11851
g9
I33
sg20
g21
sg12
I7
sg13
VIGF2BP2
p11852
sg15
I1
sasg6
(lp11853
(dp11854
g9
I44
sg10
VC0017638
p11855
sg12
I6
sg13
Vglioma
p11856
sg15
I1
sasa(dp11857
g2
VThe present study identified IGF2BP2 as a direct target of miR-188 in glioma, and IGF2BP2 under-expression served tumour-suppressive roles in glioma growth and metastasis.
p11858
sg4
(lp11859
(dp11860
g9
I29
sg20
g21
sg12
I7
sg13
VIGF2BP2
p11861
sg15
I1
sa(dp11862
g9
I29
sg20
g21
sg12
I7
sg13
VIGF2BP2
p11863
sg15
I1
sa(dp11864
g9
I59
sg20
g21
sg12
I7
sg13
VmiR-188
p11865
sg15
I1
sasg6
(lp11866
(dp11867
g9
I114
sg10
VC0027651
p11868
sg12
I6
sg13
Vtumour
p11869
sg15
I1
sa(dp11870
g9
I70
sg10
VC0017638
p11871
sg12
I6
sg13
Vglioma
p11872
sg15
I1
sa(dp11873
g9
I70
sg10
VC0017638
p11874
sg12
I6
sg13
Vglioma
p11875
sg15
I1
sa(dp11876
g9
I160
sg10
VC0027627
p11877
sg12
I10
sg13
Vmetastasis
p11878
sg15
I1
sasa(dp11879
g2
VThus, miR-188 had a similar role in glioma by inhibiting the action of its downstream target, IGF2BP2.
p11880
sg4
(lp11881
(dp11882
g9
I6
sg20
g21
sg12
I7
sg13
VmiR-188
p11883
sg15
I1
sa(dp11884
g9
I94
sg20
g21
sg12
I7
sg13
VIGF2BP2
p11885
sg15
I1
sasg6
(lp11886
(dp11887
g9
I36
sg10
VC0017638
p11888
sg12
I6
sg13
Vglioma
p11889
sg15
I1
sasa(dp11890
g2
VBackground: Serum autoantibodies against tumor-associated antigens (TAAs) are detectable in early-stage gastric cancer patients; however, the time point during cancerogenesis when they appear in circulation is still obscure.Methods: In this study, we developed a recombinant antigen microarray and analyzed the prevalence of autoantibodies against 102 TAAs in 829 gastric cancer patients and 929 healthy controls from Caucasian and Asian populations, as well as 100 patients with chronic atrophic gastritis and 775 individuals staged according to different grades of intestinal metaplasia.Results: Six antigens, including CTAG1B/CTAG2, DDX53, IGF2BP2, TP53, and MAGEA3, were predominantly reacting with sera from gastric cancer patients when compared with healthy controls, and the seroreactivity was associated with intestinal-type gastric cancer, but not with patients' Helicobacter pylori status, grade, age, gender, or stage of gastric cancer.
p11891
sg4
(lp11892
(dp11893
g9
I643
sg20
g21
sg12
I7
sg13
VIGF2BP2
p11894
sg15
I1
sa(dp11895
g9
I636
sg20
g21
sg12
I5
sg13
VDDX53
p11896
sg15
I1
sa(dp11897
g9
I41
sg20
VP51572
p11898
sg12
I25
sg13
Vtumor-associated antigens
p11899
sg15
I2
sa(dp11900
g9
I68
sg20
VP51572
p11901
sg12
I4
sg13
VTAAs
p11902
sg15
I1
sa(dp11903
g9
I629
sg20
g21
sg12
I5
sg13
VCTAG2
p11904
sg15
I1
sa(dp11905
g9
I68
sg20
VP51572
p11906
sg12
I4
sg13
VTAAs
p11907
sg15
I1
sa(dp11908
g9
I622
sg20
VP78358
p11909
sg12
I6
sg13
VCTAG1B
p11910
sg15
I1
sasg6
(lp11911
(dp11912
g9
I104
sg10
VC0024623
p11913
sg12
I14
sg13
Vgastric cancer
p11914
sg15
I2
sa(dp11915
g9
I104
sg10
VC0024623
p11916
sg12
I14
sg13
Vgastric cancer
p11917
sg15
I2
sa(dp11918
g9
I567
sg10
VC0334037
p11919
sg12
I21
sg13
Vintestinal metaplasia
p11920
sg15
I2
sa(dp11921
g9
I41
sg10
VC0027651
p11922
sg12
I5
sg13
Vtumor
p11923
sg15
I1
sa(dp11924
g9
I104
sg10
VC0024623
p11925
sg12
I14
sg13
Vgastric cancer
p11926
sg15
I2
sa(dp11927
g9
I104
sg10
VC0024623
p11928
sg12
I14
sg13
Vgastric cancer
p11929
sg15
I2
sa(dp11930
g9
I104
sg10
VC0024623
p11931
sg12
I14
sg13
Vgastric cancer
p11932
sg15
I2
sa(dp11933
g9
I480
sg10
VC0017154
p11934
sg12
I26
sg13
Vchronic atrophic gastritis
p11935
sg15
I3
sasa(dp11936
g2
VThe gene encoding the Insulin-like Growth Factor 2 mRNA binding protein 2/IMP2 is amplified and overexpressed in many human cancers, accompanied by a poorer prognosis.
p11937
sg4
(lp11938
(dp11939
g9
I74
sg20
g21
sg12
I4
sg13
VIMP2
p11940
sg15
I1
sa(dp11941
g9
I22
sg20
VP01308
p11942
sg12
I51
sg13
VInsulin-like Growth Factor 2 mRNA binding protein 2
p11943
sg15
I8
sasg6
(lp11944
(dp11945
g9
I124
sg10
VC0006826
p11946
sg12
I7
sg13
Vcancers
p11947
sg15
I1
sasa(dp11948
g2
VHerein we show in a diverse array of human cancer cells that IMP2 overexpression stimulates and IMP2 elimination diminishes proliferation by 50-80%.
p11949
sg4
(lp11950
(dp11951
g9
I61
sg20
g21
sg12
I4
sg13
VIMP2
p11952
sg15
I1
sa(dp11953
g9
I61
sg20
g21
sg12
I4
sg13
VIMP2
p11954
sg15
I1
sasg6
(lp11955
(dp11956
g9
I43
sg10
VC0006826
p11957
sg12
I6
sg13
Vcancer
p11958
sg15
I1
sa(dp11959
g9
I124
sg10
VC0334094
p11960
sg12
I13
sg13
Vproliferation
p11961
sg15
I1
sasa(dp11962
g2
VIMP2 stabilization of HMGA1 mRNA plus IMP2 stimulated IGF2 production synergistically drive cancer cell proliferation and account for IMP2's tumor promoting action.
p11963
sg4
(lp11964
(dp11965
g9
I0
sg20
g21
sg12
I4
sg13
VIMP2
p11966
sg15
I1
sa(dp11967
g9
I0
sg20
g21
sg12
I4
sg13
VIMP2
p11968
sg15
I1
sa(dp11969
g9
I54
sg20
VP01344
p11970
sg12
I4
sg13
VIGF2
p11971
sg15
I1
sa(dp11972
g9
I22
sg20
VP17096
p11973
sg12
I10
sg13
VHMGA1 mRNA
p11974
sg15
I2
sa(dp11975
g9
I0
sg20
g21
sg12
I4
sg13
VIMP2
p11976
sg15
I1
sasg6
(lp11977
(dp11978
g9
I141
sg10
VC0027651
p11979
sg12
I5
sg13
Vtumor
p11980
sg15
I1
sa(dp11981
g9
I92
sg10
VC0006826
p11982
sg12
I6
sg13
Vcancer
p11983
sg15
I1
sa(dp11984
g9
I104
sg10
VC0334094
p11985
sg12
I13
sg13
Vproliferation
p11986
sg15
I1
sasa(dp11987
g2
VIn conclusion, miR-1193 suppressed proliferation and invasion of human breast cancer cells via translational suppression of IGF2BP2.
p11988
sg4
(lp11989
(dp11990
g9
I124
sg20
g21
sg12
I7
sg13
VIGF2BP2
p11991
sg15
I1
sasg6
(lp11992
(dp11993
g9
I53
sg10
VC2699153
p11994
sg12
I8
sg13
Vinvasion
p11995
sg15
I1
sa(dp11996
g9
I109
sg10
VC0221103
p11997
sg12
I11
sg13
Vsuppression
p11998
sg15
I1
sa(dp11999
g9
I35
sg10
VC0334094
p12000
sg12
I13
sg13
Vproliferation
p12001
sg15
I1
sa(dp12002
g9
I71
sg10
VC0678222
p12003
sg12
I13
sg13
Vbreast cancer
p12004
sg15
I2
sasa(dp12005
g2
VNew genes HTRP5, CAPN6, STPK, 14-3-3PKR, and CALM1 and previously known genes including BTK, DDP, GLA, PLP, COL4A5, COL4A6, PAK3, and DCX are localized; candidate loci for other disorders for which genes have not yet been identified, including DFN-2, POF, megalocornea, and syndromic and nonsyndromic mental retardation, are also mapped in the region.
p12006
sg4
(lp12007
(dp12008
g9
I134
sg20
g21
sg12
I3
sg13
VDCX
p12009
sg15
I1
sa(dp12010
g9
I98
sg20
VP06280
p12011
sg12
I3
sg13
VGLA
p12012
sg15
I1
sa(dp12013
g9
I251
sg20
g21
sg12
I3
sg13
VPOF
p12014
sg15
I1
sa(dp12015
g9
I0
sg20
VP01701
p12016
sg12
I15
sg13
VNew genes HTRP5
p12017
sg15
I3
sa(dp12018
g9
I17
sg20
g21
sg12
I5
sg13
VCAPN6
p12019
sg15
I1
sa(dp12020
g9
I103
sg20
g21
sg12
I3
sg13
VPLP
p12021
sg15
I1
sa(dp12022
g9
I24
sg20
VP53350
p12023
sg12
I4
sg13
VSTPK
p12024
sg15
I1
sa(dp12025
g9
I88
sg20
g21
sg12
I3
sg13
VBTK
p12026
sg15
I1
sa(dp12027
g9
I108
sg20
VP29400
p12028
sg12
I6
sg13
VCOL4A5
p12029
sg15
I1
sa(dp12030
g9
I93
sg20
g21
sg12
I3
sg13
VDDP
p12031
sg15
I1
sasg6
(lp12032
(dp12033
g9
I251
sg10
VC0085215
p12034
sg12
I3
sg13
VPOF
p12035
sg15
I1
sa(dp12036
g9
I93
sg10
VC0796074
p12037
sg12
I3
sg13
VDDP
p12038
sg15
I1
sa(dp12039
g9
I301
sg10
VC0025362
p12040
sg12
I18
sg13
Vmental retardation
p12041
sg15
I2
sa(dp12042
g9
I256
sg10
VC0344530
p12043
sg12
I12
sg13
Vmegalocornea
p12044
sg15
I1
sasa(dp12045
g2
VTo study the expression status of Ras-association domain family 7 (RASSF7) and Ras-association domain family 8 (RASSF8) in nodular thyroid goiter (NTG), medullary thyroid carcinoma (MTC), and papillary thyroid carcinoma (PTC) and establish whether a correlation exists between the presence of RASSF7 and RASSF8 proteins and clinicopathological parameters of the disease.
p12046
sg4
(lp12047
(dp12048
g9
I67
sg20
g21
sg12
I6
sg13
VRASSF7
p12049
sg15
I1
sa(dp12050
g9
I67
sg20
g21
sg12
I6
sg13
VRASSF7
p12051
sg15
I1
sa(dp12052
g9
I304
sg20
g21
sg12
I15
sg13
VRASSF8 proteins
p12053
sg15
I2
sa(dp12054
g9
I79
sg20
VP01116
p12055
sg12
I31
sg13
VRas-association domain family 8
p12056
sg15
I4
sa(dp12057
g9
I112
sg20
g21
sg12
I6
sg13
VRASSF8
p12058
sg15
I1
sa(dp12059
g9
I34
sg20
VP01116
p12060
sg12
I31
sg13
VRas-association domain family 7
p12061
sg15
I4
sasg6
(lp12062
(dp12063
g9
I131
sg10
VC0018021
p12064
sg12
I14
sg13
Vthyroid goiter
p12065
sg15
I2
sa(dp12066
g9
I192
sg10
VC0238463
p12067
sg12
I27
sg13
Vpapillary thyroid carcinoma
p12068
sg15
I3
sa(dp12069
g9
I221
sg10
VC0238463
p12070
sg12
I3
sg13
VPTC
p12071
sg15
I1
sa(dp12072
g9
I182
sg10
VC1833921
p12073
sg12
I3
sg13
VMTC
p12074
sg15
I1
sa(dp12075
g9
I153
sg10
VC0238462
p12076
sg12
I27
sg13
Vmedullary thyroid carcinoma
p12077
sg15
I3
sasa(dp12078
g2
VMoreover, HO-1 diminished ischemia-induced expression of MyoD involved in satellite cell differentiation in HO-1 KO mice.
p12079
sg4
(lp12080
(dp12081
g9
I57
sg20
VP15172
p12082
sg12
I4
sg13
VMyoD
p12083
sg15
I1
sasg6
(lp12084
(dp12085
g9
I26
sg10
VC0022116
p12086
sg12
I8
sg13
Vischemia
p12087
sg15
I1
sasa(dp12088
g2
VCoprecipitation of CD36, CD9, and alpha6beta1 was also observed on platelets from a patient with Glanzmann thrombasthenia, indicating that alphaII(b)beta3 is not required for the other proteins to associate.
p12089
sg4
(lp12090
(dp12091
g9
I25
sg20
VP21926
p12092
sg12
I3
sg13
VCD9
p12093
sg15
I1
sasg6
(lp12094
(dp12095
g9
I97
sg10
VC0040015
p12096
sg12
I24
sg13
VGlanzmann thrombasthenia
p12097
sg15
I2
sasa(dp12098
g2
VTo rule out a cross-reactivity of the two polyclonal antibodies with GPIIb/IIIa, we studied PECAM1 and CD9 expression on the platelets from a patient with type I Glanzmann's thrombasthenia whose platelets are devoid of GPIIb/IIIa.
p12099
sg4
(lp12100
(dp12101
g9
I69
sg20
VP08514
p12102
sg12
I10
sg13
VGPIIb/IIIa
p12103
sg15
I1
sa(dp12104
g9
I69
sg20
VP08514
p12105
sg12
I10
sg13
VGPIIb/IIIa
p12106
sg15
I1
sa(dp12107
g9
I103
sg20
VP21926
p12108
sg12
I3
sg13
VCD9
p12109
sg15
I1
sasg6
(lp12110
(dp12111
g9
I162
sg10
VC0040015
p12112
sg12
I26
sg13
VGlanzmann's thrombasthenia
p12113
sg15
I2
sasa(dp12114
g2
VIn contrast to TASK-1, which was not differentially expressed in lung cancer vs. normal lung tissue, we found the Na+-coupled nutrient transporters, SLC5A3, SLC5A6, and SLC38A1, transporters for myo-inositol, biotin and glutamine, respectively, to be significantly overexpressed in lung adenocarcinomas.
p12115
sg4
(lp12116
(dp12117
g9
I15
sg20
g21
sg12
I6
sg13
VTASK-1
p12118
sg15
I1
sa(dp12119
g9
I114
sg20
g21
sg12
I33
sg13
VNa+-coupled nutrient transporters
p12120
sg15
I3
sa(dp12121
g9
I157
sg20
g21
sg12
I6
sg13
VSLC5A6
p12122
sg15
I1
sa(dp12123
g9
I169
sg20
g21
sg12
I7
sg13
VSLC38A1
p12124
sg15
I1
sa(dp12125
g9
I149
sg20
VP53794
p12126
sg12
I6
sg13
VSLC5A3
p12127
sg15
I1
sasg6
(lp12128
(dp12129
g9
I65
sg10
VC0684249
p12130
sg12
I11
sg13
Vlung cancer
p12131
sg15
I2
sa(dp12132
g9
I287
sg10
VC0001418
p12133
sg12
I15
sg13
Vadenocarcinomas
p12134
sg15
I1
sasa(dp12135
g2
VqPCR analysis showed elevated expression of efflux transporters (P-glycoprotein, multidrug resistant protein 2, breast cancer resistant protein) and influx transporters (folate receptor-Alfa, cationic and neutral amino acid transporter, sodium dependent multivitamin transporter) in a time dependent manner.
p12136
sg4
(lp12137
(dp12138
g9
I237
sg20
VP19525
p12139
sg12
I41
sg13
Vsodium dependent multivitamin transporter
p12140
sg15
I4
sa(dp12141
g9
I44
sg20
g21
sg12
I19
sg13
Vefflux transporters
p12142
sg15
I2
sa(dp12143
g9
I213
sg20
g21
sg12
I22
sg13
Vamino acid transporter
p12144
sg15
I3
sa(dp12145
g9
I65
sg20
VP08183
p12146
sg12
I14
sg13
VP-glycoprotein
p12147
sg15
I1
sasg6
(lp12148
(dp12149
g9
I112
sg10
VC0678222
p12150
sg12
I13
sg13
Vbreast cancer
p12151
sg15
I2
sasa(dp12152
g2
VImmunoblot analysis further confirmed elevated expression of breast cancer resistant protein and sodium dependent multivitamin transporter.
p12153
sg4
(lp12154
(dp12155
g9
I97
sg20
VP19525
p12156
sg12
I41
sg13
Vsodium dependent multivitamin transporter
p12157
sg15
I4
sasg6
(lp12158
(dp12159
g9
I61
sg10
VC0678222
p12160
sg12
I13
sg13
Vbreast cancer
p12161
sg15
I2
sasa(dp12162
g2
VAll these studies demonstrated for the first time the functional and molecular expression of sodium dependent multivitamin transporter (SMVT), a specific carrier-mediated system for biotin uptake, in human derived breast cancer (T47D) cells.
p12163
sg4
(lp12164
(dp12165
g9
I93
sg20
VP19525
p12166
sg12
I41
sg13
Vsodium dependent multivitamin transporter
p12167
sg15
I4
sa(dp12168
g9
I136
sg20
g21
sg12
I4
sg13
VSMVT
p12169
sg15
I1
sasg6
(lp12170
(dp12171
g9
I214
sg10
VC0678222
p12172
sg12
I13
sg13
Vbreast cancer
p12173
sg15
I2
sasa(dp12174
g2
VThe overall objective of this study was to investigate the differential expression of folate receptor-alpha (FR-Alfa), sodium-dependent multivitamin transporter (SMVT), and amino acid transporter [B ((0, +))] in retinoblastoma (Y-79) and retinal pigment epithelial (ARPE-19) cells.
p12175
sg4
(lp12176
(dp12177
g9
I86
sg20
VP15328
p12178
sg12
I21
sg13
Vfolate receptor-alpha
p12179
sg15
I2
sa(dp12180
g9
I162
sg20
g21
sg12
I4
sg13
VSMVT
p12181
sg15
I1
sa(dp12182
g9
I119
sg20
g21
sg12
I41
sg13
Vsodium-dependent multivitamin transporter
p12183
sg15
I3
sasg6
(lp12184
(dp12185
g9
I212
sg10
VC0035335
p12186
sg12
I14
sg13
Vretinoblastoma
p12187
sg15
I1
sasa(dp12188
g2
VThis work demonstrated for the first time the higher expression and affinity of FR-Alfa, SMVT, and B ((0, +)) mRNA levels in retinoblastoma (Y-79) cells compared with retinal pigment epithelial (ARPE-19) cells.
p12189
sg4
(lp12190
(dp12191
g9
I89
sg20
g21
sg12
I4
sg13
VSMVT
p12192
sg15
I1
sasg6
(lp12193
(dp12194
g9
I125
sg10
VC0035335
p12195
sg12
I14
sg13
Vretinoblastoma
p12196
sg15
I1
sasa(dp12197
g2
VTo synthesize a novel camptothecin-poly(ethylene glycol) conjugate (CPT-PEG) which includes biotin as a moiety to enhance nonspecific and/or targeted uptake via the sodium-dependent multivitamin transporter (SMVT) and to evaluate its anticancer activity and apoptosis induction.
p12198
sg4
(lp12199
(dp12200
g9
I165
sg20
g21
sg12
I41
sg13
Vsodium-dependent multivitamin transporter
p12201
sg15
I3
sa(dp12202
g9
I208
sg20
g21
sg12
I4
sg13
VSMVT
p12203
sg15
I1
sasg6
(lp12204
sa(dp12205
g2
VThis suggests that the targeting approach utilizing transporters such as SMVT may substantially improve the delivery of CPT and its anticancer activity by enhancing cellular permeability and possibly retention of CPT.
p12206
sg4
(lp12207
sg6
(lp12208
sa(dp12209
g2
VWe have cloned the human Na+-dependent multivitamin transporter (SMVT), which transports the water-soluble vitamins pantothenate, biotin, and lipoate, from a placental choriocarcinoma cell line (JAR).
p12210
sg4
(lp12211
(dp12212
g9
I19
sg20
g21
sg12
I44
sg13
Vhuman Na+-dependent multivitamin transporter
p12213
sg15
I4
sa(dp12214
g9
I65
sg20
g21
sg12
I4
sg13
VSMVT
p12215
sg15
I1
sasg6
(lp12216
(dp12217
g9
I158
sg10
VC0855173
p12218
sg12
I25
sg13
Vplacental choriocarcinoma
p12219
sg15
I2
sasa(dp12220
g2
VWhile the association between IL-16 plasma levels and tumor progression has been reported for many types of cancer, the mechanism for IL-16 involvement has been partially elucidated for three of the cancer types, cutaneous T cell lymphoma (CTCL), multiple myeloma (MM), and breast cancer.
p12221
sg4
(lp12222
(dp12223
g9
I30
sg20
g21
sg12
I5
sg13
VIL-16
p12224
sg15
I1
sa(dp12225
g9
I30
sg20
g21
sg12
I5
sg13
VIL-16
p12226
sg15
I1
sasg6
(lp12227
(dp12228
g9
I213
sg10
VC0079773
p12229
sg12
I25
sg13
Vcutaneous T cell lymphoma
p12230
sg15
I4
sa(dp12231
g9
I108
sg10
VC0006826
p12232
sg12
I6
sg13
Vcancer
p12233
sg15
I1
sa(dp12234
g9
I108
sg10
VC0006826
p12235
sg12
I6
sg13
Vcancer
p12236
sg15
I1
sa(dp12237
g9
I54
sg10
VC0178874
p12238
sg12
I17
sg13
Vtumor progression
p12239
sg15
I2
sa(dp12240
g9
I240
sg10
VC0079773
p12241
sg12
I4
sg13
VCTCL
p12242
sg15
I1
sa(dp12243
g9
I274
sg10
VC0678222
p12244
sg12
I13
sg13
Vbreast cancer
p12245
sg15
I2
sa(dp12246
g9
I247
sg10
VC0026764
p12247
sg12
I16
sg13
Vmultiple myeloma
p12248
sg15
I2
sasa(dp12249
g2
VNuclear translocation of pro-interleukin-16 was not observed in late stages of Sezary syndrome, indicating this loss is not reversible.
p12250
sg4
(lp12251
(dp12252
g9
I25
sg20
g21
sg12
I18
sg13
Vpro-interleukin-16
p12253
sg15
I1
sasg6
(lp12254
(dp12255
g9
I8
sg10
VC0040715
p12256
sg12
I13
sg13
Vtranslocation
p12257
sg15
I1
sa(dp12258
g9
I79
sg10
VC0036920
p12259
sg12
I15
sg13
VSezary syndrome
p12260
sg15
I2
sasa(dp12261
g2
VWe propose that it is feasible to use plasma levels of IL-16 as a potential diagnostic marker of Sezary syndrome and to use loss of intracellular IL-16 as a prognostic indicator of disease severity and stage.
p12262
sg4
(lp12263
(dp12264
g9
I55
sg20
g21
sg12
I5
sg13
VIL-16
p12265
sg15
I1
sa(dp12266
g9
I55
sg20
g21
sg12
I5
sg13
VIL-16
p12267
sg15
I1
sasg6
(lp12268
(dp12269
g9
I97
sg10
VC0036920
p12270
sg12
I15
sg13
VSezary syndrome
p12271
sg15
I2
sasa(dp12272
g2
VBy reverse transcription-polymerase chain reaction, interleukin-16 mRNA was detected in 18 of 18 mycosis fungoides lesions investigated.
p12273
sg4
(lp12274
(dp12275
g9
I52
sg20
g21
sg12
I19
sg13
Vinterleukin-16 mRNA
p12276
sg15
I2
sasg6
(lp12277
(dp12278
g9
I97
sg10
VC0026948
p12279
sg12
I17
sg13
Vmycosis fungoides
p12280
sg15
I2
sasa(dp12281
g2
VGiven the biologic properties of interleukin-16 and the parallel activation of the interleukin-2/CD25 pathway, interleukin-16 might be involved in the recruitment and stimulation of CD4+ lymphocytes in mycosis fungoides lesions and therefore contribute to the perpetuation of the associated cutaneous inflammation.
p12282
sg4
(lp12283
(dp12284
g9
I182
sg20
VP01730
p12285
sg12
I4
sg13
VCD4+
p12286
sg15
I1
sa(dp12287
g9
I83
sg20
VP60568
p12288
sg12
I13
sg13
Vinterleukin-2
p12289
sg15
I1
sa(dp12290
g9
I33
sg20
g21
sg12
I14
sg13
Vinterleukin-16
p12291
sg15
I1
sa(dp12292
g9
I33
sg20
g21
sg12
I14
sg13
Vinterleukin-16
p12293
sg15
I1
sa(dp12294
g9
I97
sg20
VP01589
p12295
sg12
I4
sg13
VCD25
p12296
sg15
I1
sasg6
(lp12297
(dp12298
g9
I202
sg10
VC0026948
p12299
sg12
I17
sg13
Vmycosis fungoides
p12300
sg15
I2
sa(dp12301
g9
I151
sg10
VC0271510
p12302
sg12
I11
sg13
Vrecruitment
p12303
sg15
I1
sa(dp12304
g9
I301
sg10
VC0021368
p12305
sg12
I12
sg13
Vinflammation
p12306
sg15
I1
sasa(dp12307
g2
VThree additional patients with possible parathyroid adenomas at 11C-choline PET/CT were ultimately found to have thyroid lesions on the basis of tissue diagnosis; however, none of these patients had abnormal calcium or parathyroid hormone levels.
p12308
sg4
(lp12309
(dp12310
g9
I219
sg20
VP01270
p12311
sg12
I19
sg13
Vparathyroid hormone
p12312
sg15
I2
sasg6
(lp12313
(dp12314
g9
I40
sg10
VC0262587
p12315
sg12
I20
sg13
Vparathyroid adenomas
p12316
sg15
I2
sasa(dp12317
g2
VPatients with primary hyperparathyroidism generally have a single parathyroid adenoma that causes excessive excretion of parathyroid hormone.
p12318
sg4
(lp12319
(dp12320
g9
I121
sg20
VP01270
p12321
sg12
I19
sg13
Vparathyroid hormone
p12322
sg15
I2
sasg6
(lp12323
(dp12324
g9
I66
sg10
VC0262587
p12325
sg12
I19
sg13
Vparathyroid adenoma
p12326
sg15
I2
sa(dp12327
g9
I14
sg10
VC0221002
p12328
sg12
I27
sg13
Vprimary hyperparathyroidism
p12329
sg15
I2
sasa(dp12330
g2
VAlthough double adenomas are not yet widely acknowledged, presurgical imaging and nuclear scans can help to localize multiple lesions, and intraoperative parathyroid hormone assays can confirm the diagnosis and cure.
p12331
sg4
(lp12332
(dp12333
g9
I154
sg20
VP01270
p12334
sg12
I19
sg13
Vparathyroid hormone
p12335
sg15
I2
sasg6
(lp12336
(dp12337
g9
I16
sg10
VC0001430
p12338
sg12
I8
sg13
Vadenomas
p12339
sg15
I1
sasa(dp12340
g2
VFinally, MMGP analysis revealed a positive correlation between the transcript levels of B7-H4 and proliferation-related genes including MKI67, CCNA1, and Myc in several patients with multiple myeloma.
p12341
sg4
(lp12342
(dp12343
g9
I154
sg20
VP12524
p12344
sg12
I3
sg13
VMyc
p12345
sg15
I1
sa(dp12346
g9
I143
sg20
VP78396
p12347
sg12
I5
sg13
VCCNA1
p12348
sg15
I1
sa(dp12349
g9
I88
sg20
g21
sg12
I5
sg13
VB7-H4
p12350
sg15
I1
sa(dp12351
g9
I136
sg20
VP46013
p12352
sg12
I5
sg13
VMKI67
p12353
sg15
I1
sa(dp12354
g9
I98
sg20
VP01893
p12355
sg12
I27
sg13
Vproliferation-related genes
p12356
sg15
I2
sasg6
(lp12357
(dp12358
g9
I98
sg10
VC0334094
p12359
sg12
I13
sg13
Vproliferation
p12360
sg15
I1
sa(dp12361
g9
I183
sg10
VC0026764
p12362
sg12
I16
sg13
Vmultiple myeloma
p12363
sg15
I2
sasa(dp12364
g2
VThe purpose of this study was to evaluate the expression of cyclin A1 mRNA in patients with myelodysplastic syndrome (MDS) and its clinical significance.
p12365
sg4
(lp12366
(dp12367
g9
I60
sg20
VP78396
p12368
sg12
I14
sg13
Vcyclin A1 mRNA
p12369
sg15
I3
sasg6
(lp12370
(dp12371
g9
I92
sg10
VC3463824
p12372
sg12
I24
sg13
Vmyelodysplastic syndrome
p12373
sg15
I2
sa(dp12374
g9
I118
sg10
VC0265219
p12375
sg12
I3
sg13
VMDS
p12376
sg15
I1
sasa(dp12377
g2
VCyclin A1 mRNA was detectable in 11 of 11 patients with acute myeloid leukemia, three of three patients with acute biphenotypic leukemia, eight of eight patients with myelodysplastic syndrome, 59 of 69 patients with chronic myelogenous leukemia (CML) at diagnosis, 13 of 15 patients with CML in blastic transformation, 10 of 18 patients with chronic lymphocytic leukemia, two of nine patients with essential thrombocythemia, and only two of 10 patients with acute lymphoblastic leukemia (ALL) with both cyclin A1 RT-PCR positive ALL leukemias being undifferentiated relapses.
p12378
sg4
(lp12379
(dp12380
g9
I0
sg20
VP78396
p12381
sg12
I14
sg13
VCyclin A1 mRNA
p12382
sg15
I3
sa(dp12383
g9
I503
sg20
VP78396
p12384
sg12
I12
sg13
Vcyclin A1 RT
p12385
sg15
I3
sasg6
(lp12386
(dp12387
g9
I488
sg10
VC1961102
p12388
sg12
I3
sg13
VALL
p12389
sg15
I1
sa(dp12390
g9
I246
sg10
VC0023473
p12391
sg12
I3
sg13
VCML
p12392
sg15
I1
sa(dp12393
g9
I109
sg10
VC0023464
p12394
sg12
I27
sg13
Vacute biphenotypic leukemia
p12395
sg15
I3
sa(dp12396
g9
I246
sg10
VC0023473
p12397
sg12
I3
sg13
VCML
p12398
sg15
I1
sa(dp12399
g9
I342
sg10
VC0023434
p12400
sg12
I28
sg13
Vchronic lymphocytic leukemia
p12401
sg15
I3
sa(dp12402
g9
I56
sg10
VC0023467
p12403
sg12
I22
sg13
Vacute myeloid leukemia
p12404
sg15
I3
sa(dp12405
g9
I167
sg10
VC0033027
p12406
sg12
I24
sg13
Vmyelodysplastic syndrome
p12407
sg15
I2
sa(dp12408
g9
I398
sg10
VC0040028
p12409
sg12
I25
sg13
Vessential thrombocythemia
p12410
sg15
I2
sa(dp12411
g9
I303
sg10
VC1510411
p12412
sg12
I14
sg13
Vtransformation
p12413
sg15
I1
sa(dp12414
g9
I216
sg10
VC0023473
p12415
sg12
I28
sg13
Vchronic myelogenous leukemia
p12416
sg15
I3
sa(dp12417
g9
I458
sg10
VC1961102
p12418
sg12
I28
sg13
Vacute lymphoblastic leukemia
p12419
sg15
I3
sa(dp12420
g9
I488
sg10
VC1961102
p12421
sg12
I3
sg13
VALL
p12422
sg15
I1
sa(dp12423
g9
I533
sg10
VC0023418
p12424
sg12
I9
sg13
Vleukemias
p12425
sg15
I1
sasa(dp12426
g2
VMice with ANP showed increased apoptosis of pancreatic acinar cells, pancreatic myeloperoxidase activity, serum lactate dehydrogenase activity, amylase, tumor necrosis factor-Alfa (TNF-Alfa), interleukin-6 (IL-6) levels as well as decreased serum IL-10 level, pancreatic expression of heat shock factor 1 (HSF1), sirtuin 1 (SIRT1) and p53, but the ratio of acetylated HSF1 and p53 was markedly increased.
p12427
sg4
(lp12428
(dp12429
g9
I80
sg20
VP05164
p12430
sg12
I15
sg13
Vmyeloperoxidase
p12431
sg15
I1
sa(dp12432
g9
I324
sg20
g21
sg12
I5
sg13
VSIRT1
p12433
sg15
I1
sa(dp12434
g9
I335
sg20
VP42771
p12435
sg12
I3
sg13
Vp53
p12436
sg15
I1
sa(dp12437
g9
I144
sg20
VP04746
p12438
sg12
I7
sg13
Vamylase
p12439
sg15
I1
sa(dp12440
g9
I313
sg20
g21
sg12
I9
sg13
Vsirtuin 1
p12441
sg15
I2
sa(dp12442
g9
I306
sg20
g21
sg12
I4
sg13
VHSF1
p12443
sg15
I1
sa(dp12444
g9
I153
sg20
VP01375
p12445
sg12
I26
sg13
Vtumor necrosis factor-Alfa
p12446
sg15
I3
sa(dp12447
g9
I285
sg20
g21
sg12
I19
sg13
Vheat shock factor 1
p12448
sg15
I4
sa(dp12449
g9
I192
sg20
VP05231
p12450
sg12
I13
sg13
Vinterleukin-6
p12451
sg15
I1
sa(dp12452
g9
I335
sg20
VP42771
p12453
sg12
I3
sg13
Vp53
p12454
sg15
I1
sa(dp12455
g9
I306
sg20
g21
sg12
I4
sg13
VHSF1
p12456
sg15
I1
sa(dp12457
g9
I106
sg20
VP49366
p12458
sg12
I27
sg13
Vserum lactate dehydrogenase
p12459
sg15
I3
sa(dp12460
g9
I241
sg20
g21
sg12
I11
sg13
Vserum IL-10
p12461
sg15
I2
sa(dp12462
g9
I10
sg20
VP16066
p12463
sg12
I3
sg13
VANP
p12464
sg15
I1
sa(dp12465
g9
I181
sg20
VP01375
p12466
sg12
I8
sg13
VTNF-Alfa
p12467
sg15
I1
sa(dp12468
g9
I207
sg20
VP05231
p12469
sg12
I4
sg13
VIL-6
p12470
sg15
I1
sasg6
(lp12471
(dp12472
g9
I153
sg10
VC0333516
p12473
sg12
I14
sg13
Vtumor necrosis
p12474
sg15
I2
sasa(dp12475
g2
VThese data suggest that resveratrol protects against L-arginine-induced ANP, which may be related to the enhancement of SIRT1-mediated deacetylation of p53 and HSF1.
p12476
sg4
(lp12477
(dp12478
g9
I72
sg20
VP16066
p12479
sg12
I3
sg13
VANP
p12480
sg15
I1
sa(dp12481
g9
I160
sg20
g21
sg12
I4
sg13
VHSF1
p12482
sg15
I1
sa(dp12483
g9
I120
sg20
g21
sg12
I5
sg13
VSIRT1
p12484
sg15
I1
sa(dp12485
g9
I152
sg20
VP42771
p12486
sg12
I3
sg13
Vp53
p12487
sg15
I1
sasg6
(lp12488
sa(dp12489
g2
VThe aim of this study was to explore the role of the p38 mitogen-activated protein kinase (p38MAPK)/p53 signaling pathway in injury to the intestinal mucosal barrier during severe acute pancreatitis (SAP).
p12490
sg4
(lp12491
(dp12492
g9
I91
sg20
g21
sg12
I7
sg13
Vp38MAPK
p12493
sg15
I1
sa(dp12494
g9
I53
sg20
g21
sg12
I36
sg13
Vp38 mitogen-activated protein kinase
p12495
sg15
I4
sa(dp12496
g9
I100
sg20
VP42771
p12497
sg12
I3
sg13
Vp53
p12498
sg15
I1
sasg6
(lp12499
(dp12500
g9
I180
sg10
VC0001339
p12501
sg12
I18
sg13
Vacute pancreatitis
p12502
sg15
I2
sasa(dp12503
g2
VFurthermore, compared with homozygous missense mutations, compound heterozygous mutations appeared to have a more severe effect on phenotype, causing more severe growth retardation in ORC4 and more frequently pulmonary emphysema in CDT1.
p12504
sg4
(lp12505
(dp12506
g9
I232
sg20
g21
sg12
I4
sg13
VCDT1
p12507
sg15
I1
sasg6
(lp12508
(dp12509
g9
I162
sg10
VC0151686
p12510
sg12
I18
sg13
Vgrowth retardation
p12511
sg15
I2
sa(dp12512
g9
I209
sg10
VC0034067
p12513
sg12
I19
sg13
Vpulmonary emphysema
p12514
sg15
I2
sasa(dp12515
g2
VWe recently identified an RBP HNRNPL as a novel prostate cancer dependency via regulation of RNA splicing, suggesting the potential to target RBP or RBP-RNA interaction to treat cancer.
p12516
sg4
(lp12517
(dp12518
g9
I26
sg20
g21
sg12
I3
sg13
VRBP
p12519
sg15
I1
sa(dp12520
g9
I26
sg20
g21
sg12
I10
sg13
VRBP HNRNPL
p12521
sg15
I2
sa(dp12522
g9
I149
sg20
g21
sg12
I7
sg13
VRBP-RNA
p12523
sg15
I1
sasg6
(lp12524
(dp12525
g9
I57
sg10
VC0006826
p12526
sg12
I6
sg13
Vcancer
p12527
sg15
I1
sa(dp12528
g9
I48
sg10
VC0600139
p12529
sg12
I15
sg13
Vprostate cancer
p12530
sg15
I2
sasa(dp12531
g2
VHNRNPL directly regulates the alternative splicing of a set of RNAs, including those encoding the androgen receptor, the key lineage-specific prostate cancer oncogene.
p12532
sg4
(lp12533
(dp12534
g9
I0
sg20
VP14866
p12535
sg12
I6
sg13
VHNRNPL
p12536
sg15
I1
sa(dp12537
g9
I98
sg20
VP10275
p12538
sg12
I17
sg13
Vandrogen receptor
p12539
sg15
I2
sasg6
(lp12540
(dp12541
g9
I142
sg10
VC0600139
p12542
sg12
I15
sg13
Vprostate cancer
p12543
sg15
I2
sasa(dp12544
g2
VCollectively, our data reveal HNRNPL and its RNA clients as players in prostate cancer growth and potential therapeutic targets.
p12545
sg4
(lp12546
sg6
(lp12547
(dp12548
g9
I71
sg10
VC0600139
p12549
sg12
I15
sg13
Vprostate cancer
p12550
sg15
I2
sasa(dp12551
g2
VHeterogeneous nuclear ribonucleoprotein L (hnRNP-L) is a promoter of various kinds of cancers, but its actions in bladder cancer (BC) are unclear.
p12552
sg4
(lp12553
(dp12554
g9
I0
sg20
VP14866
p12555
sg12
I41
sg13
VHeterogeneous nuclear ribonucleoprotein L
p12556
sg15
I4
sa(dp12557
g9
I43
sg20
VP14866
p12558
sg12
I7
sg13
VhnRNP-L
p12559
sg15
I1
sasg6
(lp12560
(dp12561
g9
I86
sg10
VC0006826
p12562
sg12
I7
sg13
Vcancers
p12563
sg15
I1
sa(dp12564
g9
I114
sg10
VC0699885
p12565
sg12
I14
sg13
Vbladder cancer
p12566
sg15
I2
sa(dp12567
g9
I130
sg10
VC0699885
p12568
sg12
I2
sg13
VBC
p12569
sg15
I1
sasa(dp12570
g2
VIn this study, we examined the role of HnRNP-L in prostate cancer (Pca).
p12571
sg4
(lp12572
(dp12573
g9
I39
sg20
VP14866
p12574
sg12
I26
sg13
VHnRNP-L in prostate cancer
p12575
sg15
I4
sa(dp12576
g9
I67
sg20
g21
sg12
I3
sg13
VPca
p12577
sg15
I1
sasg6
(lp12578
(dp12579
g9
I50
sg10
VC0600139
p12580
sg12
I15
sg13
Vprostate cancer
p12581
sg15
I2
sa(dp12582
g9
I67
sg10
VC0268398
p12583
sg12
I3
sg13
VPca
p12584
sg15
I1
sasa(dp12585
g2
VThese results suggest a rationale for dose reduction of doxorubicin and docetaxel in prostate cancer therapy, since the doses needed to achieve 50% cell death may be decreased by approximately 4- to 15-fold or 3- to 8-fold, respectively, after a pre-treatment with ciprofloxacin.
p12586
sg4
(lp12587
sg6
(lp12588
(dp12589
g9
I85
sg10
VC0600139
p12590
sg12
I15
sg13
Vprostate cancer
p12591
sg15
I2
sasa(dp12592
g2
VThis study investigated the presence of CA I and II autoantibodies in patients with iron deficiency anemia (IDA).
p12593
sg4
(lp12594
(dp12595
g9
I40
sg20
VP00915
p12596
sg12
I26
sg13
VCA I and II autoantibodies
p12597
sg15
I5
sasg6
(lp12598
(dp12599
g9
I108
sg10
VC0162316
p12600
sg12
I3
sg13
VIDA
p12601
sg15
I1
sa(dp12602
g9
I84
sg10
VC0162316
p12603
sg12
I22
sg13
Viron deficiency anemia
p12604
sg15
I3
sasa(dp12605
g2
VCompared with controls, CAIII concentration was lower in iron deficiency anemia (P&lt;0.01), but higher in beta-thalassemia anemia (P&lt;0.001).
p12606
sg4
(lp12607
(dp12608
g9
I24
sg20
VP07451
p12609
sg12
I5
sg13
VCAIII
p12610
sg15
I1
sasg6
(lp12611
(dp12612
g9
I73
sg10
VC0002871
p12613
sg12
I6
sg13
Vanemia
p12614
sg15
I1
sa(dp12615
g9
I107
sg10
VC0005283
p12616
sg12
I16
sg13
Vbeta-thalassemia
p12617
sg15
I1
sa(dp12618
g9
I57
sg10
VC0162316
p12619
sg12
I22
sg13
Viron deficiency anemia
p12620
sg15
I3
sasa(dp12621
g2
VThe levels of erythrocyte carbonic anhydrase isozymes (CA-B and CA-C) were determined by a quantitative immunochemical technique in order to elucidate their clinical significances in patients with iron deficiency anemia.
p12622
sg4
(lp12623
(dp12624
g9
I14
sg20
VP35218
p12625
sg12
I39
sg13
Verythrocyte carbonic anhydrase isozymes
p12626
sg15
I4
sasg6
(lp12627
(dp12628
g9
I197
sg10
VC0162316
p12629
sg12
I22
sg13
Viron deficiency anemia
p12630
sg15
I3
sasa(dp12631
g2
V1 The levels of erythrocyte CA-B per gram hemoglobin, CA-B per ml erythrocyte and CA-C per gram hemoglobin all increased but CA-C per ml erythrocyte did not increased in iron deficiency anemia.
p12632
sg4
(lp12633
(dp12634
g9
I42
sg20
g21
sg12
I10
sg13
Vhemoglobin
p12635
sg15
I1
sa(dp12636
g9
I37
sg20
g21
sg12
I15
sg13
Vgram hemoglobin
p12637
sg15
I2
sasg6
(lp12638
(dp12639
g9
I170
sg10
VC0162316
p12640
sg12
I22
sg13
Viron deficiency anemia
p12641
sg15
I3
sasa(dp12642
g2
VThe content of CA-B synthesized in lysates was much higher than that of CA-C. 6 In iron deficiency anemia, the increase of erythrocyte CA is speculated to be compensatory mechanism, which brought about the transportation of CO2 and right shifts of O2 dissociation curve.
p12643
sg4
(lp12644
sg6
(lp12645
(dp12646
g9
I83
sg10
VC0162316
p12647
sg12
I22
sg13
Viron deficiency anemia
p12648
sg15
I3
sa(dp12649
g9
I251
sg10
VC0086168
p12650
sg12
I12
sg13
Vdissociation
p12651
sg15
I1
sasa(dp12652
g2
VInhibition of inducible T-cell kinase (ITK), a nonreceptor tyrosine kinase, may represent a novel treatment for allergic asthma.
p12653
sg4
(lp12654
(dp12655
g9
I39
sg20
VP19823
p12656
sg12
I3
sg13
VITK
p12657
sg15
I1
sa(dp12658
g9
I14
sg20
VP19823
p12659
sg12
I23
sg13
Vinducible T-cell kinase
p12660
sg15
I3
sasg6
(lp12661
(dp12662
g9
I112
sg10
VC0155877
p12663
sg12
I15
sg13
Vallergic asthma
p12664
sg15
I2
sasa(dp12665
g2
VHere we show that Itk, a mediator of T cell receptor signalling required for Th2 immune responses and the development of asthma, is a positive regulator of Th9 differentiation.
p12666
sg4
(lp12667
(dp12668
g9
I37
sg20
g21
sg12
I15
sg13
VT cell receptor
p12669
sg15
I3
sa(dp12670
g9
I18
sg20
VP19823
p12671
sg12
I3
sg13
VItk
p12672
sg15
I1
sasg6
(lp12673
(dp12674
g9
I121
sg10
VC0004096
p12675
sg12
I6
sg13
Vasthma
p12676
sg15
I1
sasa(dp12677
g2
VCompared to wild-type mice, ITK knockout mice are resistant to asthma and exhibit reduced lung inflammation and decreased amounts of TH2-type cytokines in the bronchoalveolar lavage fluid.
p12678
sg4
(lp12679
sg6
(lp12680
(dp12681
g9
I90
sg10
VC0032285
p12682
sg12
I17
sg13
Vlung inflammation
p12683
sg15
I2
sa(dp12684
g9
I63
sg10
VC0004096
p12685
sg12
I6
sg13
Vasthma
p12686
sg15
I1
sasa(dp12687
g2
VUnexpectedly, inhibition of the kinase activity of ITK during or after antigen rechallenge in an ovalbumin-induced mouse model of asthma failed to reduce airway hyperresponsiveness and inflammation.
p12688
sg4
(lp12689
(dp12690
g9
I51
sg20
VP19823
p12691
sg12
I3
sg13
VITK
p12692
sg15
I1
sasg6
(lp12693
(dp12694
g9
I130
sg10
VC0004096
p12695
sg12
I6
sg13
Vasthma
p12696
sg15
I1
sa(dp12697
g9
I185
sg10
VC0021368
p12698
sg12
I12
sg13
Vinflammation
p12699
sg15
I1
sasa(dp12700
g2
VThus, our studies predict that inhibition of the kinase activity of ITK may not be therapeutic in patients with asthma.
p12701
sg4
(lp12702
(dp12703
g9
I68
sg20
VP19823
p12704
sg12
I3
sg13
VITK
p12705
sg15
I1
sasg6
(lp12706
(dp12707
g9
I112
sg10
VC0004096
p12708
sg12
I6
sg13
Vasthma
p12709
sg15
I1
sasa(dp12710
g2
VFeNO levels were significantly elevated in the asthma compared to the control group (26 +/- 18 versus 11 +/- 4 ppb; p &lt; 0.05), and trended higher than levels in the tetraplegia group (15 +/- 6; p = 0.08).
p12711
sg4
(lp12712
sg6
(lp12713
(dp12714
g9
I47
sg10
VC0004096
p12715
sg12
I6
sg13
Vasthma
p12716
sg15
I1
sa(dp12717
g9
I111
sg10
VC1266144
p12718
sg12
I3
sg13
Vppb
p12719
sg15
I1
sa(dp12720
g9
I168
sg10
VC0034372
p12721
sg12
I11
sg13
Vtetraplegia
p12722
sg15
I1
sasa(dp12723
g2
VThe medicinal chemistry community has directed considerable efforts toward the discovery of selective inhibitors of interleukin-2 inducible T-cell kinase (ITK), given its role in T-cell signaling downstream of the T-cell receptor (TCR) and the implications of this target for inflammatory disorders such as asthma.
p12724
sg4
(lp12725
(dp12726
g9
I130
sg20
VP19823
p12727
sg12
I23
sg13
Vinducible T-cell kinase
p12728
sg15
I3
sa(dp12729
g9
I214
sg20
g21
sg12
I15
sg13
VT-cell receptor
p12730
sg15
I2
sa(dp12731
g9
I116
sg20
VP60568
p12732
sg12
I13
sg13
Vinterleukin-2
p12733
sg15
I1
sa(dp12734
g9
I231
sg20
g21
sg12
I3
sg13
VTCR
p12735
sg15
I1
sa(dp12736
g9
I155
sg20
VP19823
p12737
sg12
I3
sg13
VITK
p12738
sg15
I1
sasg6
(lp12739
(dp12740
g9
I307
sg10
VC0004096
p12741
sg12
I6
sg13
Vasthma
p12742
sg15
I1
sasa(dp12743
g2
VThe caspase-3 apoptotic index was a strong risk factor for subsequent gestational trophoblastic neoplasia development.
p12744
sg4
(lp12745
(dp12746
g9
I4
sg20
VP42574
p12747
sg12
I9
sg13
Vcaspase-3
p12748
sg15
I1
sasg6
(lp12749
(dp12750
g9
I70
sg10
VC1135868
p12751
sg12
I35
sg13
Vgestational trophoblastic neoplasia
p12752
sg15
I3
sasa(dp12753
g2
VThe two genes were CXCL6 (chemokine (C-X-C motif) ligand 6) and BBS5 (Bardet-Biedl syndrome 5).
p12754
sg4
(lp12755
(dp12756
g9
I19
sg20
VP80162
p12757
sg12
I5
sg13
VCXCL6
p12758
sg15
I1
sa(dp12759
g9
I64
sg20
g21
sg12
I4
sg13
VBBS5
p12760
sg15
I1
sa(dp12761
g9
I70
sg20
g21
sg12
I23
sg13
VBardet-Biedl syndrome 5
p12762
sg15
I3
sa(dp12763
g9
I36
sg20
VP80162
p12764
sg12
I22
sg13
V(C-X-C motif) ligand 6
p12765
sg15
I4
sasg6
(lp12766
(dp12767
g9
I70
sg10
VC0752166
p12768
sg12
I21
sg13
VBardet-Biedl syndrome
p12769
sg15
I2
sasa(dp12770
g2
VCompared with patients with a false-positive penicillin allergy result (confirmed by negative penicillin skin testing result), patients reporting a true penicillin allergy confirmed by positive penicillin skin test results tended to be more frequently men (61.5% versus 44.5%; Delta 17.0%; 95% CI -13.5% to 42%), black (69.2% versus 44.5%; Delta 24.7%; 95% CI -6.9% to 46.8%), and have no family history of drug allergy (7.7% versus 17.5%; Delta9.8%; 95% CI -20.9% to 20.4%), but self-reported other drug allergies more frequently (61.5% versus 38.7%; Delta 22.9%; 95% CI -7.7% to 47.5%).
p12771
sg4
(lp12772
sg6
(lp12773
(dp12774
g9
I407
sg10
VC0013182
p12775
sg12
I12
sg13
Vdrug allergy
p12776
sg15
I2
sa(dp12777
g9
I45
sg10
VC0030824
p12778
sg12
I18
sg13
Vpenicillin allergy
p12779
sg15
I2
sa(dp12780
g9
I45
sg10
VC0030824
p12781
sg12
I18
sg13
Vpenicillin allergy
p12782
sg15
I2
sa(dp12783
g9
I500
sg10
VC0013182
p12784
sg12
I14
sg13
Vdrug allergies
p12785
sg15
I2
sasa(dp12786
g2
VWe identified 12 biomarkers consistently associated with either clinical groups "upstream" towards culture-positive TB on the TB disease spectrum (CD14, FCGR1A, FPR1, MMP9, RAB24, SEC14L1, and TIMP2) or "downstream" towards a decreased likelihood of TB disease (BLR1, CD3E, CD8A, IL7R, and TGFBR2), suggesting a correlation with MTB-related pathology and high relevance to a future POC test for pediatric TB.
p12787
sg4
(lp12788
(dp12789
g9
I147
sg20
VP08571
p12790
sg12
I4
sg13
VCD14
p12791
sg15
I1
sa(dp12792
g9
I173
sg20
g21
sg12
I5
sg13
VRAB24
p12793
sg15
I1
sa(dp12794
g9
I153
sg20
VP12314
p12795
sg12
I6
sg13
VFCGR1A
p12796
sg15
I1
sa(dp12797
g9
I268
sg20
VP07766
p12798
sg12
I4
sg13
VCD3E
p12799
sg15
I1
sa(dp12800
g9
I274
sg20
VP01732
p12801
sg12
I4
sg13
VCD8A
p12802
sg15
I1
sa(dp12803
g9
I262
sg20
VP32302
p12804
sg12
I4
sg13
VBLR1
p12805
sg15
I1
sa(dp12806
g9
I180
sg20
g21
sg12
I7
sg13
VSEC14L1
p12807
sg15
I1
sa(dp12808
g9
I167
sg20
VP14780
p12809
sg12
I4
sg13
VMMP9
p12810
sg15
I1
sa(dp12811
g9
I193
sg20
VP16035
p12812
sg12
I5
sg13
VTIMP2
p12813
sg15
I1
sa(dp12814
g9
I161
sg20
VP21462
p12815
sg12
I4
sg13
VFPR1
p12816
sg15
I1
sa(dp12817
g9
I290
sg20
VP37173
p12818
sg12
I6
sg13
VTGFBR2
p12819
sg15
I1
sasg6
(lp12820
(dp12821
g9
I341
sg10
VC0677042
p12822
sg12
I9
sg13
Vpathology
p12823
sg15
I1
sasa(dp12824
g2
VHowever, aberrant expression of class III Beta-tubulin has been observed in passaged RPE cells and RPE cells with dedifferentiated morphology in pathologic epiretinal membranes from idiopathic macular pucker, proliferative vitreoretinopathy (PVR) and proliferative diabetic retinopathy (PDR).
p12825
sg4
(lp12826
(dp12827
g9
I42
sg20
VP68371
p12828
sg12
I12
sg13
VBeta-tubulin
p12829
sg15
I1
sasg6
(lp12830
(dp12831
g9
I251
sg10
VC0154830
p12832
sg12
I34
sg13
Vproliferative diabetic retinopathy
p12833
sg15
I3
sa(dp12834
g9
I209
sg10
VC1860404
p12835
sg12
I31
sg13
Vproliferative vitreoretinopathy
p12836
sg15
I2
sa(dp12837
g9
I242
sg10
VC1860404
p12838
sg12
I3
sg13
VPVR
p12839
sg15
I1
sa(dp12840
g9
I287
sg10
VC0154830
p12841
sg12
I3
sg13
VPDR
p12842
sg15
I1
sa(dp12843
g9
I156
sg10
VC0339543
p12844
sg12
I20
sg13
Vepiretinal membranes
p12845
sg15
I2
sa(dp12846
g9
I193
sg10
VC0154853
p12847
sg12
I14
sg13
Vmacular pucker
p12848
sg15
I2
sasa(dp12849
g2
VDisorders in the ability ofleukocytes to produce IFN-alpha and IFN-gamma were detected in patients with bronchial asthma and allergic rhinitis.
p12850
sg4
(lp12851
(dp12852
g9
I63
sg20
VP01579
p12853
sg12
I9
sg13
VIFN-gamma
p12854
sg15
I1
sa(dp12855
g9
I49
sg20
VP01562
p12856
sg12
I9
sg13
VIFN-alpha
p12857
sg15
I1
sasg6
(lp12858
(dp12859
g9
I125
sg10
VC2607914
p12860
sg12
I17
sg13
Vallergic rhinitis
p12861
sg15
I2
sa(dp12862
g9
I104
sg10
VC0004096
p12863
sg12
I16
sg13
Vbronchial asthma
p12864
sg15
I2
sasa(dp12865
g2
VFactors underlying the 'exacerbation-prone' phenotype are incompletely understood but include extrinsic factors: cigarette smoking, medication non-compliance, psychosocial factors, and co-morbidities such as gastroesophageal reflux disease, rhinosinusitis, obesity, and intolerance to non-steroidal anti-inflammatory medications; as well as intrinsic factors such as deficient epithelial cell production of the anti-viral type I interferons (IFN-alpha and IFN-beta).
p12866
sg4
(lp12867
(dp12868
g9
I411
sg20
VP29475
p12869
sg12
I29
sg13
Vanti-viral type I interferons
p12870
sg15
I4
sa(dp12871
g9
I442
sg20
VP01562
p12872
sg12
I9
sg13
VIFN-alpha
p12873
sg15
I1
sa(dp12874
g9
I456
sg20
VP01574
p12875
sg12
I8
sg13
VIFN-beta
p12876
sg15
I1
sasg6
(lp12877
(dp12878
g9
I257
sg10
VC0028754
p12879
sg12
I7
sg13
Vobesity
p12880
sg15
I1
sa(dp12881
g9
I208
sg10
VC0017168
p12882
sg12
I31
sg13
Vgastroesophageal reflux disease
p12883
sg15
I3
sa(dp12884
g9
I241
sg10
VC0948780
p12885
sg12
I14
sg13
Vrhinosinusitis
p12886
sg15
I1
sasa(dp12887
g2
VThese data indicate that therapeutic strategies using SAHPs targeting CD36, but not necessarily mimicking all apolipoprotein A-I functions, may be considered a possible new treatment approach for inflammation-induced ALI and pulmonary edema.
p12888
sg4
(lp12889
(dp12890
g9
I110
sg20
VP02647
p12891
sg12
I18
sg13
Vapolipoprotein A-I
p12892
sg15
I2
sasg6
(lp12893
(dp12894
g9
I196
sg10
VC0021368
p12895
sg12
I12
sg13
Vinflammation
p12896
sg15
I1
sa(dp12897
g9
I225
sg10
VC0034063
p12898
sg12
I15
sg13
Vpulmonary edema
p12899
sg15
I2
sasa(dp12900
g2
VThe enhanced expression of IL-17 that is observed in patients with Crohn's disease could act on intestinal fibroblasts to induce expression of transcription factor NFKBIZ and proinflammatory chemokine CXCL1.
p12901
sg4
(lp12902
(dp12903
g9
I143
sg20
VP35398
p12904
sg12
I63
sg13
Vtranscription factor NFKBIZ and proinflammatory chemokine CXCL1
p12905
sg15
I7
sasg6
(lp12906
(dp12907
g9
I67
sg10
VC0010346
p12908
sg12
I15
sg13
VCrohn's disease
p12909
sg15
I2
sasa(dp12910
g2
VIn the majority of cases, autosomal dominant nonsyndromic hearing loss is postlingual and progressive, with the exception of hearing impairment in families in which the impairment is linked to DFNA3, DFNA8/12, and DFNA24, the novel locus described in this report.
p12911
sg4
(lp12912
(dp12913
g9
I193
sg20
g21
sg12
I5
sg13
VDFNA3
p12914
sg15
I1
sa(dp12915
g9
I200
sg20
g21
sg12
I8
sg13
VDFNA8/12
p12916
sg15
I1
sasg6
(lp12917
(dp12918
g9
I214
sg10
VC1853451
p12919
sg12
I6
sg13
VDFNA24
p12920
sg15
I1
sa(dp12921
g9
I133
sg10
VC0684336
p12922
sg12
I10
sg13
Vimpairment
p12923
sg15
I1
sa(dp12924
g9
I58
sg10
VC0011053
p12925
sg12
I12
sg13
Vhearing loss
p12926
sg15
I2
sa(dp12927
g9
I200
sg10
VC1832187
p12928
sg12
I5
sg13
VDFNA8
p12929
sg15
I1
sa(dp12930
g9
I133
sg10
VC0684336
p12931
sg12
I10
sg13
Vimpairment
p12932
sg15
I1
sasa(dp12933
g2
VThe morphological similarity and resemblance of keratin 1, 10, and 14 profiles, and p63 and Beta-catenin expression between mixed epidermal and inner root sheath hybrid cysts and keratoacanthomas suggests that hybrid cysts progressed to keratoacanthomas, and the cells from infundibular cells to inner root sheath cells of the pilar segment seem to be the origin of rat keratoacanthomas.
p12934
sg4
(lp12935
(dp12936
g9
I48
sg20
VP04264
p12937
sg12
I9
sg13
Vkeratin 1
p12938
sg15
I2
sa(dp12939
g9
I84
sg20
g21
sg12
I3
sg13
Vp63
p12940
sg15
I1
sa(dp12941
g9
I92
sg20
VP35222
p12942
sg12
I12
sg13
VBeta-catenin
p12943
sg15
I1
sasg6
(lp12944
(dp12945
g9
I179
sg10
VC0022572
p12946
sg12
I16
sg13
Vkeratoacanthomas
p12947
sg15
I1
sa(dp12948
g9
I179
sg10
VC0022572
p12949
sg12
I16
sg13
Vkeratoacanthomas
p12950
sg15
I1
sa(dp12951
g9
I169
sg10
VC0010709
p12952
sg12
I5
sg13
Vcysts
p12953
sg15
I1
sa(dp12954
g9
I179
sg10
VC0022572
p12955
sg12
I16
sg13
Vkeratoacanthomas
p12956
sg15
I1
sa(dp12957
g9
I169
sg10
VC0010709
p12958
sg12
I5
sg13
Vcysts
p12959
sg15
I1
sasa(dp12960
g2
VUCDs include a spectrum of enzyme deficiencies, namely n-acetylglutamate synthase deficiency (NAGS), carbamoyl phosphate synthetase I deficiency (CPS1), ornithine transcarbamylase deficiency (OTC), argininosuccinate lyase deficiency (ASL), citrullinemia type I (ASS1), and argininemia (ARG).
p12961
sg4
(lp12962
(dp12963
g9
I55
sg20
g21
sg12
I26
sg13
Vn-acetylglutamate synthase
p12964
sg15
I2
sa(dp12965
g9
I153
sg20
VP00480
p12966
sg12
I26
sg13
Vornithine transcarbamylase
p12967
sg15
I2
sa(dp12968
g9
I146
sg20
VP31327
p12969
sg12
I4
sg13
VCPS1
p12970
sg15
I1
sa(dp12971
g9
I101
sg20
VP31327
p12972
sg12
I32
sg13
Vcarbamoyl phosphate synthetase I
p12973
sg15
I4
sa(dp12974
g9
I262
sg20
VP00966
p12975
sg12
I4
sg13
VASS1
p12976
sg15
I1
sa(dp12977
g9
I240
sg20
VP00966
p12978
sg12
I20
sg13
Vcitrullinemia type I
p12979
sg15
I3
sa(dp12980
g9
I198
sg20
VP04424
p12981
sg12
I23
sg13
Vargininosuccinate lyase
p12982
sg15
I2
sasg6
(lp12983
(dp12984
g9
I153
sg10
VC0268542
p12985
sg12
I37
sg13
Vornithine transcarbamylase deficiency
p12986
sg15
I3
sa(dp12987
g9
I286
sg10
VC0268548
p12988
sg12
I3
sg13
VARG
p12989
sg15
I1
sa(dp12990
g9
I101
sg10
VC0751753
p12991
sg12
I43
sg13
Vcarbamoyl phosphate synthetase I deficiency
p12992
sg15
I5
sa(dp12993
g9
I240
sg10
VC0175683
p12994
sg12
I13
sg13
Vcitrullinemia
p12995
sg15
I1
sa(dp12996
g9
I55
sg10
VC0268543
p12997
sg12
I37
sg13
Vn-acetylglutamate synthase deficiency
p12998
sg15
I3
sa(dp12999
g9
I234
sg10
VC0268547
p13000
sg12
I3
sg13
VASL
p13001
sg15
I1
sa(dp13002
g9
I273
sg10
VC0268548
p13003
sg12
I11
sg13
Vargininemia
p13004
sg15
I1
sa(dp13005
g9
I94
sg10
VC0268543
p13006
sg12
I4
sg13
VNAGS
p13007
sg15
I1
sa(dp13008
g9
I198
sg10
VC0268547
p13009
sg12
I34
sg13
Vargininosuccinate lyase deficiency
p13010
sg15
I3
sa(dp13011
g9
I192
sg10
VC0268542
p13012
sg12
I3
sg13
VOTC
p13013
sg15
I1
sasa(dp13014
g2
VRecovery was also associated with maternal obesity, and there was some ethnic variation - in the adjusted analysis indigenous (Orang Asal) Malaysians had lower odds of recovery.
p13015
sg4
(lp13016
sg6
(lp13017
(dp13018
g9
I43
sg10
VC0028754
p13019
sg12
I7
sg13
Vobesity
p13020
sg15
I1
sasa(dp13021
g2
VArgininosuccinic acid lyase (ASL) deficiency, caused by mutations in the ASL gene (OMIM: 608310) is a urea cycle disorder that has pleiotropic presentations.
p13022
sg4
(lp13023
(dp13024
g9
I73
sg20
VP30566
p13025
sg12
I8
sg13
VASL gene
p13026
sg15
I2
sa(dp13027
g9
I29
sg20
VP30566
p13028
sg12
I3
sg13
VASL
p13029
sg15
I1
sa(dp13030
g9
I0
sg20
g21
sg12
I27
sg13
VArgininosuccinic acid lyase
p13031
sg15
I3
sasg6
(lp13032
(dp13033
g9
I102
sg10
VC0154246
p13034
sg12
I19
sg13
Vurea cycle disorder
p13035
sg15
I3
sasa(dp13036
g2
VThese include N-acetylglutamate synthase deficiency (NAGSD); Carbamyl phosphate synthetase 1 deficiency (CPS1D); Ornithine transcarbamylase deficiency (OTCD); Argininosuccinate synthetase deficiency (ASSD) (Citrullinemia); Argininosuccinate lyase deficiency (ASLD) (Argininosuccinic aciduria); Arginase deficiency (ARGD, Argininemia); Hyperornithinemia, hyperammonemia, homocitrullinuria (HHH) syndrome (or mitochondrial ornithine transporter 1 deficiency [ORNT1D]); and Citrullinemia type II (mitochondrial aspartate/glutamate carrier deficiency [CITRIN]).
p13037
sg4
(lp13038
(dp13039
g9
I407
sg20
g21
sg12
I37
sg13
Vmitochondrial ornithine transporter 1
p13040
sg15
I4
sa(dp13041
g9
I61
sg20
g21
sg12
I31
sg13
VCarbamyl phosphate synthetase 1
p13042
sg15
I4
sa(dp13043
g9
I223
sg20
VP04424
p13044
sg12
I23
sg13
VArgininosuccinate lyase
p13045
sg15
I2
sa(dp13046
g9
I294
sg20
VP05089
p13047
sg12
I8
sg13
VArginase
p13048
sg15
I1
sa(dp13049
g9
I113
sg20
VP00480
p13050
sg12
I26
sg13
VOrnithine transcarbamylase
p13051
sg15
I2
sa(dp13052
g9
I159
sg20
VP00966
p13053
sg12
I28
sg13
VArgininosuccinate synthetase
p13054
sg15
I2
sa(dp13055
g9
I14
sg20
g21
sg12
I26
sg13
VN-acetylglutamate synthase
p13056
sg15
I2
sa(dp13057
g9
I494
sg20
g21
sg12
I61
sg13
Vmitochondrial aspartate/glutamate carrier deficiency [CITRIN]
p13058
sg15
I5
sasg6
(lp13059
(dp13060
g9
I389
sg10
VC0268540
p13061
sg12
I3
sg13
VHHH
p13062
sg15
I1
sa(dp13063
g9
I335
sg10
VC0599035
p13064
sg12
I17
sg13
VHyperornithinemia
p13065
sg15
I1
sa(dp13066
g9
I394
sg10
VC0039082
p13067
sg12
I8
sg13
Vsyndrome
p13068
sg15
I1
sa(dp13069
g9
I159
sg10
VC0175683
p13070
sg12
I39
sg13
VArgininosuccinate synthetase deficiency
p13071
sg15
I3
sa(dp13072
g9
I14
sg10
VC0268543
p13073
sg12
I37
sg13
VN-acetylglutamate synthase deficiency
p13074
sg15
I3
sa(dp13075
g9
I315
sg10
VC0268548
p13076
sg12
I4
sg13
VARGD
p13077
sg15
I1
sa(dp13078
g9
I223
sg10
VC0268547
p13079
sg12
I34
sg13
VArgininosuccinate lyase deficiency
p13080
sg15
I3
sa(dp13081
g9
I207
sg10
VC0175683
p13082
sg12
I13
sg13
VCitrullinemia
p13083
sg15
I1
sa(dp13084
g9
I152
sg10
VC0268542
p13085
sg12
I4
sg13
VOTCD
p13086
sg15
I1
sa(dp13087
g9
I53
sg10
VC0268543
p13088
sg12
I5
sg13
VNAGSD
p13089
sg15
I1
sa(dp13090
g9
I200
sg10
VC0175683
p13091
sg12
I4
sg13
VASSD
p13092
sg15
I1
sa(dp13093
g9
I259
sg10
VC0268547
p13094
sg12
I4
sg13
VASLD
p13095
sg15
I1
sa(dp13096
g9
I207
sg10
VC0175683
p13097
sg12
I13
sg13
VCitrullinemia
p13098
sg15
I1
sa(dp13099
g9
I321
sg10
VC0268548
p13100
sg12
I11
sg13
VArgininemia
p13101
sg15
I1
sa(dp13102
g9
I266
sg10
VC0268547
p13103
sg12
I25
sg13
VArgininosuccinic aciduria
p13104
sg15
I2
sa(dp13105
g9
I354
sg10
VC0220994
p13106
sg12
I14
sg13
Vhyperammonemia
p13107
sg15
I1
sa(dp13108
g9
I113
sg10
VC0268542
p13109
sg12
I37
sg13
VOrnithine transcarbamylase deficiency
p13110
sg15
I3
sa(dp13111
g9
I294
sg10
VC0268548
p13112
sg12
I19
sg13
VArginase deficiency
p13113
sg15
I2
sasa(dp13114
g2
VCardiomyopathy [methylmalonic (MMA) and propionic aciduria (PA)], prolonged QTc interval (PA), optic nerve atrophy [MMA, isovaleric aciduria (IVA)], pancytopenia (PA), and macrocephaly [glutaric aciduria type 1 (GA1)] were exclusively found in OAD patients, whereas hepatic involvement was more frequent in UCD patients, in particular in argininosuccinate lyase (ASL) deficiency.
p13115
sg4
(lp13116
(dp13117
g9
I363
sg20
VP30566
p13118
sg12
I3
sg13
VASL
p13119
sg15
I1
sa(dp13120
g9
I338
sg20
VP04424
p13121
sg12
I23
sg13
Vargininosuccinate lyase
p13122
sg15
I2
sasg6
(lp13123
(dp13124
g9
I186
sg10
VC0268595
p13125
sg12
I24
sg13
Vglutaric aciduria type 1
p13126
sg15
I4
sa(dp13127
g9
I60
sg10
VC2717876
p13128
sg12
I2
sg13
VPA
p13129
sg15
I1
sa(dp13130
g9
I149
sg10
VC0030312
p13131
sg12
I12
sg13
Vpancytopenia
p13132
sg15
I1
sa(dp13133
g9
I121
sg10
VC0268575
p13134
sg12
I19
sg13
Visovaleric aciduria
p13135
sg15
I2
sa(dp13136
g9
I31
sg10
VC0276096
p13137
sg12
I3
sg13
VMMA
p13138
sg15
I1
sa(dp13139
g9
I60
sg10
VC2717876
p13140
sg12
I2
sg13
VPA
p13141
sg15
I1
sa(dp13142
g9
I0
sg10
VC0878544
p13143
sg12
I14
sg13
VCardiomyopathy
p13144
sg15
I1
sa(dp13145
g9
I95
sg10
VC0029124
p13146
sg12
I19
sg13
Voptic nerve atrophy
p13147
sg15
I3
sa(dp13148
g9
I40
sg10
VC2717876
p13149
sg12
I18
sg13
Vpropionic aciduria
p13150
sg15
I2
sa(dp13151
g9
I60
sg10
VC2717876
p13152
sg12
I2
sg13
VPA
p13153
sg15
I1
sa(dp13154
g9
I172
sg10
VC0221355
p13155
sg12
I12
sg13
Vmacrocephaly
p13156
sg15
I1
sa(dp13157
g9
I15
sg10
VC0276096
p13158
sg12
I14
sg13
V[methylmalonic
p13159
sg15
I1
sa(dp13160
g9
I31
sg10
VC0276096
p13161
sg12
I3
sg13
VMMA
p13162
sg15
I1
sa(dp13163
g9
I66
sg10
VC1560305
p13164
sg12
I22
sg13
Vprolonged QTc interval
p13165
sg15
I3
sa(dp13166
g9
I142
sg10
VC0268575
p13167
sg12
I3
sg13
VIVA
p13168
sg15
I1
sasa(dp13169
g2
VFifteen patients (8 argininosuccinate lyase deficiency, 3 argininosuccinic acid synthetase deficiency, 3 ornithine transcarbamylase deficiency, 1 arginase deficiency) ages 2 months through 5 years enrolled in and completed the study.
p13170
sg4
(lp13171
(dp13172
g9
I58
sg20
g21
sg12
I32
sg13
Vargininosuccinic acid synthetase
p13173
sg15
I3
sa(dp13174
g9
I20
sg20
VP04424
p13175
sg12
I23
sg13
Vargininosuccinate lyase
p13176
sg15
I2
sa(dp13177
g9
I103
sg20
VP00480
p13178
sg12
I51
sg13
V3 ornithine transcarbamylase deficiency, 1 arginase
p13179
sg15
I6
sasg6
(lp13180
(dp13181
g9
I105
sg10
VC0268542
p13182
sg12
I37
sg13
Vornithine transcarbamylase deficiency
p13183
sg15
I3
sa(dp13184
g9
I146
sg10
VC0268548
p13185
sg12
I19
sg13
Varginase deficiency
p13186
sg15
I2
sa(dp13187
g9
I58
sg10
VC0175683
p13188
sg12
I43
sg13
Vargininosuccinic acid synthetase deficiency
p13189
sg15
I4
sa(dp13190
g9
I20
sg10
VC0268547
p13191
sg12
I34
sg13
Vargininosuccinate lyase deficiency
p13192
sg15
I3
sasa(dp13193
g2
VThe 20 genes with at least a 3-fold change, annotated with known phenotypic associations in the current gene databank (phenotype association, fold change) were aspartoacylase (Canavan disease, 9.96), growth hormone receptor (Laron dwarfism, idiopathic short stature, 8.25), lipoprotein lipase (familial chylomicronemia syndrome, lipoprotein lipase deficiency, 8.00), vitamin D (1,25- dihydroxyvitamin D3) receptor (involutional osteoporosis, vitamin D resistant rickets, 7.94), intercellular adhesion molecule 1 human rhinovirus receptor (cerebral malaria susceptibility, 7.16), peroxisomal membrane protein 3 35-kDa (Refsum disease, infantile form, Zellweger syndrome-3, 6.00), Bardet-Biedl syndrome 2 (Bardet-Biedl syndrome, 5.87), ribosomal protein S19 (Diamond Blackfan anemia, 5.85), apolipoprotein C-III (hypertriglyceridemia, 5.44), argininosuccinate lyase (argininosuccinicaciduria, 5.22), myosin VA (Griscelli syndrome-type pigmentary dilution with mental retardation, 4.92), lysozyme (renal amyloidosis, 4.17), SAM domain, SH3 domain and nuclear localisation signals 1 (Cherubism, 4.12 ), von Hippel-Lindau syndrome (hemangioblastoma, cerebellar, somatic, von Hippel-Lindau syndrome, 3.94), early-onset breast cancer 1 (BRCA1, papillary serous carcinoma of the peritoneum, 3.73), UDP-N-acetylglucosamine-2-epimerase/N-acetylmannosamine kinase (inclusion body myopathy, autosomal recessive, sialuria, 3.53), apolipoprotein A-I (amyloidosis, 3 or more types, hypoalphalipoproteinemia, 3.29), midline 1 Opitz/BBB syndrome (Opitz G syndrome, type I, 3.28), ATPase, Na+/K+ transporting, alpha 2 (+) polypeptide (familial hemiplegic migraine, 3.05).
p13194
sg4
(lp13195
(dp13196
g9
I789
sg20
VP02656
p13197
sg12
I20
sg13
Vapolipoprotein C-III
p13198
sg15
I2
sa(dp13199
g9
I274
sg20
VP06858
p13200
sg12
I18
sg13
Vlipoprotein lipase
p13201
sg15
I2
sa(dp13202
g9
I898
sg20
g21
sg12
I9
sg13
Vmyosin VA
p13203
sg15
I2
sa(dp13204
g9
I274
sg20
VP06858
p13205
sg12
I18
sg13
Vlipoprotein lipase
p13206
sg15
I2
sa(dp13207
g9
I1201
sg20
VP38398
p13208
sg12
I27
sg13
Vearly-onset breast cancer 1
p13209
sg15
I4
sa(dp13210
g9
I865
sg20
VP04424
p13211
sg12
I30
sg13
Vargininosuccinicaciduria, 5.22
p13212
sg15
I2
sa(dp13213
g9
I985
sg20
VP61626
p13214
sg12
I8
sg13
Vlysozyme
p13215
sg15
I1
sa(dp13216
g9
I1417
sg20
VP02647
p13217
sg12
I18
sg13
Vapolipoprotein A-I
p13218
sg15
I2
sa(dp13219
g9
I840
sg20
VP04424
p13220
sg12
I23
sg13
Vargininosuccinate lyase
p13221
sg15
I2
sa(dp13222
g9
I200
sg20
VP10912
p13223
sg12
I23
sg13
Vgrowth hormone receptor
p13224
sg15
I3
sa(dp13225
g9
I478
sg20
VP05362
p13226
sg12
I59
sg13
Vintercellular adhesion molecule 1 human rhinovirus receptor
p13227
sg15
I7
sa(dp13228
g9
I734
sg20
VP39019
p13229
sg12
I21
sg13
Vribosomal protein S19
p13230
sg15
I3
sa(dp13231
g9
I1021
sg20
g21
sg12
I10
sg13
VSAM domain
p13232
sg15
I2
sa(dp13233
g9
I1230
sg20
VP38398
p13234
sg12
I5
sg13
VBRCA1
p13235
sg15
I1
sa(dp13236
g9
I1563
sg20
VP38606
p13237
sg12
I6
sg13
VATPase
p13238
sg15
I1
sa(dp13239
g9
I160
sg20
VP45381
p13240
sg12
I14
sg13
Vaspartoacylase
p13241
sg15
I1
sasg6
(lp13242
(dp13243
g9
I492
sg10
VC0001511
p13244
sg12
I8
sg13
Vadhesion
p13245
sg15
I1
sa(dp13246
g9
I225
sg10
VC0271568
p13247
sg12
I14
sg13
VLaron dwarfism
p13248
sg15
I2
sa(dp13249
g9
I1237
sg10
VC0334359
p13250
sg12
I26
sg13
Vpapillary serous carcinoma
p13251
sg15
I3
sa(dp13252
g9
I995
sg10
VC0268382
p13253
sg12
I17
sg13
Vrenal amyloidosis
p13254
sg15
I2
sa(dp13255
g9
I865
sg10
VC0268547
p13256
sg12
I24
sg13
Vargininosuccinicaciduria
p13257
sg15
I1
sa(dp13258
g9
I303
sg10
VC1274228
p13259
sg12
I24
sg13
Vchylomicronemia syndrome
p13260
sg15
I2
sa(dp13261
g9
I757
sg10
VC1260899
p13262
sg12
I23
sg13
VDiamond Blackfan anemia
p13263
sg15
I3
sa(dp13264
g9
I176
sg10
VC0206307
p13265
sg12
I15
sg13
VCanavan disease
p13266
sg15
I2
sa(dp13267
g9
I442
sg10
VC2363065
p13268
sg12
I27
sg13
Vvitamin D resistant rickets
p13269
sg15
I4
sa(dp13270
g9
I958
sg10
VC0025362
p13271
sg12
I18
sg13
Vmental retardation
p13272
sg15
I2
sa(dp13273
g9
I329
sg10
VC0023817
p13274
sg12
I29
sg13
Vlipoprotein lipase deficiency
p13275
sg15
I3
sa(dp13276
g9
I539
sg10
VC0024534
p13277
sg12
I16
sg13
Vcerebral malaria
p13278
sg15
I2
sa(dp13279
g9
I679
sg10
VC2936863
p13280
sg12
I23
sg13
VBardet-Biedl syndrome 2
p13281
sg15
I3
sa(dp13282
g9
I1099
sg10
VC0019562
p13283
sg12
I26
sg13
Vvon Hippel-Lindau syndrome
p13284
sg15
I3
sa(dp13285
g9
I1080
sg10
VC0008029
p13286
sg12
I9
sg13
VCherubism
p13287
sg15
I1
sa(dp13288
g9
I1400
sg10
VC0342853
p13289
sg12
I8
sg13
Vsialuria
p13290
sg15
I1
sa(dp13291
g9
I241
sg10
VC1740819
p13292
sg12
I24
sg13
Vidiopathic short stature
p13293
sg15
I3
sa(dp13294
g9
I1099
sg10
VC0019562
p13295
sg12
I26
sg13
Vvon Hippel-Lindau syndrome
p13296
sg15
I3
sa(dp13297
g9
I1213
sg10
VC0678222
p13298
sg12
I13
sg13
Vbreast cancer
p13299
sg15
I2
sa(dp13300
g9
I319
sg10
VC0039082
p13301
sg12
I8
sg13
Vsyndrome
p13302
sg15
I1
sa(dp13303
g9
I618
sg10
VC0282527
p13304
sg12
I30
sg13
VRefsum disease, infantile form
p13305
sg15
I4
sa(dp13306
g9
I1127
sg10
VC0206734
p13307
sg12
I16
sg13
Vhemangioblastoma
p13308
sg15
I1
sa(dp13309
g9
I1536
sg10
VC2936904
p13310
sg12
I10
sg13
VG syndrome
p13311
sg15
I2
sa(dp13312
g9
I650
sg10
VC0043459
p13313
sg12
I18
sg13
VZellweger syndrome
p13314
sg15
I2
sa(dp13315
g9
I1021
sg10
VC1563296
p13316
sg12
I3
sg13
VSAM
p13317
sg15
I1
sa(dp13318
g9
I415
sg10
VC0029459
p13319
sg12
I25
sg13
Vinvolutional osteoporosis
p13320
sg15
I2
sa(dp13321
g9
I1354
sg10
VC1833373
p13322
sg12
I44
sg13
Vinclusion body myopathy, autosomal recessive
p13323
sg15
I5
sa(dp13324
g9
I679
sg10
VC0752166
p13325
sg12
I21
sg13
VBardet-Biedl syndrome
p13326
sg15
I2
sa(dp13327
g9
I1617
sg10
VC0338484
p13328
sg12
I28
sg13
Vfamilial hemiplegic migraine
p13329
sg15
I3
sa(dp13330
g9
I1001
sg10
VC0002726
p13331
sg12
I11
sg13
Vamyloidosis
p13332
sg15
I1
sa(dp13333
g9
I1516
sg10
VC2936904
p13334
sg12
I12
sg13
VBBB syndrome
p13335
sg15
I2
sasa(dp13336
g2
VThirteen families were investigated, of which two were affected by N-acetylglutamate synthase deficiency, four by carbamoylphosphate synthetase 1 deficiency, one by ornithine transcarbamylase deficiency, three by argininosuccinate synthetase deficiency, two by argininosuccinate lyase deficiency, and one by arginase deficiency.
p13337
sg4
(lp13338
(dp13339
g9
I67
sg20
g21
sg12
I26
sg13
VN-acetylglutamate synthase
p13340
sg15
I2
sa(dp13341
g9
I261
sg20
VP04424
p13342
sg12
I23
sg13
Vargininosuccinate lyase
p13343
sg15
I2
sa(dp13344
g9
I213
sg20
VP00966
p13345
sg12
I28
sg13
Vargininosuccinate synthetase
p13346
sg15
I2
sa(dp13347
g9
I308
sg20
VP05089
p13348
sg12
I8
sg13
Varginase
p13349
sg15
I1
sa(dp13350
g9
I114
sg20
VP31327
p13351
sg12
I31
sg13
Vcarbamoylphosphate synthetase 1
p13352
sg15
I3
sa(dp13353
g9
I165
sg20
VP00480
p13354
sg12
I26
sg13
Vornithine transcarbamylase
p13355
sg15
I2
sasg6
(lp13356
(dp13357
g9
I213
sg10
VC0175683
p13358
sg12
I39
sg13
Vargininosuccinate synthetase deficiency
p13359
sg15
I3
sa(dp13360
g9
I308
sg10
VC0268548
p13361
sg12
I19
sg13
Varginase deficiency
p13362
sg15
I2
sa(dp13363
g9
I165
sg10
VC0268542
p13364
sg12
I37
sg13
Vornithine transcarbamylase deficiency
p13365
sg15
I3
sa(dp13366
g9
I67
sg10
VC0268543
p13367
sg12
I37
sg13
VN-acetylglutamate synthase deficiency
p13368
sg15
I3
sa(dp13369
g9
I261
sg10
VC0268547
p13370
sg12
I34
sg13
Vargininosuccinate lyase deficiency
p13371
sg15
I3
sasa(dp13372
g2
VIn this study, we examined the relationship between the lactic acid concentration and expression of LDHA and GLUT1, which are related to the Warburg effect, in human head and neck squamous cell carcinoma (HNSCC).
p13373
sg4
(lp13374
(dp13375
g9
I100
sg20
VP00338
p13376
sg12
I4
sg13
VLDHA
p13377
sg15
I1
sa(dp13378
g9
I109
sg20
VP11166
p13379
sg12
I5
sg13
VGLUT1
p13380
sg15
I1
sasg6
(lp13381
(dp13382
g9
I141
sg10
VC1520120
p13383
sg12
I14
sg13
VWarburg effect
p13384
sg15
I2
sa(dp13385
g9
I205
sg10
VC1168401
p13386
sg12
I5
sg13
VHNSCC
p13387
sg15
I1
sa(dp13388
g9
I166
sg10
VC1168401
p13389
sg12
I37
sg13
Vhead and neck squamous cell carcinoma
p13390
sg15
I6
sasa(dp13391
g2
VWe found that cetuximab downregulated lactate dehydrogenase A (LDH-A) and inhibited glycolysis in cetuximab-sensitive head and neck squamous cell carcinoma (HNSCC) cells in an HIF-1Alfa downregulation-dependent manner.
p13392
sg4
(lp13393
(dp13394
g9
I38
sg20
VP49366
p13395
sg12
I23
sg13
Vlactate dehydrogenase A
p13396
sg15
I3
sa(dp13397
g9
I63
sg20
VP00338
p13398
sg12
I5
sg13
VLDH-A
p13399
sg15
I1
sasg6
(lp13400
(dp13401
g9
I157
sg10
VC1168401
p13402
sg12
I5
sg13
VHNSCC
p13403
sg15
I1
sa(dp13404
g9
I118
sg10
VC1168401
p13405
sg12
I37
sg13
Vhead and neck squamous cell carcinoma
p13406
sg15
I6
sasa(dp13407
g2
VAn Australian cohort of 252 unrelated familial hypertrophic cardiomyopathy patients were screened for mutations in the Ca(2+) regulatory genes, sorcin (SRI), calstabin (FKBP1B), calsequestrin (CASQ2), phospholamban (PLN), sarcolipin (SLN), calreticulin (CALR3) and calmodulin (CALM).
p13408
sg4
(lp13409
(dp13410
g9
I277
sg20
g21
sg12
I4
sg13
VCALM
p13411
sg15
I1
sa(dp13412
g9
I169
sg20
VP68106
p13413
sg12
I6
sg13
VFKBP1B
p13414
sg15
I1
sa(dp13415
g9
I265
sg20
g21
sg12
I10
sg13
Vcalmodulin
p13416
sg15
I1
sa(dp13417
g9
I240
sg20
VP27797
p13418
sg12
I20
sg13
Vcalreticulin (CALR3)
p13419
sg15
I2
sa(dp13420
g9
I178
sg20
VP31415
p13421
sg12
I13
sg13
Vcalsequestrin
p13422
sg15
I1
sa(dp13423
g9
I222
sg20
g21
sg12
I10
sg13
Vsarcolipin
p13424
sg15
I1
sa(dp13425
g9
I193
sg20
g21
sg12
I5
sg13
VCASQ2
p13426
sg15
I1
sa(dp13427
g9
I234
sg20
g21
sg12
I3
sg13
VSLN
p13428
sg15
I1
sa(dp13429
g9
I144
sg20
VP30626
p13430
sg12
I12
sg13
Vsorcin (SRI)
p13431
sg15
I2
sa(dp13432
g9
I119
sg20
VP01893
p13433
sg12
I23
sg13
VCa(2+) regulatory genes
p13434
sg15
I3
sasg6
(lp13435
(dp13436
g9
I38
sg10
VC0949658
p13437
sg12
I36
sg13
Vfamilial hypertrophic cardiomyopathy
p13438
sg15
I3
sasa(dp13439
g2
VThe validated proteins contain the clinically used hepatocellular carcinoma (HCC) biomarker alpha-fetoprotein (AFP) and the reported biomarker candidates Heat shock protein HSP 90-beta (HSP90), fatty acid-binding protein, epidermal (FABP5) and alcohol dehydrogenase 4 (ADH4), which demonstrated the robustness of the strategy.
p13440
sg4
(lp13441
(dp13442
g9
I269
sg20
VP40394
p13443
sg12
I4
sg13
VADH4
p13444
sg15
I1
sa(dp13445
g9
I111
sg20
VP02771
p13446
sg12
I3
sg13
VAFP
p13447
sg15
I1
sa(dp13448
g9
I194
sg20
VP00505
p13449
sg12
I26
sg13
Vfatty acid-binding protein
p13450
sg15
I3
sa(dp13451
g9
I173
sg20
g21
sg12
I11
sg13
VHSP 90-beta
p13452
sg15
I2
sa(dp13453
g9
I222
sg20
VP08319
p13454
sg12
I45
sg13
Vepidermal (FABP5) and alcohol dehydrogenase 4
p13455
sg15
I6
sa(dp13456
g9
I92
sg20
VP02771
p13457
sg12
I17
sg13
Valpha-fetoprotein
p13458
sg15
I1
sa(dp13459
g9
I186
sg20
VP07900
p13460
sg12
I5
sg13
VHSP90
p13461
sg15
I1
sasg6
(lp13462
(dp13463
g9
I77
sg10
VC2239176
p13464
sg12
I3
sg13
VHCC
p13465
sg15
I1
sa(dp13466
g9
I51
sg10
VC2239176
p13467
sg12
I24
sg13
Vhepatocellular carcinoma
p13468
sg15
I2
sa(dp13469
g9
I173
sg10
VC0034152
p13470
sg12
I3
sg13
VHSP
p13471
sg15
I1
sasa(dp13472
g2
VIn vivo, Hsp90Beta promoted VEGFRs and CD31 expression in human hepatocellular carcinoma tumor xenografts and was associated with increased tumor microvessel density.
p13473
sg4
(lp13474
(dp13475
g9
I28
sg20
VP35968
p13476
sg12
I6
sg13
VVEGFRs
p13477
sg15
I1
sa(dp13478
g9
I39
sg20
VP69905
p13479
sg12
I4
sg13
VCD31
p13480
sg15
I1
sa(dp13481
g9
I9
sg20
VP08238
p13482
sg12
I9
sg13
VHsp90Beta
p13483
sg15
I1
sasg6
(lp13484
(dp13485
g9
I89
sg10
VC0027651
p13486
sg12
I5
sg13
Vtumor
p13487
sg15
I1
sa(dp13488
g9
I64
sg10
VC1512411
p13489
sg12
I24
sg13
Vhepatocellular carcinoma
p13490
sg15
I2
sa(dp13491
g9
I89
sg10
VC0027651
p13492
sg12
I5
sg13
Vtumor
p13493
sg15
I1
sasa(dp13494
g2
VIn this study we report an apparent synergy between TGF-Beta1 and Hsp90Beta in stimulating migratory behaviour of colon cancer cells when signalling occurs via AlfavBeta6 integrin as opposed to the canonical TGF-Beta1 pathway.
p13495
sg4
(lp13496
(dp13497
g9
I52
sg20
VP01137
p13498
sg12
I9
sg13
VTGF-Beta1
p13499
sg15
I1
sa(dp13500
g9
I52
sg20
VP01137
p13501
sg12
I23
sg13
VTGF-Beta1 and Hsp90Beta
p13502
sg15
I3
sasg6
(lp13503
(dp13504
g9
I114
sg10
VC0699790
p13505
sg12
I12
sg13
Vcolon cancer
p13506
sg15
I2
sasa(dp13507
g2
VOur findings indicate that the C allele of the novel colorectal cancer-associated variant rs2282151 is associated with increased expression levels of HSP90AB1, which is expressed higher in colorectal tumor tissues than in normal tissues.
p13508
sg4
(lp13509
(dp13510
g9
I150
sg20
VP08238
p13511
sg12
I8
sg13
VHSP90AB1
p13512
sg15
I1
sa(dp13513
g9
I53
sg20
VP31749
p13514
sg12
I46
sg13
Vcolorectal cancer-associated variant rs2282151
p13515
sg15
I4
sasg6
(lp13516
(dp13517
g9
I53
sg10
VC1527249
p13518
sg12
I17
sg13
Vcolorectal cancer
p13519
sg15
I2
sa(dp13520
g9
I189
sg10
VC0009404
p13521
sg12
I16
sg13
Vcolorectal tumor
p13522
sg15
I2
sasa(dp13523
g2
VBortezomib induced internalization and degradation of c-KIT by binding c-KIT to Cbl, an E3 ubiquitin-protein ligase, and the subsequent release of Apaf-1, which was originally bound to the c-KIT-Hsp90Beta-Apaf-1 complex, induced primary apoptosis in GIST-T1 cells.
p13524
sg4
(lp13525
(dp13526
g9
I54
sg20
VP10721
p13527
sg12
I5
sg13
Vc-KIT
p13528
sg15
I1
sa(dp13529
g9
I189
sg20
VP10721
p13530
sg12
I15
sg13
Vc-KIT-Hsp90Beta
p13531
sg15
I1
sa(dp13532
g9
I91
sg20
VP49427
p13533
sg12
I24
sg13
Vubiquitin-protein ligase
p13534
sg15
I2
sa(dp13535
g9
I80
sg20
VP22681
p13536
sg12
I3
sg13
VCbl
p13537
sg15
I1
sa(dp13538
g9
I54
sg20
VP10721
p13539
sg12
I5
sg13
Vc-KIT
p13540
sg15
I1
sasg6
(lp13541
(dp13542
g9
I250
sg10
VC1847319
p13543
sg12
I4
sg13
VGIST
p13544
sg15
I1
sasa(dp13545
g2
VBoth Annexin A1 and HSP90Beta were GlcNAcylated, and their protein expressions were elevated in colon cancer, compared to normal tissues.
p13546
sg4
(lp13547
(dp13548
g9
I5
sg20
VP04083
p13549
sg12
I10
sg13
VAnnexin A1
p13550
sg15
I2
sa(dp13551
g9
I20
sg20
VP08238
p13552
sg12
I9
sg13
VHSP90Beta
p13553
sg15
I1
sasg6
(lp13554
(dp13555
g9
I96
sg10
VC0699790
p13556
sg12
I12
sg13
Vcolon cancer
p13557
sg15
I2
sasa(dp13558
g2
VMoreover, specific changes of GlcNAc abundances in Annexin A1 and HSP90Beta suggested that tumor-specific glycan patterns could serve as candidate biomarkers of colon cancer for distinguishing cancer patients from healthy individuals.
p13559
sg4
(lp13560
(dp13561
g9
I66
sg20
VP08238
p13562
sg12
I9
sg13
VHSP90Beta
p13563
sg15
I1
sa(dp13564
g9
I51
sg20
VP04083
p13565
sg12
I10
sg13
VAnnexin A1
p13566
sg15
I2
sasg6
(lp13567
(dp13568
g9
I91
sg10
VC0027651
p13569
sg12
I5
sg13
Vtumor
p13570
sg15
I1
sa(dp13571
g9
I167
sg10
VC0006826
p13572
sg12
I6
sg13
Vcancer
p13573
sg15
I1
sa(dp13574
g9
I161
sg10
VC0699790
p13575
sg12
I12
sg13
Vcolon cancer
p13576
sg15
I2
sasa(dp13577
g2
VIn addition, the knockdown of PEPCK, which is the rate-limiting enzyme for gluconeogenesis, led to a reduction in glucose production in rat hepatoma H4IIEC3 cells.
p13578
sg4
(lp13579
(dp13580
g9
I30
sg20
VP35558
p13581
sg12
I5
sg13
VPEPCK
p13582
sg15
I1
sasg6
(lp13583
(dp13584
g9
I140
sg10
VC0023903
p13585
sg12
I8
sg13
Vhepatoma
p13586
sg15
I1
sasa(dp13587
g2
VWe recently reported expression of the chemokine receptors CXC chemokine receptor 3 (CXCR3) and CC chemokine receptor 4 (CCR4) in adult T-cell leukemia/lymphoma and showed a preferential expression of CCR4 and its association with an unfavorable outcome.
p13588
sg4
(lp13589
(dp13590
g9
I39
sg20
VP55773
p13591
sg12
I44
sg13
Vchemokine receptors CXC chemokine receptor 3
p13592
sg15
I6
sa(dp13593
g9
I96
sg20
g21
sg12
I23
sg13
VCC chemokine receptor 4
p13594
sg15
I4
sa(dp13595
g9
I121
sg20
VP51679
p13596
sg12
I4
sg13
VCCR4
p13597
sg15
I1
sa(dp13598
g9
I85
sg20
VP49682
p13599
sg12
I5
sg13
VCXCR3
p13600
sg15
I1
sa(dp13601
g9
I121
sg20
VP51679
p13602
sg12
I4
sg13
VCCR4
p13603
sg15
I1
sasg6
(lp13604
(dp13605
g9
I130
sg10
VC0023493
p13606
sg12
I30
sg13
Vadult T-cell leukemia/lymphoma
p13607
sg15
I3
sasa(dp13608
g2
VWe present a review of the current knowledge on cellular metabolism in non-cancerous and cancerous thyroid tissues, focusing on the monocarboxylate transporters MCT1 and MCT4, and on a transporter of the outer mitochondrial membrane TOMM20.
p13609
sg4
(lp13610
(dp13611
g9
I132
sg20
VP23946
p13612
sg12
I33
sg13
Vmonocarboxylate transporters MCT1
p13613
sg15
I3
sa(dp13614
g9
I204
sg20
g21
sg12
I35
sg13
Vouter mitochondrial membrane TOMM20
p13615
sg15
I4
sa(dp13616
g9
I170
sg20
g21
sg12
I4
sg13
VMCT4
p13617
sg15
I1
sasg6
(lp13618
sa(dp13619
g2
VPapillary thyroid cancer and FA thyrocytes had high staining for TOMM20 compared to NCT and nodular goiter (NG) (P &lt; 0.01).
p13620
sg4
(lp13621
(dp13622
g9
I65
sg20
g21
sg12
I6
sg13
VTOMM20
p13623
sg15
I1
sasg6
(lp13624
(dp13625
g9
I0
sg10
VC0238463
p13626
sg12
I24
sg13
VPapillary thyroid cancer
p13627
sg15
I3
sa(dp13628
g9
I108
sg10
VC1318500
p13629
sg12
I2
sg13
VNG
p13630
sg15
I1
sa(dp13631
g9
I92
sg10
VC1318500
p13632
sg12
I14
sg13
Vnodular goiter
p13633
sg15
I2
sasa(dp13634
g2
VStaining patterns of MCT1 and TOMM20 in 35 human thyroid samples (15 ATC, 12 papillary thyroid cancer [PTC], and eight non-cancerous thyroid) and nine ATC mouse orthotopic xenografts were assessed by visual and Aperio digital scoring.
p13635
sg4
(lp13636
(dp13637
g9
I21
sg20
VP23946
p13638
sg12
I15
sg13
VMCT1 and TOMM20
p13639
sg15
I3
sasg6
(lp13640
(dp13641
g9
I77
sg10
VC0238463
p13642
sg12
I24
sg13
Vpapillary thyroid cancer
p13643
sg15
I3
sa(dp13644
g9
I103
sg10
VC0238463
p13645
sg12
I3
sg13
VPTC
p13646
sg15
I1
sasa(dp13647
g2
VTOMM20 is also highly expressed in both ATC and PTC compared to non-cancerous thyroid tissue (P&lt;.01 for both).
p13648
sg4
(lp13649
(dp13650
g9
I0
sg20
g21
sg12
I6
sg13
VTOMM20
p13651
sg15
I1
sasg6
(lp13652
(dp13653
g9
I48
sg10
VC0238463
p13654
sg12
I3
sg13
VPTC
p13655
sg15
I1
sasa(dp13656
g2
VHigh MCT1 and TOMM20 expression is also found in ATC mouse xenograft tumors compared to non-cancerous thyroid tissue (P&lt;.001).
p13657
sg4
(lp13658
(dp13659
g9
I5
sg20
VP23946
p13660
sg12
I4
sg13
VMCT1
p13661
sg15
I1
sa(dp13662
g9
I14
sg20
g21
sg12
I6
sg13
VTOMM20
p13663
sg15
I1
sasg6
(lp13664
(dp13665
g9
I69
sg10
VC0027651
p13666
sg12
I6
sg13
Vtumors
p13667
sg15
I1
sasa(dp13668
g2
VATC has metabolic features that distinguish it from PTC and non-cancerous thyroid tissue, including high expression of MCT1 and TOMM20.
p13669
sg4
(lp13670
(dp13671
g9
I128
sg20
g21
sg12
I6
sg13
VTOMM20
p13672
sg15
I1
sa(dp13673
g9
I119
sg20
VP23946
p13674
sg12
I4
sg13
VMCT1
p13675
sg15
I1
sasg6
(lp13676
(dp13677
g9
I52
sg10
VC0238463
p13678
sg12
I3
sg13
VPTC
p13679
sg15
I1
sasa(dp13680
g2
VPTC has low expression of MCT1 and non-cancerous thyroid tissue has low expression of both MCT1 and TOMM20.
p13681
sg4
(lp13682
(dp13683
g9
I100
sg20
g21
sg12
I6
sg13
VTOMM20
p13684
sg15
I1
sa(dp13685
g9
I26
sg20
VP23946
p13686
sg12
I4
sg13
VMCT1
p13687
sg15
I1
sa(dp13688
g9
I26
sg20
VP23946
p13689
sg12
I4
sg13
VMCT1
p13690
sg15
I1
sa(dp13691
g9
I0
sg20
g21
sg12
I3
sg13
VPTC
p13692
sg15
I1
sasg6
(lp13693
(dp13694
g9
I0
sg10
VC0238463
p13695
sg12
I3
sg13
VPTC
p13696
sg15
I1
sasa(dp13697
g2
VAM can induce a metastatic phenotype in prostate cancer cells through its action on TRPV2 calcium channels and is also capable of influencing localised levels of RANKL in the bone to favour tumourigenesis.
p13698
sg4
(lp13699
(dp13700
g9
I84
sg20
g21
sg12
I22
sg13
VTRPV2 calcium channels
p13701
sg15
I3
sa(dp13702
g9
I162
sg20
g21
sg12
I5
sg13
VRANKL
p13703
sg15
I1
sasg6
(lp13704
(dp13705
g9
I40
sg10
VC0600139
p13706
sg12
I15
sg13
Vprostate cancer
p13707
sg15
I2
sasa(dp13708
g2
VTo determine the profiles of soluble cytokine receptors and cytokines, including mostly their ligands, in the vitreous humor of patients with B-cell vitreoretinal lymphoma (VRL) and uveitis.
p13709
sg4
(lp13710
sg6
(lp13711
(dp13712
g9
I163
sg10
VC0024299
p13713
sg12
I8
sg13
Vlymphoma
p13714
sg15
I1
sa(dp13715
g9
I182
sg10
VC0042164
p13716
sg12
I7
sg13
Vuveitis
p13717
sg15
I1
sasa(dp13718
g2
VIn analyses in patients with VRL, elevation of sVEGFR1 and sVEGFR2 levels was more prominent in patients with systemic metastatic retinal lymphoma (SMRL) than in those with primary VRL/primary central nervous system lymphoma (PVRL/PCNSL).
p13719
sg4
(lp13720
sg6
(lp13721
(dp13722
g9
I231
sg10
VC0280803
p13723
sg12
I5
sg13
VPCNSL
p13724
sg15
I1
sa(dp13725
g9
I185
sg10
VC0280803
p13726
sg12
I39
sg13
Vprimary central nervous system lymphoma
p13727
sg15
I5
sa(dp13728
g9
I130
sg10
VC0339556
p13729
sg12
I16
sg13
Vretinal lymphoma
p13730
sg15
I2
sasa(dp13731
g2
VFor example in prostate cancer cells, the TRPV2 activation following lysophospholipid or adrenomedullin stimulation enhances the invasiveness of cancer cells; furthermore, the increased malignancy of castration-resistant prostate cancer cells was associated with enhanced TRPV2 expression, mainly in metastatic prostate cancer cells.
p13732
sg4
(lp13733
(dp13734
g9
I42
sg20
g21
sg12
I5
sg13
VTRPV2
p13735
sg15
I1
sa(dp13736
g9
I42
sg20
g21
sg12
I5
sg13
VTRPV2
p13737
sg15
I1
sa(dp13738
g9
I89
sg20
VP35318
p13739
sg12
I14
sg13
Vadrenomedullin
p13740
sg15
I1
sasg6
(lp13741
(dp13742
g9
I300
sg10
VC0936223
p13743
sg12
I26
sg13
Vmetastatic prostate cancer
p13744
sg15
I3
sa(dp13745
g9
I186
sg10
VC0006826
p13746
sg12
I10
sg13
Vmalignancy
p13747
sg15
I1
sa(dp13748
g9
I15
sg10
VC0600139
p13749
sg12
I15
sg13
Vprostate cancer
p13750
sg15
I2
sa(dp13751
g9
I15
sg10
VC0600139
p13752
sg12
I15
sg13
Vprostate cancer
p13753
sg15
I2
sa(dp13754
g9
I24
sg10
VC0006826
p13755
sg12
I6
sg13
Vcancer
p13756
sg15
I1
sasa(dp13757
g2
VIn this regard, bladder cancer tumors show loss or reduction of a short TRPV2 variant during cancer progression, with increased malignancy and invasiveness.
p13758
sg4
(lp13759
(dp13760
g9
I72
sg20
g21
sg12
I5
sg13
VTRPV2
p13761
sg15
I1
sasg6
(lp13762
(dp13763
g9
I31
sg10
VC0027651
p13764
sg12
I6
sg13
Vtumors
p13765
sg15
I1
sa(dp13766
g9
I128
sg10
VC0006826
p13767
sg12
I10
sg13
Vmalignancy
p13768
sg15
I1
sa(dp13769
g9
I93
sg10
VC0178874
p13770
sg12
I18
sg13
Vcancer progression
p13771
sg15
I2
sa(dp13772
g9
I16
sg10
VC0699885
p13773
sg12
I14
sg13
Vbladder cancer
p13774
sg15
I2
sasa(dp13775
g2
VTRPV2 and TRPM7 expression levels and TRPV2 activator-induced intracellular Ca(2+) increases were significantly higher, whereas TRPV4 expression and TRPV4 activator-induced intracellular Ca(2+) increases were significantly lower in mouse bladder cancer (MBT-2) cells compared to normal mouse urothelial cells.
p13776
sg4
(lp13777
(dp13778
g9
I0
sg20
g21
sg12
I5
sg13
VTRPV2
p13779
sg15
I1
sa(dp13780
g9
I0
sg20
g21
sg12
I5
sg13
VTRPV2
p13781
sg15
I1
sa(dp13782
g9
I10
sg20
g21
sg12
I5
sg13
VTRPM7
p13783
sg15
I1
sasg6
(lp13784
(dp13785
g9
I238
sg10
VC0699885
p13786
sg12
I14
sg13
Vbladder cancer
p13787
sg15
I2
sasa(dp13788
g2
VIncreases in the expression of TRPV2 mRNA, immunoreactivity, and TRPV2 activator-induced intracellular Ca(2+) were also observed in T24 human bladder cancer cells.
p13789
sg4
(lp13790
(dp13791
g9
I31
sg20
g21
sg12
I10
sg13
VTRPV2 mRNA
p13792
sg15
I2
sa(dp13793
g9
I31
sg20
g21
sg12
I5
sg13
VTRPV2
p13794
sg15
I1
sasg6
(lp13795
(dp13796
g9
I142
sg10
VC0699885
p13797
sg12
I14
sg13
Vbladder cancer
p13798
sg15
I2
sasa(dp13799
g2
VThese results suggested that TRPV2 and TRPM7 were functionally expressed in bladder cancer cells and served as negative regulators of bladder cancer cell proliferation, most likely to prevent excess mechanical stresses.
p13800
sg4
(lp13801
(dp13802
g9
I39
sg20
g21
sg12
I5
sg13
VTRPM7
p13803
sg15
I1
sa(dp13804
g9
I29
sg20
g21
sg12
I5
sg13
VTRPV2
p13805
sg15
I1
sasg6
(lp13806
(dp13807
g9
I76
sg10
VC0699885
p13808
sg12
I14
sg13
Vbladder cancer
p13809
sg15
I2
sa(dp13810
g9
I76
sg10
VC0699885
p13811
sg12
I14
sg13
Vbladder cancer
p13812
sg15
I2
sa(dp13813
g9
I154
sg10
VC0334094
p13814
sg12
I13
sg13
Vproliferation
p13815
sg15
I1
sasa(dp13816
g2
VOn the other hand, in prostate cancer cells, Ca2+-dependent activation of TRPV2 induced by lysophospholipids increases the invasion of tumor cells.
p13817
sg4
(lp13818
(dp13819
g9
I74
sg20
g21
sg12
I5
sg13
VTRPV2
p13820
sg15
I1
sasg6
(lp13821
(dp13822
g9
I123
sg10
VC2699153
p13823
sg12
I8
sg13
Vinvasion
p13824
sg15
I1
sa(dp13825
g9
I22
sg10
VC0600139
p13826
sg12
I15
sg13
Vprostate cancer
p13827
sg15
I2
sa(dp13828
g9
I135
sg10
VC0027651
p13829
sg12
I5
sg13
Vtumor
p13830
sg15
I1
sasa(dp13831
g2
VIn addition, the progression of prostate cancer to the castration-resistant phenotype is characterized by de novo TRPV2 expression, with higher TRPV2 transcript levels in patients with metastatic cancer.
p13832
sg4
(lp13833
(dp13834
g9
I114
sg20
g21
sg12
I5
sg13
VTRPV2
p13835
sg15
I1
sa(dp13836
g9
I144
sg20
g21
sg12
I16
sg13
VTRPV2 transcript
p13837
sg15
I2
sasg6
(lp13838
(dp13839
g9
I17
sg10
VC1739135
p13840
sg12
I30
sg13
Vprogression of prostate cancer
p13841
sg15
I4
sa(dp13842
g9
I185
sg10
VC0027627
p13843
sg12
I17
sg13
Vmetastatic cancer
p13844
sg15
I2
sasa(dp13845
g2
VThe aim of the present study was to investigate the effects of TRPV2 on the proliferation, migration and invasion of 5637 bladder cancer cells in vitro.
p13846
sg4
(lp13847
(dp13848
g9
I63
sg20
g21
sg12
I5
sg13
VTRPV2
p13849
sg15
I1
sasg6
(lp13850
(dp13851
g9
I76
sg10
VC0334094
p13852
sg12
I13
sg13
Vproliferation
p13853
sg15
I1
sa(dp13854
g9
I105
sg10
VC2699153
p13855
sg12
I8
sg13
Vinvasion
p13856
sg15
I1
sa(dp13857
g9
I122
sg10
VC0699885
p13858
sg12
I14
sg13
Vbladder cancer
p13859
sg15
I2
sasa(dp13860
g2
VRat TRPV2 cDNA was transfected into 5637 bladder cancer cells and changes in the behavior of the cells were detected.
p13861
sg4
(lp13862
(dp13863
g9
I0
sg20
g21
sg12
I14
sg13
VRat TRPV2 cDNA
p13864
sg15
I3
sasg6
(lp13865
(dp13866
g9
I41
sg10
VC0699885
p13867
sg12
I14
sg13
Vbladder cancer
p13868
sg15
I2
sasa(dp13869
g2
VIt was observed that TRPV2 enhanced bladder cancer cell migration and invasion; however, it did not affect cell proliferation in vitro.
p13870
sg4
(lp13871
(dp13872
g9
I21
sg20
g21
sg12
I5
sg13
VTRPV2
p13873
sg15
I1
sasg6
(lp13874
(dp13875
g9
I112
sg10
VC0334094
p13876
sg12
I13
sg13
Vproliferation
p13877
sg15
I1
sa(dp13878
g9
I36
sg10
VC0699885
p13879
sg12
I14
sg13
Vbladder cancer
p13880
sg15
I2
sa(dp13881
g9
I70
sg10
VC2699153
p13882
sg12
I8
sg13
Vinvasion
p13883
sg15
I1
sasa(dp13884
g2
VThe results of this study suggest that TRPV2 channels are a potential therapeutic target for bladder carcinoma.
p13885
sg4
(lp13886
(dp13887
g9
I39
sg20
g21
sg12
I14
sg13
VTRPV2 channels
p13888
sg15
I2
sasg6
(lp13889
(dp13890
g9
I93
sg10
VC0699885
p13891
sg12
I17
sg13
Vbladder carcinoma
p13892
sg15
I2
sasa(dp13893
g2
VThe Transient Receptor Potential channel TRPV2 is known to promote in prostate cancer cell migration and invasive phenotype and is correlated with the stage and grade of bladder cancer.
p13894
sg4
(lp13895
(dp13896
g9
I41
sg20
g21
sg12
I5
sg13
VTRPV2
p13897
sg15
I1
sasg6
(lp13898
(dp13899
g9
I170
sg10
VC0699885
p13900
sg12
I14
sg13
Vbladder cancer
p13901
sg15
I2
sa(dp13902
g9
I70
sg10
VC0600139
p13903
sg12
I15
sg13
Vprostate cancer
p13904
sg15
I2
sasa(dp13905
g2
VInitial studies showed that expression profile of some TRP channels, notably TRP melastatin 8 (TRPM8), TRP vanilloid 6 (TRPV6),TRP canonical (TRPC6) and TRPV2, is changing during the development and the progression of prostate cancer towards the hormone-refractory stages.
p13906
sg4
(lp13907
(dp13908
g9
I95
sg20
g21
sg12
I5
sg13
VTRPM8
p13909
sg15
I1
sa(dp13910
g9
I142
sg20
g21
sg12
I5
sg13
VTRPC6
p13911
sg15
I1
sa(dp13912
g9
I55
sg20
VP13686
p13913
sg12
I3
sg13
VTRP
p13914
sg15
I1
sa(dp13915
g9
I120
sg20
g21
sg12
I5
sg13
VTRPV6
p13916
sg15
I1
sa(dp13917
g9
I103
sg20
VP13686
p13918
sg12
I15
sg13
VTRP vanilloid 6
p13919
sg15
I3
sa(dp13920
g9
I153
sg20
g21
sg12
I5
sg13
VTRPV2
p13921
sg15
I1
sa(dp13922
g9
I55
sg20
VP13686
p13923
sg12
I12
sg13
VTRP channels
p13924
sg15
I2
sa(dp13925
g9
I77
sg20
VP13686
p13926
sg12
I16
sg13
VTRP melastatin 8
p13927
sg15
I3
sasg6
(lp13928
(dp13929
g9
I203
sg10
VC1739135
p13930
sg12
I30
sg13
Vprogression of prostate cancer
p13931
sg15
I4
sasa(dp13932
g2
VThe expression of TRPV2 mRNA in bladder cancer cell lines (T24, a poorly differentiated UC cell line and RT4, a well-differentiated UC cell line) was analyzed using reverse transcriptase-polymerase chain reaction.
p13933
sg4
(lp13934
(dp13935
g9
I18
sg20
g21
sg12
I10
sg13
VTRPV2 mRNA
p13936
sg15
I2
sa(dp13937
g9
I165
sg20
VP63136
p13938
sg12
I21
sg13
Vreverse transcriptase
p13939
sg15
I2
sasg6
(lp13940
(dp13941
g9
I32
sg10
VC0699885
p13942
sg12
I14
sg13
Vbladder cancer
p13943
sg15
I2
sasa(dp13944
g2
VFurthermore, the effects of resveratrol and Shh on human colorectal cancer HCT116 cells were in a dose- and time-dependent manner.
p13945
sg4
(lp13946
(dp13947
g9
I44
sg20
g21
sg12
I3
sg13
VShh
p13948
sg15
I1
sasg6
(lp13949
(dp13950
g9
I57
sg10
VC1527249
p13951
sg12
I17
sg13
Vcolorectal cancer
p13952
sg15
I2
sasa(dp13953
g2
VFurthermore, knockdown of PFTK1 suppressed the expression of Shh as well as Smo, Ptc, and Gli-1 in colon cancer cells.
p13954
sg4
(lp13955
(dp13956
g9
I76
sg20
g21
sg12
I3
sg13
VSmo
p13957
sg15
I1
sa(dp13958
g9
I61
sg20
g21
sg12
I3
sg13
VShh
p13959
sg15
I1
sa(dp13960
g9
I81
sg20
g21
sg12
I3
sg13
VPtc
p13961
sg15
I1
sa(dp13962
g9
I90
sg20
VP08151
p13963
sg12
I5
sg13
VGli-1
p13964
sg15
I1
sasg6
(lp13965
(dp13966
g9
I99
sg10
VC0699790
p13967
sg12
I12
sg13
Vcolon cancer
p13968
sg15
I2
sa(dp13969
g9
I81
sg10
VC0238463
p13970
sg12
I3
sg13
VPtc
p13971
sg15
I1
sasa(dp13972
g2
VTaken together, these results suggest that knockdown of PFTK1 inhibited the proliferation and invasion of colon cancer cells as well as the EMT progress by suppressing the Sonic hedgehog signaling pathway.
p13973
sg4
(lp13974
(dp13975
g9
I140
sg20
g21
sg12
I3
sg13
VEMT
p13976
sg15
I1
sa(dp13977
g9
I172
sg20
g21
sg12
I14
sg13
VSonic hedgehog
p13978
sg15
I2
sasg6
(lp13979
(dp13980
g9
I106
sg10
VC0699790
p13981
sg12
I12
sg13
Vcolon cancer
p13982
sg15
I2
sa(dp13983
g9
I76
sg10
VC0334094
p13984
sg12
I13
sg13
Vproliferation
p13985
sg15
I1
sa(dp13986
g9
I94
sg10
VC2699153
p13987
sg12
I8
sg13
Vinvasion
p13988
sg15
I1
sasa(dp13989
g2
VThis case illustrates the potential severity of the renal anomalies in the BOR syndrome and the inadequacy of oligohydramnios and maternal serum alpha-fetoprotein as screening methods for renal agenesis.
p13990
sg4
(lp13991
sg6
(lp13992
(dp13993
g9
I75
sg10
VC0265234
p13994
sg12
I12
sg13
VBOR syndrome
p13995
sg15
I2
sa(dp13996
g9
I52
sg10
VC0266292
p13997
sg12
I15
sg13
Vrenal anomalies
p13998
sg15
I2
sa(dp13999
g9
I188
sg10
VC0542519
p14000
sg12
I14
sg13
Vrenal agenesis
p14001
sg15
I2
sa(dp14002
g9
I110
sg10
VC0079924
p14003
sg12
I15
sg13
Voligohydramnios
p14004
sg15
I1
sasa(dp14005
g2
VSevere sepsis and antibiotic use were both associated with moderate thrombocytopenia, and proton pump inhibitor use was statistically significant in both univariate and multivariate analysis.
p14006
sg4
(lp14007
sg6
(lp14008
(dp14009
g9
I0
sg10
VC1719672
p14010
sg12
I13
sg13
VSevere sepsis
p14011
sg15
I2
sasa(dp14012
g2
VThrombocytopenia is associated with poor prognosis, and the association between moderate thrombocytopenia and proton pump inhibitor use is relatively novel and should be validated in prospective studies.
p14013
sg4
(lp14014
sg6
(lp14015
sa(dp14016
g2
VWe identified 12 biomarkers consistently associated with either clinical groups "upstream" towards culture-positive TB on the TB disease spectrum (CD14, FCGR1A, FPR1, MMP9, RAB24, SEC14L1, and TIMP2) or "downstream" towards a decreased likelihood of TB disease (BLR1, CD3E, CD8A, IL7R, and TGFBR2), suggesting a correlation with MTB-related pathology and high relevance to a future POC test for pediatric TB.
p14017
sg4
(lp14018
(dp14019
g9
I147
sg20
VP08571
p14020
sg12
I4
sg13
VCD14
p14021
sg15
I1
sa(dp14022
g9
I173
sg20
g21
sg12
I5
sg13
VRAB24
p14023
sg15
I1
sa(dp14024
g9
I153
sg20
VP12314
p14025
sg12
I6
sg13
VFCGR1A
p14026
sg15
I1
sa(dp14027
g9
I268
sg20
VP07766
p14028
sg12
I4
sg13
VCD3E
p14029
sg15
I1
sa(dp14030
g9
I274
sg20
VP01732
p14031
sg12
I4
sg13
VCD8A
p14032
sg15
I1
sa(dp14033
g9
I262
sg20
VP32302
p14034
sg12
I4
sg13
VBLR1
p14035
sg15
I1
sa(dp14036
g9
I180
sg20
g21
sg12
I7
sg13
VSEC14L1
p14037
sg15
I1
sa(dp14038
g9
I167
sg20
VP14780
p14039
sg12
I4
sg13
VMMP9
p14040
sg15
I1
sa(dp14041
g9
I193
sg20
VP16035
p14042
sg12
I5
sg13
VTIMP2
p14043
sg15
I1
sa(dp14044
g9
I161
sg20
VP21462
p14045
sg12
I4
sg13
VFPR1
p14046
sg15
I1
sa(dp14047
g9
I290
sg20
VP37173
p14048
sg12
I6
sg13
VTGFBR2
p14049
sg15
I1
sasg6
(lp14050
(dp14051
g9
I341
sg10
VC0677042
p14052
sg12
I9
sg13
Vpathology
p14053
sg15
I1
sasa(dp14054
g2
VWestern blot assay further confirmed that anti-ICAM-T0901317 liposomes inhibited retinoblastoma (Rb) phosphorylation and MCM6 expression.
p14055
sg4
(lp14056
(dp14057
g9
I81
sg20
g21
sg12
I19
sg13
Vretinoblastoma (Rb)
p14058
sg15
I2
sa(dp14059
g9
I121
sg20
g21
sg12
I4
sg13
VMCM6
p14060
sg15
I1
sasg6
(lp14061
(dp14062
g9
I97
sg10
VC0035335
p14063
sg12
I2
sg13
VRb
p14064
sg15
I1
sa(dp14065
g9
I81
sg10
VC0035335
p14066
sg12
I14
sg13
Vretinoblastoma
p14067
sg15
I1
sasa(dp14068
g2
VInhibition of MCM6 and MCM7 expression by nTZDpa and rosiglitazone paralleled their effect to inhibit phosphorylation of the retinoblastoma protein and cell proliferation.
p14069
sg4
(lp14070
(dp14071
g9
I125
sg20
g21
sg12
I22
sg13
Vretinoblastoma protein
p14072
sg15
I2
sa(dp14073
g9
I23
sg20
VP33993
p14074
sg12
I4
sg13
VMCM7
p14075
sg15
I1
sa(dp14076
g9
I14
sg20
g21
sg12
I4
sg13
VMCM6
p14077
sg15
I1
sasg6
(lp14078
(dp14079
g9
I125
sg10
VC0035335
p14080
sg12
I14
sg13
Vretinoblastoma
p14081
sg15
I1
sa(dp14082
g9
I157
sg10
VC0334094
p14083
sg12
I13
sg13
Vproliferation
p14084
sg15
I1
sasa(dp14085
g2
VSnord3A expression was also elevated in scrapie infected mice, but not in PrP(0/0) mice, indicating that while the expression levels of this transcript may reflect diverse prion etiologies, they are not related to the loss of PrP(C)'s function.
p14086
sg4
(lp14087
(dp14088
g9
I74
sg20
g21
sg12
I3
sg13
VPrP
p14089
sg15
I1
sasg6
(lp14090
(dp14091
g9
I40
sg10
VC0036457
p14092
sg12
I7
sg13
Vscrapie
p14093
sg15
I1
sasa(dp14094
g2
VWe hypothesize that in addition to its function as a disease marker, Snord3A may play an important role in the mechanism of prion disease manifestation and progression.
p14095
sg4
(lp14096
sg6
(lp14097
(dp14098
g9
I124
sg10
VC0162534
p14099
sg12
I13
sg13
Vprion disease
p14100
sg15
I2
sasa(dp14101
g2
VHer son has type 1 diabetes, arthritis, reduced IgG levels and IgA deficiency, but has not inherited the TNFRSF13B/TACI mutation.
p14102
sg4
(lp14103
(dp14104
g9
I63
sg20
VP11912
p14105
sg12
I3
sg13
VIgA
p14106
sg15
I1
sa(dp14107
g9
I105
sg20
g21
sg12
I9
sg13
VTNFRSF13B
p14108
sg15
I1
sa(dp14109
g9
I115
sg20
g21
sg12
I4
sg13
VTACI
p14110
sg15
I1
sasg6
(lp14111
(dp14112
g9
I29
sg10
VC0003864
p14113
sg12
I9
sg13
Varthritis
p14114
sg15
I1
sa(dp14115
g9
I12
sg10
VC0011854
p14116
sg12
I15
sg13
Vtype 1 diabetes
p14117
sg15
I3
sa(dp14118
g9
I63
sg10
VC0162538
p14119
sg12
I14
sg13
VIgA deficiency
p14120
sg15
I2
sasa(dp14121
g2
VOur results support the hypothesis that increased TACI expression on NOD B cells contributes to the pathogenesis of type 1 diabetes in the NOD mouse.
p14122
sg4
(lp14123
(dp14124
g9
I69
sg20
VP54259
p14125
sg12
I5
sg13
VNOD B
p14126
sg15
I2
sa(dp14127
g9
I50
sg20
g21
sg12
I4
sg13
VTACI
p14128
sg15
I1
sasg6
(lp14129
(dp14130
g9
I116
sg10
VC0011854
p14131
sg12
I15
sg13
Vtype 1 diabetes
p14132
sg15
I3
sa(dp14133
g9
I69
sg10
VC0751781
p14134
sg12
I3
sg13
VNOD
p14135
sg15
I1
sa(dp14136
g9
I69
sg10
VC0751781
p14137
sg12
I3
sg13
VNOD
p14138
sg15
I1
sa(dp14139
g9
I100
sg10
VC0699748
p14140
sg12
I12
sg13
Vpathogenesis
p14141
sg15
I1
sasa(dp14142
g2
VA family member with a wild type TACI variant had CVID-related phenotype including IgA deficiency and type 1 diabetes.
p14143
sg4
(lp14144
(dp14145
g9
I50
sg20
g21
sg12
I22
sg13
VCVID-related phenotype
p14146
sg15
I2
sa(dp14147
g9
I23
sg20
g21
sg12
I22
sg13
Vwild type TACI variant
p14148
sg15
I4
sa(dp14149
g9
I83
sg20
VP11912
p14150
sg12
I3
sg13
VIgA
p14151
sg15
I1
sasg6
(lp14152
(dp14153
g9
I102
sg10
VC0011854
p14154
sg12
I15
sg13
Vtype 1 diabetes
p14155
sg15
I3
sa(dp14156
g9
I50
sg10
VC0009447
p14157
sg12
I4
sg13
VCVID
p14158
sg15
I1
sa(dp14159
g9
I83
sg10
VC0162538
p14160
sg12
I14
sg13
VIgA deficiency
p14161
sg15
I2
sasa(dp14162
g2
VWe mapped the loci contributing to the increased proportion of TACI(high) expressing splenic B cells and found that the control of TACI expression was strongly linked to chromosome 1, in a region which includes the insulin-dependent diabetes (Idd) 5 loci.
p14163
sg4
(lp14164
(dp14165
g9
I63
sg20
g21
sg12
I4
sg13
VTACI
p14166
sg15
I1
sa(dp14167
g9
I215
sg20
VP01308
p14168
sg12
I7
sg13
Vinsulin
p14169
sg15
I1
sasg6
(lp14170
(dp14171
g9
I215
sg10
VC0011854
p14172
sg12
I26
sg13
Vinsulin-dependent diabetes
p14173
sg15
I2
sa(dp14174
g9
I243
sg10
VC0011854
p14175
sg12
I3
sg13
VIdd
p14176
sg15
I1
sasa(dp14177
g2
VOur findings corroborate the notion that B cell deviations contribute to type 1 diabetes development, and suggest a temporal regulation of TACI(high) expression, possibly influenced by the ongoing autoimmune process.
p14178
sg4
(lp14179
sg6
(lp14180
(dp14181
g9
I73
sg10
VC0011854
p14182
sg12
I15
sg13
Vtype 1 diabetes
p14183
sg15
I3
sa(dp14184
g9
I197
sg10
VC0443146
p14185
sg12
I18
sg13
Vautoimmune process
p14186
sg15
I2
sasa(dp14187
g2
VOctamer-binding transcription factor 4 (OCT4) was closely related to pancreatic cancer progression, but its regulation in pancreatic cancer by microRNA (miRNA) is not fully clear.
p14188
sg4
(lp14189
(dp14190
g9
I0
sg20
VP15884
p14191
sg12
I38
sg13
VOctamer-binding transcription factor 4
p14192
sg15
I4
sa(dp14193
g9
I40
sg20
VP15884
p14194
sg12
I4
sg13
VOCT4
p14195
sg15
I1
sasg6
(lp14196
(dp14197
g9
I69
sg10
VC0235974
p14198
sg12
I17
sg13
Vpancreatic cancer
p14199
sg15
I2
sa(dp14200
g9
I80
sg10
VC0178874
p14201
sg12
I18
sg13
Vcancer progression
p14202
sg15
I2
sasa(dp14203
g2
VThis study was designed to investigate the expression of the T-box transcription factor 4 (TBX4), a tumor biomarker that was previously identified by proteomics, in pancreatic ductal adenocarcinoma (PDAC) and evaluate its clinical utility as a potential prognostic biomarkers for PDAC.
p14204
sg4
(lp14205
(dp14206
g9
I91
sg20
VP57082
p14207
sg12
I4
sg13
VTBX4
p14208
sg15
I1
sa(dp14209
g9
I61
sg20
VP15884
p14210
sg12
I28
sg13
VT-box transcription factor 4
p14211
sg15
I4
sasg6
(lp14212
(dp14213
g9
I100
sg10
VC0027651
p14214
sg12
I5
sg13
Vtumor
p14215
sg15
I1
sa(dp14216
g9
I199
sg10
VC1335302
p14217
sg12
I4
sg13
VPDAC
p14218
sg15
I1
sa(dp14219
g9
I199
sg10
VC1335302
p14220
sg12
I4
sg13
VPDAC
p14221
sg15
I1
sa(dp14222
g9
I165
sg10
VC1335302
p14223
sg12
I32
sg13
Vpancreatic ductal adenocarcinoma
p14224
sg15
I3
sasa(dp14225
g2
VWhereas the pathological functions of LTB4/BLT1 axis in allergy, autoimmunity and cardiovascular disorders are well established; its role in cancer is only beginning to emerge.
p14226
sg4
(lp14227
(dp14228
g9
I43
sg20
g21
sg12
I4
sg13
VBLT1
p14229
sg15
I1
sasg6
(lp14230
(dp14231
g9
I141
sg10
VC0006826
p14232
sg12
I6
sg13
Vcancer
p14233
sg15
I1
sa(dp14234
g9
I56
sg10
VC0020517
p14235
sg12
I7
sg13
Vallergy
p14236
sg15
I1
sa(dp14237
g9
I65
sg10
VC0004368
p14238
sg12
I12
sg13
Vautoimmunity
p14239
sg15
I1
sa(dp14240
g9
I82
sg10
VC0007222
p14241
sg12
I24
sg13
Vcardiovascular disorders
p14242
sg15
I2
sasa(dp14243
g2
VBioluminescence tomography (BLT) is a powerful non-invasive molecular imaging tool for in vivo studies of glioma in mice.
p14244
sg4
(lp14245
sg6
(lp14246
(dp14247
g9
I106
sg10
VC0017638
p14248
sg12
I6
sg13
Vglioma
p14249
sg15
I1
sasa(dp14250
g2
VTo the best of our knowledge, this is the first study that achieved such accurate BLT morphological reconstruction of orthotopic glioma without using any segmented tumor structure from any other structural imaging modalities as the prior for reconstruction guidance.
p14251
sg4
(lp14252
sg6
(lp14253
(dp14254
g9
I129
sg10
VC0017638
p14255
sg12
I6
sg13
Vglioma
p14256
sg15
I1
sa(dp14257
g9
I164
sg10
VC0027651
p14258
sg12
I5
sg13
Vtumor
p14259
sg15
I1
sasa(dp14260
g2
VThis enabled BLT more suitable and practical for in vivo imaging of orthotopic glioma mouse models.
p14261
sg4
(lp14262
sg6
(lp14263
(dp14264
g9
I79
sg10
VC0017638
p14265
sg12
I6
sg13
Vglioma
p14266
sg15
I1
sasa(dp14267
g2
VThe major objective of this study is to address this gap in our understanding of how IDO1 expression contributes to the biology of GBM, and whether its level of expression is a determinant of GBM patient outcome.Experimental Design: Patient-resected GBM, The Cancer Genome Atlas, human T-cell:GBM cocultures, as well as nu/nu, NOD-scid, and humanized (NSG-SGM3-BLT) mice-engrafted human GBM form the basis of our investigation.Results:In situ hybridization for IDO1 revealed transcript expression throughout patient-resected GBM, whereas immunohistochemical IDO1 positivity was highly variable.
p14268
sg4
(lp14269
(dp14270
g9
I85
sg20
VP14902
p14271
sg12
I4
sg13
VIDO1
p14272
sg15
I1
sa(dp14273
g9
I85
sg20
VP14902
p14274
sg12
I4
sg13
VIDO1
p14275
sg15
I1
sasg6
(lp14276
(dp14277
g9
I331
sg10
VC0085110
p14278
sg12
I4
sg13
Vscid
p14279
sg15
I1
sa(dp14280
g9
I131
sg10
VC0017636
p14281
sg12
I3
sg13
VGBM
p14282
sg15
I1
sa(dp14283
g9
I259
sg10
VC0006826
p14284
sg12
I6
sg13
VCancer
p14285
sg15
I1
sa(dp14286
g9
I327
sg10
VC0751781
p14287
sg12
I3
sg13
VNOD
p14288
sg15
I1
sa(dp14289
g9
I131
sg10
VC0017636
p14290
sg12
I3
sg13
VGBM
p14291
sg15
I1
sa(dp14292
g9
I131
sg10
VC0017636
p14293
sg12
I3
sg13
VGBM
p14294
sg15
I1
sa(dp14295
g9
I131
sg10
VC0017636
p14296
sg12
I3
sg13
VGBM
p14297
sg15
I1
sa(dp14298
g9
I131
sg10
VC0017636
p14299
sg12
I3
sg13
VGBM
p14300
sg15
I1
sa(dp14301
g9
I131
sg10
VC0017636
p14302
sg12
I3
sg13
VGBM
p14303
sg15
I1
sasa(dp14304
g2
VTogether with CT, BLT can provide precision radiation guidance and robust tumor volume assessment in small animal cancer research.
p14305
sg4
(lp14306
sg6
(lp14307
(dp14308
g9
I114
sg10
VC0006826
p14309
sg12
I6
sg13
Vcancer
p14310
sg15
I1
sa(dp14311
g9
I74
sg10
VC0027651
p14312
sg12
I5
sg13
Vtumor
p14313
sg15
I1
sasa(dp14314
g2
VVariation of detected bioluminescence signals emitted from molecular cancer cells was depicted on BLT images.
p14315
sg4
(lp14316
sg6
(lp14317
(dp14318
g9
I69
sg10
VC0006826
p14319
sg12
I6
sg13
Vcancer
p14320
sg15
I1
sasa(dp14321
g2
VMultispectral BLT images elaborated on early detection of cancer cells, characteristics of tumor growth, and metastasis for more accurate determination of internal bioluminescent sources.
p14322
sg4
(lp14323
sg6
(lp14324
(dp14325
g9
I58
sg10
VC0006826
p14326
sg12
I6
sg13
Vcancer
p14327
sg15
I1
sa(dp14328
g9
I91
sg10
VC0598934
p14329
sg12
I12
sg13
Vtumor growth
p14330
sg15
I2
sa(dp14331
g9
I109
sg10
VC0027627
p14332
sg12
I10
sg13
Vmetastasis
p14333
sg15
I1
sasa(dp14334
g2
VRegistration of BLT with CT images guided molecular cancer cells on anatomical coordinates.
p14335
sg4
(lp14336
sg6
(lp14337
(dp14338
g9
I52
sg10
VC0006826
p14339
sg12
I6
sg13
Vcancer
p14340
sg15
I1
sasa(dp14341
g2
VThe BLT imaging was a useful tool to localize cancer cells and to quantify radiation response.
p14342
sg4
(lp14343
sg6
(lp14344
(dp14345
g9
I46
sg10
VC0006826
p14346
sg12
I6
sg13
Vcancer
p14347
sg15
I1
sasa(dp14348
g2
VApplication of BLT led to more accurate definition of tumor volumes including molecular probe-based microscopic cancer cells.
p14349
sg4
(lp14350
sg6
(lp14351
(dp14352
g9
I54
sg10
VC0027651
p14353
sg12
I5
sg13
Vtumor
p14354
sg15
I1
sa(dp14355
g9
I112
sg10
VC0006826
p14356
sg12
I6
sg13
Vcancer
p14357
sg15
I1
sasa(dp14358
g2
VThus, in this report, we not only provide a novel strategy to expand super-charged NK cells, but also demonstrate that rapid and sustained expansion of residual T cells within the purified NK cells during expansion with DCs or OCs could be a potential mechanism by which the numbers and function of NK cells decline in cancer patients and in BLT-humanized mice.
p14359
sg4
(lp14360
sg6
(lp14361
(dp14362
g9
I220
sg10
VC0268238
p14363
sg12
I3
sg13
VDCs
p14364
sg15
I1
sa(dp14365
g9
I319
sg10
VC0006826
p14366
sg12
I6
sg13
Vcancer
p14367
sg15
I1
sasa(dp14368
g2
VVerrucous carcinoma (VC) is a variant of well-differentiated squamous cell carcinoma and in the anal region is regarded as synonymous with giant condyloma (Buschke-Loewenstein tumour) (BLT).
p14369
sg4
(lp14370
sg6
(lp14371
(dp14372
g9
I176
sg10
VC0027651
p14373
sg12
I6
sg13
Vtumour
p14374
sg15
I1
sa(dp14375
g9
I145
sg10
VC0009663
p14376
sg12
I9
sg13
Vcondyloma
p14377
sg15
I1
sa(dp14378
g9
I0
sg10
VC0206706
p14379
sg12
I19
sg13
VVerrucous carcinoma
p14380
sg15
I2
sa(dp14381
g9
I139
sg10
VC0017547
p14382
sg12
I5
sg13
Vgiant
p14383
sg15
I1
sa(dp14384
g9
I21
sg10
VC0206706
p14385
sg12
I2
sg13
VVC
p14386
sg15
I1
sa(dp14387
g9
I61
sg10
VC0007137
p14388
sg12
I23
sg13
Vsquamous cell carcinoma
p14389
sg15
I3
sasa(dp14390
g2
VTo test this idea, we infected migrating neural crest cells of chicken embryos with  replication-competent avian sarcoma virus expressing either FgfR2(C278F), a receptor mutation found in Crouzon syndrome or the ligand Fgf8.
p14391
sg4
(lp14392
(dp14393
g9
I219
sg20
VP55075
p14394
sg12
I4
sg13
VFgf8
p14395
sg15
I1
sasg6
(lp14396
(dp14397
g9
I48
sg10
VC0206138
p14398
sg12
I5
sg13
Vcrest
p14399
sg15
I1
sa(dp14400
g9
I188
sg10
VC0010273
p14401
sg12
I16
sg13
VCrouzon syndrome
p14402
sg15
I2
sa(dp14403
g9
I107
sg10
VC0004426
p14404
sg12
I13
sg13
Vavian sarcoma
p14405
sg15
I2
sasa(dp14406
g2
VThese defects are similar in presentation to several human craniofacial disorders (e.g., craniosynostosis, hemifacial microsomia), and may be related to increased levels of bone metabolism observed in ace(ti282a)/fgf8 heterozygotes.
p14407
sg4
(lp14408
(dp14409
g9
I213
sg20
VP55075
p14410
sg12
I4
sg13
Vfgf8
p14411
sg15
I1
sasg6
(lp14412
(dp14413
g9
I89
sg10
VC0010278
p14414
sg12
I16
sg13
Vcraniosynostosis
p14415
sg15
I1
sa(dp14416
g9
I107
sg10
VC1306710
p14417
sg12
I21
sg13
Vhemifacial microsomia
p14418
sg15
I2
sasa(dp14419
g2
VSince FGF8 maps to the same chromosomal region as FGFR2, has indeed been shown to be a ligand for FGFR2, and has an expression pattern consistent with limb and craniofacial anomalies, we have screened two kindreds with Pfeiffer syndrome that were previously linked to markers from 10q24-25 and a large number of individuals with craniosynostosis and limb anomalies for mutations in the coding sequence of FGF8.
p14420
sg4
(lp14421
(dp14422
g9
I6
sg20
VP55075
p14423
sg12
I4
sg13
VFGF8
p14424
sg15
I1
sa(dp14425
g9
I6
sg20
VP55075
p14426
sg12
I4
sg13
VFGF8
p14427
sg15
I1
sasg6
(lp14428
(dp14429
g9
I329
sg10
VC0010278
p14430
sg12
I16
sg13
Vcraniosynostosis
p14431
sg15
I1
sa(dp14432
g9
I219
sg10
VC0265303
p14433
sg12
I17
sg13
VPfeiffer syndrome
p14434
sg15
I2
sasa(dp14435
g2
VThe results demonstrated that rhTrx-1 significantly improved neurological functions and reduced cerebral infarction and apoptotic cell death at 24h after MCAO.
p14436
sg4
(lp14437
sg6
(lp14438
(dp14439
g9
I96
sg10
VC0038454
p14440
sg12
I19
sg13
Vcerebral infarction
p14441
sg15
I2
sasa(dp14442
g2
VTreatment with Trx1 siRNA significantly increased mortality, behavioral deficits, and cerebral infarction volume and exacerbated neuronal cell apoptotic death after MCAO injury.
p14443
sg4
(lp14444
(dp14445
g9
I15
sg20
VP60606
p14446
sg12
I10
sg13
VTrx1 siRNA
p14447
sg15
I2
sasg6
(lp14448
(dp14449
g9
I86
sg10
VC0038454
p14450
sg12
I19
sg13
Vcerebral infarction
p14451
sg15
I2
sasa(dp14452
g2
VThe results showed that intravenously administered rhTrx-1 (10 mg/kg) significantly improved neurological functions and reduced cerebral infarction and apoptotic cell death following cerebral ischemia.
p14453
sg4
(lp14454
sg6
(lp14455
(dp14456
g9
I128
sg10
VC0038454
p14457
sg12
I19
sg13
Vcerebral infarction
p14458
sg15
I2
sa(dp14459
g9
I183
sg10
VC0917798
p14460
sg12
I17
sg13
Vcerebral ischemia
p14461
sg15
I2
sasa(dp14462
g2
VFurthermore, the suppression on ONOO- formation by either rhTrx-1 or an ONOO- scavenger uric acid reduced cerebral infarct size in mice subjected to cerebral ischemia.
p14463
sg4
(lp14464
sg6
(lp14465
(dp14466
g9
I149
sg10
VC0007785
p14467
sg12
I17
sg13
Vcerebral ischemia
p14468
sg15
I2
sa(dp14469
g9
I17
sg10
VC0221103
p14470
sg12
I11
sg13
Vsuppression
p14471
sg15
I1
sa(dp14472
g9
I106
sg10
VC0007785
p14473
sg12
I16
sg13
Vcerebral infarct
p14474
sg15
I2
sasa(dp14475
g2
VProenkephalin (pro-ENK), a stable and reliable surrogate marker for unstable enkephalins, was found to be associated with acute kidney injury and chronic renal failure in previous studies.
p14476
sg4
(lp14477
(dp14478
g9
I0
sg20
VP01210
p14479
sg12
I13
sg13
VProenkephalin
p14480
sg15
I1
sa(dp14481
g9
I15
sg20
VP01210
p14482
sg12
I7
sg13
Vpro-ENK
p14483
sg15
I1
sasg6
(lp14484
(dp14485
g9
I146
sg10
VC0022661
p14486
sg12
I21
sg13
Vchronic renal failure
p14487
sg15
I3
sasa(dp14488
g2
VPENK and NGAL concentrations were measured and GFR was estimated by using the isotope dilution mass spectrometry traceable-Modification of Diet in Renal Disease (MDRD) Study and three Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equations: CKD-EPI(Cr), CDK-EPI(CysC), and CKD-EPI(Cr-CysC).
p14489
sg4
(lp14490
(dp14491
g9
I268
sg20
VP10646
p14492
sg12
I7
sg13
VCDK-EPI
p14493
sg15
I1
sa(dp14494
g9
I0
sg20
VP01210
p14495
sg12
I4
sg13
VPENK
p14496
sg15
I1
sa(dp14497
g9
I184
sg20
VP10646
p14498
sg12
I49
sg13
VChronic Kidney Disease Epidemiology Collaboration
p14499
sg15
I5
sa(dp14500
g9
I9
sg20
VP80188
p14501
sg12
I4
sg13
VNGAL
p14502
sg15
I1
sa(dp14503
g9
I295
sg20
VP22676
p14504
sg12
I7
sg13
VCr-CysC
p14505
sg15
I1
sa(dp14506
g9
I235
sg20
VP10646
p14507
sg12
I7
sg13
VCKD-EPI
p14508
sg15
I1
sasg6
(lp14509
(dp14510
g9
I184
sg10
VC1561643
p14511
sg12
I22
sg13
VChronic Kidney Disease
p14512
sg15
I3
sa(dp14513
g9
I239
sg10
VC0267963
p14514
sg12
I3
sg13
VEPI
p14515
sg15
I1
sa(dp14516
g9
I147
sg10
VC0022658
p14517
sg12
I13
sg13
VRenal Disease
p14518
sg15
I2
sa(dp14519
g9
I239
sg10
VC0267963
p14520
sg12
I3
sg13
VEPI
p14521
sg15
I1
sa(dp14522
g9
I239
sg10
VC0267963
p14523
sg12
I3
sg13
VEPI
p14524
sg15
I1
sa(dp14525
g9
I239
sg10
VC0267963
p14526
sg12
I3
sg13
VEPI
p14527
sg15
I1
sasa(dp14528
g2
VProenkephalin cleavage products stored within cells, which included the 5.3-kDa peptide, could be released upon stimulation of cells with BaCl2 (2-fold above basal levels), 8-bromo-cAMP or CRF (7- and 8-fold above basal levels, respectively), and a mixture of BaCl2 and 8-bromo-cAMP (20-fold above basal levels).
p14529
sg4
(lp14530
(dp14531
g9
I0
sg20
VP01210
p14532
sg12
I13
sg13
VProenkephalin
p14533
sg15
I1
sasg6
(lp14534
(dp14535
g9
I189
sg10
VC0022661
p14536
sg12
I3
sg13
VCRF
p14537
sg15
I1
sasa(dp14538
g2
VPart 1 focuses on anti-metabotropic glutamate receptor 1-, anti-Homer protein homolog 3-, anti-Sj/inositol 1,4,5-trisphosphate receptor- and anti-carbonic anhydrase-related protein VIII-associated autoimmune cerebellar ataxia (ACA); part 2 covers anti-protein kinase C gamma-, anti-glutamate receptor delta-2-, anti-Ca/RhoGTPase-activating protein 26- and anti-voltage-gated calcium channel-associated ACA; and part 3 reviews the current knowledge on anti-Tr/delta notch-like epidermal growth factor-related receptor-, anti-Nb/AP3B2-, anti-Yo/cerebellar degeneration-related protein 2- and Purkinje cell antibody 2-associated ACA, discusses differential diagnostic aspects and provides a summary and outlook.
p14539
sg4
(lp14540
(dp14541
g9
I59
sg20
g21
sg12
I126
sg13
Vanti-Homer protein homolog 3-, anti-Sj/inositol 1,4,5-trisphosphate receptor- and anti-carbonic anhydrase-related protein VIII
p14542
sg15
I12
sa(dp14543
g9
I527
sg20
g21
sg12
I5
sg13
VAP3B2
p14544
sg15
I1
sa(dp14545
g9
I247
sg20
VP05129
p14546
sg12
I61
sg13
Vanti-protein kinase C gamma-, anti-glutamate receptor delta-2
p14547
sg15
I7
sa(dp14548
g9
I18
sg20
VP42261
p14549
sg12
I38
sg13
Vanti-metabotropic glutamate receptor 1
p14550
sg15
I4
sa(dp14551
g9
I356
sg20
g21
sg12
I49
sg13
Vanti-voltage-gated calcium channel-associated ACA
p14552
sg15
I4
sa(dp14553
g9
I476
sg20
VP01133
p14554
sg12
I40
sg13
Vepidermal growth factor-related receptor
p14555
sg15
I4
sasg6
(lp14556
(dp14557
g9
I227
sg10
VC0007758
p14558
sg12
I3
sg13
VACA
p14559
sg15
I1
sa(dp14560
g9
I227
sg10
VC0007758
p14561
sg12
I3
sg13
VACA
p14562
sg15
I1
sa(dp14563
g9
I227
sg10
VC0007758
p14564
sg12
I3
sg13
VACA
p14565
sg15
I1
sa(dp14566
g9
I197
sg10
VC0007758
p14567
sg12
I28
sg13
Vautoimmune cerebellar ataxia
p14568
sg15
I3
sa(dp14569
g9
I543
sg10
VC0262404
p14570
sg12
I23
sg13
Vcerebellar degeneration
p14571
sg15
I2
sasa(dp14572
g2
VPart 1 focuses on anti-metabotropic glutamate receptor 1-, anti-Homer protein homolog 3-, anti-Sj/inositol 1,4,5-trisphosphate receptor- and anti-carbonic anhydrase-related protein VIII-associated autoimmune cerebellar ataxia (ACA); part 2 covers anti-protein kinase C gamma-, anti-glutamate receptor delta-2-, anti-Ca/RhoGTPase-activating protein 26- and anti-voltage-gated calcium channel-associated ACA; and part 3 reviews the current knowledge on anti-Tr/delta notch-like epidermal growth factor-related receptor-, anti-Nb/AP3B2-, anti-Yo/cerebellar degeneration-related protein 2- and Purkinje cell antibody 2-associated ACA, discusses differential diagnostic aspects, and provides a summary and outlook.
p14573
sg4
(lp14574
(dp14575
g9
I59
sg20
g21
sg12
I126
sg13
Vanti-Homer protein homolog 3-, anti-Sj/inositol 1,4,5-trisphosphate receptor- and anti-carbonic anhydrase-related protein VIII
p14576
sg15
I12
sa(dp14577
g9
I527
sg20
g21
sg12
I5
sg13
VAP3B2
p14578
sg15
I1
sa(dp14579
g9
I247
sg20
VP05129
p14580
sg12
I61
sg13
Vanti-protein kinase C gamma-, anti-glutamate receptor delta-2
p14581
sg15
I7
sa(dp14582
g9
I18
sg20
VP42261
p14583
sg12
I38
sg13
Vanti-metabotropic glutamate receptor 1
p14584
sg15
I4
sa(dp14585
g9
I356
sg20
g21
sg12
I49
sg13
Vanti-voltage-gated calcium channel-associated ACA
p14586
sg15
I4
sa(dp14587
g9
I476
sg20
VP01133
p14588
sg12
I40
sg13
Vepidermal growth factor-related receptor
p14589
sg15
I4
sasg6
(lp14590
(dp14591
g9
I227
sg10
VC0007758
p14592
sg12
I3
sg13
VACA
p14593
sg15
I1
sa(dp14594
g9
I227
sg10
VC0007758
p14595
sg12
I3
sg13
VACA
p14596
sg15
I1
sa(dp14597
g9
I227
sg10
VC0007758
p14598
sg12
I3
sg13
VACA
p14599
sg15
I1
sa(dp14600
g9
I197
sg10
VC0007758
p14601
sg12
I28
sg13
Vautoimmune cerebellar ataxia
p14602
sg15
I3
sa(dp14603
g9
I543
sg10
VC0262404
p14604
sg12
I23
sg13
Vcerebellar degeneration
p14605
sg15
I2
sasa(dp14606
g2
VPart 1 focuses on anti-metabotropic glutamate receptor 1-, anti-Homer protein homolog 3-, anti-Sj/inositol 1,4,5-trisphosphate receptor- and anti-carbonic anhydrase-related protein VIII-associated autoimmune cerebellar ataxia (ACA); part 2 covers anti-protein kinase C gamma-, anti-glutamate receptor delta-2-, anti-Ca/RhoGTPase-activating protein 26- and anti-voltage-gated calcium channel-associated ACA; and part 3 reviews the current knowledge on anti-Tr/delta notch-like epidermal growth factor-related receptor-, anti-Nb/AP3B2-, anti-Yo/cerebellar degeneration-related protein 2- and Purkinje cell antibody 2-associated ACA, discusses differential diagnostic aspects and provides a summary and outlook.
p14607
sg4
(lp14608
(dp14609
g9
I59
sg20
g21
sg12
I126
sg13
Vanti-Homer protein homolog 3-, anti-Sj/inositol 1,4,5-trisphosphate receptor- and anti-carbonic anhydrase-related protein VIII
p14610
sg15
I12
sa(dp14611
g9
I527
sg20
g21
sg12
I5
sg13
VAP3B2
p14612
sg15
I1
sa(dp14613
g9
I247
sg20
VP05129
p14614
sg12
I61
sg13
Vanti-protein kinase C gamma-, anti-glutamate receptor delta-2
p14615
sg15
I7
sa(dp14616
g9
I18
sg20
VP42261
p14617
sg12
I38
sg13
Vanti-metabotropic glutamate receptor 1
p14618
sg15
I4
sa(dp14619
g9
I356
sg20
g21
sg12
I49
sg13
Vanti-voltage-gated calcium channel-associated ACA
p14620
sg15
I4
sa(dp14621
g9
I476
sg20
VP01133
p14622
sg12
I40
sg13
Vepidermal growth factor-related receptor
p14623
sg15
I4
sasg6
(lp14624
(dp14625
g9
I227
sg10
VC0007758
p14626
sg12
I3
sg13
VACA
p14627
sg15
I1
sa(dp14628
g9
I227
sg10
VC0007758
p14629
sg12
I3
sg13
VACA
p14630
sg15
I1
sa(dp14631
g9
I227
sg10
VC0007758
p14632
sg12
I3
sg13
VACA
p14633
sg15
I1
sa(dp14634
g9
I197
sg10
VC0007758
p14635
sg12
I28
sg13
Vautoimmune cerebellar ataxia
p14636
sg15
I3
sa(dp14637
g9
I543
sg10
VC0262404
p14638
sg12
I23
sg13
Vcerebellar degeneration
p14639
sg15
I2
sasa(dp14640
g2
VLastly, a recent study identified delta/notch-like epidermal growth factor-related receptor (DNER) as the target antigen of Tr antibodies, a marker of cerebellar ataxia and Hodgkin's lymphoma.
p14641
sg4
(lp14642
(dp14643
g9
I51
sg20
VP01133
p14644
sg12
I40
sg13
Vepidermal growth factor-related receptor
p14645
sg15
I4
sasg6
(lp14646
(dp14647
g9
I173
sg10
VC0019829
p14648
sg12
I18
sg13
VHodgkin's lymphoma
p14649
sg15
I2
sa(dp14650
g9
I151
sg10
VC0007758
p14651
sg12
I17
sg13
Vcerebellar ataxia
p14652
sg15
I2
sasa(dp14653
g2
VReal-time quantitative PCR confirmed significantly increased expression of HAS2, CHSY1, and C4ST1 in the combined groups of CLE lesions (n = 8) compared to healthy controls (n = 4).
p14654
sg4
(lp14655
(dp14656
g9
I75
sg20
g21
sg12
I4
sg13
VHAS2
p14657
sg15
I1
sa(dp14658
g9
I81
sg20
g21
sg12
I5
sg13
VCHSY1
p14659
sg15
I1
sa(dp14660
g9
I92
sg20
g21
sg12
I5
sg13
VC4ST1
p14661
sg15
I1
sasg6
(lp14662
(dp14663
g9
I124
sg10
VC2931489
p14664
sg12
I3
sg13
VCLE
p14665
sg15
I1
sasa(dp14666
g2
VThus, the increase in HA in CLE presumably results from upregulation of HAS2, whereas CHSY1 and C4ST1 appear to contribute to increased CS.
p14667
sg4
(lp14668
(dp14669
g9
I96
sg20
g21
sg12
I5
sg13
VC4ST1
p14670
sg15
I1
sa(dp14671
g9
I86
sg20
g21
sg12
I5
sg13
VCHSY1
p14672
sg15
I1
sa(dp14673
g9
I72
sg20
g21
sg12
I4
sg13
VHAS2
p14674
sg15
I1
sasg6
(lp14675
(dp14676
g9
I28
sg10
VC2931489
p14677
sg12
I3
sg13
VCLE
p14678
sg15
I1
sasa(dp14679
g2
VThrough Part 4 of Maintenance of Certification for Family Physicians (MC-FP), American Board of Family Medicine (ABFM) diplomates participate in quality improvement (QI) modules for diabetes.
p14680
sg4
(lp14681
sg6
(lp14682
(dp14683
g9
I182
sg10
VC0011849
p14684
sg12
I8
sg13
Vdiabetes
p14685
sg15
I1
sasa(dp14686
g2
VFamily physicians participating in MC-FP implemented improvement projects and showed quality improvements in caring for patients with diabetes.
p14687
sg4
(lp14688
sg6
(lp14689
(dp14690
g9
I134
sg10
VC0011849
p14691
sg12
I8
sg13
Vdiabetes
p14692
sg15
I1
sasa(dp14693
g2
VInsulin-dependent diabetes mellitus (IDDM) and Graves' disease (GD) are autoimmune endocrinopathies and associated with distinct HLA-DR and -DQ alleles as well as several tumor necrosis factor alpha (TNF-alpha) and beta (TNF-beta) alleles.
p14694
sg4
(lp14695
(dp14696
g9
I129
sg20
VP30486
p14697
sg12
I6
sg13
VHLA-DR
p14698
sg15
I1
sa(dp14699
g9
I171
sg20
VP01375
p14700
sg12
I27
sg13
Vtumor necrosis factor alpha
p14701
sg15
I4
sa(dp14702
g9
I200
sg20
VP01375
p14703
sg12
I9
sg13
VTNF-alpha
p14704
sg15
I1
sa(dp14705
g9
I221
sg20
VP01375
p14706
sg12
I8
sg13
VTNF-beta
p14707
sg15
I1
sa(dp14708
g9
I0
sg20
VP01308
p14709
sg12
I7
sg13
VInsulin
p14710
sg15
I1
sasg6
(lp14711
(dp14712
g9
I64
sg10
VC0018213
p14713
sg12
I2
sg13
VGD
p14714
sg15
I1
sa(dp14715
g9
I72
sg10
VC0443146
p14716
sg12
I10
sg13
Vautoimmune
p14717
sg15
I1
sa(dp14718
g9
I171
sg10
VC0333516
p14719
sg12
I14
sg13
Vtumor necrosis
p14720
sg15
I2
sa(dp14721
g9
I0
sg10
VC0011854
p14722
sg12
I35
sg13
VInsulin-dependent diabetes mellitus
p14723
sg15
I3
sa(dp14724
g9
I47
sg10
VC0018213
p14725
sg12
I15
sg13
VGraves' disease
p14726
sg15
I2
sa(dp14727
g9
I83
sg10
VC0014130
p14728
sg12
I16
sg13
Vendocrinopathies
p14729
sg15
I1
sa(dp14730
g9
I37
sg10
VC0011854
p14731
sg12
I4
sg13
VIDDM
p14732
sg15
I1
sasa(dp14733
g2
VStudies in Caucasians have suggested that the TNFB gene might be a susceptibility gene for Graves' disease.
p14734
sg4
(lp14735
(dp14736
g9
I46
sg20
VP10515
p14737
sg12
I9
sg13
VTNFB gene
p14738
sg15
I2
sasg6
(lp14739
(dp14740
g9
I91
sg10
VC0018213
p14741
sg12
I15
sg13
VGraves' disease
p14742
sg15
I2
sasa(dp14743
g2
VTo investigate further the role of TNFB in predisposition to Graves' disease, we determined whether the TNFB disease associations in the Chinese were similar to those in Caucasians.
p14744
sg4
(lp14745
(dp14746
g9
I35
sg20
VP10515
p14747
sg12
I4
sg13
VTNFB
p14748
sg15
I1
sasg6
(lp14749
(dp14750
g9
I61
sg10
VC0018213
p14751
sg12
I15
sg13
VGraves' disease
p14752
sg15
I2
sasa(dp14753
g2
VWe conclude that the TNFB associations with Graves' disease in the Hong Kong Chinese differ between the genders and from those described in Caucasians.
p14754
sg4
(lp14755
sg6
(lp14756
(dp14757
g9
I44
sg10
VC0018213
p14758
sg12
I15
sg13
VGraves' disease
p14759
sg15
I2
sasa(dp14760
g2
VThe TNFB gene is not a susceptibility gene for Graves' disease.
p14761
sg4
(lp14762
(dp14763
g9
I4
sg20
VP10515
p14764
sg12
I9
sg13
VTNFB gene
p14765
sg15
I2
sasg6
(lp14766
(dp14767
g9
I47
sg10
VC0018213
p14768
sg12
I15
sg13
VGraves' disease
p14769
sg15
I2
sasa(dp14770
g2
VWe show here a significant association of TNF beta polymorphisms with Graves' disease.
p14771
sg4
(lp14772
(dp14773
g9
I42
sg20
VP01375
p14774
sg12
I8
sg13
VTNF beta
p14775
sg15
I2
sasg6
(lp14776
(dp14777
g9
I70
sg10
VC0018213
p14778
sg12
I15
sg13
VGraves' disease
p14779
sg15
I2
sasa(dp14780
g2
VAlthough TNF beta polymorphisms are linked to A1B8DR3, these results suggest that they represent an additional susceptibility marker in Graves' disease.
p14781
sg4
(lp14782
(dp14783
g9
I9
sg20
VP01375
p14784
sg12
I8
sg13
VTNF beta
p14785
sg15
I2
sasg6
(lp14786
(dp14787
g9
I136
sg10
VC0018213
p14788
sg12
I15
sg13
VGraves' disease
p14789
sg15
I2
sasa(dp14790
g2
VHere, we summarize our findings of targeted SOX9 destruction by SCFFBW7 (Skp1/Cul1/F-box) in medulloblastoma and its potential for therapeutic intervention.
p14791
sg4
(lp14792
(dp14793
g9
I78
sg20
g21
sg12
I4
sg13
VCul1
p14794
sg15
I1
sa(dp14795
g9
I44
sg20
VP48436
p14796
sg12
I16
sg13
VSOX9 destruction
p14797
sg15
I2
sa(dp14798
g9
I73
sg20
VP63208
p14799
sg12
I4
sg13
VSkp1
p14800
sg15
I1
sasg6
(lp14801
(dp14802
g9
I93
sg10
VC0025149
p14803
sg12
I15
sg13
Vmedulloblastoma
p14804
sg15
I1
sasa(dp14805
g2
VA point mutation in mouse Vps33a (Buff mouse) causes albinism and bleeding (Hermansky-Pudlak syndrome) because of abnormalities in the trafficking of melanosomes and platelets.
p14806
sg4
(lp14807
(dp14808
g9
I26
sg20
g21
sg12
I6
sg13
VVps33a
p14809
sg15
I1
sasg6
(lp14810
(dp14811
g9
I53
sg10
VC0001916
p14812
sg12
I8
sg13
Valbinism
p14813
sg15
I1
sa(dp14814
g9
I66
sg10
VC0019080
p14815
sg12
I8
sg13
Vbleeding
p14816
sg15
I1
sa(dp14817
g9
I76
sg10
VC0079504
p14818
sg12
I25
sg13
VHermansky-Pudlak syndrome
p14819
sg15
I2
sasa(dp14820
g2
VA mutation in the Vps33a gene causes Hermansky-Pudlak Syndrome (HPS)-like-symptoms in the buff (bf) mouse mutant.
p14821
sg4
(lp14822
(dp14823
g9
I18
sg20
g21
sg12
I11
sg13
VVps33a gene
p14824
sg15
I2
sasg6
(lp14825
(dp14826
g9
I64
sg10
VC0242994
p14827
sg12
I3
sg13
VHPS
p14828
sg15
I1
sa(dp14829
g9
I37
sg10
VC0079504
p14830
sg12
I25
sg13
VHermansky-Pudlak Syndrome
p14831
sg15
I2
sa(dp14832
g9
I106
sg10
VC0596988
p14833
sg12
I6
sg13
Vmutant
p14834
sg15
I1
sasa(dp14835
g2
VEpicardial LGEs were identified in 10/13 and pericarditis in 6/13 RAH.
p14836
sg4
(lp14837
sg6
(lp14838
(dp14839
g9
I45
sg10
VC0031046
p14840
sg12
I12
sg13
Vpericarditis
p14841
sg15
I1
sasa(dp14842
g2
VAn RA relapse was observed after 7-40 days in 10/13 RAH with myopericarditis.
p14843
sg4
(lp14844
sg6
(lp14845
(dp14846
g9
I6
sg10
VC0277556
p14847
sg12
I7
sg13
Vrelapse
p14848
sg15
I1
sa(dp14849
g9
I61
sg10
VC0854532
p14850
sg12
I15
sg13
Vmyopericarditis
p14851
sg15
I1
sasa(dp14852
g2
VWe found that LGI3 and its receptors, ADAM22 and ADAM23, were significantly downregulated in glioma tissues.
p14853
sg4
(lp14854
(dp14855
g9
I49
sg20
g21
sg12
I6
sg13
VADAM23
p14856
sg15
I1
sa(dp14857
g9
I14
sg20
g21
sg12
I4
sg13
VLGI3
p14858
sg15
I1
sa(dp14859
g9
I38
sg20
g21
sg12
I6
sg13
VADAM22
p14860
sg15
I1
sasg6
(lp14861
(dp14862
g9
I93
sg10
VC0017638
p14863
sg12
I6
sg13
Vglioma
p14864
sg15
I1
sasa(dp14865
g2
VAnalysis of expression microarray data of glioma cohorts demonstrated that low expression levels of LGI3, ADAM22 and ADAM23 were significantly associated with poor prognosis of glioma.
p14866
sg4
(lp14867
(dp14868
g9
I106
sg20
g21
sg12
I6
sg13
VADAM22
p14869
sg15
I1
sa(dp14870
g9
I100
sg20
g21
sg12
I4
sg13
VLGI3
p14871
sg15
I1
sa(dp14872
g9
I117
sg20
g21
sg12
I6
sg13
VADAM23
p14873
sg15
I1
sasg6
(lp14874
(dp14875
g9
I42
sg10
VC0017638
p14876
sg12
I6
sg13
Vglioma
p14877
sg15
I1
sa(dp14878
g9
I42
sg10
VC0017638
p14879
sg12
I6
sg13
Vglioma
p14880
sg15
I1
sasa(dp14881
g2
VRather, we observed that, in ADAM23-heterotypic environments, ADAM23-negative cells promote tumor growth and metastasis by enhancing the proliferation and invasion of adjacent A23-positive cells through the production of LGI4 (Leucine-rich Glioma Inactivated 4) and nitric oxide (NO).
p14882
sg4
(lp14883
(dp14884
g9
I227
sg20
VP30740
p14885
sg12
I33
sg13
VLeucine-rich Glioma Inactivated 4
p14886
sg15
I4
sa(dp14887
g9
I221
sg20
g21
sg12
I4
sg13
VLGI4
p14888
sg15
I1
sasg6
(lp14889
(dp14890
g9
I92
sg10
VC0598934
p14891
sg12
I12
sg13
Vtumor growth
p14892
sg15
I2
sa(dp14893
g9
I137
sg10
VC0334094
p14894
sg12
I13
sg13
Vproliferation
p14895
sg15
I1
sa(dp14896
g9
I155
sg10
VC2699153
p14897
sg12
I8
sg13
Vinvasion
p14898
sg15
I1
sa(dp14899
g9
I240
sg10
VC0017638
p14900
sg12
I6
sg13
VGlioma
p14901
sg15
I1
sa(dp14902
g9
I109
sg10
VC0027627
p14903
sg12
I10
sg13
Vmetastasis
p14904
sg15
I1
sasa(dp14905
g2
VThe aim of the present study was to evaluate ADAM28 and Insulin Like Growth Factor Binding Protein-3 (IGFBP-3)) gene expression in colorectal carcinoma tissues with regard to the overweight or obese status of the patients using an oligonucleotide microarray technique.
p14906
sg4
(lp14907
(dp14908
g9
I102
sg20
VP17936
p14909
sg12
I7
sg13
VIGFBP-3
p14910
sg15
I1
sa(dp14911
g9
I45
sg20
g21
sg12
I6
sg13
VADAM28
p14912
sg15
I1
sa(dp14913
g9
I56
sg20
VP01308
p14914
sg12
I44
sg13
VInsulin Like Growth Factor Binding Protein-3
p14915
sg15
I6
sasg6
(lp14916
(dp14917
g9
I193
sg10
VC0028754
p14918
sg12
I5
sg13
Vobese
p14919
sg15
I1
sa(dp14920
g9
I131
sg10
VC0009402
p14921
sg12
I20
sg13
Vcolorectal carcinoma
p14922
sg15
I2
sa(dp14923
g9
I179
sg10
VC0497406
p14924
sg12
I10
sg13
Voverweight
p14925
sg15
I1
sasa(dp14926
g2
VThe expression of cancer stem cell marker cluster of differentiation 271 (CD271) was determined in traditional two-dimensional (2D) and 3D cultures of C918 uveal melanoma cells by fluorescent immunocytochemistry.
p14927
sg4
(lp14928
sg6
(lp14929
(dp14930
g9
I156
sg10
VC0220633
p14931
sg12
I14
sg13
Vuveal melanoma
p14932
sg15
I2
sa(dp14933
g9
I18
sg10
VC0006826
p14934
sg12
I6
sg13
Vcancer
p14935
sg15
I1
sasa(dp14936
g2
VThe missense mutation (c.370G &gt; A) in the TGFBI gene and insert mutation (c.1456-1457ins GAT) in the KRT12 gene were identified in a 23-year-old male patient with concurrent KC and GCD.
p14937
sg4
(lp14938
(dp14939
g9
I77
sg20
g21
sg12
I18
sg13
Vc.1456-1457ins GAT
p14940
sg15
I2
sa(dp14941
g9
I104
sg20
g21
sg12
I10
sg13
VKRT12 gene
p14942
sg15
I2
sasg6
(lp14943
sa(dp14944
g2
VThis study investigated the TGFBI gene mutation types in outpatients clinically diagnosed with granular corneal dystrophy (GCD) prior to phototherapeutic keratectomy (PTK), also calculated the mutation rate of subjects with normal corneas, but positive family history.
p14945
sg4
(lp14946
(dp14947
g9
I167
sg20
g21
sg12
I3
sg13
VPTK
p14948
sg15
I1
sa(dp14949
g9
I137
sg20
g21
sg12
I28
sg13
Vphototherapeutic keratectomy
p14950
sg15
I2
sasg6
(lp14951
(dp14952
g9
I95
sg10
VC0018179
p14953
sg12
I26
sg13
Vgranular corneal dystrophy
p14954
sg15
I3
sa(dp14955
g9
I123
sg10
VC0018179
p14956
sg12
I3
sg13
VGCD
p14957
sg15
I1
sasa(dp14958
g2
VTo describe 2 unrelated families with multiple members demonstrating a less commonly recognized vortex pattern of corneal deposits confirmed to be granular corneal dystrophy type 1 (GCD1) after identification of the p.(Arg555Trp) mutation in the transforming growth factor Beta-induced gene (TGFBI).
p14959
sg4
(lp14960
(dp14961
g9
I246
sg20
VP18075
p14962
sg12
I31
sg13
Vtransforming growth factor Beta
p14963
sg15
I4
sasg6
(lp14964
(dp14965
g9
I182
sg10
VC1641846
p14966
sg12
I4
sg13
VGCD1
p14967
sg15
I1
sa(dp14968
g9
I114
sg10
VC0162281
p14969
sg12
I16
sg13
Vcorneal deposits
p14970
sg15
I2
sa(dp14971
g9
I147
sg10
VC1641846
p14972
sg12
I33
sg13
Vgranular corneal dystrophy type 1
p14973
sg15
I5
sasa(dp14974
g2
VScreening of TGFBI in both families revealed a heterozygous missense mutation [p.(Arg555Trp)] in exon 12, confirming the diagnosis of GCD1.
p14975
sg4
(lp14976
sg6
(lp14977
(dp14978
g9
I134
sg10
VC1641846
p14979
sg12
I4
sg13
VGCD1
p14980
sg15
I1
sasa(dp14981
g2
VAlthough this pattern of dystrophic deposits is not recognized by clinicians as a typical phenotype of GCD1, it is consistent with the production of the majority of the TGFBI protein by the corneal epithelium.
p14982
sg4
(lp14983
sg6
(lp14984
(dp14985
g9
I103
sg10
VC1641846
p14986
sg12
I4
sg13
VGCD1
p14987
sg15
I1
sasa(dp14988
g2
VIn this study, patients with macular corneal dystrophy (MCD; n = 18), granular corneal dystrophy type 1 (GCD1; n = 12), and lattice corneal dystrophy type 1 (LCD1; n = 4), as well as 50 healthy controls, were subjected to clinical and genetic examinations.
p14989
sg4
(lp14990
sg6
(lp14991
(dp14992
g9
I158
sg10
VC1690006
p14993
sg12
I4
sg13
VLCD1
p14994
sg15
I1
sa(dp14995
g9
I70
sg10
VC1641846
p14996
sg12
I33
sg13
Vgranular corneal dystrophy type 1
p14997
sg15
I5
sa(dp14998
g9
I105
sg10
VC1641846
p14999
sg12
I4
sg13
VGCD1
p15000
sg15
I1
sa(dp15001
g9
I29
sg10
VC0024439
p15002
sg12
I25
sg13
Vmacular corneal dystrophy
p15003
sg15
I3
sa(dp15004
g9
I56
sg10
VC1636149
p15005
sg12
I3
sg13
VMCD
p15006
sg15
I1
sa(dp15007
g9
I124
sg10
VC2931650
p15008
sg12
I32
sg13
Vlattice corneal dystrophy type 1
p15009
sg15
I5
sasa(dp15010
g2
VVariations were analyzed with DNA sequencing in the coding region of CHST6 in patients with MCD and exons 4 and 12 in TGFBI in patients with LCD1 and GCD1.
p15011
sg4
(lp15012
(dp15013
g9
I69
sg20
g21
sg12
I5
sg13
VCHST6
p15014
sg15
I1
sasg6
(lp15015
(dp15016
g9
I141
sg10
VC1690006
p15017
sg12
I4
sg13
VLCD1
p15018
sg15
I1
sa(dp15019
g9
I92
sg10
VC1636149
p15020
sg12
I3
sg13
VMCD
p15021
sg15
I1
sa(dp15022
g9
I150
sg10
VC1641846
p15023
sg12
I4
sg13
VGCD1
p15024
sg15
I1
sasa(dp15025
g2
VThe previously reported R555W mutation in TGFBI was detected in 12 patients with GCD1, and the R124C mutation in TGFBI was detected in four patients with LCD1.
p15026
sg4
(lp15027
sg6
(lp15028
(dp15029
g9
I81
sg10
VC1641846
p15030
sg12
I4
sg13
VGCD1
p15031
sg15
I1
sa(dp15032
g9
I154
sg10
VC1690006
p15033
sg12
I4
sg13
VLCD1
p15034
sg15
I1
sasa(dp15035
g2
VWe detected previously reported, well-known hot spot mutations in TGFBI in the patients with GCD1 and LCD1.
p15036
sg4
(lp15037
sg6
(lp15038
(dp15039
g9
I93
sg10
VC1641846
p15040
sg12
I4
sg13
VGCD1
p15041
sg15
I1
sa(dp15042
g9
I44
sg10
VC0263214
p15043
sg12
I8
sg13
Vhot spot
p15044
sg15
I2
sa(dp15045
g9
I102
sg10
VC1690006
p15046
sg12
I4
sg13
VLCD1
p15047
sg15
I1
sasa(dp15048
g2
VTGFBeta1-induced expression of transforming growth factor Beta-induced protein (TGFBIp) and extracellular matrix (ECM) genes plays a major role in the development of granular corneal dystrophy type 2 (GCD2: also called Avellino corneal dystrophy).
p15049
sg4
(lp15050
(dp15051
g9
I0
sg20
VP01137
p15052
sg12
I8
sg13
VTGFBeta1
p15053
sg15
I1
sa(dp15054
g9
I31
sg20
VP18075
p15055
sg12
I31
sg13
Vtransforming growth factor Beta
p15056
sg15
I4
sa(dp15057
g9
I92
sg20
g21
sg12
I32
sg13
Vextracellular matrix (ECM) genes
p15058
sg15
I4
sasg6
(lp15059
(dp15060
g9
I219
sg10
VC1275685
p15061
sg12
I26
sg13
VAvellino corneal dystrophy
p15062
sg15
I3
sa(dp15063
g9
I166
sg10
VC1275685
p15064
sg12
I33
sg13
Vgranular corneal dystrophy type 2
p15065
sg15
I5
sasa(dp15066
g2
VWe examined the role of chromatin markers such as histone H3 lysine methylation (H3Kme) in TGFBeta1-induced TGFBIp and ECM gene expression in normal and GCD2-derived human corneal fibroblasts.
p15067
sg4
(lp15068
(dp15069
g9
I91
sg20
VP01137
p15070
sg12
I8
sg13
VTGFBeta1
p15071
sg15
I1
sa(dp15072
g9
I119
sg20
g21
sg12
I8
sg13
VECM gene
p15073
sg15
I2
sa(dp15074
g9
I50
sg20
g21
sg12
I10
sg13
Vhistone H3
p15075
sg15
I2
sasg6
(lp15076
sa(dp15077
g2
VTranscription and extracellular-secretion levels of TGFBIp were high in normal cells compared with those in GCD2-derived cells and were related to H3K4me3 levels but not to DNA methylation over the TGFBI locus.
p15078
sg4
(lp15079
sg6
(lp15080
sa(dp15081
g2
VThis study expands on our previous research investigating dystrophic stromal aggregates, with the aim of better elucidating the pathomechanism of two conditions arising from the most common TGFBI mutations: granular corneal dystrophy type 1 (GCD1; R555W) and lattice corneal dystrophy type 1 (LCD1; R124C).
p15082
sg4
(lp15083
sg6
(lp15084
(dp15085
g9
I259
sg10
VC2931650
p15086
sg12
I32
sg13
Vlattice corneal dystrophy type 1
p15087
sg15
I5
sa(dp15088
g9
I207
sg10
VC1641846
p15089
sg12
I33
sg13
Vgranular corneal dystrophy type 1
p15090
sg15
I5
sa(dp15091
g9
I293
sg10
VC1690006
p15092
sg12
I4
sg13
VLCD1
p15093
sg15
I1
sa(dp15094
g9
I242
sg10
VC1641846
p15095
sg12
I4
sg13
VGCD1
p15096
sg15
I1
sasa(dp15097
g2
VPatient corneas with GCD1 and LCD1 were stained with hematoxylin and eosin and Congo red to visualize stromal nonamyloid and amyloid deposits, respectively.
p15098
sg4
(lp15099
sg6
(lp15100
(dp15101
g9
I30
sg10
VC1690006
p15102
sg12
I4
sg13
VLCD1
p15103
sg15
I1
sa(dp15104
g9
I21
sg10
VC1641846
p15105
sg12
I4
sg13
VGCD1
p15106
sg15
I1
sa(dp15107
g9
I125
sg10
VC2936349
p15108
sg12
I16
sg13
Vamyloid deposits
p15109
sg15
I2
sasa(dp15110
g2
VAn increase in the number of residues experiencing cleavage was observed in both GCD1 aggregates and LCD1 deposits.
p15111
sg4
(lp15112
sg6
(lp15113
(dp15114
g9
I81
sg10
VC1641846
p15115
sg12
I4
sg13
VGCD1
p15116
sg15
I1
sa(dp15117
g9
I101
sg10
VC1690006
p15118
sg12
I4
sg13
VLCD1
p15119
sg15
I1
sasa(dp15120
g2
VThe study reveals previously unknown differences between the protein composition of GCD1 and LCD1 aggregates, and confirms the presence of the HtrA1 protease in LCD1-amyloid aggregates.
p15121
sg4
(lp15122
(dp15123
g9
I143
sg20
g21
sg12
I14
sg13
VHtrA1 protease
p15124
sg15
I2
sasg6
(lp15125
(dp15126
g9
I93
sg10
VC1690006
p15127
sg12
I4
sg13
VLCD1
p15128
sg15
I1
sa(dp15129
g9
I93
sg10
VC1690006
p15130
sg12
I4
sg13
VLCD1
p15131
sg15
I1
sa(dp15132
g9
I166
sg10
VC0011560
p15133
sg12
I7
sg13
Vamyloid
p15134
sg15
I1
sa(dp15135
g9
I84
sg10
VC1641846
p15136
sg12
I4
sg13
VGCD1
p15137
sg15
I1
sasa(dp15138
g2
VGCD is a Category 1, Stromal, TGFBI-associated corneal dystrophy.
p15139
sg4
(lp15140
sg6
(lp15141
(dp15142
g9
I47
sg10
VC0010036
p15143
sg12
I17
sg13
Vcorneal dystrophy
p15144
sg15
I2
sasa(dp15145
g2
VWe show here that the Arg555Trp mutant of the fourth fasciclin 1 (FAS1-4) domain of the protein (TGFBIp/keratoepithelin/Betaig-h3), associated with granular corneal dystrophy type 1, is significantly less susceptible to proteolysis by thermolysin and trypsin than the WT domain.
p15146
sg4
(lp15147
(dp15148
g9
I66
sg20
g21
sg12
I6
sg13
VFAS1-4
p15149
sg15
I1
sa(dp15150
g9
I251
sg20
VP35030
p15151
sg12
I7
sg13
Vtrypsin
p15152
sg15
I1
sa(dp15153
g9
I22
sg20
g21
sg12
I16
sg13
VArg555Trp mutant
p15154
sg15
I2
sasg6
(lp15155
(dp15156
g9
I32
sg10
VC0596988
p15157
sg12
I6
sg13
Vmutant
p15158
sg15
I1
sa(dp15159
g9
I148
sg10
VC0018179
p15160
sg12
I26
sg13
Vgranular corneal dystrophy
p15161
sg15
I3
sasa(dp15162
g2
VMiR-139-5p has been reported to be overexpressed in many types of cancers, but its role in bladder cancer has not been elucidated yet.
p15163
sg4
(lp15164
(dp15165
g9
I0
sg20
g21
sg12
I10
sg13
VMiR-139-5p
p15166
sg15
I1
sasg6
(lp15167
(dp15168
g9
I91
sg10
VC0699885
p15169
sg12
I14
sg13
Vbladder cancer
p15170
sg15
I2
sa(dp15171
g9
I66
sg10
VC0006826
p15172
sg12
I7
sg13
Vcancers
p15173
sg15
I1
sasa(dp15174
g2
VHere, we report that miR-139-5p functions as a tumor suppressor in bladder cancer and inhibits the cancer stem cell self-renewal by targeting Bmi1 directly.
p15175
sg4
(lp15176
(dp15177
g9
I21
sg20
g21
sg12
I10
sg13
VmiR-139-5p
p15178
sg15
I1
sa(dp15179
g9
I142
sg20
VP35226
p15180
sg12
I4
sg13
VBmi1
p15181
sg15
I1
sasg6
(lp15182
(dp15183
g9
I47
sg10
VC0027651
p15184
sg12
I5
sg13
Vtumor
p15185
sg15
I1
sa(dp15186
g9
I67
sg10
VC0699885
p15187
sg12
I14
sg13
Vbladder cancer
p15188
sg15
I2
sa(dp15189
g9
I75
sg10
VC0006826
p15190
sg12
I6
sg13
Vcancer
p15191
sg15
I1
sasa(dp15192
g2
VWe found that miR-139-5p expression was significantly downregulated in the bladder cancer specimens compared with that in adjacent normal tissues.
p15193
sg4
(lp15194
(dp15195
g9
I14
sg20
g21
sg12
I10
sg13
VmiR-139-5p
p15196
sg15
I1
sasg6
(lp15197
(dp15198
g9
I75
sg10
VC0699885
p15199
sg12
I14
sg13
Vbladder cancer
p15200
sg15
I2
sasa(dp15201
g2
VIn vitro, restoration of miR-139-5p expression significantly inhibited the proliferation of bladder cancer cells.
p15202
sg4
(lp15203
(dp15204
g9
I25
sg20
g21
sg12
I10
sg13
VmiR-139-5p
p15205
sg15
I1
sasg6
(lp15206
(dp15207
g9
I75
sg10
VC0334094
p15208
sg12
I13
sg13
Vproliferation
p15209
sg15
I1
sa(dp15210
g9
I92
sg10
VC0699885
p15211
sg12
I14
sg13
Vbladder cancer
p15212
sg15
I2
sasa(dp15213
g2
VStem cell-related proteins such as c-MYC, NANOG, OCT4, and KLF4 and signaling pathways such as Wnt signaling were suppressed by restoration of miR-139-5p in bladder cancer cells.
p15214
sg4
(lp15215
(dp15216
g9
I143
sg20
g21
sg12
I10
sg13
VmiR-139-5p
p15217
sg15
I1
sa(dp15218
g9
I42
sg20
g21
sg12
I5
sg13
VNANOG
p15219
sg15
I1
sa(dp15220
g9
I35
sg20
VP12524
p15221
sg12
I5
sg13
Vc-MYC
p15222
sg15
I1
sa(dp15223
g9
I59
sg20
g21
sg12
I4
sg13
VKLF4
p15224
sg15
I1
sa(dp15225
g9
I0
sg20
VP02649
p15226
sg12
I26
sg13
VStem cell-related proteins
p15227
sg15
I3
sasg6
(lp15228
(dp15229
g9
I157
sg10
VC0699885
p15230
sg12
I14
sg13
Vbladder cancer
p15231
sg15
I2
sasa(dp15232
g2
VIn addition, miR-139-5p expression also blocked self-renewal of bladder cancer stem cells by inhibiting Bmi1.
p15233
sg4
(lp15234
(dp15235
g9
I104
sg20
VP35226
p15236
sg12
I4
sg13
VBmi1
p15237
sg15
I1
sa(dp15238
g9
I13
sg20
g21
sg12
I10
sg13
VmiR-139-5p
p15239
sg15
I1
sasg6
(lp15240
(dp15241
g9
I64
sg10
VC0699885
p15242
sg12
I14
sg13
Vbladder cancer
p15243
sg15
I2
sasa(dp15244
g2
VIn summary, our study supports that miR-139-5p acts as a tumor suppressor in bladder cancer development and suppresses cancer stem cell property of bladder cancer.
p15245
sg4
(lp15246
(dp15247
g9
I36
sg20
g21
sg12
I10
sg13
VmiR-139-5p
p15248
sg15
I1
sasg6
(lp15249
(dp15250
g9
I77
sg10
VC0699885
p15251
sg12
I14
sg13
Vbladder cancer
p15252
sg15
I2
sa(dp15253
g9
I57
sg10
VC0027651
p15254
sg12
I5
sg13
Vtumor
p15255
sg15
I1
sa(dp15256
g9
I77
sg10
VC0699885
p15257
sg12
I14
sg13
Vbladder cancer
p15258
sg15
I2
sa(dp15259
g9
I85
sg10
VC0006826
p15260
sg12
I6
sg13
Vcancer
p15261
sg15
I1
sasa(dp15262
g2
VOur study also suggests that miR-139-5p has the potential to be used as a therapeutic molecule for bladder cancer treatment.
p15263
sg4
(lp15264
(dp15265
g9
I29
sg20
g21
sg12
I10
sg13
VmiR-139-5p
p15266
sg15
I1
sasg6
(lp15267
(dp15268
g9
I99
sg10
VC0699885
p15269
sg12
I14
sg13
Vbladder cancer
p15270
sg15
I2
sasa(dp15271
g2
VWe present a case with CblC disease and pulmonary arterial hypertension (PAH) as the main symptom.
p15272
sg4
(lp15273
(dp15274
g9
I23
sg20
g21
sg12
I4
sg13
VCblC
p15275
sg15
I1
sasg6
(lp15276
(dp15277
g9
I40
sg10
VC0152171
p15278
sg12
I31
sg13
Vpulmonary arterial hypertension
p15279
sg15
I3
sa(dp15280
g9
I73
sg10
VC0152171
p15281
sg12
I3
sg13
VPAH
p15282
sg15
I1
sa(dp15283
g9
I90
sg10
VC1457887
p15284
sg12
I7
sg13
Vsymptom
p15285
sg15
I1
sasa(dp15286
g2
VCblC disease should be considered in the differential diagnosis of pulmonary hypertension.
p15287
sg4
(lp15288
(dp15289
g9
I0
sg20
g21
sg12
I4
sg13
VCblC
p15290
sg15
I1
sasg6
(lp15291
(dp15292
g9
I67
sg10
VC0020542
p15293
sg12
I22
sg13
Vpulmonary hypertension
p15294
sg15
I2
sasa(dp15295
g2
VGenetic association of rs678849 along with neuroimaging and biomarker phenotypes, parallel with the known involvements of the OPRD1 in drug abuse, provided additional support for targeting these receptors as potential therapeutic targets in both neurodegenerative diseases and neuropsychiactric disorders such as Alzheimer's disease.
p15296
sg4
(lp15297
(dp15298
g9
I126
sg20
VP41143
p15299
sg12
I5
sg13
VOPRD1
p15300
sg15
I1
sasg6
(lp15301
(dp15302
g9
I313
sg10
VC1521724
p15303
sg12
I19
sg13
VAlzheimer's disease
p15304
sg15
I2
sa(dp15305
g9
I246
sg10
VC0524851
p15306
sg12
I26
sg13
Vneurodegenerative diseases
p15307
sg15
I2
sa(dp15308
g9
I135
sg10
VC0013146
p15309
sg12
I10
sg13
Vdrug abuse
p15310
sg15
I2
sasa(dp15311
g2
VRecently, a robust up-regulation of human natural killer-1 sulfotransferase (HNK-1ST) was found in several subsets of melanoma cells during RA-mediated differentiation.
p15312
sg4
(lp15313
(dp15314
g9
I36
sg20
g21
sg12
I39
sg13
Vhuman natural killer-1 sulfotransferase
p15315
sg15
I4
sa(dp15316
g9
I77
sg20
g21
sg12
I7
sg13
VHNK-1ST
p15317
sg15
I1
sasg6
(lp15318
(dp15319
g9
I118
sg10
VC0025202
p15320
sg12
I8
sg13
Vmelanoma
p15321
sg15
I1
sasa(dp15322
g2
VHere, we show that HNK-1ST changed the glycosylation state and reduced the ligand binding activity of Alfa-dystroglycan (Alfa-DG) in RA-treated S91 melanoma cells, which contributed to an attenuation of cell migration.
p15323
sg4
(lp15324
(dp15325
g9
I121
sg20
g21
sg12
I7
sg13
VAlfa-DG
p15326
sg15
I1
sa(dp15327
g9
I102
sg20
g21
sg12
I17
sg13
VAlfa-dystroglycan
p15328
sg15
I1
sa(dp15329
g9
I19
sg20
g21
sg12
I7
sg13
VHNK-1ST
p15330
sg15
I1
sasg6
(lp15331
(dp15332
g9
I148
sg10
VC0025202
p15333
sg12
I8
sg13
Vmelanoma
p15334
sg15
I1
sasa(dp15335
g2
VTen genes of importance for HNK-1 biosynthesis (B3GAT1, B3GAT2, and CHST10) or for the formation of perineuronal nets (TNR, BCAN, NCAN, HAPLN1, HAPLN2, HAPLN3, and HAPLN4) were investigated for potential involvement in schizophrenia (SCZ) susceptibility, by genotyping 104 tagSNPs in the Scandinavian Collaboration on Psychiatric Etiology sample (849 cases; 1602 control subjects).
p15336
sg4
(lp15337
(dp15338
g9
I144
sg20
g21
sg12
I6
sg13
VHAPLN2
p15339
sg15
I1
sa(dp15340
g9
I28
sg20
g21
sg12
I5
sg13
VHNK-1
p15341
sg15
I1
sa(dp15342
g9
I119
sg20
g21
sg12
I3
sg13
VTNR
p15343
sg15
I1
sa(dp15344
g9
I83
sg20
g21
sg12
I34
sg13
Vthe formation of perineuronal nets
p15345
sg15
I5
sa(dp15346
g9
I130
sg20
g21
sg12
I4
sg13
VNCAN
p15347
sg15
I1
sa(dp15348
g9
I136
sg20
VP10915
p15349
sg12
I6
sg13
VHAPLN1
p15350
sg15
I1
sa(dp15351
g9
I124
sg20
g21
sg12
I4
sg13
VBCAN
p15352
sg15
I1
sa(dp15353
g9
I152
sg20
g21
sg12
I6
sg13
VHAPLN3
p15354
sg15
I1
sa(dp15355
g9
I48
sg20
g21
sg12
I6
sg13
VB3GAT1
p15356
sg15
I1
sa(dp15357
g9
I68
sg20
g21
sg12
I6
sg13
VCHST10
p15358
sg15
I1
sa(dp15359
g9
I56
sg20
g21
sg12
I6
sg13
VB3GAT2
p15360
sg15
I1
sa(dp15361
g9
I164
sg20
g21
sg12
I6
sg13
VHAPLN4
p15362
sg15
I1
sasg6
(lp15363
(dp15364
g9
I234
sg10
VC0036341
p15365
sg12
I3
sg13
VSCZ
p15366
sg15
I1
sa(dp15367
g9
I219
sg10
VC0036341
p15368
sg12
I13
sg13
Vschizophrenia
p15369
sg15
I1
sasa(dp15370
g2
VWe show that CHST10 is also regulated by RARgamma in a significant subset of human melanoma cells, and three-dimensional cell culture migration assays suggest that CHST10 functions as a suppressor of invasiveness, but not proliferation, in these cells.
p15371
sg4
(lp15372
(dp15373
g9
I41
sg20
VP13631
p15374
sg12
I8
sg13
VRARgamma
p15375
sg15
I1
sa(dp15376
g9
I13
sg20
g21
sg12
I6
sg13
VCHST10
p15377
sg15
I1
sa(dp15378
g9
I13
sg20
g21
sg12
I6
sg13
VCHST10
p15379
sg15
I1
sasg6
(lp15380
(dp15381
g9
I83
sg10
VC0025202
p15382
sg12
I8
sg13
Vmelanoma
p15383
sg15
I1
sa(dp15384
g9
I222
sg10
VC0334094
p15385
sg12
I13
sg13
Vproliferation
p15386
sg15
I1
sasa(dp15387
g2
VInduction of CHST10 by RARgamma-activating retinoids may present a novel therapeutic strategy to inhibit invasiveness in a subset of melanoma patients.
p15388
sg4
(lp15389
(dp15390
g9
I23
sg20
VP13631
p15391
sg12
I8
sg13
VRARgamma
p15392
sg15
I1
sa(dp15393
g9
I13
sg20
g21
sg12
I6
sg13
VCHST10
p15394
sg15
I1
sasg6
(lp15395
(dp15396
g9
I133
sg10
VC0025202
p15397
sg12
I8
sg13
Vmelanoma
p15398
sg15
I1
sasa(dp15399
g2
VNo disease-associated mutations were detected in the candidate genes SEMA4C, CNGA3 or HNK1ST from within the region.
p15400
sg4
(lp15401
(dp15402
g9
I77
sg20
g21
sg12
I5
sg13
VCNGA3
p15403
sg15
I1
sa(dp15404
g9
I86
sg20
g21
sg12
I6
sg13
VHNK1ST
p15405
sg15
I1
sa(dp15406
g9
I69
sg20
g21
sg12
I6
sg13
VSEMA4C
p15407
sg15
I1
sasg6
(lp15408
sa(dp15409
g2
VMost XLMTM patients develop severe muscle weakness leading to respiratory failure and death, typically within 2 years of age.
p15410
sg4
(lp15411
sg6
(lp15412
(dp15413
g9
I35
sg10
VC0030552
p15414
sg12
I15
sg13
Vmuscle weakness
p15415
sg15
I2
sa(dp15416
g9
I62
sg10
VC1145670
p15417
sg12
I19
sg13
Vrespiratory failure
p15418
sg15
I2
sa(dp15419
g9
I5
sg10
VC0410203
p15420
sg12
I5
sg13
VXLMTM
p15421
sg15
I1
sasa(dp15422
g2
VMutations in the MTM1 gene cause X-linked myotubular myopathy (XLMTM), characterized by neonatal hypotonia and respiratory failure, and are responsible for a premature mortality in affected males.
p15423
sg4
(lp15424
(dp15425
g9
I17
sg20
g21
sg12
I9
sg13
VMTM1 gene
p15426
sg15
I2
sasg6
(lp15427
(dp15428
g9
I17
sg10
VC0410203
p15429
sg12
I4
sg13
VMTM1
p15430
sg15
I1
sa(dp15431
g9
I33
sg10
VC0410203
p15432
sg12
I28
sg13
VX-linked myotubular myopathy
p15433
sg15
I3
sa(dp15434
g9
I88
sg10
VC0270971
p15435
sg12
I18
sg13
Vneonatal hypotonia
p15436
sg15
I2
sa(dp15437
g9
I63
sg10
VC0410203
p15438
sg12
I5
sg13
VXLMTM
p15439
sg15
I1
sa(dp15440
g9
I111
sg10
VC1145670
p15441
sg12
I19
sg13
Vrespiratory failure
p15442
sg15
I2
sasa(dp15443
g2
VX-linked myotubular myopathy (XLMTM) is a congenital neuromuscular disorder defined by severe hypotonia, respiratory failure and histopathologic changes in muscle biopsy.
p15444
sg4
(lp15445
sg6
(lp15446
(dp15447
g9
I0
sg10
VC0410203
p15448
sg12
I28
sg13
VX-linked myotubular myopathy
p15449
sg15
I3
sa(dp15450
g9
I105
sg10
VC1145670
p15451
sg12
I19
sg13
Vrespiratory failure
p15452
sg15
I2
sa(dp15453
g9
I30
sg10
VC0410203
p15454
sg12
I5
sg13
VXLMTM
p15455
sg15
I1
sa(dp15456
g9
I94
sg10
VC0026827
p15457
sg12
I9
sg13
Vhypotonia
p15458
sg15
I1
sa(dp15459
g9
I42
sg10
VC0596371
p15460
sg12
I33
sg13
Vcongenital neuromuscular disorder
p15461
sg15
I3
sasa(dp15462
g2
VCentronuclear (myotubular) myopathy (CNM) is congenital and produces various degrees of muscular weakness and associated complications such as respiratory failure.
p15463
sg4
(lp15464
sg6
(lp15465
(dp15466
g9
I27
sg10
VC0026848
p15467
sg12
I8
sg13
Vmyopathy
p15468
sg15
I1
sa(dp15469
g9
I143
sg10
VC1145670
p15470
sg12
I19
sg13
Vrespiratory failure
p15471
sg15
I2
sa(dp15472
g9
I88
sg10
VC0151786
p15473
sg12
I17
sg13
Vmuscular weakness
p15474
sg15
I2
sasa(dp15475
g2
VPatients with XLMTM often have severe perinatal weakness that requires mechanical ventilation to prevent death from respiratory failure.
p15476
sg4
(lp15477
sg6
(lp15478
(dp15479
g9
I48
sg10
VC1883552
p15480
sg12
I8
sg13
Vweakness
p15481
sg15
I1
sa(dp15482
g9
I116
sg10
VC1145670
p15483
sg12
I19
sg13
Vrespiratory failure
p15484
sg15
I2
sa(dp15485
g9
I14
sg10
VC0410203
p15486
sg12
I5
sg13
VXLMTM
p15487
sg15
I1
sasa(dp15488
g2
VThis review addresses hearing loss as it occurs and has been reported in Muenke syndrome as well as six additional FGFR related craniosynostosis syndromes (Apert syndrome, Pfeiffer syndrome, Crouzon syndrome, Beare-Stevenson syndrome, Crouzon syndrome with acanthosis nigricans, and Jackson-Weiss syndrome.
p15489
sg4
(lp15490
sg6
(lp15491
(dp15492
g9
I235
sg10
VC2677099
p15493
sg12
I42
sg13
VCrouzon syndrome with acanthosis nigricans
p15494
sg15
I5
sa(dp15495
g9
I22
sg10
VC0011053
p15496
sg12
I12
sg13
Vhearing loss
p15497
sg15
I2
sa(dp15498
g9
I162
sg10
VC0220658
p15499
sg12
I18
sg13
Vsyndrome, Pfeiffer
p15500
sg15
I2
sa(dp15501
g9
I128
sg10
VC0010278
p15502
sg12
I26
sg13
Vcraniosynostosis syndromes
p15503
sg15
I2
sa(dp15504
g9
I181
sg10
VC2931196
p15505
sg12
I17
sg13
Vsyndrome, Crouzon
p15506
sg15
I2
sa(dp15507
g9
I283
sg10
VC0795998
p15508
sg12
I22
sg13
VJackson-Weiss syndrome
p15509
sg15
I2
sa(dp15510
g9
I209
sg10
VC1852406
p15511
sg12
I24
sg13
VBeare-Stevenson syndrome
p15512
sg15
I2
sa(dp15513
g9
I73
sg10
VC1864436
p15514
sg12
I15
sg13
VMuenke syndrome
p15515
sg15
I2
sa(dp15516
g9
I80
sg10
VC0039082
p15517
sg12
I8
sg13
Vsyndrome
p15518
sg15
I1
sa(dp15519
g9
I181
sg10
VC2931196
p15520
sg12
I17
sg13
Vsyndrome, Crouzon
p15521
sg15
I2
sasa(dp15522
g2
VOur literature review revealed the following incidences of hearing loss in FGFR craniosynostoses: 61% in Muenke syndrome, 80% in Apert Syndrome, 92% in Pfeiffer syndrome, 74% in Crouzon syndrome, 68% in Jackson Weiss syndrome, 4% in Beare Stevenson syndrome and 14% in Crouzon syndrome with Acanthosis Nigricans.
p15523
sg4
(lp15524
sg6
(lp15525
(dp15526
g9
I112
sg10
VC0039082
p15527
sg12
I8
sg13
Vsyndrome
p15528
sg15
I1
sa(dp15529
g9
I59
sg10
VC0011053
p15530
sg12
I12
sg13
Vhearing loss
p15531
sg15
I2
sa(dp15532
g9
I80
sg10
VC0010278
p15533
sg12
I16
sg13
Vcraniosynostoses
p15534
sg15
I1
sa(dp15535
g9
I203
sg10
VC0795998
p15536
sg12
I22
sg13
VJackson Weiss syndrome
p15537
sg15
I3
sa(dp15538
g9
I269
sg10
VC2677099
p15539
sg12
I42
sg13
VCrouzon syndrome with Acanthosis Nigricans
p15540
sg15
I5
sa(dp15541
g9
I105
sg10
VC1864436
p15542
sg12
I15
sg13
VMuenke syndrome
p15543
sg15
I2
sa(dp15544
g9
I178
sg10
VC0010273
p15545
sg12
I16
sg13
VCrouzon syndrome
p15546
sg15
I2
sa(dp15547
g9
I152
sg10
VC0265303
p15548
sg12
I17
sg13
VPfeiffer syndrome
p15549
sg15
I2
sa(dp15550
g9
I129
sg10
VC0001193
p15551
sg12
I14
sg13
VApert Syndrome
p15552
sg15
I2
sasa(dp15553
g2
VThis study reveals the pleiotropic effects of the FGFR2 Y394C mutation evidenced by cutis gyrata, acanthosis nigricans, and craniosynostosis and provides a useful model for investigating the molecular mechanisms of skin and skull development.
p15554
sg4
(lp15555
sg6
(lp15556
(dp15557
g9
I98
sg10
VC0000889
p15558
sg12
I20
sg13
Vacanthosis nigricans
p15559
sg15
I2
sa(dp15560
g9
I124
sg10
VC0010278
p15561
sg12
I16
sg13
Vcraniosynostosis
p15562
sg15
I1
sasa(dp15563
g2
VSome cases of congenital skeletal disorders with an FGFR2 mutation show skin phenotypes, including acne, cutis gyrata, and acanthosis nigricans.
p15564
sg4
(lp15565
sg6
(lp15566
(dp15567
g9
I99
sg10
VC0001144
p15568
sg12
I4
sg13
Vacne
p15569
sg15
I1
sa(dp15570
g9
I123
sg10
VC0000889
p15571
sg12
I20
sg13
Vacanthosis nigricans
p15572
sg15
I2
sasa(dp15573
g2
VPeripheral nerve and spinal cord injuries, along with other painful syndromes such as fibromyalgia, diabetic neuropathy, chemotherapeutic neuropathy, trigeminal neuralgia, complex regional pain syndrome, and/or irritable bowel syndrome, cause several neuroplasticity changes in the nervous system along its entire axis affecting the different neuronal nuclei.
p15574
sg4
(lp15575
sg6
(lp15576
(dp15577
g9
I282
sg10
VC0027769
p15578
sg12
I7
sg13
Vnervous
p15579
sg15
I1
sa(dp15580
g9
I100
sg10
VC0011882
p15581
sg12
I19
sg13
Vdiabetic neuropathy
p15582
sg15
I2
sa(dp15583
g9
I60
sg10
VC0030193
p15584
sg12
I7
sg13
Vpainful
p15585
sg15
I1
sa(dp15586
g9
I86
sg10
VC0016053
p15587
sg12
I12
sg13
Vfibromyalgia
p15588
sg15
I1
sa(dp15589
g9
I172
sg10
VC0458219
p15590
sg12
I30
sg13
Vcomplex regional pain syndrome
p15591
sg15
I4
sa(dp15592
g9
I161
sg10
VC0027796
p15593
sg12
I9
sg13
Vneuralgia
p15594
sg15
I1
sa(dp15595
g9
I211
sg10
VC0022104
p15596
sg12
I24
sg13
Virritable bowel syndrome
p15597
sg15
I3
sa(dp15598
g9
I138
sg10
VC0152177
p15599
sg12
I22
sg13
Vneuropathy, trigeminal
p15600
sg15
I2
sa(dp15601
g9
I68
sg10
VC0039082
p15602
sg12
I9
sg13
Vsyndromes
p15603
sg15
I1
sa(dp15604
g9
I28
sg10
VC0035334
p15605
sg12
I4
sg13
Vcord
p15606
sg15
I1
sasa(dp15607
g2
VSortilin-related receptor with LDLR class A repeats (SORLA, SORL1, or LR11) is a genetic risk factor associated with Alzheimer's disease (AD).
p15608
sg4
(lp15609
(dp15610
g9
I0
sg20
g21
sg12
I51
sg13
VSortilin-related receptor with LDLR class A repeats
p15611
sg15
I7
sa(dp15612
g9
I60
sg20
g21
sg12
I5
sg13
VSORL1
p15613
sg15
I1
sa(dp15614
g9
I53
sg20
g21
sg12
I5
sg13
VSORLA
p15615
sg15
I1
sasg6
(lp15616
(dp15617
g9
I138
sg10
VC1521724
p15618
sg12
I2
sg13
VAD
p15619
sg15
I1
sa(dp15620
g9
I117
sg10
VC1521724
p15621
sg12
I19
sg13
VAlzheimer's disease
p15622
sg15
I2
sasa(dp15623
g2
VA meta-analysis was performed to identify empirical data assessing the effects of a single nucleotide polymorphisms of sortilin-related receptor on Alzheimer's disease based on 14 studies involving 37941 cases and 49727 control studies.
p15624
sg4
(lp15625
(dp15626
g9
I119
sg20
g21
sg12
I25
sg13
Vsortilin-related receptor
p15627
sg15
I2
sasg6
(lp15628
(dp15629
g9
I148
sg10
VC1521724
p15630
sg12
I19
sg13
VAlzheimer's disease
p15631
sg15
I2
sasa(dp15632
g2
VGiven these data, we provide crucial evidence to manifest that a significant relationship exists between SORL1 polymorphisms and the susceptibility of Alzheimer's disease.
p15633
sg4
(lp15634
(dp15635
g9
I105
sg20
g21
sg12
I5
sg13
VSORL1
p15636
sg15
I1
sasg6
(lp15637
(dp15638
g9
I151
sg10
VC1521724
p15639
sg12
I19
sg13
VAlzheimer's disease
p15640
sg15
I2
sasa(dp15641
g2
VFurthermore, a third SORL1 variant, c.5195G &gt; C, recently identified in a Swedish case control cohort included in the European Early-Onset Dementia (EU EOD) consortium study, was detected in two affected siblings in a third family with familial EOAD.
p15642
sg4
(lp15643
(dp15644
g9
I21
sg20
g21
sg12
I13
sg13
VSORL1 variant
p15645
sg15
I2
sasg6
(lp15646
(dp15647
g9
I142
sg10
VC0497327
p15648
sg12
I8
sg13
VDementia
p15649
sg15
I1
sasa(dp15650
g2
VThrombospondin-1 (TSP1) is a ligand for CD47 and TSP1-/- mice are protected from pulmonary hypertension (PH).
p15651
sg4
(lp15652
(dp15653
g9
I18
sg20
VP07996
p15654
sg12
I4
sg13
VTSP1
p15655
sg15
I1
sa(dp15656
g9
I18
sg20
VP07996
p15657
sg12
I4
sg13
VTSP1
p15658
sg15
I1
sa(dp15659
g9
I0
sg20
VP07996
p15660
sg12
I16
sg13
VThrombospondin-1
p15661
sg15
I1
sa(dp15662
g9
I40
sg20
g21
sg12
I4
sg13
VCD47
p15663
sg15
I1
sasg6
(lp15664
(dp15665
g9
I105
sg10
VC0020542
p15666
sg12
I2
sg13
VPH
p15667
sg15
I1
sa(dp15668
g9
I81
sg10
VC0020542
p15669
sg12
I22
sg13
Vpulmonary hypertension
p15670
sg15
I2
sasa(dp15671
g2
VWe further discuss therapeutic strategies for enhancing or inhibiting CD47 signaling and applications of such agents in preclinical models of ischemia and ischemia/reperfusion injuries, organ transplantation, pulmonary hypertension, radioprotection, and cancer.
p15672
sg4
(lp15673
(dp15674
g9
I70
sg20
g21
sg12
I4
sg13
VCD47
p15675
sg15
I1
sasg6
(lp15676
(dp15677
g9
I142
sg10
VC0022116
p15678
sg12
I8
sg13
Vischemia
p15679
sg15
I1
sa(dp15680
g9
I254
sg10
VC0006826
p15681
sg12
I6
sg13
Vcancer
p15682
sg15
I1
sa(dp15683
g9
I209
sg10
VC0020542
p15684
sg12
I22
sg13
Vpulmonary hypertension
p15685
sg15
I2
sa(dp15686
g9
I142
sg10
VC0022116
p15687
sg12
I8
sg13
Vischemia
p15688
sg15
I1
sasa(dp15689
g2
VIn present study, anticancer activity of ethanol extract of Chinese propolis (EECP) at 25, 50, 100, and 200  my g/mL was explored by testing the cytotoxicity in MCF-7 (human breast cancer ER(+)) and MDA-MB-231 (human breast cancer ER(-)) cells.
p15690
sg4
(lp15691
sg6
(lp15692
(dp15693
g9
I145
sg10
VC0596402
p15694
sg12
I12
sg13
Vcytotoxicity
p15695
sg15
I1
sa(dp15696
g9
I174
sg10
VC0678222
p15697
sg12
I13
sg13
Vbreast cancer
p15698
sg15
I2
sa(dp15699
g9
I174
sg10
VC0678222
p15700
sg12
I13
sg13
Vbreast cancer
p15701
sg15
I2
sasa(dp15702
g2
VWe exposed human pancreatic cancer cell line MiaPaCa-2 (CRL-1420) to 34  my g/mL of LE for 24, 48, and 72 hours.
p15703
sg4
(lp15704
sg6
(lp15705
(dp15706
g9
I17
sg10
VC0235974
p15707
sg12
I17
sg13
Vpancreatic cancer
p15708
sg15
I2
sasa(dp15709
g2
VIn addition, variations in JAG1 have been found to be associated with multiple types of cancer including breast cancer and adrenocortical carcinoma.
p15710
sg4
(lp15711
(dp15712
g9
I27
sg20
VP78504
p15713
sg12
I4
sg13
VJAG1
p15714
sg15
I1
sasg6
(lp15715
(dp15716
g9
I105
sg10
VC0678222
p15717
sg12
I13
sg13
Vbreast cancer
p15718
sg15
I2
sa(dp15719
g9
I88
sg10
VC0006826
p15720
sg12
I6
sg13
Vcancer
p15721
sg15
I1
sa(dp15722
g9
I123
sg10
VC0206686
p15723
sg12
I24
sg13
Vadrenocortical carcinoma
p15724
sg15
I2
sasa(dp15725
g2
VThe role of the extract in pancreatic cancer treatment was associated with down-regulation of Notch-4 and Jagged-1 in Notch signaling pathway.
p15726
sg4
(lp15727
sg6
(lp15728
(dp15729
g9
I27
sg10
VC0235974
p15730
sg12
I17
sg13
Vpancreatic cancer
p15731
sg15
I2
sasa(dp15732
g2
VThe patient was a 64-year-old man with situs inversus totalis who had previously undergone sigmoidectomy with regional lymphadenectomy for sigmoid colon cancer at age 62.
p15733
sg4
(lp15734
sg6
(lp15735
(dp15736
g9
I39
sg10
VC0037221
p15737
sg12
I14
sg13
Vsitus inversus
p15738
sg15
I2
sa(dp15739
g9
I139
sg10
VC0751498
p15740
sg12
I20
sg13
Vsigmoid colon cancer
p15741
sg15
I3
sasa(dp15742
g2
VFor the treatment of hepatic metastases from sigmoid colon cancer in a patient with situs inversus totalis, "left" hepatic lobectomy, partial hepatectomy, and radiofrequency ablation therapy were performed.
p15743
sg4
(lp15744
sg6
(lp15745
(dp15746
g9
I21
sg10
VC0494165
p15747
sg12
I18
sg13
Vhepatic metastases
p15748
sg15
I2
sa(dp15749
g9
I45
sg10
VC0751498
p15750
sg12
I20
sg13
Vsigmoid colon cancer
p15751
sg15
I3
sa(dp15752
g9
I84
sg10
VC0037221
p15753
sg12
I14
sg13
Vsitus inversus
p15754
sg15
I2
sasa(dp15755
g2
VOn day 25, pulmonary eosinophilia, airway hyperresponsiveness, mucus hypersecretion, inflammatory cytokines such as IL-4, -5 and -13 in BAL fluid, gene expression of inflammatory mediators such as 5-LOX, E-selectin, VCAM-1, CCL5, TNF-Alfa, AMCase, Ym2, YKL-40, Muc5ac, CCL2 and iNOS in animal lung tissues, and serum IgE were determined.
p15756
sg4
(lp15757
(dp15758
g9
I278
sg20
g21
sg12
I4
sg13
ViNOS
p15759
sg15
I1
sa(dp15760
g9
I269
sg20
VP13500
p15761
sg12
I4
sg13
VCCL2
p15762
sg15
I1
sa(dp15763
g9
I224
sg20
VP13501
p15764
sg12
I4
sg13
VCCL5
p15765
sg15
I1
sa(dp15766
g9
I311
sg20
VP01854
p15767
sg12
I9
sg13
Vserum IgE
p15768
sg15
I2
sa(dp15769
g9
I204
sg20
VP16581
p15770
sg12
I10
sg13
VE-selectin
p15771
sg15
I1
sa(dp15772
g9
I230
sg20
VP01375
p15773
sg12
I8
sg13
VTNF-Alfa
p15774
sg15
I1
sa(dp15775
g9
I197
sg20
VP09917
p15776
sg12
I5
sg13
V5-LOX
p15777
sg15
I1
sa(dp15778
g9
I116
sg20
VP05112
p15779
sg12
I4
sg13
VIL-4
p15780
sg15
I1
sa(dp15781
g9
I216
sg20
VP19320
p15782
sg12
I6
sg13
VVCAM-1
p15783
sg15
I1
sa(dp15784
g9
I253
sg20
VP36222
p15785
sg12
I6
sg13
VYKL-40
p15786
sg15
I1
sasg6
(lp15787
(dp15788
g9
I317
sg10
VC0270850
p15789
sg12
I3
sg13
VIgE
p15790
sg15
I1
sa(dp15791
g9
I11
sg10
VC0034068
p15792
sg12
I22
sg13
Vpulmonary eosinophilia
p15793
sg15
I2
sasa(dp15794
g2
VOur results show that tropical pulmonary eosinophilia mice exhibited increased levels of IL-4, IL-5, CCL5, and CCL11 in the bronchoalveolar lavage fluid and lung parenchyma along with elevated titers of IgE and IgG subtypes in the serum.
p15795
sg4
(lp15796
(dp15797
g9
I95
sg20
VP05113
p15798
sg12
I4
sg13
VIL-5
p15799
sg15
I1
sa(dp15800
g9
I203
sg20
VP01854
p15801
sg12
I3
sg13
VIgE
p15802
sg15
I1
sa(dp15803
g9
I111
sg20
VP51671
p15804
sg12
I5
sg13
VCCL11
p15805
sg15
I1
sa(dp15806
g9
I89
sg20
VP05112
p15807
sg12
I4
sg13
VIL-4
p15808
sg15
I1
sa(dp15809
g9
I101
sg20
VP13501
p15810
sg12
I4
sg13
VCCL5
p15811
sg15
I1
sasg6
(lp15812
(dp15813
g9
I203
sg10
VC0270850
p15814
sg12
I3
sg13
VIgE
p15815
sg15
I1
sa(dp15816
g9
I22
sg10
VC0014458
p15817
sg12
I31
sg13
Vtropical pulmonary eosinophilia
p15818
sg15
I3
sasa(dp15819
g2
VA(2B) R deficiency resulted in a dramatic reduction on Th2-type airways responses with decreased pulmonary eosinophilia without augmenting neutrophilia, and decreased lung IL-4, IL-5, and IL-13 production.
p15820
sg4
(lp15821
(dp15822
g9
I188
sg20
VP35225
p15823
sg12
I5
sg13
VIL-13
p15824
sg15
I1
sa(dp15825
g9
I167
sg20
VP05112
p15826
sg12
I9
sg13
Vlung IL-4
p15827
sg15
I2
sa(dp15828
g9
I178
sg20
VP05113
p15829
sg12
I4
sg13
VIL-5
p15830
sg15
I1
sasg6
(lp15831
(dp15832
g9
I97
sg10
VC0034068
p15833
sg12
I22
sg13
Vpulmonary eosinophilia
p15834
sg15
I2
sasa(dp15835
g2
VBoth isoforms caused pulmonary infiltration of lymphocytes and neutrophils, whereas mm IL-33 also caused pulmonary eosinophilia and goblet cell hyperplasia and increased expression of IL-4, IL-5, IL-13, IL-17, MCP-1, and KC.
p15836
sg4
(lp15837
(dp15838
g9
I190
sg20
VP05113
p15839
sg12
I4
sg13
VIL-5
p15840
sg15
I1
sa(dp15841
g9
I184
sg20
VP05112
p15842
sg12
I4
sg13
VIL-4
p15843
sg15
I1
sa(dp15844
g9
I210
sg20
VP41597
p15845
sg12
I5
sg13
VMCP-1
p15846
sg15
I1
sa(dp15847
g9
I196
sg20
VP35225
p15848
sg12
I5
sg13
VIL-13
p15849
sg15
I1
sasg6
(lp15850
(dp15851
g9
I21
sg10
VC0235896
p15852
sg12
I22
sg13
Vpulmonary infiltration
p15853
sg15
I2
sa(dp15854
g9
I144
sg10
VC0020507
p15855
sg12
I11
sg13
Vhyperplasia
p15856
sg15
I1
sa(dp15857
g9
I105
sg10
VC0034068
p15858
sg12
I22
sg13
Vpulmonary eosinophilia
p15859
sg15
I2
sasa(dp15860
g2
VGermline deficiency of the cell surface receptor chain ST2 abrogated the mm IL-33-induced Th2-associated effects (pulmonary eosinophilia, goblet cell hyperplasia, and increased IL-4 and IL-5), yet the lymphocytic infiltration induced by full-length mouse IL-33 or mm IL-33 was not fully abrogated by the absence of ST2.
p15861
sg4
(lp15862
(dp15863
g9
I177
sg20
VP05112
p15864
sg12
I4
sg13
VIL-4
p15865
sg15
I1
sa(dp15866
g9
I237
sg20
g21
sg12
I23
sg13
Vfull-length mouse IL-33
p15867
sg15
I3
sa(dp15868
g9
I186
sg20
VP05113
p15869
sg12
I4
sg13
VIL-5
p15870
sg15
I1
sasg6
(lp15871
(dp15872
g9
I114
sg10
VC0034068
p15873
sg12
I22
sg13
Vpulmonary eosinophilia
p15874
sg15
I2
sa(dp15875
g9
I201
sg10
VC1262091
p15876
sg12
I24
sg13
Vlymphocytic infiltration
p15877
sg15
I2
sa(dp15878
g9
I150
sg10
VC0020507
p15879
sg12
I11
sg13
Vhyperplasia
p15880
sg15
I1
sasa(dp15881
g2
VOVA-challenged STAT6-/- mice had neither AHR nor pulmonary eosinophilia, but had increased expression of mRNA for TNF-Alfa, IFN-Gamma and IL-4.
p15882
sg4
(lp15883
(dp15884
g9
I138
sg20
VP05112
p15885
sg12
I4
sg13
VIL-4
p15886
sg15
I1
sa(dp15887
g9
I114
sg20
VP01375
p15888
sg12
I3
sg13
VTNF
p15889
sg15
I1
sa(dp15890
g9
I124
sg20
VP01579
p15891
sg12
I9
sg13
VIFN-Gamma
p15892
sg15
I1
sa(dp15893
g9
I41
sg20
VP35869
p15894
sg12
I3
sg13
VAHR
p15895
sg15
I1
sa(dp15896
g9
I15
sg20
VP42226
p15897
sg12
I5
sg13
VSTAT6
p15898
sg15
I1
sasg6
(lp15899
(dp15900
g9
I49
sg10
VC0034068
p15901
sg12
I22
sg13
Vpulmonary eosinophilia
p15902
sg15
I2
sasa(dp15903
g2
VGLP-1R agonists are used to treat diabetes and obesity, and a GLP-2R agonist is approved to treat short bowel syndrome.
p15904
sg4
(lp15905
(dp15906
g9
I0
sg20
g21
sg12
I6
sg13
VGLP-1R
p15907
sg15
I1
sa(dp15908
g9
I62
sg20
g21
sg12
I6
sg13
VGLP-2R
p15909
sg15
I1
sasg6
(lp15910
(dp15911
g9
I47
sg10
VC0028754
p15912
sg12
I7
sg13
Vobesity
p15913
sg15
I1
sa(dp15914
g9
I98
sg10
VC0036992
p15915
sg12
I20
sg13
Vshort bowel syndrome
p15916
sg15
I3
sa(dp15917
g9
I34
sg10
VC0011849
p15918
sg12
I8
sg13
Vdiabetes
p15919
sg15
I1
sasa(dp15920
g2
VRNA-seq analysis and quantitative real-time polymerase chain reaction (qRT-PCR) were performed to evaluate the presence of GLP-1R and GLP-2R in EAT and subcutaneous fat (SAT) obtained from 8 subjects with coronary artery disease and type 2 diabetes mellitus undergoing elective cardiac surgery.
p15921
sg4
(lp15922
(dp15923
g9
I134
sg20
g21
sg12
I6
sg13
VGLP-2R
p15924
sg15
I1
sa(dp15925
g9
I123
sg20
g21
sg12
I6
sg13
VGLP-1R
p15926
sg15
I1
sasg6
(lp15927
(dp15928
g9
I205
sg10
VC1956346
p15929
sg12
I23
sg13
Vcoronary artery disease
p15930
sg15
I3
sa(dp15931
g9
I233
sg10
VC0011860
p15932
sg12
I24
sg13
Vtype 2 diabetes mellitus
p15933
sg15
I4
sasa(dp15934
g2
VGastric tissue samples of non-obese patients (NOB, n=10) and obese patients without diabetes (OB, n=31) and with diabetes (OWD, n=12) were used to evaluate GLP2R expression and distribution.
p15935
sg4
(lp15936
(dp15937
g9
I156
sg20
g21
sg12
I5
sg13
VGLP2R
p15938
sg15
I1
sasg6
(lp15939
(dp15940
g9
I30
sg10
VC0028754
p15941
sg12
I5
sg13
Vobese
p15942
sg15
I1
sa(dp15943
g9
I84
sg10
VC0011849
p15944
sg12
I8
sg13
Vdiabetes
p15945
sg15
I1
sa(dp15946
g9
I30
sg10
VC0028754
p15947
sg12
I5
sg13
Vobese
p15948
sg15
I1
sa(dp15949
g9
I84
sg10
VC0011849
p15950
sg12
I8
sg13
Vdiabetes
p15951
sg15
I1
sasa(dp15952
g2
VThis is the first evidence of increased GLP2R expression in chief cells of patients with severe obesity regardless of diabetes status.
p15953
sg4
(lp15954
(dp15955
g9
I40
sg20
g21
sg12
I5
sg13
VGLP2R
p15956
sg15
I1
sasg6
(lp15957
(dp15958
g9
I118
sg10
VC0011849
p15959
sg12
I8
sg13
Vdiabetes
p15960
sg15
I1
sa(dp15961
g9
I89
sg10
VC0028756
p15962
sg12
I14
sg13
Vsevere obesity
p15963
sg15
I2
sasa(dp15964
g2
VWe examined the importance of GLP-2 receptor (GLP-2R) signaling for glucose homeostasis in multiple models of metabolic stress, diabetes, and obesity.
p15965
sg4
(lp15966
(dp15967
g9
I30
sg20
g21
sg12
I14
sg13
VGLP-2 receptor
p15968
sg15
I2
sa(dp15969
g9
I46
sg20
g21
sg12
I6
sg13
VGLP-2R
p15970
sg15
I1
sasg6
(lp15971
(dp15972
g9
I128
sg10
VC0011849
p15973
sg12
I8
sg13
Vdiabetes
p15974
sg15
I1
sa(dp15975
g9
I142
sg10
VC0028754
p15976
sg12
I7
sg13
Vobesity
p15977
sg15
I1
sasa(dp15978
g2
VMoreover, glucose homeostasis was comparable in Glp2r(-/-) and Glp2r(+/+) mice fed a high-fat diet for 5 months or after induction of streptozotocin-induced diabetes.
p15979
sg4
(lp15980
(dp15981
g9
I48
sg20
g21
sg12
I5
sg13
VGlp2r
p15982
sg15
I1
sa(dp15983
g9
I48
sg20
g21
sg12
I5
sg13
VGlp2r
p15984
sg15
I1
sasg6
(lp15985
(dp15986
g9
I157
sg10
VC0011849
p15987
sg12
I8
sg13
Vdiabetes
p15988
sg15
I1
sasa(dp15989
g2
VIn a model of tubulointerstitial fibrosis induced by unilateral ureteral obstruction in mice, increased collagen I protein content and an almost complete disappearance of erythropoietin mRNA expression were observed in the ureteral ligated kidney with respect to the contralateral control.
p15990
sg4
(lp15991
(dp15992
g9
I171
sg20
VP01588
p15993
sg12
I19
sg13
Verythropoietin mRNA
p15994
sg15
I2
sa(dp15995
g9
I104
sg20
VP42768
p15996
sg12
I18
sg13
Vcollagen I protein
p15997
sg15
I3
sasg6
(lp15998
(dp15999
g9
I33
sg10
VC0016059
p16000
sg12
I8
sg13
Vfibrosis
p16001
sg15
I1
sa(dp16002
g9
I64
sg10
VC0041956
p16003
sg12
I20
sg13
Vureteral obstruction
p16004
sg15
I2
sasa(dp16005
g2
VIn the present study, employing a mouse model of renal tubulointerstitial fibrosis induced by unilateral ureteral obstruction (UUO), we demonstrated that EPO markedly reduced the disruption of the tubular basement membrane (TBM) through attenuating the activation of tissue plasminogen activator (tPA) and matrix metalloproteinase 9 (MMP9), the major matrix proteolytic network in the obstructed kidney.
p16006
sg4
(lp16007
(dp16008
g9
I297
sg20
VP00747
p16009
sg12
I3
sg13
VtPA
p16010
sg15
I1
sa(dp16011
g9
I306
sg20
VP14780
p16012
sg12
I26
sg13
Vmatrix metalloproteinase 9
p16013
sg15
I3
sa(dp16014
g9
I154
sg20
VP01588
p16015
sg12
I3
sg13
VEPO
p16016
sg15
I1
sa(dp16017
g9
I267
sg20
VP00747
p16018
sg12
I28
sg13
Vtissue plasminogen activator
p16019
sg15
I3
sa(dp16020
g9
I334
sg20
VP14780
p16021
sg12
I4
sg13
VMMP9
p16022
sg15
I1
sasg6
(lp16023
(dp16024
g9
I127
sg10
VC0041956
p16025
sg12
I3
sg13
VUUO
p16026
sg15
I1
sa(dp16027
g9
I74
sg10
VC0016059
p16028
sg12
I8
sg13
Vfibrosis
p16029
sg15
I1
sa(dp16030
g9
I105
sg10
VC0041956
p16031
sg12
I20
sg13
Vureteral obstruction
p16032
sg15
I2
sasa(dp16033
g2
VThe MVs derived from untreated MSCs (MSC-MVs) or from MSCs incubated in different concentrations of EPO (1, 10, 100, and 500 IU/ml EPO-MVs) were used to treat renal injury of unilateral ureteral obstruction (UUO) in vivo, and transforming growth factor-Beta1 (TGF-Beta1)-induced fibrosis in a human renal proximal tubular epithelial (HK2) cell line in vitro.
p16034
sg4
(lp16035
(dp16036
g9
I100
sg20
VP01588
p16037
sg12
I3
sg13
VEPO
p16038
sg15
I1
sa(dp16039
g9
I226
sg20
VP01137
p16040
sg12
I32
sg13
Vtransforming growth factor-Beta1
p16041
sg15
I3
sa(dp16042
g9
I260
sg20
VP01137
p16043
sg12
I9
sg13
VTGF-Beta1
p16044
sg15
I1
sasg6
(lp16045
(dp16046
g9
I208
sg10
VC0041956
p16047
sg12
I3
sg13
VUUO
p16048
sg15
I1
sa(dp16049
g9
I186
sg10
VC0041956
p16050
sg12
I20
sg13
Vureteral obstruction
p16051
sg15
I2
sa(dp16052
g9
I279
sg10
VC0016059
p16053
sg12
I8
sg13
Vfibrosis
p16054
sg15
I1
sasa(dp16055
g2
VTwenty-four male C57BL6 mice were randomly divided into four groups, each comprising six mice: (i) control group (Sh); (ii) unilateral ureteral obstruction (UUO) plus vehicle group (U+V); (#\u2172) UUO plus 300 U/kg body weight recombinant human (rh)EPO (U+E1) and (#\u2173) UUO plus 1,000 U/kg body weight rhEPO (U+E2).
p16056
sg4
(lp16057
(dp16058
g9
I245
sg20
VP01588
p16059
sg12
I3
sg13
VEPO
p16060
sg15
I1
sasg6
(lp16061
(dp16062
g9
I157
sg10
VC0041956
p16063
sg12
I3
sg13
VUUO
p16064
sg15
I1
sa(dp16065
g9
I157
sg10
VC0041956
p16066
sg12
I3
sg13
VUUO
p16067
sg15
I1
sa(dp16068
g9
I135
sg10
VC0041956
p16069
sg12
I20
sg13
Vureteral obstruction
p16070
sg15
I2
sa(dp16071
g9
I157
sg10
VC0041956
p16072
sg12
I3
sg13
VUUO
p16073
sg15
I1
sasa(dp16074
g2
VThe aim of this study is to show and compare the actions of Simvastatin (Simv) and Erythropoietin (Epo) in renal expression of nuclear factor kappa B (NFKB), transforming growth factor-Beta (TGF-Beta), basic fibroblast growth factor (bFGF), platelet-derived growth factor B (PDGF-B), fibronectin and development of interstitial fibrosis in rats with unilateral ureteral obstruction (UUO).
p16075
sg4
(lp16076
(dp16077
g9
I151
sg20
g21
sg12
I4
sg13
VNFKB
p16078
sg15
I1
sa(dp16079
g9
I99
sg20
VP01588
p16080
sg12
I3
sg13
VEpo
p16081
sg15
I1
sa(dp16082
g9
I158
sg20
VP18075
p16083
sg12
I31
sg13
Vtransforming growth factor-Beta
p16084
sg15
I3
sa(dp16085
g9
I191
sg20
VP18075
p16086
sg12
I8
sg13
VTGF-Beta
p16087
sg15
I1
sa(dp16088
g9
I275
sg20
VP01127
p16089
sg12
I6
sg13
VPDGF-B
p16090
sg15
I1
sa(dp16091
g9
I83
sg20
VP01588
p16092
sg12
I14
sg13
VErythropoietin
p16093
sg15
I1
sa(dp16094
g9
I234
sg20
VP53370
p16095
sg12
I4
sg13
VbFGF
p16096
sg15
I1
sa(dp16097
g9
I127
sg20
VP01160
p16098
sg12
I22
sg13
Vnuclear factor kappa B
p16099
sg15
I4
sa(dp16100
g9
I241
sg20
VP01127
p16101
sg12
I32
sg13
Vplatelet-derived growth factor B
p16102
sg15
I4
sa(dp16103
g9
I202
sg20
VP53370
p16104
sg12
I30
sg13
Vbasic fibroblast growth factor
p16105
sg15
I4
sasg6
(lp16106
(dp16107
g9
I383
sg10
VC0041956
p16108
sg12
I3
sg13
VUUO
p16109
sg15
I1
sa(dp16110
g9
I315
sg10
VC0240035
p16111
sg12
I21
sg13
Vinterstitial fibrosis
p16112
sg15
I2
sa(dp16113
g9
I361
sg10
VC0041956
p16114
sg12
I20
sg13
Vureteral obstruction
p16115
sg15
I2
sasa(dp16116
g2
VIn a novel mouse model, unilateral ureteral obstruction-induced inflammatory milieu activated NFKB and Smad signaling pathways in REPs, rapidly repressed the Epo-producing potential of REPs, and led to myofibroblast transformation of these cells.
p16117
sg4
(lp16118
(dp16119
g9
I94
sg20
g21
sg12
I4
sg13
VNFKB
p16120
sg15
I1
sa(dp16121
g9
I158
sg20
VP01588
p16122
sg12
I3
sg13
VEpo
p16123
sg15
I1
sasg6
(lp16124
(dp16125
g9
I35
sg10
VC0041956
p16126
sg12
I20
sg13
Vureteral obstruction
p16127
sg15
I2
sa(dp16128
g9
I216
sg10
VC1510411
p16129
sg12
I14
sg13
Vtransformation
p16130
sg15
I1
sasa(dp16131
g2
VReversing the unilateral ureteral obstruction-induced inflammatory microenvironment restored the Epo-producing potential and the physiologic phenotype of REPs.
p16132
sg4
(lp16133
(dp16134
g9
I97
sg20
VP01588
p16135
sg12
I3
sg13
VEpo
p16136
sg15
I1
sasg6
(lp16137
(dp16138
g9
I25
sg10
VC0041956
p16139
sg12
I20
sg13
Vureteral obstruction
p16140
sg15
I2
sasa(dp16141
g2
VSecondary polycythemia with increased production of erythropoietin (EPO) is known to occur in kidney diseases such as hydronephrosis and cystic disease, but the mechanism remains unclear.
p16142
sg4
(lp16143
(dp16144
g9
I52
sg20
VP01588
p16145
sg12
I14
sg13
Verythropoietin
p16146
sg15
I1
sa(dp16147
g9
I68
sg20
VP01588
p16148
sg12
I3
sg13
VEPO
p16149
sg15
I1
sasg6
(lp16150
(dp16151
g9
I118
sg10
VC0020295
p16152
sg12
I14
sg13
Vhydronephrosis
p16153
sg15
I1
sa(dp16154
g9
I0
sg10
VC1318533
p16155
sg12
I22
sg13
VSecondary polycythemia
p16156
sg15
I2
sa(dp16157
g9
I137
sg10
VC0334054
p16158
sg12
I14
sg13
Vcystic disease
p16159
sg15
I2
sa(dp16160
g9
I94
sg10
VC0022658
p16161
sg12
I15
sg13
Vkidney diseases
p16162
sg15
I2
sasa(dp16163
g2
VDecompartmentalized hemoglobin, arginase 1, asymmetric dimethylarginine, and adenine nucleotides are all products of hemolysis that promote vasomotor dysfunction, proliferative vasculopathy, and a multitude of clinical complications of pulmonary and systemic vasculopathy, including pulmonary hypertension, leg ulcers, priapism, chronic kidney disease, and large-artery ischemic stroke.
p16164
sg4
(lp16165
(dp16166
g9
I20
sg20
g21
sg12
I10
sg13
Vhemoglobin
p16167
sg15
I1
sa(dp16168
g9
I32
sg20
VP05089
p16169
sg12
I10
sg13
Varginase 1
p16170
sg15
I2
sasg6
(lp16171
(dp16172
g9
I307
sg10
VC0023223
p16173
sg12
I10
sg13
Vleg ulcers
p16174
sg15
I2
sa(dp16175
g9
I329
sg10
VC1561643
p16176
sg12
I22
sg13
Vchronic kidney disease
p16177
sg15
I3
sa(dp16178
g9
I163
sg10
VC0334094
p16179
sg12
I13
sg13
Vproliferative
p16180
sg15
I1
sa(dp16181
g9
I283
sg10
VC0020542
p16182
sg12
I22
sg13
Vpulmonary hypertension
p16183
sg15
I2
sa(dp16184
g9
I370
sg10
VC3272363
p16185
sg12
I15
sg13
Vischemic stroke
p16186
sg15
I2
sa(dp16187
g9
I117
sg10
VC0019054
p16188
sg12
I9
sg13
Vhemolysis
p16189
sg15
I1
sa(dp16190
g9
I319
sg10
VC0033117
p16191
sg12
I8
sg13
Vpriapism
p16192
sg15
I1
sasa(dp16193
g2
VWe report a patient with bilateral incyclotorsion, asymmetric facial palsy, monocular depression deficiency, and unilateral Type 3 Duane syndrome, along with contralateral anotia and a midline cleft palate.
p16194
sg4
(lp16195
sg6
(lp16196
(dp16197
g9
I172
sg10
VC0702139
p16198
sg12
I6
sg13
Vanotia
p16199
sg15
I1
sa(dp16200
g9
I86
sg10
VC0011581
p16201
sg12
I10
sg13
Vdepression
p16202
sg15
I1
sa(dp16203
g9
I193
sg10
VC0008925
p16204
sg12
I12
sg13
Vcleft palate
p16205
sg15
I2
sa(dp16206
g9
I131
sg10
VC0013261
p16207
sg12
I14
sg13
VDuane syndrome
p16208
sg15
I2
sa(dp16209
g9
I62
sg10
VC0015469
p16210
sg12
I12
sg13
Vfacial palsy
p16211
sg15
I2
sasa(dp16212
g2
VThe authors report a child with features of Cardiofacial syndrome with anotia and facial paralysis.
p16213
sg4
(lp16214
sg6
(lp16215
(dp16216
g9
I82
sg10
VC0015469
p16217
sg12
I16
sg13
Vfacial paralysis
p16218
sg15
I2
sa(dp16219
g9
I44
sg10
VC0431406
p16220
sg12
I21
sg13
VCardiofacial syndrome
p16221
sg15
I2
sa(dp16222
g9
I71
sg10
VC0702139
p16223
sg12
I6
sg13
Vanotia
p16224
sg15
I1
sasa(dp16225
g2
VThirty-three cases had microtia or anotia, and all instances of facial palsy were associated with auricular malformation.
p16226
sg4
(lp16227
sg6
(lp16228
(dp16229
g9
I64
sg10
VC0015469
p16230
sg12
I12
sg13
Vfacial palsy
p16231
sg15
I2
sa(dp16232
g9
I23
sg10
VC0152423
p16233
sg12
I8
sg13
Vmicrotia
p16234
sg15
I1
sa(dp16235
g9
I108
sg10
VC0000768
p16236
sg12
I12
sg13
Vmalformation
p16237
sg15
I1
sa(dp16238
g9
I35
sg10
VC0702139
p16239
sg12
I6
sg13
Vanotia
p16240
sg15
I1
sasa(dp16241
g2
VA girl was born with anotia, facial palsy and cardiac malformations.
p16242
sg4
(lp16243
sg6
(lp16244
(dp16245
g9
I21
sg10
VC0702139
p16246
sg12
I6
sg13
Vanotia
p16247
sg15
I1
sa(dp16248
g9
I29
sg10
VC0015469
p16249
sg12
I12
sg13
Vfacial palsy
p16250
sg15
I2
sa(dp16251
g9
I54
sg10
VC0000768
p16252
sg12
I13
sg13
Vmalformations
p16253
sg15
I1
sasa(dp16254
g2
VFreshly isolated LSECs, Kupffer cells (KCs), and stabilin-1- and stabilin-2-transfected human embryonic kidney cells were incubated with fluorescently labeled or radiolabeled oxLDLs [oxidized for 3 h (oxLDL(3)), 6 h, or 24 h (oxLDL(24))] to measure endocytosis.
p16255
sg4
(lp16256
(dp16257
g9
I49
sg20
g21
sg12
I26
sg13
Vstabilin-1- and stabilin-2
p16258
sg15
I3
sasg6
(lp16259
(dp16260
g9
I39
sg10
VC0022575
p16261
sg12
I3
sg13
VKCs
p16262
sg15
I1
sa(dp16263
g9
I24
sg10
VC0022575
p16264
sg12
I13
sg13
VKupffer cells
p16265
sg15
I2
sasa(dp16266
g2
VFurthermore, pleiotrophin (PTN), an endogenous ligand of Ptprz, also induced gastritis specifically in Ptprz+/+ mice when administered orally.
p16267
sg4
(lp16268
(dp16269
g9
I27
sg20
VP21246
p16270
sg12
I3
sg13
VPTN
p16271
sg15
I1
sa(dp16272
g9
I13
sg20
VP21246
p16273
sg12
I12
sg13
Vpleiotrophin
p16274
sg15
I1
sasg6
(lp16275
(dp16276
g9
I77
sg10
VC0017152
p16277
sg12
I9
sg13
Vgastritis
p16278
sg15
I1
sasa(dp16279
g2
VWe aimed to determine whether serum levels of Krebs von den Lungen-6 (KL-6) and surfactant protein-D (SP-D) correlate with SSc/MCTD-associated ILD activity.
p16280
sg4
(lp16281
(dp16282
g9
I102
sg20
VP35247
p16283
sg12
I4
sg13
VSP-D
p16284
sg15
I1
sa(dp16285
g9
I80
sg20
VP35453
p16286
sg12
I20
sg13
Vsurfactant protein-D
p16287
sg15
I2
sasg6
(lp16288
(dp16289
g9
I127
sg10
VC0026272
p16290
sg12
I4
sg13
VMCTD
p16291
sg15
I1
sasa(dp16292
g2
VSerum KL-6 correlated positively with diffusing capacity of the lung for carbon monoxide (DLCO) (% predicted) and disease extent on HRCT, and the changes in serum levels of KL-6 were significantly related to the changes in forced vital capacity (FVC) in SSc/MCTD-associated ILD.
p16293
sg4
(lp16294
(dp16295
g9
I0
sg20
g21
sg12
I10
sg13
VSerum KL-6
p16296
sg15
I2
sasg6
(lp16297
(dp16298
g9
I258
sg10
VC0026272
p16299
sg12
I4
sg13
VMCTD
p16300
sg15
I1
sasa(dp16301
g2
VOur study suggests that serum KL-6 can be a useful monitoring tool of SSc/MCTD-associated ILD activity.
p16302
sg4
(lp16303
(dp16304
g9
I24
sg20
g21
sg12
I10
sg13
Vserum KL-6
p16305
sg15
I2
sasg6
(lp16306
(dp16307
g9
I74
sg10
VC0026272
p16308
sg12
I4
sg13
VMCTD
p16309
sg15
I1
sasa(dp16310
g2
VThe KL-6 levels did not differ significantly according to the connective tissue diseases in the diagnostic groups (systemic lupus erythematosus, Sjoegren's syndrome, rheumatoid arthritis, mixed connective tissue disease, scleroderma, polymyositis/ dermatomyositis).
p16311
sg4
(lp16312
sg6
(lp16313
(dp16314
g9
I221
sg10
VC0011644
p16315
sg12
I11
sg13
Vscleroderma
p16316
sg15
I1
sa(dp16317
g9
I234
sg10
VC0085655
p16318
sg12
I12
sg13
Vpolymyositis
p16319
sg15
I1
sa(dp16320
g9
I166
sg10
VC0003873
p16321
sg12
I20
sg13
Vrheumatoid arthritis
p16322
sg15
I2
sa(dp16323
g9
I145
sg10
VC1527336
p16324
sg12
I19
sg13
VSjoegren's syndrome
p16325
sg15
I2
sa(dp16326
g9
I115
sg10
VC0024141
p16327
sg12
I28
sg13
Vsystemic lupus erythematosus
p16328
sg15
I3
sa(dp16329
g9
I62
sg10
VC0009782
p16330
sg12
I26
sg13
Vconnective tissue diseases
p16331
sg15
I3
sa(dp16332
g9
I188
sg10
VC0026272
p16333
sg12
I31
sg13
Vmixed connective tissue disease
p16334
sg15
I4
sa(dp16335
g9
I248
sg10
VC0221056
p16336
sg12
I15
sg13
Vdermatomyositis
p16337
sg15
I1
sasa(dp16338
g2
VTo quantify and compare human mucin 1 (MUC1) protein and mRNA expression in tears and conjunctival epithelial cells collected from Sjogren's syndrome (SS), non-Sjogren's keratoconjunctivitus sicca (KCS) and non-dry eyed (NDE) control subjects.
p16339
sg4
(lp16340
(dp16341
g9
I24
sg20
g21
sg12
I13
sg13
Vhuman mucin 1
p16342
sg15
I3
sasg6
(lp16343
(dp16344
g9
I131
sg10
VC1527336
p16345
sg12
I18
sg13
VSjogren's syndrome
p16346
sg15
I2
sa(dp16347
g9
I131
sg10
VC1527336
p16348
sg12
I9
sg13
VSjogren's
p16349
sg15
I1
sa(dp16350
g9
I198
sg10
VC0022575
p16351
sg12
I3
sg13
VKCS
p16352
sg15
I1
sa(dp16353
g9
I170
sg10
VC0022575
p16354
sg12
I26
sg13
Vkeratoconjunctivitus sicca
p16355
sg15
I2
sa(dp16356
g9
I151
sg10
VC1527336
p16357
sg12
I2
sg13
VSS
p16358
sg15
I1
sasa(dp16359
g2
VWe studied 21 patients referred for idiopathic short stature, 5 with clinically suspected hypochondroplasia and 4 with achondroplasia.
p16360
sg4
(lp16361
sg6
(lp16362
(dp16363
g9
I90
sg10
VC0410529
p16364
sg12
I17
sg13
Vhypochondroplasia
p16365
sg15
I1
sa(dp16366
g9
I119
sg10
VC0001080
p16367
sg12
I14
sg13
Vachondroplasia
p16368
sg15
I1
sa(dp16369
g9
I36
sg10
VC1740819
p16370
sg12
I24
sg13
Vidiopathic short stature
p16371
sg15
I3
sasa(dp16372
g2
VA series of 140 patients with short stature operated on for limb lengthening (80 had achondroplasia, 20 had hypochondroplasia, 20 had Turner syndrome, 10 had idiopathic short stature due to an undemonstrated cause, 5 regarded their stature as too short, and 5 had a psychopathic personality due to dysmorphophobia that had developed because of their short stature) was reviewed.
p16373
sg4
(lp16374
sg6
(lp16375
(dp16376
g9
I30
sg10
VC0013336
p16377
sg12
I13
sg13
Vshort stature
p16378
sg15
I2
sa(dp16379
g9
I108
sg10
VC0410529
p16380
sg12
I17
sg13
Vhypochondroplasia
p16381
sg15
I1
sa(dp16382
g9
I30
sg10
VC0013336
p16383
sg12
I13
sg13
Vshort stature
p16384
sg15
I2
sa(dp16385
g9
I298
sg10
VC0005887
p16386
sg12
I15
sg13
Vdysmorphophobia
p16387
sg15
I1
sa(dp16388
g9
I85
sg10
VC0001080
p16389
sg12
I14
sg13
Vachondroplasia
p16390
sg15
I1
sa(dp16391
g9
I266
sg10
VC0003431
p16392
sg12
I24
sg13
Vpsychopathic personality
p16393
sg15
I2
sa(dp16394
g9
I134
sg10
VC0041408
p16395
sg12
I15
sg13
VTurner syndrome
p16396
sg15
I2
sa(dp16397
g9
I158
sg10
VC1740819
p16398
sg12
I24
sg13
Vidiopathic short stature
p16399
sg15
I3
sasa(dp16400
g2
VIn the present study, we investigated whether the impairment of IRS-1-mediated insulin signaling contributes to neurite outgrowth and neuronal loss, both in mice fed a high-fat diet and in mouse neuroblastoma (Neuro2A) cells.
p16401
sg4
(lp16402
(dp16403
g9
I64
sg20
VP35568
p16404
sg12
I5
sg13
VIRS-1
p16405
sg15
I1
sa(dp16406
g9
I79
sg20
VP01308
p16407
sg12
I7
sg13
Vinsulin
p16408
sg15
I1
sasg6
(lp16409
(dp16410
g9
I50
sg10
VC0684336
p16411
sg12
I10
sg13
Vimpairment
p16412
sg15
I1
sa(dp16413
g9
I189
sg10
VC1524043
p16414
sg12
I19
sg13
Vmouse neuroblastoma
p16415
sg15
I2
sasa(dp16416
g2
VTo investigate the changes caused by the inhibition of IRS-1-mediated insulin signaling in neuroblastoma cells, we performed Western blot analysis, reverse transcription-PCR, and immunochemical analysis.
p16417
sg4
(lp16418
(dp16419
g9
I55
sg20
VP35568
p16420
sg12
I5
sg13
VIRS-1
p16421
sg15
I1
sa(dp16422
g9
I70
sg20
VP01308
p16423
sg12
I7
sg13
Vinsulin
p16424
sg15
I1
sasg6
(lp16425
(dp16426
g9
I91
sg10
VC0027819
p16427
sg12
I13
sg13
Vneuroblastoma
p16428
sg15
I1
sasa(dp16429
g2
VmiR-145 might act as a tumor suppressor in uveal melanoma, and downregulation of the target IRS-1 might be a potential mechanism.
p16430
sg4
(lp16431
(dp16432
g9
I0
sg20
g21
sg12
I7
sg13
VmiR-145
p16433
sg15
I1
sa(dp16434
g9
I85
sg20
VP35568
p16435
sg12
I12
sg13
Vtarget IRS-1
p16436
sg15
I2
sasg6
(lp16437
(dp16438
g9
I23
sg10
VC0027651
p16439
sg12
I5
sg13
Vtumor
p16440
sg15
I1
sa(dp16441
g9
I43
sg10
VC0220633
p16442
sg12
I14
sg13
Vuveal melanoma
p16443
sg15
I2
sasa(dp16444
g2
VAlmost a decade ago, we reported the presence of nuclear IRS-1 in medulloblastoma clinical samples, which express viral oncoprotein, large T-antigen of human polyomavirus JC (JCV T-antigen).
p16445
sg4
(lp16446
(dp16447
g9
I133
sg20
VP14209
p16448
sg12
I15
sg13
Vlarge T-antigen
p16449
sg15
I2
sa(dp16450
g9
I175
sg20
VP14209
p16451
sg12
I13
sg13
VJCV T-antigen
p16452
sg15
I2
sasg6
(lp16453
(dp16454
g9
I66
sg10
VC0025149
p16455
sg12
I15
sg13
Vmedulloblastoma
p16456
sg15
I1
sasa(dp16457
g2
VMore recently, nuclear IRS-1 was detected in breast cancer cells in association with estrogen receptor alpha (ERAlfa), and in JC virus negative medulloblastoma cells expressing estrogen receptor beta (ERBeta), further implicating nuclear IRS-1 in cellular transformation.
p16458
sg4
(lp16459
(dp16460
g9
I85
sg20
VP03372
p16461
sg12
I23
sg13
Vestrogen receptor alpha
p16462
sg15
I3
sa(dp16463
g9
I177
sg20
VP03372
p16464
sg12
I22
sg13
Vestrogen receptor beta
p16465
sg15
I3
sa(dp16466
g9
I15
sg20
VP35568
p16467
sg12
I13
sg13
Vnuclear IRS-1
p16468
sg15
I2
sa(dp16469
g9
I201
sg20
VP03372
p16470
sg12
I6
sg13
VERBeta
p16471
sg15
I1
sasg6
(lp16472
(dp16473
g9
I247
sg10
VC1510411
p16474
sg12
I23
sg13
Vcellular transformation
p16475
sg15
I2
sa(dp16476
g9
I45
sg10
VC0678222
p16477
sg12
I13
sg13
Vbreast cancer
p16478
sg15
I2
sa(dp16479
g9
I144
sg10
VC0025149
p16480
sg12
I15
sg13
Vmedulloblastoma
p16481
sg15
I1
sasa(dp16482
g2
VWe have previously reported that ERBeta, which is highly expressed in medulloblastomas, translocates insulin receptor substrate 1 (IRS-1) to the nucleus, and that nuclear IRS-1 binds to Rad51 and attenuates homologous recombination directed DNA repair (HRR).
p16483
sg4
(lp16484
(dp16485
g9
I186
sg20
g21
sg12
I5
sg13
VRad51
p16486
sg15
I1
sa(dp16487
g9
I101
sg20
VP35568
p16488
sg12
I28
sg13
Vinsulin receptor substrate 1
p16489
sg15
I4
sa(dp16490
g9
I163
sg20
VP35568
p16491
sg12
I13
sg13
Vnuclear IRS-1
p16492
sg15
I2
sa(dp16493
g9
I131
sg20
VP35568
p16494
sg12
I5
sg13
VIRS-1
p16495
sg15
I1
sasg6
(lp16496
(dp16497
g9
I70
sg10
VC0025149
p16498
sg12
I16
sg13
Vmedulloblastomas
p16499
sg15
I1
sasa.